<SEC-DOCUMENT>0001397702-20-000031.txt : 20200813
<SEC-HEADER>0001397702-20-000031.hdr.sgml : 20200813
<ACCEPTANCE-DATETIME>20200813160216
ACCESSION NUMBER:		0001397702-20-000031
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200813
DATE AS OF CHANGE:		20200813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silk Road Medical Inc
		CENTRAL INDEX KEY:			0001397702
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				208777622
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38847
		FILM NUMBER:		201099228

	BUSINESS ADDRESS:	
		STREET 1:		1213 INNSBRUCK DR.
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94089-2918
		BUSINESS PHONE:		6505669060

	MAIL ADDRESS:	
		STREET 1:		1213 INNSBRUCK DR.
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94089-2918
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>silk-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:9bdc0587-bada-46ac-a409-f4831c8e244f,g:1209e878-563a-4edf-b13c-0faadaf6133a,d:0f5f7f4a40e74f9186fba54ac93b1916--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:silk="http://silkroadmed.com/20200630" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>silk-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV8zLTEtMS0xLTA_660b0ae1-3761-498b-870f-657aa174d66c">0001397702</ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV80LTEtMS0xLTA_e2f88909-f544-4fac-a1c4-55156e2f001e">December 31</ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV8xMS0xLTEtMS0w_d30c3591-a552-4842-978f-76023e46b59d">2020</ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV8xMi0xLTEtMS0w_97bc135c-629f-4ddd-9662-87156b346067">Q2</ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV8xMy0xLTEtMS0w_466b5b4c-0171-45b4-8d30-4b2cf0323d7a">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ie760fc97ef2b4f50b5ec97d0f5ebe0b2_D20190313-20190313" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNy9mcmFnOjg3N2YzMzUxNGIyZTRhZDRiYTRlMTAxZDNlOTdkYmEwL3RleHRyZWdpb246ODc3ZjMzNTE0YjJlNGFkNGJhNGUxMDFkM2U5N2RiYTBfMTM_b95f22f9-45e2-41f5-b7ee-58b9a8f725c6">.3704</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="silk-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4cae094a657c4ffe9478c2d84e706b28_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4192fdc2c1f247de9e20017c4c131295_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e3e7e58fd643a9b81d6acc10d20212_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01edde7dedb544328d6997373cf6ad4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02f7ba2764646e98fe313a3f6b45aff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0efec5d2df54499d877b5b7f2c50296e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b35b01b32f46f2bee4f4a23b7012a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98288daaa954dd1875ff62ad62c8371_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412e80de80294636915c387579e51a98_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2813994ece5044d3b7db1695fbd0eb1f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893baa7990094d9996aef955612bf12c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if97360d0e3024fcd99b7a9761e90b309_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad155abbc9754495b06722da098ba394_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b44a6c1a4d7438a86dff3e0e151961a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i250d8d2fc5a44833b091f0a0021c1f1f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa53cd55d6d640ff87711fd4e0f8ef56_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d433da600ff424d9072d74a4800426b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71269ca1bb0048df93fdfb7f60583aca_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1ba60825d14c648abad9bad89c5116_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5c4b78f734744bb9a7efbc2c9838e21_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01cbace60dde45c3b3e3b6d6de1dc3cb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5abe689d4c9b45d590e6081f66e9d892_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e493ed76734fa9b072ff4c78d00454_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba95761be90e4d0b871436b1bc3e613f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie87ca05332314ce38d1c838f1918033d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if195c2966bd4478b9a536e42c4729969_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i267c658bb1a64c4cb3087e17e6ba0504_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9766f2a2b567462db339a57d15a9b202_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44fb74c77caa45feb1b93e73036b664d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f3122f97654386982663f091f8be2a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18115e334dfb4939bf22d7f51604a743_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2974baeced5b42539df2ce7e5d9fd970_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69b6f1148feb4497b99389b263100226_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia013b4eb40114308be33eb29a813111d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b16f07a785142d7af5301cf48c4d820_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa337a09be04535b922d4ff23c908d4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b2a6a89c1143b79a1fde2400691f14_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd18f4a372d4ab3bbe21e94964f88b0_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35d13e334d474ffca707c39e945c4b18_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i042388ebf8da4a30880f8f9e5c039e53_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6892eaf5054997bc5db44ea630d3b8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2e3b1c19991473a9eda55c27b7a6352_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857c634bdb34432c8b74d2c01c998fde_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d224a2b66764827814bf9c8f036c6fd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb63e8b0926842298836b1c7a48b5ad7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e86f21e817747e1b323fa24e138daa7_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i907247d422b04c4daa972b713b2650e5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8771181b78740329cdb8290b99f0331_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b36e442f3114a22ba850f63b846e6f4_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdf7b91752347eb8ff1ad32bb419fc9_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9634e8ac71464a7c94802f90d75471fa_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7239974596a4a39bd1824a432c2fd56_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ad5239b3db46d4ad0d92c5293e2141_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05076e6e126f4a39a7b296a201b34ff2_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic94b432f83144c5da9c031a5551750d7_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide2816e79e1b4022bf0287f80bb4fdf9_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:SecondPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41cc7674876049d3a0d3f79031ac5f2e_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3c231e674e41edb75743c3010ec1df_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:SecondPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43b4977769d4b22b03b8b2e1b372461_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1f341d7b77348a3a2568b670d478a67_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingSharesFromCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f15ecda3b414074877b40741ff55576_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingSharesFromExistingShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8daaa359899f42abbc96d5a68e4e2aca_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie760fc97ef2b4f50b5ec97d0f5ebe0b2_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2667bba4254c478e4e02407240ad78_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ceb4ffa58a401ba6b8f294d3cb104c_D20190501-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704ad274cb0749d5930b69ce8f613a81_D20190501-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e17ff70ca0d48c8b577b81e25ba591d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic416bec949ed4e3ca81268307a41e37e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i474e71f940ab46279c176f0b19975770_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6a67bd46361461c9d492414aa7bffdd_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>silk:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia45c7bb5cadd4ff3928225d7854fc6cf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7eaae44effa4a9db07cdb54dcc04049_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11c28dea9564c599548f654617f2d82_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieef0e9ab0a544219ad78c50b68f4791d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027eeae537b5468592e241128284b992_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b02921cf0f4f00aa9fe9fdfd871170_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0130e277a457479f8eb98ee94adf3d31_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7abe1f43259b4a54b976c268c96c3db6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie05b32828f264722b8556b4370fc6692_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f148c7c1d24480baf7b80e8a13fd5a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c333b7cb2584fb0bf52ab8951d3b428_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ef50b8f524a4cf1a7fbc3e5edfecf52_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbe32b015af345959821be4df0dcaeac_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37bbce2b0c0c4aed8cf5b3c35c01dcae_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbd828ff8134720a052fc51c726266a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i295a9086a57e41eba3c2236e5dc80ef0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad31c85169dc429b85ce034ad39eb103_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63598873c0f044d4b705b1cafa4240b7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cde6c49eff04e36b1db4f65acf663c3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c32e22f95c44cab38971bc9fab5004_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e712413f6848d9a5e188b7a113c60d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e1c06ac263949cf803aa266d7e0c236_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bee5fc72654faebc87e97e419f58c1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5bfe7df3c84fe6850ff62b8c098b26_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11dd8af0811b4ebab5f6adef8864c4f1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8bebd551d147b992e253b95baa195f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedefabef8f124e819f3337024626dc4e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2abf6f3595684efe9f063ff9b69fec7f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aae1b1ed715477dad46b3078e21b40b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9a7836694f4cf3b50a9134284d8b4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9636c3ae224c4f7f893c191a0ab12002_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ab7e26b0e64cffa5cca122155110e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide59561146c34abbbab1296d346d7f2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c98a1a3cac34c2fbc05c0e88a578e09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c935ab0c1f241b990bc79b98b3645b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1de230599454417b163ebfe37b873d5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i145dc0fcbfe64370a9f24164b7dd43f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8245985bc354b6a86396bc01b5213d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib148be5a80234007ae139c5a4efdfc61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1a76cb4479a4ff989b812aac949063e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if53f29868f76491f8fd58d9c3303f998_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide4b8aa16b5440ec854fbf0906b9c133_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67ffbfb49b864745af10bab7a89329f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5a347102e80443a82dea892692d5746_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46860657c50f45ee882f2df2d5f623d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc96a72145c469d9ab6fb5c89bafb0e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3830c20a6ee94b1488be7319d791f2d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ebd01da1cc2487a91876a8405b5628b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac0ccc5a7ea8414bb1a711a6955e7342_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i665e3a1be7a84f788bd449d1334d492c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628752f4a1c64849a99d7a5f207dd092_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf14871d54b5439a835298db12c36739_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8c8ea18544f4f62b607863b3c6653ed_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46da514145b4750ada52675069ab829_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7700ecb8225940a282f94f4767f6615f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf867c38014844e5818ec341fda982bd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5f4685798604a6d9460510b4c4c15a7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f195d63bab41439dde63c7ec42a7a3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54064e0090149959fffc8a7f4540977_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c26d0ce983a467cace48304d4c14c29_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia147919f6a044ff88de323227052e424_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecc6e45694f94ee2a9737c2166fb37d1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3a50b23b354642957be1435413bcd9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic00908a653674eb4a8e9bac56051e1a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070bfe38bf2d4977b7e7675ca0fe38ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084603b74ef54fce8e75cc1061fc2af7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb20a2f0bf24dd08225af4dac73faaa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3400703ba5ec4dafa9f83491b25fdc9b_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i790a1c16fe884cfc81603c5b990067c9_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0624ae02355943f3919d91e6d60daf82_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05691cc4d2eb407b8735756cfcce9745_I20170430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3af30497630e46e0b5dbb159697d1735_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d81a47bada34ef9be4c34a930d81f1e_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab64d89eb0c493488e9f83a19562b4d_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59b0ae0ca9845038632b9400107e7e6_I20190501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1e85f6d793488db550a9cd9ebeec00_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i159d0d96431346b8906e3a743106810e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i819cbd89b0e044588cd3162b0ae7dad0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448c71a8e90245efa333cff2acf26e6f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic379c431ee4f4674ab4bd3200cc4d510_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633031055692460588cb4386c56f8095_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie917c02865cd4fba8e0243a7cd29e649_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i417623c9d2f24af1b9f527fefb005c13_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieebe6a801a53498d95a8594bf16d9080_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7140d4200a4dc5bdacecc60d872d6b_D20170701-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife031befc9a54c529bec50b02c7d0159_I20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98995d7c6a444311ad86aee8421c9d3a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i496155293b1d4422b3ea42fef3be00b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9dcdcdf5e9b496689dbd352302af644_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84de79cfd01646ca80f851b0e71fec3e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>silk:vote</xbrli:measure></xbrli:unit><xbrli:context id="i6113484aa6d4421ebce5390fc3eaf952_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7df1fe52b16e418da8983a23cd31db62_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2378c3bc6251483cab8274447be641b8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd9fbf4e28c4a2fbde835757d39a1e5_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b705b1bf16749838adb0a5da76d687c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23898085ac8458bb0cac28efb4aaef4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f162f8f289492a97ccfe1e594fa809_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:NonqualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice3001c6ee614220ac19207889d5aa37_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie82a229840ec40d79a480525255fd532_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a6f5fdcd6894037a81fa4bc82914447_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2811c603862b4d7ea5a7fa37dea521c1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039961495a884a188b5d3e7bda9008a4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515f2625685e47a3a0c3f87208b405e1_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eb1770831844300ae09b328b18c5397_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454e6e1c1e7148d2abad0f588fcee401_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dfbb8e51673404eb0624832076ff097_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bea4ee895a74d1aaedf0a333c0c6f4c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70be1e0534404d08896dbc0a988ff250_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c173a6496b4596bfce7f7c0833e719_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i220629dc98834984b7d11f79d2fe810b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4dc7821cccc41989da58dcccb531642_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia742a060c2af4302bfd4a0bd4786b675_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia43e704ab79f493585f933259edc8540_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4024977785b1424fab65d0622c295161_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cbb5c9c3ef24d45998860f450b433d3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2826aabff8b4439e8abd78eb9018b593_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab80b98eced34b02a24687725a852684_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b281a430c8c4aada7ebc48e15d5e031_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5f9129abc84b8e85adb2e73a6a2964_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87005078ae94c2ba819b718b9a86599_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f2446a5cb34a2c800a0378dc3c54f6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d1215e8500c43c59e1c45a0496eabb7_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a29f695f4e8418b88fdf2ecd941252f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c1ae90727004ccfbf97f186ac2e0781_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8664b40a2ba4c69b62ac361f5b299d4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a7af5bbd93b4d26b19182dbb32d2697_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2473c0e76af946f0a8d35143cb16bdc7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia946f02d9b0346d3bb893b131d264f0e_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001397702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_1"></div><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549 </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.834%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.330%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.836%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:15pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl84Ng_26b79d6a-09f3-401a-889d-edd5e3009317">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">REGISTRATION STATEMENT </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;">Under </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;">The Securities Act of 1933</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.834%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.330%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.836%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-bottom:3pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:0.1%;"></td><td style="width:2.577%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.223%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6ZjVkZjM2OTc4Mjk1NGY1ZGJjMGQ4NzBlZWU1ZjM5NjIvdGFibGVyYW5nZTpmNWRmMzY5NzgyOTU0ZjVkYmMwZDg3MGVlZTVmMzk2Ml8wLTAtMS0xLTA_cb78b751-1439-49fd-af3b-09a08fade9d5">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8xOTQ_ee07f679-b329-4866-aa3d-48df81bd07f9">June 30, 2020</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:0.1%;"></td><td style="width:2.577%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.223%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6MzFkY2UzNDY2Yjg2NGZlM2FkMTdmNGQ2OWJhOGEwY2UvdGFibGVyYW5nZTozMWRjZTM0NjZiODY0ZmUzYWQxN2Y0ZDY5YmE4YTBjZV8wLTAtMS0xLTA_16db32d6-2723-4cd8-b37d-c8ebf5187079">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">For transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Commission File Number &#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8yNzI_b68fd5af-f64e-4d00-9bb5-26c0b20b766c">001-38847</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.834%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.330%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.836%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:15pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8yODI_2ac99c53-8362-45cd-aa21-9b6791e050ac">SILK ROAD MEDICAL, INC.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.834%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.330%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.836%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6NWNmYmFkMmZlMjA3NDhkOGI3ZWIwNTE1MWFjOTkzZTYvdGFibGVyYW5nZTo1Y2ZiYWQyZmUyMDc0OGQ4YjdlYjA1MTUxYWM5OTNlNl8wLTAtMS0xLTA_e1fb1419-3785-4067-b794-fd9b069e96eb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3841</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6NWNmYmFkMmZlMjA3NDhkOGI3ZWIwNTE1MWFjOTkzZTYvdGFibGVyYW5nZTo1Y2ZiYWQyZmUyMDc0OGQ4YjdlYjA1MTUxYWM5OTNlNl8wLTItMS0xLTA_0f007e57-ede7-43a8-b15f-5a627d5314cc">20-8777622</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Primary Standard Industrial<br/>Classification Code Number)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNDc_c292db7b-81a4-40a6-81bd-c8c595abaa68">1213 Innsbruck Dr.</ix:nonNumeric> <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNTA_564d6793-bfba-437d-a5d0-c2adf65e45ae">Sunnyvale</ix:nonNumeric>, <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNTQ_4bed2542-f792-4f72-854c-629b710ea900">CA</ix:nonNumeric> <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNTc_4d93a8e7-da12-452b-be3b-1a4f280f4267">94089</ix:nonNumeric> (<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNjE_a0cc7b66-d9dd-485c-9cd9-e07f21135cc1">408</ix:nonNumeric>) <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNjU_daaa2818-db75-4d4d-9c84-aee9c3a08573">720-9002</ix:nonNumeric> </span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="text-align:center;margin-bottom:3pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.834%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.330%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.836%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Erica J. Rogers</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Chief Executive Officer </span></div><div style="text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">1213 Innsbruck Dr. Sunnyvale, CA 94089 (408) 720-9002  </span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%;"> </span></div><div style="margin-bottom:3pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:36.834%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.330%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.836%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8xMDM5_eee35da2-969e-4d74-86fb-7bb1191f4938">Yes</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:18pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8xMzYw_6226901b-caae-4f05-b051-d0f924455ae4">Yes</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:18pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and "emerging growth company" in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:3pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.666%;"><tr><td style="width:1.0%;"></td><td style="width:22.137%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.673%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.977%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.137%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.676%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6MzRjYzVlMjFhMGJhNGY5ZGI2M2E1ZTVhOGVhY2VkN2EvdGFibGVyYW5nZTozNGNjNWUyMWEwYmE0ZjlkYjYzYTVlNWE4ZWFjZWQ3YV8xLTAtMS0xLTA_43e06f19-7421-46fc-98bd-c03df03205a1">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6MzRjYzVlMjFhMGJhNGY5ZGI2M2E1ZTVhOGVhY2VkN2EvdGFibGVyYW5nZTozNGNjNWUyMWEwYmE0ZjlkYjYzYTVlNWE4ZWFjZWQ3YV8xLTQtMS0xLTA_532c06c1-81dc-4d33-a99b-79b8c0f230c7">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6MzRjYzVlMjFhMGJhNGY5ZGI2M2E1ZTVhOGVhY2VkN2EvdGFibGVyYW5nZTozNGNjNWUyMWEwYmE0ZjlkYjYzYTVlNWE4ZWFjZWQ3YV8yLTEtMS0xLTA_72885cef-8a3a-46a5-898b-5d2a0d63776d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:18pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).  Yes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8yMDkx_f4b3add0-e2a6-448f-8fd6-da93d84ac9e6">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="text-indent:18pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.472%;"><tr><td style="width:1.0%;"></td><td style="width:24.844%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:29.554%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.602%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6Njg4ODA4MTMxN2M2NDJlMWI2NzIwYzRmZjAxZWI3YmQvdGFibGVyYW5nZTo2ODg4MDgxMzE3YzY0MmUxYjY3MjBjNGZmMDFlYjdiZF8xLTAtMS0xLTA_3cfc71bd-ab27-43d1-83f8-ff315fb972e3">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6Njg4ODA4MTMxN2M2NDJlMWI2NzIwYzRmZjAxZWI3YmQvdGFibGVyYW5nZTo2ODg4MDgxMzE3YzY0MmUxYjY3MjBjNGZmMDFlYjdiZF8xLTEtMS0xLTA_5898a84e-27b9-4769-9a00-5ca6094b6447">SILK</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6Njg4ODA4MTMxN2M2NDJlMWI2NzIwYzRmZjAxZWI3YmQvdGFibGVyYW5nZTo2ODg4MDgxMzE3YzY0MmUxYjY3MjBjNGZmMDFlYjdiZF8xLTItMS0xLTA_26421d7b-b5ac-4082-92fb-a60ca7d39a3b">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of July 31, 2020, the number of outstanding shares of the registrant's common stock, par value $0.001 per share, was <ix:nonFraction unitRef="shares" contextRef="i4cae094a657c4ffe9478c2d84e706b28_I20200731" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8yMjgy_ef226199-da8a-4eb6-a009-c1368d3187d0">33,679,635</ix:nonFraction>.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:7.455%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.134%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.411%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_13">Part I: Financial Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_16">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_16">Unaudited Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_19">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_22">Condensed Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_25">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_25">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_28">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_28">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_31">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_82">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_82">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_82">29</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_88">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_88">Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_88">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_91">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_91">40</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_94">Part II: Other Information</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_97">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_97">42</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_100">Item 1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_100">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_100">42</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_103">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_103">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_103">90</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_88">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_88">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_88">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_91">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_91">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_91">40</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_112">Item 5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_112">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_112">91</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_115">Item 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_115">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_115">91</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_118">Signatures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#i0f5f7f4a40e74f9186fba54ac93b1916_118">94</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">CAUTIONARY NOTES REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition.  Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements.  In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These forward-looking statements include, but are not limited to, statements about:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our plans to conduct further clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our plans and expected timeline related to our products, or developing new products, to address additional indications or otherwise;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the expected use of our products by physicians;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations regarding the number of procedures performed with our products, the number of physicians we expect to train, and the number of our sales territories;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain, maintain and expand regulatory clearances for our products and any new products we create;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the expected growth of our business and our organization;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations regarding government and third-party payer coverage and reimbursement;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain an adequate supply of materials and components for our products from our third-party suppliers, most of whom are single-source suppliers;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to manufacture sufficient quantities of our products with sufficient quality;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain and maintain intellectual property protection for our products and our business;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to expand our business into new geographic markets;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our compliance with extensive Nasdaq requirements and government laws, rules and regulations both in the United States and internationally;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to identify and develop new and planned products and/or acquire new products;&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations regarding the impact of the COVID-19 pandemic on our business; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">developments and projections relating to ou</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">r competitors or our industry; and</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our intended use of net proceeds from our public offerings.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that it is important to communicate our future expectations to our investors.  However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements.  These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control.  As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate.  Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q.  We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.  You should not rely upon forward-looking statements as predictions of future events.  Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.  We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the SEC as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">Part I. Financial Information</span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_16"></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Item 1: Unaudited Condensed Financial Statements</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Silk Road Medical, Inc.<br/>Condensed Balance Sheets<br/>(unaudited)</span></td></tr></table></div><div style="margin-bottom:6pt;"><span><br/></span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_19"></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.903%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.905%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except share and per share data)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNC0xLTEtMS0w_31b20d37-00c1-4bd3-9439-829db303da30">73,442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNC0zLTEtMS0w_2f901a64-bda5-4a8a-b810-f17dd5f8e7ad">39,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNS0xLTEtMS0w_0ab6aa39-7cb2-46e1-8fb1-2657f4ad4290">84,416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNS0zLTEtMS0w_5a0871a3-a49f-44a5-97a1-2696bbf1479e">51,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNi0xLTEtMS0w_5c1a92c0-7662-43ca-9a6a-9dd1e71ceb52">7,753</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNi0zLTEtMS0w_3532462f-c6cc-4dee-b83e-06c0a99dace7">8,601</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNy0xLTEtMS0w_82eda87c-00c9-4f17-9df3-38b4522c6a86">11,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNy0zLTEtMS0w_ec5211ae-6caf-4bdf-9b1b-e855a1c62c7b">10,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfOC0xLTEtMS0w_b72c6f0f-914b-4293-b0f9-f876d5ae17ef">3,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfOC0zLTEtMS0w_1228093b-f2a9-490e-932a-1b3b7867ae04">2,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfOS0xLTEtMS0w_f8c8459a-a292-4afa-a993-aaf9d7b66fc3">181,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfOS0zLTEtMS0w_ae5f7b48-8514-4d83-baba-8b47934e1090">112,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTAtMS0xLTEtMA_7dedbd2c-6c79-4c7f-8097-5d55a83cc1e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTAtMy0xLTEtMA_3a5b3c13-451f-444f-ba6a-02d81b7650b1">18,224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTEtMS0xLTEtMA_3a4bbd54-5641-4418-b290-3afe7c2fad37">2,885</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTEtMy0xLTEtMA_59f81b49-fb4c-4c14-8382-02418a22aff4">2,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTItMS0xLTEtMA_a65b476e-f242-44b6-9f6d-60da47584f20">310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTItMy0xLTEtMA_06b51ac1-794e-4f02-8cfa-b5494fcedccc">310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTMtMS0xLTEtMA_b7e8d3be-fe6e-4438-bcb4-b39d1f8640f8">3,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTMtMy0xLTEtMA_742c1466-5609-410d-bb88-cdd6d7dcb669">3,644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTQtMS0xLTEtMA_bc4cf2a3-8cf9-4fdb-af3c-40973ec53877">187,523</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTQtMy0xLTEtMA_793a0628-1209-4ffd-8934-c20288334e02">137,402</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTctMS0xLTEtMA_7aa3f907-d44a-4311-a5f4-841f33b864e2">2,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTctMy0xLTEtMA_9d129dfa-2595-4af8-a26f-e45c38eae182">1,898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTgtMS0xLTEtMA_ef54f71a-08fe-49ac-839c-8fd1e734ac27">9,142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTgtMy0xLTEtMA_f2bf8ccf-472c-4a11-bd74-11932032be89">15,034</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTktMS0xLTEtMA_13cc2aa5-400f-4f3d-90d1-14c8386e3b91">11,684</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTktMy0xLTEtMA_bb481926-bac8-446e-9175-7ecd4ad2083d">16,932</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjAtMS0xLTEtMA_d937f305-47fd-4d6f-badf-90c838129f03">45,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjAtMy0xLTEtMA_d3f90005-200e-4c5b-ad9e-7bd9a9dc03e8">44,879</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjEtMS0xLTEtMA_2c0f9d26-6b65-43c7-b04b-6977522ba3ac">3,693</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjEtMy0xLTEtMA_e9648d80-5f04-438a-afee-3b1b96e2fa25">3,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjItMS0xLTEtMA_6c2c89c8-6e45-4280-8161-38839142d026">60,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjItMy0xLTEtMA_a0a754a7-58e4-456b-bbda-5e0f9a0d7c87">65,511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjMtMS0xLTEtMA_d55aa532-1429-4335-be85-c009991a78e7"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjMtMy0xLTEtMA_d21cf64f-d831-4190-aa40-1ced172687c5"></ix:nonFraction></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmFjZmQ1NDM3OWMzMDRkMTFiMjAyMGRkNDhmNGNhMmJmXzIx_59aae767-2a0b-4eab-87a5-970b2287134b"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmFjZmQ1NDM3OWMzMDRkMTFiMjAyMGRkNDhmNGNhMmJmXzIx_ef418542-1ffe-4dda-ac25-bdb60b5e5d72">0.001</ix:nonFraction></ix:nonFraction> par value</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Shares authorized: <ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmJlYjM0YWUxOTQ3NTQ0ODhiOTQxN2RmZGJmZDIyNDE3XzIz_374e364d-364d-48f9-ac7c-ef2f4644bdea"><ix:nonFraction unitRef="shares" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmJlYjM0YWUxOTQ3NTQ0ODhiOTQxN2RmZGJmZDIyNDE3XzIz_9b9c4546-b2b5-476f-8666-7cffeb49ea2b">5,000,000</ix:nonFraction></ix:nonFraction> at June&#160;30, 2020 and December&#160;31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Shares issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjg3YjExNzlhNDhjZjQ0OGRiMTRhOGI2NmFmNmFjYjQ5XzM1_25764e43-6af3-4881-ba76-f5e24bdcbdce"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjg3YjExNzlhNDhjZjQ0OGRiMTRhOGI2NmFmNmFjYjQ5XzM1_9a74e809-1fc8-44a4-aa86-714a654f74c8"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjg3YjExNzlhNDhjZjQ0OGRiMTRhOGI2NmFmNmFjYjQ5XzM1_a8330323-bee1-4304-8393-5c525197a16f"><ix:nonFraction unitRef="shares" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjg3YjExNzlhNDhjZjQ0OGRiMTRhOGI2NmFmNmFjYjQ5XzM1_b069c124-288b-468d-862e-34ce223ef6ce">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMS0xLTEtMA_f7bdbb00-ad76-4ca5-81f8-22db58ac18e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMy0xLTEtMA_22591c2b-ab1a-4d37-9a45-181e31760835">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZjOGQ5OWRmYzQ2YzRhMDA5ZjNkNDhkYjgyNTMyYjU2XzE4_13b88fb4-6921-4d07-a637-ad224662655a"><ix:nonFraction unitRef="usdPerShare" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZjOGQ5OWRmYzQ2YzRhMDA5ZjNkNDhkYjgyNTMyYjU2XzE4_92191fca-eaa9-4f6b-b838-ead533c3d61b">0.001</ix:nonFraction></ix:nonFraction> par value </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Shares authorized: <ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmM1YTQyNzhhMmQ4NDRjMzRiY2ZhNmY2NjE0MTdjOWE1XzIz_19954524-4d8b-41b6-aa5f-b9a7e6493c3b"><ix:nonFraction unitRef="shares" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmM1YTQyNzhhMmQ4NDRjMzRiY2ZhNmY2NjE0MTdjOWE1XzIz_73fc58ed-01f0-45ba-b3a1-2b805555120e">100,000,000</ix:nonFraction></ix:nonFraction> at June&#160;30, 2020 and December&#160;31, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Shares issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjNkZWJhMTY3NDNlMDQyZDM4ZjRkYmQ1YTkwYzBmOGZmXzM1_b8ae431b-8a22-4cc2-8ce3-e3833fad1d0b"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjNkZWJhMTY3NDNlMDQyZDM4ZjRkYmQ1YTkwYzBmOGZmXzM1_dd3f075e-1bec-4866-9098-0e4877144e18">33,610,099</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjNkZWJhMTY3NDNlMDQyZDM4ZjRkYmQ1YTkwYzBmOGZmXzQy_757fd9b9-b743-4e26-aa26-3bcb8baebd54"><ix:nonFraction unitRef="shares" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjNkZWJhMTY3NDNlMDQyZDM4ZjRkYmQ1YTkwYzBmOGZmXzQy_c5a43e60-94fb-445a-98e6-52b25afea177">31,255,267</ix:nonFraction></ix:nonFraction> at June&#160;30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMS0xLTEtMA_280528ba-9783-4e93-8b1d-93ab6f3200f0">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMy0xLTEtMA_f0717659-b28c-4c9f-be85-10e177c056ca">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzEtMS0xLTEtMA_5cdf1255-a583-4359-ab2d-e980fbad1b9e">338,550</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzEtMy0xLTEtMA_ea024362-b815-4856-a255-573c2dca6ce7">263,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzItMS0xLTEtMA_217658d0-e2e7-4f51-b02b-86e5b674439f">316</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzItMy0xLTEtMA_eafd1b31-942c-4b65-85aa-20f98f2965bb">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzMtMS0xLTEtMA_e5e0c414-cbb6-433e-9891-2a1ae1d62daa">211,820</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzMtMy0xLTEtMA_4a911af3-3e27-466e-934b-070db7f2e57e">191,526</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzQtMS0xLTEtMA_de0d7fcd-51ad-4355-abee-a895ff41ef59">127,080</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzQtMy0xLTEtMA_94d4bf0c-e3f5-40be-bc12-6dd6306951a6">71,891</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzUtMS0xLTEtMA_6f596b22-a6ea-4560-9f38-e9182f0ced02">187,523</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzUtMy0xLTEtMA_0aa855f5-941a-4658-bca4-64bb35c122ef">137,402</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Condensed Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:35.420%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.127%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.436%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.127%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.436%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.127%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.131%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except share and per share data)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMy0xLTEtMS0zNTk_fac33f3f-97d3-4a7d-8fa9-e1cf8927fbac">15,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMy0zLTEtMS0zNTk_2c7b815d-3743-4ebb-b2e2-7b1074d7ee09">14,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMy0xLTEtMS0w_ca1155bc-e573-441f-89da-4795a950e457">34,027</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMy0zLTEtMS0w_8cf52d02-0934-431b-9bc2-3e465ecfdc4b">27,694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNC0xLTEtMS0zNTk_79fe1d92-59d4-4101-a0b1-644036664f5d">5,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNC0zLTEtMS0zNTk_d9ac9817-4a30-4b7a-ada3-ce736d77e06c">3,697</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNC0xLTEtMS0w_c01fa4b5-7ddb-4833-af5a-c2ae0acba5e3">10,586</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNC0zLTEtMS0w_f7cbd8d2-e7c8-4cd2-9cd6-945717648486">7,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross profit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNS0xLTEtMS0zNTk_bf9b8f6c-b55b-488e-8c55-63b602bd0b06">9,758</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNS0zLTEtMS0zNTk_8a20956b-8513-4cd4-99bd-0346deee8d2e">11,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNS0xLTEtMS0w_dafbd3ba-be5d-431f-a075-6f0ba2d14a88">23,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNS0zLTEtMS0w_63e2f673-ec3d-4e6a-8d9a-0e4ac0f5af5c">20,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNy0xLTEtMS0zNTk_64565220-d7f9-4429-9833-ec368fb13734">3,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNy0zLTEtMS0zNTk_db6e034a-184a-4eac-996f-01a0da5dc780">3,113</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNy0xLTEtMS0w_ec45b880-6056-442e-bd5a-843d762dec5e">6,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNy0zLTEtMS0w_eef3baf9-51ab-407b-8239-fa8cc80c3c77">5,820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOC0xLTEtMS0zNTk_1ae0b858-7a85-4295-a78b-7192e79ba511">15,758</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOC0zLTEtMS0zNTk_7e9bdf4f-73df-4582-ac25-627710e6b44d">14,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOC0xLTEtMS0w_195af06b-969a-487d-82f7-e86720c375d3">35,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOC0zLTEtMS0w_241acc7a-1ca1-43ef-9088-132082a6f0df">28,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOS0xLTEtMS0zNTk_3e77edd4-3b9f-4600-9326-9b86413c5989">19,151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOS0zLTEtMS0zNTk_a6fd7715-6416-43f0-9915-ac50b7e423a3">17,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOS0xLTEtMS0w_b4ffdcde-2f0f-40e3-afd6-739298db0a3e">41,972</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOS0zLTEtMS0w_47d63aeb-d500-4668-b352-e9b0319a2804">33,821</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTAtMS0xLTEtMzU5_5e5fdc69-c23a-48d6-8dfa-1b7d79d4b797">9,393</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTAtMy0xLTEtMzU5_31dc5b4f-a442-4927-99f7-40c21147378a">6,017</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTAtMS0xLTEtMA_cbfad264-db50-4092-a0b4-673732c9b1cf">18,531</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTAtMy0xLTEtMA_c8fef88c-0f44-459a-bed6-94f556a88d35">13,162</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTEtMS0xLTEtMzU5_398606ef-994f-47b2-8564-e000daba7144">299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTEtMy0xLTEtMzU5_fc5bd795-58a4-4e86-8cbb-610b25a704f0">598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTEtMS0xLTEtMA_a5c9eca5-b0c4-4422-bc4a-662984f0c8f3">702</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTEtMy0xLTEtMA_9fd82cc0-bcc1-4457-a362-8888240fc62d">650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTItMS0xLTEtMzU5_a1bdac6e-d29d-4dfb-b805-6cad3dafc01c">1,203</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTItMy0xLTEtMzU5_f6617e8b-9fd5-440a-aa62-d8d825d36412">1,207</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTItMS0xLTEtMA_c40abeb5-8c9e-466d-927b-1187b0f8f93f">2,406</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTItMy0xLTEtMA_7ab5f935-c27b-47e3-b155-c2c0acd9c3c5">2,560</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTMtMS0xLTEtMzU5_ad00b052-1dad-4769-9b37-e005e7c5f6eb">56</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTMtMy0xLTEtMzU5_b74c1291-35fb-4c0f-b2c6-73e1a842e22a">5,333</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTMtMS0xLTEtMA_d608921e-e65a-42df-963f-3b81f4a09cfa">59</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTMtMy0xLTEtMA_d71788c7-e98b-4675-b857-2a0146d4ad96">21,045</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTQtMS0xLTEtMzU5_1f86bd9a-5c3c-48d0-9a5b-1564cf64c564">10,353</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTQtMy0xLTEtMzU5_66ec344f-c2d9-4bd1-8a09-f005bdc7721f">11,959</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTQtMS0xLTEtMA_25dc7e5b-66d8-4f22-ba75-dd5d034ce8fd">20,294</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTQtMy0xLTEtMA_272518d4-b292-44e7-90d1-7f340e11c298">36,117</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain (loss) on investments, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTYtMS0xLTEtMzU5_0ea2112f-c9dc-4137-a250-fbe9d57907ab">126</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTYtMy0xLTEtMzU5_eafd44ed-6de9-45c2-94cc-c6d8aef7795c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTYtMS0xLTEtMA_5e5dbad0-aad7-4528-a02b-ee0023ec07b5">314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTYtMy0xLTEtMA_a155737d-0df9-48c5-8b31-20801a5a5460">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTctMS0xLTEtMzU5_938f259a-4ff6-4426-b700-4ac2839c4fc2">126</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTctMy0xLTEtMzU5_259409a8-eb20-400f-9e18-307e43609d8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTctMS0xLTEtMA_2decf19c-43ab-4727-b85c-f13fd274a38c">314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTctMy0xLTEtMA_fe8f0700-1abe-4cf4-b393-ef9a8cffa586">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTgtMS0xLTEtMzU5_d3238122-de73-46e8-ac7d-e103dc3ccf11">10,479</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTgtMy0xLTEtMzU5_d8c4141d-578f-4049-9114-9e5828c842b0">11,959</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTgtMS0xLTEtMA_d2af5e85-2c96-4c20-aa28-6434acfbffab">19,980</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTgtMy0xLTEtMA_a946c601-bfc8-4b79-bb7d-bf9f60e87652">36,117</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTktMS0xLTEtMzU5_08d73136-b8b4-4053-b927-e3fc1776c45f">0.32</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTktMy0xLTEtMzU5_6b04ec3f-befb-4600-a7c8-5e69f8136b58">0.42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTktMS0xLTEtMA_acf52adb-5081-49b5-b2f1-836ba229baba">0.63</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTktMy0xLTEtMA_b97ca1ac-0934-4b3e-9c1d-48273aa803f0">2.42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares used to compute net loss per share, basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMjAtMS0xLTEtMzU5_4957e866-d4c8-415b-ac1b-4f1ad5e31c4e">32,682,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMjAtMy0xLTEtMzU5_8262d080-25dc-4da9-95c0-1fbd791c386c">28,458,793</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMjAtMS0xLTEtMA_a5de77f0-5a6f-4b9d-81ab-494eb987089e">32,010,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMjAtMy0xLTEtMA_5a1ce8c1-8d5b-4a7f-b638-eac29a791734">14,905,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:97.222%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.074%;"><tr><td style="width:1.0%;"></td><td style="width:42.275%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.294%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.267%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.593%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.267%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.228%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.267%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.995%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.267%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.397%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.267%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.883%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except share data)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Balances at December 31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie9e3e7e58fd643a9b81d6acc10d20212_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi0xLTEtMS0w_c2167fe2-2e74-48ce-86cc-c686b6e4e8bb">31,255,267</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9e3e7e58fd643a9b81d6acc10d20212_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi0zLTEtMS0w_7e84d80a-5554-47a9-8895-0dbee680ca02">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01edde7dedb544328d6997373cf6ad4a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi01LTEtMS0w_033ab2c1-87b0-4762-b3db-458c24ab86d6">263,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia02f7ba2764646e98fe313a3f6b45aff_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi03LTEtMS0w_e22cf88f-c840-40a3-9fff-ac73252c3c16">191,526</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0efec5d2df54499d877b5b7f2c50296e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi05LTEtMS0w_1fb323d6-ba22-4db9-99ba-892b8ae789fe">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi0xMS0xLTEtMA_2de11fca-9363-4a4a-9315-00c430040801">71,891</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i63b35b01b32f46f2bee4f4a23b7012a2_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMy0xLTEtMS0w_0ee6b361-4fc6-4cd4-a5e2-52f24f333402">140,370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia98288daaa954dd1875ff62ad62c8371_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMy01LTEtMS0w_a89442d2-5988-4260-a7ae-564b972354be">274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412e80de80294636915c387579e51a98_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMy0xMS0xLTEtMA_090022b8-e98d-4d1f-a87e-8c500becf6c0">274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia98288daaa954dd1875ff62ad62c8371_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNC01LTEtMS0w_4dc934f9-bf17-4884-a42b-3a8c2c6c0f33">1,293</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412e80de80294636915c387579e51a98_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNC0xMS0xLTEtMA_2643fc60-1771-43be-b1ca-7a945f5c0101">1,293</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2813994ece5044d3b7db1695fbd0eb1f_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNS03LTEtMS0w_eefedd8a-e86d-4a06-b38c-bc262eda964c">9,941</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412e80de80294636915c387579e51a98_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNS0xMS0xLTEtMA_da16e683-c478-499b-9394-e78dc97f9514">9,941</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Unrealized gain on investments, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i893baa7990094d9996aef955612bf12c_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNi05LTEtMS0w_0edc470e-373d-4204-9513-802221f57b1a">440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412e80de80294636915c387579e51a98_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNi0xMS0xLTEtMA_4af319ba-b688-4610-adc8-5d24a60a6105">440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Balances at March 31, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if97360d0e3024fcd99b7a9761e90b309_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy0xLTEtMS0w_8188426d-7f6b-4aa5-99f1-08526aceb40b">31,395,637</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if97360d0e3024fcd99b7a9761e90b309_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy0zLTEtMS0w_e21edf4a-1b86-4d91-b542-0d544260da6e">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad155abbc9754495b06722da098ba394_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy01LTEtMS0w_b64e59ad-3c88-4aa3-92f8-1512b0761269">264,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9b44a6c1a4d7438a86dff3e0e151961a_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy03LTEtMS0w_ffe8c84c-5486-439c-9ec6-5c8886b5de3d">201,467</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i250d8d2fc5a44833b091f0a0021c1f1f_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy05LTEtMS0w_efac4f46-11e8-49f1-8013-4b65913edeb9">442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa53cd55d6d640ff87711fd4e0f8ef56_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy0xMS0xLTEtMA_44957733-8b75-4c74-b0f0-e907bf540d52">63,957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock in connection with public offering, net of underwriting discount, commissions and offering costs of $<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0wLTEtMS0zMDE1L3RleHRyZWdpb246OWVmN2VmMTNmYzYyNGJiN2EwODQxM2I2M2M3ZDIwZjZfMTA5OTUxMTYyNzkxNw_9e0aa8a4-bae3-4506-816a-da9c909e0ed9">4,457</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8d433da600ff424d9072d74a4800426b_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0xLTEtMS01OTM_68a3ae1a-893e-47ad-94ca-dad9bea1e2ce">1,923,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d433da600ff424d9072d74a4800426b_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0zLTEtMS01OTM_40b71db7-5ee0-451b-ba58-dae2eaf53a53">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71269ca1bb0048df93fdfb7f60583aca_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC01LTEtMS01OTM_cb5cbdc9-656b-4d30-8c0f-0d2c84a98b2b">70,541</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f1ba60825d14c648abad9bad89c5116_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0xMS0xLTEtNTg3_68ab7845-c619-4bb7-83d4-2550f401334c">70,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if5c4b78f734744bb9a7efbc2c9838e21_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0xLTEtMS00NA_8c622d08-be96-4015-9669-39b1d3fb3bb1">265,467</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5c4b78f734744bb9a7efbc2c9838e21_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0zLTEtMS00NA_e1089268-6f51-4b01-99dd-cebc84eef36f">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01cbace60dde45c3b3e3b6d6de1dc3cb_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC01LTEtMS00NA_73ba2a09-d946-4cb1-be0a-81f9262ed100">603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0xMS0xLTEtNDQ_d41b1e11-935b-48f7-bc49-e00f2f90169c">604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if5c4b78f734744bb9a7efbc2c9838e21_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtMS0xLTEtNTkz_d7691bdf-c76f-46fd-a1d7-617b09a351a3">25,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01cbace60dde45c3b3e3b6d6de1dc3cb_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtNS0xLTEtNTkz_a8914bb8-97da-44f7-a7f5-4e819a54fb14">801</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtMTEtMS0xLTU4Nw_a61502aa-2ae2-4e85-a2f2-715c3c2f4936">801</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01cbace60dde45c3b3e3b6d6de1dc3cb_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOS01LTEtMS00NA_97f66e3d-f6ee-45ad-95f2-fa0eda84ba4c">1,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOS0xMS0xLTEtNDQ_d3b7c667-778f-44c6-a5da-f70b07159bd7">1,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5abe689d4c9b45d590e6081f66e9d892_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtNy0xLTEtNDQ_ef82c480-528c-4f61-a30e-481b6aac6139">10,353</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtMTEtMS0xLTQ0_458e91c0-1d4e-44d0-932a-047069ded363">10,353</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized loss on investments, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i95e493ed76734fa9b072ff4c78d00454_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTEtOS0xLTEtNDQ_235b5aea-764c-4540-b28d-432c4f0dbd5b">126</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTEtMTEtMS0xLTQ0_1acdc813-eea5-4c6c-a305-bb9d6507a745">126</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Balances at June 30, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iba95761be90e4d0b871436b1bc3e613f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItMS0xLTEtNDQ_3e098de5-ac37-4e15-b9c4-4a0894a69975">33,610,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba95761be90e4d0b871436b1bc3e613f_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItMy0xLTEtNDQ_915933cd-5a05-45a3-9db1-f28de9332825">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie87ca05332314ce38d1c838f1918033d_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItNS0xLTEtNDQ_579eb07e-fd95-4a2a-9323-eec5ec36907b">338,550</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if195c2966bd4478b9a536e42c4729969_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItNy0xLTEtNDQ_9a927162-4ba4-44d4-a442-dd1fa8110c4c">211,820</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i267c658bb1a64c4cb3087e17e6ba0504_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItOS0xLTEtNDQ_725d0638-36ee-4167-8124-099678b565f0">316</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItMTEtMS0xLTQ0_ea814cc8-cfeb-494d-9010-677e53978183">127,080</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:97.222%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.652%;"><tr><td style="width:1.0%;"></td><td style="width:24.829%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.710%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.264%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.549%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.264%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.264%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.246%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.380%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.549%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.264%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.175%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.264%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.943%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.264%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.336%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.264%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.835%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except share data)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable Convertible<br/>Preferred Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xLTEtMS0w_174a386e-1bbc-4990-be6d-d1c78793d3af">21,233,190</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0zLTEtMS0w_02753622-0e8e-49b9-a2c6-06e9c7c4500a"><ix:nonFraction unitRef="usd" contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0zLTEtMS0w_d14488d4-7182-49fb-9fd0-7aeac235ffff">105,235</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i44fb74c77caa45feb1b93e73036b664d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi02LTEtMS0w_ac38ea50-dc71-4ab3-a92f-90e0ec626122">1,135,310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44fb74c77caa45feb1b93e73036b664d_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi04LTEtMS0w_7bf34633-3849-4405-bac3-a1b817ffbe78">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97f3122f97654386982663f091f8be2a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xMC0xLTEtMA_4affc8e6-4896-47e7-aaea-dd6b3ed34313">4,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i18115e334dfb4939bf22d7f51604a743_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xMi0xLTEtMA_2f21c417-2c1d-4992-b72e-3bf373b6fb8d">139,111</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2974baeced5b42539df2ce7e5d9fd970_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xNC0xLTEtMA_61eab91f-b3a4-4490-af00-51ed5f64fa5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xNi0xLTEtMA_1604fc90-dc16-4fff-934b-79b17c42f710">134,553</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of Series C preferred stock warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMy0xLTEtMS0w_310340f5-ba5d-4ca1-b6b2-992ead130806">4,915</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMy0zLTEtMS0w_f78e2714-d762-4ace-9125-4e4323c48851">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia013b4eb40114308be33eb29a813111d_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNC02LTEtMS0w_b597fca7-f7d2-42d8-b50d-bf10794a2dac">251,305</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b16f07a785142d7af5301cf48c4d820_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNC0xMC0xLTEtMA_aa28af89-45ab-443e-8132-17d8aeec7092">375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNC0xNi0xLTEtMA_15b09f95-239d-479d-a1cd-c48c453b63f0">375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b16f07a785142d7af5301cf48c4d820_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNS0xMC0xLTEtMA_2ed296e7-95bb-459a-9fe2-bd776983236c">262</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNS0xNi0xLTEtMA_b95d0e05-d8c5-4d7c-84a0-6c709385aaeb">262</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Net loss and comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4fa337a09be04535b922d4ff23c908d4_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNi0xMi0xLTEtMA_5caaa073-07d1-4ccb-b155-cd65f582802b"><ix:nonFraction unitRef="usd" contextRef="i4fa337a09be04535b922d4ff23c908d4_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNi0xMi0xLTEtMA_c81cec6f-5d3d-4b19-aa75-1591c79c2fae">24,158</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNi0xNi0xLTEtMA_3b48794c-199b-4668-9f09-cd295e2ff7b4"><ix:nonFraction unitRef="usd" contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNi0xNi0xLTEtMA_6c31c829-b1bd-45a9-a1c0-44dc2f4c0c72">24,158</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Balances at March 31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib2b2a6a89c1143b79a1fde2400691f14_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xLTEtMS0w_1004ecfc-a8b3-41e2-96bc-6cccc2ba8428">21,238,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2b2a6a89c1143b79a1fde2400691f14_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0zLTEtMS0w_ed4659a1-784a-4743-92af-240207d3fca1">105,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9fd18f4a372d4ab3bbe21e94964f88b0_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy02LTEtMS0w_3177a640-0d50-4b00-86b4-da7b77dc1c3b">1,386,615</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fd18f4a372d4ab3bbe21e94964f88b0_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy04LTEtMS0w_94886cc6-b38d-40d6-9dd8-f616162a6201">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35d13e334d474ffca707c39e945c4b18_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xMC0xLTEtMA_1e41ed29-e330-4ceb-aba6-d5a09ba0e2ac">5,194</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i042388ebf8da4a30880f8f9e5c039e53_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xMi0xLTEtMA_dec7aa45-5640-4caf-af15-ac41e3c7d4ca">163,269</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c6892eaf5054997bc5db44ea630d3b8_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xNC0xLTEtMA_b5e163e7-8dee-4dcb-8c2c-3cbe6cf08136">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib2b2a6a89c1143b79a1fde2400691f14_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xNi0xLTEtMA_3879811f-b8ca-4a79-a1f9-066cbce8af5b">158,074</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of Series C preferred stock warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOC0xLTEtMS01NA_cec4a785-b52d-4b4a-809f-4e05d5de801b">287,446</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOC0zLTEtMS01NA_5105fa7b-0061-4d67-a30e-d3f4c5e3ebc5">1,754</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of common stock warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id2e3b1c19991473a9eda55c27b7a6352_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS02LTEtMS02MzI_fde20aab-51b9-4aa8-88be-861d13400112">3,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i857c634bdb34432c8b74d2c01c998fde_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS0xMC0xLTEtNjMy_49905adb-881a-41ea-90d6-5f75bc8ef710">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS0xNi0xLTEtNjM4_03559c94-e6d1-4091-8104-3ec08eef6a4e">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock in IPO, net of underwriting discount, commissions and offering costs of $<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMC0xLTEtMzAwMS90ZXh0cmVnaW9uOjFmYTU5NTNlODM1MjRlNDNhNzRjOTc4N2UwY2ViYzg4XzEwOTk1MTE2Mjc4OTQ_e7090daf-c230-410f-b1c8-e4a6210b202a">10,961</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtNi0xLTEtNjMy_d3f4e421-ef63-4fbe-9ddc-643cff5e2bca">6,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtOC0xLTEtNjMy_e0385237-9a66-412c-bd2e-ed12f6e39727">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d224a2b66764827814bf9c8f036c6fd_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMTAtMS0xLTYzMg_9d0b5b0e-4332-4698-95b4-59b7b61472f1">109,033</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMTYtMS0xLTYzOA_cba5cc84-f247-407e-b10e-58e4d162ec5c">109,039</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMS0xLTEtNjI2_aa2a360b-cb7f-484a-9544-d731f1e271d1">23,178,555</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMy0xLTEtNjI2_362574e3-5851-4413-9423-1a2deb57eccf">144,140</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtNi0xLTEtNjMy_ed1cd11f-fd76-40cb-ba42-358dd975e841">23,178,555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtOC0xLTEtNjMy_d7414fe0-2949-45ce-aa34-65266bba87d5">23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d224a2b66764827814bf9c8f036c6fd_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTAtMS0xLTYzMg_b466dcd6-6bc2-4e09-86a9-ba13edce9702">144,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTYtMS0xLTYzOA_d1cfe018-94b6-4f6d-9010-16569f14b29e">144,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net exercise of Series C preferred stock warrants in connection with IPO</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMS0xLTEtNjI2_6d24ecea-b379-4afc-9ff6-fae90de383c3">1,653,004</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMy0xLTEtNjI2_d97c941e-3405-41d9-ae55-39f60a7eac1c">37,121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net exercise of common stock warrants in connection with IPO</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTMtNi0xLTEtNjMy_8058499f-9d4c-4d7d-b748-e52740d2ca36">2,204</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id2e3b1c19991473a9eda55c27b7a6352_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS02LTEtMS01NA_7de7c58a-bb8b-415e-80b2-73cd80ed4bdd">176,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2e3b1c19991473a9eda55c27b7a6352_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS04LTEtMS01NA_ea3729da-f817-487a-aebf-55d1ebfebaf3">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i857c634bdb34432c8b74d2c01c998fde_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS0xMC0xLTEtNTQ_c159cf20-1b7f-4198-8015-e8e446a3ef88">363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS0xNi0xLTEtNTQ_b793e2e7-cd97-41e6-9727-d3048341232a">364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i857c634bdb34432c8b74d2c01c998fde_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMTAtMS0xLTU0_9d310b01-e9e1-4101-9f1f-d5cc50856a57">836</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMTYtMS0xLTU0_5aa97a02-41f4-4380-9ba7-92dddadff903">836</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb63e8b0926842298836b1c7a48b5ad7_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTItMS0xLTU0_881b3e7b-165c-418b-a634-422e599b18ba"><ix:nonFraction unitRef="usd" contextRef="ieb63e8b0926842298836b1c7a48b5ad7_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTItMS0xLTU0_8b1600ba-7d16-48ea-bbcc-737193cf9837">11,959</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTYtMS0xLTU0_aca65261-f892-4ca0-a563-81fb8fcdb222"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTYtMS0xLTU0_cbacc542-5632-4590-8781-ed70f3b42f54">11,959</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Balances at June 30, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7e86f21e817747e1b323fa24e138daa7_I20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMS0xLTEtNTQ_e86e21c2-ef1b-4643-bedd-981d603a32f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e86f21e817747e1b323fa24e138daa7_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMy0xLTEtNTQ_f986d528-b127-47e0-b7c5-1ae06669a8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i907247d422b04c4daa972b713b2650e5_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItNi0xLTEtNTQ_609c1d3a-a195-4568-adf0-35221d1a35e0">30,747,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i907247d422b04c4daa972b713b2650e5_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItOC0xLTEtNTQ_0c5a58e7-cb80-4596-948a-fb221a2e794e">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8771181b78740329cdb8290b99f0331_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMTAtMS0xLTU0_67b2f636-9a61-4590-bc34-7ee7271f8de9">259,574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b36e442f3114a22ba850f63b846e6f4_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMTItMS0xLTU0_04973859-1ac8-40b3-99e4-8ccbbb2d9677">175,228</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bdf7b91752347eb8ff1ad32bb419fc9_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMTQtMS0xLTU0_81659f6b-ae71-4d7d-9b41-e6e2fb460540">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e86f21e817747e1b323fa24e138daa7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMTYtMS0xLTU0_c1fe5ba2-a8fd-4ceb-9173-633cb1d95712">84,377</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Condensed Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:65.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.384%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.386%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMy0xLTEtMS0w_01462749-945b-4c5a-a1c6-ad9ea8748894">20,294</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMy0zLTEtMS0w_670cdcc9-f268-4d41-8f45-7a5d73cbf661">36,117</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNS0xLTEtMS0w_b0745ddf-0e47-4bf2-9775-18f0a5d6a6a6">368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNS0zLTEtMS0w_29e4fc95-82e0-49c4-86e0-0d6c139d050b">350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNi0xLTEtMS0w_60b6dc3a-75af-45d5-b7f4-587dcec212a9">2,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNi0zLTEtMS0w_5969a341-4332-4ac7-be9a-9ede21a73e52">1,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of redeemable convertible preferred stock warrant liability</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNy0xLTEtMS0w_9bb07b4e-be47-4764-8744-c42654d18706">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNy0zLTEtMS0w_a1a07634-13c4-4d07-847f-ebcada0ef295">21,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of premiums (accretion of discounts) on investments, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfOC0xLTEtMS0w_caae7c0d-5616-43a8-bbf0-eedbbf427ade">57</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfOC0zLTEtMS0w_dd33d3fe-1cac-4b07-a1fc-00eb8ef66817">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfOS0xLTEtMS0w_d88ad6dc-1b80-4d25-bb0d-ff30702692a2">23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfOS0zLTEtMS0w_bfa1f0ca-3946-4d6f-b839-2fa084f1a96d">22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of right-of-use asset</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="silk:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTAtMS0xLTEtMA_d16dcd56-dae1-4a22-a194-f0788e505a8d">295</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="silk:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTAtMy0xLTEtMA_007d15d6-c596-4b94-9d83-58e0e44a241d">300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash interest expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTEtMS0xLTEtMA_83a35479-5ef4-44c8-b68f-90597e2c4e16">167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTEtMy0xLTEtMA_6a3e768c-c126-4216-ac4a-698cf9bde85e">555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on disposal of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTItMi0xLTEtNjkw_b0c36ff0-e83c-4f18-a5ec-f9915d8c6bdf">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTItNC0xLTEtNjkw_4d48e627-0718-41de-8492-4598e0c5e470">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in provision for doubtful accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTItMS0xLTEtMA_526e27ef-1ba8-43db-9178-2769de512b13">9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTItMy0xLTEtMA_03295a3e-c0ff-4eab-8fdd-0f12b291d452">123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for excess and obsolete inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTMtMS0xLTEtMA_f0a4150b-8896-4464-8db7-69695650e699">105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTMtMy0xLTEtMA_51eda68c-27da-48a8-be48-8f52b987e23e">43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTUtMS0xLTEtMA_a9b675d5-38ff-404d-bc3e-4bbaa3b7cbb7">857</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTUtMy0xLTEtMA_46fb17ec-44f4-4c3e-bbb6-bf47b246e96d">1,622</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTYtMS0xLTEtMA_e4cf59cd-c200-4f8c-bdd2-c6bcd2d7a167">1,404</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTYtMy0xLTEtMA_54efdff1-fb1c-4a97-8086-8927e83a4167">3,262</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTctMS0xLTEtMA_914cfc2b-ad01-44d4-88be-dd65723bac31">986</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTctMy0xLTEtMA_2da32777-993a-4d7a-91a2-f7f8254eb8a3">1,841</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTgtMS0xLTEtMA_e7d12ec8-2157-42d0-8646-28f694cfde66">117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTgtMy0xLTEtMA_a61a8fa0-84d6-45ce-a431-ca1786a0de50">756</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTktMS0xLTEtMA_1795f788-3e68-4698-8f1f-c744d3b240f6">262</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTktMy0xLTEtMA_5b541a2c-a064-4189-9873-775ff41d22a8">45</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjAtMS0xLTEtMA_b1bbec7e-b5bb-4182-9936-dbed4dc22874">5,925</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjAtMy0xLTEtMA_15b5e029-161b-439e-a8ff-69c74d9ced18">978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjEtMS0xLTEtMA_79034843-d35d-48c1-801f-9208002f1ea2">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjEtMy0xLTEtMA_48c53bfe-f835-4d78-8959-9c494a33f444">372</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:47.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjItMS0xLTEtMA_bfcac4f6-0653-4427-9848-3c9c5436547c">23,376</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjItMy0xLTEtMA_750cd500-2f7e-45a4-8031-a4470f0c1da8">18,003</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjUtMS0xLTEtMA_b153c0c1-3da6-4cfb-a11f-009d625412ba">479</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjUtMy0xLTEtMA_32c2c29f-3396-4fe8-913e-476eae33a1ba">206</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjctMS0xLTEtMA_6f4ea492-4d16-4326-b026-f100b7e91911">23,606</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjctMy0xLTEtMA_73d83156-ddab-4813-95c1-f97517a7d764">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturity of investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjgtMS0xLTEtMA_248a2d61-3403-4d21-a238-9929db8573ae">9,180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjgtMy0xLTEtMA_89f3a2b4-1764-458b-b50e-f5ca6c4d9667">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:47.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjktMS0xLTEtMA_32455115-dcce-4011-8769-ce57e40d1079">14,905</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjktMy0xLTEtMA_bde4f2e5-b6fd-4745-bc27-d6863afe7fb5">206</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzMtMS0xLTEtMA_72ce8d33-9cd4-4239-86a1-5b62df86bd81">70,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzMtMy0xLTEtMA_dd875787-9c26-459d-8f02-bdf94ce6ef03">108,913</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzQtMS0xLTEtMA_6a583ebf-9b15-48f5-a1ff-de1f9af2dd64">1,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzQtMy0xLTEtMA_5e856e4e-d1db-4d33-b321-ada863f2c62b">738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of redeemable convertible preferred stock warrants</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9634e8ac71464a7c94802f90d75471fa_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzUtMS0xLTEtMA_55008034-527b-492f-95e3-65a374e973ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7239974596a4a39bd1824a432c2fd56_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzUtMy0xLTEtMA_b005162e-ac85-4aa8-b5be-5d3aef232b82">1,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i57ad5239b3db46d4ad0d92c5293e2141_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzYtNS0xLTEtOTM_f468ad78-6486-4bfe-80e2-446c5a71fda2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05076e6e126f4a39a7b296a201b34ff2_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzYtNy0xLTEtOTM_50550219-d789-4e72-8ce9-709001627689">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:47.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzgtMS0xLTEtMA_7924cb8b-a460-4c3f-aac0-b95ecf99e17a">72,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzgtMy0xLTEtMA_b593b978-58e9-4271-8a79-70c8f8c0ee17">111,466</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzktMS0xLTEtMA_4f8fc6d0-c3f0-4291-a99a-84d2d48f6605">34,261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzktMy0xLTEtMA_e554b2bf-01af-437c-8abb-c3dbe345223b">93,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDAtMS0xLTEtMA_996b29fc-2337-46ed-ac69-1b6a541c49d9">39,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDAtMy0xLTEtMA_8c325910-1485-492d-9626-2008e7899ab7">25,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDEtMS0xLTEtMA_8681a4fd-9d21-42b6-b539-decd8c5fe5c1">73,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e86f21e817747e1b323fa24e138daa7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDEtMy0xLTEtMA_c4c4dbe5-deba-4f02-8a0b-1050ba6f5f63">118,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDQtMS0xLTEtMA_4c084eee-3de1-4822-b461-edaf40aaa20b">2,216</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDQtMy0xLTEtMA_b45eec9e-2b20-4f35-96ec-97e396b38703">1,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities for purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDctMS0xLTEtMA_413c1468-992c-4c74-8cec-7c8df2150042">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDctMy0xLTEtMA_fff463d2-4868-496c-a35a-39adbb62dea4">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Offering costs in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" name="silk:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDktMS0xLTEtMA_5aa3b33d-3ac4-4fdf-a145-b2a49a335781">320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" name="silk:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDktMy0xLTEtMA_f297e36c-2d6c-4db9-aa90-4a4cafdc36e1">358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use asset obtained in exchange for lease obligation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNTAtMS0xLTEtMA_a92d2d3e-4bac-4329-8618-54e0b5620520">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNTAtMy0xLTEtMA_6cb856a7-d536-4fbb-9360-5c1919574b2f">3,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net exercise of convertible preferred stock warrants to preferred stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDktMi0xLTEtNzI2_60fec3dd-86ed-40e2-812b-75f40d6c44a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDktNC0xLTEtNzI2_b0f9b00c-cdae-4073-af66-4892f443abeb">37,121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of convertible preferred stock to common stock upon initial public offering</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNTAtMi0xLTEtNzI2_edfec398-87bf-4ad0-b108-bb5a40848d5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNTAtNC0xLTEtNzI2_76913e48-774e-4f78-9230-e31d7001ca9f">144,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div><span><br/></span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_34"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjc0ODc3OTA3Njc0Ng_e1333c82-67a2-4e11-8b77-98cb388753c6" continuedAt="ia409ce15e752405e93623ce5635f0670" escape="true">Formation and Business of the Company </ix:nonNumeric></span></div><ix:continuation id="ia409ce15e752405e93623ce5635f0670"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The Company</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Silk Road Medical, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on March&#160;21,&#160;2007.  The Company has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke.  The Company's portfolio of TCAR products enable a new procedure, referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles.  The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  The Company commercialized its products in the United States in April 2016.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 13, 2019, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a 1-for-2.7 reverse stock split of the Company&#8217;s common stock and redeemable convertible preferred stock to be consummated prior to the effectiveness of the Company&#8217;s planned initial public offering, or IPO.  The reverse stock split was effected on March 27, 2019.  The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.  All the common stock, redeemable convertible preferred stock, stock options and warrants, and related per share amounts in the condensed financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Public Offerings</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTc1NA_02294e93-5f93-418a-947f-bcafcd289ed3">6,000,000</ix:nonFraction> shares of its common stock in its IPO at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic94b432f83144c5da9c031a5551750d7_I20190430" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTgyNQ_f23747ee-39bf-4042-88b3-d18a8746f315">20.00</ix:nonFraction> per share, for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTg3Mw_82791fe5-9d0c-4ffe-9fcf-e7b7edbe301c">109,119,000</ix:nonFraction> after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430" decimals="-3" format="ixt:numdotdecimal" name="silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTk0OA_f1311725-fb70-45ca-80c2-0f4fe026bfa6">8,400,000</ix:nonFraction> and expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTk4MQ_b10f654f-2b34-4b6b-922f-6946c3001b2c">2,481,000</ix:nonFraction>. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock and the Company's outstanding warrants to purchase shares of common and redeemable convertible preferred stock were exercised, or automatically net exercised absent a prior election.  The exercises resulted in the reclassification of the fair value of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company completed a secondary public offering of <ix:nonFraction unitRef="shares" contextRef="ide2816e79e1b4022bf0287f80bb4fdf9_D20190801-20190831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjU0NA_1d6cacfd-3c7e-4f5e-be93-5f4b378069ee">4,200,000</ix:nonFraction> shares of its common stock sold by certain selling stockholders, and the exercise in full of the underwriters' option to purchase <ix:nonFraction unitRef="shares" contextRef="i41cc7674876049d3a0d3f79031ac5f2e_D20190801-20190831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjY3Nw_f31f74e8-add8-4df4-bbee-fcd7f2c1e173">630,000</ix:nonFraction> additional shares of its common stock from certain selling stockholders, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7c3c231e674e41edb75743c3010ec1df_I20190831" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjc4Mw_c64afa65-223f-4600-97fa-3a8a05dc5dc8">39.50</ix:nonFraction> per share.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In May 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="ia43b4977769d4b22b03b8b2e1b372461_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzQwMw_0591aef4-4dc5-4448-b503-072d1011d2f7">6,808,154</ix:nonFraction> shares of its common stock, of which <ix:nonFraction unitRef="shares" contextRef="ib1f341d7b77348a3a2568b670d478a67_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzQwOQ_b08c2593-2dcd-4681-8b9b-b137129321c3">1,923,076</ix:nonFraction> shares were offered for sale by the Company and the remaining <ix:nonFraction unitRef="shares" contextRef="i4f15ecda3b414074877b40741ff55576_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzQxMg_6eda7d56-d3c7-4afb-a5ef-46f2f2604ef5">4,885,078</ix:nonFraction> shares were offered for sale by certain selling stockholders, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8daaa359899f42abbc96d5a68e4e2aca_I20200531" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzczNA_5266ef22-67ef-4de7-a16e-711acdcc690e">39.00</ix:nonFraction> per share. The Company received cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1Nzc4Mg_15b4d4bc-a82f-4f72-808a-5fb0546c3842">70,543,000</ix:nonFraction> after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531" decimals="-3" format="ixt:numdotdecimal" name="silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzgwMQ_1c392e04-d230-45c5-adbd-f08d583632f2">3,750,000</ix:nonFraction> and expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1Nzg4OA_898c2ab3-5e87-49e2-b2f6-613b40f4ade0">707,000</ix:nonFraction>. Also in May 2020, the underwriters fully exercised their option to purchase <ix:nonFraction unitRef="shares" contextRef="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjE5OTAyMzI2Mjg2MA_c314595b-2525-404d-938e-c52646e74a51">1,021,223</ix:nonFraction> additional shares of common stock from the selling stockholders.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2Mzg_668d2058-2935-4290-b959-a39ce7b3b99b" continuedAt="i2e089b83242747a48585eff6b8a8263d" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i2e089b83242747a48585eff6b8a8263d" continuedAt="i5deac0b42c51498dabbda43080e38689"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTM_b08741a3-1431-4d69-8a52-a02e48989f46" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Preparation</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of&#160;December&#160;31, 2019, and related disclosures,&#160;have been derived from the audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&#160;These unaudited condensed financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s condensed financial information. The results of operations for the three and six months ended June&#160;30, 2020&#160;are not necessarily indicative of the results to be expected for the year ending&#160;December&#160;31, 2020&#160;or for any other interim period or for any other future year.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended&#160;December 31, 2019&#160;included in the Company's annual report on Form 10-K filed with the SEC on March 2, 2020.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adjustment to Prior Period Financial Statements</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has adjusted the accompanying Condensed Statement of Cash Flows for the six months ended June 30, 2019 to increase each of the accounts receivable, net, and accrued liabilities amounts by $<ix:nonFraction unitRef="usd" contextRef="iba2667bba4254c478e4e02407240ad78_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfNjA0NzMxMzk3OTQ5Nw_1fa05f41-9b9f-4b6d-9a0a-05db908b5cf4"><ix:nonFraction unitRef="usd" contextRef="iba2667bba4254c478e4e02407240ad78_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfNjA0NzMxMzk3OTQ5Nw_2c461057-490a-4b23-9fc2-09d1f3022e8f">601,000</ix:nonFraction></ix:nonFraction> for an immaterial prior period error in the classification of provisions for returns from customers.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzY_842253e2-3a8f-4619-b170-7857417393a7" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the provision for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Due to the coronavirus (&#8220;COVID-19&#8221;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="i5deac0b42c51498dabbda43080e38689" continuedAt="i63ec1224ad3845c4bd399e1468249159"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzA_b5aca841-553e-40b0-8781-20caf016e23f" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has evaluated the estimated fair value of its financial instruments as of June&#160;30, 2020 and December&#160;31, 2019.  The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzE_66e20d37-7815-42ef-8ad5-7da34d676911" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of June&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents are entirely comprised of investments in money market funds.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash as of June&#160;30, 2020 and December&#160;31, 2019 consists of a letter of credit of $<ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfNTM0NQ_a5b594b0-e665-4494-bcb2-d8994069acb5"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfNTM0NQ_fe915620-116d-4984-99a1-2e96d6a32b04">310,000</ix:nonFraction></ix:nonFraction> representing collateral for the Company's facility lease.   </span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2Mzc_c0a5a1e7-b62e-4204-a408-f76dc4fafd48" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Investments</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date.  Long-term investments have maturities greater than one year as of the balance sheet date.  All investments are recorded at fair value based on the fair value hierarchy.  Money market funds and United States treasury bills with an original maturity less than 90 days are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method.  Realized gains and losses are included in earnings, and are der</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ived for specific-identification method for determining the costs of investments sold.  Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTQ_5170961b-204a-42c7-9e1f-4b3d93b78c6b" continuedAt="i53aac34335b44ac3bdf79ab17cd2636c" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to risks related to the public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#8217;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="i63ec1224ad3845c4bd399e1468249159" continuedAt="i84adf91983c140b098db4a3c58536026"><ix:continuation id="i53aac34335b44ac3bdf79ab17cd2636c"><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#8217;s revenue while the pandemic continues.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and United States treasury bills. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three and six months ended June&#160;30, 2020 and 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States.  At June&#160;30, 2020 and December&#160;31, 2019, no customer represented 10% or more of the Company&#8217;s accounts receivable.  For the three and six months ended June&#160;30, 2020 and 2019, there were no customers that represented 10% or more of revenue.  </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company manufactures certain of its commercial products in-house.  Certain of the Company&#8217;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent.  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">currently approved portfolio of products.  If clearance for the products in the current portfolio </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div></ix:continuation><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NDM_a4f94ec3-f333-4b6b-8f89-011b893cdf11" continuedAt="i4e0904e0c7eb41ee8d5d2170f5321b21" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leases</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="i84adf91983c140b098db4a3c58536026" continuedAt="if4863820b083402e9baa46a7ec9ae38c"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4e0904e0c7eb41ee8d5d2170f5321b21">contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company&#8217;s considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.</ix:continuation></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="silk:WarrantsClassifiedAsLiabilitiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MjU_bb65ae32-2cc0-4f17-bd22-01f57dfaa6b9" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock Warrant Liability</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the condensed statements of operations and comprehensive loss.  The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised.  Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#8217; equity.  Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzI_129fb65d-6e4e-47ab-8d0f-d6ae3c4f2134" continuedAt="ibf33a2dd321845b7a4420741479b6efc" escape="true">Redeemable Convertible Preferred Stock</ix:nonNumeric></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ibf33a2dd321845b7a4420741479b6efc">Prior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#8217; equity on the condensed balance sheet as events triggering the liquidation preferences were not solely within the Company&#8217;s control.</ix:continuation>  Upon the closing of the Company's IPO, all shares of convertible preferred stock then outstanding converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i42ceb4ffa58a401ba6b8f294d3cb104c_D20190501-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMTQ4NjU_3cf18e28-227a-431d-b5eb-38d3ccd7c1a2">23,178,555</ix:nonFraction> shares of common stock&#160;resulting in the reclassification of $<ix:nonFraction unitRef="usd" contextRef="i704ad274cb0749d5930b69ce8f613a81_D20190501-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMTQ5Mjk_35d96cde-5431-4e8e-b818-98d11cfbbbaf">144,140,000</ix:nonFraction> from outside of stockholders&#8217; equity to additional paid-in capital.</span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NDU_79d1c6d6-7861-4b36-942d-80017d812a74" continuedAt="i165182ab70dc4dadbf1d5b219f2dbc44" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reven</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ue Recognition</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." &#160;Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i) identify the contract(s) with a customer; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii) identify the performance obligations in the contract; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii) determine the transaction price;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv) allocate the transaction price to the performance obligations in the contract; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="if4863820b083402e9baa46a7ec9ae38c" continuedAt="ia6adb21713574218a4e5cb6621dae261"><ix:continuation id="i165182ab70dc4dadbf1d5b219f2dbc44" continuedAt="i517ea811cf4c4710a9c625f83e5e35e7"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMTU5NTQ_26b54290-f850-4836-8069-f847b007cb0c">179,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMTU5NjE_9f41d437-66c9-48af-a990-65e7b7cf9996">128,000</ix:nonFraction>, respectively, of unbilled receivables, which are included in accounts receivable, net on the condensed balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#8217;s standard terms and conditions.&#160;&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For sales where the Company&#8217;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#8217;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectability is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale. As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component. The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the&#160;condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the condensed balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cost of Goods Sold</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company manufactures certain of its </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">portfolio of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="ia6adb21713574218a4e5cb6621dae261" continuedAt="i3ec90cb9a5ab42fd8cba84477be4b5b4"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i517ea811cf4c4710a9c625f83e5e35e7">excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.</ix:continuation></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTc_27a329f0-3b03-4273-b701-0ebaa75b4dee" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock&#8211;Based Compensation</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718,&#160;"Compensation-Stock Compensation."  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions. The Company accounts for option forfeitures as they occur.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzQ_22c1f078-eb8e-4c62-9662-05d9e5c4c036" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the condensed financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also follows the provisions of ASC 740-10, "A</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ccounting for Uncertainty in Income Taxes."  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the condensed financial statements.  It is the Company's policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTE_685bf594-b917-4628-a651-844e51ace937" continuedAt="i6dab4dd66ab240ee99ba036d18d8b3f8" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> months ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the condensed </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="i3ec90cb9a5ab42fd8cba84477be4b5b4"><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6dab4dd66ab240ee99ba036d18d8b3f8">statements of operations and comprehensive loss.  Accumulated other comprehensive income or loss is presented in the accompanying condensed balance sheet as a component of stockholders' equity.</ix:continuation>  For the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> months ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June&#160;30, 2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, there was no difference between the Company's comprehensive loss and its net loss. </span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTI_6fbca779-23aa-4c76-9d66-23cf4b8a5bae" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net Loss per Share</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#8217;s redeemable convertible preferred stock participate in any dividends declared by the Company and were therefore considered to be participating securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MjY_42414737-7359-4be4-8336-a53e90e0c1c9" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share was determined as follows (in thousands, except share and per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.673%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.461%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.463%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMi0xLTEtMS0w_df45be31-6546-44b7-af39-0926d790ac08">10,353</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMi0zLTEtMS0w_2f3f7329-db42-4419-b3fa-080ae640a297">11,959</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMi01LTEtMS0xMjQ_4cafc534-0c6b-4ac0-a7cb-6485d8073569">20,294</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMi03LTEtMS0xMjQ_42685bf7-485c-4a0a-9571-a955f2158b9c">36,117</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common stock outstanding used to compute net loss per share, basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMy0xLTEtMS0w_922acb2e-c94a-4697-82fc-a8bc84227ba5">32,682,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMy0zLTEtMS0w_ace5e99f-45c9-4530-aa31-6ec26c5d67b4">28,458,793</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMy01LTEtMS0xMjQ_b41c5a7b-3f39-4374-ae2c-6eb8bc7dc9cc">32,010,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMy03LTEtMS0xMjQ_d811fedc-fa0a-4373-a6b6-0893eba6de81">14,905,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfNC0xLTEtMS0w_5a63bb28-4275-40fb-bc94-f578e3f0f71f">0.32</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfNC0zLTEtMS0w_55cb1ec7-b658-4377-b7e8-372f311c5fbc">0.42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfNC01LTEtMS0xMjQ_c14d86d3-ff94-4195-9c2c-7454d9454403">0.63</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfNC03LTEtMS0xMjQ_2de59db9-627e-4911-b276-cf7027121915">2.42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;"><span><br/></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NDg_3d90c6c4-450f-4aec-8daa-8ee38c0f9834" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company's net loss:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e17ff70ca0d48c8b577b81e25ba591d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNC0xLTEtMS0w_1e74de43-c138-470a-bf48-138d1d0bfac6">4,632,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic416bec949ed4e3ca81268307a41e37e_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNC0zLTEtMS0w_586c20cd-6d3d-419e-a0ea-4a6a078807e9">4,683,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i474e71f940ab46279c176f0b19975770_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNi0xLTEtMS0w_d21e75c3-e6fe-4346-b10f-74a2640903c4">39,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if6a67bd46361461c9d492414aa7bffdd_D20190101-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNi0zLTEtMS0w_31c6a94f-8ae1-4110-9fd9-e7e743934d72">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNy0xLTEtMS0w_be86946b-da48-419a-aeb8-0397d784dcf7">4,671,955</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNy0zLTEtMS0w_f9183477-12a2-4381-a72b-add2a9d0f2a1">4,683,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2Mjg_4d43ed4e-7d5c-4464-a5b9-b2d0b7cfe8b4" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Segment and Geographical Information</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates and manages its business as <ix:nonFraction unitRef="segment" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjE5OTAyMzI4NjU1Nw_87fcbdc4-19d4-42d2-8e3b-97b44f4ee375"><ix:nonFraction unitRef="segment" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjE5OTAyMzI4NjU1Nw_8e667f90-847a-4f7c-a32b-da6e46e7ade7">one</ix:nonFraction></ix:nonFraction> reportable and operating segment.  The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.  All of the Company&#8217;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment and the Company's right-of-use asset.  All of the Company&#8217;s revenue was in the United States for the three and six months ended June&#160;30, 2020 and 2019, based on the shipping location of the external customer.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80Ni9mcmFnOjUzNmMxZjBkZDMzZjQ0MGViNmU5YmQyMzM1Yzc4NzI2L3RleHRyZWdpb246NTM2YzFmMGRkMzNmNDQwZWI2ZTliZDIzMzVjNzg3MjZfMjU3Mw_5a853218-3915-4577-9351-b46246603c61" continuedAt="ie470b83a5bca40d5b1c53c9727612acb" escape="true"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80Ni9mcmFnOjUzNmMxZjBkZDMzZjQ0MGViNmU5YmQyMzM1Yzc4NzI2L3RleHRyZWdpb246NTM2YzFmMGRkMzNmNDQwZWI2ZTliZDIzMzVjNzg3MjZfMjU3NA_63857d70-e454-4202-9375-54c41b6c9b32" continuedAt="i7a96d0475a6c4d3daabe927f7c2d2d9f" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ie470b83a5bca40d5b1c53c9727612acb"><ix:continuation id="i7a96d0475a6c4d3daabe927f7c2d2d9f"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 would originally be effective for the Company on January 1, 2023.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  As of June 30, 2020, the Company no longer qualifies as a smaller reporting company, accordingly </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">will now become effective for the Company on January 1, 2021. The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 will become effective for the Company on January 1, 2021.  Early adoption is permitted.  The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div id="i0f5f7f4a40e74f9186fba54ac93b1916_49"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RleHRyZWdpb246MTg1OGVlMGVmYTkxNGJhNmE1YTU2NDI0ZjQ2MDFiMTZfMjM5OQ_8874e935-1ff0-422f-b3bb-07678da615bc" continuedAt="i5bdb981a4773483ea581359278a0d3cd" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i5bdb981a4773483ea581359278a0d3cd" continuedAt="idc05cdc201c946cd8a93a1143c7317fc"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, investments, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and the Company's previously outstanding preferred stock warrants</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.  A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; quoted prices in active markets for identical assets or liabilities;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; observable inputs other than quoted prices in active markets for identical assets and liabilities;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; unobservable inputs.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="idc05cdc201c946cd8a93a1143c7317fc"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.  The Company&#8217;s</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cash equivalents</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.  The corporate bonds/notes, commercial paper, asset-backed securities and U.S. government securities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RleHRyZWdpb246MTg1OGVlMGVmYTkxNGJhNmE1YTU2NDI0ZjQ2MDFiMTZfMjQwMw_d20f2d49-570a-46d7-bde3-848bc08db9ba" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The following tables sets forth by level within the fair value hierarchy the Company&#8217;s assets that are reported at fair value as of June&#160;30, 2020 and December&#160;31, 2019, using the inputs defined above (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:37.743%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.583%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.583%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.583%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.585%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia45c7bb5cadd4ff3928225d7854fc6cf_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfMy0xLTEtMS0w_c399fd80-9eb3-46c7-9e69-27a3bec1cacf">72,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7eaae44effa4a9db07cdb54dcc04049_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfMy0zLTEtMS0w_88f76a44-890d-4893-942c-51e4d8cdef24">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie11c28dea9564c599548f654617f2d82_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfMy01LTEtMS0w_8de6b901-61bd-4706-993b-7d93fe0a001e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieef0e9ab0a544219ad78c50b68f4791d_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfMy03LTEtMS0w_61579800-b574-4e8b-84d6-9ab84110192b">72,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i027eeae537b5468592e241128284b992_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNC0xLTEtMS0w_988ba0f0-db24-4889-9be3-339d84296f98">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2b02921cf0f4f00aa9fe9fdfd871170_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNC0zLTEtMS0w_fcce919b-cbcc-453d-a2aa-e29b87e32f55">9,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0130e277a457479f8eb98ee94adf3d31_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNC01LTEtMS0w_2880941a-a9f5-496e-abae-7f0516519163">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7abe1f43259b4a54b976c268c96c3db6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNC03LTEtMS0w_9587813e-a2b4-4ee9-9bba-2aceb7d423a7">9,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie05b32828f264722b8556b4370fc6692_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNS0xLTEtMS0w_97e23eda-7078-4357-8578-2b4f16d7dbb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97f148c7c1d24480baf7b80e8a13fd5a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNS0zLTEtMS0w_7d7fbe09-ecab-487c-a01a-e5075a80b74a">11,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c333b7cb2584fb0bf52ab8951d3b428_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNS01LTEtMS0w_f6ae080a-6eae-4550-b9e9-779be4ef8bda">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ef50b8f524a4cf1a7fbc3e5edfecf52_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNS03LTEtMS0w_0e94823b-b518-444a-a32a-a64182252393">11,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbe32b015af345959821be4df0dcaeac_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNi0xLTEtMS0w_ab2fec29-5ad6-46df-ad6e-5ca8f170131f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37bbce2b0c0c4aed8cf5b3c35c01dcae_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNi0zLTEtMS0w_161059ea-57fb-416a-a296-04d98b53b0e9">10,742</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2dbd828ff8134720a052fc51c726266a_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNi01LTEtMS0w_00672f1f-2943-4f06-9c89-94c75b80c6f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i295a9086a57e41eba3c2236e5dc80ef0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNi03LTEtMS0w_e10a94d7-6d67-4d06-8c3b-12fae4e960da">10,742</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad31c85169dc429b85ce034ad39eb103_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNy0xLTEtMS0w_67c83896-87fe-441d-874d-a6d920a4d7f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63598873c0f044d4b705b1cafa4240b7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNy0zLTEtMS0w_eabcd37f-ce3e-406a-9eb1-87f64e9f3e94">49,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7cde6c49eff04e36b1db4f65acf663c3_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNy01LTEtMS0w_25231ac6-05a1-429d-9279-ea7f80206550">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88c32e22f95c44cab38971bc9fab5004_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNy03LTEtMS0w_850c8d6f-c66f-4dd8-8f8a-950e531c083c">49,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i26e712413f6848d9a5e188b7a113c60d_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOC0xLTEtMS0w_e8086717-5b4a-480e-99a7-767fb8ee3241">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e1c06ac263949cf803aa266d7e0c236_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOC0zLTEtMS0w_c0137bec-fe7d-491a-9900-2538a1f26c8b">2,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i34bee5fc72654faebc87e97e419f58c1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOC01LTEtMS0w_74c2b040-0075-4c56-98bd-dda31af75ce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a5bfe7df3c84fe6850ff62b8c098b26_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOC03LTEtMS0w_28acbfee-2af0-46c7-9caa-9839ca3d6aa9">2,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11dd8af0811b4ebab5f6adef8864c4f1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOS0xLTEtMS0w_e5910990-2fd8-4b9b-89b2-b9bfeb5ece0b">72,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e8bebd551d147b992e253b95baa195f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOS0zLTEtMS0w_62b4926d-f0a7-4542-8f37-a6f849dbdcff">84,416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedefabef8f124e819f3337024626dc4e_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOS01LTEtMS0w_7cd917cc-9e54-41c9-91bb-a9dd6fe8f19b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2abf6f3595684efe9f063ff9b69fec7f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOS03LTEtMS0w_81b1b5a9-16f2-4b07-b363-1a2f031f7831">157,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:37.743%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.583%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.583%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.583%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.585%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9aae1b1ed715477dad46b3078e21b40b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfMy0xLTEtMS0w_29d09a82-3fda-4226-b6e1-5550fff5af22">34,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b9a7836694f4cf3b50a9134284d8b4e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfMy0zLTEtMS0w_d69210b2-4693-4101-b3f0-5c940cf12a70">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9636c3ae224c4f7f893c191a0ab12002_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfMy01LTEtMS0w_f4f103d1-e58c-497f-99da-77ff89d81318">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76ab7e26b0e64cffa5cca122155110e9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfMy03LTEtMS0w_377e9104-4155-41cd-8de1-84f540511442">34,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide59561146c34abbbab1296d346d7f2b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNC0xLTEtMS0w_e98aebc3-1571-4f8c-90cd-4b6f07b9c37d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c98a1a3cac34c2fbc05c0e88a578e09_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNC0zLTEtMS0w_54f74f2e-cfd7-4c03-842a-f94f18d97bf1">9,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c935ab0c1f241b990bc79b98b3645b3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNC01LTEtMS0w_83af72cd-5e7d-4108-84db-ff25fbc1cdfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1de230599454417b163ebfe37b873d5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNC03LTEtMS0w_610175f5-d6ee-4444-a068-822d5132a537">9,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i145dc0fcbfe64370a9f24164b7dd43f8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNS0xLTEtMS0w_7aa692e2-2f1a-4ea8-bf2b-e724185999e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8245985bc354b6a86396bc01b5213d9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNS0zLTEtMS0w_ae6364d7-151c-4acb-bd87-022a7e07336d">10,176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib148be5a80234007ae139c5a4efdfc61_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNS01LTEtMS0w_6e0c10a4-8c20-4141-ba52-d37bcfdb748a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1a76cb4479a4ff989b812aac949063e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNS03LTEtMS0w_394c2d58-10d4-4c8b-9616-cc9a2a01fd0a">10,176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if53f29868f76491f8fd58d9c3303f998_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNi0xLTEtMS0w_553bdb55-8028-4448-981e-e1f8de0952b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide4b8aa16b5440ec854fbf0906b9c133_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNi0zLTEtMS0w_3e946a51-e059-4c73-9820-c57855a5b370">44,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67ffbfb49b864745af10bab7a89329f9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNi01LTEtMS0w_08dc5455-c9de-44b6-ad46-6c3419bd92a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5a347102e80443a82dea892692d5746_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNi03LTEtMS0w_a2772c10-780f-4e8f-9b23-408db53708d9">44,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46860657c50f45ee882f2df2d5f623d7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNy0xLTEtMS0w_e610694a-6952-493c-9b89-1845abccca81">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8dc96a72145c469d9ab6fb5c89bafb0e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNy0zLTEtMS0w_b1e77a47-3c5a-4271-aadd-3b233ef2c4a3">5,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3830c20a6ee94b1488be7319d791f2d8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNy01LTEtMS0w_080faf5a-109a-4dfd-ae1e-933402ffdb99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ebd01da1cc2487a91876a8405b5628b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNy03LTEtMS0w_0db32486-45db-4fee-93e6-abfbd66a80a7">5,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac0ccc5a7ea8414bb1a711a6955e7342_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfOC0xLTEtMS0w_d63588f4-2388-42c7-b42a-3a0e04c5172d">34,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i665e3a1be7a84f788bd449d1334d492c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfOC0zLTEtMS0w_1678aa18-7adf-44e9-a640-9091abc2fe98">69,732</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i628752f4a1c64849a99d7a5f207dd092_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfOC01LTEtMS0w_5f366e79-6188-4b22-b46f-83012304de76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf14871d54b5439a835298db12c36739_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfOC03LTEtMS0w_a94acf33-baf9-4e26-bd3b-c07bbf21436d">104,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There were no transfers between fair value hierarchy levels during the three and six months ended June&#160;30, 2020 and 2019.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzgy_f8cbc581-595b-4e63-b8f8-f4b80525cc4d" continuedAt="ifa9e3bce31d14c38a35698bc92fb8cd4" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ifa9e3bce31d14c38a35698bc92fb8cd4" continuedAt="i7c2173807b21463db5aff26694d80d31"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Investments</span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzg3_b630d51d-0c51-4f17-997e-97859cd149de" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company's available-for-sale investments as of June&#160;30, 2020 and December&#160;31, 2019 are as follows (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:34.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.185%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.224%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.188%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8c8ea18544f4f62b607863b3c6653ed_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMy0xLTEtMS0w_4349cf54-fa6e-4e93-81c7-72657ceb2fc5">72,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8c8ea18544f4f62b607863b3c6653ed_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMy0zLTEtMS0w_1dc56f32-aaab-4c0d-a8a1-2ec0f6561a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8c8ea18544f4f62b607863b3c6653ed_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMy01LTEtMS0w_8a66ba81-d4d2-47f6-aa73-51031627d470">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8c8ea18544f4f62b607863b3c6653ed_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMy03LTEtMS0w_91cde707-dd77-4316-aaa9-a701757252e0">72,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id46da514145b4750ada52675069ab829_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNC0xLTEtMS0w_4351061c-7170-4a22-8ecd-b33d856ea825">9,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id46da514145b4750ada52675069ab829_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNC0zLTEtMS0w_390b6fc4-f4f7-44d3-9fc0-ed1d1b7fae92">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id46da514145b4750ada52675069ab829_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNC01LTEtMS0w_dd4ac5d3-0525-4d21-92ca-b56265dc90c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id46da514145b4750ada52675069ab829_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNC03LTEtMS0w_d5ac5a9d-50a8-46a7-b793-89658bf2ed14">9,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNS0xLTEtMS0w_ddce6376-aba6-4c9c-949f-2ad3eb700ba9">11,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNS0zLTEtMS0w_34a896be-a758-43ab-a630-d8ef6f0ca7d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNS01LTEtMS0w_6b23bb77-7417-4d22-b45b-513631dfffa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNS03LTEtMS0w_510e9021-84ea-466f-a3b0-3fd3ff27d45f">11,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNi0xLTEtMS0w_f4fa7695-3bba-4974-b8b8-ee5257d935e2">10,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNi0zLTEtMS0w_4b60efab-c728-45e4-b88c-80ec427fa1cf">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNi01LTEtMS0w_f772e484-0f30-4683-bd46-47c1d77fbc93">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNi03LTEtMS0w_0a5842f3-4741-4df5-9fec-c5176bc2a570">10,742</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf867c38014844e5818ec341fda982bd_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNy0xLTEtMS0w_e129b551-4609-415a-a60e-0315ae940342">49,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf867c38014844e5818ec341fda982bd_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNy0zLTEtMS0w_d171a2b6-fb6e-4d09-a50e-8b2a6a8dfe42">281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf867c38014844e5818ec341fda982bd_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNy01LTEtMS0w_3f5568e8-4169-4003-913f-eaa508a1814c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf867c38014844e5818ec341fda982bd_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNy03LTEtMS0w_10af6310-a0a3-4002-bd63-1d4544050365">49,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5f4685798604a6d9460510b4c4c15a7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOC0xLTEtMS0w_c0d19b16-a981-41e7-a358-47eca1696425">2,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5f4685798604a6d9460510b4c4c15a7_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOC0zLTEtMS0w_c1ac3147-e1f2-480b-b906-9115c7c9924b">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5f4685798604a6d9460510b4c4c15a7_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOC01LTEtMS0w_5dd77890-53d7-40ab-a041-dbd080784bee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5f4685798604a6d9460510b4c4c15a7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOC03LTEtMS0w_35509884-38f2-45c2-8459-e32fb659d236">2,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOS0xLTEtMS0w_7e3d89e8-c374-415e-98ef-6904fad1769a">157,024</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOS0zLTEtMS0w_00edbb9a-0354-47f6-b2a7-8ac66619c6c2">317</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOS01LTEtMS0w_3b24b1e3-963e-4a73-b3a3-04e7f53da5d1">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOS03LTEtMS0w_2a636c7a-b914-4079-8fcc-890e2f0df501">157,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6f195d63bab41439dde63c7ec42a7a3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMTEtNy0xLTEtMA_5a550430-5456-4bbf-b44d-7ee329ab90bd">72,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic54064e0090149959fffc8a7f4540977_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMTItNy0xLTEtMA_018bda87-e52b-4ca6-9379-811ecb7c79b7">84,416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMTQtNy0xLTEtMA_e0db5639-f77a-4815-9d18-7f20a186300e">157,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:34.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.185%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.224%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.188%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c26d0ce983a467cace48304d4c14c29_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMy0xLTEtMS0w_95e3bbf0-33ef-4aea-bcbc-cf229d4241ae">34,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c26d0ce983a467cace48304d4c14c29_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMy0zLTEtMS0w_b7814e8f-c528-4279-9cbe-6a338e7d2ddb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c26d0ce983a467cace48304d4c14c29_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMy01LTEtMS0w_42d3f56e-eb8a-4b25-9571-e08eb39df22b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c26d0ce983a467cace48304d4c14c29_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMy03LTEtMS0w_27b50e24-e9e9-4bcb-8215-33bcfdc0dc39">34,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia147919f6a044ff88de323227052e424_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNC0xLTEtMS0w_d5eb11e8-cf7a-4122-957e-2a932c6e4263">9,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia147919f6a044ff88de323227052e424_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNC0zLTEtMS0w_cb5f5308-f956-4db7-bd8f-dffd1731d913">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia147919f6a044ff88de323227052e424_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNC01LTEtMS0w_d3e1b28b-4137-4daa-8a84-bfd055a9de3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia147919f6a044ff88de323227052e424_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNC03LTEtMS0w_8d068dac-d759-468a-b710-2e6bc2371c5d">9,919</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNS0xLTEtMS0w_128281f6-5d6b-4f93-8594-50e821b3866c">10,180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNS0zLTEtMS0w_c6f23a67-adbb-440b-a91b-d3345b8a991d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNS01LTEtMS0w_8298eec1-f13a-46fb-969a-572a0e22a47c">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNS03LTEtMS0w_50e1ae49-b2de-46be-93ec-48e9c5aef08b">10,176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNi0xLTEtMS0w_a6b3c209-6163-45f2-89ab-68ebd031b1f0">44,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNi0zLTEtMS0w_680b5a48-4247-4e62-980b-f4c3ff540182">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNi01LTEtMS0w_448ac72a-7c73-4564-830d-a85766c60342">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNi03LTEtMS0w_6f2c7fe4-62b7-4e80-b4ad-e4d7e7fd9869">44,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic00908a653674eb4a8e9bac56051e1a9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNy0xLTEtMS0w_85f7ffdb-5de4-4398-a4e7-64bc90a70438">5,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic00908a653674eb4a8e9bac56051e1a9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNy0zLTEtMS0w_463bb369-287c-4657-827c-a07b5d87cfd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic00908a653674eb4a8e9bac56051e1a9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNy01LTEtMS0w_ff8f9c17-e237-4260-be30-9f419682f035">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic00908a653674eb4a8e9bac56051e1a9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNy03LTEtMS0w_1147780a-370e-4b92-bbf0-5a4c3f457c3f">5,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfOC0xLTEtMS0w_dd27876f-0d7d-404c-8d96-63eadc8ef4c6">104,093</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfOC0zLTEtMS0w_2e44b092-ed93-4c99-a6ee-23c285f5d8c3">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfOC01LTEtMS0w_a16c3e63-34bb-4474-a94e-928a95dda119">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfOC03LTEtMS0w_f858230c-4aa4-4e84-9a08-5025643af358">104,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i070bfe38bf2d4977b7e7675ca0fe38ef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMTAtNy0xLTEtMA_ada0efb1-79f7-4797-bd1f-0c4daede548d">34,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i084603b74ef54fce8e75cc1061fc2af7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMTEtNy0xLTEtMA_08b3b6ad-9fa0-4aa2-a455-a1c23534f7d8">51,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifeb20a2f0bf24dd08225af4dac73faaa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMTItNy0xLTEtMA_7eb7aeaa-9c17-4808-8160-5b0c0f7c0542">18,224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMTMtNy0xLTEtMA_e959b820-a05b-4830-9e75-ff533a9a1980">104,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="i7c2173807b21463db5aff26694d80d31" continuedAt="i681cc5b990e9471580a810f3966d3df3"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzg4_1e6f8918-e8d0-4feb-b4dc-36d6360588e3" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of the Company&#8217;s cash equivalents, short-term and long-term investments classified by maturity as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:62.102%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.467%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.790%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts maturing within one year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfMi0xLTEtMS0w_91399969-7152-4276-807a-5fe6f9ef38f4">157,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfMi0zLTEtMS0w_147ae569-8f51-4f45-aa9b-5ff00c102bec">85,871</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts maturing after one year through two years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:zerodash" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfMy0xLTEtMS0w_b7e9f972-2d87-42ed-849d-d476eb6bc548">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfMy0zLTEtMS0w_5d123da0-c6e8-4eba-82d5-f2dbf7f92555">18,224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfNC0xLTEtMS0w_2a3d52fc-1409-4e5f-afca-70d9d544735e">157,340</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfNC0zLTEtMS0w_5d06289a-c19e-4449-857d-4ed6e36467e3">104,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Available-for-sale investments held as of June&#160;30, 2020 had a weighted average days to maturity of <ix:nonNumeric contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" format="ixt-sec:durday" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNDM0_0c8a148e-6666-4a8b-a06c-b6f144ed3251">164</ix:nonNumeric> days. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzg0_5c6d3f68-174e-40fc-b3c3-5fd54b3ea590" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.185%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.185%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.185%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.189%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than 12 months</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than 12 months</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Loss</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfMy0xLTEtMS0w_40324940-a958-49d9-855b-b7369b97973e">2,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfMy0zLTEtMS0w_1825abac-7aa8-4f45-b913-d551bb151837">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfMy01LTEtMS0w_0bafe412-c28e-40bc-91b8-38ec02121ba7">10,128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfMy03LTEtMS0w_215578b1-4864-4fe1-91fd-0354cd877af8">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf867c38014844e5818ec341fda982bd_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNS0xLTEtMS0w_5c130571-8c29-43e3-be70-5c56f04fe482">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf867c38014844e5818ec341fda982bd_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNS0zLTEtMS0w_7db818ca-4e91-42f4-bff0-2e0bc128c47c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNS01LTEtMS0w_7b4e444d-49f3-444d-a3b5-a431024bf110">19,067</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNS03LTEtMS0w_3c2f54d3-397b-4ef0-8214-012aef03d8e5">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNi0xLTEtMS0w_5380b0f5-2c06-4593-bc8e-9b3a825a5e04">2,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNi0zLTEtMS0w_73c0d007-8e2f-4150-ab47-7ca15dd45c6c">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNi01LTEtMS0w_e23803bc-5cc0-46b1-8bb3-fb0bf1145f52">29,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNi03LTEtMS0w_5ed5e2b6-b34a-414d-a2dd-df7f1e5fb720">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inventories</span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzg5_080ea9ea-537e-4e5e-b4fb-d205f20686d3" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Components of inventories were as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:67.341%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.890%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.967%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfMi0xLTEtMS0w_5ddb11fc-338d-4d39-833f-a16c318eca6a">1,736</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfMi0zLTEtMS0w_8f5bc47a-c354-4ae8-bab0-018d4168064e">1,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfNC0xLTEtMS0w_fa2dafb0-58a9-4463-a1cb-57c80cc3a93f">9,885</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfNC0zLTEtMS0w_c1726ca7-022a-4511-9bbd-952d7a731474">9,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfNS0xLTEtMS0w_380436be-41fa-4898-b8a6-27c9bb793177">11,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfNS0zLTEtMS0w_1ced13f1-73c0-4dab-8f47-b1b6428b4e61">10,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, there were <ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNjgz_c3851d29-a6c1-41cb-b10a-fe521a66b9a1"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNjgz_ead8772d-5b45-41a9-b1fd-9af61853f698">no</ix:nonFraction></ix:nonFraction> work-in-process inventories.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="i681cc5b990e9471580a810f3966d3df3"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzkw_8d3c2580-7be7-4fe5-88a9-6bc63fc90bdf" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%;"><tr><td style="width:1.0%;"></td><td style="width:64.344%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.264%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.605%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.587%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll and related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMi0xLTEtMS0w_91f3f762-39e9-4e2b-97bc-8c647a4bf1e3">5,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMi0zLTEtMS0w_7358ddb2-d02b-4040-9636-9b82a1f3d1d5">9,151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for sales returns</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="silk:ProvisionsForSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMy0xLTEtMS0w_68f04664-ef80-45b5-9f91-079be71bf029">920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="silk:ProvisionsForSalesReturns" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMy0zLTEtMS0w_136f66cb-eee1-4170-a3a3-18a36ca182cd">2,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNC0xLTEtMS0w_e0f4d081-7f24-497e-aa81-730d95b92156">593</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNC0zLTEtMS0w_edb0b93c-55d8-4a97-a088-b435de9b0c80">682</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNS0xLTEtMS0w_7b741191-2f1e-4ade-bbd0-dd427cc72f19">809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNS0zLTEtMS0w_28ecd4cc-c29c-4aab-a560-7e5709f577a9">769</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued royalty expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNi0xLTEtMS0w_1e547e4b-ee54-469b-ade2-b81bd81c3cbc">333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNi0zLTEtMS0w_d2d5a84e-198c-431f-abe3-c0fe985c08fc">470</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNy0xLTEtMS0w_3825a2ab-c195-4525-82ed-fe8c646b22be">335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNy0zLTEtMS0w_4565c579-b9f7-496b-8f86-456a18e5c8ae">304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued travel expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="silk:AccruedTravelExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfOC0xLTEtMS0w_e583b634-12bf-4adf-bfc6-f845adf5d2b1">273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="silk:AccruedTravelExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfOC0zLTEtMS0w_2b087a6d-590c-4c8b-81e8-7ac570532117">431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="silk:AccruedClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfOS0xLTEtMS0w_984d2c61-f884-4bcb-8bab-1df48fe571fc">181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="silk:AccruedClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfOS0zLTEtMS0w_4c918c9d-8eb9-4dae-8c6a-66521e7397b4">241</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMTAtMS0xLTEtMA_345578c6-6285-4fc9-917c-00d7884ece36">346</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMTAtMy0xLTEtMA_280cce89-c2a0-428b-95ee-03853690acdd">567</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMTEtMS0xLTEtMA_14711d68-1dfc-4120-bb2b-f8bf69b245d0">9,142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMTEtMy0xLTEtMA_c85401d3-f039-4dc9-9d0f-0cdfc5943af4">15,034</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_58"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTM2Mg_298c63e4-fed7-4430-be32-eb774115f373" continuedAt="i30efa37c0e434210b996cf11d2038e88" escape="true">Long-term Debt</ix:nonNumeric></span></div><ix:continuation id="i30efa37c0e434210b996cf11d2038e88" continuedAt="i615e5795c727434bb262ca98636f5be7"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October&#160;2015, the Company entered into a term loan agreement with CRG.  The term loan agreement provides for up to $<ix:nonFraction unitRef="usd" contextRef="i3400703ba5ec4dafa9f83491b25fdc9b_I20151031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTI2Mg_87de2e8b-9be7-4bef-bbfe-08f54d7779a2">30,000,000</ix:nonFraction> in term loans split into two tranches as follows: (i) the Tranche A Loans provided for $<ix:nonFraction unitRef="usd" contextRef="i790a1c16fe884cfc81603c5b990067c9_I20151031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTI4OA_53e08e09-88c7-435a-a172-b88974cff232">20,000,000</ix:nonFraction> in term loans, and (ii) the Tranche B Loans provided for up to $<ix:nonFraction unitRef="usd" contextRef="i0624ae02355943f3919d91e6d60daf82_I20151031" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTIzNw_f447b177-49a1-442d-a2eb-1f73711fd6b8">10,000,000</ix:nonFraction> in term loans.  The Company drew down the Tranche A Loans on October 13, 2015.  The Tranche B Loans were available to be drawn prior to March 29, 2017.  In January 2017, the term loan agreement was amended to extend the commitment period of the Tranche B Loans to April 28, 2017.  In April 2017, the Company drew down $<ix:nonFraction unitRef="usd" contextRef="i05691cc4d2eb407b8735756cfcce9745_I20170430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTMxMg_f6d11dbb-40f3-4363-8106-48193dd7ffce">5,000,000</ix:nonFraction> of the available Tranche B Loans.  </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the Company entered into Amendment No. 5 to the term loan agreement with CRG.  Under the amended terms of the amended loan agreement the maturity date was extended to December 31, 2022 and the repayment schedule of the existing term loans were changed to interest only so that the outstanding principal amount of the term loans will be payable in a single installment at maturity.  The related fixed interest rate was changed to equal <ix:nonFraction unitRef="number" contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTMzMQ_01a40fdd-3f17-4d80-aa74-b47461ae9710">10.75</ix:nonFraction>% per annum, due and payable quarterly in arrears.  At the election of the Company, <ix:nonFraction unitRef="number" contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930" decimals="INF" name="silk:DebtInstrumentInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTM0NQ_d91e04f3-13b6-482e-9a1e-c97c16771923">2.75</ix:nonFraction>% of the interest due and payable may be &#8220;paid in kind&#8221; and added to the then outstanding principal and <ix:nonFraction unitRef="number" contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930" decimals="INF" name="silk:DebtInstrumentInterestRatePaidInCash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTM1Nw_ea82412b-d3ee-414c-b01e-f407ab4e20f4">8.0</ix:nonFraction>% of the interest due and payable paid in cash.  All unpaid principal, and accrued and unpaid interest, is due and payable in full on December 31,&#160;2022.  The amended term loan agreement also provided for additional term loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTM3Ng_c72747f2-8df3-40fd-a01d-4a6b17d03088">25,000,000</ix:nonFraction> and allowed for the conversion into shares of common stock, at the Company&#8217;s option, of up to <ix:nonFraction unitRef="number" contextRef="i6d81a47bada34ef9be4c34a930d81f1e_D20180901-20180930" decimals="INF" name="silk:DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMTY3MQ_60a13888-d407-420f-b2f5-7b866791916c">25</ix:nonFraction>% of the outstanding loans under the term loan agreement in connection with an initial public offering of the Company&#8217;s common stock which results in market capitalization of at least $<ix:nonFraction unitRef="usd" contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentConvertibleMarketCapitalization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMTg1Ng_eda6560c-7e0b-43e9-ad3f-5bc0183eadef">250,000,000</ix:nonFraction>.  In September 2018, the Company drew down an additional $<ix:nonFraction unitRef="usd" contextRef="icab64d89eb0c493488e9f83a19562b4d_I20180930" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtMaximumBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQwMQ_67613c1e-83a3-45e7-ace3-6bb4452dd52a">15,000,000</ix:nonFraction> under the term loan agreement with CRG. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As provided for under the terms of the amended term loan agreement, the related fixed interest rate was further reduced to <ix:nonFraction unitRef="number" contextRef="ic59b0ae0ca9845038632b9400107e7e6_I20190501" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjA4Mw_bbebcf33-34de-4cfa-bc45-342dc6200ed9">10.0</ix:nonFraction>% upon the consummation of the Company's IPO in April 2019.  Also, post consummation of the Company's IPO, <ix:nonFraction unitRef="number" contextRef="ic59b0ae0ca9845038632b9400107e7e6_I20190501" decimals="INF" name="silk:DebtInstrumentInterestRatePaidInCash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5MQ_469e0515-93be-4f7e-96df-dd416dd285d3">8.0</ix:nonFraction>% of the interest is due and payable in cash and at the election of the Company, <ix:nonFraction unitRef="number" contextRef="ic59b0ae0ca9845038632b9400107e7e6_I20190501" decimals="INF" name="silk:DebtInstrumentInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjI3Mw_8fb1bb69-09f3-4f01-8302-99aa1a0fba52">2.0</ix:nonFraction>% of the interest due and payable may be "paid in kind". </span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, the Company entered into Amendment No. 7 to the term loan agreeme</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">nt with CRG to reflect flexibility with respect to permitted cash investments.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may voluntarily prepay the borrowings in full.  The Tranche A borrowing required a payment, on the borrowing date, of a financing fee equal to <ix:nonFraction unitRef="number" contextRef="i790a1c16fe884cfc81603c5b990067c9_I20151031" decimals="INF" name="silk:DebtInstrumentInterestRateFinancingFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQyMA_8aab0ec4-285e-45d8-84c7-78e09bc990d8">1.75</ix:nonFraction>% of the borrowed loan principal, which is </span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="i615e5795c727434bb262ca98636f5be7"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">recorded as a discount to the debt.  In addition, a facility fee equal to <ix:nonFraction unitRef="number" contextRef="i790a1c16fe884cfc81603c5b990067c9_I20151031" decimals="INF" name="silk:DebtInstrumentInterestRateFacilityFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQzMg_ac5a7556-15f4-4e2c-b0a7-4eb51299a2bf">5.0</ix:nonFraction>% of the amounts borrowed plus any "paid in kind" is payable at the end of the term or when the borrowings are repaid in full.  A long-term liability is being accreted using the effective interest method for the facility fee over the term of the loan agreement.  The borrowings are collateralized by a security interest in substantially all of the Company&#8217;s assets.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to financial covenants related to liquidity and minimum trailing revenue targets that began in December&#160;31, 2016 and are tested on an annual basis.  The liquidity covenant requires the Company to maintain an amount which shall exceed the greater of (i) $<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantMaximumLiquidityAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQ0OQ_9c24d1e4-33c4-401e-956f-9884604cd09a">3,000,000</ix:nonFraction> and (ii) the minimum cash balance, if any, required of the Company by a creditor to the extent the&#160;Company has incurred permitted priority debt.  The Company had to achieve minimum net revenue of $<ix:nonFraction unitRef="usd" contextRef="i7b1e85f6d793488db550a9cd9ebeec00_D20160101-20161231" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantMinimumNetRevenueAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzYwNQ_296a8f2e-6da5-4e8d-a552-d7ea847a7930">1,000,000</ix:nonFraction> in 2016, $<ix:nonFraction unitRef="usd" contextRef="i159d0d96431346b8906e3a743106810e_D20170101-20171231" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantMinimumNetRevenueAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzYxNw_64eef6b2-9203-4776-bee1-aebf4c7abebe">5,000,000</ix:nonFraction> in 2017, $<ix:nonFraction unitRef="usd" contextRef="i819cbd89b0e044588cd3162b0ae7dad0_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantMinimumNetRevenueAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzYyOQ_aa53c8fc-9998-4175-abc9-e60099600146">15,000,000</ix:nonFraction> in 2018, $<ix:nonFraction unitRef="usd" contextRef="i448c71a8e90245efa333cff2acf26e6f_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantMinimumNetRevenueAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzY0MQ_e519911d-df7a-42ff-b29d-fb6508700c43">30,000,000</ix:nonFraction> in 2019 and must achieve minimum net revenue of $<ix:nonFraction unitRef="usd" contextRef="ic379c431ee4f4674ab4bd3200cc4d510_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="silk:DebtInstrumentCovenantMinimumNetRevenueAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzY5Mg_625c6d68-6327-49d7-a8af-1e0384b8b9ba">40,000,000</ix:nonFraction> in 2020. The liquidity financial covenant has a <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:durday" name="silk:DebtInstrumentLiquidityCovenantTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzc0Mw_680f5d30-655e-492d-af25-909c33b82dcb">90</ix:nonNumeric>-day equity cure period following end of the calendar year to issue additional shares of equity interests in exchange for cash, or to borrow permitted cure debt.  In addition, the term loan agreement prohibits the payment of cash dividends on the Company&#8217;s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates.  CRG may accelerate the payment terms of the term loan agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the term loan agreement, the failure of the Company to adhere to the covenants set forth in the term loan agreement, the insolvency of the Company or upon the occurrence of a material adverse change.  As of June&#160;30, 2020, the Company was in compliance with all applicable financial covenants.  As of June&#160;30, 2020, management does not believe that it is probable that the above clauses will be triggered within the next twelve months, and therefore, the debt is classified as long-term on the condensed balance sheet.</span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfNTY2OQ_93b3b683-9cd1-4614-ad03-29235a31db55" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future maturities under the term loan agreement as of June&#160;30, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.256%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period Ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfMS0yLTEtMS0w_9df6a581-3b39-4592-b242-296068bebb7d">2,240</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfMi0yLTEtMS0w_01ef190d-37b8-4311-9fe8-3d7a7f252082">4,442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfMy0yLTEtMS0w_f6141e21-8a0d-44ad-9ebd-c01018854fbc">48,255</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="silk:LongTermDebtGrossBeforeAccretionOfClosingFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfNC0yLTEtMS0w_4d2556b3-93a9-4d08-8918-70db1e2e5fab">54,937</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add: Accretion of closing fees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="silk:LongTermDebtAccretionOfClosingFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfNS0yLTEtMS0w_be690105-0aa2-4329-82bf-22e2a92aac31">1,369</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfNi0yLTEtMS0w_7ecd9928-78bf-4e73-87ab-5e9f98c80089">56,306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amount representing interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="silk:LongTermDebtUnpaidInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfNy0yLTEtMS0w_fe96d562-a3f2-4b56-b722-af5962c73fac">11,124</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amount representing debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfOC0yLTEtMS0w_0c3f93b6-bfa4-48c6-88c1-0afc8c9974a9">116</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfOS0yLTEtMS0w_41d2001d-7ca3-4d31-afd8-097ff59b3afe">45,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2015, CRG purchased <ix:nonFraction unitRef="shares" contextRef="i633031055692460588cb4386c56f8095_D20151001-20151031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQ4Mg_6402f97d-2ef0-4c01-bdd7-5a4c799ed4ea">327,759</ix:nonFraction> shares of the Company&#8217;s Series C redeemable convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="ie917c02865cd4fba8e0243a7cd29e649_I20151031" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQ2Nw_238a2ede-58cf-4450-9216-205d1493dc85">6.11</ix:nonFraction> per share.  In addition, CRG received warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i417623c9d2f24af1b9f527fefb005c13_I20151031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQ5OQ_e4acfd65-f4b1-4a17-b2ce-71799823ab34">163,877</ix:nonFraction> shares of the Company&#8217;s Series C redeemable convertible preferred stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie917c02865cd4fba8e0243a7cd29e649_I20151031" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfNTI0Ng_a4c4be14-98b9-4f5f-acd2-a6c53c1f6c7c">6.11</ix:nonFraction> per share.  Upon the closing of the IPO, the warrants were net exercised, based on the initial public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ieebe6a801a53498d95a8594bf16d9080_I20151031" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTU3Mw_aef77954-70a4-44f6-abf5-4c55a08f1a40">20.00</ix:nonFraction> per share, into&#160;shares of common stock. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2017, CRG purchased an additional <ix:nonFraction unitRef="shares" contextRef="i6c7140d4200a4dc5bdacecc60d872d6b_D20170701-20170731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTUxNg_7b5c288c-c2a8-4ccb-8625-0db57515da95">163,877</ix:nonFraction> shares of the Company&#8217;s Series C convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="ife031befc9a54c529bec50b02c7d0159_I20170731" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTUzMQ_617fb619-c272-4882-8a79-8d1e731bc437">6.11</ix:nonFraction> per share.  Upon the closing of the IPO, the Series C redeemable convertible preferred stock shares were converted into&#160;shares of common stock.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMzEwMQ_f3785e1d-55d6-498e-a9bb-d42c3570741e" continuedAt="i033a4a8cd6fe42e980044d5f1afc42ef" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i033a4a8cd6fe42e980044d5f1afc42ef" continuedAt="ie3895da1cc7d4ba782c022a2db225656"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating Lease and Rights-of-Use</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s operating lease obligation consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2024.  The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of <ix:nonNumeric contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMzcw_809a0ec5-e5de-4700-a8b3-103732d2ab07">five years</ix:nonNumeric>.  Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNDAy_a4a97185-8d19-4ef5-b7e9-799d4d99f065"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNDAy_fe90b7d2-775a-444d-ade4-0f638c803220">217,000</ix:nonFraction></ix:nonFraction> for each of the three months ended June 30, 2020 and 2019 and $<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTA5OTUxMTYzMDg4MA_7f6d95a9-f8e7-4741-86db-2555f3a7256c"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTA5OTUxMTYzMDg4MA_a839712f-a267-48ff-9866-beedab4e2316">435,000</ix:nonFraction></ix:nonFraction> for each of the six months ended June 30, 2020 and 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNTQ2_1d907aa2-5a7d-44b1-98bc-48333f9ae6d9">188,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTA5OTUxMTYzMDg4NA_e50951bd-4c53-40eb-bc1a-758b432ab516">372,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNTUz_6e057a09-197a-4d20-bb47-da120f34bb0b">169,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTA5OTUxMTYzMDg5NQ_931c90a9-69a9-46fc-bd69-84e8cee91532">363,000</ix:nonFraction> for the three and six months ended June&#160;30, 2020 and 2019, respectively.  As of June&#160;30, 2020, the weighted average discount rate was approximately <ix:nonFraction unitRef="number" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNjY5_80150309-1f4c-48b2-93fd-c6f1622be9a0">6.50</ix:nonFraction>% and the weighted average remaining lease term was <ix:nonNumeric contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNzIy_a071f83a-6f52-4cb7-9700-17455eb88dde">4.33</ix:nonNumeric> years.  <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="silk:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMzA5Nw_ba0b1c37-6753-49a9-95a5-a67455b8b7d1" continuedAt="i1831811093f14e55b31a8a6eebdd9910" escape="true">Balance sheet information as of June&#160;30, 2020 consists of the following (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;"><ix:continuation id="i1831811093f14e55b31a8a6eebdd9910"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:78.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.591%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Lease:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset in other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOjc1OWQzZWFmNjAyYTQ0N2NhMWNlYjJhYTkzMDM1YTI2L3RhYmxlcmFuZ2U6NzU5ZDNlYWY2MDJhNDQ3Y2ExY2ViMmFhOTMwMzVhMjZfMS0yLTEtMS0w_1abbfd54-5135-41d7-9ac4-a302e7b73687">3,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability in accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOjc1OWQzZWFmNjAyYTQ0N2NhMWNlYjJhYTkzMDM1YTI2L3RhYmxlcmFuZ2U6NzU5ZDNlYWY2MDJhNDQ3Y2ExY2ViMmFhOTMwMzVhMjZfMi0yLTEtMS0w_c7f265fc-b41a-4b23-be60-cde8ccdf9697">809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability in other liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOjc1OWQzZWFmNjAyYTQ0N2NhMWNlYjJhYTkzMDM1YTI2L3RhYmxlcmFuZ2U6NzU5ZDNlYWY2MDJhNDQ3Y2ExY2ViMmFhOTMwMzVhMjZfMy0yLTEtMS0w_f5d84c09-50d9-46f1-832c-ac2faac9ec62">3,288</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOjc1OWQzZWFmNjAyYTQ0N2NhMWNlYjJhYTkzMDM1YTI2L3RhYmxlcmFuZ2U6NzU5ZDNlYWY2MDJhNDQ3Y2ExY2ViMmFhOTMwMzVhMjZfNC0yLTEtMS0w_3c76a7f7-e31a-4ada-902f-20c9c40ddff5">4,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMzA5OQ_f0681bb0-1782-4cee-a241-3c862a445933" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s operating lease maturities as of June&#160;30, 2020 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.256%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period Ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfMS0yLTEtMS0w_57917704-959a-48c1-87bd-8779101d6cb8">525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="silk:LesseeOperatingLeaseLiabilityToBePaidYearOne" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfMi0yLTEtMS0w_7412b9d8-d355-4559-abab-50dbae04fd97">1,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfMy0yLTEtMS0w_9a94d50e-0732-4973-a2c6-cd09920f12f9">1,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfNC0yLTEtMS0w_1f881261-c282-4e76-88ec-1bce72525d01">1,127</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfNS0yLTEtMS0w_70996437-2c0d-4e70-b970-135f780e4fd8">904</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfNi0yLTEtMS0w_cbf07fbe-ceb4-40de-acba-dbfe7deabb5f">4,718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfNy0yLTEtMS0w_ab20c606-5194-43c9-8f05-5a82dafeec10">621</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfOC0yLTEtMS0w_745a5b83-9b9e-44d6-862a-87bf2cf02b5c">4,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Purchase Obligations</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. As of June&#160;30, 2020, the Company had non-cancellable purchase obligations to suppliers of $<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTEzMA_65d9cd78-b526-459b-8a6f-51394307b9a3">6,640,000</ix:nonFraction>.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indemnification</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty.  The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made.  To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="ie3895da1cc7d4ba782c022a2db225656"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws.  The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity.  The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance.  The Company believes that the fair value of these indemnification obligations is minimal.  Accordingly, the Company has not recognized any liabilities relating to these obligations as of June&#160;30, 2020.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contingencies </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows.  From time to time, the Company may pursue litigation to assert its legal right and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual at June&#160;30, 2020 and December&#160;31, 2019.</span></div></ix:continuation><div id="i0f5f7f4a40e74f9186fba54ac93b1916_64"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjc0ODc3OTA3MDA3Mw_87474fd9-61c0-4bbd-a5f8-f11bf811bd32" continuedAt="i9ac967cd5ed3490d9d87bf635fe0839b" escape="true">Redeemable Convertible Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="i9ac967cd5ed3490d9d87bf635fe0839b" continuedAt="i085658c4790e49b8ab98a0c6520fc75a"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into shares of common stock. As of June&#160;30, 2020 and December 31, 2019, the Company does <ix:nonFraction unitRef="shares" contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjI3_097bf0ec-1fae-4c0a-94a7-11c71260ea60"><ix:nonFraction unitRef="shares" contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjI3_b0a7127e-7c0f-4e0b-8138-cc7eea23a906"><ix:nonFraction unitRef="shares" contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjI3_c80ae1bc-4723-473a-85ad-5cb175e26a7f"><ix:nonFraction unitRef="shares" contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjI3_cba3f41d-6fa3-423b-aebb-f925cf487eb3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t have any convertible preferred stock issued or outstanding.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock Warrant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">s</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the Company's IPO, all of the outstanding convertible preferred stock warrants were exercised, or net exercised based on the IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9dcdcdf5e9b496689dbd352302af644_I20200630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNDk0NzgwMjMyNTYzNA_d589f590-11b8-4110-ac8b-e4810f486e56">20.00</ix:nonFraction> per share, into&#160;<ix:nonFraction unitRef="shares" contextRef="i84de79cfd01646ca80f851b0e71fec3e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNDk0NzgwMjMyNTY1Mg_103e8956-7991-4e8b-b9ad-d4d6f3050e47">1,945,365</ix:nonFraction> shares of common stock. As of June&#160;30, 2020 and December 31, 2019, the Company does <ix:nonFraction unitRef="shares" contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNTY5_097bf0ec-1fae-4c0a-94a7-11c71260ea60"><ix:nonFraction unitRef="shares" contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNTY5_b0a7127e-7c0f-4e0b-8138-cc7eea23a906"><ix:nonFraction unitRef="shares" contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNTY5_c80ae1bc-4723-473a-85ad-5cb175e26a7f"><ix:nonFraction unitRef="shares" contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNTY5_cba3f41d-6fa3-423b-aebb-f925cf487eb3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t have any convertible preferred stock warrants outstanding.</span></div></ix:continuation><div id="i0f5f7f4a40e74f9186fba54ac93b1916_67"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.&#160;&#160;&#160;&#160;<ix:continuation id="i085658c4790e49b8ab98a0c6520fc75a" continuedAt="i8f4addaf086448beaadb7d524b060a9a">Stockholders Equity</ix:continuation></span></div><ix:continuation id="i8f4addaf086448beaadb7d524b060a9a"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to <ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjA0OQ_1e257701-dd7d-4d0f-80bd-93915e469cca">5,000,000</ix:nonFraction> shares of preferred stock with $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjA2Nw_c216748c-052a-411d-a1b8-d5f7e8989c35">0.001</ix:nonFraction> par value per share, of which <ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfMjI5_75d82630-c2a0-4af1-9030-81b52a4fc67b"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfMjI5_7d2bdf21-7c01-4b48-85a9-b30374ea2ec9">no</ix:nonFraction></ix:nonFraction> shares were issued and outstanding.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to <ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfMzk1_da132236-7c43-4c5b-8d84-51468a969ff4">100,000,000</ix:nonFraction> shares of common stock with $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDI2_56dcf95b-f264-44e7-818b-49728e7da5ad">0.001</ix:nonFraction> par value per share, of which <ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDU5_26602a01-28d6-4257-8f20-a667e8517bfd"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDU5_e0ef9fd2-0d31-4f3d-9488-49a9eacf73e5">33,610,099</ix:nonFraction></ix:nonFraction> shares were issued and outstanding.  The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors.  As of June&#160;30, 2020, <ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNjYz_63e8d34f-56a6-461c-933e-93c1c38f805d">no</ix:nonFraction> dividends have been declared to date.  Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="silk:CommonStockVotePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjEwNg_993f1a2b-5d64-4855-8281-7110714d2362">one</ix:nonFraction> vote.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock Warrant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">s</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the IPO, the common stock warrants were cash, or net exercised based on the IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9dcdcdf5e9b496689dbd352302af644_I20200630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjA5NQ_4d4a2051-dfda-4ba2-a217-c4e4b0d4e5c5">20.00</ix:nonFraction> per share, into <ix:nonFraction unitRef="shares" contextRef="i6113484aa6d4421ebce5390fc3eaf952_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjA4MQ_a834b738-5c1d-4fd4-a7b4-c74c57a9a207">5,968</ix:nonFraction> shares of common stock.  As of June&#160;30, 2020 and December 31, 2019, the Company does <ix:nonFraction unitRef="shares" contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfOTgy_097bf0ec-1fae-4c0a-94a7-11c71260ea60"><ix:nonFraction unitRef="shares" contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfOTgy_b0a7127e-7c0f-4e0b-8138-cc7eea23a906"><ix:nonFraction unitRef="shares" contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfOTgy_c80ae1bc-4723-473a-85ad-5cb175e26a7f"><ix:nonFraction unitRef="shares" contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfOTgy_cba3f41d-6fa3-423b-aebb-f925cf487eb3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t have any common stock warrants outstanding.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMxMQ_70235573-9a24-4901-aeec-e898d9f55c75" continuedAt="i9cf9d02062674c829a92d518f10fa1bb" escape="true">Stock Option Plans</ix:nonNumeric></span></div><ix:continuation id="i9cf9d02062674c829a92d518f10fa1bb" continuedAt="if9e47201b55241fd8cce71c100d5adbc"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company&#8217;s Board of Directors approved the adoption of the 2019 Equity Incentive Plan, or the 2019 Plan, which became effective immediately prior to the Company's IPO. The 2019 Plan replaced the 2007 Stock Option Plan which was terminated immediately prior to consummation of the Company&#8217;s IPO, collectively the &#8220;Plans.&#8221; The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants.  A total of <ix:nonFraction unitRef="shares" contextRef="i7df1fe52b16e418da8983a23cd31db62_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNjE5_5d57cc33-bc12-4065-83f1-36da2b89c91c">2,317,000</ix:nonFraction> shares of common stock were initially reserved for issuance pursuant to the 2019 Plan.  In addition, the shares reserved for issuance under the 2019 Plan will also include shares reserved but not issued under the 2007 Stock Option Plan, plus any share awards granted under the 2007 Stock Option Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased.  In addition, the number of shares available for issuance under the 2019 Plan will also include an annual increase on the first day of each fiscal year beginning in fiscal 2020, equal to the lesser of (i) <ix:nonFraction unitRef="shares" contextRef="i2378c3bc6251483cab8274447be641b8_I20190331" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMTIyOA_b31631ed-ef52-4e19-8031-bf8a2176d549">3,000,000</ix:nonFraction> shares; (ii) <ix:nonFraction unitRef="number" contextRef="i3dd9fbf4e28c4a2fbde835757d39a1e5_D20190301-20190331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMTI0NA_5106d3f2-50a9-458e-87f4-c658c4b8fa5e">4.0</ix:nonFraction>% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors.  As of June&#160;30, 2020, the Company has reserved <ix:nonFraction unitRef="shares" contextRef="i6b705b1bf16749838adb0a5da76d687c_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMTQ0Ng_2b5de8d2-f619-4452-81d5-8476ee3f7077">3,631,205</ix:nonFraction> shares of common stock for issuance under the 2019 Plan.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exercise price of ISOs and NSOs shall not be less than <ix:nonFraction unitRef="number" contextRef="ie23898085ac8458bb0cac28efb4aaef4_I20200630" decimals="INF" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTUyMA_46db0a22-32e3-4da4-a0ee-5dd7fe3ec05f">100</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i53f162f8f289492a97ccfe1e594fa809_I20200630" decimals="INF" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTUzMA_0a9960ba-abe3-44fc-b964-53d575fbd761">85</ix:nonFraction>% of the estimated fair value of the shares on the date of grant, respectively, as determined by the Board of Directors.  The exercise price of ISOs and NSOs granted to a 10% stockholder shall not be less than <ix:nonFraction unitRef="number" contextRef="ice3001c6ee614220ac19207889d5aa37_I20200630" decimals="INF" name="silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTU0MA_6c43583b-e4b3-427b-a0be-e681d5793508">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  To date, options have a term of <ix:nonNumeric contextRef="ie82a229840ec40d79a480525255fd532_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTQ4MQ_ab16fc75-9c00-499c-b55d-c71aa2aad130">10</ix:nonNumeric> years and generally vest over <ix:nonNumeric contextRef="ie82a229840ec40d79a480525255fd532_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTUwMg_21ab492a-28fb-4427-abc2-3a3ff2c67805">4</ix:nonNumeric> years from the date of grant.</span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMwOA_16760f14-1ce8-4690-9b60-fcc940a5fd74" escape="true"><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock option activity under the Company&#8217;s Plans is set forth below:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:33.096%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.416%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.179%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.465%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options Outstanding</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares Available for Grant</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy0xLTEtMS0w_4da289ea-c8c0-4287-af26-2589350e12f0">1,554,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy0zLTEtMS0w_e2751f16-1c87-4587-a18a-6d5cc1d5fa40">4,310,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy01LTEtMS0w_0c79c814-5a7b-4f7f-9f63-39d8ca552144">7.91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i448c71a8e90245efa333cff2acf26e6f_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy03LTEtMS0w_4f349cba-9fad-4e4b-910d-4afedb6c8a37">7.27</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy05LTEtMS0w_3c1ba3f0-0176-47ba-a122-f942dfcc4f81">140,234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Authorized</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfOC0xLTEtMS0w_77c10e04-155b-47f2-9bb4-858f527c307f">1,250,210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfOS0xLTEtMS0w_bf14cfd8-6e7d-4847-8935-81554b9a1723">752,258</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfOS0zLTEtMS0w_f514453b-212e-4396-9dae-719b01a625c7">752,258</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfOS01LTEtMS0w_3e461f2b-b074-48cc-a8a3-dba1fb5063e8">33.86</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTAtMy0xLTEtMA_e2428c18-c3c0-4a44-8f93-f56df0715566">405,837</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTAtNS0xLTEtMA_12aeec45-8d66-4468-af50-fac0db005445">2.16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options cancelled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTEtMS0xLTEtMA_3f064456-23b9-4741-a4f5-6c19beedeb83">24,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTEtMy0xLTEtMA_624c1af8-e42f-46b4-8f1e-6a2595319f35">24,345</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTEtNS0xLTEtMA_a4a84cae-b73e-4e8e-8b62-31a7836dcc75">17.28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItMS0xLTEtMA_a3935d0f-c6ae-4250-b7a5-b852f218cf94">2,076,987</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItMy0xLTEtMA_43a4cea9-4215-405c-823f-39bc16843519">4,632,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItNS0xLTEtMA_bb9e29e4-d9dd-4abc-8a88-bac45e096381">12.57</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItNy0xLTEtMA_5fd219a8-eac6-437d-aab8-b549f7df3466">7.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItOS0xLTEtMA_2b7a98b6-946a-48f6-a7dc-4c0cdbc2db2b">136,505</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and exercisable at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTMtMy0xLTEtMA_ae960b08-1285-4939-b282-fd53335389be">2,554,809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTMtNS0xLTEtMA_22423c5f-1f0d-4a02-8c55-7dbda9f0ee29">5.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTMtNy0xLTEtMA_e592327d-752e-49e6-a755-2390e9520d74">6.40</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTMtOS0xLTEtMA_9f21e8c6-a5ff-4fd9-ac1e-7556400929b2">91,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTQtMy0xLTEtMA_ab5f098c-5540-43ce-9a06-5cd6c77f3821">4,632,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTQtNS0xLTEtMA_1e281f2d-7c3d-4217-8b5a-56450f90df8e">12.57</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTQtNy0xLTEtMA_3ea975ee-f79a-44df-ab0e-6a87eedd5aaf">7.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTQtOS0xLTEtMA_b8a2fe42-9608-49d3-80d6-c53aca8a2303">136,505</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic value of options exercised during the six months ended June 30, 2020, was $<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjExNg_0fdfcf45-fa26-40b9-97de-6a8ba45a8116">15,048,000</ix:nonFraction>.  The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. </span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="if9e47201b55241fd8cce71c100d5adbc" continuedAt="i73bf21b97b7843d79f504f7c97709822"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Restricted Stock Units</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company began granting restricted stock units, or RSUs, under the 2019 Plan.  RSUs generally vest over <ix:nonNumeric contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjQ1OA_7e5db4ee-595e-4d92-a0a9-77c33bd4260c">four years</ix:nonNumeric> in annual equal increments, <ix:nonFraction unitRef="shares" contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjQ4Mg_7fe1b92d-159f-468d-8e01-13672e233924">no</ix:nonFraction> RSUs vested during the six months ended June 30, 2020.  <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMxMw_a7b365d1-835f-4f05-a995-6259f47a711d" continuedAt="i4a4ad91cb71b406d88233c61cb6de621" escape="true">The fair value of RSUs is based on the Company&#8217;s closing stock price on the date of grant. A summary of RSUs activity for the six months ended June 30, 2020 is as follows:</ix:nonNumeric></span></div><div><ix:continuation id="i4a4ad91cb71b406d88233c61cb6de621"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:69.864%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.443%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.504%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.443%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.346%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Restricted Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7a6f5fdcd6894037a81fa4bc82914447_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMS0yLTEtMS0w_af7453cd-b931-4b87-9f2d-d9b283ea7526">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a6f5fdcd6894037a81fa4bc82914447_I20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMS00LTEtMS0w_acb01375-0154-4eda-95d9-15af4e9b0178">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMi0yLTEtMS0w_c5cf163e-73cc-455f-b12f-559473dfc9a2">39,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMi00LTEtMS0w_3fda6c3b-aa99-4fca-a87c-2099b18560b2">31.18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMy0yLTEtMS0w_22beab9c-f41d-4516-9d0e-953788910e2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMy00LTEtMS0w_b1fe6b9c-b414-4bd7-8362-d376c6b8b75c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNC0yLTEtMS0w_5a8fefd8-e55e-46b6-a114-a9b6fe948c84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNC00LTEtMS0w_9cab61e9-cc3f-4c61-94ec-709aacf2ad37">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNS0yLTEtMS0w_519ecc29-604f-43c9-a3d4-3d1d1e3a92c5">39,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNS00LTEtMS0w_8ad91aaa-24b0-4921-bcb0-43d136f3341e">31.18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNi0yLTEtMS0w_c9146250-ecb9-4994-bcd7-ba4eb9f5855d">39,089</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNi00LTEtMS0w_099b529b-ba7d-4656-940d-383773878251">31.18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2019 Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company's Board of Directors adopted the 2019 Employee Stock Purchase Plan, or 2019 ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions.  A total of <ix:nonFraction unitRef="shares" contextRef="i039961495a884a188b5d3e7bda9008a4_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjk5MA_7fa7491b-87bc-4cbc-98f3-552b008a5419">434,000</ix:nonFraction> shares of common stock were initially reserved for issuance and will be increased on the first day of each fiscal year, beginning in 2020, by an amount equal to the lesser of (i)&#160;<ix:nonFraction unitRef="shares" contextRef="i039961495a884a188b5d3e7bda9008a4_I20190331" decimals="INF" format="ixt:numdotdecimal" name="silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzE3Mg_a5f6c28e-3f38-4d6a-9598-7112c48b6093">1,200,000</ix:nonFraction> shares (ii)&#160;<ix:nonFraction unitRef="number" contextRef="i515f2625685e47a3a0c3f87208b405e1_D20190301-20190331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzE4Nw_e7eb92fe-8f4d-4f8f-9955-6df8cd834425">1.0</ix:nonFraction>% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors.  As of June&#160;30, 2020, the Company has reserved <ix:nonFraction unitRef="shares" contextRef="i3eb1770831844300ae09b328b18c5397_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzM4OQ_4f74383c-3910-4073-9957-a7e5086ec3d9">746,552</ix:nonFraction> shares of common stock for issuance under the 2019 ESPP.  The price of the common stock purchased will be the lower of <ix:nonFraction unitRef="number" contextRef="i454e6e1c1e7148d2abad0f588fcee401_D20200101-20200630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzUxMQ_e9235266-2dc7-48f1-b4b6-3250f2ae516c">85</ix:nonFraction>% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period.  The 2019 ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019.  The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="i454e6e1c1e7148d2abad0f588fcee401_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzk3MA_0be7950d-cd9f-4cb0-bc36-74f2f00ad567">87,567</ix:nonFraction> shares of common stock have been issued to employees participating in the 2019 ESPP and <ix:nonFraction unitRef="shares" contextRef="i3eb1770831844300ae09b328b18c5397_I20200630" decimals="INF" format="ixt:numdotdecimal" name="silk:CommonStockCapitalSharesAvailableForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNDA2MQ_1ace289a-d086-4737-b901-7037062f611c">658,985</ix:nonFraction> shares were available for future issuance under the 2019 ESPP.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><ix:continuation id="i73bf21b97b7843d79f504f7c97709822"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company estimated the fair value of stock options using the Black&#8211;Scholes option pricing model.  The fair value of employee and nonemployee stock options is being amortized on a straight&#8211;line basis over the requisite service period of the awards.  <ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMwMA_2bef589e-fe3d-4d9f-b8b4-e5a559fe8533" continuedAt="i034fbdde886c46bcbf14d43ffd5f1a42" escape="true">The fair value of employee and nonemployee stock options was estimated using the following assumptions for the three and six months ended June&#160;30, 2020 and 2019:</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><ix:continuation id="i034fbdde886c46bcbf14d43ffd5f1a42"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:32.455%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.867%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i0dfbb8e51673404eb0624832076ff097_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi0xLTEtMS0wL3RleHRyZWdpb246ZWNlYjYyOTQwM2IzNGE3MThjNzkxODcyNGY3YzI2MmNfMjE5OTAyMzI1NTU3Nw_2b006933-2c87-48a6-bbbb-a6293e1bee02">5.25</ix:nonNumeric> - <ix:nonNumeric contextRef="i1bea4ee895a74d1aaedf0a333c0c6f4c_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi0xLTEtMS0wL3RleHRyZWdpb246ZWNlYjYyOTQwM2IzNGE3MThjNzkxODcyNGY3YzI2MmNfMjE5OTAyMzI1NTU3MQ_e19fdffb-d3ca-46d8-912b-2098c7aab96b">6.25</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i70be1e0534404d08896dbc0a988ff250_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi0zLTEtMS0wL3RleHRyZWdpb246NTVkYmUwMWY5YTI2NGFmMmIwMGI5N2I1ZWM5NWNmNjBfMjE5OTAyMzI1NTU3MQ_ac0cf071-6850-4477-8e67-43e1379932af">5.00</ix:nonNumeric> - <ix:nonNumeric contextRef="i73c173a6496b4596bfce7f7c0833e719_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi0zLTEtMS0wL3RleHRyZWdpb246NTVkYmUwMWY5YTI2NGFmMmIwMGI5N2I1ZWM5NWNmNjBfMjE5OTAyMzI1NTU3Nw_ab19225d-beca-46ae-acd8-805365bbaeab">6.25</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i220629dc98834984b7d11f79d2fe810b_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi01LTEtMS0xNzQvdGV4dHJlZ2lvbjpkOTNmMzNjYmM4YTk0MTZiODQyYWUzNjNhYmJlMTIyYV8yMTk5MDIzMjU1NTcx_7a90a4a2-c4b0-43fd-983e-b5661a16bf8a">5.25</ix:nonNumeric> - <ix:nonNumeric contextRef="ic4dc7821cccc41989da58dcccb531642_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi01LTEtMS0xNzQvdGV4dHJlZ2lvbjpkOTNmMzNjYmM4YTk0MTZiODQyYWUzNjNhYmJlMTIyYV8yMTk5MDIzMjU1NTc3_5eba936c-3cfb-441a-b357-71bed2daaad1">6.25</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ia742a060c2af4302bfd4a0bd4786b675_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi03LTEtMS0xNzQvdGV4dHJlZ2lvbjo0YTMxZWVmNzgxNTg0YjE1ODFiY2FlOTEwZDVkYjgyZV8yMTk5MDIzMjU1NTcx_656669bd-c3cf-462f-a8bd-b9796a088bfd">5.00</ix:nonNumeric> - <ix:nonNumeric contextRef="ia43e704ab79f493585f933259edc8540_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi03LTEtMS0xNzQvdGV4dHJlZ2lvbjo0YTMxZWVmNzgxNTg0YjE1ODFiY2FlOTEwZDVkYjgyZV8yMTk5MDIzMjU1NTc3_529d30ff-2e4e-45c2-a29d-e20b6b973b8b">6.25</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy0xLTEtMS0wL3RleHRyZWdpb246MzQ2ODQxMWRhZThiNDM5MjhiZTBjYmUyNDczZjdhOWVfMjE5OTAyMzI1NTU5NA_29fd20d0-bf2b-432d-8ad7-e85cb8382298">46.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy0xLTEtMS0wL3RleHRyZWdpb246MzQ2ODQxMWRhZThiNDM5MjhiZTBjYmUyNDczZjdhOWVfMjE5OTAyMzI1NTYwMQ_6da7b21b-3c23-4472-906c-046ecd086256">47.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy0zLTEtMS0wL3RleHRyZWdpb246ZDlmYjY5N2Q3YjA4NDQxNmJmZmI1NjdhM2M5NjJmNjVfMjE5OTAyMzI1NTU3NA_8bfc445a-316b-42c7-81e7-bdef57f52343">42.7</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy0zLTEtMS0wL3RleHRyZWdpb246ZDlmYjY5N2Q3YjA4NDQxNmJmZmI1NjdhM2M5NjJmNjVfMjE5OTAyMzI1NTU4MQ_be81f9c4-4fbc-4f71-8918-8e40308302e8">42.9</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy01LTEtMS0xNzQvdGV4dHJlZ2lvbjpjMjQyZjVkZDNkNzQ0OTg4ODgwNjNlZTIxNzRlYTMwN18yMTk5MDIzMjU1NTc0_abb9c8a5-fedc-4a14-a87f-ed2f7e1549b6">42.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy01LTEtMS0xNzQvdGV4dHJlZ2lvbjpjMjQyZjVkZDNkNzQ0OTg4ODgwNjNlZTIxNzRlYTMwN18yMTk5MDIzMjU1NTgx_4d944dcb-7582-48f1-9c06-1b6db85f5bc3">47.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy03LTEtMS0xNzQvdGV4dHJlZ2lvbjpkZGY3ODc1YzJhYjE0MDk3YWRlNTdkMTAyMzAwNTgxOV8yMTk5MDIzMjU1NTc0_b961c79b-bf23-48b0-b9df-cdea4b0b5d57">42.7</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy03LTEtMS0xNzQvdGV4dHJlZ2lvbjpkZGY3ODc1YzJhYjE0MDk3YWRlNTdkMTAyMzAwNTgxOV8yMTk5MDIzMjU1NTgx_7fe419f1-92a9-4f84-92f5-2cabf7f4eda0">42.9</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC0xLTEtMS0wL3RleHRyZWdpb246NWQ1YzE0MTEwOTYwNDk1YTk1NGQzMzFiNWM3MWVmMWRfNA_084bdb3c-7547-4872-8ab7-0b541e875024">0.42</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC0xLTEtMS0wL3RleHRyZWdpb246NWQ1YzE0MTEwOTYwNDk1YTk1NGQzMzFiNWM3MWVmMWRfOQ_7afb91de-9151-4530-b921-3656c8efe407">0.56</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC0zLTEtMS0wL3RleHRyZWdpb246N2VmYWZlMWRiYzc1NGIyNWExNDE0ZTgwYzQ0NTZiMTNfMjE5OTAyMzI1NTU4NA_fdbf1963-b6cd-4743-a0f7-2764f76b8e15">1.86</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC0zLTEtMS0wL3RleHRyZWdpb246N2VmYWZlMWRiYzc1NGIyNWExNDE0ZTgwYzQ0NTZiMTNfMjE5OTAyMzI1NTU5MQ_68ce5692-b37a-4d5d-b574-75a3a4aa56a7">2.37</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC01LTEtMS0xNzQvdGV4dHJlZ2lvbjpiM2YwYTMxNTU3NGU0MTdlYjJjYTgzY2I0ZjcxZTc1Yl8yMTk5MDIzMjU1NTc0_5d5bbfa8-f2b8-4a13-86e2-b12ce12ed3e4">0.42</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC01LTEtMS0xNzQvdGV4dHJlZ2lvbjpiM2YwYTMxNTU3NGU0MTdlYjJjYTgzY2I0ZjcxZTc1Yl8yMTk5MDIzMjU1NTgx_53e7950d-5ebb-4027-a428-4c63b5d8b65f">1.41</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC03LTEtMS0xNzQvdGV4dHJlZ2lvbjpjNzIzMTk1ZDFlNzM0MzBlOTk3NWMwZTU0ZTE0MzEzYl8yMTk5MDIzMjU1NTc0_25f4cd94-ed21-4614-b116-78c0458e9424">1.86</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC03LTEtMS0xNzQvdGV4dHJlZ2lvbjpjNzIzMTk1ZDFlNzM0MzBlOTk3NWMwZTU0ZTE0MzEzYl8yMTk5MDIzMjU1NTgx_0be5b8e0-bc30-4373-bd3a-a5f9394acb6e">2.54</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNS0xLTEtMS0w_01ecaf83-f9d9-4497-b869-bf507bcf869d">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNS0zLTEtMS0w_4a6d226a-a635-4075-a658-c0c3db8c7df5">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNS01LTEtMS0xNzQ_49e8f25b-b2f3-4d09-b10f-3074578515bf">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNS03LTEtMS0xNzQ_027843e6-14c7-4999-976d-fcb199069d9c">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="silk:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMwMQ_eaa8920d-2b7f-4c75-b20a-d249042eb4bf" escape="true"><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the shares to be issued under the Company&#8217;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and six months ended June&#160;30, 2020:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:32.455%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.826%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.224%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.544%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.028%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMS0xLTEtMS0w_ca7b608a-7200-47ee-9ab2-0a391945c677">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4024977785b1424fab65d0622c295161_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMi0zLTEtMS05ODA_fdc7a4ba-334e-4505-870e-7f9b51a22675">0.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMi01LTEtMS05OTA_5d235890-3ad7-43f6-bcf9-d26ce64c26ef">0.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMS0zLTEtMS0xOTY_3b8a00be-fcec-456d-9e6f-efbdccb4389f">0.63</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMi0xLTEtMS0w_4689ce92-7d73-4b1f-82c7-a570ae24894b">76.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4024977785b1424fab65d0622c295161_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy0zLTEtMS05ODA_a915d7ea-58d4-4df1-9fff-ac7fbc6b9ddb">47.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy01LTEtMS05OTAvdGV4dHJlZ2lvbjoyYzJjNTY2YjExMmQ0M2I1ODc2YzExZDllNDM4OGQ3OV8yMTk5MDIzMjU1NTc0_ca0e5368-3ab4-435a-bb0b-22a00f3225e5">44.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy01LTEtMS05OTAvdGV4dHJlZ2lvbjoyYzJjNTY2YjExMmQ0M2I1ODc2YzExZDllNDM4OGQ3OV8yMTk5MDIzMjU1NTgx_8df0c796-98f4-419a-b7ed-5e2730ad287f">76.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMi0zLTEtMS0xOTY_d2524166-63ad-45cb-aae2-8f881cfaa81d">47.8</ix:nonFraction>%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy0xLTEtMS0w_8bb61677-e3b2-41ba-9273-8045c6c4bf53">0.14</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4024977785b1424fab65d0622c295161_D20190401-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC0zLTEtMS05ODA_e8aed7c3-2950-4d22-a623-6a7b66734eb0">2.45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC01LTEtMS05OTAvdGV4dHJlZ2lvbjplMWMzNGNiMmRkZmM0NTcxYmU0YzU0YTY3OGQ5NTIxZF8yMTk5MDIzMjU1NTc0_358ff5ab-bd4f-4bdd-b23f-25cdeb86ec6a">0.14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC01LTEtMS05OTAvdGV4dHJlZ2lvbjplMWMzNGNiMmRkZmM0NTcxYmU0YzU0YTY3OGQ5NTIxZF8yMTk5MDIzMjU1NTgx_0e8ee7b5-8307-4a34-8381-2dbb4c643dec">1.58</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy0zLTEtMS0xOTY_634d2cce-32d5-4f69-a426-37d412c867af">2.45</ix:nonFraction>%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC0xLTEtMS0w_1026d27b-dbef-4953-89f5-14f6bcd2eff6">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4024977785b1424fab65d0622c295161_D20190401-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNS0zLTEtMS05ODA_399627e1-32ad-4ff7-b1c2-a82e861117c0">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNS01LTEtMS05OTA_66f02785-5157-41f0-bb8f-3b526f5712ab">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC0zLTEtMS0xOTY_4a0b1821-8c30-48a5-a885-c00edbdf7949">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMwNg_db70d14b-c60e-48c4-9147-03a370b581ab" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense relating to the Company's stock options, RSUs and 2019 ESPP during the three and six months ended June&#160;30, 2020 and stock-based compensation expense related to the Company's stock options and 2019 ESPP during the three and six months ended June&#160;30, 2019, is as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.794%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.823%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cbb5c9c3ef24d45998860f450b433d3_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMi0xLTEtMS0w_bdde82f6-6991-41f8-8ef2-ca3e393534b0">89</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2826aabff8b4439e8abd78eb9018b593_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMi0zLTEtMS0w_a160578d-14f1-424d-984a-3146c0d7073e">54</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab80b98eced34b02a24687725a852684_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMi01LTEtMS0yNTg_4aa1451a-cd6c-4fcd-90f5-02fb5d426219">153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b281a430c8c4aada7ebc48e15d5e031_D20190101-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMi03LTEtMS0yNTg_9564480f-764d-454f-8dce-43e2d3f1d746">69</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e5f9129abc84b8e85adb2e73a6a2964_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMy0xLTEtMS0w_638fefba-bf13-4492-a8b0-3c267e06404d">246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id87005078ae94c2ba819b718b9a86599_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMy0zLTEtMS0w_25a8e3a2-c3c0-4175-a48c-27838dec4098">127</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55f2446a5cb34a2c800a0378dc3c54f6_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMy01LTEtMS0yNTg_9dafedd7-e1c3-4da3-8796-272a6265936d">423</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5d1215e8500c43c59e1c45a0496eabb7_D20190101-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMy03LTEtMS0yNTg_104f6be5-a4f9-45cb-aa1b-cad1a328fcab">155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a29f695f4e8418b88fdf2ecd941252f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNC0xLTEtMS0w_6010aac7-c3df-4578-b92b-8197dca88b35">1,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c1ae90727004ccfbf97f186ac2e0781_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNC0zLTEtMS0w_31145c1f-f09a-47fd-8324-087279619292">655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8664b40a2ba4c69b62ac361f5b299d4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNC01LTEtMS0yNTg_a8914595-6f51-4806-b3d9-fa3b3a24a86a">2,371</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a7af5bbd93b4d26b19182dbb32d2697_D20190101-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNC03LTEtMS0yNTg_97e09a6a-0dfa-49a4-8135-b874b7db9dee">875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNS0xLTEtMS0w_e87048bb-6940-4a72-8bd2-05288f5468da">1,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNS0zLTEtMS0w_f5861c31-a333-440f-acf1-4773adcbc1e3">836</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNS01LTEtMS0yNTg_9b74840a-4e0b-4f17-8409-bb8d21fdc860">2,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNS03LTEtMS0yNTg_4e454814-081d-41c1-b63e-750b305fed9c">1,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, there was total unrecognized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTA3NQ_0c0e8e1e-2cf6-459b-b995-d4d135f1d6d0">16,986,000</ix:nonFraction> related to stock options expected to be recognized over a period of approximately <ix:nonNumeric contextRef="i454e6e1c1e7148d2abad0f588fcee401_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTE2MA_a4744e84-9390-4f64-a3af-0240823e82f0">3.24</ix:nonNumeric> years, a total of $<ix:nonFraction unitRef="usd" contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTE3OA_a366fef9-230a-4037-b322-7c61ba1743f7">1,119,000</ix:nonFraction> of unrecognized compensation costs related to unvested RSUs expected to be recognized over a period of approximately <ix:nonNumeric contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTI5OA_c999fdfe-20b2-44e5-80cb-fcf8329645ed">3.68</ix:nonNumeric> years and $<ix:nonFraction unitRef="usd" contextRef="i2473c0e76af946f0a8d35143cb16bdc7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTIxNg_8a38d11f-ed72-4a03-8f05-f1adab0783f8">303,000</ix:nonFraction> of unrecognized compensation costs related to the ESPP, which the Company will recognize over <ix:nonNumeric contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTIyNQ_68f979e2-ffc2-49c8-aa56-a4632fab5948">0.4</ix:nonNumeric> years.</span></div></ix:continuation><div id="i0f5f7f4a40e74f9186fba54ac93b1916_76"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-bottom:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%;">Silk Road Medical, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Notes to Condensed Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">(unaudited)</span></div></td></tr></table></div></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" name="us-gaap:DefinedContributionPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMjc0ODc3OTA3MDAxMQ_e4e3fa0e-eec9-46c8-ad87-4c4b5bf775dc" continuedAt="i07ba7c5e82e14c96b66273d875b8d20a" escape="true">401(k) Plan</ix:nonNumeric></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i07ba7c5e82e14c96b66273d875b8d20a">The Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code (&#8220;IRC&#8221;) under which participants may contribute up to <ix:nonFraction unitRef="number" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMTcy_7a99757f-da9b-4d88-86c8-5f17a8fe294e">90</ix:nonFraction>% of their eligible compensation, subject to maximum deferral limits specified by the IRC.  Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at <ix:nonFraction unitRef="number" contextRef="ia946f02d9b0346d3bb893b131d264f0e_D20200101-20200101" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMzY4_11d1acf5-4d9d-45f8-9edb-e50d6e1be147">50</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="ia946f02d9b0346d3bb893b131d264f0e_D20200101-20200101" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMzg0_83b3e94a-04d2-4554-8879-dab8e14fd2a8">5</ix:nonFraction>% of compensation deferred to the 401(k) plan. The Company's matching contributions were $<ix:nonFraction unitRef="usd" contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfNDc0_bcc97a8c-9d03-40f9-96e3-a794c47c0462">229,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMTA5OTUxMTYyODM3NQ_e3463960-3dea-4c71-8b39-ce8c3de8ea1c">522,000</ix:nonFraction> for the three and six months ended June&#160;30, 2020, respectively.</ix:continuation></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 2: Management Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled &#8220;Selected financial data&#8221; and our condensed financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q.  This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management.  Our actual results could differ materially from those discussed in these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Quarterly Report on Form 10-Q entitled &#8220;Risk Factors.&#8221;</span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_85"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a medical device company focused on reducing the risk of stroke and its devastating impact.  We believe a key to stroke prevention is minimally-invasive and technologically advanced intervention to safely and effectively treat carotid artery disease, one of the leading causes of stroke.  We have pioneered a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which we seek to establish as the standard of care.  We manufacture and sell in the United States our portfolio of TCAR products, which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We began commercializing our products in the United States in late 2015.  Our products are currently the only devices cleared and approved by the FDA specifically for transcarotid use.  While our current commercial focus is on the U.S. market, our products have obtained CE Mark approval, allowing us to commercialize in Europe in the future.  We also intend to pursue regulatory clearances in China, Japan, and other select international markets.  TCAR is reimbursed based on established current procedural technology, or CPT, codes and International Classification of Diseases, or ICD-10, codes related to carotid stenting that track to Medicare Severity Diagnosis Related Group, or MS-DRG, classifications.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We designed our commercial strategy and built our direct sales force with a particular focus on vascular surgery practices.  Vascular surgeons are skilled in endovascular procedures, and our sales and marketing efforts are focused on driving adoption and supporting their practice development by offering them an innovative, safe, effective and minimally-invasive alternative for treating carotid artery disease.  We also market to other specialists with experience in CEA or CAS with the appropriate skill set for TCAR, including neurosurgeons, cardiothoracic surgeons and non-surgical interventionalists in radiology, neuroradiology and cardiology.  We also work on developing strong relationships with physicians and hospitals that we have identified as key opinion leaders.  We consider the hospitals and medical centers where the procedure is performed to be our customers, as they typically are responsible for purchasing our products. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We manufacture and distribute the ENROUTE NPS at our facility in Sunnyvale, California, using components and sub-assemblies manufactured both in-house and by third party manufacturers and suppliers.  We purchase our other products from third-party contract manufacturers, including our ENROUTE stent.  Many of these third-party manufacturers and outside vendors are currently single-source suppliers.  While we expect that our existing manufacturing facility will be sufficient to meet our anticipated growth through at least the next four years </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">we are in the process of supplementing our distribution </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">operations with a third-party logistics and warehousing service and are considering additional lease facilities.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we completed our initial public offering by issuing 6,000,000 shares of common stock, at a public offering price of $20.00 per share, for net proceeds of approximately $109.1 million after deducting underwriting discounts and commissions and expenses. In August 2019, we completed a secondary public offering of 4,200,000 shares of common stock by selling stockholders, and the exercise in full of the underwriters' option to purchase 630,000 additional shares of common stock from selling stockholders, at a public offering price of $39.50 per share. We received no proceeds from the sale of our common stock by the selling stockholders.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to our initial public offering in April 2019, our primary sources of capital were private placements of convertible preferred stock, debt financing arrangements and revenue from sales of our products.  As of&#160;June&#160;30, 2020, we had cash and cash equivalents of $73.4&#160;million, investments of $84.4 million, long-term debt of $45.1&#160;million and an accumulated deficit of $211.8&#160;million.  </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In May 2020, we completed an underwritten public offering of 6,808,154 shares of our common stock, of which we offered 1,923,076 shares for sale and the remaining 4,885,078 shares were offered for sale by certain selling stockholders, at a public offering price of $39.00 per share.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">From the public offering, we received cash proceeds of approximately $70.5 million, net of underwriting discounts and commissions and offering costs which were paid by us. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Also, in May 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We did not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COVID-19 Pandemic</span></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are subject to risks related to the public health crises such as the global pandemic associated with COVID-19. In December 2019, a novel strain of coronavirus, SARS-CoV-2, was reported to have surfaced in Wuhan, China. Since then, SARS-CoV-2, and the resulting disease COVID-19, has spread to most countries, and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact our operations and revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The pandemic has also reduced our expectations for the growth rates in the number of TCAR procedures to be performed in the future. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as many health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended, canceled or deferred to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will significantly reduce our expected revenue while the pandemic continues.  As well, due to presumed fear and anxiety, some patients are not accessing routine or emergency health care which may impact our expected procedures and revenue.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Numerous state and local jurisdictions have imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Starting in mid-March 2020, the governor of California, where our facilities are located, issued &#8220;shelter-in-place&#8221; or &#8220;stay at home&#8221; orders restricting non-essential activities, travel and business operations for an indefinite period of time, subject to certain exceptions for necessary activities. Such orders or restrictions have resulted in our facilities closing, work stoppages, slowdowns and delays, travel restrictions and cancellation of events, among other effects, thereby negatively impacting our operations.</span></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Other disruptions or potential disruptions include restrictions on our personnel to travel and access customers for selling, marketing, training, case support and product development feedback; delays in approvals by regulatory bodies; delays in product development efforts; and additional government requirements or other incremental mitigation efforts that may further impact our capacity to manufacture, sell and support the use of our products.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect these challenges to continue to impact our expected number of procedures through the remainder of 2020 and likely into 2021, but the extent cannot be quantified at this time. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our procedure volumes were lowest in April, then recovered in May and further in June, although we have recently begun to experience more regional variability and procedure slowdowns due to the resurgence of COVID-19 cases and related restrictions.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have also withdrawn our previously announced annual guidance for 2020 given the continued uncertainties resulting from the COVID-19 pandemic.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Key Business Metric - Number of U.S. TCAR procedures</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We regularly review a number of operating and financial metrics, including the number of procedures performed in the United States, to evaluate our business, measure our performance, identify trends affecting our business, formulate our business plan and make strategic decisions. The following table lists the number of procedures performed in each of the years ended as indicated:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:62.147%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.414%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.414%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.419%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ended December 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of procedures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,573&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2020, physicians performed approximately 4,640 procedures. We define a procedure as any instance in which our ENROUTE NPS is used and for which we have a record that the procedure was performed.  A procedure that is started and then aborted, or converted to a different procedure, after the ENROUTE NPS is used would count as a procedure. The number of procedures is an indicator of our ability to drive adoption and generate revenue, and is helpful in tracking the progress of our business. We believe that it is representative of our current business; however, we anticipate this may be substituted for additional or different metrics as our business grows. </span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Components of our Results of Operations</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We currently derive all of our revenue from the sale of our portfolio of TCAR products to hospitals and medical centers in the United States.  Each of our products is purchased individually, and the majority of our revenue is derived from sales of the ENROUTE NPS and ENROUTE stent.  No single customer accounted for 10% or more of our revenue during the three and six months ended June&#160;30, 2020 and 2019.&#160;We would expect revenue to increase in absolute dollars as we expand our sales territories, new a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ccounts and trained physician base and as existing physicians perform more TCAR procedures. H</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">owever, we anticipate the response to the COVID-19 pandemic will continue to impact revenue over the short term as some </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">procedures are temporarily deferred due to restrictions on elective surgical procedures.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our revenue to fluctuate from quarter-to-quarter due to a variety of factors, including seasonality.  For example, in the first quarter, our results can be harmed by adverse weather and by resetting of annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures.  Holiday and summer vacations by physicians and/or their patients can also affect procedure volumes that in turn affect hospital ordering patterns. We have also seen procedure volumes moderate during major medical conferences when significant portions of our customer base are attending the conferences.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Goods Sold and Gross Margin</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We manufacture the ENROUTE NPS in California at our facility in Sunnyvale.  We purchase our other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, direct labor, manufacturing overhead, reserves for excess, obsolete and non-sellable inventories as well as distribution-related expenses.  Overhead costs include </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as those incurred for shipping our products and royalties related to the sale of our ENROUTE stent.  We expense all inventory provisions as cost of goods sold.  We record adjustments to our inventory valuation for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions.  We expect cost of goods sold to increase in absolute dollars to the extent more of our products are sold.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We calculate gross margin as gross profit divided by revenue.  Our gross margin has been and will continue to be affected by a variety of factors, primarily average selling prices, product sales mix, production and ordering volumes, manufacturing costs, product yields, replacement of expired product, headcount and cost-reduction strategies.  We expect our gross margin to increase over the long term as our production and ordering volumes increase and as we spread the fixed portion of our overhead costs over a larger number of units produced.  We intend to use our design, engineering and manufacturing know-how and capabilities to further advance and improve the efficiency of our manufacturing processes, which we believe will reduce costs and have a positive long-term impact on our gross margin.  However, our gross margin could fluctuate from quarter to quarter as we introduce new products, due to the timing of certain manufacturing engineering projects, as we adopt new manufacturing processes and technologies and as we expand our distribution operations and infrastructure to support long term growth and risk mitigation.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, we expect the COVID-19 pandemic will continue to negatively impact our gross margin in the near term due to unfavorable production variances as a result of lower production and lower demand.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Research and development, or R&amp;D, expenses consist primarily of engineering, product development, clinical studies to develop and support our products, regulatory expenses, medical affairs, and other costs associated with products and technologies that are in development.  These expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead expenses.  Additionally, R&amp;D expenses include costs associated with our clinical studies, including clinical trial design, clinical trial site initiation and study costs, data management, related travel expenses and the cost of products used for clinical trials, internal and external costs associated with our regulatory compliance and quality assurance functions and overhead costs.  We expect R&amp;D expenses as a percentage of revenue to vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trial and other related activities.  </span><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We anticipate the COVID-19 pandemic </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">shelter-in-place policies and restrictions to continue to delay our product development efforts and clinical and regulatory matters </span><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">in 2020 and perhaps into 2021.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling, General and Administrative Expenses</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Selling, general and administrative, or SG&amp;A, expenses consist primarily of compensation for personnel, including stock-based compensation, related to selling and marketing functions, physician education programs, commercial operations and analytics, reimbursement, finance, information technology and human resource functions.  Other SG&amp;A expenses include sales commissions, training, travel expenses, promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, professional services fees (including legal, audit and tax fees), insurance costs, general corporate expenses and allocated facilities-related expenses.  We expect SG&amp;A expenses to continue to increase in absolute dollars as we expand our infrastructure to both drive and support anticipated growth in revenue, due to additional legal, accounting, insurance and other expenses associated with being a public company, and as we continue exploring sales and marketing expansion opportunities in international geographies. </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect the COVID-19 pandemic to continue to modulate our SG&amp;A expenses over the short term as the shelter-in-place policies extend a</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">nd as a result of the reduction in travel, tradeshow and other expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.  Given the continued uncertainties we also undertook preemptive steps to curtail near-term spending during the second quarter, including temporarily delaying previously contemplated executive salary increases to the third quarter, slowing hiring initiatives and reducing non-essential sales, general, and administrative expenses. Some expenses originally planned for the second and third quarter of 2020, including physician training courses and advertising campaigns, have been deferred to later time periods or canceled outright.  The outbreak and persistence of COVID-19 in international markets that we have targeted for our international expansion may also delay preparation for and launch of such expansion efforts.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Income (Expense), net</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income (expense), net consists primarily of cash interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and issuance costs associated with our term loan agreement. We may, at our election, pay a portion of the interest on our term loan through the incurrence of additional indebtedness as payment-in-kind, or PIK.  Our interest expense was partially offset by interest income earned on our cash, cash equivalents and investments.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income (Expense), net</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income (expense), net primarily consists of gains and losses resulting from the remeasurement of the fair value of our convertible preferred stock warrant liability at each balance sheet date.  We recorded adjustments to the estimated fair value of the convertible preferred stock warrants until they were exercised in connection with our initial public offering in April 2019.  At such time, the final fair value of the warrant liability was reclassified to stockholders&#8217; equity and we no longer recorded any related periodic fair value adjustments.  </span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Results of Operations:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:32.872%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.764%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.764%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.436%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.764%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.436%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.768%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,094&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs of goods sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,586&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross profit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,758&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,113&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,758&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,972&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,821&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,393)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,017)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,531)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,162)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(904)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(609)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,704)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,910)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,333)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(59)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,045)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,353)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,959)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,294)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,117)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of Three Months Ended June 30, 2020 and 2019</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Revenue increased $0.2&#160;million, or&#160;1%, to $15.1&#160;million during the three months ended June 30, 2020, compared to the three months ended June 30, 2019.  Revenue for the three months ended June 30, 2020, included the recognition of $1.3 million in deferred revenue due to a decrease in the provision for sales returns.  In the past, we shipped products with shorter than normal shelf life to customers. To the extent those products are not used before expiry, we established a reserve given the </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">potential we may accept a return and provide an exchange. The decrease in the provision for sales returns was due to the full expiration of these shorter shelf life products in the second quarter, coupled with the downward trend of our historical returns experience. Excluding the contribution of the $1.3 million, revenue for the three months ended June 30, 2020 decreased $1.1 million, or 8%, compared to the three months ended June 30, 2019. The decrease in revenue during the three months ended June 30, 2020, was attributable to the continued impact of COVID-19 as healthcare systems diverted resources to meet the increasing demands of managing COVID-19 and deferred procedures.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We do not ant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">icipate a future potential decrease in the sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> return provision to materially impact subsequent quarters. </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Cost of Goods Sold and Gross Margin. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Cost of goods sold increased $1.6 million, or&#160;44%, to $5.3&#160;million during the three months ended June 30, 2020, compared to the three months ended June 30, 2019.  This increase was attributabl</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">e to unfavorable production variances as a result of temporarily idled manufacturing operations and lower than anticipated demand, partially offset by our lower sales volume during the three months ended June 30, 2020.  Gross margin for the three months ended June 30, 2020 decreased to&#160;65%, compared to 75% in the three months ended June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.  Gross margin decreases were driven by unfavorable production variances as a result of temporarily idled manufacturing operations and lower than anticipated demand, partially offset by the decrease in our provision for sales returns.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> R&amp;D expenses increased $0.3 million, or&#160;9%, to $3.4&#160;million during the three months ended June 30, 2020, compared to $3.1 million during the three months ended June 30, 2019.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in R&amp;D expenses was primarily attributable to an increase of $0.6&#160;million in personnel-related expenses, including stock-based compensation, as a result of increased headcount, and an increase of $0.2 million in outside services, partially offset by a decrease of a decrease of $0.3 million in clinical and regulatory expense and a decrease of $0.2 million in travel expenses.</span><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, General and Administrative Expenses. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> SG&amp;A expenses increased $1.6&#160;million, or&#160;11%, to $15.8&#160;million during the three months ended June 30, 2020, compared to $14.1&#160;million during the three months ended June 30, 2019.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in SG&amp;A costs was due to the continued commercialization of our products, marketing efforts and general corporate and other costs associated with operating as a public company although during the current quarter our SG&amp;A expense growth was modulated by cost control initiatives and the slowdown in travel and other expenses due to the COVID-19 pandemic</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in SG&amp;A expenses is primarily attributable to an increase of $2.9 million in personnel-related expenses, an increase of $0.3 million in consulting, legal and professional fees and an increase of $0.2 million in insurance costs, partially offset by a decrease of $1.3 million in physician training and travel related costs and a decrease of $0.5 million in marketing and tradeshow expenses. Personnel-related expenses included stock-based compensation expense of $1.3&#160;million and $0.6 million for the three months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest Income (Expense), Net. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Interest income (expense), net increased $0.3&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, or&#160;48%, to an expense of $0.9&#160;million during the three months ended June 30, 2020, compared to an expense of $0.6&#160;million during the three months ended June 30, 2019.  This increase in net interest expense was attributable to a decrease in interest income due to lower interest rates during the three months ended June 30, 2020 in comparison with the prior period. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Income (Expense), Net. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Other income (expense), net decreased to an expense of $0.1 million during the three months ended June 30, 2020, compared to an expense of $5.3 million during the three months ended June 30, 2019.  Other income (expense), net for the three months ended June 30, 2019 was primarily attributable to the remeasurement of our convertible preferred stock warrants and recognition of the change in fair value during the period.  We recorded adjustments to the estimated fair value of the convertible preferred stock warrants until they were exercised in connection with our initial public offering in April 2019. </span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Comparison of Six Months Ended June 30, 2020 and 2019</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Revenue increased $6.3 million, or 23%, to $34.0 million during the six months ended June 30, 2020, compared to $27.7 million during the six months ended June 30, 2019. The increase in revenue was attributable to an increase in the number of products sold as we expanded our sales territories, increased the number of new accounts, trained more physicians in TCAR and as physicians performed more TCAR procedures. R</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">evenue for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">six months ended June 30, 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, included the recognition of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> $1.3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">million in deferred revenue due to a decrease in the provision for sales returns.  In the past, we shipped products with shorter than normal shelf life to customers. To the extent those products are not used before expiry, we established a reserve given the potential we may accept a return and provide an exchange. The decrease in the provision for sales returns was due to the full expiration of these shorter shelf life products in the second quarter, coupled with the downward trend of our historical returns experience. Excluding the contribution of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> $1.3 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">million, revenue for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">six months ended June 30, 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> increased $5.0 million, or 18%, compared to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">six months ended June 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We do not ant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">icipate future potential decreases in the sales</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> return provision to materially impact subsequent quarters. </span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Cost of Goods Sold and Gross Margin. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Cost of goods sold increased $3.6 million, or 50%, to $10.6 million during the six months ended June 30, 2020, compared to $7.0 million during the six months ended June 30, 2019. This increase was attributable to the increase in the number of products sold and also to unfavorable production variances as a result of temporarily idled manufacturing operations and lower than anticipated demand due to the COVID-19 pandemic. Gross margin for the six months ended June 30, 2020 decreased to 69%, compared to 75% in the six months ended June 30, 2019. Gross margin decreases were driven by unfavorable production variances as a result of temporarily idl</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ed manufacturing operations and lower than anticipated demand, partially offset by the decrease in our provision for sales returns.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Research and Development Expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">R&amp;D expenses increased $0.7 million, or 12%, to $6.5 million during the six months ended June 30, 2020, compared to $5.8 million during the six months ended June 30, 2019. The increase in R&amp;D expenses was primarily attributable to an increase of $1.0 million in personnel-related expenses including stock-based compensation, an increase of $0.3 million in outside services and an increase of $0.2 million in product development materials and costs, partially offset by a decrease of a decrease of $0.5 million in clinical and regulatory expense and a decrease of $0.3 million in travel and demo equipment expenses.</span><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">  </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Selling, General and Administrative Expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">SG&amp;A expenses increased $7.4 million, or 27%, to $35.5 million during the six months ended June 30, 2020, compared to $28.0 million during the six months ended June 30, 2019. The increase in SG&amp;A costs was due to the continued commercialization of our products and general corporate and other costs associated with operating as a public company. The increase in SG&amp;A expenses is primarily attributable to an increase of $8.0 million in personnel-related expenses, an increase of $0.6 million in insurance costs, an increase of $0.5 million in consulting, legal and professional fees and an increase of $0.4 million in software related expense partially offset by a decrease of $1.6 million in physician training and travel related costs and a decrease of $0.5 million in marketing, tradeshow and promotional costs.  Personnel-related expenses included stock-based compensation expense of $2.4 million and $0.8 million for the six months ended June 30, 2020 and </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, respectively.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Interest Income (Expense), Net. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Interest income (expense), net decreased $0.2 million, or 11%, to an expense of $1.7 million during the six months ended June 30, 2020, compared to an expense of $1.9 million during the six months ended June 30, 2019. This decrease in expense was attributable to an increase in interest income due to higher cash, cash equivalent and investments balances during the six months ended June 30, 2020.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Other Income (Expense), Net. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Other income (expense), net decreased to an expense of $0.1 million during the six months ended June 30, 2020, compared to an expense of $21.0 million during the six months ended June 30, 2019. Other income (expense), net for the six months ended June 30, 2019 was primarily attributable to the reme</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">asurement of our convertible preferred stock warrants and recognition of </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">the change in fair value during the period.  We recorded adjustments to the estimated fair value of the convertible preferred stock warrants until they were exercised in connection with our initial public offering in April 2019. </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of&#160;June&#160;30, 2020, we had cash and cash equivalents of $73.4&#160;million, investments of $84.4 million, an accumulated deficit of $211.8 million and $45.1&#160;million outstanding under our term loan agreement.  No borrowings remain available under this credit facility.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we completed our initial public offering by issuing 6,000,000 shares of common stock, at a public offering price of $20.00 per share, for net proceeds of approximately $109.1 million after deducting underwriting discounts and commissions and expenses. In August 2019, we completed a secondary public offering of 4,200,000 shares of common stock by selling stockholders, and the exercise in full of the underwriters' option to purchase 630,000 additional shares of common stock from selling stockholders, at a public offering price of $39.50 per share. We received no proceeds from the sale of the common stock by the selling stockholders.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, we completed an underwritten public offering of 6,808,154 shares of our common stock, of which we offered 1,923,076 shares for sale and the remaining 4,885,078 shares were offered for sale by certain selling stockholders, at a public offering price of $39.00 per share.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From the public offering, we received cash proceeds of approximately $70.5 million, net of underwriting discounts and commissions and offering costs which were paid by us. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Also, in May 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to our public offerings, our primary sources of capital were private placements of convertible preferred stock, debt financing agreements and revenue from the sale of our products.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our cash and cash equivalents and available-for-sale investments as of June&#160;30, 2020, together with our expected revenue will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flows for each of the periods presented below:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.070%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.743%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.745%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23,376)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,003)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,905)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(206)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,542&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#FFFFFF;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#FFFFFF;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Used in Operating Activities</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities for the six months ended June 30, 2020 was $23.4&#160;million, consisting primarily of a net loss of $20.3&#160;million and an increase in net operating assets of $7.1&#160;million, partially offset by non-cash charges of $4.0&#160;million. The increase in net operating assets was primarily due to an increase in inventories to support the growth of our operations, an increase in prepaid expenses and other current assets and a decrease in accrued liabilities, partially offset by decreases in accounts receivable and increases in accounts payable, due to timing of payments and growth of our operations. The non-cash charges primarily consisted of stock-based compensation, depreciation and amortization, provision for excess and obsolete inventories, non-cash interest expense and other charges related to our term loan agreement.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities for the six months ended June 30, 2019 was $18.0&#160;million, consisting primarily of a net loss of $36.1&#160;million and an increase in net operating assets of $5.4&#160;million, partially offset by non-cash charges of $23.5&#160;million.&#160;The increase in net operating assets was primarily due to an increase in accounts receivable, inventories and prepaid expenses and other current assets to support the growth of our operations, partially offset by a decrease in other assets and increases in accrued and other liabilities, due to timing of payments and growth of our operations. The non-cash charges primarily consisted of depreciation, stock-based compensation, provision for accounts receivable allowances, non-cash interest expense and other charges related to our term loan agreement, and increase in the fair value of the convertible preferred stock warrants.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Used in Investing Activities</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities in the six months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was $14.9&#160;million. Cash used in investing reflected purchases of purchases of property and equipment of $0.5 million and net purchases of inves</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">tments of $14.4 million. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities in the six months ended June 30, 2019 was $0.2 million consisting of purchases of property and equipment.  </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Provided by Financing Activities</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities in the six months ended June 30, 2020 was $72.5&#160;million, consisting of proceeds of $70.9 million from our public offering, net of issuance costs paid, and proceeds of $1.7 million from stock option exercises and purchases under our employee stock purchase plan.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities in the six months ended June 30, 2019 was $111.5&#160;million, primarily attributable to proceeds of $108.9 million from our initial public offering, net of issuance costs paid, and proceeds from stock option exercises of $0.7 million and warrant exercises of $1.8 million.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have no off-balance sheet arrangements, such as structured finance, special purpose entities, or variable interest entities.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Contractual Obligations and Commitments</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our principal obligations consist of the operating lease for our facility, our term loan agreement and non-cancellable inventory purchase commitments. The non-cancellable purchase commitments primarily consist of ENROUTE stents and other inventory components.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes to our contractual obligations from those described in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 2, 2020.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles.  The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures.  Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. There have been no significant and material changes in our critical accounting policies during the three and six months ended June&#160;30, 2020, as compared to those disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations - Critical Accounting Policies and Estimates&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 2, 2020.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Recently Issued Accounting Pronouncements </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 3 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q for new accounting pronouncements not yet adopted as of the date of this Quarterly Report on Form 10-Q.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 3: Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risks in the ordinary course of our business. These risks primarily include risk related to interest rate sensitivities and foreign currency exchange rate sensitivity.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We had cash, cash equivalents and investments of $157.9 million as of June&#160;30, 2020; which consisted of bank deposits, money market funds, U.S. treasury bills, U.S. government securities, corporate bonds/notes, asset-backed securities and commercial paper. The primary objectives of our investment activities are the preservation of capital and support of our liquidity requirements. Our investments are exposed to market risk due to fluctuations in interest rates, which may affect our income and the fair market value of our investments.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not enter into investments for trading or speculative purposes and have not used any</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">derivative financial instruments to manage our interest rate risk exposure. A hypothetical 10% change in</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">interest rates would not have a material impact on the value of our cash and cash equivalents or our</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">investments as of June&#160;30, 2020.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Risk</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December 31, 2019, our cash and cash equivalents were maintained with two financial institutions in the United States, and our current deposits are likely in excess of insured limits.  We have reviewed the financial statements of these institutions and believe each to have sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us.  Our cash equivalents and investments are invested in highly rated money market funds, U.S. treasury bills, U.S. government securities, corporate bonds/notes, asset-backed securities and commercial paper.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our accounts receivable primarily relate to revenue from the sale of our products to hospitals and medical centers in the United States.  No customer represented 10% or more of our accounts receivable as of June&#160;30, 2020 or December 31, 2019.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Risk</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business is primarily conducted in U.S. dollars.  Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our results of operations, financial position or cash flows.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 4. Controls and Procedures</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this quarterly report.  Based on that evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were not effective as described below.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, our management, including our President and Chief Executive Officer and our Chief Financial Officer, has concluded that, notwithstanding the identified material weaknesses in our internal control over financial reporting, the condensed financial statements in this Quarterly Report fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Material Weakness in Internal Control Over Financial Reporting</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the audit of our financial statements as of and for the year ended December&#160;31, 2017, we identified material weaknesses in our internal control over financial reporting. A &#8220;material weakness&#8221; is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determined that we had material weaknesses because we did not maintain a sufficient complement of personnel with an appropriate degree of knowledge, experience, and training, commensurate with our accounting and reporting requirements.  As a result, there were a number of post initial close&#160;adjustments that were material to the financial statements.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The second material weakness relates to the fact that we did not appropriately design and implement controls over the review and approval of manual journal entries and the related supporting journal entry calculations, resulting in inappropriate segregation of duties over manual journal entries.  This material weakness could result in a misstatement of account balances or disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Remediation Plan and Other Information</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With the oversight of senior management and our audit committee, we began the implementation of remediation steps in 2018. These efforts focused on (i)&#160;the hiring of personnel with technical accounting and financial reporting experience and (ii)&#160;the implementation of improved accounting and financial reporting procedures and systems to improve the completeness, timeliness and accuracy of our financial reporting and disclosures including the assessment of more judgmental areas of accounting.  While we believe the measures described above will remediate the material weaknesses identified and strengthen our internal control over financial reporting, both the implemented and enhanced controls have not operated for a sufficient period of time to demonstrate that the material weaknesses are fully remediated.  As such, the remediation initiatives outlined above were not sufficient to fully remediate the material weaknesses in internal control over financial reporting for the three and six months ended June 30, 2020. We are committed to continuing to improve our internal control processes and will continue to diligently and vigorously review our financial reporting controls and procedures.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As described under the Remediation Plan and Other Information section above, we continued to enhance controls related to our journal entry process during the quarter ended June 30, 2020. There were no other changes in our internal control over financial reporting that occurred during the most </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">recent fiscal quarter c</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">overed by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Limitations on Effectiveness of Controls and Procedures</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.  In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">Part II. Other Information</span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_97"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 1. Legal Proceedings</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time we may become involved in legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business.</span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_100"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 1A. Risk Factors</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition, results of operations and future growth prospects. Our business could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations and future prospects. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the other information contained in this Quarterly Report on Form 10-Q, including our condensed financial statements and related notes. Please also see &#8220;Cautionary Notes Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Risks Related to Our Business</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are an early-stage company with a history of net losses, we expect to incur operating losses in the future and we may not be able to achieve or sustain profitability.  We have a limited history operating as a commercial company.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses since our inception in March 2007.  For the six months ended June&#160;30, 2020 and 2019, we had a net loss of $20.3 million, and $36.1 million, respectively, and we expect to continue to incur additional losses in the future.  As of June&#160;30, 2020, we had an accumulated deficit of $211.8 million.  To date, we have financed our operations primarily through equity and debt financings and from sales of our portfolio of TCAR products that enable transcarotid artery revascularization, or TCAR.  The losses and accumulated deficit have primarily been due to the substantial investments we have made to develop our products, as well as for costs related to general research and development, including clinical and regulatory initiatives to obtain marketing approval, sales and marketing efforts and infrastructure improvements.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We fully commercialized our products in the United States in 2016 and therefore do not have a long history operating as a commercial company.  Over the next several years, we expect to continue to devote a substantial amount of our resources to expand commercialization efforts and increase adoption of TCAR using our products, improve and expand reimbursement for TCAR, and develop additional products.  In addition, as a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company.  Accordingly, we expect to continue to incur operating losses for the foreseeable future and we cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will sustain profitability.  Our failure to achieve and sustain profitability in the future will make it more difficult to finance our business and accomplish our strategic objectives, which would have a material adverse effect on our business, financial condition and results of operations and cause the market price of our common stock to decline.  In addition, failure of our products to significantly penetrate the target markets would negatively affect our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on, and currently sell products to enable, TCAR, a single and new procedure.  We have limited commercial sales experience regarding TCAR, which makes it difficult to evaluate our current business, predict our future prospects and forecast our financial performance and growth.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, all of our revenue has been derived, and we expect it to continue to be derived in the near term, from sales of our products that enable TCAR.  TCAR is a relatively new treatment option for certain patients diagnosed with carotid artery disease and, as a result, physician awareness of TCAR and our products, and experience with TCAR and our products, is limited.  As a result, our company and products have limited brand recognition and TCAR has limited recognition within the medical industry.  The novelty of TCAR and our products that enable the procedure, together with our limited commercialization experience, make it difficult to evaluate our current business and predict our future prospects.  A number of factors that are outside of our control may contribute to fluctuations in our financial results, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Physician and hospital demand for our products and the extent of adoption of TCAR, including the rate at which physicians recommend our products and TCAR to their patients;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Positive or negative media coverage, or public, patient and/or physician perception, of our products and TCAR or competing products and procedures;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Any safety or effectiveness concerns that arise regarding our products or TCAR;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Unanticipated delays in product development or product launches;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our ability to maintain our current or obtain further regulatory clearances or approvals;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays in, or failure of, product, component and material deliveries by our third-party suppliers; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Introduction of new products or procedures for treating carotid artery disease that compete with our products and the TCAR procedure.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is therefore difficult to predict our future financial performance and growth, and such forecasts are inherently limited and subject to a number of uncertainties.  If our assumptions regarding the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, because we devote substantially all of our resources to our products that enable TCAR and rely on our products and the adoption of TCAR as our sole source of revenue, any factors that negatively impact our products or TCAR, or result in a decrease in sales of products, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business is dependent upon the broad adoption of TCAR by hospitals and physicians.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, a substantial majority of our product sales and revenue have been derived from a limited number of hospitals and physicians who have adopted TCAR.  Our future growth and profitability largely depends on our ability to increase physician awareness of TCAR and on the willingness of physicians to adopt our products and TCAR, and to recommend the procedure to their patients.  Physicians may not adopt our products unless they are able to determine, based on experience, clinical data, medical society recommendations and other analyses, that our products provide a safe and effective treatment alternative for carotid artery disease.  Even if we are able to raise awareness among physicians, physicians tend to be slow in changing their medical treatment practices and may be hesitant to select our products or TCAR for recommendation to patients for a variety of reasons, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Long-standing relationships with competing companies and distributors that sell other products, such as stents and embolic protection devices for transfemoral carotid artery stenting, or CAS;</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Competitive response and negative selling efforts from providers of alternative carotid revascularization products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Lack of experience with our products and concerns that we are relatively new to market;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Perceived liability risk generally associated with the use of new products and procedures;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Lack or perceived lack of sufficient clinical evidence, including long-term data, supporting clinical benefits;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Reluctance to change to or use new products and procedures;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Perceptions that our products are unproven; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Time commitment and skill development that may be required to gain familiarity and proficiency with TCAR and our products.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Physicians play a significant role in determining the course of a patient&#8217;s treatment for carotid artery disease and, as a result, the type of treatment that will be recommended or provided to a patient.  We focus our sales, marketing and education efforts primarily on vascular surgeons, and aim to educate referring physicians such as vascular surgeons, cardiologists, radiologists, neurologists, neurosurgeons and general practitioners regarding the patient population that would benefit from TCAR.  However, we cannot assure you that we will achieve broad education or market acceptance among these practitioners.  For example, if diagnosing physicians that serve as the primary point of contact for patients are not made aware of TCAR, they may not refer patients to physicians for treatment using our products, and those patients may instead not seek treatment at all or may be treated with alternative procedures.  In addition, some physicians may choose to utilize TCAR on only a subset of their total patient population or may not adopt TCAR at all.  If a physician experiences an adverse event in one or more of their TCAR patients or elects to convert TCAR to CEA mid-procedure, they may not continue offering and performing TCAR at the same rate or at all.  Further, as TCAR is a new procedure, it may not fit into the workstreams of certain physicians.  If we are not able to effectively demonstrate that TCAR is beneficial in a broad range of patients, adoption of TCAR will be limited and may not occur as rapidly as we anticipate or at all, which would have a material adverse effect on our business, financial condition and results of operations.  We cannot assure you that TCAR or our products will achieve broad market acceptance among hospitals and physicians.  Any failure of TCAR or our products to satisfy demand or to achieve meaningful market acceptance and penetration will harm our future prospects and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the medical device industry&#8217;s relationship with physicians is under increasing scrutiny by the Health and Human Services Office of the Inspector General, or OIG, the Department of Justice, or DOJ, state attorneys general, and other foreign and domestic government agencies.  Our failure to comply with laws, rules and regulations governing our relationships with physicians, or an investigation into our compliance by the OIG, DOJ, state attorneys general or other government agencies, could significantly harm our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In most cases, before physicians can use our products for the first time, our products must be approved for use by a hospital's new product or value analysis committee, or the staff of a hospital or health system.  Following such approval, we may be required to enter into a purchase contract.  Such approvals or requirements to enter into a purchase contract could deter or delay the use of our products by physicians.  We cannot provide assurance that our efforts to obtain such approvals, enter into purchase contracts, or generate adoption will be successful or increase the use of our products, and if we are not successful, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Adoption of TCAR depends upon positive clinical data and medical society recommendations, and negative clinical data or medical society recommendations would adversely affect our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The rate of adoption of TCAR and sales of our products that facilitate the procedure is heavily influenced by clinical data.  Although the Society for Vascular Surgery&#8217;s TCAR Surveillance Project contains real world data comparing procedures, we have not conducted head-to-head clinical trials to compare TCAR to the procedures historically available to patients, such as CEA or CAS, which may limit the adoption of TCAR.  Additionally, the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> clinical trial is currently funded by the National Institutes of Health, which compares the effectiveness of each of CEA and CAS with best medical management solutions.  Although we estimate that enrollment</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> will not be completed until 2024, int</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">erim results have been released from time to time.  At the completion of the four-year follow-up, the trial could conclude that medical management alone achieves the same therapeutic results as CEA and/or CAS, which could have an adverse impact on the adoption of TCAR.  Finally, our competitors and third parties may also conduct clinical trials of our products without our participation.  Unfavorable or inconsistent clinical data from existing or future clinical trials conducted by us, our competitors or third parties, the interpretation of our or other clinical data or findings of new or more frequent adverse events, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As physicians are influenced by guidelines issued by physician organizations, such as the Society for Vascular Surgery, the rate of adoption of TCAR and sales of our products that facilitate the procedure are also heavily influenced by medical society recommendations.  We believe the Society for Vascular Surgery&#8217;s Clinical Practice Guidelines, or SVS Guidelines, are of particular importance to the broader market acceptance of TCAR.  The most current SVS Guidelines on the management of carotid artery disease, published in 2011, do not specifically mention TCAR as a treatment for carotid artery disease, but generally discuss CAS and embolic protection methods, including flow reversal.  If the next version of the SVS Guidelines do not recommend TCAR, or if the Society for Vascular Surgery issues a negative or limited statement regarding TCAR, physicians may not adopt or continue to use TCAR or our products at the same rate or at all, which would have a material adverse effect on our business, financial condition and results of operations.  Additionally, if key opinion leaders who currently support TCAR cease to recommend TCAR or our products, our business, financial condition and results of operations will be adversely affected.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Adoption of TCAR depends upon appropriate physician training, and inadequate training may lead to negative patient outcomes, affect adoption of TCAR and adversely affect our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of TCAR depends in part on the skill of the physician performing the procedure and on our customers&#8217; adherence to appropriate patient selection and proper techniques provided in training sessions conducted by our training faculty.  For example, we train our customers to ensure correct use of our ENROUTE NPS and proper deployment of our ENROUTE stent.  However, physicians rely on their previous medical training and experience when performing TCAR, and we cannot guarantee that all such physicians will have the necessary surgical and endovascular skills to perform the procedure.  While we mandate physician attendance at our TCAR training program or training with proctors, we do not control which physicians perform TCAR or how much training they receive.  Physicians who have not completed our training sessions may nonetheless attempt to perform TCAR.  If physicians perform TCAR in a manner that is inconsistent with its labeled indications, with components that are not our products or without adhering to or completing our training sessions, their patient outcomes may not be consistent with the outcomes achieved in our and other clinical trials, studies or registries of TCAR.  This result may negatively impact the perception of patient benefit and safety and limit adoption of TCAR and our products that facilitate the procedure, which would have a material adverse effect on our business, financial condition and results of operations.  Additionally, physician organizations may adopt physician credentialing guidelines requiring TCAR training more extensive than our training program.  If physicians conclude that we do not provide adequate TCAR training, they may be less likely to adopt TCAR and our </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">products, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The COVID-19 pandemic and efforts to reduce its spread has impacted, and may in the future periods negatively impact, our business and operations.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">The spread of COVID-19 in the United States has resulted in travel restrictions impacting our sales professionals and therapy development specialists who support them. However, our field-based team continues to be available to support TCAR procedures, either in person or virtually. Our field team may, however, choose not to enter hospitals due to preexisting conditions, personal choice, or on doctors&#8217; orders or may be unable to enter hospitals due to hospital policy</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">. During the second quarter we also cancelled most of our training programs, resulting in fewer new physicians trained on the TCAR procedure relative to our plans. In addition, hospitals may reduce staffing and postpone certain procedures in response to COVID-19 or divert resources to treat those patients with COVID-19. Some hospitals have also restricted or limited access for non-patients, including our sales professionals and therapy develo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">pment specialists, which has negatively impacted our access to physicians and their patients. New hospital sanitization and social distancing protocols, as well as increased competition for operating room and hybrid operating rooms within hospitals that have dedicated certain resources only to COVID-19 patients, may impact our business and operations. Additionally, we anticipate that an increase in the unemployment rate due to the impact of COVID-19 may decrease the number of potential patients with health insurance, which may result in fewer diagnoses, lower number of procedures, or result in a shift to procedures which are reimbursed by government payers. As hospitals cancel and defer elective surgeries, it reduces their revenue and impacts their financial results, which could result in pricing pressure on our products as they seek cost savings. Prolonged restrictions relating to COVID-19 could adversely affect our procedures and the revenue we derive as a result. Additionally, some hospitals may have cash flow problems or cease doing business due to the impact of COVID-19 on their operations, which could reduce the number of hospitals where TCAR is performed and adversely affect our ability to collect amounts due to us and our revenue as a result. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect these challenges to continue to impact our number of procedures through the second half of 2020, and likely into 2021, but the extent cannot be quantified at this time. Our cus</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">tomers&#8217; patients are also experiencing the economic impact of the current pandemic.&#160;Even an important surgical procedure like TCAR may be less of a priority than other priorities for those patients who have lost their jobs, are furloughed, have reduced work hours or are worried about the continuation of their medical insurance. Patients may also be reluctant to visit their physicians at their offices or in hospitals due to fear of contracting COVID-19. Physicians may not be performing as many diagnostic tests for their patients and the labs where these tests are performed may not be open, staffed adequately or open the entire day. Even where physicians continue to treat symptomatic patients, treatment of asymptomatic patients is being deferred in many cases in areas where COVID-19 cases and hospitalizations are significant. The reduction in diagnostic testing and physician visits, the increase in deferred treatment, and patient behaviors are translating into fewer than expected TCAR procedures being performed in the current environment.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Governmental mandates related to COVID-19 or other infectious diseases have impacted, and we expect them to continue to impact, our personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which would disrupt our supply chain and/or reduce our margins. For instance, on or about March 16, 2020, the Health Officers of the county of Santa Clara, where our headquarters, distribution and ENROUTE NPS assembly and packaging facility is located, issued a mandatory shelter-in-place orders. On July 2, 2020, the Health Officers issued an order relaxing certain requirements but requiring all businesses in the county to continue to require workers to do their jobs from home whenever possible, and provided further that workers are permitted to go into work only to complete the job duties they cannot complete from home.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">While we have continued to operate with remote employees and essential employees on site, an extended implementation of this Governmental mandate could impact our ability to operate effectively and conduct ongoing manufacturing or research and development activities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">However, we are considered an essential business under applicable state rules and had the option to restart our manufacturing operations at any time. We have necessary components and raw materials on hand and appropriate distancing policies and protocols</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> established to continue manufacturing and other operations. Additionally, we </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">believe we have finished goods inventory on hand to react appropriately to an increase in demand. We anticipate that even if there is a significant increase in demand for our products due to the deferred procedure volume backlog, new sanitization protocols and other capacity constraints may limit the efficient distribution of our finished products if the impact of COVID-19 is prolonged.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we expect the COVID-19 pandemic to impact our business over the short term as some procedures are temporarily deferred or cancelled altogether, we have taken swift and proactive measures to minimize business disruptions and preserve financial flexibility. In assessing our own cash conservation options, during the second quarter we have taken preemptive steps to curtail near-term spending, including temporarily delaying previously contemplated executive salary increases to the third quarter, slowing hiring initiatives and reducing non-essential sales, general, and administrative expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some expenses planned for the second quarter of 2020, including physician training courses and advertising campaigns, were deferred to later time periods or canceled outright. In the event that COVID-19 continues to limit our procedures and resulting revenue, we may have to reduc</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">e our employees&#8217; work hours, furlough employees, reduce salaries, variable compensation and benefits, or implement a reduction-in-force. We may also solicit voluntary leaves of absence from our employees as a cash conservation strategy. Our ongoing operations may be impacted as a result of employees assuming additional roles and responsibilities within our organization and we would have fewer resources available to run our operations, which would reduce our expenses, but could also negatively impact our business operations and revenue as a result. We may also encounter voluntary departures of key employees due to any of the foregoing actions that we undertake. If key personnel or large groups of our employees contract the virus, that may also impact our business and operations. In the meantime, we have taken steps to provide for our employees, including providing the ability for employees to work remotely and implementing strategies to support appropriate social distancing techniques for onsite employees. We are also assessing our business continuity plans in the context of this pandemic.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outbreak and persistence of COVID-19 in international markets that we have targeted for our international expansion may also delay preparation for and launch of such expansion efforts. Regulatory timelines for approval in some countries have been delayed. The spread of an infectious disease, including COVID-19, could also result in the inability of our suppliers to deliver components or raw materials to us on a timely basis. If there were a shortage of supply, the cost of these materials or components may increase and harm our ability to provide our products on a cost-effective basis. In connection with any supply shortages in the future, reliable and cost-effective replacement sources may not be available on short notice or at all, and this may force us to increase prices and face a corresponding decrease in demand for our products. In the event that any of our suppliers were to discontinue production of our key product components, developing alternate sources of supply for these components would be time consuming, difficult and costly. The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including the duration and severity of the pandemic, the actions taken to reduce the transmission of COVID-19, and the speed with which normal economic and operating conditions resume, among others.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As permitted by the CARES Act, we have deferred the employer portion of social security taxes and plan to apply for employee retention credits. We continue to review and may seek other available benefits under CARES Act. We cannot predict the manner in which such benefits will be allocated or administered and we cannot assure you that we will be able to access such benefits in a timely manner or at all. Certain of the benefits under the CARES Act have not previously been administered on the present scale or at all. Government or third party program administrators may impose additional conditions and restrictions on our operations and the benefits may otherwise provide less relief than we contemplate. If the U.S. government or any other governmental authority agrees to provide crisis relief assistance that we accept, it may impose certain requirements on the recipients of the aid, including restrictions on executive officer compensation, dividends, prepayment of debt, limitations on debt and other similar restrictions that will apply for a period of time after the aid is repaid or redeemed in full. We cannot assure you that any such government crisis relief assistance will not significantly limit our corporate activities or be on terms that are favorable to us. Such restrictions and terms could adversely impact our business and operations.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finally, we anticipate that the COVID-19 pandemic may impact clinical and regulatory matters. While we do not have any clinical trials currently in process for regulatory purposes, COVID-19 is delaying enrollment in new clinical trials across the medical device industry and may affect any new trials we decide to pursue. Our ongoing diffusion weighted imaging trials in the US and Europe are experiencing patient enrollment delays. Additionally, we may experience regulatory delays in our effort to seek a label expansion for the ENROUTE stent in standard surgical risk patients, as the FDA has from time to time diverted resources to address the impact of COVID-19. COVID-19 may cause disruptions that could have a material adverse impact on our clinical trial plans and timelines, including:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">Delays in receiving authorizations from local regulatory authorities, ethics committees and institutional review boards to initiate planned clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays or difficulties in enrolling patients in our clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruptions in global shipping that may affect the transport of clinical trial materials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays in necessary interactions with local regulators, ethics committees and other third parties and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Refusal of the FDA to accept data from clinical trials in affected geographies.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the delay or denial of regulatory approvals or clearances of our product.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, the FDA and other global health regulatory agencies may also experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced and, as a result, review, inspection and other timelines may be materially delayed. For example, in response to the global pandemic of COVID-19, on March 10, 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products, and subsequently, on March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. In July 2020, the FDA announced its intentions to restart prioritized domestic on-site inspections, but noted that the resumption of inspections would depend on data about the COVID-19 trajectory in a given state and locality and the rules and guidelines put in place by state and local governments. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. It is unknown how long such delays or disruptions could last. Any elongation or de-prioritization of our clinical or other product development activities or delay in regulatory review resulting from such disruptions could materially affect our results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ultimate impact of COVID-19 is highly uncertain and subject to change. This impact could have a material, adverse impact on our liquidity, capital resources, operations and business and those of the third parties on which we rely. The extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. We do not yet know the full extent of potential delays or impacts on our business, financial condition and results of operations. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of COVID-19 on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity and our ability to operate.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including driving hospitals to tighten budgets and curtail spending, which would negatively impact our sales and business. In addition, higher unemployment or reductions in business benefits plans could result in fewer commercially insured patients, which could negatively impact our revenue and business as a result. A weak or declining economy could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the economic climate and financial market conditions could adversely affect our business.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We seek to maintain sufficient levels of inventory in order to protect ourselves from supply interruptions, but keep limited components, sub-assemblies, materials and finished products on hand. To ensure adequate inventory supply and manage our operations with our manufacturing partners and suppliers, we forecast anticipated materials requirements and demand for our products in order to predict inventory needs and then place orders with our suppliers based on these predictions. Our ability to accurately forecast demand for our products would be negatively affected by many factors, including our limited historical commercial experience regarding TCAR, rapid growth, pandemics, failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our products, our failure to accurately forecast customer acceptance of new products, changes to hospital capacity, staffing, procedure and protocol changes, unanticipated changes </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory levels in excess of customer demand may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs. In the past, we have shipped products with shorter than normal shelf life to customers, and to the extent those products are not used and expire, we may exchange them, and this may materially and adversely affect our gross margin. Conversely, if we underestimate customer demand for our products or our own requirements for components, subassemblies and materials, our manufacturing partners and suppliers may not be able to deliver components, sub-assemblies and materials to meet our requirements and our manufacturing may be affected by the impact of COVID-19 on our suppliers, which could result in inadequate inventory levels or interruptions, delays or cancellations of deliveries to our customers, any of which would damage our reputation, customer relationships and business. In addition, several components, sub-assemblies and materials incorporated into our products require lengthy order lead times, and additional supplies or materials may not be available when required on terms that are acceptable to us or our manufacturing partners, or at all, and our manufacturing partners and suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, any of which could have an adverse effect on our ability to meet customer demand for our products and our results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have limited long-term data regarding the safety and effectiveness of our products, including our ENROUTE stent and TCAR generally.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our products enable TCAR, which is a relatively new procedure, and our success depends on acceptance of our products and TCAR by the medical industry, including physicians and hospitals.  The FDA reviews our products for safety and effectiveness, prior to commercial launch of these products. Thereafter, physicians, through their own use of the products and evaluation of clinical data, make their own decisions as to whether our products are safe and effective for their patients and improve their clinical outcomes.  Important factors upon which the effectiveness of our products, including our ENROUTE stent, will be measured include but are not limited to long-term data regarding the risk of stroke and death and the rates of restenosis and reintervention following TCAR.  The long-term clinical benefits of procedures that use our products are not fully known.  We have limited data on the ENROUTE stent and TCAR up to one year.  Any failure of our stent or in-stent restenosis of the carotid artery following deployment of the stent could deter physicians from adopting our products and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The results of short-term clinical experience of our products do not necessarily predict long-term clinical benefit.  We believe that physicians will compare the rates of long-term risk of stroke and death, as well as restenosis and reintervention for procedures using our products, against alternative procedures, such as CEA and CAS.  If the long-term data do not meet physicians&#8217; expectations, or if long-term data indicate that our products are not as safe or effective as other treatment options or as current short-term data would suggest, our products may not become widely adopted, physicians may recommend alternative treatments for their patients and our business could be harmed.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are not able to maintain adequate levels of third-party coverage and reimbursement for the procedures using our products, if third parties rescind or modify their coverage or delay payments, or if patients are left with significant out-of-pocket costs, it would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">TCAR is currently covered under certain circumstances for certain patients by the Centers for Medicare and Medicaid Services, and has been covered by some commercial payers, independent networks and other entities not governed by the National Coverage Determination.  In the United States, we derive our revenue from sales to hospitals and medical centers, which typically bill all or a portion of the costs and fees associated with our products to various third-party payers, including Medicare, Medicaid, Veterans&#8217; Administration, private commercial insurance companies, health maintenance organizations and other healthcare-related organizations, and then bill patients for any applicable </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">deductibles or co-payments.  For example, our contracts are with the hospitals and medical centers that purchase our products for use with TCAR and not with the commercial payers.  As a result, access to adequate coverage and reimbursement for our products by third-party payers is essential to the acceptance of our products by our customers.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, in the United States, there is no uniform policy of coverage and reimbursement for medical device products and services among third-party payers, so coverage and reimbursement can differ significantly from payer to payer, and each coverage decision and level of reimbursement is independent.  As a result, third-party reimbursement may not be available or adequate for our products, and there is no guarantee that we will be able to maintain our current levels of coverage or reimbursement or be able to expand coverage to other insurance carriers.  Further, payers continually review new technologies for possible coverage and can, without notice, deny or limit coverage for products and procedures or delay coverage approval until further clinical data are available.  As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained.  If third-party reimbursement is not available or adequate for TCAR procedures using our products, or if there is any decline in the amount that payers are willing to reimburse our customers for TCAR or our products, new customers may not adopt, or may reduce their rate of adoption of, our products and we could experience additional pricing pressure, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our products are reimbursed primarily on a per-patient prior authorization basis for patients covered by commercial insurers and on a medical necessity basis for certain patients covered by the Centers for Medicare and Medicaid Services.  Based on reimbursement information regarding CEA and CAS, we estimate that approximately 75% of carotid procedures are reimbursed by Medicare/Medicaid and approximately 25% are reimbursed by commercial payers.  Current Procedure Terminology, or CPT, codes are developed and issued by the American Medical Association, or AMA.  The U.S. Centers for Medicare &amp; Medicaid Services, or CMS, determines Medicare physician payments based on formulas within the Medicare Resource-Based Relative Value Scale, which uses Relative Value Units, or RVUs.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The AMA/Specialty Society RVS Update Committee, or RUC, provides periodic recommendations to CMS on the RVU values, but CMS makes the final decisions about Medicare payments. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In the future, Medicare physician payments for TCAR using our products may change based on a new RUC review recommendation.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CMS makes the final determination regarding Medicare hospital and physician payments.  I</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">f the Society for Vascular Surgery recommended changes to the RVUs or declined to support the use of TCAR or the Medicare National Coverage Determination no longer covers TCAR, there would be a material adverse effect on our business, financial condition and results of operations.  If this were to occur, commercial insurance companies could also adjust payment rates at which they reimburse TCAR using our products.  Other carotid artery disease treatments, such as CEA, may be more widely covered or subject to different co-pay policies and requirements.  If patients are required to cover all or a part of the cost of TCAR or our products out-of-pocket, they may be less likely to elect to use our products and/or undergo the procedure.  Additionally, patients may elect to reduce or defer out-of-pocket costs during times of economic uncertainty or periods of legislative change.  If hospital, physician and/or patient demand for TCAR, and thus our products that facilitate the procedure, is adversely affected by third-party reimbursement policies and decisions, it will have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Internationally, reimbursement systems in foreign markets vary significantly by country and by region within some countries, and reimbursement approvals must be obtained on a country-by-country basis.  In certain international markets, a product must be approved for reimbursement before it can be approved for sale in that country.  Additionally, many international markets have government-managed healthcare systems that control reimbursement for products and procedures.  In most markets there are both private insurance systems and government-managed systems.  If sufficient levels of coverage and </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">reimbursement are not available for TCAR or our current or future products, in either the United States or internationally, the demand for our products and our revenues will be adversely affected.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, when payers combine their operations, the combined company may elect to reimburse for TCAR at the lowest rate paid by any of the participants in the consolidation or use its increased size to negotiate reduced rates.  If one of the payers participating in the consolidation does not reimburse for TCAR at all, the combined company may elect not to reimburse for TCAR, which would adversely impact our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations in our intellectual property license from Cardinal Health, we could lose license rights that are important to our business. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to a license agreement with Cordis Corporation, or Cordis, which was acquired by Cardinal Health, under which Cordis has granted us a worldwide, non-exclusive, royalty-bearing license to certain of its intellectual property related to the PRECISE&#174; carotid stent for transcervical treatment of carotid artery disease with an intravascular stent for certain applications for accessing blood vessels through the neck and cervical area. This license agreement imposes, and we expect that any future license agreements will impose, certain diligence, royalty, and other obligations on us. If we fail to comply with these obligations, our licensors, including Cardinal Health, may have the right to reduce the scope of our rights or terminate these agreements, in which event we may not be able to develop and market any product that is covered by these agreements. Termination of this license for failure to comply with such obligations or for other reasons, or reduction or elimination of our licensed rights under it or any other license, may result in our having to negotiate new or reinstated licenses on less favorable terms or our not having sufficient intellectual property rights to operate our business or cause us to enter into a new license for a different stent. The occurrence of such events could materially harm our business and financial condition. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we in-license, and any failure by us or our licensors, including Cordis, to obtain, maintain, defend and enforce these rights could have a material adverse effect on our business. In some cases we do not have control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on Cardinal Health to supply the ENROUTE stent, and if Cardinal Health fails to supply the ENROUTE stent in sufficient quantities or at all, it will have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on Cardinal Health to manufacture the ENROUTE stent pursuant to a supply agreement between us and Cordis Corporation, which was acquired by Cardinal Health.  We strive to maintain an inventory of several months&#8217; worth of ENROUTE stents to guard against potential shortfalls in supply, and we estimate that it would take one to two years to find an alternative supplier for our ENROUTE stent and multiple years to identify and seek approval for another stent, and in each case qualify it for use with our other products.  In addition, Cardinal Health currently manufactures the ENROUTE stent at a facility in Juarez, Mexico. This facility could become subject to a COVID-19 outbreak which would cause Cardinal Health to have to shut down manufacturing operations, which would in turn present risk to the ongoing supply of our stents used in TCAR procedures. The current political and trade relationship between the United States and Mexico is strained and may deteriorate.  If Cardinal Health&#8217;s ability to manufacture the ENROUTE stent is interrupted as a result, or if Cardinal Health breaches its supply agreement with us, we may not have a sufficient number of stents for delivery to support TCAR procedures.  Any shortfall in the supply of ENROUTE stents may result in lower adoption rates for TCAR, fewer TCAR procedures being performed generally, and a material adverse effect on our business, financial condition and results of operations.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">TCAR involves surgical risks and is contraindicated in certain patients, which may limit adoption.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risks of TCAR using our products include the risks that are common to surgical and endovascular procedures, including perforation, dissection, embolization, bleeding, infection, nerve injury and restenosis.  Endovascular procedures occurring in the carotid arteries also include the additional risks of stroke, heart attack and death.  We are aware of certain characteristics and features of TCAR that may prevent widespread market adoption, including the fact that physicians would need to adopt a new procedure, and that training for physicians will be required to enable them to effectively operate our products.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current products are contraindicated, and therefore should not be used, in certain patients.  Our ENROUTE NPS is contraindicated in patients in whom antiplatelet and/or anticoagulation therapy is contraindicated; patients with uncorrected bleeding disorders; patients with severe disease of the ipsilateral common carotid artery; and patients with uncontrollable intolerance to flow reversal.  Our ENROUTE stent is contraindicated in patients in whom antiplatelet and/or anticoagulation therapy is contraindicated; patients in whom the ENROUTE NPS is unable to be placed; patients with uncorrected bleeding disorders; patients with known allergies to nitinol; and patients with lesions in the ostium of the common carotid artery.  Our ENHANCE peripheral access kit is contraindicated in patients with a known or suspected obstruction in the vessel.  Our ENROUTE guidewire is contraindicated in patients judged not acceptable for percutaneous intervention.  Additionally, patients that lack at least five centimeters of common carotid artery free of significant disease are not indicated for our ENROUTE NPS.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have limited experience manufacturing our products in commercial quantities and we face manufacturing risks that may adversely affect our ability to manufacture products and could reduce our gross margins and negatively affect our business and operating results.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business strategy depends on our ability to manufacture our current and future products in sufficient quantities and on a timely basis to meet customer demand, while adhering to product quality standards, complying with regulatory quality system requirements and managing manufacturing costs.  We have a facility located in Sunnyvale, California, where we assemble and package certain of our products, and inspect, release and ship all of our products.  We currently produce our ENROUTE NPS at this facility, and we and the contract manufacturers of our other products do not have redundant facilities.  If our or our manufacturing partners&#8217; facilities suffers damage, or a force majeure event, this could materially impact our ability to operate.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also subject to numerous other risks relating to our manufacturing capabilities, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quality and reliability of components, sub-assemblies and materials that we source from third-party suppliers, who are required to meet our quality specifications, the majority of which are our single source suppliers for the products they supply;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our or our manufacturing partners&#8217; inability to secure components, sub-assemblies and materials in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our or our manufacturing partners&#8217; inability to maintain compliance with quality system requirements or pass regulatory quality inspections;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our or our manufacturing partners&#8217; failure to increase production capacity or volumes to meet demand;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our or our manufacturing partners&#8217; inability to design or modify production processes to enable us to produce future products efficiently or implement changes in current products in response to design or regulatory requirements; and</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternative suppliers for components in a timely manner.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These risks are likely to be exacerbated by our limited experience with our current products and manufacturing processes.  As demand for our products increases, we will have to invest additional resources to purchase components, sub-assemblies and materials, hire and train employees and enhance our manufacturing processes.  If we fail to increase our production capacity efficiently, we may not be able to fill customer orders on a timely basis, our sales may not increase in line with our expectations and our operating margins could fluctuate or decline.  In addition, although we expect some of our products in development to share product features, components, sub-assemblies and materials with our existing products, the manufacture of these products may require modification of our or our manufacturing partners&#8217; current production processes or unique production processes, the hiring of specialized employees, the identification of new suppliers for specific components, sub-assemblies and materials or the development of new manufacturing technologies.  It may not be possible for us or our manufacturing partners&#8217; to manufacture these products at a cost or in quantities sufficient to make these products commercially viable or to maintain current operating margins, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on a limited number of single source suppliers to manufacture our components, sub-assemblies and materials, which makes us vulnerable to supply shortages and price fluctuations that could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on single source suppliers for the components, sub-assemblies and materials for our ENROUTE NPS.  These components, sub-assemblies and materials are critical and there are relatively few alternative sources of supply.  We have not qualified or obtained necessary regulatory approvals for additional suppliers for most of these components, sub-assemblies and materials, and we do not carry a significant inventory of these items.  While we believe that alternative sources of supply may be available, we cannot be certain whether they will be available if and when we need them, or that any alternative suppliers would be able to provide the quantity and quality of components and materials that we would need to manufacture our products if our existing suppliers were unable to satisfy our supply requirements.  To utilize other supply sources, we would need to identify and qualify new suppliers to our quality standards and obtain any additional regulatory approvals required to change suppliers, which could result in manufacturing delays and increase our expenses.  Our manufacturing partners rely on single source suppliers as well, and are subject to the foregoing risks.  </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our and our manufacturing partners&#8217; dependence on third-party suppliers subjects us to a number of risks that could impact our ability to manufacture our products and harm our business, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Interruption of supply resulting from modifications to, or discontinuation of, a supplier&#8217;s operations;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays in product shipments resulting from uncorrected defects, reliability issues or a supplier&#8217;s failure to produce components that consistently meet our quality specifications;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Price fluctuations due to a lack of long-term supply arrangements with our suppliers for key components;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Inability to obtain adequate supply in a timely manner or on commercially reasonable terms;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Difficulty identifying and qualifying alternative suppliers for components in a timely manner;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Inability of suppliers to comply with applicable provisions of the QSR or other applicable laws or regulations enforced by the FDA and state regulatory authorities;</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Inability to adequately ensure the quality of products and components manufactured by third parties;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Production delays related to the evaluation and testing of products and components from alternative suppliers and corresponding regulatory qualifications;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Delays in delivery by our suppliers due to changes in demand from us or their other customers; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">An outbreak of disease or similar public health threat, such as the existing threat of COVID-19, particularly as it may impact our supply chain.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we require our third-party suppliers to supply us with components that meet our specifications and comply with applicable provisions of the QSR and other applicable legal and regulatory requirements in our agreements and contracts, and we perform incoming inspection, testing or other acceptance activities to ensure the components meet our requirements, there is a risk that our suppliers will not always act consistent with our best interests, and may not always supply components that meet our requirements or supply components in a timely manner.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We seek to maintain sufficient levels of inventory in order to protect ourselves from supply interruptions, but keep limited components, sub-assemblies, materials and finished products on hand.  To ensure adequate inventory supply and manage our operations with our manufacturing partners and suppliers, we forecast anticipated materials requirements and demand for our products in order to predict inventory needs and then place orders with our suppliers based on these predictions.  Our ability to accurately forecast demand for our products could be negatively affected by many factors, including our limited historical commercial experience regarding TCAR, rapid growth, failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our products, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory levels in excess of customer demand may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs.  From time to time, we ship products with short shelf life to customers for procedures, and to the extent those products are not used and expire, we may exchange them, and this may materially and adversely affect our gross margin.  Conversely, if we underestimate customer demand for our products or our own requirements for components, subassemblies and materials, our manufacturing partners and suppliers may not be able to deliver components, sub-assemblies and materials to meet our requirements, which could result in inadequate inventory levels or interruptions, delays or cancellations of deliveries to our customers, any of which would damage our reputation, customer relationships and business.  In addition, several components, sub-assemblies and materials incorporated into our products require lengthy order lead times, and additional supplies or materials may not be available when required on terms that are acceptable to us or our manufacturing partners, or at all, and our manufacturing partners and suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, any of which could have an adverse effect on our ability to meet customer demand for our products and our results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of our business.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our quarterly and annual results of operations, including our revenue, net income or net loss and cash flow, may vary significantly in the future, and period-to-period comparisons of our operating results may not be meaningful.  Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance.  Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business.  Fluctuations in quarterly and annual results may decrease the value of our common stock.  Because our quarterly results may fluctuate, period-to-period comparisons may not be the best indication of the underlying results of our business and should only be relied upon as one factor in determining how our business is performing.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have a limited total addressable market based on our current labeling restrictions.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total addressable market for TCAR is limited by a number of factors.  Approximately 168,000 patients with carotid artery disease in the United States received treatment in the form of surgical or endovascular intervention in 2018.  Of this group, we estimate that approximately one-third would be outside the scope of the FDA-approved labeling for the ENROUTE stent, as those patients are not deemed to be at high risk for adverse events from CEA, or high surgical risk.  The current FDA-approved labeling for the ENROUTE stent is limited to patients at high risk for adverse events from CEA. Patients at high risk for adverse events from CEA are defined as having significant comorbidities and/or anatomic risk factors, and/or advanced age, that would make them riskier candidates for CEA.  Furthermore, the safety and effectiveness of TCAR has not been established for certain patients. For example, the FDA-cleared labeling for the ENROUTE NPS states that patients should have at least five centimeters of common carotid artery free of significant disease for initial access to the artery and positioning of the ENROUTE sheath.  In addition, per the FDA-approved labeling for the ENROUTE stent, TCAR is limited to asymptomatic patients with carotid artery stenosis of at least 80% and symptomatic patients with carotid artery stenosis of at least 50%, both of which must also be high surgical risk. In addition, physicians may choose to perform CEA in patients with certain anatomical characteristics, including heavily calcified carotid arteries, calcified lesions and severe vessel tortuosity.  Finally, current labeling for our products includes contraindications for certain patients, thus further reducing our total addressable market. </span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Expanding the addressable market for TCAR is dependent upon labeling and reimbursement expansion initiatives.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ENROUTE stent is not currently indicated for use in standard surgical risk patients.  To access a larger portion of the market for carotid artery disease, we will need to obtain approval by the FDA for a label expansion of the ENROUTE stent in standard surgical risk patients and obtain corresponding reimbursement coverage expansion for TCAR.  FDA approval of an ENROUTE stent label expansion may require additional data from clinical studies or registries, which we intend to pursue.  However, there are no guarantees that we will be able to obtain such clinical study or registry data or FDA approval of a label expansion for the ENROUTE stent, or that any label expansion or additional reimbursement coverage will be sufficient to adequately access the standard risk portion of the market for carotid artery disease patients.  If we are unable to obtain labeling and reimbursement coverage expansion, it may have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in public health insurance coverage and government reimbursement rates for the TCAR procedures using our products could affect the adoption of our products and our future revenue.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The federal government is considering ways to change, and has changed, the manner in which healthcare services are paid for in the United States.  Individual states may also enact legislation that impacts Medicaid payments to hospitals and physicians.  In addition, CMS establishes Medicare payment levels for hospitals and physicians on an annual basis, which can increase or decrease payment to such entities.  Internationally, medical reimbursement systems vary significantly from country to country, with some countries limiting medical centers&#8217; spending through fixed budgets, regardless of levels of patient </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">treatment, and other countries requiring application for, and approval of, government or third-party reimbursement.  Even if we succeed in bringing our products to market in additional foreign countries, uncertainties regarding future healthcare policy, legislation and regulation, as well as private market practices, could affect our ability to sell our products in commercially acceptable quantities at acceptable prices.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and profitability.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In an effort to reduce costs, many hospitals in the United States have become members of Group Purchasing Organizations, or GPOs, and Integrated Delivery Networks, or IDNs.  GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and then offer these negotiated prices to affiliated hospitals and other members.  GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process.  Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors.  Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs.  Furthermore, the increasing leverage of organized buying groups may reduce market prices for our products and/or require administrative fees, thereby reducing our revenue and/or margins.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders.  Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers.  Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#8217; notice.  Accordingly, the members of such groups may choose to purchase alternative products due to the price or quality offered by other companies, which could result in a decline in our revenue.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to achieve or maintain satisfactory pricing and margins for our products.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Manufacturers of medical devices have a history of price competition, and we can give no assurance that we will be able to achieve satisfactory prices for our products or maintain prices at the levels we have historically achieved.  Any decline in the amount that payers reimburse our customers for TCAR could make it difficult for customers to continue using, or to adopt, our products and could create additional pricing pressure for us.  If we are forced to lower the price we charge for our products, our gross margins will decrease, which will adversely affect our ability to invest in and grow our business.  If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode.  We will continue to be subject to significant pricing pressure, which could harm our business and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any growth that we experience in the future will require us to expand our sales, general and administrative personnel, manufacturing and distribution operations, and facilities and information technology infrastructure.  In addition to the need to scale our organization, future growth will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees.  Rapid expansion in personnel could mean that less experienced people manufacture, market and sell our products, which could result in inefficiencies and unanticipated costs, reduced quality and disruptions to our operations.  In addition, rapid and significant growth may strain our administrative and operational infrastructure.  Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">procedures.  If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As demand for our products or any of our future products increases, we will need to continue to scale our capacity, expand customer service, billing and systems processes and enhance our internal quality assurance program.  We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business.  Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs or inability to meet increased demand.  If we encounter difficulty meeting market demand, quality standards or physician expectations, our reputation could be harmed and our business could suffer.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Due to our recent growth in our business, we are actively looking for additional facilities to store finished goods and to supplement the shipping and receiving capacity of our main offices in Sunnyvale, California.  We are also searching for additi</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">onal space to provide offices for the employees we expect to hire in California.  We determined to supplement our distribution </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">operations with third-party logistics and warehousing services in another part of the country, and are in the process of enabling these services to be fully operational.  There is competition for office, shipping and warehousing space in the San Francisco Bay area and we can provide no assurance that we will find additional space or that such space will be on reasonable terms or that we will be successful in our efforts to contract with third parties elsewhere to augment our logistics and warehousing capabilities.  If we are unable to obtain additional space or support on commercially reasonable terms our costs may go up or our business operations may be adversely affected.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our manufacturing facility becomes damaged or inoperable, or if we are required to vacate a facility, we may be unable to produce the products we manufacture or we may experience delays in production or an increase in costs, which could adversely affect our results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently maintain our research and development, manufacturing and non-field-based sales, general and administrative operations in a building located in Sunnyvale, California, which is situated on or near earthquake fault lines, and we do not have redundant facilities.  Should our building be significantly damaged or destroyed by natural or man-made disasters, such as earthquakes, fires or other events, it could take months to relocate or rebuild, during which time our employees may seek other positions, our research, development and manufacturing would cease or be delayed and our products may be unavailable.  Moreover, the use of a new facility or new manufacturing, quality control, or environmental control equipment or systems generally requires FDA review and, with respect to certain products, approval of a PMA supplement.  Because of the time required to authorize manufacturing in a new facility under FDA, the State of California and non-U.S. regulatory requirements, we may not be able to resume production on a timely basis even if we are able to replace production capacity in the event we lose manufacturing capacity.  While we maintain property and business interruption insurance, such insurance has limits and would only cover the cost of rebuilding and relocating and lost revenue, but not general damage, losses caused by earthquakes, losses we may suffer due to our products being replaced by competitors&#8217; products or loss in value due to associated decreases in our stock price.  The inability to perform our research, development and manufacturing activities, combined with our limited inventory of materials and components and manufactured products, may cause physicians to discontinue using our products or harm our reputation, and we may be unable to reestablish relationships with such physicians in the future.  Consequently, a catastrophic event at our facility could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, the current lease for our manufacturing facility expires in 2024, and our operations are growing at a pace that may require us to find a replacement or expansion facility sooner.  We may be unable to renew our lease or find a new facility on commercially reasonable terms.  I</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">f we were unable or unwilling to renew at the proposed rates, relocating our manufacturing facility would involve significant expense in connection with the movement and installation of key manufacturing equipment and any necessary recertification with regulatory bodies, and we cannot assure investors that such a move would </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">not delay or otherwise adversely affect our manufacturing activities or operating results.  If our manufacturing capabilities were impaired by our move, we may not be able to manufacture and ship our products in a timely manner, which would adversely impact our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we rely on our manufacturing partners to supply certain of our products, and our partners are subject to similar risks with respect to their facilities.  If our manufacturing partners&#8217; facilities are damaged or destroyed and their ability to supply products to us is limited, it could negatively affect our reputation, physician relationships and TCAR adoption, all of which could have a material adverse effect on our business, financial condition and results of operations.  Several of our products are sterilized at a particular third party facility, with limited alternate facilities. If an event occurs that results in damage to or closure of one or more of such facilities, we may be unable to sterilize such products at the previous levels or at all. Because of the time required to approve and license a sterilization facility, a third party may not be available on a timely basis to replace capacity in the event sterilization capacity is lost.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have limited experience in training and marketing and selling our products, and if we fail in our training, to increase our sales and marketing capabilities or to develop broad brand awareness, our growth will be impeded and our business will suffer.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have limited experience marketing and selling our products.  We currently rely on our direct sales force to sell our products in targeted geographic regions in the U.S., and any failure to maintain and grow our direct sales force could harm our business.  The members of our direct sales force are highly trained and possess substantial technical and clinical expertise, which we believe is critical in driving adoption of TCAR.  The members of our U.S. sales force are at-will employees.  The loss of these personnel to competitors, or otherwise, could materially harm our business.  If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical and clinical expertise and qualifications, or if we are unable to successfully instill such technical and clinical expertise in replacement personnel, our revenues and results of operations could be materially harmed.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to generate future growth, we plan to continue to expand and leverage our sales, marketing, and medical affairs infrastructure to increase our trained physician and hospital customer base and our business.  Identifying and recruiting qualified sales, marketing and medical affairs personnel and training them on TCAR, on applicable federal and state laws and regulations, and on our internal policies and procedures requires significant time, expense and attention.  It often takes several months or more before a sales representative is fully trained and productive.  Our sales force may subject us to higher fixed costs than those of companies with competing products, such as stents, that utilize independent third parties, which could place us at a competitive disadvantage.  Our business may be harmed if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products.  Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time or timely reduce fixed costs, could have a material adverse effect on our business, financial condition and results of operations.  Our ability to increase our customer base and achieve broader market acceptance of our products will depend to a significant extent on our ability to expand our marketing efforts.  We plan to dedicate significant resources to our marketing programs.  Our business may be harmed if our marketing efforts and expenditures do not generate a corresponding increase in revenue.  In addition, we believe that developing and maintaining broad awareness of our brand is critical to achieving broad acceptance of our products and penetrating new accounts.  Brand promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand.  Our medical affairs department may not train physicians at a rate sufficient to expand our physician base in a manner consistent with our business plan.  If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad adoption of our products.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The market for our products is highly competitive.  If our competitors are able to develop or market carotid artery disease treatments that are safer, more effective or gain greater acceptance in the marketplace, than any products we develop, our commercial opportunities will be reduced or eliminated.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our industry is highly competitive, subject to change and significantly affected by new product introductions and other activities of industry participants.  We are initially positioning TCAR as an alternative to CEA and CAS in high surgical risk patients.  CEA has historically been performed by vascular surgeons as the primary surgical solution for carotid artery disease.  The major manufacturers of products, such as patches and shunts, used in connection with CEA include LeMaitre Vascular, Getinge / Maquet, Baxter, Terumo, Gore and Edwards.  Some competitors market products for use in CAS, such as peripheral access kits, stents, distal and proximal embolic protection devices, guidewires, balloons and sheaths.  Such companies include Abbott, Boston Scientific, Cardinal Health, Medtronic, Terumo, Gore and InspireMD.  These technologies, other products that are in current clinical trials, new drugs or additional indications for existing drugs could demonstrate better safety, effectiveness, clinical results, lower costs or greater physician and patient acceptance.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We compete, or may compete in the future, against other companies which have longer operating histories, more established products and greater resources, which may prevent us from achieving significant market penetration or improved operating results.  These companies enjoy several competitive advantages, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Greater financial and human capital resources;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Significantly greater name recognition;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Established relationships with vascular surgeons and other treating specialties, referring physicians, customers and third-party payers;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Additional lines of products, and the ability to offer rebates or bundle products to offer greater discounts or incentives to gain a competitive advantage; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Established sales, marketing and worldwide distribution networks.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of the size of the market opportunity for the treatment of carotid artery disease, we believe potential competitors have historically dedicated and will continue to dedicate significant resources to aggressively promote their products or develop new products.  New treatment options may be developed that could compete more effectively with our products due to the prevalence of carotid artery disease and the extensive research efforts and technological progress that exist within the market.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Defects or failures associated with our products could lead to recalls, safety alerts or litigation, as well as significant costs and negative publicity.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business is subject to significant risks associated with manufacture, distribution and use of medical devices that are placed inside the human body, including the risk that patients may be severely injured by or even die from the misuse or malfunction of our products caused by design flaws or manufacturing defects.  In addition, component failures, design defects, off-label uses or inadequate disclosure of product-related information could also result in an unsafe condition or the injury or death of a patient.  These problems could lead to a recall or market withdrawal of, or issuance of a safety alert relating to, our products and could result in significant costs, negative publicity and adverse competitive pressure.  The circumstances giving rise to recalls are unpredictable, and any recalls of existing or future products could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We provide a limited warranty that our products are free of material defects and conform to specifications, and offer to repair, replace or refund the purchase price of defective products.  As a result, we bear the risk of potential warranty claims on our products.  In the event that we attempt to recover some or all of the expenses associated with a warranty claim against us from our suppliers or vendors, we may not be successful in claiming recovery under any warranty or indemnity provided to us by such suppliers or vendors and any recovery from such vendor or supplier may not be adequate.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The medical device industry has historically been subject to extensive litigation over product liability claims.  Operating in the area of the neck with the brain as the end organ is dangerous and presents risks of adverse events such as bleeding, arterial dissection, cranial nerve injury, myocardial infarction, stroke and death, which subject us to a greater risk of being involved in litigation than companies with products used in less critical areas of the body.  We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury or death, even if due to physician error.  In addition, an injury or death that is caused by the activities of our suppliers, such as those that provide us with components and raw materials, or by an aspect of a treatment used in combination with our products, such as a complementary drug or anesthesia, may be the basis for a claim against us by patients, hospitals, physicians or others purchasing or using our products, even if our products were not the actual cause of such injury or death.  We may choose to settle any claims to avoid fault and complication not due to failure of our products.  An adverse outcome involving one of our products could result in reduced market acceptance and demand for all of our products, and could harm our reputation and our ability to market our products in the future.  In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of regulatory reviews of our premarket notifications or applications for marketing.  Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we carry product liability insurance in the United States and in other countries in which we conduct business, including for clinical trials and product marketing, we can give no assurance that such coverage will be available or adequate to satisfy any claims.  Product liability insurance is expensive, subject to significant deductibles and exclusions, and may not be available on acceptable terms, if at all.  If we are unable to obtain or maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we could be exposed to significant liabilities.  A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition and results of operations.  Defending a suit, regardless of its merit or eventual outcome, could be costly, could divert management&#8217;s attention from our business and might result in adverse publicity, which could result in reduced acceptance of our products in the market, product recalls or market withdrawals.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are required to file adverse event reports under Medical Device Reporting, or MDR, regulations with the FDA, which reports are publicly available on the FDA&#8217;s website.  We are required to file MDRs if our products may have caused or contributed to a serious injury or death or malfunctioned in a way that could likely cause or contribute to a serious injury or death if it were to recur.  Any such MDR that reports a significant adverse event could result in negative publicity, which could harm our reputation and future sales.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to compete depends on our ability to innovate successfully and deliver any new products in a timely manner.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The market for our products is competitive, dynamic, and marked by rapid and substantial technological development and product innovation.  New entrants or existing competitors could attempt to develop products that compete directly with ours.  Demand for our products and future related products could be diminished by equivalent or superior products and technologies offered by competitors.  If we </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">are unable to innovate successfully, our products could become obsolete and our revenue would decline as our customers purchase our competitors&#8217; products.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are currently focused on development of existing products for TCAR and other indications, new products for TCAR and new products for other indications.  If we are unable to develop new products, applications or features due to constraints, such as insufficient cash resources, high employee turnover, inability to hire personnel with sufficient technical skills or a lack of other research and development resources, we may not be able to maintain our competitive position compared to other companies.  Furthermore, many of our competitors devote a considerably greater amount of funds to their research and development programs than we do, and those that do not may be acquired by larger companies that would allocate greater resources to research and development programs.  Our failure or inability to devote adequate research and development resources or compete effectively with the research and development programs of our competitors could harm our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any significant delays in our product launches may significantly impede our ability to enter or compete in a given market and may reduce the sales that we are able to generate from these products.  We may experience delays in any phase of a product development, including during research and development, clinical trials, regulatory review, manufacturing and marketing.  Delays in product introductions could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The failure of TCAR to meet patient expectations or the occurrence of adverse events from TCAR could impair our financial performance.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future success depends upon patients having an experience with TCAR that meets their expectations in order to increase physician demand for our products as a result of positive feedback, social media and word-of-mouth.  Patients may be dissatisfied if their expectations of the procedure and results, among other things, are not met.  Despite what we believe to be the safety profile of our products, patients may experience adverse events such as arterial restenosis or dissection, cranial nerve injury, wound complications, transient ischemic attacks, stroke, heart attack, and death.  If the results of TCAR do not meet the expectations of the patients, or patients experience adverse events, it could discourage patients from referring TCAR to others.  Dissatisfied patients may express negative opinions through social media.  Any failure to meet patient expectations and any resulting negative publicity could harm our reputation and future sales.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success depends largely on the continued services of key members of our executive management team and others in key management positions.  For example, the services of Erica Rogers, our Chief Executive Officer, and Lucas Buchanan, our Chief Financial Officer, are essential to driving adoption of our products, executing on our corporate strategy and ensuring the continued operations and integrity of financial reporting within our company.  In addition, the services of Andrew Davis, our Chief Commercial Officer, are critical to driving the growth in sales of our products.  Any of our employees may terminate their employment with us at any time.  We do not currently maintain key person life insurance policies on any of our employees.  If we lose one or more key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our research and development programs, and sales efforts depend on our ability to attract and retain highly skilled engineers and sales professionals.  We may not be able to attract or retain qualified engineers and sales professionals in the future due to the competition for qualified personnel.  We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications.  Many of the companies with which we compete for experienced personnel have greater resources than we do.  When we hire employees from competitors or other companies, their former employers have previously and may in the future attempt to assert that </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">these employees or we have breached legal obligations, which may result in a diversion of our time and resources and, potentially, damages.  In addition, job candidates and existing employees, particularly in the San Francisco Bay Area, often consider the value of the stock awards they receive in connection with their employment along with salary, benefits and other factors.  If the perceived benefits of our stock awards decline, either because we are a public company or for other reasons, it may harm our ability to recruit and retain highly skilled employees.  If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The use, misuse or off-label use of our products may result in injuries that lead to product liability suits, which could be costly to our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ENROUTE stent has been approved by the FDA for the treatment of high surgical risk patients who require carotid revascularization and meet certain treatment parameters.  If physicians expand the patient population in which they elect to use our products that is outside of the intended use approved by the FDA, then the use, misuse, or off-label use of our products may result in outcomes and adverse events including stroke, myocardial infarction and death, potentially leading to product liability claims.  Our products are not indicated for use in all patients with carotid artery disease, and therefore cannot be marketed or advertised in the United States for certain uses without additional approvals or clearances from the FDA.  However, we cannot prevent a physician from using our products for off-label applications or using components or products that are not our products when performing TCAR.  In addition, we cannot guarantee that physicians are trained by us or their peers prior to utilizing our products.  Complications resulting from the use of our products off-label or use by physicians who have not been trained appropriately, or at all, may expose us to product liability claims and harm our reputation.  Moreover, if the FDA determines that our promotional materials or physician training, including our paid consultants&#8217; educational materials, constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to enforcement action, including warning letters, untitled letters, fines, penalties, or seizures.  If we are found to have promoted such off-label uses, we may become subject to significant liability.  The federal government has levied large civil and criminal fines and/or other penalties against companies for alleged improper promotion and has investigated, prosecuted, and/or enjoined several companies from engaging in off-label promotion.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, if our products are defectively designed, manufactured or labeled, contain defective components or are misused, we may become subject to costly litigation initiated by physicians, hospitals or patients.  Product liability claims are especially prevalent in the medical device industry and could harm our reputation, divert management&#8217;s attention from our core business, be expensive to defend and may result in sizable damage awards against us.  Although we maintain product liability insurance, we may not have sufficient insurance coverage for future product liability claims.  We may not be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities.  Any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation, significantly increase our expenses, and reduce product sales.  Product liability claims could cause us to incur significant legal fees and deductibles and claims in excess of our insurance coverage would be paid out of cash reserves, harming our financial condition and operating results.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may need substantial additional funding and may not be able to raise capital when needed, which could force us to delay, reduce or eliminate our product development programs and commercialization efforts.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our cash and cash equivalents and investments as of June&#160;30, 2020 and expected revenue will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months.  However, we have based these estimates on assumptions that may prove to be incorrect, and we could spend our available financial resources much faster than we currently expect.  Our future funding requirements will depend on many factors, including:</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The degree and rate of market acceptance of TCAR and our products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Whether we acquire third-party companies, products or technologies;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Restructuring, refinancing or repayment of debt;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The scope and timing of investment in our sales force; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The scope and timing of investment in physician training;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The scope, rate of progress and cost of our current or future clinical studies;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The scope, rate of progress and cost of our research and development activities; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The scope, rate of progress and cost of additional regulatory clearances or approvals; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The costs associated with any product recall that may occur;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The costs of attaining, defending and enforcing our intellectual property rights;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The impact of COVID-19 on our business and operations;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The emergence of competing technologies or other adverse market developments; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The rate at which we expand internationally.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may seek to raise additional capital through equity offerings or debt financings and such additional financing may not be available to us on acceptable terms, or at all.  In addition, any additional equity or debt financing that we raise may contain terms that are not favorable to us or our stockholders.  For example, if we raise funds by issuing equity or equity-linked securities, the issuance of such securities could result in dilution to our stockholders.  Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock.  In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the terms of debt securities issued or borrowings could impose significant restrictions on our operations including restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to pay dividends, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business.  </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms, such as relinquishment or licensing of certain technologies or products that we otherwise would seek to develop or commercialize ourselves, or reserve for future potential arrangements when we might otherwise be able to achieve more favorable terms.  In addition, we may be forced to work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to us.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to obtain adequate financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, or delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products.  If this were to occur, our ability to grow and support our business and to respond to market challenges could be significantly limited, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had an aggregate of approximately $45.1&#160;million in principal and interest outstanding under our term loan agreement.  We must make significant interest only quarterly payments under the loan agreement, which has diverted and will continue to divert resources from other activities.  Our obligations under the term loan agreement are collateralized by substantially all of our assets, including our material intellectual property, and we are subject to customary financial and operating covenants limiting our ability to, among other things, relocate or dispose of assets, undergo a change in control, merge or consolidate, enter into certain transactions with affiliates, make acquisitions, incur debt, pay dividends, grant liens, repurchase stock and make investments, in each case subject to certain exceptions.  The covenants related to the term loan agreement, as well as any future financing agreements into which we may enter, may restrict our ability to finance our operations and engage in, expand or otherwise pursue our business activities and strategies.  While we have not previously breached and are not currently in breach of these or any other covenants contained in our term loan agreement, there can be no guarantee that we will not breach these covenants in the future.  Our ability to comply with these covenants may be affected by events beyond our control, and future breaches of any of these covenants could result in a default under the loan agreement.  If not waived, future defaults could cause all of the outstanding indebtedness under the term loan agreement to become immediately due and payable and terminate commitments to extend further credit.  If we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in the event of a default, our assets could be foreclosed upon and we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate and continue our business as a going concern.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may acquire other companies or technologies, or enter into license agreements, distribution arrangements or strategic partnerships, which could fail to result in a commercial product or generate sales, divert our management&#8217;s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we currently have no agreements or commitments to complete any such transactions and are not involved in negotiations to do so, we may in the future seek to acquire, license or invest in businesses, products or technologies that we believe could complement or expand our portfolio, enhance our technical capabilities or otherwise offer growth opportunities.  We could also seek to enter into distribution arrangements or strategic partnerships with third parties that we believe could increase our revenue or offer other commercial benefits.  However, we cannot assure you that we would be able to successfully complete any acquisition, license agreement or distribution agreement we choose to pursue, or that we would be able to successfully integrate any business or product or technology in a cost-effective and non-disruptive manner.  Similarly, we cannot guarantee that we would derive benefits from any distribution arrangement or other strategic partnership.  The pursuit of potential acquisition, license or partnering opportunities may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable transactions, whether or not they are consummated.  We may not be able to identify desirable acquisition targets or strategic partners, or be successful in entering into an agreement with any particular target or partner, or obtain the expected benefits of any acquisition, license, investment or other strategic partnership arrangement.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, the growth of our operations has been largely organic, and we have limited experience in acquiring other businesses or technologies.  We may not be able to successfully integrate any acquired personnel, operations and technologies, or effectively manage the combined business following an acquisition.  Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results.  In addition, if an acquired business, product or technology fails to meet our expectations, our operating results, business and financial condition may suffer.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to utilize our net operating loss carryforwards may be limited</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, we had U.S. federal and state net operating loss carryforwards, or NOLs, of $167.9&#160;million and $148.4 million, respectively.  Our U.S. federal NOLs arising in tax years ending on or before December 31, 2017 are subject to expiration and will begin to expire in 2027 (U.S. federal NOLs arising in tax years ending after December 31, 2017 are not subject to expiration) and our state NOLs will begin to expire in 2028.  We may use these NOLs to offset taxable income for U.S. federal and state income tax purposes.  However, Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, may limit the NOLs we may use in any year for U.S. federal income tax purposes in the event of certain changes in ownership of our company.  An &#8220;ownership change&#8221; pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period.  Similar rules may apply under state tax laws.  Although we have not performed a formal study under Section 382 of the Code, we believe we may have experienced at least one &#8220;ownership change&#8221; in the past and may have experienced others.  In addition, future issuances or sales of our stock, including certain transactions involving our stock that are outside of our control, could result in future &#8220;ownership changes.&#8221; &#8220;Ownership changes&#8221; that have occurred in the past or that may occur in the future could result in the imposition of an annual limit on the amount of pre-ownership change NOLs and other tax attributes we can use to reduce our taxable income or income tax liability, potentially increasing and accelerating our liability for income taxes, and also potentially causing those tax attributes to expire unused.  Any limitation on using NOLs could, depending on the extent of such limitation and the NOLs previously used, result in our retaining less cash after payment of U.S. federal and state income taxes during any year in which we have taxable income, rather than losses, than we would be entitled to retain if such NOLs were available as an offset against such income for U.S. federal and state income tax reporting purposes, which could adversely impact our operating results.  Furthermore, under the Tax Cuts and Jobs Act of 2017, although the treatment of U.S. federal NOLs arising in tax years beginning on or before December 31, 2017 has generally not changed, U.S. federal NOLs arising in tax years beginning after December 31, 2017 may only be used to offset 80% of our taxable income.  This change may require us to pay U.S. federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">As international expansion of our business occurs, it will expose us to market, regulatory, political, operational, financial, legal and economic risks associated with doing business outside of the United States.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our long-term strategy is to increase our international presence, including but not limited to securing regulatory approvals in Japan and China.  We have the right to affix the CE Mark to our products, allowing us to commercialize in Europe in the future.  This strategy may include establishing and maintaining physician outreach and education capabilities outside of the United States and expanding our relationships with international distributors, providers and payers.  Doing business internationally involves a number of risks, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Difficulties in staffing and managing our international operations; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Reduced or varied protection for intellectual property rights in some countries; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Obtaining regulatory clearance where required for our products in various countries;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Requirements to maintain data and the processing of that data on servers located within such countries;</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems;  </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Difficulties in adequately training and managing international distributors;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Limits on our ability to penetrate international markets if we are required to manufacture our products locally;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Financial risks, such as longer payment cycles, difficulty collecting accounts receivable, foreign tax laws and complexities of foreign value-added tax systems, the effect of local and regional financial pressures on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Restrictions on the site-of-service for use of our products and the economics related thereto for physicians, providers and payers;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Natural disasters, political and economic instability, including wars, terrorism, political unrest, outbreak of disease, boycotts, curtailment of trade and other market restrictions; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Regulatory and compliance risks that relate to maintaining accurate information and control over activities subject to regulation under the United States Foreign Corrupt Practices Act of 1977, or FCPA, U.K. Bribery Act of 2010 and comparable laws and regulations in other countries.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these factors could significantly harm our future international expansion and operations and, consequently, have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, pursuant to the terms of our intellectual property license with Cardinal Health, there are certain restrictions on our ability to sell the ENROUTE stent through select direct competitors of Cordis Corporation.  If we are unable to locate international distributors that are not select direct competitors to Cordis Corporation, to market and sell our ENROUTE stent, our ability to expand our business internationally may be harmed, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or our customers or patients, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of our business, we may become exposed to, or collect and store sensitive data, including procedure-based information and legally-protected health information, credit card, and other financial information, insurance information, and other potentially personally identifiable information.  We also store sensitive intellectual property and other proprietary business information.  Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology, or IT, and infrastructure, and that of our other technology partners, may be vulnerable to cyber attacks by hackers or viruses or breached due to employee error, malfeasance or other disruptions.  We rely extensively on IT systems, networks and services, including internet sites, data hosting and processing facilities and tools, physical security systems and other hardware, software and technical applications and platforms, some of which are managed, hosted, provided and/or used by third-parties or their vendors, to assist in conducting our business.  A significant breakdown, invasion, corruption, destruction or interruption of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations.  The ever-increasing use and evolution of technology, including cloud-based computing, </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices.  We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers.  Although the aggregate impact on our operations and financial condition has not been material to date, we have been the target of events of this nature and expect them to continue as cybersecurity threats have been rapidly evolving in sophistication and becoming more prevalent in the industry.  We are investing in protections and monitoring practices of our data and IT to reduce these risks and continue to monitor our systems on an ongoing basis for any current or potential threats.  There can be no assurance, however, that our efforts will prevent breakdowns or breaches to our or our third-party providers&#8217; databases or systems that could adversely affect our business.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We could be adversely affected by violations of the FCPA and similar worldwide anti-bribery laws and any investigation, and the outcome of any investigation, by government agencies of possible violations by us of the FCPA could have a material adverse effect on our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FCPA and similar worldwide anti-bribery laws prohibit companies and their intermediaries from corruptly providing any benefits to government officials for the purpose of obtaining or retaining business.  We are in the process of further enhancing policies and procedures intended to help ensure compliance with these laws.  In the future, we may operate in parts of the world that have experienced governmental corruption to some degree.  Moreover, because of the significant role government entities play in the regulation of many foreign healthcare markets, we may be exposed to heightened FCPA and similar risks arising from our efforts to seek regulatory approval of and reimbursement for our products in such countries.  We cannot assure you that our internal control policies and procedures will protect us from improper acts committed by our employees or agents.  Violations of these laws, or allegations of such violations, would significantly disrupt our business and have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Intellectual Property</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage.  It is possible that U.S. and foreign patents and pending patent applications or trademarks controlled by third parties may be alleged to cover our products, or that we may be accused of misappropriating third parties&#8217; trade secrets.  Additionally, our products include components that we purchase from vendors, and may include design components that are outside of our direct control.  Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products or to use product names.  Moreover, in recent years, individuals and groups that are non-practicing entities, commonly referred to as &#8220;patent trolls,&#8221; have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements.  From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others.  The defense of these matters can be time consuming, costly to defend in litigation, divert management&#8217;s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments.  Vendors from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third-party&#8217;s patent or trademark or of misappropriating a third-party&#8217;s trade secret.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our products. Competitors may also contest our patents, if issued, by showing the patent examiner that the invention was not original, was not novel or was obvious. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees and consultants and any other partners or collaborators who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, if such patents, trademarks, or trade secrets are successfully asserted against us, this may harm our business and result in injunctions preventing us from selling our products, license fees, damages and the payment of attorney fees and court costs.  In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties.  Although patent, trademark, trade secret, and other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties.  We may be unable to obtain necessary licenses on satisfactory terms, if at all.  If we do not obtain necessary licenses, we may not be able to redesign our products to avoid infringement.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similarly, interference or derivation proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office, or USPTO, may be necessary to determine priority with respect to our patents, patent applications, trademarks or trademark applications.  We may also become involved in other proceedings, such as reexamination, inter parties review, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others.  Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing our products or using product names, which would have a significant adverse impact on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we may file lawsuits or initiate other proceedings to protect or enforce our patents, trademarks or other intellectual property rights, which could be expensive, time consuming and unsuccessful.  Competitors may infringe our issued patents, trademarks or other intellectual property.  To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming.  Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property.  In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.  Furthermore, even if our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business&#160;caused by the infringer&#8217;s competition in the market.  An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our success will depend on our ability to obtain, maintain and protect our intellectual property rights.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to remain competitive, we must develop, maintain and protect the proprietary aspects of our brands, technologies and data.  We rely on a combination of contractual provisions, confidentiality procedures and patent, copyright, trademark, trade secret and other intellectual property laws to protect the proprietary aspects of our brands, technologies and data.  These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information.  Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining and maintaining other intellectual property rights.  We may not be able to obtain or maintain intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage.  In addition, our trade secrets, data and know-how could be subject to unauthorized use, misappropriation, or disclosure to unauthorized parties, despite our efforts to enter into confidentiality agreements with our employees, consultants, clients and other vendors who have access to such information, and could otherwise become known or be independently discovered by third parties.  Our intellectual property, including trademarks, could be challenged, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks.  If any of the foregoing occurs, we could be forced to re-brand our products, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm.  Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion.  Failure to obtain and maintain intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses.  The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our trademarks, data, technology and other intellectual property and services, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely, in part, on our ability to obtain, maintain, expand, enforce, and defend the scope of our intellectual property portfolio or other proprietary rights, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights.  The process of applying for and obtaining a patent is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our proprietary rights at all.  Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary.  In addition, the issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties.  Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our technology.  Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.  Issued patents may be challenged, narrowed, invalidated or circumvented.  Decisions by courts and governmental patent agencies may introduce uncertainty in the enforceability or scope of patents owned by or licensed to us.  Furthermore, the issuance of a patent does not give us the right to practice the patented invention.  Third parties may have blocking patents that could prevent us from marketing our own products and practicing our own technology.  Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products.  In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement.  In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid, unenforceable or not infringed; competitors may then be able to market products and use manufacturing and analytical processes that are substantially similar to ours.  Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information that is not patentable or that we elect not to patent.  However, trade secrets can be difficult to protect and some courts are less willing or unwilling to protect trade secrets.  To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators and others upon the commencement of their relationship with us.  We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes.  We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions.  These contracts may not provide meaningful protection for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information.  There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by competitors.  Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate.  In addition, the laws of many foreign countries will not protect our intellectual property or other proprietary rights to the same extent as the laws of the United States.  Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to international markets or require costly efforts to protect our technology.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct competition.  A third party could, without authorization, copy or otherwise obtain and use our products or technology, or develop similar technology.  Our competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology.  Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our products, brand and business.  The theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the differentiation of our products and harm our business, the value of our investment in research and development or acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary information.  Any of the foregoing could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, it is possible that others will independently develop the same or similar technology or otherwise obtain access to our unpatented technology, and in such cases we could not assert any trade secret rights against such parties.  Costly and time consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions.  If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology similar to ours or competing technologies, our competitive market position could be materially and adversely affected.  In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products, we may not be able to stop a competitor from marketing products that are the same as or similar to our products, which would have a material adverse effect on our business.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A company may attempt to commercialize competing products utilizing our proprietary design, trademarks or tradenames in foreign countries where we do not have any patents or patent applications and where legal recourse may be limited.  This may have a significant commercial impact on our foreign business operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Filing, prosecuting and defending patents or trademarks on our current and future products in all countries throughout the world would be prohibitively expensive.  The requirements for patentability and trademarking may differ in certain countries, particularly developing countries.  The laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States.  Consequently, we may not be able to prevent third parties from utilizing our inventions and trademarks in all countries outside the United States.  Competitors may use our technologies or trademarks in jurisdictions where we have not obtained patent or trademark protection to develop or market their own products and further, may export otherwise infringing products to territories where we have patent and trademark protection, but enforcement on infringing activities is inadequate.  These products or trademarks may compete with our products or trademarks, and our patents, trademarks or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.  The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trademarks and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents and trademarks or marketing of competing products in violation of our proprietary rights generally.  Proceedings to enforce our patent and trademarks rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents and trademarks at risk of being invalidated or interpreted narrowly and our patent or trademark applications at risk, and could provoke third parties to assert claims against us.  We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.  In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties.  In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents.  This could limit our potential revenue opportunities.  Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">intellectual property that we own or license.  Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors.  Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment.  Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property or disclosed the alleged trade secrets or other proprietary information, of these former employers or competitors.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity.  Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all.  If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An inability to incorporate technologies or features that are important or essential to our products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our products.  In addition, we may lose valuable intellectual property rights or personnel.  Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management.  Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives.  A loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.  In 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law.  The Leahy-Smith Act includes a number of significant changes to U.S. patent law.  These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation.  These also include provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings.  Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier.  The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2013.  Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.  The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications.  Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted.  Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted.  We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies.  Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on suppliers, vendors, outsourcing partners, consultants, alliance partners and other third parties to research, develop, manufacture and commercialize our products and manage certain parts of our business.  Using these third parties poses a number of risks, such as: (i) they may not perform to our standards or legal requirements; (ii) they may not produce reliable results; (iii) they may not perform in a timely manner; (iv) they may not maintain confidentiality of our proprietary information; (v) disputes may arise with respect to ownership of rights to technology developed with our partners; and (vi) disagreements could cause delays in, or termination of, the research, development or commercialization of our products or result in litigation or arbitration.  Moreover, some third parties are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, in addition to country-specific privacy and data security risk given current legal and regulatory environments.  Failure of third parties to meet their contractual, regulatory, and other obligations may materially affect our business.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on trademarks, service marks, tradenames and brand names to distinguish our products from the products of our competitors, and have registered or applied to register these trademarks.  We cannot assure you that our trademark applications will be approved.  During trademark registration proceedings, we may receive rejections.  Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections.  In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks.  Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.  In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and marketing new brands and managing through regulatory implications such as relabeling.  At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion.  Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection.  Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Government Regulation</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could harm our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs.  In March 2010, the Affordable Care Act was enacted in the United States, which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers.  Among other ways in which it may affect our business, the Affordable Care Act:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Expanded the eligibility criteria for Medicaid programs.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not yet know the full impact that the Affordable Care Act will have on our business.  The taxes imposed by the Affordable Care Act and the expansion in the government&#8217;s role in the U.S. healthcare industry may result in decreased sale of our products and, lower reimbursement by payers for our products, all of which may have a material adverse effect on our business, financial condition and results of operations.  The Trump Administration and the U.S. Congress may take further action regarding the Affordable Care Act, including, but not limited to, repeal or replacement.  Most recently, the Tax Cuts and Jobs Act of 2017 was enacted, which, among other things, removes penalties for not complying with the individual mandate to carry health insurance.  Additionally, all or a portion of the Affordable Care Act and related subsequent legislation may be modified, repealed or otherwise invalidated through judicial challenge, which could result in lower numbers of insured individuals, reduced coverage for insured individuals and adversely affect our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted.  On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken.  On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.  The Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, enacted on April&#160;16, 2015, repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments scheduled to begin in 2019 that are based on various performance measures and physicians&#8217; participation in alternative payment models such as accountable care organizations.  It is unclear what effect new quality and payment programs, such as MACRA, may have on our business, financial condition, results of operations or cash flows.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect additional state and federal healthcare policies and reform measures to be adopted in the future.&#160; Any of these could make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained.&#160; They could result in reduced demand for our products or result in additional pricing pressure.&#160; Any such reforms could have a material adverse effect on our industry generally and on our customers.&#160; Any changes of, or uncertainty with respect to, future coverage or reimbursement rates could affect demand for our products, which in turn could impact our ability to successfully commercialize our products and could have an adverse material effect on our business, financial condition and results of </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">operations. &#160;Changes and reforms in the European Union and other countries where we may decide to commercialize could have similar effects.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in the CMS fee schedules may harm our revenue and operating results.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Government payers, such as Centers for Medicare and Medicaid Services, or CMS, as well as insurers, have increased their efforts to control the cost, utilization and delivery of healthcare services.  From time to time, the U.S. Congress has considered and implemented changes in the CMS fee schedules in conjunction with budgetary legislation.  Reductions of reimbursement by Medicare or Medicaid for procedures that use our products or changes in policy regarding coverage of these procedures, such as adding requirements for payment, or prior authorizations, may be implemented from time to time.  Reductions in the reimbursement rates and changes in payment policies of other third-party payers may occur as well.  Similar changes in the past have resulted in reduced payments for procedures that use medical device products as well as added costs and have added more complex regulatory and administrative requirements.  Further changes in federal, state, local and third-party payer regulations or policies may have a material adverse impact on the demand for our products and on our business.  Actions by agencies regulating insurance or changes in other laws, regulations, or policies may also have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with broad based healthcare and other governmental regulations, we could face substantial fines and penalties and our business, results of operations and financial condition could be adversely affected.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The products we offer are highly regulated, and there can be no assurance that the regulatory environment in which we operate will not change significantly and adversely in the future.  Our arrangements with physicians, hospitals and medical centers will expose us to broadly applicable fraud and abuse and other laws and regulations that may restrict the financial arrangements and relationships through which we market, sell and distribute our products.  Our employees, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.  Federal and state healthcare laws and regulations that may affect our ability to conduct business, include, without limitation:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Federal and state laws and regulations regarding billing and claims payment applicable to TCAR and regulatory agencies enforcing those laws and regulations;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">FDA prohibitions against the advertisement, promotion and labeling of our products for off-label uses, or uses outside the specific indications approved by the FDA;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The federal Anti-Kickback Statute, which broadly prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the CMS programs.  A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation.  Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.  Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $176,495 for each violation, plus up to three times the remuneration involved.  Civil penalties for such conduct can further be assessed under the federal False Claims Act.  Violations can also result in criminal penalties, including criminal fines of up to $100,000 and imprisonment of up to 10&#160;years.  Similarly, violations can result in mandatory exclusion from participation in government healthcare programs, including Medicare and Medicaid;</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government.  These laws can apply to manufacturers who provide inaccurate information on coverage, coding, and reimbursement of their products to persons who bill third-party payers.  Private individuals can bring False Claims Act &#8220;qui tam&#8221; actions, on behalf of the government and such individuals, commonly known as &#8220;whistleblowers,&#8221; may share in amounts paid by the entity to the government in fines or settlement.  When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties ranging from $11,655 to $23,331 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making, or causing to be made, false statements relating to healthcare matters;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The FCPA, the U.K. Bribery Act of 2010, and other local anti-corruption laws that apply to our international activities;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The federal Physician Payment Sunshine Act, or Open Payments, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or Affordable Care Act, and its implementing regulations, which requires manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to licensed physicians, certain other healthcare professionals, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations, to report annually ownership and investment interests held by physicians and their immediate family members.  Additionally, on October 24, 2018, President Trump signed into law the &#8220;Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act&#8221; which in part (under a provision entitled &#8220;Fighting the Opioid Epidemic with Sunshine&#8221;) extends the reporting and transparency requirements for physicians in the Physician Payments Sunshine Act to physician assistants, nurse practitioners, and other mid-level practitioners (with reporting requirements going into effect in 2022 for payments made in 2021).  Applicable manufacturers are required to submit annual reports to CMS.  Our failure to submit required information on time may result in civil monetary penalties of $11,766 per failure up to an aggregate of $176,495 per year (or up to an aggregate of $1.177 million per year for &#8220;knowing failures&#8221;), for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; HIPAA also created criminal liability for knowingly and willfully falsifying or concealing a material fact or making a materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.  Failure to comply with the HIPAA privacy and security standards when applicable can result in civil monetary penalties up to $59,522 per violation, not to exceed $1.79&#160;million per calendar year for non-compliance of an identical provision, and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment.  </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">State attorneys general can also bring a civil action to enjoin a HIPAA violation or to obtain statutory damages on behalf of residents of his or her state; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers or patients; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers, foreign and state laws, including the E.U. General Data Protection Regulation, or GDPR, governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions or safe harbors, it is possible that some of our activities, such as stock-option compensation paid to physicians, could be subject to challenge under one or more of such laws.  Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.  We may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures.  The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations.  Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.  If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant criminal, civil, and administrative penalties, damages, fines, imprisonment, for individuals, exclusion from participation in government programs, such as Medicare and Medicaid, and we could be required to curtail or cease our operations.  Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to obtain and maintain necessary regulatory clearances or approvals for our products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our products are subject to extensive regulation by the FDA in the United States and by regulatory agencies in other countries where we do business.  Government regulations specific to medical devices are wide ranging and govern, among other things:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Product design, development and manufacture;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Laboratory, preclinical and clinical testing, labeling, packaging, storage and distribution;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Premarketing clearance or approval;</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Record keeping;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Product marketing, promotion and advertising, sales and distribution; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Post marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before a new medical device, or a new intended use for an existing product, can be marketed in the United States, a company must first submit and receive either 510(k) clearance pursuant to Section 510(k) of the Food, Drug and Cosmetic Act, or the FDCA, or approval of a premarket approval, or PMA, application from the FDA, unless an exemption applies.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In many cases, the process of obtaining PMA approval, which was required for the ENROUTE stent, is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process.  In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, in order to clear the proposed device for marketing.  To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device.  Clinical data is sometimes required to support substantial equivalence.  In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based on extensive data, including technical, pre-clinical, clinical trial, manufacturing and labeling data.  The PMA process is typically required for devices for which the 510(k) process cannot be used and that are deemed to pose the greatest risk.  Modifications to products that are approved through a PMA application generally need prior FDA approval of a PMA supplement.  Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k), or such modification may put the device into class III and require PMA approval.  The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but may last longer.  The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained.  Any delay or failure to obtain necessary regulatory approvals or clearances would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are safe or effective for their intended uses;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The disagreement of the FDA or the applicable foreign regulatory body with the design, conduct or implementation of our clinical trials or the analyses or interpretation of data from pre-clinical studies or clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Serious and unexpected adverse device effects experienced by participants in our clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">An advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product;</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The applicable regulatory authority may identify significant deficiencies in our manufacturing processes, facilities or analytical methods or those of our third party contract manufacturers;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The FDA or foreign regulatory authorities may audit our clinical trial data and conclude that the data is not sufficiently reliable to support approval or clearance.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similarly, regulators may determine that our financial relationships with our principal investigators resulted in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial itself.  Even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product.  Moreover, the FDA and European Union regulatory authorities strictly regulate the labeling, promotion and advertising of our products, including comparative and superiority claims vis a vis competitors&#8217; products, that may be made about products.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a condition of approving a PMA application, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device.  As a part of our PMA approval, we agreed with the FDA to conduct a post-approval study at a minimum of 30 sites in the United States to evaluate the safety and effectiveness of our products in at least 600 subjects. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> We have completed enrollment in this study and submitted our final report to the FDA. On February 11, 2020 we received notice from the FDA of their review and that we have fulfilled the post-approval study requirement.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">A PMA supplement with the updated labeling was submitted to FDA in December 2019 and subsequently approved by FDA in June 2020. The updated labeling included outcomes and adverse event data from the ROADSTER 2 Post-Approval Study. Failure to have conducted the post-approval study in compliance with applicable regulations or to have timely completed required post-approval studies or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm our business.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we are required to investigate all product complaints we receive, and timely file reports with the FDA, including MDRs that require that we report to regulatory authorities if our products may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur.&#160; If these reports are not submitted in a timely manner, regulators may impose sanctions and we may be subject to product liability or regulatory enforcement actions, including warning letters, untitled letters, fines, civil penalties, recalls, seizures, operating restrictions, denial of requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products, withdrawal of current 510(k) clearances or premarket approvals and narrowing of approved or cleared product labeling, all of which could harm our business.&#160; In addition, the FDA may provide notice of and conduct additional inspections, such as &#8220;for cause&#8221; inspections, of our business, sites and facilities as part of its review process.  We previously identified the need to implement corrective actions to our complaint handling procedures, which may have caused a delay in timely submission of 51 MDR reports to the FDA since we began commercialization in 2015.&#160; As of July 31, 2020, we had filed</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> 198 M</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">DR reports with the FDA for adverse events including stroke, arterial dissection, stent thrombosis and wound complications.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we initiate a correction or removal action for our products to reduce a significant risk to health posed by our products, we would be required to submit a publicly available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies.  This report could be classified by </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the FDA as a device recall which could lead to increased scrutiny by the FDA, other international regulatory agencies and our customers regarding the quality and safety of our products.  Furthermore, the submission of these reports could be used by competitors against us and cause physicians to delay or cancel prescriptions, which could harm our reputation.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA and the Federal Trade Commission, or FTC, also regulate the advertising, promotion and labeling of our products to ensure that the claims we make are consistent with our regulatory clearances and approvals, that there is adequate and reasonable scientific data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect.  If the FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including adverse publicity, warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA and state authorities have broad investigation and enforcement powers.  Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizure of our products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Operating restrictions, partial suspension or total shutdown of production;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Denial of our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Withdrawal of 510(k) clearance or premarket approvals that have already been granted; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Criminal prosecution.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of these events were to occur, our business and financial condition could be harmed.  In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our products.  For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law.  The Cures Act, among other things, is intended to modernize the regulation of medical devices and spur innovation, but its ultimate implementation is unclear.  If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, financial condition and results of operations.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our clinical trials may fail to demonstrate competent and reliable evidence of the safety and effectiveness of our products, which would prevent or delay commercialization of our products in development.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may be required to conduct clinical studies that demonstrate competent and reliable evidence that our products are safe and effective before we can commercialize our products.&#160; Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.  We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our products for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">resources, which may not be available to us, to conduct additional trials in support of potential approval of our products. Even if regulatory approval is secured for any of our products, the terms of such approval may limit the scope and use of our products, which may also limit their commercial potential.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Material modifications to our products may require new 510(k) clearances, premarket approval, or CE Marks, or may require us to recall or cease marketing our products until new clearances or approvals are obtained.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Material modifications to the intended use or technological characteristics of our products will require new 510(k) clearances, premarket approvals or CE Marks prior to implementing the modifications, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained.  Furthermore, changes to our manufacturing facility or supplier of components used in our products require prior FDA approval of a PMA supplement.  The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance; however, the FDA can review a manufacturer&#8217;s decision.  Any modification to an FDA cleared device that would significantly affect its safety or effectiveness or that would constitute a major change in its intended use would require a new 510(k) clearance or approval of a PMA supplement.  We may not be able to obtain additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, our products in a timely fashion, or at all.  Delays in obtaining required future clearances would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.  We have made modifications to our products in the past that we believe do not require additional clearances or approvals, and we may make additional modifications in the future.  If the FDA or an EU Notified Body disagrees and requires new clearances or approvals for any of these modifications, we may be required to recall and to stop selling or marketing our products as modified, which could harm our operating results and require us to redesign our products.  In these circumstances, we may be subject to significant enforcement actions.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we, or our suppliers, fail to comply with the FDA&#8217;s QSR or the European Union&#8217;s Medical Device Directive, our manufacturing or distribution operations could be delayed or shut down and our revenue could suffer.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our manufacturing and design processes and those of our third-party component suppliers are required to comply with the FDA&#8217;s Quality System Regulation, or QSR, and the European Union&#8217;s Medical Device Directive, or MDD, both of which cover procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our products.  We are also subject to similar state requirements and licenses, and to ongoing ISO 13485 compliance in our operations, including design, manufacturing, and service, to maintain our CE Mark.  In addition, we must engage in extensive recordkeeping and reporting and must make available our facilities and records for periodic unannounced inspections by governmental agencies, including the FDA, state authorities, EU Notified Bodies and comparable agencies in other countries.  If we fail a regulatory inspection, our operations could be disrupted and our manufacturing interrupted.  Failure to take timely and adequate corrective action in response to an adverse regulatory inspection could result in, among other things, a shutdown of our manufacturing or product distribution operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our device, operating restrictions and criminal prosecutions, any of which would cause our business to suffer.  Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our products and cause our revenue to decline.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are registered with the FDA as a medical device specifications developer and manufacturer.  The FDA has broad post-market and regulatory enforcement powers.  We are subject to unannounced inspections by the FDA and the Food and Drug Branch of the California Department of Public Health, or CDPH, and our Notified Body to determine our compliance with the QSR and other regulations at both our design and manufacturing facilities, and these inspections may include the manufacturing facilities of our </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">suppliers.  These inspections may be initiated as a result of concerns regarding the safety of our products or the components thereof.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We can provide no assurance that we will continue to remain in material compliance with the QSR or MDD.  If the FDA, CDPH or our notified body in the European Union, the British Standards Institution, or BSI, inspect any of our facilities and discover compliance problems, we may have to cease manufacturing and product distribution until we can take the appropriate remedial steps to correct the audit findings.  Taking corrective action may be expensive, time consuming and a distraction for management and if we experience a delay at our manufacturing facility we may be unable to produce our products, which would harm our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With the transition from the MDD to the new European Union Medical Device Regulation, or MDR, notified bodies are required to seek designation to operate as conformity assessment authorities under the new law,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> which is effective in May 2021. BSI,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> our notified body, successfully obtained designation to operate as conformity assessment authorities under the new law.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The impact of the new EU Medical Device Regulation may be costly and disruptive to our business.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, the European Union released new regulations to ensure patient safety with the use of pharmaceuticals, medical devices and in-vitro diagnostics that will go into effect starting in May 2021. The new regulations replace predecessor directives and emphasize a global convergence of regulations.  Major changes include:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Reclassification of some products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Greater emphasis on clinical data;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Data transparency, including publication of clinical trial data and safety summaries;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Defined content and structure for technical files to support registration;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Unique device identification system;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Greater burden on post-market surveillance and clinical follow-up;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Reduction of adverse event reporting time from 30 to 15 days after the event; and </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">More power to notified bodies.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Complying with these new regulations may result in Europe being less attractive as a &#8220;first market&#8221; destination.  Marketing authorization timelines will become more protracted and the costs of operating in Europe will increase. A significantly more costly path to regulatory compliance is anticipated.  Adjusting to the new Medical Device Regulation may prove to be costly and disruptive to our business.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our products may in the future be subject to product recalls that could harm our reputation.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA and similar governmental authorities in other countries have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture.  A government mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors or design or labeling defects.  Recalls of our products would divert managerial attention, be expensive, harm our reputation with customers and harm our financial condition and results of operations.  A recall announcement would also negatively affect our stock price.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compliance with environmental laws and regulations could be expensive, and failure to comply with these laws and regulations could subject us to significant liability.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development and manufacturing operations involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances.  Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence.  Compliance with environmental laws and regulations may be expensive and noncompliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs.  Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations.  We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes.  The expense associated with environmental regulation and remediation could harm our financial condition and operating results.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Ownership of Our Common Stock</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Changes in analysts&#8217; estimates, investors&#8217; perceptions, recommendations by securities analysts or our failure to achieve analysts&#8217; estimates;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quarterly variations in our or our competitors&#8217; results of operations;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Periodic fluctuations in our revenue, which could be due in part to the way in which we recognize revenue;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">General market conditions and other factors unrelated to our operating performance or the operating performance of our competitors;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Changes in reimbursement by current or potential payers;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Changes in operating performance and stock market valuations of other technology companies generally, or those in the medical device industry in particular;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Actual or anticipated changes in regulatory oversight of our products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The results of our clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The loss of key personnel, including changes in our board of directors and management;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Product recalls or other problems associated with our products;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Legislation or regulation of our market;</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Lawsuits threatened or filed against us, including litigation by current or former employees alleging wrongful termination, sexual harassment, whistleblower or other claims;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The announcement of new products or product enhancements by us or our competitors;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Announced or completed acquisitions of businesses or technologies by us or our competitors;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Announcements related to patents issued to us or our competitors and related litigation; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Developments in our industry.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, in the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and harm our business, results of operations, financial condition and reputation. These factors may materially and adversely affect the market price of our common stock.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our share price and trading volume could decline.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business, our market and our competitors.  We do not have any control over these analysts.  If one or more of the analysts who cover us downgrade our shares or change their opinion of our business, our share price would likely decline.  If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lapse of lock-up and other legal restrictions on resale, the trading price of our common stock could decline.  If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of an aggregate of 1,456,462 shares of our outstanding common stock, have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders.  R</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">egistration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule 144 under the Securities Act.  Any sales of securities by these stockholders could have a material adverse effect on the market price of our common stock.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of June&#160;30, 2020, our directors, officers and each stockholder holding 5% or more of our outstanding common stock and their affiliates beneficially owned approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">30.0% of o</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ur outstanding common stock in the aggregate. Actions taken by these stockholders may have the effect of delaying or </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">preventing a change in control, might adversely affect the market price of our common stock and may not be in the best interests of other stockholders.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have previously identified two material weaknesses in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the completion of our initial public offering, we were a private company and had limited accounting and financial reporting personnel and other resources with which to address our internal controls and procedures.  In connection with the audit of our financial statements for the year ended December 31, 2017, we and our independent registered public accounting firm identified two material weaknesses in our internal control over financial reporting.  A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determined that we had a material weakness because we did not maintain a sufficient complement of personnel with an appropriate degree of knowledge, experience, and training, commensurate with our accounting and reporting requirements.  As a result, there were a number of post initial close&#160;adjustments that were material to the financial statements.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The second material weakness relates to the fact that we did not appropriately design and implement controls over the review and approval of manual journal entries and the related supporting journal entry calculations, resulting in inappropriate segregation of duties over manual journal entries.  This material weakness could result in a misstatement of account balances or disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With the oversight of senior management and our audit committee, we began the implementation of remediation steps in 2018. These efforts focused on (i)&#160;the hiring of personnel with technical accounting and financial reporting experience and (ii)&#160;the implementation of improved accounting and financial reporting procedures and systems to improve the completeness, timeliness and accuracy of our financial reporting and disclosures including the assessment of more judgmental areas of accounting.  We believe the measures described above will remediate the material weaknesses identified and strengthen our internal control over financial reporting.  While we believe the steps taken in our remediation initiatives outlined above are sufficient to remediate the material weaknesses in internal control over financial reporting, our improvements, including the enhanced controls, have not operated for a sufficient period of time to demonstrate that the material weaknesses are fully remediated.  As such, the remediation initiatives outlined above were not sufficient to fully remediate the material weaknesses in internal control over financial reporting for the six months ended June&#160;30, 2020. We are committed to continuing to improve our internal control processes and will continue to diligently and vigorously review our financial reporting controls and procedures.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we continue with our plan to remediate the material weaknesses, we cannot predict the success of such plan or the outcome of our assessment of these plans at this time.  We can give no assurance that this implementation will remediate these deficiencies in internal control or that additional material weaknesses or significant deficiencies in our internal control over financial reporting will not be identified in the future.  Our failure to implement and maintain effective internal control over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements, causing us to fail to meet our reporting obligations.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are obligated to develop and maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, to furnish a report by management on the effectiveness of our internal control over financial reporting for the year ended December 31, 2020.  This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting.  Based on our market capitalization as of June 30, 2020, we will be required to comply with, among other requirements, the auditor attestation requirements of Section 404 for our next annual report.  If we have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are continuing the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404, and we may not be able to complete our evaluation, testing and any required remediation in a timely fashion.  Our compliance with Section 404 will require that we incur substantial accounting expense and expend significant management efforts</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  We recently engaged outside consultants and intend that they function in the capacity of an internal audit group, and we will need to continue to hire additional consultants, accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During our evaluation of our internal control, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">if we are unable to remediate our material weaknesses or if we identify additional material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective.  We cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future.  Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations.  If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have an additional material weakness in our internal control over financial reporting, we could los</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">e investor confidence in the accuracy and completeness of our financial reports, the market price of our ordinary shares could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.  Failure to remedy our current and any future material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are a &#8220;smaller reporting company&#8221; and we cannot be certain if the reduced disclosure requirements applicable to us will make our common stock less attractive to investors.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a smaller reporting company, we may take advantage of certain exemptions from reporting requirements that are applicable to other public companies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot predict if investors will find our common stock less attractive to the extent we rely on available exemptions.  If some investors do find our common stock less attractive, there may be a less active trading market for our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">common stock and our stock price may be more volatile or may decline.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions in our amended and restated certificate of incorporation and bylaws, and Delaware law, could discourage a change in control of our company or a change in our management.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated certificate of incorporation and bylaws contain provisions that might enable our management to resist a takeover.  These provisions include:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A classified board of directors;</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Advance notice requirements applicable to stockholders for matters to be brought before a meeting of stockholders and requirements as to the form and content of a stockholders&#8217; notice;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A supermajority stockholder vote requirement for amending certain provisions of our amended and restated certificate of incorporation and bylaws;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Allowing stockholders to remove directors only for cause;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A requirement that the authorized number of directors may be changed only by resolution of the board of directors;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Allowing all vacancies, including newly created directorships, to be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum, except as otherwise required by law;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A requirement that our stockholders may only take action at annual or special meetings of our stockholders and not by written consent;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Limiting the forum to Delaware for certain litigation against us; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Limiting the persons that can call special meetings of our stockholders to our board of directors, the chairperson of our board of directors, the chief executive officer or the president, in the absence of a chief executive officer.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These provisions might discourage, delay or prevent a change in control of our company or a change in our management.  The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.  In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder.  See &#8220;Description of Capital Stock.&#8221;</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our amended and restated certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; abilities to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated certificate of incorporation and bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&#160;any action asserting a claim against the company or any director or officer of the company arising pursuant to any provision of the Delaware General Corporation Law, (4)&#160;any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or bylaws, or (5)&#160;any other action asserting a claim that is governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware or federal court located within the State of Delaware if the Court of Chancery does not have jurisdiction, in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants. A complaint asserting a cause of action under the Securities Act may be brought in state or federal court.  With respect to the Securities Exchange Act of 1934, or Exchange Act, only claims brought derivatively under the Exchange Act would be subject to the forum </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">selection clause described above.  The enforceability of similar choice of forum provisions in other companies' certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation and bylaws to be inapplicable or unenforceable in such action.  Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.  Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation and bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and operating results.  Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of our stock.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never paid cash dividends and do not anticipate paying cash dividends in the foreseeable future.  The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects for future earnings and other factors our board of directors may deem relevant.  In addition, our loan agreement limits our ability to, among other things, pay dividends or make other distributions or payments on account of our common stock, in each case subject to certain exceptions.  If we do not pay dividends, our stock may be less valuable because a return on your investment will only occur if our stock price appreciates and you then sell our common stock.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our chief financial officer had not previously been the chief financial officer of a publicly traded company and our chief executive officer had not previously been the chief executive officer of a publicly traded company.  As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control.  We are required, pursuant to Section 404, to evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report after the completion of our initial public offering in April 2019, provide a management report on the internal control over financial reporting.  This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting.  Based on our market capitalization as of June 30, 2020, we will also be required to comply with, among other requirements, the auditor attestation requirements of Section 404 for our next annual report. If we then have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm.  If we </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">are unable to remediate our material weaknesses or if we </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">have an additional material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated.  We are implementing the process and documentation necessary to perform the evaluation needed to comply with Section 404.  We may not be able to complete our evaluation, testing and any required remediation in a timely fashion.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">are unable to remediate our material weaknesses or if we </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">have additional material weaknesses in our internal control over financial reporting in the future, we may not detect errors on a timely basis and our financial statements may be materially misstated.  Although we have begun the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404, we may not be able to complete our evaluation, testing and any required remediation in a timely fashion.  Our compliance with Section 404 will require that we incur substantial accounting expense and expend significant management effort</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">s. We recently engaged outside </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">consultants and intend that they function in the capacity of an internal audit group, and we will need to continue to hire additional consultants, accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During our evaluation of our internal control, if we </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">are unable to remediate our material weaknesses or if we </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">identify additional material weaknesses in our internal control over financial reporting in the future, we will be unable to assert that our internal control over financial reporting is effective.  We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future.  Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations.  If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we were </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">unable to remediate our material weaknesses or we </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">have a material weakness or significant deficiency in our internal control over financial reporting in the future, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our ordinary shares could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions or other remedies.  Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_103"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Unregistered Sales of Equity Securities</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Proceeds from Public Offering of Common Stock</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our initial public offering of 6,000,000 shares of common stock was effected through a registration statement on Form S-1 (File No. 333-230045), which was declared effective on April 3, 2019 and pursuant to which we sold an aggregate 6,000,000 shares of our common stock at a public offering price of $20.00 per share for an aggregate offering price of $120.0 million. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On April 4, 2019, the underwriters fully exercised their option to purchase 900,000 additional shares of common stock from the selling stockholders pursuant to the underwriting agreement. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">When our initial public offering closed on April 8, 2019, we received net proceeds of $109.1 million, after deducting underwriting discounts and commissions of $8.4 million and other expenses of $2.5 million. No payments for such expenses were made directly or indirectly to any of our officers or directors or persons holding 10 percent or more of our securities.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated acted as representatives of the underwriters for the offering.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on April 4, 2019 pursuant to Rule 424(b) of the Securities Act.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In May 2020, we completed an underwritten public offering of 6,808,154 shares of common stock through a registration statement on Form S-3/ASR (File No. 333-238007), which was automatically effective upon filing on May 5, 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to this registration statement we sold an aggregate 1,923,076 shares of our common stock at a public offering price of $39.00 per share for an aggregate offering price of $75.0 million, and certain selling stockholders sold an additional 4,885,078 shares of common stock.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We received cash proceeds of approximately $70.5 million, net of underwriting discounts and commissions of approximately $3.8 million and offering costs of approximately $0.7 million. On May 20, 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">stock from the selling stockholders pursuant to the underwriting agreement.  We did not receive any of the proceeds from the sale of the shares of common stock by the selling stockholders.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">J.P. Morgan Securities LLC and BofA Securities, Inc. acted as representatives of the underwriters for the offering.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There has been no material change in the planned use of proceeds from the public offering as described in our final prospectus supplement filed with the SEC on May 7, 2020 pursuant to Rule 424(b) of the Securities Act.</span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_106"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 3.  Defaults Upon Senior Securities</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_109"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 4.  Mine Safety Disclosures</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_112"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 5.  Other Information</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in Delaware on March 21, 2007 as Silk Road Medical, Inc. Our principal executive offices are located at 1213 Innsbruck Drive, Sunnyvale, CA 94089, and our telephone number is (408) 720-9002. Our website address is www.silkroadmed.com. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that information we post on social media channels could be deemed to be material information. We encourage investors, our customers and others interested in our company to review the information we post on our Facebook page (https://www.facebook.com/SilkRoadMed/) and Twitter feed (https://twitter.com/silkroadmed). The information on, or that may be accessed through, our website and social media channels is not incorporated by reference into this Quarterly Report on Form 10-Q and should not be considered a part of this Quarterly Report on Form 10-Q.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On August 6, 2020, Donald J. Zurbay was appointed by the Board to serve on the Compensation Committee. Following the appointment, the Compensation Committee consisted of Tony M. Chou, M.D. (Chairperson), Ruoxi Chen and Donald J. Zurbay. Mr. Zurbay will receive standard compensation for his membership on the Committee.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span><br/></span></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_115"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item 6. Exhibit Index</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exhibits listed in the accompanying index to exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form&#160;10-Q.</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:7.470%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:50.487%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.260%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.075%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.223%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.475%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporated by Reference</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">File No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filing Date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of Amendment of Amended and Restated Certificate of Incorporation of the registrant as currently in effect.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bylaws of the registrant as currently in effect.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Specimen Common Stock Certificate of the registrant.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended and Restated Registration Rights Agreement by and among the registrant and certain stockholders, dated July 7, 2017.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended and Restated Stockholders Agreement by and among the registrant and certain stockholders, dated July 7, 2017.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendment to the Amended and Restated Registration Rights Agreement, dated March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.8</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form of Indemnification Agreement for directors and executive officers.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:7.470%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:50.487%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.260%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.075%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.223%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.475%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2007 Stock Plan, as amended, and related form agreement.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019 Employee Stock Purchase Plan and related form agreements.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Incentive Compensation Plan.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019 Equity Incentive Plan and related form agreements.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6#**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supply Agreement by and between the registrant and Cordis Corporation, dated October 21, 2011, as amended by the Amendment dated March 12, 2012, the Second Amendment to Supply Agreement dated July 12, 2012, the Third Amendment to Supply Agreement dated April 19, 2013 and the Fourth Amendment to Supply Agreement dated April 9, 2018.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.6</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7#**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License Agreement by and between the registrant and Cordis Corporation, dated December 17, 2010.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quality Assurance Agreement by and among the registrant and Lake Region Medical and affiliates, dated May 4, 2015.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9#**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amended and Restated Manufacturing and Supply Agreement by and between the registrant and Galt Medical Corporation, dated January 10, 2018.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.9</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term Loan Agreement by and among the registrant, certain affiliates of CRG Partners III L.P. as lenders and certain subsidiary guarantors, dated October 13, 2015, as amended by Amendment No. 1 to Term Loan Agreement dated January 3, 2017, Amendment No. 2 to Term Loan Agreement dated June 22, 2017, Amendment No. 3 to Term Loan Agreement dated November 30, 2017, Amendment No. 4 to Term Loan Agreement dated June 25, 2018, Amendment No. 5 to Term Loan Agreement dated September 4, 2018, Amendment No. 6 to Term Loan Agreement dated November 14, 2018 and effective as of October 31, 2018, and Amendment No. 7 to Term Loan Agreement dated June 11, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-233044</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.10</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8/6/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Agreement by and between the registrant and Hanover Properties Ltd., dated November 30, 2017.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.11</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/4/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.12**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Director Offer Letter for Donald Zurbay dated as of February 6, 2018.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.13+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Confirmatory Employment Letter between the registrant and Erica Rogers, dated as of March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.14+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Confirmatory Employment Letter between the registrant and Lucas Buchanan, dated as of March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.15+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Confirmatory Employment Letter between the registrant and Richard Ruedy, dated as of March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.16+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Confirmatory Employment Letter between the registrant and Andrew Davis, dated as of March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.17+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Control and Severance Agreement between the registrant and Erica Rogers, dated as of March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.18</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.18+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Control and Severance Agreement between the registrant and Lucas Buchanan, dated as of March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.19</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.19+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Control and Severance Agreement between the registrant and Richard Ruedy, dated as of March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.20+**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Control and Severance Agreement between the registrant and Andrew Davis, dated as of March 21, 2019.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-230045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.21</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3/25/2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q22020exhibit311.htm">31.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q22020exhibit311.htm">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q22020exhibit311.htm">*</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q22020exhibit311.htm">Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q22020exhibit312.htm">31.2*</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q22020exhibit312.htm">Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q22020exhibit321.htm">32.1*</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q22020exhibit321.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document.  The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:7.470%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:50.487%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.260%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.075%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.223%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.475%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">*&#160;Filed herewith.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">**&#160;Previously filed.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">+&#160;Indicates management contract or compensatory plan.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">#&#160;Portions of the exhibit have been omitted pursuant to a request for confidential treatment. The omitted information has been filed separately with the SEC.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i0f5f7f4a40e74f9186fba54ac93b1916_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="text-indent:18pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form&#160;10-Q to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:35.980%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.583%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.487%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SILK ROAD MEDICAL, INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 13, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Erica J. Rogers</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Erica J. Rogers</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">President, Chief Executive Officer and Director (principal executive officer)</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 13, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Lucas W. Buchanan</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Lucas W. Buchanan</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Chief Financial Officer (principal financial officer and principal accounting officer)</span></div></td></tr></table></div><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>q22020exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib9e449ede67441f58c895153a8031c39_1"></div><div style="min-height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;margin-top:1.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:13.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Pursuant to</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Securities Exchange Act Rules 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">As Adopted Pursuant to</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:13.2pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Erica J. Rogers, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I have reviewed this Quarterly Report on Form 10-Q of Silk Road Medical, Inc.&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">b.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">c.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">b.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Erica J. Rogers</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Erica J. Rogers</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President, Chief Executive Officer and Director</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Principal Executive Officer)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:2.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; August 13, 2020</font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>q22020exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib230ed4c03af4a62bc60188944177cd2_1"></div><div style="min-height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:13.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Pursuant to</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Securities Exchange Act Rules 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">As Adopted Pursuant to</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:13.2pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Lucas W. Buchanan, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">I have reviewed this Quarterly Report on Form 10-Q of Silk Road Medical, Inc.&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">b.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">c.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.361%;"><tr><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.423%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.154%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">a.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.972%;"><tr><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.473%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.950%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">b.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Lucas W. Buchanan</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lucas W. Buchanan</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Principal Financial and Accounting Officer)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:2.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; August 13, 2020</font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>q22020exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if362f7f1e7c749f985946ad02eb12cfe_1"></div><div style="min-height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;margin-top:13.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:13.2pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report of Silk Road Medical, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June 30, 2020, as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Erica J. Rogers, as Chief Executive Officer of the Company, and Lucas W. Buchanan, as Chief Financial Officer of the Company, each hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), to his knowledge&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.861%;"><tr><td style="width:1.0%;"></td><td style="width:1.927%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.927%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.146%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The Report, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act of 1934, as amended&#59; and</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.861%;"><tr><td style="width:1.0%;"></td><td style="width:1.927%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.927%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.146%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6.6pt;"><font><br></font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Erica J. Rogers</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Erica J. Rogers</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President, Chief Executive Officer and Director</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(Principal Executive Officer)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:2.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; August 13, 2020</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Lucas W. Buchanan</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lucas W. Buchanan</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(Principal Financial and Accounting Officer)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:2.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; August 13, 2020</font></div><div style="margin-top:13.2pt;"><font><br></font></div><div style="margin-top:13.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Silk Road Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>silk-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9bdc0587-bada-46ac-a409-f4831c8e244f,g:1209e878-563a-4edf-b13c-0faadaf6133a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:silk="http://silkroadmed.com/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://silkroadmed.com/20200630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="silk-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://silkroadmed.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://silkroadmed.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" roleURI="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical">
        <link:definition>1005006 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://silkroadmed.com/role/CondensedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FormationandBusinessoftheCompany" roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompany">
        <link:definition>2101101 - Disclosure - Formation and Business of the Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FormationandBusinessoftheCompanyDetails" roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails">
        <link:definition>2402401 - Disclosure - Formation and Business of the Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Adjustment to Prior Period Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Segment and Geographical Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://silkroadmed.com/role/RecentAccountingPronouncements">
        <link:definition>2113103 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://silkroadmed.com/role/FairValueMeasurements">
        <link:definition>2114104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://silkroadmed.com/role/FairValueMeasurementsTables">
        <link:definition>2315302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" roleURI="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails">
        <link:definition>2416409 - Disclosure - Fair Value Measurements - Recurring Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://silkroadmed.com/role/BalanceSheetComponents">
        <link:definition>2117105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsTables">
        <link:definition>2318303 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails">
        <link:definition>2419410 - Disclosure - Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails">
        <link:definition>2420411 - Disclosure - Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsNarrativeDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails">
        <link:definition>2421412 - Disclosure - Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails">
        <link:definition>2422413 - Disclosure - Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofInventoryDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails">
        <link:definition>2423414 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>2424415 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://silkroadmed.com/role/LongtermDebt">
        <link:definition>2125106 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://silkroadmed.com/role/LongtermDebtTables">
        <link:definition>2326304 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTermLoanNarrativeDetails" roleURI="http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails">
        <link:definition>2427416 - Disclosure - Long-term Debt - Term Loan Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtFutureMaturitiesUndertheTermLoanDetails" roleURI="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails">
        <link:definition>2428417 - Disclosure - Long-term Debt - Future Maturities Under the Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtSeriesCNarrativeDetails" roleURI="http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails">
        <link:definition>2429418 - Disclosure - Long-term Debt - Series C Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://silkroadmed.com/role/CommitmentsandContingencies">
        <link:definition>2130107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesTables">
        <link:definition>2331305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseNarrativeDetails" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails">
        <link:definition>2432419 - Disclosure - Commitments and Contingencies - Lease Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesBalanceSheetInformationDetails" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails">
        <link:definition>2433420 - Disclosure - Commitments and Contingencies - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails">
        <link:definition>2434421 - Disclosure - Commitments and Contingencies - Operating Lease Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1">
        <link:definition>2434421 - Disclosure - Commitments and Contingencies - Operating Lease Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesPurchaseObligationNarrativeDetails" roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails">
        <link:definition>2435422 - Disclosure - Commitments and Contingencies - Purchase Obligation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStock" roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock">
        <link:definition>2136108 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockNarrativeDetails" roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails">
        <link:definition>2437423 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://silkroadmed.com/role/StockholdersEquity">
        <link:definition>2138109 - Disclosure - Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://silkroadmed.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2439424 - Disclosure - Stockholders Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlans" roleURI="http://silkroadmed.com/role/StockOptionPlans">
        <link:definition>2140110 - Disclosure - Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansTables" roleURI="http://silkroadmed.com/role/StockOptionPlansTables">
        <link:definition>2341306 - Disclosure - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansNarrativeDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails">
        <link:definition>2442425 - Disclosure - Stock Option Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansActivityUnderCompensationPlanDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails">
        <link:definition>2443426 - Disclosure - Stock Option Plans - Activity Under Compensation Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansRSUsDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansRSUsDetails">
        <link:definition>2444427 - Disclosure - Stock Option Plans - RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansFairValueofStockOptionsDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails">
        <link:definition>2445428 - Disclosure - Stock Option Plans - Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlansStockbasedCompensationDetails" roleURI="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails">
        <link:definition>2446429 - Disclosure - Stock Option Plans - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://silkroadmed.com/role/A401kPlan">
        <link:definition>2147111 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://silkroadmed.com/role/A401kPlanDetails">
        <link:definition>2448430 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" abstract="false" name="WarrantsClassifiedAsLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="silk_LongTermDebtGrossBeforeAccretionOfClosingFees" abstract="false" name="LongTermDebtGrossBeforeAccretionOfClosingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_RedeemableConvertiblePreferredStockWarrantsMember" abstract="true" name="RedeemableConvertiblePreferredStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_TwoThousandNineteenStockOptionPlanMember" abstract="true" name="TwoThousandNineteenStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentInterestRateFinancingFee" abstract="false" name="DebtInstrumentInterestRateFinancingFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_PublicStockOfferingSharesFromExistingShareholdersMember" abstract="true" name="PublicStockOfferingSharesFromExistingShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_CommonStockWarrantMember" abstract="true" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_AccruedTravelExpensesCurrent" abstract="false" name="AccruedTravelExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_LongTermDebtUnpaidInterest" abstract="false" name="LongTermDebtUnpaidInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" abstract="false" name="TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_DebtInstrumentCovenantMinimumNetRevenueAmount" abstract="false" name="DebtInstrumentCovenantMinimumNetRevenueAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" abstract="false" name="NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_SecondPublicOfferingMember" abstract="true" name="SecondPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_PreferredStockWarrantsMember" abstract="true" name="PreferredStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" abstract="false" name="TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_DebtInstrumentInterestRateFacilityFee" abstract="false" name="DebtInstrumentInterestRateFacilityFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_DebtInstrumentInterestRatePaidInKind" abstract="false" name="DebtInstrumentInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_TermLoanTrancheAMember" abstract="true" name="TermLoanTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentLiquidityCovenantTerm" abstract="false" name="DebtInstrumentLiquidityCovenantTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="silk_IncentiveandNonqualifiedStockOptionMember" abstract="true" name="IncentiveandNonqualifiedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" abstract="false" name="CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_AccruedClinicalExpensesCurrent" abstract="false" name="AccruedClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_LongTermDebtAccretionOfClosingFees" abstract="false" name="LongTermDebtAccretionOfClosingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="silk_CommonStockCapitalSharesAvailableForFutureIssuance" abstract="false" name="CommonStockCapitalSharesAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="silk_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="silk_CommonStockVotePerShare" abstract="false" name="CommonStockVotePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="silk_NonqualifiedStockOptionsMember" abstract="true" name="NonqualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_PublicStockOfferingSharesFromCompanyMember" abstract="true" name="PublicStockOfferingSharesFromCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtInstrumentCovenantMaximumLiquidityAmount" abstract="false" name="DebtInstrumentCovenantMaximumLiquidityAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_OperatingLeaseRightOfUseAssetAmortization" abstract="false" name="OperatingLeaseRightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_LesseeOperatingLeaseLiabilityToBePaidYearOne" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" abstract="false" name="DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_TermLoanTrancheBMember" abstract="true" name="TermLoanTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_DebtMaximumBorrowingCapacity" abstract="false" name="DebtMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_StockIssuanceCostsIncurredButNotYetPaid" abstract="false" name="StockIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" abstract="false" name="PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_IncentiveStockOptionMember" abstract="true" name="IncentiveStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="silk_ProvisionsForSalesReturns" abstract="false" name="ProvisionsForSalesReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_DebtInstrumentInterestRatePaidInCash" abstract="false" name="DebtInstrumentInterestRatePaidInCash" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="silk_DebtInstrumentConvertibleMarketCapitalization" abstract="false" name="DebtInstrumentConvertibleMarketCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" abstract="false" name="CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="silk_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>silk-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9bdc0587-bada-46ac-a409-f4831c8e244f,g:1209e878-563a-4edf-b13c-0faadaf6133a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://silkroadmed.com/role/CoverPage" xlink:type="simple" xlink:href="silk-20200630.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e1fb7e07-2e4f-422d-927e-7de3d2ef52e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ce524691-ed99-46df-88fb-a242ac12aca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1fb7e07-2e4f-422d-927e-7de3d2ef52e8" xlink:to="loc_us-gaap_AssetsCurrent_ce524691-ed99-46df-88fb-a242ac12aca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_5ea7cc43-cbe3-4dd2-8669-f6db76f641b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1fb7e07-2e4f-422d-927e-7de3d2ef52e8" xlink:to="loc_us-gaap_LongTermInvestments_5ea7cc43-cbe3-4dd2-8669-f6db76f641b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8c408658-7802-44ee-81a5-47c6c8371596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1fb7e07-2e4f-422d-927e-7de3d2ef52e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8c408658-7802-44ee-81a5-47c6c8371596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7e6b98ea-d1e5-4bb8-9b8d-91bcd9fe9e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1fb7e07-2e4f-422d-927e-7de3d2ef52e8" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7e6b98ea-d1e5-4bb8-9b8d-91bcd9fe9e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_421e987d-75aa-4edc-93af-107fe50131b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e1fb7e07-2e4f-422d-927e-7de3d2ef52e8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_421e987d-75aa-4edc-93af-107fe50131b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aca88df7-29c2-4596-b780-dc1fb6338bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d3cd9270-2c71-4980-8038-7f1ea2d64914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aca88df7-29c2-4596-b780-dc1fb6338bfb" xlink:to="loc_us-gaap_Liabilities_d3cd9270-2c71-4980-8038-7f1ea2d64914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21c66ed6-1d35-430e-bd45-2950d06aa951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aca88df7-29c2-4596-b780-dc1fb6338bfb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21c66ed6-1d35-430e-bd45-2950d06aa951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2585dd83-fdb7-4d58-b28f-2dc4ea6177f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aca88df7-29c2-4596-b780-dc1fb6338bfb" xlink:to="loc_us-gaap_PreferredStockValue_2585dd83-fdb7-4d58-b28f-2dc4ea6177f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35f302bf-be81-4e11-a737-a026dea2c54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aca88df7-29c2-4596-b780-dc1fb6338bfb" xlink:to="loc_us-gaap_StockholdersEquity_35f302bf-be81-4e11-a737-a026dea2c54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0dae2a88-2438-4db8-9e03-47d800b7924d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4ce68ab7-501a-4333-b654-c859ae9cb86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0dae2a88-2438-4db8-9e03-47d800b7924d" xlink:to="loc_us-gaap_CommonStockValue_4ce68ab7-501a-4333-b654-c859ae9cb86d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_feb1d631-9a58-4c86-9de1-125125fbef2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0dae2a88-2438-4db8-9e03-47d800b7924d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_feb1d631-9a58-4c86-9de1-125125fbef2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c0369ba2-bee3-4a06-a6b5-24378e8127f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0dae2a88-2438-4db8-9e03-47d800b7924d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c0369ba2-bee3-4a06-a6b5-24378e8127f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e74b945d-5abb-43e8-8a91-bc655d2db300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0dae2a88-2438-4db8-9e03-47d800b7924d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e74b945d-5abb-43e8-8a91-bc655d2db300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_559d6841-16d0-4064-934f-d8a207e75a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a6add03e-efd1-4aea-9f92-d3a0a381f55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_559d6841-16d0-4064-934f-d8a207e75a6e" xlink:to="loc_us-gaap_AccountsPayableCurrent_a6add03e-efd1-4aea-9f92-d3a0a381f55d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b070d58a-720d-4693-aba7-d8c637be30fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_559d6841-16d0-4064-934f-d8a207e75a6e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b070d58a-720d-4693-aba7-d8c637be30fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d7c35126-72fc-4ca6-a10f-c263f2dd6bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_398dd111-f254-4bc7-98ce-577b3d982cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d7c35126-72fc-4ca6-a10f-c263f2dd6bd6" xlink:to="loc_us-gaap_LiabilitiesCurrent_398dd111-f254-4bc7-98ce-577b3d982cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4a631a40-bfaf-400b-b76e-921d15299264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d7c35126-72fc-4ca6-a10f-c263f2dd6bd6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4a631a40-bfaf-400b-b76e-921d15299264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a089c638-a7d4-4a07-8f7f-8e99c75af5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d7c35126-72fc-4ca6-a10f-c263f2dd6bd6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a089c638-a7d4-4a07-8f7f-8e99c75af5eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_224f1cd8-7715-44e4-ac99-70effd506f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1c0776f-656b-48a9-b15a-5f8bdbdf602a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_224f1cd8-7715-44e4-ac99-70effd506f9c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1c0776f-656b-48a9-b15a-5f8bdbdf602a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_43bff46f-c8f3-4372-804d-218139ab3a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_224f1cd8-7715-44e4-ac99-70effd506f9c" xlink:to="loc_us-gaap_ShortTermInvestments_43bff46f-c8f3-4372-804d-218139ab3a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ad39013e-11f3-4ff1-8f9b-32ba09911771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_224f1cd8-7715-44e4-ac99-70effd506f9c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ad39013e-11f3-4ff1-8f9b-32ba09911771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c0edb859-918c-4134-82c2-315d1650ab22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_224f1cd8-7715-44e4-ac99-70effd506f9c" xlink:to="loc_us-gaap_InventoryNet_c0edb859-918c-4134-82c2-315d1650ab22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cb7aef01-02d3-4fca-93e0-a74286026e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_224f1cd8-7715-44e4-ac99-70effd506f9c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cb7aef01-02d3-4fca-93e0-a74286026e2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent_a6f9176a-b323-4993-8c65-2d0646fcd9e2" xlink:href="silk-20200630.xsd#silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4eccf862-ea3f-4ca8-b5ee-3a5ca94d834b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent_a6f9176a-b323-4993-8c65-2d0646fcd9e2" xlink:to="loc_us-gaap_NetIncomeLoss_4eccf862-ea3f-4ca8-b5ee-3a5ca94d834b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e619f9c1-bd6a-4c58-b11c-4e71b1016595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent_a6f9176a-b323-4993-8c65-2d0646fcd9e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e619f9c1-bd6a-4c58-b11c-4e71b1016595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c9e6f701-d688-4738-8577-b8b86811065c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_23ee4135-833d-4f24-b299-e69f2691f25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c9e6f701-d688-4738-8577-b8b86811065c" xlink:to="loc_us-gaap_OperatingIncomeLoss_23ee4135-833d-4f24-b299-e69f2691f25b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b79dc551-83cb-44b9-a20f-08490e181af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c9e6f701-d688-4738-8577-b8b86811065c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b79dc551-83cb-44b9-a20f-08490e181af3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5076f842-c104-47e3-a2c4-cefaf91bf1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c9e6f701-d688-4738-8577-b8b86811065c" xlink:to="loc_us-gaap_InterestExpense_5076f842-c104-47e3-a2c4-cefaf91bf1bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d29a42dd-7388-47aa-8fa4-2aa678edff73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c9e6f701-d688-4738-8577-b8b86811065c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d29a42dd-7388-47aa-8fa4-2aa678edff73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_0a7fe8f7-ed18-4f73-97f6-5c3da4f97c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09f7d541-1a8e-454f-9bd2-0c6f0bbb9ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0a7fe8f7-ed18-4f73-97f6-5c3da4f97c13" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09f7d541-1a8e-454f-9bd2-0c6f0bbb9ff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b7180297-e2ab-4aa0-b9f8-1b57556e020f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0a7fe8f7-ed18-4f73-97f6-5c3da4f97c13" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b7180297-e2ab-4aa0-b9f8-1b57556e020f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c852544-33d8-427d-89c3-c0ded569138e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_7186430a-fd57-469b-b42b-8a69bd0f9ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9c852544-33d8-427d-89c3-c0ded569138e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_7186430a-fd57-469b-b42b-8a69bd0f9ec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2049e497-8e8d-4a0f-bcaf-ddda6c6780c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6654fbad-c917-4af9-ba93-8a0eb26b73fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2049e497-8e8d-4a0f-bcaf-ddda6c6780c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6654fbad-c917-4af9-ba93-8a0eb26b73fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_024f7d6b-10b6-432a-bee9-d7d97c2f30a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2049e497-8e8d-4a0f-bcaf-ddda6c6780c2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_024f7d6b-10b6-432a-bee9-d7d97c2f30a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7d29934f-6aa7-4bb2-8a3d-838578bc92bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b1b634c8-8072-4688-b78b-e9975441faee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7d29934f-6aa7-4bb2-8a3d-838578bc92bf" xlink:to="loc_us-gaap_GrossProfit_b1b634c8-8072-4688-b78b-e9975441faee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_74b17e07-9409-46ac-819b-a375b5c30a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7d29934f-6aa7-4bb2-8a3d-838578bc92bf" xlink:to="loc_us-gaap_OperatingExpenses_74b17e07-9409-46ac-819b-a375b5c30a60" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85733ec1-b9dc-487c-aeb0-0c424f57f655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c8ad5d22-5365-4e78-8126-e199a3850307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85733ec1-b9dc-487c-aeb0-0c424f57f655" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c8ad5d22-5365-4e78-8126-e199a3850307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ac17c15-6544-49f4-be3f-0fdd4bfdf209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85733ec1-b9dc-487c-aeb0-0c424f57f655" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ac17c15-6544-49f4-be3f-0fdd4bfdf209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ede2ea7-9db8-465e-8c2e-c4831634b014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85733ec1-b9dc-487c-aeb0-0c424f57f655" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ede2ea7-9db8-465e-8c2e-c4831634b014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_161859fc-c86d-4935-95b6-de47a131bc9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5b8147e5-e04c-4b56-8f9f-5828958eca9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_161859fc-c86d-4935-95b6-de47a131bc9f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5b8147e5-e04c-4b56-8f9f-5828958eca9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_b891190b-410a-42ae-ae77-6664c804709f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_161859fc-c86d-4935-95b6-de47a131bc9f" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_b891190b-410a-42ae-ae77-6664c804709f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a815479b-033d-4af6-bcd4-b6c6c501ff29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_161859fc-c86d-4935-95b6-de47a131bc9f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a815479b-033d-4af6-bcd4-b6c6c501ff29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2eab718e-fedf-4fe1-824f-302dfa51ce2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2eab718e-fedf-4fe1-824f-302dfa51ce2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cb85f0af-b092-4039-92f3-bbec443e5fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_ShareBasedCompensation_cb85f0af-b092-4039-92f3-bbec443e5fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_138cc0f6-7cb0-4cb3-a133-e5efbc09623b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_138cc0f6-7cb0-4cb3-a133-e5efbc09623b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b01c0dee-632c-4e6d-9632-f38ce884ab7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b01c0dee-632c-4e6d-9632-f38ce884ab7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_OperatingLeaseRightOfUseAssetAmortization_f039d90a-7a1b-4f93-991f-a2022c57208f" xlink:href="silk-20200630.xsd#silk_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_silk_OperatingLeaseRightOfUseAssetAmortization_f039d90a-7a1b-4f93-991f-a2022c57208f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_97e08a74-6e3b-4cea-b9c7-a561d5694169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_PaidInKindInterest_97e08a74-6e3b-4cea-b9c7-a561d5694169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_2cbd7923-7d14-4f56-bde3-dd1999de415b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_2cbd7923-7d14-4f56-bde3-dd1999de415b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0e964ac7-4c9a-4c8a-bbdf-dbb438e83615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_InventoryWriteDown_0e964ac7-4c9a-4c8a-bbdf-dbb438e83615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3097fef0-f8e1-406b-9919-b8ddb6f219ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3097fef0-f8e1-406b-9919-b8ddb6f219ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fa8d70de-dfd7-4038-9bbc-ad688928e4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fa8d70de-dfd7-4038-9bbc-ad688928e4c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_34de8985-aaa0-48e5-b8bc-613ba11d99f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_34de8985-aaa0-48e5-b8bc-613ba11d99f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4040ee94-47fe-49f0-ad14-f94485c518de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4040ee94-47fe-49f0-ad14-f94485c518de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c1f63d29-3ac9-42ce-811a-355b2dad557e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c1f63d29-3ac9-42ce-811a-355b2dad557e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_92ee6f61-e2f8-4903-8456-90fde97121e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_92ee6f61-e2f8-4903-8456-90fde97121e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c62d91aa-bdda-4c1b-a21f-c3f55fd27d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c62d91aa-bdda-4c1b-a21f-c3f55fd27d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d65a3683-1008-4095-aa5c-0a6a70a0c75a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_ProfitLoss_d65a3683-1008-4095-aa5c-0a6a70a0c75a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_19cc9639-a10c-460a-a312-6bafc62694f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_19cc9639-a10c-460a-a312-6bafc62694f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9f24d599-b521-4482-818e-cb8b7a504447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d927eb3-84ba-4213-9551-f08b056d7168" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9f24d599-b521-4482-818e-cb8b7a504447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e1e9ff7-2969-4568-9634-4bb2d08323fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_9c318b43-23d5-40b0-96ab-cdd050f1e3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e1e9ff7-2969-4568-9634-4bb2d08323fa" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_9c318b43-23d5-40b0-96ab-cdd050f1e3a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1c8883f2-5bd4-4399-8957-0eacaf80ca12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e1e9ff7-2969-4568-9634-4bb2d08323fa" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1c8883f2-5bd4-4399-8957-0eacaf80ca12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b6544a14-9d94-426f-ac5d-498cafcd6ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9e1e9ff7-2969-4568-9634-4bb2d08323fa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b6544a14-9d94-426f-ac5d-498cafcd6ea5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="simple" xlink:href="silk-20200630.xsd#FormationandBusinessoftheCompany"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#FormationandBusinessoftheCompanyDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="silk-20200630.xsd#RecentAccountingPronouncements"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_661955af-4d35-466e-88e4-6ec447ea6604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c5dab2c3-6bf5-41dd-afe5-164e641bfe92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_661955af-4d35-466e-88e4-6ec447ea6604" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c5dab2c3-6bf5-41dd-afe5-164e641bfe92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae0f68f8-1025-46c2-9969-52b25cb5c22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0608ce60-4536-4551-9ea1-2f74b3d45c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae0f68f8-1025-46c2-9969-52b25cb5c22a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0608ce60-4536-4551-9ea1-2f74b3d45c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_86373208-a116-40b7-a885-529148510201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae0f68f8-1025-46c2-9969-52b25cb5c22a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_86373208-a116-40b7-a885-529148510201" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff04118d-1c24-482a-a7fc-219c225060ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae0f68f8-1025-46c2-9969-52b25cb5c22a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff04118d-1c24-482a-a7fc-219c225060ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_af39d062-2dc8-4211-8657-120283850b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_fcfdcce0-15bf-4d28-bd41-93ae40c6902b" xlink:href="silk-20200630.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_af39d062-2dc8-4211-8657-120283850b99" xlink:to="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_fcfdcce0-15bf-4d28-bd41-93ae40c6902b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_11557146-ab51-4ebe-a634-2e45ed2a726e" xlink:href="silk-20200630.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_af39d062-2dc8-4211-8657-120283850b99" xlink:to="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_11557146-ab51-4ebe-a634-2e45ed2a726e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0b0512c9-a394-4ed2-9c2d-643e8dd8db72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_fde54c2f-150e-4af8-abb1-bdf684e4fcea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0b0512c9-a394-4ed2-9c2d-643e8dd8db72" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_fde54c2f-150e-4af8-abb1-bdf684e4fcea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_baa7456e-2a87-4d30-b540-2ec1e6db5452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0b0512c9-a394-4ed2-9c2d-643e8dd8db72" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_baa7456e-2a87-4d30-b540-2ec1e6db5452" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e97745de-da71-45ce-8db4-d2517f61a17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e97745de-da71-45ce-8db4-d2517f61a17d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_85306292-55f7-497f-b78e-1056cec3a38c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_85306292-55f7-497f-b78e-1056cec3a38c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_185ca302-858f-413c-90c0-6d645ebcdf52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_185ca302-858f-413c-90c0-6d645ebcdf52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_e2f3b273-6b76-4a26-a318-4badbc1c8147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_e2f3b273-6b76-4a26-a318-4badbc1c8147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f35772bc-7187-4780-aa8e-aa058e649c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f35772bc-7187-4780-aa8e-aa058e649c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedTravelExpensesCurrent_17ea197c-187d-4250-ab8b-7f5fd9bc8d63" xlink:href="silk-20200630.xsd#silk_AccruedTravelExpensesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_silk_AccruedTravelExpensesCurrent_17ea197c-187d-4250-ab8b-7f5fd9bc8d63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedClinicalExpensesCurrent_b6f64643-c13e-495a-89ec-994af33f1aff" xlink:href="silk-20200630.xsd#silk_AccruedClinicalExpensesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_silk_AccruedClinicalExpensesCurrent_b6f64643-c13e-495a-89ec-994af33f1aff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79da855c-e487-432b-b045-16558f39dcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79da855c-e487-432b-b045-16558f39dcfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ProvisionsForSalesReturns_1ffabf78-2140-446b-9046-3a2649373a62" xlink:href="silk-20200630.xsd#silk_ProvisionsForSalesReturns"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03731692-49d1-41b4-997f-107a6d6f41e2" xlink:to="loc_silk_ProvisionsForSalesReturns_1ffabf78-2140-446b-9046-3a2649373a62" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebt" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebt"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtTermLoanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtFutureMaturitiesUndertheTermLoanDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_aca5b3a8-0552-4c27-9bb5-8b51a40cc7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_d1ccafcd-2d3d-4dd4-8a87-9b59fb392919" xlink:href="silk-20200630.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_aca5b3a8-0552-4c27-9bb5-8b51a40cc7ac" xlink:to="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_d1ccafcd-2d3d-4dd4-8a87-9b59fb392919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtAccretionOfClosingFees_a7964f3e-a4b3-4e7c-9dc5-7afbf06fab1c" xlink:href="silk-20200630.xsd#silk_LongTermDebtAccretionOfClosingFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_aca5b3a8-0552-4c27-9bb5-8b51a40cc7ac" xlink:to="loc_silk_LongTermDebtAccretionOfClosingFees_a7964f3e-a4b3-4e7c-9dc5-7afbf06fab1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_e855e7f9-2ea5-4b50-9727-480db40b2d4f" xlink:href="silk-20200630.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_30642073-7f25-48ee-a474-9706628adbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_e855e7f9-2ea5-4b50-9727-480db40b2d4f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_30642073-7f25-48ee-a474-9706628adbe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_41aa762e-d74c-4e32-96c9-6817f074786c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_e855e7f9-2ea5-4b50-9727-480db40b2d4f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_41aa762e-d74c-4e32-96c9-6817f074786c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_67f3a9c7-7f04-40d5-9e08-23dcd93919cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_e855e7f9-2ea5-4b50-9727-480db40b2d4f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_67f3a9c7-7f04-40d5-9e08-23dcd93919cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4041b396-3e71-43f6-a7e9-c325af97ecd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8eadaa29-13b3-4695-bba1-8c9dfd85a59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4041b396-3e71-43f6-a7e9-c325af97ecd1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8eadaa29-13b3-4695-bba1-8c9dfd85a59f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtUnpaidInterest_c52da844-f5e6-4948-8a98-c5df0d58c5c5" xlink:href="silk-20200630.xsd#silk_LongTermDebtUnpaidInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4041b396-3e71-43f6-a7e9-c325af97ecd1" xlink:to="loc_silk_LongTermDebtUnpaidInterest_c52da844-f5e6-4948-8a98-c5df0d58c5c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_fc805b27-c85b-4398-9e0f-987483789146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4041b396-3e71-43f6-a7e9-c325af97ecd1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_fc805b27-c85b-4398-9e0f-987483789146" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtSeriesCNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesLeaseNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f000ce57-da44-4ec0-bf85-760dba75d470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e60b7f6c-5a98-4be9-b138-61dc2b9768df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f000ce57-da44-4ec0-bf85-760dba75d470" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e60b7f6c-5a98-4be9-b138-61dc2b9768df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e53fe247-e865-4ba4-933f-f033c51bbe49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f000ce57-da44-4ec0-bf85-760dba75d470" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e53fe247-e865-4ba4-933f-f033c51bbe49" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_804d53bc-9576-4a80-ac54-48124afc1ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d652585e-4dcb-42b9-a71d-f1bafc32154f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_804d53bc-9576-4a80-ac54-48124afc1ada" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d652585e-4dcb-42b9-a71d-f1bafc32154f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_10ed0aae-369f-49c2-bc33-be7aa0061050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_804d53bc-9576-4a80-ac54-48124afc1ada" xlink:to="loc_us-gaap_OperatingLeaseLiability_10ed0aae-369f-49c2-bc33-be7aa0061050" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199401c3-c859-4fdb-ba5a-6db3e3f4cf34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_29acb81c-69bd-40d0-aa18-f52cfd5f4ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199401c3-c859-4fdb-ba5a-6db3e3f4cf34" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_29acb81c-69bd-40d0-aa18-f52cfd5f4ed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_29ed5f3a-a60b-4b80-9ba1-bc5475f771f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199401c3-c859-4fdb-ba5a-6db3e3f4cf34" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_29ed5f3a-a60b-4b80-9ba1-bc5475f771f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne_19c28a50-ed67-46c1-857d-abbc63ead884" xlink:href="silk-20200630.xsd#silk_LesseeOperatingLeaseLiabilityToBePaidYearOne"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199401c3-c859-4fdb-ba5a-6db3e3f4cf34" xlink:to="loc_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne_19c28a50-ed67-46c1-857d-abbc63ead884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ed9f4f90-2890-4e6c-9092-92067a5d1311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199401c3-c859-4fdb-ba5a-6db3e3f4cf34" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ed9f4f90-2890-4e6c-9092-92067a5d1311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5c4ae493-5b09-48e2-9241-57b5f2c7bfb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199401c3-c859-4fdb-ba5a-6db3e3f4cf34" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5c4ae493-5b09-48e2-9241-57b5f2c7bfb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesPurchaseObligationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="silk-20200630.xsd#RedeemableConvertiblePreferredStock"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#RedeemableConvertiblePreferredStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="silk-20200630.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlans" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlans"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansTables"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansActivityUnderCompensationPlanDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansRSUsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansFairValueofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansStockbasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlan" xlink:type="simple" xlink:href="silk-20200630.xsd#A401kPlan"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/A401kPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#A401kPlanDetails"/>
  <link:calculationLink xlink:role="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>silk-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9bdc0587-bada-46ac-a409-f4831c8e244f,g:1209e878-563a-4edf-b13c-0faadaf6133a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CoverPage" xlink:type="simple" xlink:href="silk-20200630.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CoverPage" xlink:type="extended" id="i7bbeec21e0324cb492429f767abbd859_CoverPage"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedBalanceSheets"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CondensedBalanceSheets" xlink:type="extended" id="if6d963a2757c4f258037220dce0ff05e_CondensedBalanceSheets"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" id="i03caa6cabdc145d99db6b4044e6f89fc_CondensedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i747e72fe4eb04c978312ec8884ca820c_CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="i9b9f492deab545b9b4efead653876d65_CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3b9520c7-7176-4455-82a5-99d27382e849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b9520c7-7176-4455-82a5-99d27382e849" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4c7f0e02-f829-4c01-a386-ca9cea223c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_4c7f0e02-f829-4c01-a386-ca9cea223c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a2d1acbc-8edc-40ad-8c6c-abbbfc6ef378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a2d1acbc-8edc-40ad-8c6c-abbbfc6ef378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_97f4f547-5523-4b40-9762-859f717e185e" xlink:href="silk-20200630.xsd#silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_97f4f547-5523-4b40-9762-859f717e185e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_a5febff6-9079-4b0a-871c-d3fee2eaa8fd" xlink:href="silk-20200630.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_a5febff6-9079-4b0a-871c-d3fee2eaa8fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_76de8540-1874-4fc3-8730-38f90164e03b" xlink:href="silk-20200630.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_76de8540-1874-4fc3-8730-38f90164e03b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_980b5c4f-1154-4ffc-82e3-b2ab9ba139c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_980b5c4f-1154-4ffc-82e3-b2ab9ba139c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_83ce478c-b79e-4542-9ae3-c55b6966c77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_04d02796-b785-4a16-a9b3-40f279ba908d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b9520c7-7176-4455-82a5-99d27382e849" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_83cba244-dee6-4cc2-bab4-e5356566e3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_SharesOutstanding_83cba244-dee6-4cc2-bab4-e5356566e3a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7bea39fb-14ef-4844-9cbf-670c5b479f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockholdersEquity_7bea39fb-14ef-4844-9cbf-670c5b479f45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f6f6863c-bcd5-47ff-ae3e-f4cd2b7b6aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f6f6863c-bcd5-47ff-ae3e-f4cd2b7b6aca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2efc1d33-ffa6-4fab-8088-1deea3b3441b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2efc1d33-ffa6-4fab-8088-1deea3b3441b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d35eed1f-a9b0-4112-9938-a038c25a5051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d35eed1f-a9b0-4112-9938-a038c25a5051" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_880b9dc9-fea8-4011-9c59-f8be4cb463c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_880b9dc9-fea8-4011-9c59-f8be4cb463c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_492c54d4-6d13-4aef-a773-40d750c2b903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_492c54d4-6d13-4aef-a773-40d750c2b903" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8657d862-30b8-48f3-9b60-b722d613f1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8657d862-30b8-48f3-9b60-b722d613f1bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ba5ba8fe-4980-4b87-81a9-d7149e65ddd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ba5ba8fe-4980-4b87-81a9-d7149e65ddd8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_666fd80f-7e4c-4a95-bd8c-ae051381a689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_666fd80f-7e4c-4a95-bd8c-ae051381a689" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7d740cf-5127-46cf-be43-347ec1cf1764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7d740cf-5127-46cf-be43-347ec1cf1764" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e9c08992-a054-47bb-9c74-1b7b58ac7dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_ProfitLoss_e9c08992-a054-47bb-9c74-1b7b58ac7dac" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7c258cd3-3b48-437f-8440-519218377002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7c258cd3-3b48-437f-8440-519218377002" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d2b43062-1f93-4aee-84bc-5032dc878e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d2b43062-1f93-4aee-84bc-5032dc878e61" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_eb820b32-5642-4a20-a19c-93668464f3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b8c42c0b-4385-43cf-b5be-66ff47e87bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3b9520c7-7176-4455-82a5-99d27382e849" xlink:to="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5fc02a8d-6aec-4cee-bf21-759730569227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5fc02a8d-6aec-4cee-bf21-759730569227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5fc02a8d-6aec-4cee-bf21-759730569227_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fc02a8d-6aec-4cee-bf21-759730569227" xlink:to="loc_us-gaap_EquityComponentDomain_5fc02a8d-6aec-4cee-bf21-759730569227_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fc02a8d-6aec-4cee-bf21-759730569227" xlink:to="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ffd442ee-6d76-457c-ac82-c950a7c14749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:to="loc_us-gaap_CommonStockMember_ffd442ee-6d76-457c-ac82-c950a7c14749" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0a366413-95e8-4da6-9b28-8656ecac9f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0a366413-95e8-4da6-9b28-8656ecac9f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8efe7579-40c9-41d9-af92-475c785dbd9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:to="loc_us-gaap_RetainedEarningsMember_8efe7579-40c9-41d9-af92-475c785dbd9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d22df29a-75cd-4522-983a-b5116558ab92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d22df29a-75cd-4522-983a-b5116558ab92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_00079cc9-f2fd-4fef-a54e-1b01555c3ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_00079cc9-f2fd-4fef-a54e-1b01555c3ccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00079cc9-f2fd-4fef-a54e-1b01555c3ccc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_00079cc9-f2fd-4fef-a54e-1b01555c3ccc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_00079cc9-f2fd-4fef-a54e-1b01555c3ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3b4f2c4c-38c2-41e1-bb2e-79a541a2c0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_00079cc9-f2fd-4fef-a54e-1b01555c3ccc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3b4f2c4c-38c2-41e1-bb2e-79a541a2c0b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_5facf079-f210-414c-9cb4-2d7293f7e391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3b4f2c4c-38c2-41e1-bb2e-79a541a2c0b4" xlink:to="loc_us-gaap_IPOMember_5facf079-f210-414c-9cb4-2d7293f7e391" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended" id="ieccddfcda0e94906b65263d43fcfbc3c_CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofCashFlows" xlink:type="extended" id="ibd06c2e2a8c046e6bb4eb99125bb3bfd_CondensedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_49b11574-ec1a-4c55-a862-44335b5f8669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:to="loc_us-gaap_ProfitLoss_49b11574-ec1a-4c55-a862-44335b5f8669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2fbf342f-a602-4080-a81f-c69d3d0b7045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2fbf342f-a602-4080-a81f-c69d3d0b7045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9abb500f-98ec-49b8-973f-26ae91d7432e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_ShareBasedCompensation_9abb500f-98ec-49b8-973f-26ae91d7432e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_ba449b03-1b11-4a6a-88bf-725329512e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_ba449b03-1b11-4a6a-88bf-725329512e1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5c641d49-7f85-49ef-99b4-80cac6a9dbff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5c641d49-7f85-49ef-99b4-80cac6a9dbff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1bcf7fe4-f43c-4481-9cd3-b759d80ae848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1bcf7fe4-f43c-4481-9cd3-b759d80ae848" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_OperatingLeaseRightOfUseAssetAmortization_f9d0bf04-a9e5-4ad2-897d-13a5dfb10c39" xlink:href="silk-20200630.xsd#silk_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_silk_OperatingLeaseRightOfUseAssetAmortization_f9d0bf04-a9e5-4ad2-897d-13a5dfb10c39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_8693e723-74db-412b-bb48-e24ac3e7adac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_PaidInKindInterest_8693e723-74db-412b-bb48-e24ac3e7adac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_bde54571-4775-4c21-836d-43da184612d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_bde54571-4775-4c21-836d-43da184612d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c82465f0-ab6d-406a-9f51-8eacea9a12a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c82465f0-ab6d-406a-9f51-8eacea9a12a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d60516f5-5b3e-4093-b384-eb32a67a7b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_InventoryWriteDown_d60516f5-5b3e-4093-b384-eb32a67a7b68" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9277075b-6140-4574-a88b-e8a44fe2f636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9277075b-6140-4574-a88b-e8a44fe2f636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_206e6477-dae2-4a65-8140-c17828ab163a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_206e6477-dae2-4a65-8140-c17828ab163a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a816159-d1f3-45f2-9def-efb068ede7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a816159-d1f3-45f2-9def-efb068ede7d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e61740f1-6f08-4567-b5cf-cf528fab4df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e61740f1-6f08-4567-b5cf-cf528fab4df0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_372b2280-cc32-4cd0-a9bb-ea9133af4cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_372b2280-cc32-4cd0-a9bb-ea9133af4cc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_51eea56f-0b7d-4523-a78c-433b5264020b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_51eea56f-0b7d-4523-a78c-433b5264020b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3864c651-af44-48ac-a762-dc6f362667dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3864c651-af44-48ac-a762-dc6f362667dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64d801b0-d9d5-4c26-acc2-a2ed69d63d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64d801b0-d9d5-4c26-acc2-a2ed69d63d45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84cea608-d1a5-44b8-a007-3f2ae1f590d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84cea608-d1a5-44b8-a007-3f2ae1f590d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_9097f72c-ab19-4da4-9c6e-9cfd708ecc32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_9097f72c-ab19-4da4-9c6e-9cfd708ecc32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_ff0efea2-9c88-4997-80c3-8573efc79f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_ff0efea2-9c88-4997-80c3-8573efc79f89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d4c4a0fe-3176-4916-9c49-fe5532aaf6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d4c4a0fe-3176-4916-9c49-fe5532aaf6df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c02f77b8-524f-4c02-bf20-e4d8473f7adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c02f77b8-524f-4c02-bf20-e4d8473f7adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6359f789-4b8b-44d4-adc4-319f00b801c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6359f789-4b8b-44d4-adc4-319f00b801c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_224930c2-e28d-45ba-b60c-87c513fcc0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_224930c2-e28d-45ba-b60c-87c513fcc0c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65467d1c-ece0-44c6-ad3e-997d956ae1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65467d1c-ece0-44c6-ad3e-997d956ae1ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a545dea-a599-4f0c-8550-e7fb19da40c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a545dea-a599-4f0c-8550-e7fb19da40c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddceb16b-34da-42e4-89a2-2619cf549064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddceb16b-34da-42e4-89a2-2619cf549064" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ef625f0-6d12-4809-afc0-6afe5bd527bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5eba8d8b-ffb5-4fee-b70b-8249b015acf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5eba8d8b-ffb5-4fee-b70b-8249b015acf4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_374de7c1-9dbb-4fdb-a65f-2acce2e16135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5eba8d8b-ffb5-4fee-b70b-8249b015acf4" xlink:to="loc_us-gaap_InterestPaidNet_374de7c1-9dbb-4fdb-a65f-2acce2e16135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6fd0a10-59e0-4add-9b34-99bd3bcb6c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6fd0a10-59e0-4add-9b34-99bd3bcb6c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuanceCostsIncurredButNotYetPaid_881abf93-b553-49ac-ae05-c4368816812e" xlink:href="silk-20200630.xsd#silk_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_silk_StockIssuanceCostsIncurredButNotYetPaid_881abf93-b553-49ac-ae05-c4368816812e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bb359c15-d146-42b0-b2b6-bd5607987a75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bb359c15-d146-42b0-b2b6-bd5607987a75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_d68b3f91-aa5f-44c7-8d4a-65d91e134cff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_d68b3f91-aa5f-44c7-8d4a-65d91e134cff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_37e4e444-f88f-4f2c-a782-c9a689149a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_37e4e444-f88f-4f2c-a782-c9a689149a47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7b485bc8-8a33-43b7-b8ea-6b830651b2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_StatementTable_7b485bc8-8a33-43b7-b8ea-6b830651b2a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f3908382-d9dd-447a-9887-11ef822afa09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7b485bc8-8a33-43b7-b8ea-6b830651b2a1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f3908382-d9dd-447a-9887-11ef822afa09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f3908382-d9dd-447a-9887-11ef822afa09_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f3908382-d9dd-447a-9887-11ef822afa09" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f3908382-d9dd-447a-9887-11ef822afa09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_02ccc6e0-4656-402f-96d5-1a1330405792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f3908382-d9dd-447a-9887-11ef822afa09" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_02ccc6e0-4656-402f-96d5-1a1330405792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_3510eaed-c19a-4f97-a550-67a79feead34" xlink:href="silk-20200630.xsd#silk_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_02ccc6e0-4656-402f-96d5-1a1330405792" xlink:to="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_3510eaed-c19a-4f97-a550-67a79feead34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_746873a2-e0aa-4a4a-a436-880b41ed9fb9" xlink:href="silk-20200630.xsd#silk_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_02ccc6e0-4656-402f-96d5-1a1330405792" xlink:to="loc_silk_CommonStockWarrantMember_746873a2-e0aa-4a4a-a436-880b41ed9fb9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="simple" xlink:href="silk-20200630.xsd#FormationandBusinessoftheCompany"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="extended" id="i5f0ce3398bbe46a49344a4ad3a657354_FormationandBusinessoftheCompany"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#FormationandBusinessoftheCompanyDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="extended" id="iaa15cbab477c4052b9c6529452e3bd28_FormationandBusinessoftheCompanyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_676f7a6d-f428-446d-b4e9-848aea8b8e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_676f7a6d-f428-446d-b4e9-848aea8b8e32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_465cabd7-a27a-4232-85d0-9e3a2fcce1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_465cabd7-a27a-4232-85d0-9e3a2fcce1d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f1b380b9-2195-4aff-9f3e-727276435b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f1b380b9-2195-4aff-9f3e-727276435b20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_88278130-0168-4029-bb82-67bae7daa2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_88278130-0168-4029-bb82-67bae7daa2d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_c6419690-fc79-4594-816a-567c5658324d" xlink:href="silk-20200630.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_c6419690-fc79-4594-816a-567c5658324d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_08be1c25-44a5-4fd4-b434-a5cb32c7a0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_08be1c25-44a5-4fd4-b434-a5cb32c7a0c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f20f5cf5-68e8-470f-8d62-4fc5e4870a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_SubsequentEventTable_f20f5cf5-68e8-470f-8d62-4fc5e4870a6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2248771c-a3de-44be-bf37-7459d0a35a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f20f5cf5-68e8-470f-8d62-4fc5e4870a6e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2248771c-a3de-44be-bf37-7459d0a35a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2248771c-a3de-44be-bf37-7459d0a35a8b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2248771c-a3de-44be-bf37-7459d0a35a8b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2248771c-a3de-44be-bf37-7459d0a35a8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2248771c-a3de-44be-bf37-7459d0a35a8b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_07da3b7c-7e34-4c96-aacd-28620ca76412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:to="loc_us-gaap_IPOMember_07da3b7c-7e34-4c96-aacd-28620ca76412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SecondPublicOfferingMember_23969859-4d72-4d7f-939f-528c59ceeb10" xlink:href="silk-20200630.xsd#silk_SecondPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:to="loc_silk_SecondPublicOfferingMember_23969859-4d72-4d7f-939f-528c59ceeb10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingMember_b3b60fb9-c0f2-4528-b857-51ba41d454d1" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:to="loc_silk_PublicStockOfferingMember_b3b60fb9-c0f2-4528-b857-51ba41d454d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromCompanyMember_3fc06a07-ddcd-4fc3-8584-ae8ee19d33b3" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingSharesFromCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_PublicStockOfferingMember_b3b60fb9-c0f2-4528-b857-51ba41d454d1" xlink:to="loc_silk_PublicStockOfferingSharesFromCompanyMember_3fc06a07-ddcd-4fc3-8584-ae8ee19d33b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember_92084fc4-266d-4624-8100-99d8d1f2c38f" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingSharesFromExistingShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_silk_PublicStockOfferingMember_b3b60fb9-c0f2-4528-b857-51ba41d454d1" xlink:to="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember_92084fc4-266d-4624-8100-99d8d1f2c38f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_5b13b87b-6127-4ecc-b583-53641479e6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:to="loc_us-gaap_OverAllotmentOptionMember_5b13b87b-6127-4ecc-b583-53641479e6f8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ibaca277aaf444eba9dde8e3c9ff2cff9_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="iae3743fb4bba4d89b84fd2747371d8a5_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="if53e7fe83e0f4dc9953fedbd15cffe10_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails" xlink:type="extended" id="i9cf169b3235d409c95a1d4db4d3acb1f_SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_ffc3fa80-4755-411d-8d80-fcfab1091538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a903a83-089d-40da-8937-86c864704618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_ffc3fa80-4755-411d-8d80-fcfab1091538" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a903a83-089d-40da-8937-86c864704618" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b7c902e1-58c8-4c75-9a79-a9328a7e2c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_ffc3fa80-4755-411d-8d80-fcfab1091538" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b7c902e1-58c8-4c75-9a79-a9328a7e2c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1cbe5f5d-3514-430f-804e-b4855bcd9541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_ffc3fa80-4755-411d-8d80-fcfab1091538" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1cbe5f5d-3514-430f-804e-b4855bcd9541" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1cbe5f5d-3514-430f-804e-b4855bcd9541" xlink:to="loc_srt_RestatementAxis_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2" xlink:to="loc_srt_RestatementDomain_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_0c7f8fdd-9687-4e04-8362-a368213b958a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2" xlink:to="loc_srt_RestatementDomain_0c7f8fdd-9687-4e04-8362-a368213b958a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_a44e025f-f754-4c76-8726-524e51c10224" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_0c7f8fdd-9687-4e04-8362-a368213b958a" xlink:to="loc_srt_RestatementAdjustmentMember_a44e025f-f754-4c76-8726-524e51c10224" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i77ef5acbe3cf4815b7a93246d53bbb17_SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="extended" id="ica7edd6f40904843b5ef9c387fc7e480_SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2d76a0b9-e1ee-40f2-b810-624019a92719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_70d4c933-1643-4e68-8c33-8011fc3e0f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2d76a0b9-e1ee-40f2-b810-624019a92719" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_70d4c933-1643-4e68-8c33-8011fc3e0f9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c5c660c4-4094-4883-a323-8b3f07504f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2d76a0b9-e1ee-40f2-b810-624019a92719" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c5c660c4-4094-4883-a323-8b3f07504f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4748475f-3e98-4054-8e22-056795381f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2d76a0b9-e1ee-40f2-b810-624019a92719" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4748475f-3e98-4054-8e22-056795381f2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_40287c75-e78d-400b-b92e-c33b280c4bda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4748475f-3e98-4054-8e22-056795381f2f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_40287c75-e78d-400b-b92e-c33b280c4bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_40287c75-e78d-400b-b92e-c33b280c4bda_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_40287c75-e78d-400b-b92e-c33b280c4bda" xlink:to="loc_us-gaap_ClassOfStockDomain_40287c75-e78d-400b-b92e-c33b280c4bda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd712da6-eaae-4464-8793-457e9a933811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_40287c75-e78d-400b-b92e-c33b280c4bda" xlink:to="loc_us-gaap_ClassOfStockDomain_dd712da6-eaae-4464-8793-457e9a933811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_96fa1159-1dbe-4b61-80ed-6f539f647d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dd712da6-eaae-4464-8793-457e9a933811" xlink:to="loc_us-gaap_CommonStockMember_96fa1159-1dbe-4b61-80ed-6f539f647d97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" id="i86d379f867b9429f832fd9b0702dd941_SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="extended" id="i91b7656290af4c8d94ff4981f7e72e36_SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="extended" id="i8872f1efbaaa4dbc9587f7e3b0b71d56_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9d997dca-f522-4bd5-8ad6-87d18bc72d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ddcdd52-60cb-48b4-9d48-5f2c9e12254e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9d997dca-f522-4bd5-8ad6-87d18bc72d94" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ddcdd52-60cb-48b4-9d48-5f2c9e12254e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2b3494c-3af0-4b70-a48f-0dd584fa8480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9d997dca-f522-4bd5-8ad6-87d18bc72d94" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2b3494c-3af0-4b70-a48f-0dd584fa8480" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2b3494c-3af0-4b70-a48f-0dd584fa8480" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c27945a8-fd78-47a1-9a7b-fd5e06caaf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c27945a8-fd78-47a1-9a7b-fd5e06caaf1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6af2472f-fc7f-4432-81eb-bf265e6d0ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6af2472f-fc7f-4432-81eb-bf265e6d0ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_07e6760a-501e-4de8-8090-6d5283e8bdfc" xlink:href="silk-20200630.xsd#silk_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:to="loc_silk_CommonStockWarrantMember_07e6760a-501e-4de8-8090-6d5283e8bdfc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="extended" id="i996c3217064e4aa3aaaf64f4f3cf0e57_SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="silk-20200630.xsd#RecentAccountingPronouncements"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="extended" id="i565649982ec54d8eb1af8804fb39728a_RecentAccountingPronouncements"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="extended" id="idb743bbb5a614f548468c4344c1ea4a5_FairValueMeasurements"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="extended" id="ifdb5fe7a44844dbda9287ee098d964cb_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="extended" id="ief660c0eae534c0481969bd05f49d625_FairValueMeasurementsRecurringAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab79734a-453b-4ed7-9a67-56daabbcd455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b75852c4-c076-4f7d-be62-ca3172fb0fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab79734a-453b-4ed7-9a67-56daabbcd455" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b75852c4-c076-4f7d-be62-ca3172fb0fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5cbefaec-c2f4-4ef7-bb92-760f48c8961e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab79734a-453b-4ed7-9a67-56daabbcd455" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5cbefaec-c2f4-4ef7-bb92-760f48c8961e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab79734a-453b-4ed7-9a67-56daabbcd455" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3cd955b1-6872-4850-ab0c-d30aa1a745d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3cd955b1-6872-4850-ab0c-d30aa1a745d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3cd955b1-6872-4850-ab0c-d30aa1a745d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3cd955b1-6872-4850-ab0c-d30aa1a745d5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3cd955b1-6872-4850-ab0c-d30aa1a745d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_acc4f819-9019-4ad2-a95c-7b4bfc596994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3cd955b1-6872-4850-ab0c-d30aa1a745d5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_acc4f819-9019-4ad2-a95c-7b4bfc596994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f30bcc87-c5eb-402d-99e6-7c810d0eaf77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_acc4f819-9019-4ad2-a95c-7b4bfc596994" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f30bcc87-c5eb-402d-99e6-7c810d0eaf77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d38be227-2224-42ff-93c1-b2fbbff96796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d38be227-2224-42ff-93c1-b2fbbff96796" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d38be227-2224-42ff-93c1-b2fbbff96796_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d38be227-2224-42ff-93c1-b2fbbff96796" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d38be227-2224-42ff-93c1-b2fbbff96796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d38be227-2224-42ff-93c1-b2fbbff96796" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_99ea09ad-23c2-49c4-ad6f-ec24ee7da281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_99ea09ad-23c2-49c4-ad6f-ec24ee7da281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a241b636-f28d-4bf1-8fc2-6119a3374e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a241b636-f28d-4bf1-8fc2-6119a3374e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_889f17ed-c8d8-448b-b89c-42aa640409a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_889f17ed-c8d8-448b-b89c-42aa640409a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0b487cbd-9381-4f1c-bea9-719c1bb3e926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0b487cbd-9381-4f1c-bea9-719c1bb3e926" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b487cbd-9381-4f1c-bea9-719c1bb3e926_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b487cbd-9381-4f1c-bea9-719c1bb3e926" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0b487cbd-9381-4f1c-bea9-719c1bb3e926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b487cbd-9381-4f1c-bea9-719c1bb3e926" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_50fee8f6-4eac-4950-ae4a-eb91ebbc0b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_MoneyMarketFundsMember_50fee8f6-4eac-4950-ae4a-eb91ebbc0b1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_3a0d5264-8b7a-4243-a475-7aeccf968f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_3a0d5264-8b7a-4243-a475-7aeccf968f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_8e76cef6-56b2-4775-8554-69f4ffd48c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_8e76cef6-56b2-4775-8554-69f4ffd48c28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e2cc6bf7-2158-4328-bf6c-63581df1c60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e2cc6bf7-2158-4328-bf6c-63581df1c60e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9f5cf037-5ae6-4392-be1f-f24349cea0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9f5cf037-5ae6-4392-be1f-f24349cea0b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d294ec60-feda-402b-acdc-550a696d2042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d294ec60-feda-402b-acdc-550a696d2042" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="extended" id="ia967e87d88d341498244a5186912d477_BalanceSheetComponents"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="extended" id="id18c64b3623e4b53b6503724b10e5a94_BalanceSheetComponentsTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="extended" id="i1cc8db4ba1af42d58734dcf4cf236993_BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4b0018f-9763-4bde-87f6-a9fc243920d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4b0018f-9763-4bde-87f6-a9fc243920d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3cf942d2-f270-41f2-b7f2-27c481033d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3cf942d2-f270-41f2-b7f2-27c481033d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db370ceb-d332-4778-813a-97eefb8d78d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db370ceb-d332-4778-813a-97eefb8d78d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001c7a84-7777-4a7f-8026-f5c5a5f7cab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001c7a84-7777-4a7f-8026-f5c5a5f7cab6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_042c3194-6b9b-4276-814f-a3cca932a7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_042c3194-6b9b-4276-814f-a3cca932a7ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_69870824-8847-46da-b49d-a9d2be59ea27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_042c3194-6b9b-4276-814f-a3cca932a7ba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_69870824-8847-46da-b49d-a9d2be59ea27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69870824-8847-46da-b49d-a9d2be59ea27_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69870824-8847-46da-b49d-a9d2be59ea27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69870824-8847-46da-b49d-a9d2be59ea27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69870824-8847-46da-b49d-a9d2be59ea27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8e085851-5fe0-4f5e-8bfc-d54641ec610b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8e085851-5fe0-4f5e-8bfc-d54641ec610b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_e260319c-7b68-4d40-94aa-c39a82406ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_e260319c-7b68-4d40-94aa-c39a82406ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4d7bc8fe-12c9-415d-a079-90ac9355c1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_CommercialPaperMember_4d7bc8fe-12c9-415d-a079-90ac9355c1a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a1a0010a-a30f-4f02-b642-589c251adf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a1a0010a-a30f-4f02-b642-589c251adf15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_21664627-f3fe-4528-93ff-02473eae46d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_21664627-f3fe-4528-93ff-02473eae46d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_26230ca0-a2d4-496b-a2f5-5cf51078aa8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_26230ca0-a2d4-496b-a2f5-5cf51078aa8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_849514e8-5af2-4eb6-93af-52dbf4be698f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_CashEquivalentsMember_849514e8-5af2-4eb6-93af-52dbf4be698f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_4223a3c7-f1d7-4e75-a02c-afe0bea87bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_4223a3c7-f1d7-4e75-a02c-afe0bea87bab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermInvestmentsMember_fe830f52-99cd-490c-b829-e950a45ff60f" xlink:href="silk-20200630.xsd#silk_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_silk_LongTermInvestmentsMember_fe830f52-99cd-490c-b829-e950a45ff60f" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="extended" id="ide47918ed407466fa676cf2833db377f_BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended" id="i0d32d56807d24deeaf6dc74cdedf3fd0_BalanceSheetComponentsNarrativeDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended" id="ifec0ef73e0d147f8bda4014844621925_BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e7735c77-f73c-4d92-aee6-0ca5729ff35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f2df528f-b67e-435e-a241-08c328746764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e7735c77-f73c-4d92-aee6-0ca5729ff35c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f2df528f-b67e-435e-a241-08c328746764" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1cc18943-4cc4-4fd0-8200-2f0fdb6a7d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e7735c77-f73c-4d92-aee6-0ca5729ff35c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1cc18943-4cc4-4fd0-8200-2f0fdb6a7d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a88d9347-0231-4e1f-81fb-b1bcc58adc0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e7735c77-f73c-4d92-aee6-0ca5729ff35c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a88d9347-0231-4e1f-81fb-b1bcc58adc0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78575b72-398a-4220-ae28-f8dbf4fbb3bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a88d9347-0231-4e1f-81fb-b1bcc58adc0d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78575b72-398a-4220-ae28-f8dbf4fbb3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78575b72-398a-4220-ae28-f8dbf4fbb3bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78575b72-398a-4220-ae28-f8dbf4fbb3bb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78575b72-398a-4220-ae28-f8dbf4fbb3bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78575b72-398a-4220-ae28-f8dbf4fbb3bb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e22ad4a4-ca2c-4172-9b05-654d5813f860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e22ad4a4-ca2c-4172-9b05-654d5813f860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_f2e0b765-4021-48b7-b435-561531393a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_f2e0b765-4021-48b7-b435-561531393a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_91ba0e0e-1737-4a2b-8bb3-61960582448d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_91ba0e0e-1737-4a2b-8bb3-61960582448d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="extended" id="i673ce72c616a48e89262aaf1b4d43a74_BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended" id="ifffc6c683bc74e40a4088bb282713b54_BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebt" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebt"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebt" xlink:type="extended" id="ia686edfbca3945f1a634fdbad9c98b63_LongtermDebt"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="extended" id="i8a596ee5d1a5468e9beb245e2caa9f1c_LongtermDebtTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtTermLoanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails" xlink:type="extended" id="i8ee9f4b414d5453bab1e04bff7f9f4e4_LongtermDebtTermLoanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtMaximumBorrowingCapacity_88a93f48-5c2f-4b0c-b29e-79394488ef2a" xlink:href="silk-20200630.xsd#silk_DebtMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtMaximumBorrowingCapacity_88a93f48-5c2f-4b0c-b29e-79394488ef2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d61a6d9f-96ba-4e4d-a487-37153c1d9dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d61a6d9f-96ba-4e4d-a487-37153c1d9dd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b086dfc-3b15-401d-bd76-dc495610a644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b086dfc-3b15-401d-bd76-dc495610a644" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInKind_946b0c1b-6fd1-40ba-8d2b-d3248b3423d8" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentInterestRatePaidInKind_946b0c1b-6fd1-40ba-8d2b-d3248b3423d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInCash_9b062685-1f60-4a29-b7ba-a5218a133cbe" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRatePaidInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentInterestRatePaidInCash_9b062685-1f60-4a29-b7ba-a5218a133cbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans_7da06829-acb2-471f-8855-a1e746fc9b17" xlink:href="silk-20200630.xsd#silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans_7da06829-acb2-471f-8855-a1e746fc9b17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentConvertibleMarketCapitalization_fe83245c-86f8-4132-a83f-3d9fbbce3b3b" xlink:href="silk-20200630.xsd#silk_DebtInstrumentConvertibleMarketCapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentConvertibleMarketCapitalization_fe83245c-86f8-4132-a83f-3d9fbbce3b3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRateFinancingFee_2d442b4b-5c72-4e1c-94b3-7c81c4f9a32f" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRateFinancingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentInterestRateFinancingFee_2d442b4b-5c72-4e1c-94b3-7c81c4f9a32f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRateFacilityFee_b3afd869-af28-46bc-b077-1a60fdb87be8" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRateFacilityFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentInterestRateFacilityFee_b3afd869-af28-46bc-b077-1a60fdb87be8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMaximumLiquidityAmount_a2ecb33b-84e9-4e3b-b74c-3def9878ef6f" xlink:href="silk-20200630.xsd#silk_DebtInstrumentCovenantMaximumLiquidityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentCovenantMaximumLiquidityAmount_a2ecb33b-84e9-4e3b-b74c-3def9878ef6f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMinimumNetRevenueAmount_1b03d2fe-5fba-40bf-b394-bbf5c4b5c5fb" xlink:href="silk-20200630.xsd#silk_DebtInstrumentCovenantMinimumNetRevenueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentCovenantMinimumNetRevenueAmount_1b03d2fe-5fba-40bf-b394-bbf5c4b5c5fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentLiquidityCovenantTerm_0e3c5466-b332-4b81-a303-83619b4a7929" xlink:href="silk-20200630.xsd#silk_DebtInstrumentLiquidityCovenantTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentLiquidityCovenantTerm_0e3c5466-b332-4b81-a303-83619b4a7929" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_34465ef0-5588-4a4d-9603-cdb4bfcce136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_34465ef0-5588-4a4d-9603-cdb4bfcce136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_34465ef0-5588-4a4d-9603-cdb4bfcce136_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_34465ef0-5588-4a4d-9603-cdb4bfcce136" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_34465ef0-5588-4a4d-9603-cdb4bfcce136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_34465ef0-5588-4a4d-9603-cdb4bfcce136" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanMember_8f775025-7ce2-4893-a1fb-e1daad1f8a16" xlink:href="silk-20200630.xsd#silk_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:to="loc_silk_TermLoanMember_8f775025-7ce2-4893-a1fb-e1daad1f8a16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheAMember_733cdb3a-9e9d-42e4-b849-93834498b184" xlink:href="silk-20200630.xsd#silk_TermLoanTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:to="loc_silk_TermLoanTrancheAMember_733cdb3a-9e9d-42e4-b849-93834498b184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheBMember_4b724b42-db73-4b19-9b58-74d5fa2550b3" xlink:href="silk-20200630.xsd#silk_TermLoanTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:to="loc_silk_TermLoanTrancheBMember_4b724b42-db73-4b19-9b58-74d5fa2550b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_58af2c52-5d04-479d-ba4d-87567c4648fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:to="loc_srt_StatementScenarioAxis_58af2c52-5d04-479d-ba4d-87567c4648fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_58af2c52-5d04-479d-ba4d-87567c4648fb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_58af2c52-5d04-479d-ba4d-87567c4648fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_58af2c52-5d04-479d-ba4d-87567c4648fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_afa32fe7-1e39-4b47-acc9-48800ba6ef39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_58af2c52-5d04-479d-ba4d-87567c4648fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_afa32fe7-1e39-4b47-acc9-48800ba6ef39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3263f3af-ece0-4f0f-b0ed-ebd2c2c58dcc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_afa32fe7-1e39-4b47-acc9-48800ba6ef39" xlink:to="loc_srt_ScenarioForecastMember_3263f3af-ece0-4f0f-b0ed-ebd2c2c58dcc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtFutureMaturitiesUndertheTermLoanDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="extended" id="i93cc116602214123990712710831e6c4_LongtermDebtFutureMaturitiesUndertheTermLoanDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtSeriesCNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails" xlink:type="extended" id="ic67ca132ee1142428527cf31a1038360_LongtermDebtSeriesCNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_163903af-aea0-4e0a-8c0f-4b7dbd42195f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_163903af-aea0-4e0a-8c0f-4b7dbd42195f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_12530fa4-9962-4751-a236-1bfc8353f896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_12530fa4-9962-4751-a236-1bfc8353f896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0fe00ceb-f1ab-49c5-b59d-13e8d828fa85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0fe00ceb-f1ab-49c5-b59d-13e8d828fa85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_df86137c-671b-4cf1-bd6d-b701c47a055c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_df86137c-671b-4cf1-bd6d-b701c47a055c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_df86137c-671b-4cf1-bd6d-b701c47a055c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_df86137c-671b-4cf1-bd6d-b701c47a055c" xlink:to="loc_us-gaap_ClassOfStockDomain_df86137c-671b-4cf1-bd6d-b701c47a055c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ff624f9-ab44-4ca8-9a4e-949009069b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_df86137c-671b-4cf1-bd6d-b701c47a055c" xlink:to="loc_us-gaap_ClassOfStockDomain_4ff624f9-ab44-4ca8-9a4e-949009069b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_9915b953-90e1-4655-a26b-65a6c165a778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4ff624f9-ab44-4ca8-9a4e-949009069b1d" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_9915b953-90e1-4655-a26b-65a6c165a778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f308083a-7bf5-454c-b881-8820c7cd2f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f308083a-7bf5-454c-b881-8820c7cd2f94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f308083a-7bf5-454c-b881-8820c7cd2f94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f308083a-7bf5-454c-b881-8820c7cd2f94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f308083a-7bf5-454c-b881-8820c7cd2f94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_13a840be-3d4b-4e80-bbf1-e197a7965fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f308083a-7bf5-454c-b881-8820c7cd2f94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_13a840be-3d4b-4e80-bbf1-e197a7965fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PreferredStockWarrantsMember_205721b5-79bd-4c6e-9a7a-ebe2e146d144" xlink:href="silk-20200630.xsd#silk_PreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13a840be-3d4b-4e80-bbf1-e197a7965fd4" xlink:to="loc_silk_PreferredStockWarrantsMember_205721b5-79bd-4c6e-9a7a-ebe2e146d144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c802e357-f445-41c8-ad07-5690191a1bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c802e357-f445-41c8-ad07-5690191a1bed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c802e357-f445-41c8-ad07-5690191a1bed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c802e357-f445-41c8-ad07-5690191a1bed" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c802e357-f445-41c8-ad07-5690191a1bed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4b31175c-3bfe-4516-910a-ab07ca465c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c802e357-f445-41c8-ad07-5690191a1bed" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4b31175c-3bfe-4516-910a-ab07ca465c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_092ba936-4917-46b9-9c9b-b1f804491fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4b31175c-3bfe-4516-910a-ab07ca465c2c" xlink:to="loc_us-gaap_IPOMember_092ba936-4917-46b9-9c9b-b1f804491fb5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="extended" id="i8e83ebaca7aa4ab0a2caad8b5b7dae72_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i06aaa5e54de54d35a75ae8fc0806a33e_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesLeaseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="extended" id="i9b91ad1d1ab64acb8bb6e78d3057c0fc_CommitmentsandContingenciesLeaseNarrativeDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="extended" id="ic0da193a36e643469243cba3a4fde13a_CommitmentsandContingenciesBalanceSheetInformationDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="extended" id="ic754924ba6864d42878ff6671c3d2562_CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesPurchaseObligationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails" xlink:type="extended" id="ibb96572fe0ef474c991bf1373eeca850_CommitmentsandContingenciesPurchaseObligationNarrativeDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="silk-20200630.xsd#RedeemableConvertiblePreferredStock"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended" id="ie8732e8f7a1346a3b6e1c79374112dd4_RedeemableConvertiblePreferredStock"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#RedeemableConvertiblePreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="extended" id="ibc47344ac70845399b57069f69d3a00f_RedeemableConvertiblePreferredStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_d4a11cb4-c66c-4fd3-998b-59ebaa223c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_d4a11cb4-c66c-4fd3-998b-59ebaa223c38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_9658993f-16d5-47e2-86f7-0057d49966bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_9658993f-16d5-47e2-86f7-0057d49966bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_25bd2fae-e8a5-4076-b0a8-c0a2ba156df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_25bd2fae-e8a5-4076-b0a8-c0a2ba156df4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_f8de4f81-04f2-446d-a454-439dcb8d8b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_f8de4f81-04f2-446d-a454-439dcb8d8b0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_66966a38-1b7e-4558-bf47-f62d2e9ad8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_66966a38-1b7e-4558-bf47-f62d2e9ad8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_66966a38-1b7e-4558-bf47-f62d2e9ad8c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66966a38-1b7e-4558-bf47-f62d2e9ad8c2" xlink:to="loc_us-gaap_ClassOfStockDomain_66966a38-1b7e-4558-bf47-f62d2e9ad8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1171f170-88fc-4bad-861f-71e460eafa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66966a38-1b7e-4558-bf47-f62d2e9ad8c2" xlink:to="loc_us-gaap_ClassOfStockDomain_1171f170-88fc-4bad-861f-71e460eafa95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_766ced19-91aa-41fe-847d-5d4a6ac60db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1171f170-88fc-4bad-861f-71e460eafa95" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_766ced19-91aa-41fe-847d-5d4a6ac60db4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6135b1f8-4b99-4837-8ecc-d2ccdae379f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6135b1f8-4b99-4837-8ecc-d2ccdae379f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_e0dabc43-a4be-4cdb-8aaf-e6209abcb49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6135b1f8-4b99-4837-8ecc-d2ccdae379f6" xlink:to="loc_us-gaap_IPOMember_e0dabc43-a4be-4cdb-8aaf-e6209abcb49c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ddf8f2d3-a754-412d-8c37-a958095e294f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ddf8f2d3-a754-412d-8c37-a958095e294f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ddf8f2d3-a754-412d-8c37-a958095e294f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ddf8f2d3-a754-412d-8c37-a958095e294f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ddf8f2d3-a754-412d-8c37-a958095e294f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_565d8698-3540-442d-a5c3-c1d86f52aeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ddf8f2d3-a754-412d-8c37-a958095e294f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_565d8698-3540-442d-a5c3-c1d86f52aeb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PreferredStockWarrantsMember_7ad0463f-4275-4ad8-8053-e598d6dffadb" xlink:href="silk-20200630.xsd#silk_PreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_565d8698-3540-442d-a5c3-c1d86f52aeb8" xlink:to="loc_silk_PreferredStockWarrantsMember_7ad0463f-4275-4ad8-8053-e598d6dffadb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="silk-20200630.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockholdersEquity" xlink:type="extended" id="i1a55cfc76552421fbfb5eaa53a300775_StockholdersEquity"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="icfb6e7769d5947aea6aec05917dab088_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cba6e092-3a3b-47cd-926f-99bfda612b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cba6e092-3a3b-47cd-926f-99bfda612b03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7db30c37-d6c2-4d52-9c9f-142c84e094a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7db30c37-d6c2-4d52-9c9f-142c84e094a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3b10cd47-d2cc-4478-a961-69262392554d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3b10cd47-d2cc-4478-a961-69262392554d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_93eed189-7749-4f31-a650-403fa4270952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_93eed189-7749-4f31-a650-403fa4270952" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b448488d-dac7-4ba9-8151-de349e4be165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b448488d-dac7-4ba9-8151-de349e4be165" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_66c71fe6-8143-4e42-ab73-544780862d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_66c71fe6-8143-4e42-ab73-544780862d68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eeb6d55a-4a8e-45c7-b2ee-605f46d29927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_CommonStockSharesIssued_eeb6d55a-4a8e-45c7-b2ee-605f46d29927" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cfbc241c-83e6-4eee-bcfe-daf0b3eaad1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cfbc241c-83e6-4eee-bcfe-daf0b3eaad1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_18e38571-8766-4ae4-aef8-4d7acaa3c408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_DividendsCommonStock_18e38571-8766-4ae4-aef8-4d7acaa3c408" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockVotePerShare_07b71a0a-8d33-4b0a-bcad-db6d0caf9a8b" xlink:href="silk-20200630.xsd#silk_CommonStockVotePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_silk_CommonStockVotePerShare_07b71a0a-8d33-4b0a-bcad-db6d0caf9a8b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6a661528-7ee7-4cdb-aef7-dc876a074330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6a661528-7ee7-4cdb-aef7-dc876a074330" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_39fa32ce-6d15-41d8-9c48-cbff4474ad03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_39fa32ce-6d15-41d8-9c48-cbff4474ad03" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1f66325c-347a-4a53-b3dc-4021803c776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1f66325c-347a-4a53-b3dc-4021803c776c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1f66325c-347a-4a53-b3dc-4021803c776c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1f66325c-347a-4a53-b3dc-4021803c776c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1f66325c-347a-4a53-b3dc-4021803c776c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc651cf2-76e5-4d82-951f-e5ce1cfe2de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1f66325c-347a-4a53-b3dc-4021803c776c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc651cf2-76e5-4d82-951f-e5ce1cfe2de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_ca9663e2-ffd2-4859-b98d-66ad8a59cd3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc651cf2-76e5-4d82-951f-e5ce1cfe2de8" xlink:to="loc_us-gaap_IPOMember_ca9663e2-ffd2-4859-b98d-66ad8a59cd3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_96dc95ab-f31d-4a17-a67f-89617a83fd25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_96dc95ab-f31d-4a17-a67f-89617a83fd25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_96dc95ab-f31d-4a17-a67f-89617a83fd25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_96dc95ab-f31d-4a17-a67f-89617a83fd25" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_96dc95ab-f31d-4a17-a67f-89617a83fd25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4dc64c8a-72f2-45e7-b0ad-d289cafbac18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_96dc95ab-f31d-4a17-a67f-89617a83fd25" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4dc64c8a-72f2-45e7-b0ad-d289cafbac18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_1c099cfc-9281-4e4d-a395-df7a96a99b31" xlink:href="silk-20200630.xsd#silk_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4dc64c8a-72f2-45e7-b0ad-d289cafbac18" xlink:to="loc_silk_CommonStockWarrantMember_1c099cfc-9281-4e4d-a395-df7a96a99b31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlans" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlans"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlans" xlink:type="extended" id="i5bad08f5cce1473ab6137a4267d6c779_StockOptionPlans"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansTables"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="extended" id="ie64aa38f488b4b3fbb056e9bebe8c278_StockOptionPlansTables"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="extended" id="i80d11097b8fe4b738d8da92dab9a4380_StockOptionPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9acb538b-e8c2-40b0-920e-2830f950a6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9acb538b-e8c2-40b0-920e-2830f950a6e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_aec3244b-23a3-4590-9494-ce7170e89268" xlink:href="silk-20200630.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_aec3244b-23a3-4590-9494-ce7170e89268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_6622eb31-443c-4dcb-80ee-861a0b56243e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_6622eb31-443c-4dcb-80ee-861a0b56243e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice_1f4a91ed-8386-433e-a453-6dcc507d01b7" xlink:href="silk-20200630.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice_1f4a91ed-8386-433e-a453-6dcc507d01b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_964f82be-f37c-4b76-a46b-d49712b43d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_964f82be-f37c-4b76-a46b-d49712b43d41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c4e4ad8e-0fc9-4772-9e3f-95ee51d4d374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c4e4ad8e-0fc9-4772-9e3f-95ee51d4d374" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b991aa46-6638-4a90-9320-e363717343d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b991aa46-6638-4a90-9320-e363717343d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a91ce1c7-5ce2-401d-98cd-b75138db0dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a91ce1c7-5ce2-401d-98cd-b75138db0dc2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7183f689-6f48-4b4c-a5e3-c5301f6432c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7183f689-6f48-4b4c-a5e3-c5301f6432c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5aa889dc-51e8-40f5-ac67-13a06eb56fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5aa889dc-51e8-40f5-ac67-13a06eb56fc4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2cb87a35-77c6-493f-93a2-e30c2b51c6db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2cb87a35-77c6-493f-93a2-e30c2b51c6db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance_038936d2-8ec5-4abb-9fe7-35fb570f1ca1" xlink:href="silk-20200630.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance_038936d2-8ec5-4abb-9fe7-35fb570f1ca1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_aaa1f6de-3de8-4d2d-a335-8291ee972941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_aaa1f6de-3de8-4d2d-a335-8291ee972941" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_691f50b4-9c12-4237-8caa-34bb14e07eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_691f50b4-9c12-4237-8caa-34bb14e07eba" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f05a8002-ab19-49cd-bd6e-9aacffdb97c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f05a8002-ab19-49cd-bd6e-9aacffdb97c8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9fb6e70-499f-4fa2-a5eb-b9cd01b63807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9fb6e70-499f-4fa2-a5eb-b9cd01b63807" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_us-gaap_PlanNameAxis_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd" xlink:to="loc_us-gaap_PlanNameDomain_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2c49961e-2a2b-458d-877e-dc88074402ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd" xlink:to="loc_us-gaap_PlanNameDomain_2c49961e-2a2b-458d-877e-dc88074402ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember_7df93d9b-1f1e-4f1c-9625-31dd29925984" xlink:href="silk-20200630.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2c49961e-2a2b-458d-877e-dc88074402ef" xlink:to="loc_silk_TwoThousandNineteenStockOptionPlanMember_7df93d9b-1f1e-4f1c-9625-31dd29925984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ac76304-e2af-42bf-a05c-78b43b15756e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_srt_RangeAxis_6ac76304-e2af-42bf-a05c-78b43b15756e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ac76304-e2af-42bf-a05c-78b43b15756e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6ac76304-e2af-42bf-a05c-78b43b15756e" xlink:to="loc_srt_RangeMember_6ac76304-e2af-42bf-a05c-78b43b15756e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dc1991fa-3809-4c3b-891d-5d828019789a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6ac76304-e2af-42bf-a05c-78b43b15756e" xlink:to="loc_srt_RangeMember_dc1991fa-3809-4c3b-891d-5d828019789a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cc87e7b1-0106-43a6-ac25-e8d662b0e8f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dc1991fa-3809-4c3b-891d-5d828019789a" xlink:to="loc_srt_MaximumMember_cc87e7b1-0106-43a6-ac25-e8d662b0e8f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4a80335a-e8a3-4297-aaa6-62d4f75da070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_us-gaap_AwardTypeAxis_4a80335a-e8a3-4297-aaa6-62d4f75da070" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a80335a-e8a3-4297-aaa6-62d4f75da070_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4a80335a-e8a3-4297-aaa6-62d4f75da070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a80335a-e8a3-4297-aaa6-62d4f75da070_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4a80335a-e8a3-4297-aaa6-62d4f75da070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveStockOptionMember_3c9b9f8b-a41b-4744-9bd8-e3fb2df95e5e" xlink:href="silk-20200630.xsd#silk_IncentiveStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_silk_IncentiveStockOptionMember_3c9b9f8b-a41b-4744-9bd8-e3fb2df95e5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NonqualifiedStockOptionsMember_211e0694-dd59-4dd7-9fb9-4f1f59cf5611" xlink:href="silk-20200630.xsd#silk_NonqualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_silk_NonqualifiedStockOptionsMember_211e0694-dd59-4dd7-9fb9-4f1f59cf5611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionMember_0fc45a61-ee56-4c7d-ac1a-4ea69705fb98" xlink:href="silk-20200630.xsd#silk_IncentiveandNonqualifiedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_silk_IncentiveandNonqualifiedStockOptionMember_0fc45a61-ee56-4c7d-ac1a-4ea69705fb98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_de1dddbf-0e73-47fd-b87b-570e0de8249f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_de1dddbf-0e73-47fd-b87b-570e0de8249f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29ba8c5b-7f5c-4866-ae06-348012c04c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29ba8c5b-7f5c-4866-ae06-348012c04c86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d17c330b-241b-4896-b5fc-4daf27d6678c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_us-gaap_EmployeeStockMember_d17c330b-241b-4896-b5fc-4daf27d6678c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1" xlink:to="loc_us-gaap_RelatedPartyDomain_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c9eaf732-7f96-41b3-a261-0308bf4a9e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1" xlink:to="loc_us-gaap_RelatedPartyDomain_c9eaf732-7f96-41b3-a261-0308bf4a9e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_800aa535-b225-4bd3-9da8-9fcef5002705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c9eaf732-7f96-41b3-a261-0308bf4a9e9f" xlink:to="loc_us-gaap_PrincipalOwnerMember_800aa535-b225-4bd3-9da8-9fcef5002705" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansActivityUnderCompensationPlanDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="extended" id="if34f48fc173547d68f9cc7cb6f919edd_StockOptionPlansActivityUnderCompensationPlanDetails"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansRSUsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="extended" id="iddd46809cca34ef5be0a0b1719b89642_StockOptionPlansRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd29cbb-8d64-4a99-a7bc-a369bba4cd9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd29cbb-8d64-4a99-a7bc-a369bba4cd9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd483126-dd06-4c60-855f-18e2685f4af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd483126-dd06-4c60-855f-18e2685f4af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_42c3c713-927c-49e2-912e-fd9195358941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_42c3c713-927c-49e2-912e-fd9195358941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54514205-02de-412d-addc-6e6486652c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54514205-02de-412d-addc-6e6486652c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66aaf9ef-e249-4910-8f85-05f855b9495c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66aaf9ef-e249-4910-8f85-05f855b9495c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_91c20739-146e-4f72-9ff5-5c9b8ebeca32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd29cbb-8d64-4a99-a7bc-a369bba4cd9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_22f401b3-14cf-4373-af02-8f866de764ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_22f401b3-14cf-4373-af02-8f866de764ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba8c6a89-78d5-4177-98c8-8e41d6a59fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba8c6a89-78d5-4177-98c8-8e41d6a59fd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c36b0cf5-f23c-421b-87b2-50f94ad2e67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c36b0cf5-f23c-421b-87b2-50f94ad2e67b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_195f6ea8-5432-4097-87ce-d0eb533c827a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_195f6ea8-5432-4097-87ce-d0eb533c827a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9eb7649e-8c75-4fe8-97ca-e472fb9cf3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cffad89-ba8c-4911-8dfb-832500ce2068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd29cbb-8d64-4a99-a7bc-a369bba4cd9d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cffad89-ba8c-4911-8dfb-832500ce2068" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a17522b7-ded4-42d4-a5c1-8ab8d356211e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cffad89-ba8c-4911-8dfb-832500ce2068" xlink:to="loc_us-gaap_AwardTypeAxis_a17522b7-ded4-42d4-a5c1-8ab8d356211e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a17522b7-ded4-42d4-a5c1-8ab8d356211e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a17522b7-ded4-42d4-a5c1-8ab8d356211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a17522b7-ded4-42d4-a5c1-8ab8d356211e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e35ed9f-a0cd-4ccc-8ca2-0a533679c91b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a17522b7-ded4-42d4-a5c1-8ab8d356211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e35ed9f-a0cd-4ccc-8ca2-0a533679c91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cc3087d2-8041-4f63-b6a3-f8d9ae424a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e35ed9f-a0cd-4ccc-8ca2-0a533679c91b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cc3087d2-8041-4f63-b6a3-f8d9ae424a41" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansFairValueofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="extended" id="iab26cc5e180a47e88a2111cbb4616271_StockOptionPlansFairValueofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6dbad2cb-0342-40b4-ba6a-182492a68742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6dbad2cb-0342-40b4-ba6a-182492a68742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e196644e-003d-4179-9fa1-ac03b732c8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e196644e-003d-4179-9fa1-ac03b732c8bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_47be5e85-2240-49d1-98ea-74daf694c2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_47be5e85-2240-49d1-98ea-74daf694c2d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b83586a6-3e1a-405a-a10e-35b7cb6faa60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b83586a6-3e1a-405a-a10e-35b7cb6faa60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dea56f94-dd81-490b-8c25-79bdcc77d78b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dea56f94-dd81-490b-8c25-79bdcc77d78b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d6619171-c46a-4ba9-8f45-d99b9dcdf34e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d6619171-c46a-4ba9-8f45-d99b9dcdf34e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c75e12d6-0d25-4254-a0f5-824ffcaa81a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c75e12d6-0d25-4254-a0f5-824ffcaa81a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8fb6c5c9-b7f6-4a49-b7a5-7eb346dd9e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8fb6c5c9-b7f6-4a49-b7a5-7eb346dd9e56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24656d08-1f70-4719-bcbc-fe020a8867c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:to="loc_us-gaap_AwardTypeAxis_24656d08-1f70-4719-bcbc-fe020a8867c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24656d08-1f70-4719-bcbc-fe020a8867c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_24656d08-1f70-4719-bcbc-fe020a8867c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_24656d08-1f70-4719-bcbc-fe020a8867c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76183c29-34d6-4a75-a701-e0941e3e71bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_24656d08-1f70-4719-bcbc-fe020a8867c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76183c29-34d6-4a75-a701-e0941e3e71bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e5039d99-e073-48a8-a0c8-1fa99beb2874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76183c29-34d6-4a75-a701-e0941e3e71bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e5039d99-e073-48a8-a0c8-1fa99beb2874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4d8a86bf-487c-470d-b450-02fbc046a043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76183c29-34d6-4a75-a701-e0941e3e71bb" xlink:to="loc_us-gaap_EmployeeStockMember_4d8a86bf-487c-470d-b450-02fbc046a043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:to="loc_srt_RangeAxis_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d" xlink:to="loc_srt_RangeMember_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19b1ad4b-1ca7-4cd7-994f-72c05e7cd2be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d" xlink:to="loc_srt_RangeMember_19b1ad4b-1ca7-4cd7-994f-72c05e7cd2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aa9fcb49-f0f3-46cd-8f1f-c522afccf171" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_19b1ad4b-1ca7-4cd7-994f-72c05e7cd2be" xlink:to="loc_srt_MinimumMember_aa9fcb49-f0f3-46cd-8f1f-c522afccf171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a388e6d7-6783-4e27-9fb3-a7aa0af6aed5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_19b1ad4b-1ca7-4cd7-994f-72c05e7cd2be" xlink:to="loc_srt_MaximumMember_a388e6d7-6783-4e27-9fb3-a7aa0af6aed5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="extended" id="i623f39d5408d4b02a30063009cd91051_StockOptionPlansStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_847f1dd7-c703-4a63-b7ba-29538004a0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d7efa9dc-239a-491f-98a7-808a35e386c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_847f1dd7-c703-4a63-b7ba-29538004a0a1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d7efa9dc-239a-491f-98a7-808a35e386c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fcdec384-ca3a-4c19-bca5-aeef5c809863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_847f1dd7-c703-4a63-b7ba-29538004a0a1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fcdec384-ca3a-4c19-bca5-aeef5c809863" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_984e2335-7302-4db5-9d00-f545ebad9c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fcdec384-ca3a-4c19-bca5-aeef5c809863" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_984e2335-7302-4db5-9d00-f545ebad9c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_984e2335-7302-4db5-9d00-f545ebad9c37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_984e2335-7302-4db5-9d00-f545ebad9c37" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_984e2335-7302-4db5-9d00-f545ebad9c37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_984e2335-7302-4db5-9d00-f545ebad9c37" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ba023e0a-76ad-4755-9d7f-a85164c84443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:to="loc_us-gaap_CostOfSalesMember_ba023e0a-76ad-4755-9d7f-a85164c84443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37266ec1-a606-4737-bf26-2ab3ffe888cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37266ec1-a606-4737-bf26-2ab3ffe888cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ac2f6e7e-1a3b-47da-b865-e6dc0c62a50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ac2f6e7e-1a3b-47da-b865-e6dc0c62a50f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlan" xlink:type="simple" xlink:href="silk-20200630.xsd#A401kPlan"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/A401kPlan" xlink:type="extended" id="i3d0212c11c564af28030c684d452b077_A401kPlan"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#A401kPlanDetails"/>
  <link:definitionLink xlink:role="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="extended" id="i0fdf6859fbec4b04b4c69761b37cb162_A401kPlanDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>silk-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9bdc0587-bada-46ac-a409-f4831c8e244f,g:1209e878-563a-4edf-b13c-0faadaf6133a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ab643f85-4ade-4c0a-95b9-01911f65e4a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_49e47863-1e8a-4082-bf8c-65af5b1e0091_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ef7f6656-5961-4d7f-b8b3-3c7825a58c77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, awards outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_05c0d692-db2b-4a76-ad1b-a3d12c4ce055_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_aa8737f1-9822-4907-b2a2-c7b481ee3d90_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a747ea81-bd79-461a-bcd0-c29fa03c688e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be219b3c-c912-4968-a99e-c3c4fdebdc8c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0d6139e6-1368-43dc-b03b-ce0ba525a4ea_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77172b92-0013-423f-889a-3b52c37db646_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInKind_48dccbf0-6ce2-4359-a50a-07bf0a578c92_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate paid-in-kind</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInKind_label_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Paid-In-Kind</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInKind_documentation_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Paid-In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInKind" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentInterestRatePaidInKind" xlink:to="lab_silk_DebtInstrumentInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29cfe3f1-88c0-4bd2-8e16-c3e500170c79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_42d91cbd-b1cb-40d9-91d2-937d8580e495_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_665e54fa-fa52-4973-b278-26b3d9ee320a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_2dc86213-5545-40cd-90c0-c58bb9a47acd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for excess and obsolete inventories</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_IncentiveStockOptionMember_35a005ba-da50-4370-9e46-fde7f56fc8bf_terseLabel_en-US" xlink:label="lab_silk_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISO</link:label>
    <link:label id="lab_silk_IncentiveStockOptionMember_label_en-US" xlink:label="lab_silk_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:label id="lab_silk_IncentiveStockOptionMember_documentation_en-US" xlink:label="lab_silk_IncentiveStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveStockOptionMember" xlink:href="silk-20200630.xsd#silk_IncentiveStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_IncentiveStockOptionMember" xlink:to="lab_silk_IncentiveStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_7fdece37-fa1d-49d5-89f7-aa26361e9733_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockAbstract_0ab8d8d8-6bdb-403d-85b7-891ef7b2ae34_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockAbstract" xlink:to="lab_us-gaap_DividendsCommonStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_3c339710-ec54-411e-8543-e04698b24bb8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of redeemable convertible preferred stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1e096359-2864-427e-a019-5f8ffcd0cae7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bdd79bd6-9365-42ab-a2c1-3293fc530add_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b58f7d9c-5cd4-4a24-9cb7-aadef5c1dc31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2e72268e-5631-4503-b9e7-204c27177bd2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PublicStockOfferingMember_afd60e97-49e9-499a-847d-21d6d66bde31_terseLabel_en-US" xlink:label="lab_silk_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_silk_PublicStockOfferingMember_label_en-US" xlink:label="lab_silk_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_silk_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_silk_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingMember" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PublicStockOfferingMember" xlink:to="lab_silk_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b8c91d54-764a-44d0-bcbb-c8aa3387e251_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d86c23d7-3a69-42b4-8c75-8449df92b6e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_fe41cb45-7a89-4b28-88cc-3a39c9746b56_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock upon IPO</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6abd6d02-b88c-49f9-a18e-c63a3108bfc0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_430e88f5-d0a2-412b-82e3-123599283ec2_terseLabel_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant</link:label>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_label_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_documentation_en-US" xlink:label="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:href="silk-20200630.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:to="lab_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5f70cc69-d43a-4e08-a165-9d2b3da9bcd5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96176e44-4e8c-4f24-a33c-7b8c2ae9b9d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f0d2f182-8a17-49ee-b2a8-cb0e4bdbf52e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_1bb5653e-c936-4d1b-ac17-717cc11af7c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_ee9c9c93-ad4b-4741-abfa-0ac5361fc8af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_faf1dcf9-2d95-4705-ae22-233a19be94f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1e689784-83a6-4523-a85b-d3e54ae59c36_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage employee contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_10b563da-7858-4254-8048-df6cf0e2d658_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_80e7968f-360e-416b-8b40-ec418ab7e3a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0250675f-d98c-43e7-9b57-f3513c7b0a10_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_48a2b6e0-1b02-43aa-a9ec-32a11ea13d62_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_13b83901-5a76-4e87-8c46-d47490596912_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5bf76726-8b70-4f47-996e-fc68a29f6187_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bb92c17c-2344-4768-bb16-76bd48e6e40d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_81bc0ed5-5e1c-4cd0-b83f-f9af8cfa734a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d9b218aa-7d43-4aae-b3d7-00e99a7cf848_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b9adc07e-c667-4200-b930-601f7b76fb3f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_715d75eb-1c7c-42be-ac89-0c8371c2b219_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_2307637b-bddd-4a6f-a872-073e0cf677a7_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_270de2c9-fb8f-4a84-8778-8daea505ac10_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4b5e008e-2993-4a76-9e8c-ea85d7bbd784_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset in other non-current assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_caf78a78-8ba2-4006-b8e8-e7deaf03143f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9c656ae3-433c-423e-9369-1132efd1d792_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9c6ce383-de9c-4949-a449-747d1f94678a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d10dce7a-fcea-4308-b345-367a3a372b07_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_194b82a8-9db1-41b2-9f5e-13bed1e487f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Measure on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b53bab4f-c55f-4bce-8de3-923f67c747ef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs related to the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_228b1acc-5b51-47ac-8846-903aa6d1725d_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_a601bfcb-3299-4a21-89ad-31f98fd6052c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_eec9d0e7-cc5e-45ad-83d4-9ff769b1986c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued and outstanding: none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1f91a2d7-9e4f-4a19-8c95-1c7f466b6735_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2c969211-59dd-4e6b-ad4b-4c9df0896fc9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TermLoanMember_a2de0ef3-0efc-4095-97c2-0435d61c73ac_terseLabel_en-US" xlink:label="lab_silk_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_silk_TermLoanMember_label_en-US" xlink:label="lab_silk_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_silk_TermLoanMember_documentation_en-US" xlink:label="lab_silk_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanMember" xlink:href="silk-20200630.xsd#silk_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TermLoanMember" xlink:to="lab_silk_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_570c761f-90c7-48c6-a783-049c35948363_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_7270cc2b-6ed9-4484-817c-7a8b924701d9_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20d2a06e-ab58-449f-996d-0318899feca8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_a210c5a7-eaad-40e8-9a0e-a95c4322987d_totalLabel_en-US" xlink:label="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross before accretion of closing fees</link:label>
    <link:label id="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_label_en-US" xlink:label="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross, Before Accretion Of Closing Fees</link:label>
    <link:label id="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_documentation_en-US" xlink:label="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross, Before Accretion Of Closing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:href="silk-20200630.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:to="lab_silk_LongTermDebtGrossBeforeAccretionOfClosingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a98c04a9-d61f-4c8a-b98a-dfec5d69200a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1ea71ed3-3bab-4d80-99fe-022607276220_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_fe0e3329-58d1-44e4-b608-b11d20a39189_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6d507ed5-2872-4acf-ae6d-64265e5e8a4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_78580356-f844-4a44-91c3-b3a3ea44287a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_24b5f9d7-01f0-458b-808f-3e8bafc00740_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_634f0dd2-5060-44b7-b511-c8d78cafb7d2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_53ee8ff2-5b7a-4109-9c69-59de88313e78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_c0498c5f-4e9b-432c-bbc8-3988ace17c43_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivables</link:label>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_5054bf41-90e7-4873-80e2-db4ff7972193_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_15fc5d55-d758-4983-8612-410208874afe_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f70d3490-6498-4407-b0e9-5c9da9dcad5a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1529c966-d6f8-4205-b43c-d041a49aeea3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_75b9112d-8edd-4ead-baa3-519d15b485fe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_16bee062-af18-4352-b08b-c432ea6982e5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_08ac9e40-e11e-4bd9-81b5-5f756ffd697d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_OperatingLeaseRightOfUseAssetAmortization_1245ebe6-626f-45a2-a819-e7b771dfb5be_terseLabel_en-US" xlink:label="lab_silk_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_silk_OperatingLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_silk_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization</link:label>
    <link:label id="lab_silk_OperatingLeaseRightOfUseAssetAmortization_documentation_en-US" xlink:label="lab_silk_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_OperatingLeaseRightOfUseAssetAmortization" xlink:href="silk-20200630.xsd#silk_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_OperatingLeaseRightOfUseAssetAmortization" xlink:to="lab_silk_OperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_08e0f499-30db-4eff-9f87-9736d8d92e23_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bbb2c7d1-64a0-4624-821e-cc6cbf7db5bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_8324e730-ef19-42b6-aaf4-8b35161da340_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c218735c-efa3-498a-a9a6-5f06a856d6e7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b912c5ad-1bd8-456c-b25f-902a7d700e74_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5c49ef40-64de-43be-84f7-f7272ce8ad6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0f741c4a-803a-4aa5-aecc-dd5b75eb97e1_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6efb7348-a73d-4bc5-bf19-23a15b57813b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInCash_c0a88f74-7af2-4c82-b2e1-e9b195452c8f_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate paid in cash</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInCash_label_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Paid In Cash</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRatePaidInCash_documentation_en-US" xlink:label="lab_silk_DebtInstrumentInterestRatePaidInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Paid In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInCash" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRatePaidInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentInterestRatePaidInCash" xlink:to="lab_silk_DebtInstrumentInterestRatePaidInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_a99c963c-f493-43cc-aff7-e4171a6d3029_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_e59e674b-977e-426c-b6c7-a2584c156836_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average days to maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_cb73583b-3cbe-40ec-bc30-ea67e873efe0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_2492343d-3af5-444c-a2a2-b8291220ef8a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1330a405-d373-40db-b263-5e61c01d91bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cc1fba81-5588-4b41-91ac-7ee254773ceb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f61ca146-a75a-4fd3-9136-f78dab0b2d63_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_489f1bcd-c320-4676-bfb1-cc7b266997c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6b7ccf5e-f5ca-48cc-b53c-ef480509158a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d1e3e1ad-2361-422d-b88f-cf15a60f58f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_404a30f9-ca29-4a8e-93e9-7c32854ba781_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c3de966d-6f0e-44c8-a05c-e85205a7537b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PublicStockOfferingSharesFromCompanyMember_6adf56cb-7e80-448a-8768-24a45b3638f4_terseLabel_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company</link:label>
    <link:label id="lab_silk_PublicStockOfferingSharesFromCompanyMember_label_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company [Member]</link:label>
    <link:label id="lab_silk_PublicStockOfferingSharesFromCompanyMember_documentation_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromCompanyMember" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingSharesFromCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PublicStockOfferingSharesFromCompanyMember" xlink:to="lab_silk_PublicStockOfferingSharesFromCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_38895c8c-7462-4288-9b4b-4e06fb77d3cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Determination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_46da8617-5e50-4bbd-8f4d-4d11fc433ff2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_154e7de0-dc47-462d-9698-cf6e0500fec0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStockAbstract_0b0bec53-1445-498a-be8c-13f8d9441157_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract" xlink:to="lab_us-gaap_DividendsPreferredStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_05cff8ac-e802-471b-adc5-111642393d8d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_924b35c6-3d3c-409c-99eb-f11a248ba805_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b6966889-a02f-49d9-94b1-0f5f6c3e0786_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_30c6a941-99d8-4f18-b519-0cd97acf841b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_NonqualifiedStockOptionsMember_70a29118-1cf1-40e9-8572-c50448265d46_terseLabel_en-US" xlink:label="lab_silk_NonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NSO</link:label>
    <link:label id="lab_silk_NonqualifiedStockOptionsMember_label_en-US" xlink:label="lab_silk_NonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Stock Options [Member]</link:label>
    <link:label id="lab_silk_NonqualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_silk_NonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NonqualifiedStockOptionsMember" xlink:href="silk-20200630.xsd#silk_NonqualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_NonqualifiedStockOptionsMember" xlink:to="lab_silk_NonqualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_95915f2d-61c5-4704-bb4a-e123f0accf6a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TermLoanTrancheAMember_f95c4f6f-6580-40f8-9908-39cfa6815fe4_terseLabel_en-US" xlink:label="lab_silk_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche A</link:label>
    <link:label id="lab_silk_TermLoanTrancheAMember_label_en-US" xlink:label="lab_silk_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche A [Member]</link:label>
    <link:label id="lab_silk_TermLoanTrancheAMember_documentation_en-US" xlink:label="lab_silk_TermLoanTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheAMember" xlink:href="silk-20200630.xsd#silk_TermLoanTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TermLoanTrancheAMember" xlink:to="lab_silk_TermLoanTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0685a3f6-9ce0-40f9-9f3e-86f7e273a22b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_549baf65-cdc1-4f09-a28e-32c0f2141a6f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_becb28c2-7ec6-45c1-8cb1-fbc4b1ab90be_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e2e715d1-da08-48a9-b504-8830471c60f3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09633955-406d-42c7-a531-c249004ee7ee_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c3c311ce-bb22-4f2b-952d-e8b8f8e486ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c0bbc763-70eb-4db5-ba9d-bbac39b336ef_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fccbb506-4f23-45be-ace6-de3eb5e0d89f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_9694f3c3-595b-4d41-aa7e-8d6bd444251b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable convertible preferred stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5830635f-5bcd-437b-add0-39e8090edde6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b2205d24-7a08-45f6-881a-ae1bb3bc9344_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expensed not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_23ae3bac-7cb5-4a98-85ba-df40fc917f05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5b528f36-3f4b-4605-af83-6ed1ff30ed48_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_6ae58498-2dea-4bef-9622-d0b95194d1aa_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b5bca395-ac7c-4ac3-8197-e202d7d1b52d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CommonStockWarrantMember_2005594e-d53a-4059-a69d-d4b7c0e1d2af_terseLabel_en-US" xlink:label="lab_silk_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant</link:label>
    <link:label id="lab_silk_CommonStockWarrantMember_1bf47b4f-a660-483e-851a-9f33fb7d2b1d_verboseLabel_en-US" xlink:label="lab_silk_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant</link:label>
    <link:label id="lab_silk_CommonStockWarrantMember_label_en-US" xlink:label="lab_silk_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:label id="lab_silk_CommonStockWarrantMember_documentation_en-US" xlink:label="lab_silk_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember" xlink:href="silk-20200630.xsd#silk_CommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CommonStockWarrantMember" xlink:to="lab_silk_CommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_3aea1008-ee3f-4b46-b8fc-5c7debcd5a07_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred stock to common stock upon initial public offering</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_b70ca569-e5f0-4f93-903d-cca2da6eccf8_terseLabel_en-US" xlink:label="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:label id="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_label_en-US" xlink:label="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1 [Table Text Block]</link:label>
    <link:label id="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_documentation_en-US" xlink:label="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:href="silk-20200630.xsd#silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:to="lab_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_65731301-e49e-4ef2-bbc0-ffe53ec4b672_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_e8f8e507-b7f2-436d-8bfa-28fa5b9ead87_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_16330486-eb54-454d-9f12-c02772dee52e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_abca763c-0e01-426b-b833-51c216ebc826_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_54571180-65a4-4f89-baa1-68b69873f497_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_581902dd-ae5b-48e8-9191-1cc084f92746_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_6a20f88d-d829-4439-bacb-fde432a08c82_terseLabel_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts maturing after one year through two years</link:label>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_label_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</link:label>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_documentation_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:href="silk-20200630.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:to="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b206ebb0-ab42-4cda-b82a-427f7a77c740_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7ad66a09-b4f6-407a-ba52-8cf559e2a0e6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d12002de-5bfe-47b4-9240-655626294f58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5ac3ed78-f3df-48bb-85a5-53bffc382a57_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_a5be8dfc-54c1-4180-b7af-0d4ee58f9464_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3ecb60a1-5d21-4be9-828a-71f9545bf4a7_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2cafbdc7-db95-4dd5-9451-5e8c0c317320_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_da9d8c9d-7902-4eae-85d0-cd7836145353_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_0d798f6a-ab2f-4d98-a43d-6c7bdd934f39_negatedTerseLabel_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO (in shares)</link:label>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_label_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares</link:label>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_documentation_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:href="silk-20200630.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:to="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adf548df-99a6-4595-9cb0-91c1e849d1b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75a6d1c9-918e-4068-b507-c5c11046083e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PreferredStockWarrantsMember_b7f31e9f-0b52-498e-8d04-d57a71360fdd_terseLabel_en-US" xlink:label="lab_silk_PreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Warrants</link:label>
    <link:label id="lab_silk_PreferredStockWarrantsMember_label_en-US" xlink:label="lab_silk_PreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_silk_PreferredStockWarrantsMember_documentation_en-US" xlink:label="lab_silk_PreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PreferredStockWarrantsMember" xlink:href="silk-20200630.xsd#silk_PreferredStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PreferredStockWarrantsMember" xlink:to="lab_silk_PreferredStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3cd0fdf6-5a2f-4fc3-85f1-2a1f467b4e97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19cd3dad-81e3-438c-9893-f276dd772c4c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ProvisionsForSalesReturns_c0f1dcfd-df99-4179-9b63-92b8f4fe3703_terseLabel_en-US" xlink:label="lab_silk_ProvisionsForSalesReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for sales returns</link:label>
    <link:label id="lab_silk_ProvisionsForSalesReturns_label_en-US" xlink:label="lab_silk_ProvisionsForSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Sales Returns</link:label>
    <link:label id="lab_silk_ProvisionsForSalesReturns_documentation_en-US" xlink:label="lab_silk_ProvisionsForSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Sales Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ProvisionsForSalesReturns" xlink:href="silk-20200630.xsd#silk_ProvisionsForSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ProvisionsForSalesReturns" xlink:to="lab_silk_ProvisionsForSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6ad23530-7cf3-498b-8141-6c2cb33997ab_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_e0f65f21-70f5-469e-9ff9-fa2fb50e235a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_1daa4bf0-c75b-437c-af0b-8472fb191b83_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk, and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_4b82cdd8-0c78-407e-accf-a6a0a3290b7c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a9cf1405-0e85-46e1-bd07-dbf4102f7108_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_281f9203-372b-4b41-a5d1-29739fef51d5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock issued, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bc31077a-7969-4eeb-b59f-635e71fee7f0_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_18dc4862-3a5c-420a-9189-5d55a8185f6c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_a66975be-e2ec-46f7-9e57-adae4669f1a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_4aab13a9-6f2e-4b9a-a5c1-afe1b0d06476_terseLabel_en-US" xlink:label="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_label_en-US" xlink:label="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Classified As Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_documentation_en-US" xlink:label="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Classified As Liabilities [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:href="silk-20200630.xsd#silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:to="lab_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_20b5f275-39c1-404a-93d5-9ac6622eb582_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_65d995cf-3b65-42a9-af58-71a32214169b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_77c93607-5adb-4378-beef-3bb4e7edced7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expensed not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_692afae5-9520-424b-b910-159d839f193d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d5797e19-8dea-4c5a-8f51-63a44f190bed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f93029ac-3a1c-4398-9eec-d23e2e504911_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_df13aacd-1062-4464-a7e6-e12b1802c00c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b8b18416-eee8-4835-ad3e-869251e06363_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_AccruedClinicalExpensesCurrent_3a8f32fe-04d6-4a9b-9aab-4405f86df838_terseLabel_en-US" xlink:label="lab_silk_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical expenses</link:label>
    <link:label id="lab_silk_AccruedClinicalExpensesCurrent_label_en-US" xlink:label="lab_silk_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses, Current</link:label>
    <link:label id="lab_silk_AccruedClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_silk_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedClinicalExpensesCurrent" xlink:href="silk-20200630.xsd#silk_AccruedClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_AccruedClinicalExpensesCurrent" xlink:to="lab_silk_AccruedClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_41212d26-fd35-4c12-b513-e0b3f62c7524_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock_ffbce0df-0c95-4840-890a-2db33355d978_terseLabel_en-US" xlink:label="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Information</link:label>
    <link:label id="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="silk-20200630.xsd#silk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_silk_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_ced20537-3a6f-4cd6-b316-c0b1fe5ead75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a70d7a7d-f466-415d-bbd5-c904bd7b7106_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b9e8b088-aec4-41d3-9946-6420ee8b0ca5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_4ec8a5fa-52f5-45b8-b6d3-69f843777d0f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1c10a65d-96d1-4adb-91c1-623cf1ffaa06_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_74adb62c-b677-4017-b179-ea3d47bfbfb8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4bc2fb92-b2cc-43f1-8800-e899daf9426b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ea511566-9872-462f-aaf0-9909c402eab0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3d447678-1e91-4dec-9d83-ac1b2df43930_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_bb756cab-fdde-42af-bb27-fdf9faf58e66_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4dde8768-f62d-43a5-b8a1-8d71d6513a3e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e5d16548-34ea-4ff1-9bee-f5aa41d2ad02_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ca79886-c742-40f9-ad77-f12225300d14_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_785d6a72-fb95-4656-be44-184306fbef4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1a570099-e941-4b05-9762-b05e4f3429ed_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d7219058-52c5-459e-95bc-4d8d9d887282_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_523fceb9-cf8e-4fc0-8182-d82ff1dc1090_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentCovenantMaximumLiquidityAmount_f7471363-6ca0-46bd-b839-bf613e8be67e_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMaximumLiquidityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum liquidity amount</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantMaximumLiquidityAmount_label_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMaximumLiquidityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Liquidity, Amount</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantMaximumLiquidityAmount_documentation_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMaximumLiquidityAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Liquidity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMaximumLiquidityAmount" xlink:href="silk-20200630.xsd#silk_DebtInstrumentCovenantMaximumLiquidityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentCovenantMaximumLiquidityAmount" xlink:to="lab_silk_DebtInstrumentCovenantMaximumLiquidityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_69d97d0c-fb98-4606-9cf8-0071aa6d2c55_terseLabel_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts maturing within one year</link:label>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_label_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</link:label>
    <link:label id="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_documentation_en-US" xlink:label="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:href="silk-20200630.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:to="lab_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_5f20f946-766f-4137-ae20-0814c380fbeb_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_9c4085d6-e1f6-478b-9f41-9d95c5f0a3ca_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7480e47d-d3a9-4fc1-9b33-c1ae43ca73c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2e88424a-9120-4917-9f8b-c290a9573da0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_e92c8045-5bc1-42ca-8c17-64279f3901b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_43277cea-ea66-4b6a-839f-80568b6b2798_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3ba74e4c-f52a-44ab-82e4-10fa17296b2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_66c72600-c54a-4edb-892f-b04038b5e3ab_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_7c7f3b2b-8435-49f2-b8c4-41e37427cccf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_71e8a7d7-bca2-4468-a2ea-611d2a6505f8_terseLabel_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10% Stockholders</link:label>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_label_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalOwnerMember" xlink:to="lab_us-gaap_PrincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2149454f-af66-4a9a-9732-58875060440e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8efa50b7-915b-41c3-b4db-1312677f53ef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c24e2066-4713-4573-b313-de6ceccfd1cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17b2f99a-b667-47e2-82b4-2cf17b8020dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_d0d2c052-930f-4b5f-b742-f9c3e9af2dc9_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of convertible preferred stock warrants to preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7e33dad2-205a-4548-8795-0f0a076f39f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability in other liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30e66d78-bbf4-4e42-a0f2-89b6ba49729a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_2d34da7b-8958-41e7-b6cf-e1ac9b3e30db_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_1df78414-729e-4b6b-a0e0-be9a5705c0bb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_2e354f06-87cb-4745-82b8-308654a0925a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty expense</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_059cb8e2-0a73-414c-b0d8-674c18fb0822_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amount representing debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_08b9f7fd-71eb-4493-958b-b8770ef30858_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_efc2dd72-288c-43c0-80aa-1a59695796c9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_143e6b6d-d8cd-40e6-a239-dd288d7bcd1f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentInterestRateFinancingFee_3851a1c1-d546-455b-8eae-663fc0697ce7_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentInterestRateFinancingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing fee</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRateFinancingFee_label_en-US" xlink:label="lab_silk_DebtInstrumentInterestRateFinancingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Financing Fee</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRateFinancingFee_documentation_en-US" xlink:label="lab_silk_DebtInstrumentInterestRateFinancingFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Financing Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRateFinancingFee" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRateFinancingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentInterestRateFinancingFee" xlink:to="lab_silk_DebtInstrumentInterestRateFinancingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_78c7ae2e-2cc1-4634-9ff2-8acbb1b5f32e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_defac839-eadf-4201-b789-a12dfa1cec2f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b95cd2a0-0406-4037-ac64-abc013fb082a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_86be64c2-dbe1-4aa5-b7bc-70d817e469f9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_809fc4bd-71c0-463f-a8d4-278368154cb2_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_54ea1330-df29-4d71-bafe-9bf6d6cc372d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_79c0375b-1984-4dab-81df-7ef9b46d05a8_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9b73b4a4-d4b1-4fef-9ec1-d0607c833299_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_9ac14df9-4a13-4880-aa18-55f09ce75fe6_terseLabel_en-US" xlink:label="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares issued (in shares)</link:label>
    <link:label id="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="silk-20200630.xsd#silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_85a3adb2-73a8-4b91-9336-fb33b775a1a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_3d7b2d94-9856-4144-9e79-fc94e96057ff_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fa011af4-9847-42c2-a1d6-748244a13e5c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_cb25343a-11e2-4667-b1e9-e45c2a859eca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_c85c9bac-29bb-4946-8aa1-1adbd17d9b47_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_2667d607-56b3-4c4d-9c26-b1a67672f550_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_124461b0-ce34-435b-b2db-f66528932ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_91d1ff07-22e8-440a-9ecf-26d56b7d618a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_155f2ba3-5bf7-4227-94f8-cb68e01a4e20_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of the Available-For-Sale Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_21b62e7f-f97c-47ec-878d-34d373b1765b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of matching contribution of the employee's pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentLiquidityCovenantTerm_047294fe-aa5a-4ccf-862a-0e40ad0ca7d1_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentLiquidityCovenantTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity cure period</link:label>
    <link:label id="lab_silk_DebtInstrumentLiquidityCovenantTerm_label_en-US" xlink:label="lab_silk_DebtInstrumentLiquidityCovenantTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Liquidity Covenant, Term</link:label>
    <link:label id="lab_silk_DebtInstrumentLiquidityCovenantTerm_documentation_en-US" xlink:label="lab_silk_DebtInstrumentLiquidityCovenantTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Liquidity Covenant, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentLiquidityCovenantTerm" xlink:href="silk-20200630.xsd#silk_DebtInstrumentLiquidityCovenantTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentLiquidityCovenantTerm" xlink:to="lab_silk_DebtInstrumentLiquidityCovenantTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_168be556-4867-4c86-8db5-0c99df1734d4_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of minimum payments</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_70968b2b-c18d-4da2-b5b3-5805178efab7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtMaximumBorrowingCapacity_a82e6bce-6147-4727-9967-56b862ed4749_terseLabel_en-US" xlink:label="lab_silk_DebtMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan agreement amount</link:label>
    <link:label id="lab_silk_DebtMaximumBorrowingCapacity_label_en-US" xlink:label="lab_silk_DebtMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_silk_DebtMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_silk_DebtMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtMaximumBorrowingCapacity" xlink:href="silk-20200630.xsd#silk_DebtMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtMaximumBorrowingCapacity" xlink:to="lab_silk_DebtMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a483dcf9-63c7-46ab-af4c-602b52074ddf_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (accretion of discounts) on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4ec8a342-b19b-4f0a-a56a-4018d200b8b9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c94820f9-51f3-4b04-8942-56cf1d50ca2c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f17055e5-5b79-4280-80c6-d295028339a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9a9e5e99-b0c3-4f79-b146-64d3c7eb92c1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, gross</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fd434ae-ce17-415f-9380-6eed12e192e8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3adf992d-e92d-4946-9495-1335ddedca97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2071dd77-a23f-4380-847a-a0b5a4f0b3be_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_7e6dfa39-711a-400f-88ed-3ff315be9616_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished products</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a7606cc-f6a8-44b3-993d-972e4998b767_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8d01442b-a07b-431f-9805-2aa0d79279a5_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d35fd44c-b9ca-45ce-a586-ce9e80ef205f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_64402d3a-9ad0-427c-8c30-dc270a5a16ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability in accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d7d78833-583b-4dd4-98ad-44d0b5a8d704_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs of unvested RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39a39c3c-3ff0-409c-a6e7-852a9a6cf86c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bd082b9f-a348-4931-9cb0-1d88c0870b0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used for Estimating Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_460c3911-e58c-49f6-909c-58dca113ec7d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_d9dcb0ca-1f49-4353-a5f9-1901217998f3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution match percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_09740b5c-f745-4f91-8394-3e7565f2f64c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ce6a3455-6aff-4d21-b238-cdd7f1bf9f2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b550d0f6-d294-426d-bada-6acd9cc8e0e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_73b209c2-dfdd-4022-887c-968d661c7baa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bf72f9cb-d273-4e35-b615-3dd295ed877a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_06ffd37d-6b2e-4473-93f0-52d84e4b9733_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_70b97092-7494-4079-838d-9c35c74cf7dd_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2a3a4553-ba10-40be-b0f4-42cef12f49a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans_debcf313-764a-461b-ab8c-90d297e251fd_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding loans</link:label>
    <link:label id="lab_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans_label_en-US" xlink:label="lab_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Percentage Of Outstanding Loans</link:label>
    <link:label id="lab_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans_documentation_en-US" xlink:label="lab_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Maximum Percentage Of Outstanding Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" xlink:href="silk-20200630.xsd#silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" xlink:to="lab_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TermLoanTrancheBMember_020e08f3-99fa-4c90-ac4f-db775383270d_terseLabel_en-US" xlink:label="lab_silk_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche B</link:label>
    <link:label id="lab_silk_TermLoanTrancheBMember_label_en-US" xlink:label="lab_silk_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche B [Member]</link:label>
    <link:label id="lab_silk_TermLoanTrancheBMember_documentation_en-US" xlink:label="lab_silk_TermLoanTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, Tranche B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheBMember" xlink:href="silk-20200630.xsd#silk_TermLoanTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TermLoanTrancheBMember" xlink:to="lab_silk_TermLoanTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent_6563acd2-d896-4536-b8e3-4e600259cb65_totalLabel_en-US" xlink:label="lab_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) And Comprehensive Income (Loss), Net Of Tax, Attributable To Parent</link:label>
    <link:label id="lab_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent_documentation_en-US" xlink:label="lab_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) And Comprehensive Income (Loss), Net Of Tax, Attributable To Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" xlink:href="silk-20200630.xsd#silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" xlink:to="lab_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_073e86db-fbea-4fe6-9950-5da84d681c48_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_07327c03-e624-430d-9b2a-a4879d9efd00_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ed2be2bf-3fea-4eec-a2fb-7b12c24affc1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_585a80ad-7b48-4193-a84f-e3e39ffa3787_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_9e16e368-6fd2-4019-a029-bb15df87ee3c_terseLabel_en-US" xlink:label="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_label_en-US" xlink:label="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Stock Issuance Underwriting Discounts And Commissions</link:label>
    <link:label id="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_documentation_en-US" xlink:label="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Stock Issuance Underwriting Discounts And Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:href="silk-20200630.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:to="lab_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2fca1cd4-ad25-44a5-8d12-f503dac9c301_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2e349435-0b93-4702-8d62-b23c4cf30c00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_173bf8d4-4485-4cee-b2d7-71f85e16e226_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2799b168-550e-4e67-a947-7740bc0680fb_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of Series C preferred stock warrants in connection with IPO</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_2d42a799-ba2a-4c19-9252-ed06cf68908f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3b5690d1-0754-4661-b7fe-afcea6a64d16_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_52f99bb4-bc81-4131-adcd-5908a8a3854f_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_17820749-f7f9-447d-a6b3-1d816835b022_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ad6d427f-30af-440f-b15c-2e38e53b22c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d5bbe30-8164-4c02-94d1-463c14b53317_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_aa25992c-cb2e-45ea-8906-de4e0e11154c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_b6678a08-386a-485f-8552-c012af6b91d4_terseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares allowable under the plan (in shares)</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="silk-20200630.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_d4538a91-6d0c-468f-880c-0861daabaa27_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5a02fec0-5931-4666-b0cf-c294d04fbbf0_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_de36e486-a92a-4eda-b7b0-e5e7468e7f11_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1307b37c-c20a-46dc-b992-88ee27e0b777_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares used to compute net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a381589b-65b3-4b5c-bbed-306d852e47fa_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common stock outstanding used to compute net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0e672e19-dbaa-478c-a409-362916a16c46_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of purchase of price of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_33020343-a427-4db0-b489-bab8af9377f8_negatedTerseLabel_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO</link:label>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_label_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease For Conversion Of Convertible Securities, Value</link:label>
    <link:label id="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_documentation_en-US" xlink:label="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease For Conversion Of Convertible Securities, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:href="silk-20200630.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:to="lab_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b24cae0b-f146-4cc1-8584-5853640b8c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentConvertibleMarketCapitalization_6101a9ef-42b1-49d1-9cc7-f15984218702_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentConvertibleMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market capitalization (greater than)</link:label>
    <link:label id="lab_silk_DebtInstrumentConvertibleMarketCapitalization_label_en-US" xlink:label="lab_silk_DebtInstrumentConvertibleMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Market Capitalization</link:label>
    <link:label id="lab_silk_DebtInstrumentConvertibleMarketCapitalization_documentation_en-US" xlink:label="lab_silk_DebtInstrumentConvertibleMarketCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Market Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentConvertibleMarketCapitalization" xlink:href="silk-20200630.xsd#silk_DebtInstrumentConvertibleMarketCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentConvertibleMarketCapitalization" xlink:to="lab_silk_DebtInstrumentConvertibleMarketCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_602d6039-09a0-4540-969e-016af7a75037_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_439eccae-cf2e-425e-a148-e41d05e37980_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_c4335d03-88e3-4a91-b531-adf305ddb561_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8f9db92f-6bc1-44e8-bd53-1b395f2809cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_804d189f-33e5-455a-b6df-942bb81e337a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_cd1cf073-9bd7-436e-a037-1a47679183c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e716864c-0529-4398-9a09-de407fd84181_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentCovenantMinimumNetRevenueAmount_eb530548-24bf-465e-8987-5be1124f3a69_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMinimumNetRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum net revenue target</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantMinimumNetRevenueAmount_label_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMinimumNetRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Net Revenue, Amount</link:label>
    <link:label id="lab_silk_DebtInstrumentCovenantMinimumNetRevenueAmount_documentation_en-US" xlink:label="lab_silk_DebtInstrumentCovenantMinimumNetRevenueAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Net Revenue, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMinimumNetRevenueAmount" xlink:href="silk-20200630.xsd#silk_DebtInstrumentCovenantMinimumNetRevenueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentCovenantMinimumNetRevenueAmount" xlink:to="lab_silk_DebtInstrumentCovenantMinimumNetRevenueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_05a389f4-7041-4a5f-8b6f-c3882e952a41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9f31c573-81ef-4932-8a95-bd7f899299aa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_af6d3dd2-0d39-4f3b-b8c7-49f01578c06b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of outstanding shares of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7e08ffbc-c28f-44bc-b41b-7defdb1bcf98_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_75a49228-1f32-4818-af9e-5bd778a5265f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_880126ce-254f-44d1-9136-def322da8e03_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_34ea0673-31a0-4482-a739-32bdd7db4337_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1a234c24-9487-4cdc-a9e5-c281fed59476_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, vested and expect to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_57e953f5-57f7-4954-a8cd-d7afb443cd0b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bbf33b8-6870-4b70-a8b5-8874f093bbfd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c352a625-de40-4b69-9b9d-f1f9d8eea3ce_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e61da2a1-48d0-49bc-8785-e2051ead477f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_7963ac8d-59c1-487b-a365-bf65fe2488a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_51536d22-ae37-417a-9d96-47ff525f6e9e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0497be3-351d-49ac-af04-5e969a425748_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_37dc9e17-603e-4b62-b24b-54d261c073e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_1b33f229-7d03-430c-965a-0a4b3c290561_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3fa730da-8a1c-4336-b3ff-ef1ee47dd45d_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_34793f4a-18c6-47d8-a362-f8f6c46b3342_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5df8ddf2-3115-436d-a700-b3a0f3672f87_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued and outstanding: 33,610,099 and 31,255,267 at June&#160;30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_3d2aa6bc-f7d7-4fdd-a762-aaa414dc71fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_65ab57fe-6c63-4626-ac9d-700b16b38cd8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9b8c695c-41d6-42fc-b706-b0004337d5b5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_SecondPublicOfferingMember_5d5cd9db-03bd-4879-9f3b-5f89efbad15f_terseLabel_en-US" xlink:label="lab_silk_SecondPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Public Offering</link:label>
    <link:label id="lab_silk_SecondPublicOfferingMember_label_en-US" xlink:label="lab_silk_SecondPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Public Offering [Member]</link:label>
    <link:label id="lab_silk_SecondPublicOfferingMember_documentation_en-US" xlink:label="lab_silk_SecondPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SecondPublicOfferingMember" xlink:href="silk-20200630.xsd#silk_SecondPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_SecondPublicOfferingMember" xlink:to="lab_silk_SecondPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9609d42a-c40d-4ec0-b218-5abac34e876e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_26680d4a-2972-47f8-89fd-cebe51277544_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1c79672b-6c5f-45d7-843a-1241039a03c0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_006dfdba-ab75-4aee-bed8-f448661ac8d7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_59e5cdf1-8fce-4e65-9bcd-30fe3a9065be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8bbdcad8-1be8-4caf-9c24-a969d3a504a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_f2f3f7a7-4bdc-492f-9e87-58a182684ade_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72a55270-9e81-4626-847a-740367017fa6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_22da8243-d1f9-41b6-9c79-dac79c665b61_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e7694d7f-da36-4189-9ede-9dcc6a29e8f7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f5a9188c-a34e-4aca-9a1c-67fceb3b997b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne_b61f3566-3085-4cf4-9e94-3405c34ce8cf_terseLabel_en-US" xlink:label="lab_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne_label_en-US" xlink:label="lab_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, Year One</link:label>
    <link:label id="lab_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne_documentation_en-US" xlink:label="lab_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne" xlink:href="silk-20200630.xsd#silk_LesseeOperatingLeaseLiabilityToBePaidYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne" xlink:to="lab_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d877dc7f-c7b3-4d98-976c-2218b2b285c7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8ded6ee0-8eb5-453e-84af-751ac9b05fa7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_StockIssuanceCostsIncurredButNotYetPaid_6b3798d8-fb2d-4336-94eb-392131735223_terseLabel_en-US" xlink:label="lab_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_silk_StockIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_silk_StockIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:href="silk-20200630.xsd#silk_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_silk_StockIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_587f933c-4b7e-4662-a66e-119bee3f95d2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_26166cf0-d64b-4aab-a1a8-f6ac4f6228a5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_caa63eac-54a5-46c8-8e9d-2861f772e9cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_89de6690-182c-456a-9861-d9fba419db24_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c00051eb-9db4-425f-aeb2-3c6935494ee0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8746438c-5f2f-4f6c-a142-19ba7902cc18_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ba0e7526-334f-4bf2-bce5-f8e454c9c5cb_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_72bf2f1f-c948-4423-afa5-9f3aa07251e5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c95e1a73-445b-4d27-812f-ab4eefa3bd79_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_17827bd6-1577-46b4-a69b-2c6fabc8a43c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_9807f658-5589-4f10-82e5-6f2a74f1d5fe_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_021fd0e0-5f33-42ea-909b-1ccfcf8fbb1a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a4782182-e2ee-4c88-b61f-1209cbe1c66c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c441b8b1-da93-4e51-9519-8c7272c657f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_41585592-591c-41be-9f04-b0b3dcfd2d50_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_79a11df9-b419-4dee-9307-7b5393c57054_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LongTermDebtUnpaidInterest_e659320c-9eb2-4aa9-b7d1-40f3ec8455fa_negatedTerseLabel_en-US" xlink:label="lab_silk_LongTermDebtUnpaidInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amount representing interest</link:label>
    <link:label id="lab_silk_LongTermDebtUnpaidInterest_label_en-US" xlink:label="lab_silk_LongTermDebtUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Unpaid Interest</link:label>
    <link:label id="lab_silk_LongTermDebtUnpaidInterest_documentation_en-US" xlink:label="lab_silk_LongTermDebtUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Unpaid Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtUnpaidInterest" xlink:href="silk-20200630.xsd#silk_LongTermDebtUnpaidInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LongTermDebtUnpaidInterest" xlink:to="lab_silk_LongTermDebtUnpaidInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c02fc8fa-2444-485f-9a55-794be4be7f55_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_047721ea-78fe-4476-bf82-626bb320f22a_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LongTermDebtAccretionOfClosingFees_ee5ac378-d977-42fc-b282-4f8b11d163fe_terseLabel_en-US" xlink:label="lab_silk_LongTermDebtAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Accretion of closing fees</link:label>
    <link:label id="lab_silk_LongTermDebtAccretionOfClosingFees_label_en-US" xlink:label="lab_silk_LongTermDebtAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Accretion Of Closing Fees</link:label>
    <link:label id="lab_silk_LongTermDebtAccretionOfClosingFees_documentation_en-US" xlink:label="lab_silk_LongTermDebtAccretionOfClosingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Accretion Of Closing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtAccretionOfClosingFees" xlink:href="silk-20200630.xsd#silk_LongTermDebtAccretionOfClosingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LongTermDebtAccretionOfClosingFees" xlink:to="lab_silk_LongTermDebtAccretionOfClosingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51fd221b-00be-4660-9b53-3e5fc1c6ba03_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1f284dda-21b0-4bbd-9f9e-10a78eeb34b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fc655330-82d0-428f-830d-1c2114e56266_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_22602048-12a5-45e9-ae69-a2b83f8a0918_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4f5b9e7d-6485-4fa6-8182-880be280ff50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_5312e2f7-aabd-4efa-9966-6a86ca42abb4_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cb87ccd1-5b0e-40cd-af53-95f6decf59cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_866dc624-fda3-4bcb-a833-94c2e67d0ba0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8af185a9-988f-4174-9c91-750d2aace520_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8e7acdfd-8cd4-4e74-bec7-e64f872f040d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e51c6433-7dd5-4d9d-abfd-6071dfb7bfd5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6c64f2a0-256a-4562-97c3-a5b78d734d99_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adbf979d-17e7-42d0-8345-63ff8f06f76f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d41a5d55-4fea-4c7b-8c3f-67d4b6a5be7b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f6f8ccf-1236-4be8-88de-839ae2968b4a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ab57d24b-605f-4aa3-a90b-8101574ab978_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0bbe3457-908f-4ab5-ab07-2441deeb35c3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_707905a3-0e70-469b-a5d3-8c0cfecda115_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8b5be82b-550f-4170-8f69-99694e85f424_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_35e7be5f-f6f9-45b9-8ae9-6bcbf39633a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_906168a8-5ed9-4483-948e-8dff284f9a14_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57cc08a8-2f8a-4ece-8f6c-b075f09b1947_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_13f6c5cd-6a7f-456e-84b6-0c1545be0a80_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_AccruedTravelExpensesCurrent_d1fd3dea-d6ab-4f7a-b364-bc1c9257dac5_terseLabel_en-US" xlink:label="lab_silk_AccruedTravelExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued travel expenses</link:label>
    <link:label id="lab_silk_AccruedTravelExpensesCurrent_label_en-US" xlink:label="lab_silk_AccruedTravelExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Travel Expenses, Current</link:label>
    <link:label id="lab_silk_AccruedTravelExpensesCurrent_documentation_en-US" xlink:label="lab_silk_AccruedTravelExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Travel Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedTravelExpensesCurrent" xlink:href="silk-20200630.xsd#silk_AccruedTravelExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_AccruedTravelExpensesCurrent" xlink:to="lab_silk_AccruedTravelExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_43bd2041-99f5-4bb7-bd14-d7408720f078_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_56c671b9-38b7-470d-ae3a-51e436e36347_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7fa45f91-8616-4359-a9d1-82ec346e3828_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ad4b4b7e-1984-45af-9d2f-027b3778262e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of stock issued in ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_de55fcb7-575d-4804-bf1a-84a5742dc97d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense Relating to Stock Options to Employees and Nonemployees</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fe8a1aae-a83b-4841-b789-8a126eb4b938_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a1333829-f733-4494-9b69-f29fe8ce7dca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_b6c55e41-3e6c-42a7-bdba-d6afdb996fff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer discretionary contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fca6d302-5c77-4d2f-a2e3-2f8b3dbcb211_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_74038272-8903-4110-8adc-aba64f2a96b5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_87ca0281-247e-46fe-8a34-5e77a8fb552d_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7fd09f73-dd94-4063-a1ec-7f06ca6596c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e75a3777-b3a9-4373-bc7d-febf2c44478b_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e660cf94-1557-4b41-83ae-b434976e46ae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0e709f9a-50d7-4a47-890f-33dd226b0304_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_d8847944-e798-4dfe-99c4-fb013b92d200_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in provision for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionMember_c08f309a-58c3-4919-b56a-097d8de25bcd_terseLabel_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISO and NSO</link:label>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionMember_label_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and Nonqualified Stock Option [Member]</link:label>
    <link:label id="lab_silk_IncentiveandNonqualifiedStockOptionMember_documentation_en-US" xlink:label="lab_silk_IncentiveandNonqualifiedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive and Nonqualified Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionMember" xlink:href="silk-20200630.xsd#silk_IncentiveandNonqualifiedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_IncentiveandNonqualifiedStockOptionMember" xlink:to="lab_silk_IncentiveandNonqualifiedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9519d0a4-32dd-4da7-983e-ad41b599c83e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_07c75034-abbb-4dd2-9ce6-dc4938584e31_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e2139451-a72a-4db3-b88d-5cc698b021b1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_94a8b467-a0a7-4ab1-9861-b5595048ac07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_77a60f79-7c7f-48ec-96a6-2c39592e6260_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_LongTermInvestmentsMember_e4e2add4-6811-4af4-8396-44482780afe0_terseLabel_en-US" xlink:label="lab_silk_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_silk_LongTermInvestmentsMember_label_en-US" xlink:label="lab_silk_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments [Member]</link:label>
    <link:label id="lab_silk_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_silk_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermInvestmentsMember" xlink:href="silk-20200630.xsd#silk_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_LongTermInvestmentsMember" xlink:to="lab_silk_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c8aaa999-c0a1-408c-94f6-ca55beccbc94_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1f9b8efc-fb9f-4c8c-b2e3-66911b303870_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8ab3f9f4-c069-4551-b46e-088145a9c360_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_16599a5a-18ba-415f-803f-58ba27dd9f31_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a42ecf24-0ee1-41a4-b19b-55900cd84a6f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Preparation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance_39ddaaa4-6f65-41c9-a203-4ad7ea0b5c83_terseLabel_en-US" xlink:label="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance_label_en-US" xlink:label="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Available For Future Issuance</link:label>
    <link:label id="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Available For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:href="silk-20200630.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:to="lab_silk_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fcb52ce4-b4e9-4fe8-a3c1-2f527a294cca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_30bc044c-4341-44a4-89f9-4095435a55ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2eec5a97-10a0-4505-a366-1db03140e8d7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c47abc3b-c2bd-4961-b828-0beb7c8dcc4b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0309ad57-da73-4c27-a25c-bdcefd6d5238_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c4120a04-c404-42ed-8a47-0d6d40cdbbc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a415d334-29b8-469d-9e09-1ad4370acf2e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Formation and Business of the Company</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd208c94-ca5d-4902-8c80-095795d4015a_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c38b3453-c4aa-4faf-8004-84fff9a30355_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a103253e-131b-4f4a-8516-99ea9e849987_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0f68723c-c6d5-4686-b799-2616f50527c1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_09313f16-894c-4c81-89c6-73481374c3db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7c5d69f-eb4f-4713-bac3-5f0e0f149108_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d033f03c-eb43-432a-9452-6ee1165fa185_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember_9152ba54-ae72-446d-aeb8-c41a44ebd99f_verboseLabel_en-US" xlink:label="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember_label_en-US" xlink:label="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember_documentation_en-US" xlink:label="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:href="silk-20200630.xsd#silk_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:to="lab_silk_RedeemableConvertiblePreferredStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_bc5c582d-7b0d-461c-abc0-310b7245765d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Maturities Under the Term Loan Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4f26e6f7-62b2-4670-aace-800e79d5d22d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_9d6ff496-3f1b-46d1-b5dc-f3f37c0bb7a3_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d6bb0c7a-baeb-4f62-aa1e-bc8153d9ae32_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a0ea2f2d-ab3a-4b4a-8ade-9bb742f1daa2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_ce8ef5a0-d49e-443f-a140-8bd9e16d5855_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_31855dfe-7a9b-4a21-98ca-1cb049e1cc71_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_fda25dea-59ba-4f9c-86f1-0ad4872a73c5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_93b67e71-0f58-4ade-b3de-97b04abbf3c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_781f9ed4-7d22-4cf0-896e-9a840fb864c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ab39f7ab-c5ce-49fd-a9ef-0e3261baa3be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt drawn down</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_137d3095-5ac9-4740-835d-118f31844b33_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_871b5c1a-9663-4d50-ade4-1c6ba2c23de3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_a4a4a1c8-129f-4341-9373-9ed47777365d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice_fd05f0bc-a255-4d7c-bb7a-141ee99db496_terseLabel_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise threshold as a percentage of fair value of shares</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice_label_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Threshold As A Percentage Of Share Price</link:label>
    <link:label id="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice_documentation_en-US" xlink:label="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Threshold As A Percentage Of Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" xlink:href="silk-20200630.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" xlink:to="lab_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d68df12b-bed2-42ad-89c5-8c6acc6735e4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5723ae40-b240-41d0-9a27-cc1b7110b846_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_CommonStockVotePerShare_8703804b-0a02-4313-a430-851e88b9c7c1_terseLabel_en-US" xlink:label="lab_silk_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes entitled per share of common stock</link:label>
    <link:label id="lab_silk_CommonStockVotePerShare_label_en-US" xlink:label="lab_silk_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:label id="lab_silk_CommonStockVotePerShare_documentation_en-US" xlink:label="lab_silk_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockVotePerShare" xlink:href="silk-20200630.xsd#silk_CommonStockVotePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_CommonStockVotePerShare" xlink:to="lab_silk_CommonStockVotePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f7972f1f-7103-4211-8111-06de9d71a86f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b11eea9d-bf92-4470-bc46-4b7014fd33a9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0bf63366-d6e0-4855-81ef-9be072b9b99b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5288849c-e62e-4c9b-9b2d-1c48698fb77f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d5d2a005-37da-4df5-8b20-3d4c72c2b041_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_DebtInstrumentInterestRateFacilityFee_d11781a3-038f-47de-bf90-57f3d52305b5_terseLabel_en-US" xlink:label="lab_silk_DebtInstrumentInterestRateFacilityFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRateFacilityFee_label_en-US" xlink:label="lab_silk_DebtInstrumentInterestRateFacilityFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Facility Fee</link:label>
    <link:label id="lab_silk_DebtInstrumentInterestRateFacilityFee_documentation_en-US" xlink:label="lab_silk_DebtInstrumentInterestRateFacilityFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Facility Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRateFacilityFee" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRateFacilityFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_DebtInstrumentInterestRateFacilityFee" xlink:to="lab_silk_DebtInstrumentInterestRateFacilityFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03d5cb0f-4a18-45db-ad71-e07375900f26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cf603c27-57ea-4efc-b9e9-fbd59468e107_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_8dd9ef93-6dac-4dd0-ae79-0c538bfa1ac2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bd1cd3f3-8385-44d6-95bf-00f9f01f1c66_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), awards outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2664d93b-91c4-466e-806a-08b097981c3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_519e37d9-ac85-44ee-a62c-428a4e50496a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b358ee84-35b4-411d-aca3-ef9c6232d51e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0650107b-c162-4c16-9f14-605307288835_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds/notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9bcea9cf-85ae-41fb-98e0-abd1395bb7c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, vested and exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember_63abf17b-6d15-4ceb-bf7a-9cd7e0bf47b5_terseLabel_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Existing Shareholders</link:label>
    <link:label id="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember_label_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Existing Shareholders [Member]</link:label>
    <link:label id="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember_documentation_en-US" xlink:label="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Existing Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingSharesFromExistingShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:to="lab_silk_PublicStockOfferingSharesFromExistingShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df386f0d-d0d7-4da5-934e-84a5d49f70e6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_silk_TwoThousandNineteenStockOptionPlanMember_bc4128f7-4138-4b6d-b5ed-24a92219bdb3_terseLabel_en-US" xlink:label="lab_silk_TwoThousandNineteenStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Option Plan</link:label>
    <link:label id="lab_silk_TwoThousandNineteenStockOptionPlanMember_label_en-US" xlink:label="lab_silk_TwoThousandNineteenStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Stock Option Plan [Member]</link:label>
    <link:label id="lab_silk_TwoThousandNineteenStockOptionPlanMember_documentation_en-US" xlink:label="lab_silk_TwoThousandNineteenStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember" xlink:href="silk-20200630.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_silk_TwoThousandNineteenStockOptionPlanMember" xlink:to="lab_silk_TwoThousandNineteenStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f6bd7e37-a974-4759-9d03-664cf469edeb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_04c1ff61-b4f8-4e45-a445-17acf98cfe78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a948d40a-876d-4f81-a147-d48629a5cd7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8a40fec7-9676-4d63-8a37-e27d6e407859_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_682945c0-0b30-4796-b604-7458cff8b6f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8bef17a0-4279-420b-986d-7ad9a7c242b6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_917137b1-828b-4212-a21b-9a36f5e93847_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_fad12a56-e3df-4c56-b98e-4e887d9c32dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>silk-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9bdc0587-bada-46ac-a409-f4831c8e244f,g:1209e878-563a-4edf-b13c-0faadaf6133a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://silkroadmed.com/role/CoverPage" xlink:type="simple" xlink:href="silk-20200630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_84e6156f-c657-4c26-91eb-3eb4929dafa6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_DocumentType_84e6156f-c657-4c26-91eb-3eb4929dafa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_cf2660d9-5393-46c2-8d4a-dbf0b9b69e9f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_DocumentQuarterlyReport_cf2660d9-5393-46c2-8d4a-dbf0b9b69e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1e9e9465-cbd9-42a4-b235-0c1ccc249b25" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_DocumentPeriodEndDate_1e9e9465-cbd9-42a4-b235-0c1ccc249b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2d11d38c-30a2-4229-b93c-fefef03569f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_DocumentTransitionReport_2d11d38c-30a2-4229-b93c-fefef03569f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8a8ff21d-ba00-484d-8145-29ad82c61a26" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityFileNumber_8a8ff21d-ba00-484d-8145-29ad82c61a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_64871cb6-3dfd-42b9-b5ea-ca8d6c08e801" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityRegistrantName_64871cb6-3dfd-42b9-b5ea-ca8d6c08e801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3612079e-fb79-4c6d-a1f2-46d4990041fa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3612079e-fb79-4c6d-a1f2-46d4990041fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ae8ee0ae-4f60-4536-9f0a-26a02b541d8e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityTaxIdentificationNumber_ae8ee0ae-4f60-4536-9f0a-26a02b541d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_91d11ebd-1f65-4c51-a24f-8b391398a6a9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityAddressAddressLine1_91d11ebd-1f65-4c51-a24f-8b391398a6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5bd2c5bc-c9d5-4f3e-9189-9e0189a415de" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityAddressCityOrTown_5bd2c5bc-c9d5-4f3e-9189-9e0189a415de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e63e0d96-1fc8-4876-9ba8-9120d34617e2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityAddressStateOrProvince_e63e0d96-1fc8-4876-9ba8-9120d34617e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_97d35fe2-5a9f-46b0-8796-4dd9a4646522" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityAddressPostalZipCode_97d35fe2-5a9f-46b0-8796-4dd9a4646522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5073f4ec-5f3d-41d6-a4e1-88e100f74ba8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_CityAreaCode_5073f4ec-5f3d-41d6-a4e1-88e100f74ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_78ca4c65-135c-408d-a60b-95cb94f28280" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_LocalPhoneNumber_78ca4c65-135c-408d-a60b-95cb94f28280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f4901294-71d0-4f10-858b-b201bf96d93b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityCurrentReportingStatus_f4901294-71d0-4f10-858b-b201bf96d93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cddb8002-bee7-4477-8e47-e0ad185caa70" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityInteractiveDataCurrent_cddb8002-bee7-4477-8e47-e0ad185caa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6767783f-819a-453a-aba0-a84c5079efb4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityFilerCategory_6767783f-819a-453a-aba0-a84c5079efb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a8cd24e3-2e5d-417c-9576-62b460a9aa65" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntitySmallBusiness_a8cd24e3-2e5d-417c-9576-62b460a9aa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2b76054f-f697-4126-8e2d-310c9e0532dd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityEmergingGrowthCompany_2b76054f-f697-4126-8e2d-310c9e0532dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ceba1234-b509-4bdc-ab31-dd69a701951e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityShellCompany_ceba1234-b509-4bdc-ab31-dd69a701951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ff572c77-fe21-478a-aa2a-8ca4cd3cae15" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_Security12bTitle_ff572c77-fe21-478a-aa2a-8ca4cd3cae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5b228846-d135-4a0c-8818-cfb026192e5e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_TradingSymbol_5b228846-d135-4a0c-8818-cfb026192e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6451d091-630a-4c21-8a04-e2fe2f30ccdf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_SecurityExchangeName_6451d091-630a-4c21-8a04-e2fe2f30ccdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c28e0aa1-b335-4660-b67f-dff562147684" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c28e0aa1-b335-4660-b67f-dff562147684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_791d28f7-412e-449b-a84a-1f4828537fcc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_EntityCentralIndexKey_791d28f7-412e-449b-a84a-1f4828537fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9c1c416c-38ba-4016-8e89-196e7748ba6f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_CurrentFiscalYearEndDate_9c1c416c-38ba-4016-8e89-196e7748ba6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_dad5f0fb-99d5-407b-a12a-d510dd711af4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_DocumentFiscalYearFocus_dad5f0fb-99d5-407b-a12a-d510dd711af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_32c771fd-0ee7-425f-95d7-bc7fba60927e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_DocumentFiscalPeriodFocus_32c771fd-0ee7-425f-95d7-bc7fba60927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4c5d60e5-7157-4799-a905-623a1c538f89" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_51685b5e-4956-4ad6-a484-f96fac5f9414" xlink:to="loc_dei_AmendmentFlag_4c5d60e5-7157-4799-a905-623a1c538f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ba3e0e18-1f0b-4665-bee3-04e7f1755b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_440fd9cd-b190-4ac1-9954-454a9734b992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ba3e0e18-1f0b-4665-bee3-04e7f1755b92" xlink:to="loc_us-gaap_AssetsAbstract_440fd9cd-b190-4ac1-9954-454a9734b992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3bbe36a6-74b0-4f75-a4cc-db2a2fa31dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_440fd9cd-b190-4ac1-9954-454a9734b992" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3bbe36a6-74b0-4f75-a4cc-db2a2fa31dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22750e48-a22b-4a77-9eab-fb15fea7887d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bbe36a6-74b0-4f75-a4cc-db2a2fa31dfb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22750e48-a22b-4a77-9eab-fb15fea7887d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d07d0fae-5728-4771-9de5-111d18c65410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bbe36a6-74b0-4f75-a4cc-db2a2fa31dfb" xlink:to="loc_us-gaap_ShortTermInvestments_d07d0fae-5728-4771-9de5-111d18c65410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_927d66d2-eb49-45d5-927e-98c620091c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bbe36a6-74b0-4f75-a4cc-db2a2fa31dfb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_927d66d2-eb49-45d5-927e-98c620091c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5de8c4c4-b25e-44b6-ba4e-743b8042013b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bbe36a6-74b0-4f75-a4cc-db2a2fa31dfb" xlink:to="loc_us-gaap_InventoryNet_5de8c4c4-b25e-44b6-ba4e-743b8042013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8ac0c935-2c1d-497d-a28c-744685664a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bbe36a6-74b0-4f75-a4cc-db2a2fa31dfb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8ac0c935-2c1d-497d-a28c-744685664a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4c911e71-97d6-4c74-b592-fd930a9fbc45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bbe36a6-74b0-4f75-a4cc-db2a2fa31dfb" xlink:to="loc_us-gaap_AssetsCurrent_4c911e71-97d6-4c74-b592-fd930a9fbc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_de51a4f8-6754-4586-b1fb-c6ccac96083b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_440fd9cd-b190-4ac1-9954-454a9734b992" xlink:to="loc_us-gaap_LongTermInvestments_de51a4f8-6754-4586-b1fb-c6ccac96083b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0f2b8cad-c1c4-4131-9c94-0255bf291cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_440fd9cd-b190-4ac1-9954-454a9734b992" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0f2b8cad-c1c4-4131-9c94-0255bf291cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_466e551e-dd35-443c-9ee2-05a4a9ebbb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_440fd9cd-b190-4ac1-9954-454a9734b992" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_466e551e-dd35-443c-9ee2-05a4a9ebbb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_efab626d-370b-44cb-a56e-ad4d7da03c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_440fd9cd-b190-4ac1-9954-454a9734b992" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_efab626d-370b-44cb-a56e-ad4d7da03c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_db1e61a5-cf28-4a25-b8d0-fb0dcfe93964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_440fd9cd-b190-4ac1-9954-454a9734b992" xlink:to="loc_us-gaap_Assets_db1e61a5-cf28-4a25-b8d0-fb0dcfe93964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ba3e0e18-1f0b-4665-bee3-04e7f1755b92" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_558130d7-7726-433a-9084-b4dc5ed59751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_558130d7-7726-433a-9084-b4dc5ed59751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ed13b83a-a686-41a7-ab09-94c7c9d7bc8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558130d7-7726-433a-9084-b4dc5ed59751" xlink:to="loc_us-gaap_AccountsPayableCurrent_ed13b83a-a686-41a7-ab09-94c7c9d7bc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8467bb52-d45c-414e-a6ff-47b4b2a2e53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558130d7-7726-433a-9084-b4dc5ed59751" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8467bb52-d45c-414e-a6ff-47b4b2a2e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e904572f-7544-4b72-a9c3-b65966bad85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558130d7-7726-433a-9084-b4dc5ed59751" xlink:to="loc_us-gaap_LiabilitiesCurrent_e904572f-7544-4b72-a9c3-b65966bad85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1ee628a3-e792-457f-93c2-d1043551c3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1ee628a3-e792-457f-93c2-d1043551c3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b9c2728e-d3bd-4159-8a47-f62ec77bdb76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b9c2728e-d3bd-4159-8a47-f62ec77bdb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af74082b-b373-44a9-84f7-af868ba137e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:to="loc_us-gaap_Liabilities_af74082b-b373-44a9-84f7-af868ba137e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f03a63ae-797e-46c9-ad39-f930fa417ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f03a63ae-797e-46c9-ad39-f930fa417ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5d42e2e9-a000-47f1-b0d3-eec77d7f81af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5d42e2e9-a000-47f1-b0d3-eec77d7f81af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockAbstract_fedb8b04-d45d-48be-817c-9ffd5146c981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5d42e2e9-a000-47f1-b0d3-eec77d7f81af" xlink:to="loc_us-gaap_DividendsPreferredStockAbstract_fedb8b04-d45d-48be-817c-9ffd5146c981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ddad0c57-f898-46d9-89fb-2f77676d9833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_fedb8b04-d45d-48be-817c-9ffd5146c981" xlink:to="loc_us-gaap_PreferredStockValue_ddad0c57-f898-46d9-89fb-2f77676d9833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockAbstract_2fb4b616-8a08-4940-b39c-7860a30ccd72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5d42e2e9-a000-47f1-b0d3-eec77d7f81af" xlink:to="loc_us-gaap_DividendsCommonStockAbstract_2fb4b616-8a08-4940-b39c-7860a30ccd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e99128b0-41b5-4904-87e3-ee7e747203f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsCommonStockAbstract_2fb4b616-8a08-4940-b39c-7860a30ccd72" xlink:to="loc_us-gaap_CommonStockValue_e99128b0-41b5-4904-87e3-ee7e747203f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d1a0e4e8-2db4-43c8-8739-51282bcf6d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5d42e2e9-a000-47f1-b0d3-eec77d7f81af" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d1a0e4e8-2db4-43c8-8739-51282bcf6d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0761f67-9f89-4f95-9b4e-49d67b925b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5d42e2e9-a000-47f1-b0d3-eec77d7f81af" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0761f67-9f89-4f95-9b4e-49d67b925b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dbb1b012-6d53-407b-98f1-57c735d094c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5d42e2e9-a000-47f1-b0d3-eec77d7f81af" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dbb1b012-6d53-407b-98f1-57c735d094c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa94897a-4056-4510-8492-bb9e917ba653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5d42e2e9-a000-47f1-b0d3-eec77d7f81af" xlink:to="loc_us-gaap_StockholdersEquity_fa94897a-4056-4510-8492-bb9e917ba653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e93f27b4-7286-4a21-b8e5-115180bd7723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_66f07104-657b-4551-8382-ae3270b1c80b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e93f27b4-7286-4a21-b8e5-115180bd7723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94d962b3-2820-476b-a3ca-6c7fcd99cec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94d962b3-2820-476b-a3ca-6c7fcd99cec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e330bf62-dcb3-4ebc-97f5-ccc77397b835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e330bf62-dcb3-4ebc-97f5-ccc77397b835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9a868d15-7a1d-4100-b1ad-254b0951e23e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9a868d15-7a1d-4100-b1ad-254b0951e23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_999b5359-a4e3-4fa3-967b-77100dff9fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_999b5359-a4e3-4fa3-967b-77100dff9fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18a4c47f-0eaa-45d2-bc84-13bf7ffb19d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18a4c47f-0eaa-45d2-bc84-13bf7ffb19d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_07ff38ef-01bf-4d98-bb4f-97325fe7e259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_07ff38ef-01bf-4d98-bb4f-97325fe7e259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bc45ee2d-9055-4da6-9ad3-caccfe2d3b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:to="loc_us-gaap_CommonStockSharesIssued_bc45ee2d-9055-4da6-9ad3-caccfe2d3b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d5fac23f-c386-4609-988b-7a340f1febcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_790f9b84-9b5c-446a-9ea7-8eebff9651cc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d5fac23f-c386-4609-988b-7a340f1febcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_807b922d-ecf4-4e68-b2a6-38dac012459e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_807b922d-ecf4-4e68-b2a6-38dac012459e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9d30f97c-24c3-49c7-b8aa-0c51a8738aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9d30f97c-24c3-49c7-b8aa-0c51a8738aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4673ef07-3fbc-4f64-ab22-4f162ef46c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_GrossProfit_4673ef07-3fbc-4f64-ab22-4f162ef46c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_308cb305-eec7-482a-ba94-77444ded416c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_308cb305-eec7-482a-ba94-77444ded416c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fed6152d-3e49-4ed2-86f8-e841c94cbcb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_308cb305-eec7-482a-ba94-77444ded416c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fed6152d-3e49-4ed2-86f8-e841c94cbcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8de328de-6108-4300-b7bc-6637abbb9435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_308cb305-eec7-482a-ba94-77444ded416c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8de328de-6108-4300-b7bc-6637abbb9435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6b811fc0-e739-4773-9dd0-64782d13946e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_308cb305-eec7-482a-ba94-77444ded416c" xlink:to="loc_us-gaap_OperatingExpenses_6b811fc0-e739-4773-9dd0-64782d13946e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_08cf4bfb-13ad-438b-9fd3-a7e0aa73746f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_OperatingIncomeLoss_08cf4bfb-13ad-438b-9fd3-a7e0aa73746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d5f0ea5a-5b8f-4428-8f23-3f87a722ee26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d5f0ea5a-5b8f-4428-8f23-3f87a722ee26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_29b3cef3-aa90-4d12-81fa-ed69fe5638d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_InterestExpense_29b3cef3-aa90-4d12-81fa-ed69fe5638d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_af112807-4dbd-45a8-ba64-cf32e929ab0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_af112807-4dbd-45a8-ba64-cf32e929ab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1bbc9171-a368-4171-9872-697a0dc552d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_NetIncomeLoss_1bbc9171-a368-4171-9872-697a0dc552d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f91ccb9c-2032-4699-8a5c-75f1d9fe06ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f91ccb9c-2032-4699-8a5c-75f1d9fe06ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_41cfe886-a6fe-4b91-8209-27d152fb72f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f91ccb9c-2032-4699-8a5c-75f1d9fe06ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_41cfe886-a6fe-4b91-8209-27d152fb72f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88dec647-a7fb-4f62-982a-e6aba2238ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f91ccb9c-2032-4699-8a5c-75f1d9fe06ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88dec647-a7fb-4f62-982a-e6aba2238ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent_ae149b30-c46c-4264-a5af-8b774ff59a5a" xlink:href="silk-20200630.xsd#silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent_ae149b30-c46c-4264-a5af-8b774ff59a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_62bff2e0-7d58-4b67-a660-ab426e8081b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_62bff2e0-7d58-4b67-a660-ab426e8081b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_dbf33a7a-f388-4c65-85c3-c16335102cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3b084133-1dd9-4ad1-941c-43f90cf48c9d" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_dbf33a7a-f388-4c65-85c3-c16335102cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_520a7527-752b-4ef8-8aa4-b4c0e6a66518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_520a7527-752b-4ef8-8aa4-b4c0e6a66518" xlink:to="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5fc02a8d-6aec-4cee-bf21-759730569227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5fc02a8d-6aec-4cee-bf21-759730569227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fc02a8d-6aec-4cee-bf21-759730569227" xlink:to="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ffd442ee-6d76-457c-ac82-c950a7c14749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:to="loc_us-gaap_CommonStockMember_ffd442ee-6d76-457c-ac82-c950a7c14749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0a366413-95e8-4da6-9b28-8656ecac9f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0a366413-95e8-4da6-9b28-8656ecac9f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8efe7579-40c9-41d9-af92-475c785dbd9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:to="loc_us-gaap_RetainedEarningsMember_8efe7579-40c9-41d9-af92-475c785dbd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d22df29a-75cd-4522-983a-b5116558ab92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56e91c8a-c3b9-4814-aa3b-92021c70e311" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d22df29a-75cd-4522-983a-b5116558ab92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_00079cc9-f2fd-4fef-a54e-1b01555c3ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_00079cc9-f2fd-4fef-a54e-1b01555c3ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3b4f2c4c-38c2-41e1-bb2e-79a541a2c0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_00079cc9-f2fd-4fef-a54e-1b01555c3ccc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3b4f2c4c-38c2-41e1-bb2e-79a541a2c0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_5facf079-f210-414c-9cb4-2d7293f7e391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3b4f2c4c-38c2-41e1-bb2e-79a541a2c0b4" xlink:to="loc_us-gaap_IPOMember_5facf079-f210-414c-9cb4-2d7293f7e391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3b9520c7-7176-4455-82a5-99d27382e849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5e0b7a5a-c164-4ace-8ab5-8705234945f0" xlink:to="loc_us-gaap_StatementLineItems_3b9520c7-7176-4455-82a5-99d27382e849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b9520c7-7176-4455-82a5-99d27382e849" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4c7f0e02-f829-4c01-a386-ca9cea223c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_4c7f0e02-f829-4c01-a386-ca9cea223c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a2d1acbc-8edc-40ad-8c6c-abbbfc6ef378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a2d1acbc-8edc-40ad-8c6c-abbbfc6ef378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_97f4f547-5523-4b40-9762-859f717e185e" xlink:href="silk-20200630.xsd#silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_97f4f547-5523-4b40-9762-859f717e185e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_a5febff6-9079-4b0a-871c-d3fee2eaa8fd" xlink:href="silk-20200630.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares_a5febff6-9079-4b0a-871c-d3fee2eaa8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_76de8540-1874-4fc3-8730-38f90164e03b" xlink:href="silk-20200630.xsd#silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue_76de8540-1874-4fc3-8730-38f90164e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_980b5c4f-1154-4ffc-82e3-b2ab9ba139c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_980b5c4f-1154-4ffc-82e3-b2ab9ba139c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_83ce478c-b79e-4542-9ae3-c55b6966c77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_83ce478c-b79e-4542-9ae3-c55b6966c77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_04d02796-b785-4a16-a9b3-40f279ba908d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5864cadd-dfb3-4c2c-883e-50cbf34b684b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_04d02796-b785-4a16-a9b3-40f279ba908d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b9520c7-7176-4455-82a5-99d27382e849" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_83cba244-dee6-4cc2-bab4-e5356566e3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_SharesOutstanding_83cba244-dee6-4cc2-bab4-e5356566e3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7bea39fb-14ef-4844-9cbf-670c5b479f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockholdersEquity_7bea39fb-14ef-4844-9cbf-670c5b479f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f6f6863c-bcd5-47ff-ae3e-f4cd2b7b6aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f6f6863c-bcd5-47ff-ae3e-f4cd2b7b6aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2efc1d33-ffa6-4fab-8088-1deea3b3441b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2efc1d33-ffa6-4fab-8088-1deea3b3441b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d35eed1f-a9b0-4112-9938-a038c25a5051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d35eed1f-a9b0-4112-9938-a038c25a5051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_880b9dc9-fea8-4011-9c59-f8be4cb463c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_880b9dc9-fea8-4011-9c59-f8be4cb463c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_492c54d4-6d13-4aef-a773-40d750c2b903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_492c54d4-6d13-4aef-a773-40d750c2b903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8657d862-30b8-48f3-9b60-b722d613f1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8657d862-30b8-48f3-9b60-b722d613f1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ba5ba8fe-4980-4b87-81a9-d7149e65ddd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ba5ba8fe-4980-4b87-81a9-d7149e65ddd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_666fd80f-7e4c-4a95-bd8c-ae051381a689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_666fd80f-7e4c-4a95-bd8c-ae051381a689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7d740cf-5127-46cf-be43-347ec1cf1764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7d740cf-5127-46cf-be43-347ec1cf1764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e9c08992-a054-47bb-9c74-1b7b58ac7dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_ProfitLoss_e9c08992-a054-47bb-9c74-1b7b58ac7dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7c258cd3-3b48-437f-8440-519218377002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7c258cd3-3b48-437f-8440-519218377002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d2b43062-1f93-4aee-84bc-5032dc878e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_d2b43062-1f93-4aee-84bc-5032dc878e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_eb820b32-5642-4a20-a19c-93668464f3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_SharesOutstanding_eb820b32-5642-4a20-a19c-93668464f3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b8c42c0b-4385-43cf-b5be-66ff47e87bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84755318-6027-4688-b3ba-2e64213b548c" xlink:to="loc_us-gaap_StockholdersEquity_b8c42c0b-4385-43cf-b5be-66ff47e87bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4392ddb5-5753-4acf-9394-7959cef082ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a45e19a5-c25e-47d0-9924-2269803a1a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4392ddb5-5753-4acf-9394-7959cef082ca" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a45e19a5-c25e-47d0-9924-2269803a1a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="silk-20200630.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8afd37cb-f71b-4f7d-ad80-759e8f838715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7b485bc8-8a33-43b7-b8ea-6b830651b2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8afd37cb-f71b-4f7d-ad80-759e8f838715" xlink:to="loc_us-gaap_StatementTable_7b485bc8-8a33-43b7-b8ea-6b830651b2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f3908382-d9dd-447a-9887-11ef822afa09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b485bc8-8a33-43b7-b8ea-6b830651b2a1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f3908382-d9dd-447a-9887-11ef822afa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_02ccc6e0-4656-402f-96d5-1a1330405792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f3908382-d9dd-447a-9887-11ef822afa09" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_02ccc6e0-4656-402f-96d5-1a1330405792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_3510eaed-c19a-4f97-a550-67a79feead34" xlink:href="silk-20200630.xsd#silk_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_02ccc6e0-4656-402f-96d5-1a1330405792" xlink:to="loc_silk_RedeemableConvertiblePreferredStockWarrantsMember_3510eaed-c19a-4f97-a550-67a79feead34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_746873a2-e0aa-4a4a-a436-880b41ed9fb9" xlink:href="silk-20200630.xsd#silk_CommonStockWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_02ccc6e0-4656-402f-96d5-1a1330405792" xlink:to="loc_silk_CommonStockWarrantMember_746873a2-e0aa-4a4a-a436-880b41ed9fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b485bc8-8a33-43b7-b8ea-6b830651b2a1" xlink:to="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_49b11574-ec1a-4c55-a862-44335b5f8669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:to="loc_us-gaap_ProfitLoss_49b11574-ec1a-4c55-a862-44335b5f8669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2fbf342f-a602-4080-a81f-c69d3d0b7045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2fbf342f-a602-4080-a81f-c69d3d0b7045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9abb500f-98ec-49b8-973f-26ae91d7432e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_ShareBasedCompensation_9abb500f-98ec-49b8-973f-26ae91d7432e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_ba449b03-1b11-4a6a-88bf-725329512e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_ba449b03-1b11-4a6a-88bf-725329512e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5c641d49-7f85-49ef-99b4-80cac6a9dbff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5c641d49-7f85-49ef-99b4-80cac6a9dbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1bcf7fe4-f43c-4481-9cd3-b759d80ae848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1bcf7fe4-f43c-4481-9cd3-b759d80ae848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_OperatingLeaseRightOfUseAssetAmortization_f9d0bf04-a9e5-4ad2-897d-13a5dfb10c39" xlink:href="silk-20200630.xsd#silk_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_silk_OperatingLeaseRightOfUseAssetAmortization_f9d0bf04-a9e5-4ad2-897d-13a5dfb10c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_8693e723-74db-412b-bb48-e24ac3e7adac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_PaidInKindInterest_8693e723-74db-412b-bb48-e24ac3e7adac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_bde54571-4775-4c21-836d-43da184612d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_bde54571-4775-4c21-836d-43da184612d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c82465f0-ab6d-406a-9f51-8eacea9a12a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c82465f0-ab6d-406a-9f51-8eacea9a12a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d60516f5-5b3e-4093-b384-eb32a67a7b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79d1c2e3-5ecb-48a7-827f-89f9811071cf" xlink:to="loc_us-gaap_InventoryWriteDown_d60516f5-5b3e-4093-b384-eb32a67a7b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9277075b-6140-4574-a88b-e8a44fe2f636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9277075b-6140-4574-a88b-e8a44fe2f636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_206e6477-dae2-4a65-8140-c17828ab163a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_206e6477-dae2-4a65-8140-c17828ab163a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a816159-d1f3-45f2-9def-efb068ede7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a816159-d1f3-45f2-9def-efb068ede7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e61740f1-6f08-4567-b5cf-cf528fab4df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e61740f1-6f08-4567-b5cf-cf528fab4df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_372b2280-cc32-4cd0-a9bb-ea9133af4cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_372b2280-cc32-4cd0-a9bb-ea9133af4cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_51eea56f-0b7d-4523-a78c-433b5264020b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_51eea56f-0b7d-4523-a78c-433b5264020b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3864c651-af44-48ac-a762-dc6f362667dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e06b035f-13de-4c3b-9b18-1486104f4627" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3864c651-af44-48ac-a762-dc6f362667dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64d801b0-d9d5-4c26-acc2-a2ed69d63d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33719897-d121-44da-b5fd-68ae20949607" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64d801b0-d9d5-4c26-acc2-a2ed69d63d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84cea608-d1a5-44b8-a007-3f2ae1f590d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_84cea608-d1a5-44b8-a007-3f2ae1f590d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_9097f72c-ab19-4da4-9c6e-9cfd708ecc32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_9097f72c-ab19-4da4-9c6e-9cfd708ecc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_ff0efea2-9c88-4997-80c3-8573efc79f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments_ff0efea2-9c88-4997-80c3-8573efc79f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d4c4a0fe-3176-4916-9c49-fe5532aaf6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_45a42f4b-94b5-43c3-b98d-76eb85bb1655" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d4c4a0fe-3176-4916-9c49-fe5532aaf6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c02f77b8-524f-4c02-bf20-e4d8473f7adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c02f77b8-524f-4c02-bf20-e4d8473f7adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6359f789-4b8b-44d4-adc4-319f00b801c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6359f789-4b8b-44d4-adc4-319f00b801c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_224930c2-e28d-45ba-b60c-87c513fcc0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_224930c2-e28d-45ba-b60c-87c513fcc0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65467d1c-ece0-44c6-ad3e-997d956ae1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd0e52b9-cbf9-4c3b-871e-422a9ad28f85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65467d1c-ece0-44c6-ad3e-997d956ae1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a545dea-a599-4f0c-8550-e7fb19da40c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a545dea-a599-4f0c-8550-e7fb19da40c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddceb16b-34da-42e4-89a2-2619cf549064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddceb16b-34da-42e4-89a2-2619cf549064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ef625f0-6d12-4809-afc0-6afe5bd527bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3ef625f0-6d12-4809-afc0-6afe5bd527bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5eba8d8b-ffb5-4fee-b70b-8249b015acf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5eba8d8b-ffb5-4fee-b70b-8249b015acf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_374de7c1-9dbb-4fdb-a65f-2acce2e16135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5eba8d8b-ffb5-4fee-b70b-8249b015acf4" xlink:to="loc_us-gaap_InterestPaidNet_374de7c1-9dbb-4fdb-a65f-2acce2e16135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3f852b66-d020-475d-85a5-1fe9ad6a7b7b" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6fd0a10-59e0-4add-9b34-99bd3bcb6c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6fd0a10-59e0-4add-9b34-99bd3bcb6c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_StockIssuanceCostsIncurredButNotYetPaid_881abf93-b553-49ac-ae05-c4368816812e" xlink:href="silk-20200630.xsd#silk_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_silk_StockIssuanceCostsIncurredButNotYetPaid_881abf93-b553-49ac-ae05-c4368816812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bb359c15-d146-42b0-b2b6-bd5607987a75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bb359c15-d146-42b0-b2b6-bd5607987a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_d68b3f91-aa5f-44c7-8d4a-65d91e134cff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_d68b3f91-aa5f-44c7-8d4a-65d91e134cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_37e4e444-f88f-4f2c-a782-c9a689149a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_978697aa-a4af-43f3-bcdb-e0d8219f189b" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_37e4e444-f88f-4f2c-a782-c9a689149a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="simple" xlink:href="silk-20200630.xsd#FormationandBusinessoftheCompany"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a3cbf57-2947-4d3b-bb9e-f086bd21bfcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_98574fff-988c-4542-a56b-003b5502c73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a3cbf57-2947-4d3b-bb9e-f086bd21bfcb" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_98574fff-988c-4542-a56b-003b5502c73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#FormationandBusinessoftheCompanyDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_679414ff-4322-4e98-b091-cbd6762837ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f20f5cf5-68e8-470f-8d62-4fc5e4870a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_679414ff-4322-4e98-b091-cbd6762837ad" xlink:to="loc_us-gaap_SubsequentEventTable_f20f5cf5-68e8-470f-8d62-4fc5e4870a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2248771c-a3de-44be-bf37-7459d0a35a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f20f5cf5-68e8-470f-8d62-4fc5e4870a6e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2248771c-a3de-44be-bf37-7459d0a35a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2248771c-a3de-44be-bf37-7459d0a35a8b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_07da3b7c-7e34-4c96-aacd-28620ca76412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:to="loc_us-gaap_IPOMember_07da3b7c-7e34-4c96-aacd-28620ca76412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SecondPublicOfferingMember_23969859-4d72-4d7f-939f-528c59ceeb10" xlink:href="silk-20200630.xsd#silk_SecondPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:to="loc_silk_SecondPublicOfferingMember_23969859-4d72-4d7f-939f-528c59ceeb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingMember_b3b60fb9-c0f2-4528-b857-51ba41d454d1" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:to="loc_silk_PublicStockOfferingMember_b3b60fb9-c0f2-4528-b857-51ba41d454d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromCompanyMember_3fc06a07-ddcd-4fc3-8584-ae8ee19d33b3" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingSharesFromCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_PublicStockOfferingMember_b3b60fb9-c0f2-4528-b857-51ba41d454d1" xlink:to="loc_silk_PublicStockOfferingSharesFromCompanyMember_3fc06a07-ddcd-4fc3-8584-ae8ee19d33b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember_92084fc4-266d-4624-8100-99d8d1f2c38f" xlink:href="silk-20200630.xsd#silk_PublicStockOfferingSharesFromExistingShareholdersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_PublicStockOfferingMember_b3b60fb9-c0f2-4528-b857-51ba41d454d1" xlink:to="loc_silk_PublicStockOfferingSharesFromExistingShareholdersMember_92084fc4-266d-4624-8100-99d8d1f2c38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_5b13b87b-6127-4ecc-b583-53641479e6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_700be414-5f47-49ee-b744-f39eb51ea315" xlink:to="loc_us-gaap_OverAllotmentOptionMember_5b13b87b-6127-4ecc-b583-53641479e6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f20f5cf5-68e8-470f-8d62-4fc5e4870a6e" xlink:to="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_676f7a6d-f428-446d-b4e9-848aea8b8e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_676f7a6d-f428-446d-b4e9-848aea8b8e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_465cabd7-a27a-4232-85d0-9e3a2fcce1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_465cabd7-a27a-4232-85d0-9e3a2fcce1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f1b380b9-2195-4aff-9f3e-727276435b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f1b380b9-2195-4aff-9f3e-727276435b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_88278130-0168-4029-bb82-67bae7daa2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_88278130-0168-4029-bb82-67bae7daa2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_c6419690-fc79-4594-816a-567c5658324d" xlink:href="silk-20200630.xsd#silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions_c6419690-fc79-4594-816a-567c5658324d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_08be1c25-44a5-4fd4-b434-a5cb32c7a0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8f2193d8-61f9-4a8d-9761-8b1d4ac0bf9c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_08be1c25-44a5-4fd4-b434-a5cb32c7a0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6fb6d78d-585f-4ebe-b690-451dd3336345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_fa59ee97-5a7d-4cb6-a2a2-6efad19e9999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6fb6d78d-585f-4ebe-b690-451dd3336345" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_fa59ee97-5a7d-4cb6-a2a2-6efad19e9999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_18d7fd23-bfa3-4c1d-ae83-6a6cd7826902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_18d7fd23-bfa3-4c1d-ae83-6a6cd7826902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_74d77a72-60fc-4e88-ad21-18fec85b7450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_UseOfEstimates_74d77a72-60fc-4e88-ad21-18fec85b7450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a6002184-55ed-4143-99bd-bb3620d36135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_a6002184-55ed-4143-99bd-bb3620d36135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e518cad2-1b20-4357-a662-f757180c48f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e518cad2-1b20-4357-a662-f757180c48f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_accd1a43-27d7-4186-a2f0-fa6ad77f2b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_accd1a43-27d7-4186-a2f0-fa6ad77f2b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_38eae31e-b920-458a-890e-829e3a81282a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_38eae31e-b920-458a-890e-829e3a81282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_6be2b824-5653-4b55-91f3-57ddcb7fbb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_6be2b824-5653-4b55-91f3-57ddcb7fbb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_9d0664c3-6ec5-4111-99e2-5fc059013558" xlink:href="silk-20200630.xsd#silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_9d0664c3-6ec5-4111-99e2-5fc059013558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_6a0c2ba7-070f-478d-aa2b-107b165b309e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_6a0c2ba7-070f-478d-aa2b-107b165b309e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c5f3b898-bcdf-4357-beb3-baabd161a0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c5f3b898-bcdf-4357-beb3-baabd161a0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4072cb31-31a9-4a7c-b4f3-a591952c6413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4072cb31-31a9-4a7c-b4f3-a591952c6413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_99c6af23-e588-4e55-ba54-6c527f47162a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_99c6af23-e588-4e55-ba54-6c527f47162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_eda41e01-42f4-4fdd-9179-3473dc72edd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_eda41e01-42f4-4fdd-9179-3473dc72edd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1394a855-e55d-423d-8fec-879f805366c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1394a855-e55d-423d-8fec-879f805366c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2604f417-3471-459e-9e86-5ac30c591897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2604f417-3471-459e-9e86-5ac30c591897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38ab320e-c5a3-471b-80ce-966631bce86c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aaf032fb-b836-4786-acc0-4ef4d3ba324d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38ab320e-c5a3-471b-80ce-966631bce86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4ed44c59-b76f-45c1-987a-6f62bf7b3fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_19670b9b-54a2-4613-b8c5-11446e6d9dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4ed44c59-b76f-45c1-987a-6f62bf7b3fd8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_19670b9b-54a2-4613-b8c5-11446e6d9dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d96a500b-f392-4d60-9433-3a46ceef28b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4ed44c59-b76f-45c1-987a-6f62bf7b3fd8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d96a500b-f392-4d60-9433-3a46ceef28b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5d526487-ef9c-4caf-bf00-5980b2c500da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1cbe5f5d-3514-430f-804e-b4855bcd9541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d526487-ef9c-4caf-bf00-5980b2c500da" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1cbe5f5d-3514-430f-804e-b4855bcd9541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1cbe5f5d-3514-430f-804e-b4855bcd9541" xlink:to="loc_srt_RestatementAxis_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_0c7f8fdd-9687-4e04-8362-a368213b958a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_e7658f6b-6fc4-4118-bd7f-1a90cc8bf8b2" xlink:to="loc_srt_RestatementDomain_0c7f8fdd-9687-4e04-8362-a368213b958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_a44e025f-f754-4c76-8726-524e51c10224" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_0c7f8fdd-9687-4e04-8362-a368213b958a" xlink:to="loc_srt_RestatementAdjustmentMember_a44e025f-f754-4c76-8726-524e51c10224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_ffc3fa80-4755-411d-8d80-fcfab1091538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1cbe5f5d-3514-430f-804e-b4855bcd9541" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_ffc3fa80-4755-411d-8d80-fcfab1091538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a903a83-089d-40da-8937-86c864704618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_ffc3fa80-4755-411d-8d80-fcfab1091538" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a903a83-089d-40da-8937-86c864704618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b7c902e1-58c8-4c75-9a79-a9328a7e2c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_ffc3fa80-4755-411d-8d80-fcfab1091538" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b7c902e1-58c8-4c75-9a79-a9328a7e2c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d003475-02a8-416b-b484-5b2b0774bd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_59cd8439-9537-49d2-8aaa-850425f7fef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d003475-02a8-416b-b484-5b2b0774bd4e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_59cd8439-9537-49d2-8aaa-850425f7fef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3ee0980d-683e-4ba7-a9f6-a179b5e55b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4748475f-3e98-4054-8e22-056795381f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3ee0980d-683e-4ba7-a9f6-a179b5e55b57" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4748475f-3e98-4054-8e22-056795381f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_40287c75-e78d-400b-b92e-c33b280c4bda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4748475f-3e98-4054-8e22-056795381f2f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_40287c75-e78d-400b-b92e-c33b280c4bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd712da6-eaae-4464-8793-457e9a933811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_40287c75-e78d-400b-b92e-c33b280c4bda" xlink:to="loc_us-gaap_ClassOfStockDomain_dd712da6-eaae-4464-8793-457e9a933811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_96fa1159-1dbe-4b61-80ed-6f539f647d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dd712da6-eaae-4464-8793-457e9a933811" xlink:to="loc_us-gaap_CommonStockMember_96fa1159-1dbe-4b61-80ed-6f539f647d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2d76a0b9-e1ee-40f2-b810-624019a92719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4748475f-3e98-4054-8e22-056795381f2f" xlink:to="loc_us-gaap_ClassOfStockLineItems_2d76a0b9-e1ee-40f2-b810-624019a92719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_70d4c933-1643-4e68-8c33-8011fc3e0f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2d76a0b9-e1ee-40f2-b810-624019a92719" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_70d4c933-1643-4e68-8c33-8011fc3e0f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c5c660c4-4094-4883-a323-8b3f07504f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2d76a0b9-e1ee-40f2-b810-624019a92719" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c5c660c4-4094-4883-a323-8b3f07504f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_771b7414-6917-4a97-a4d4-9f9438e7649c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_d9cb4b43-33b1-49ab-b285-a093753f43e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_771b7414-6917-4a97-a4d4-9f9438e7649c" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_d9cb4b43-33b1-49ab-b285-a093753f43e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12da7933-f8bf-42a4-9ea2-0ef8d41841e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9b37414b-8864-4bcc-a5fb-6c2e031405f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12da7933-f8bf-42a4-9ea2-0ef8d41841e7" xlink:to="loc_us-gaap_NetIncomeLoss_9b37414b-8864-4bcc-a5fb-6c2e031405f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_63e17561-fe29-45f0-aa29-ac49008b69ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12da7933-f8bf-42a4-9ea2-0ef8d41841e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_63e17561-fe29-45f0-aa29-ac49008b69ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1bf9f127-cff4-4cfa-84d9-784998187b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12da7933-f8bf-42a4-9ea2-0ef8d41841e7" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1bf9f127-cff4-4cfa-84d9-784998187b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_df749bd3-b236-435a-9fad-d684323d9019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2b3494c-3af0-4b70-a48f-0dd584fa8480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df749bd3-b236-435a-9fad-d684323d9019" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2b3494c-3af0-4b70-a48f-0dd584fa8480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2b3494c-3af0-4b70-a48f-0dd584fa8480" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8ea17bf4-fd3b-4ff0-a919-02ae50b12ee5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c27945a8-fd78-47a1-9a7b-fd5e06caaf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c27945a8-fd78-47a1-9a7b-fd5e06caaf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6af2472f-fc7f-4432-81eb-bf265e6d0ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6af2472f-fc7f-4432-81eb-bf265e6d0ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_07e6760a-501e-4de8-8090-6d5283e8bdfc" xlink:href="silk-20200630.xsd#silk_CommonStockWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d4d1f18-1d75-425f-927a-3056f027390f" xlink:to="loc_silk_CommonStockWarrantMember_07e6760a-501e-4de8-8090-6d5283e8bdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9d997dca-f522-4bd5-8ad6-87d18bc72d94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b2b3494c-3af0-4b70-a48f-0dd584fa8480" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9d997dca-f522-4bd5-8ad6-87d18bc72d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ddcdd52-60cb-48b4-9d48-5f2c9e12254e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9d997dca-f522-4bd5-8ad6-87d18bc72d94" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ddcdd52-60cb-48b4-9d48-5f2c9e12254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cf796f86-85f2-4cc8-8b58-c0ff2fc52223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9fc57b8c-2be8-4b8d-a626-bc3d257539b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf796f86-85f2-4cc8-8b58-c0ff2fc52223" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9fc57b8c-2be8-4b8d-a626-bc3d257539b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_cda196b3-59fa-4717-a557-6883851dfa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf796f86-85f2-4cc8-8b58-c0ff2fc52223" xlink:to="loc_us-gaap_NumberOfReportableSegments_cda196b3-59fa-4717-a557-6883851dfa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="silk-20200630.xsd#RecentAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_2b3f94c7-6575-4b60-9a13-6a41873673ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_8b2da3ab-b60e-4b12-9d56-76fadcee2a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_2b3f94c7-6575-4b60-9a13-6a41873673ed" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_8b2da3ab-b60e-4b12-9d56-76fadcee2a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_86db0972-a8cd-4edb-acdb-fd8bdc6c1eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5e1cc91d-721f-43ca-b340-1df17db8be08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86db0972-a8cd-4edb-acdb-fd8bdc6c1eb1" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5e1cc91d-721f-43ca-b340-1df17db8be08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99166b2f-efef-41d7-b1c4-10dcecb7c3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_19b1b47b-4f6f-4801-abef-fb575f3c290b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99166b2f-efef-41d7-b1c4-10dcecb7c3cd" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_19b1b47b-4f6f-4801-abef-fb575f3c290b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9f16cc36-2ea0-430e-b5da-ae8cfa63e327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9f16cc36-2ea0-430e-b5da-ae8cfa63e327" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3cd955b1-6872-4850-ab0c-d30aa1a745d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3cd955b1-6872-4850-ab0c-d30aa1a745d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_acc4f819-9019-4ad2-a95c-7b4bfc596994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3cd955b1-6872-4850-ab0c-d30aa1a745d5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_acc4f819-9019-4ad2-a95c-7b4bfc596994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f30bcc87-c5eb-402d-99e6-7c810d0eaf77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_acc4f819-9019-4ad2-a95c-7b4bfc596994" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f30bcc87-c5eb-402d-99e6-7c810d0eaf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d38be227-2224-42ff-93c1-b2fbbff96796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d38be227-2224-42ff-93c1-b2fbbff96796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d38be227-2224-42ff-93c1-b2fbbff96796" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_99ea09ad-23c2-49c4-ad6f-ec24ee7da281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_99ea09ad-23c2-49c4-ad6f-ec24ee7da281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a241b636-f28d-4bf1-8fc2-6119a3374e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a241b636-f28d-4bf1-8fc2-6119a3374e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_889f17ed-c8d8-448b-b89c-42aa640409a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41445fb9-80da-484a-929e-6c05a2b46620" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_889f17ed-c8d8-448b-b89c-42aa640409a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0b487cbd-9381-4f1c-bea9-719c1bb3e926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0b487cbd-9381-4f1c-bea9-719c1bb3e926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0b487cbd-9381-4f1c-bea9-719c1bb3e926" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_50fee8f6-4eac-4950-ae4a-eb91ebbc0b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_MoneyMarketFundsMember_50fee8f6-4eac-4950-ae4a-eb91ebbc0b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_3a0d5264-8b7a-4243-a475-7aeccf968f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_3a0d5264-8b7a-4243-a475-7aeccf968f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_8e76cef6-56b2-4775-8554-69f4ffd48c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_8e76cef6-56b2-4775-8554-69f4ffd48c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e2cc6bf7-2158-4328-bf6c-63581df1c60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e2cc6bf7-2158-4328-bf6c-63581df1c60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9f5cf037-5ae6-4392-be1f-f24349cea0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9f5cf037-5ae6-4392-be1f-f24349cea0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d294ec60-feda-402b-acdc-550a696d2042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1474a795-b535-4740-ab79-60ac6b656622" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d294ec60-feda-402b-acdc-550a696d2042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab79734a-453b-4ed7-9a67-56daabbcd455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_39e37cdd-115a-4b7e-acca-3be56ea85328" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab79734a-453b-4ed7-9a67-56daabbcd455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b75852c4-c076-4f7d-be62-ca3172fb0fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab79734a-453b-4ed7-9a67-56daabbcd455" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b75852c4-c076-4f7d-be62-ca3172fb0fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5cbefaec-c2f4-4ef7-bb92-760f48c8961e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab79734a-453b-4ed7-9a67-56daabbcd455" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5cbefaec-c2f4-4ef7-bb92-760f48c8961e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dbe8622a-f843-476e-b05f-262fefa2b69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_57602f0c-aa03-43fb-9b06-27a1e40d2466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dbe8622a-f843-476e-b05f-262fefa2b69e" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_57602f0c-aa03-43fb-9b06-27a1e40d2466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_871190c8-a060-42fe-a142-4bae64afa475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e321f280-c5cd-49cc-99b9-086fbc6bfead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_871190c8-a060-42fe-a142-4bae64afa475" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e321f280-c5cd-49cc-99b9-086fbc6bfead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0a17e36f-9be5-4a8f-9642-33cd33bc3df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_871190c8-a060-42fe-a142-4bae64afa475" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_0a17e36f-9be5-4a8f-9642-33cd33bc3df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6f5d83e1-9b40-4e33-bffa-6bbcbae6fb5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_871190c8-a060-42fe-a142-4bae64afa475" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_6f5d83e1-9b40-4e33-bffa-6bbcbae6fb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6e6e3f2e-bad1-4d6d-81cd-933d16a5c534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_871190c8-a060-42fe-a142-4bae64afa475" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6e6e3f2e-bad1-4d6d-81cd-933d16a5c534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7cf78a34-a015-4f8c-8bd0-2b83dbdedd6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_871190c8-a060-42fe-a142-4bae64afa475" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7cf78a34-a015-4f8c-8bd0-2b83dbdedd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2bb0af06-8c39-4cdc-9a5e-74cb47caef69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_042c3194-6b9b-4276-814f-a3cca932a7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2bb0af06-8c39-4cdc-9a5e-74cb47caef69" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_042c3194-6b9b-4276-814f-a3cca932a7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_69870824-8847-46da-b49d-a9d2be59ea27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_042c3194-6b9b-4276-814f-a3cca932a7ba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_69870824-8847-46da-b49d-a9d2be59ea27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_69870824-8847-46da-b49d-a9d2be59ea27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8e085851-5fe0-4f5e-8bfc-d54641ec610b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8e085851-5fe0-4f5e-8bfc-d54641ec610b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_e260319c-7b68-4d40-94aa-c39a82406ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_e260319c-7b68-4d40-94aa-c39a82406ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4d7bc8fe-12c9-415d-a079-90ac9355c1a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_CommercialPaperMember_4d7bc8fe-12c9-415d-a079-90ac9355c1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a1a0010a-a30f-4f02-b642-589c251adf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a1a0010a-a30f-4f02-b642-589c251adf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_21664627-f3fe-4528-93ff-02473eae46d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_21664627-f3fe-4528-93ff-02473eae46d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_26230ca0-a2d4-496b-a2f5-5cf51078aa8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_26230ca0-a2d4-496b-a2f5-5cf51078aa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_849514e8-5af2-4eb6-93af-52dbf4be698f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_CashEquivalentsMember_849514e8-5af2-4eb6-93af-52dbf4be698f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_4223a3c7-f1d7-4e75-a02c-afe0bea87bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_4223a3c7-f1d7-4e75-a02c-afe0bea87bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermInvestmentsMember_fe830f52-99cd-490c-b829-e950a45ff60f" xlink:href="silk-20200630.xsd#silk_LongTermInvestmentsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8741b5-8f8f-4578-8eff-6ba0a51fc74c" xlink:to="loc_silk_LongTermInvestmentsMember_fe830f52-99cd-490c-b829-e950a45ff60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_042c3194-6b9b-4276-814f-a3cca932a7ba" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4b0018f-9763-4bde-87f6-a9fc243920d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4b0018f-9763-4bde-87f6-a9fc243920d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3cf942d2-f270-41f2-b7f2-27c481033d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3cf942d2-f270-41f2-b7f2-27c481033d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db370ceb-d332-4778-813a-97eefb8d78d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db370ceb-d332-4778-813a-97eefb8d78d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001c7a84-7777-4a7f-8026-f5c5a5f7cab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bca6fcd-cd69-4f0d-98bb-f2cbc109dd54" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001c7a84-7777-4a7f-8026-f5c5a5f7cab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c35dd780-e0e0-43fb-9e79-fc98b4c03da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_0bbe0af6-0a60-48a6-95ce-15080ebd83a8" xlink:href="silk-20200630.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c35dd780-e0e0-43fb-9e79-fc98b4c03da2" xlink:to="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear_0bbe0af6-0a60-48a6-95ce-15080ebd83a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_1f3b6381-340d-4c63-b2e5-68f9f11836ba" xlink:href="silk-20200630.xsd#silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c35dd780-e0e0-43fb-9e79-fc98b4c03da2" xlink:to="loc_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears_1f3b6381-340d-4c63-b2e5-68f9f11836ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ddc5748b-ec50-4c78-8b2a-83d0f394d68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c35dd780-e0e0-43fb-9e79-fc98b4c03da2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ddc5748b-ec50-4c78-8b2a-83d0f394d68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6bd4ba3-6b4e-4ffe-b2ee-1d1edd6cab78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_6b71211f-89bd-4a95-a530-865f01371d89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6bd4ba3-6b4e-4ffe-b2ee-1d1edd6cab78" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_6b71211f-89bd-4a95-a530-865f01371d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a32c2138-3c85-4d47-9411-fb946aa56f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6bd4ba3-6b4e-4ffe-b2ee-1d1edd6cab78" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a32c2138-3c85-4d47-9411-fb946aa56f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61aa6a00-82f0-4d48-bb47-c47f80457471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a88d9347-0231-4e1f-81fb-b1bcc58adc0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61aa6a00-82f0-4d48-bb47-c47f80457471" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a88d9347-0231-4e1f-81fb-b1bcc58adc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78575b72-398a-4220-ae28-f8dbf4fbb3bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a88d9347-0231-4e1f-81fb-b1bcc58adc0d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78575b72-398a-4220-ae28-f8dbf4fbb3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78575b72-398a-4220-ae28-f8dbf4fbb3bb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e22ad4a4-ca2c-4172-9b05-654d5813f860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e22ad4a4-ca2c-4172-9b05-654d5813f860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_f2e0b765-4021-48b7-b435-561531393a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_f2e0b765-4021-48b7-b435-561531393a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_91ba0e0e-1737-4a2b-8bb3-61960582448d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2f61705b-a60a-4581-87bd-5edc759d5440" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_91ba0e0e-1737-4a2b-8bb3-61960582448d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e7735c77-f73c-4d92-aee6-0ca5729ff35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a88d9347-0231-4e1f-81fb-b1bcc58adc0d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e7735c77-f73c-4d92-aee6-0ca5729ff35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f2df528f-b67e-435e-a241-08c328746764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e7735c77-f73c-4d92-aee6-0ca5729ff35c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f2df528f-b67e-435e-a241-08c328746764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1cc18943-4cc4-4fd0-8200-2f0fdb6a7d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e7735c77-f73c-4d92-aee6-0ca5729ff35c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1cc18943-4cc4-4fd0-8200-2f0fdb6a7d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2e5b1c87-229a-4f7e-b950-cc64a8f74fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0c714b22-d760-4ac6-9b39-df5256095f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2e5b1c87-229a-4f7e-b950-cc64a8f74fc4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0c714b22-d760-4ac6-9b39-df5256095f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_984a2ff0-f724-4b30-af55-a9c5aa4d01ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2e5b1c87-229a-4f7e-b950-cc64a8f74fc4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_984a2ff0-f724-4b30-af55-a9c5aa4d01ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dba53b27-1058-4c40-b486-8a0b83e674c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2e5b1c87-229a-4f7e-b950-cc64a8f74fc4" xlink:to="loc_us-gaap_InventoryNet_dba53b27-1058-4c40-b486-8a0b83e674c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e9b433f8-5f6f-4bc3-8e66-c335b598ef51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e9b433f8-5f6f-4bc3-8e66-c335b598ef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ProvisionsForSalesReturns_816e54da-ef09-468a-8ac6-1fe26c7dd1fd" xlink:href="silk-20200630.xsd#silk_ProvisionsForSalesReturns"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_silk_ProvisionsForSalesReturns_816e54da-ef09-468a-8ac6-1fe26c7dd1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_281fe4d0-bcc3-4816-9b7d-b7f63f3c8c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_281fe4d0-bcc3-4816-9b7d-b7f63f3c8c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b8619407-3470-4abb-b80a-036e17087080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b8619407-3470-4abb-b80a-036e17087080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_dce16892-bdc1-47f7-95fa-8c791fae1d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_dce16892-bdc1-47f7-95fa-8c791fae1d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_632295ac-4c1b-4a66-9c0f-3a296818c41c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_632295ac-4c1b-4a66-9c0f-3a296818c41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedTravelExpensesCurrent_c3327f2e-9b91-460f-959f-537af9d4baa6" xlink:href="silk-20200630.xsd#silk_AccruedTravelExpensesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_silk_AccruedTravelExpensesCurrent_c3327f2e-9b91-460f-959f-537af9d4baa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AccruedClinicalExpensesCurrent_3df9f61c-cc1f-437a-be06-26438f960c76" xlink:href="silk-20200630.xsd#silk_AccruedClinicalExpensesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_silk_AccruedClinicalExpensesCurrent_3df9f61c-cc1f-437a-be06-26438f960c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3eda0fc9-520c-4779-9e9d-895a49e69d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3eda0fc9-520c-4779-9e9d-895a49e69d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0b8a3923-6697-47ab-8202-f1a05eb0c1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb2e7775-0cde-4b38-b71d-8bda712319e2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0b8a3923-6697-47ab-8202-f1a05eb0c1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebt" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d47c656c-6f75-44db-ab46-11fd009e0f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a5e5157e-334e-4840-a57d-b2227388d568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d47c656c-6f75-44db-ab46-11fd009e0f57" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a5e5157e-334e-4840-a57d-b2227388d568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_744b4b2a-7f41-4f76-b027-95e6a618ccb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c5b96a32-79ab-44e5-9ee9-d6c5d0530862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_744b4b2a-7f41-4f76-b027-95e6a618ccb9" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c5b96a32-79ab-44e5-9ee9-d6c5d0530862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtTermLoanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_385d05e7-7964-4cdb-a7f1-9c740fb60b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_385d05e7-7964-4cdb-a7f1-9c740fb60b89" xlink:to="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_34465ef0-5588-4a4d-9603-cdb4bfcce136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_34465ef0-5588-4a4d-9603-cdb4bfcce136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_34465ef0-5588-4a4d-9603-cdb4bfcce136" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanMember_8f775025-7ce2-4893-a1fb-e1daad1f8a16" xlink:href="silk-20200630.xsd#silk_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:to="loc_silk_TermLoanMember_8f775025-7ce2-4893-a1fb-e1daad1f8a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheAMember_733cdb3a-9e9d-42e4-b849-93834498b184" xlink:href="silk-20200630.xsd#silk_TermLoanTrancheAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:to="loc_silk_TermLoanTrancheAMember_733cdb3a-9e9d-42e4-b849-93834498b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TermLoanTrancheBMember_4b724b42-db73-4b19-9b58-74d5fa2550b3" xlink:href="silk-20200630.xsd#silk_TermLoanTrancheBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f484b2f5-aa42-49d4-9828-59d70acdee6d" xlink:to="loc_silk_TermLoanTrancheBMember_4b724b42-db73-4b19-9b58-74d5fa2550b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_58af2c52-5d04-479d-ba4d-87567c4648fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:to="loc_srt_StatementScenarioAxis_58af2c52-5d04-479d-ba4d-87567c4648fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_afa32fe7-1e39-4b47-acc9-48800ba6ef39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_58af2c52-5d04-479d-ba4d-87567c4648fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_afa32fe7-1e39-4b47-acc9-48800ba6ef39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3263f3af-ece0-4f0f-b0ed-ebd2c2c58dcc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_afa32fe7-1e39-4b47-acc9-48800ba6ef39" xlink:to="loc_srt_ScenarioForecastMember_3263f3af-ece0-4f0f-b0ed-ebd2c2c58dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2184d09-31d9-424f-bb6b-8920d69d6900" xlink:to="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtMaximumBorrowingCapacity_88a93f48-5c2f-4b0c-b29e-79394488ef2a" xlink:href="silk-20200630.xsd#silk_DebtMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtMaximumBorrowingCapacity_88a93f48-5c2f-4b0c-b29e-79394488ef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d61a6d9f-96ba-4e4d-a487-37153c1d9dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d61a6d9f-96ba-4e4d-a487-37153c1d9dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b086dfc-3b15-401d-bd76-dc495610a644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b086dfc-3b15-401d-bd76-dc495610a644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInKind_946b0c1b-6fd1-40ba-8d2b-d3248b3423d8" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentInterestRatePaidInKind_946b0c1b-6fd1-40ba-8d2b-d3248b3423d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRatePaidInCash_9b062685-1f60-4a29-b7ba-a5218a133cbe" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRatePaidInCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentInterestRatePaidInCash_9b062685-1f60-4a29-b7ba-a5218a133cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans_7da06829-acb2-471f-8855-a1e746fc9b17" xlink:href="silk-20200630.xsd#silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans_7da06829-acb2-471f-8855-a1e746fc9b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentConvertibleMarketCapitalization_fe83245c-86f8-4132-a83f-3d9fbbce3b3b" xlink:href="silk-20200630.xsd#silk_DebtInstrumentConvertibleMarketCapitalization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentConvertibleMarketCapitalization_fe83245c-86f8-4132-a83f-3d9fbbce3b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRateFinancingFee_2d442b4b-5c72-4e1c-94b3-7c81c4f9a32f" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRateFinancingFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentInterestRateFinancingFee_2d442b4b-5c72-4e1c-94b3-7c81c4f9a32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentInterestRateFacilityFee_b3afd869-af28-46bc-b077-1a60fdb87be8" xlink:href="silk-20200630.xsd#silk_DebtInstrumentInterestRateFacilityFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentInterestRateFacilityFee_b3afd869-af28-46bc-b077-1a60fdb87be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMaximumLiquidityAmount_a2ecb33b-84e9-4e3b-b74c-3def9878ef6f" xlink:href="silk-20200630.xsd#silk_DebtInstrumentCovenantMaximumLiquidityAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentCovenantMaximumLiquidityAmount_a2ecb33b-84e9-4e3b-b74c-3def9878ef6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentCovenantMinimumNetRevenueAmount_1b03d2fe-5fba-40bf-b394-bbf5c4b5c5fb" xlink:href="silk-20200630.xsd#silk_DebtInstrumentCovenantMinimumNetRevenueAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentCovenantMinimumNetRevenueAmount_1b03d2fe-5fba-40bf-b394-bbf5c4b5c5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_DebtInstrumentLiquidityCovenantTerm_0e3c5466-b332-4b81-a303-83619b4a7929" xlink:href="silk-20200630.xsd#silk_DebtInstrumentLiquidityCovenantTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_18bea215-4e60-41df-8d36-ad06aa3dbdcb" xlink:to="loc_silk_DebtInstrumentLiquidityCovenantTerm_0e3c5466-b332-4b81-a303-83619b4a7929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtFutureMaturitiesUndertheTermLoanDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7fc1c8bb-4260-4557-a63d-58175e64f35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7fc1c8bb-4260-4557-a63d-58175e64f35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_924af078-6bcb-40b5-9497-b74aa7e07579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_924af078-6bcb-40b5-9497-b74aa7e07579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7769e2b9-77c2-48db-ad47-10a5a7af6116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7769e2b9-77c2-48db-ad47-10a5a7af6116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_07e81fa3-eb34-4fa7-8314-b241d403fe28" xlink:href="silk-20200630.xsd#silk_LongTermDebtGrossBeforeAccretionOfClosingFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_silk_LongTermDebtGrossBeforeAccretionOfClosingFees_07e81fa3-eb34-4fa7-8314-b241d403fe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtAccretionOfClosingFees_26338bda-78c5-42c6-a9b9-829b8a50498f" xlink:href="silk-20200630.xsd#silk_LongTermDebtAccretionOfClosingFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_silk_LongTermDebtAccretionOfClosingFees_26338bda-78c5-42c6-a9b9-829b8a50498f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4f4d3659-f02d-4948-b5ec-8527fdabe653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4f4d3659-f02d-4948-b5ec-8527fdabe653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LongTermDebtUnpaidInterest_4838ffcb-6948-47ce-8ade-90938f3c9ea3" xlink:href="silk-20200630.xsd#silk_LongTermDebtUnpaidInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_silk_LongTermDebtUnpaidInterest_4838ffcb-6948-47ce-8ade-90938f3c9ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_999b4b36-2b71-4cf4-97e8-c838ed5c10db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_999b4b36-2b71-4cf4-97e8-c838ed5c10db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b77b2f84-07e0-4a06-8384-4c3b95c54c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41d9457c-9d8c-4a56-a3c3-4721719b7bed" xlink:to="loc_us-gaap_LongTermDebt_b77b2f84-07e0-4a06-8384-4c3b95c54c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#LongtermDebtSeriesCNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a37483ec-9512-4492-b5e7-81873d4c5f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a37483ec-9512-4492-b5e7-81873d4c5f94" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_df86137c-671b-4cf1-bd6d-b701c47a055c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_df86137c-671b-4cf1-bd6d-b701c47a055c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ff624f9-ab44-4ca8-9a4e-949009069b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_df86137c-671b-4cf1-bd6d-b701c47a055c" xlink:to="loc_us-gaap_ClassOfStockDomain_4ff624f9-ab44-4ca8-9a4e-949009069b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_9915b953-90e1-4655-a26b-65a6c165a778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4ff624f9-ab44-4ca8-9a4e-949009069b1d" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_9915b953-90e1-4655-a26b-65a6c165a778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f308083a-7bf5-454c-b881-8820c7cd2f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f308083a-7bf5-454c-b881-8820c7cd2f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_13a840be-3d4b-4e80-bbf1-e197a7965fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f308083a-7bf5-454c-b881-8820c7cd2f94" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_13a840be-3d4b-4e80-bbf1-e197a7965fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PreferredStockWarrantsMember_205721b5-79bd-4c6e-9a7a-ebe2e146d144" xlink:href="silk-20200630.xsd#silk_PreferredStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13a840be-3d4b-4e80-bbf1-e197a7965fd4" xlink:to="loc_silk_PreferredStockWarrantsMember_205721b5-79bd-4c6e-9a7a-ebe2e146d144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c802e357-f445-41c8-ad07-5690191a1bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c802e357-f445-41c8-ad07-5690191a1bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4b31175c-3bfe-4516-910a-ab07ca465c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c802e357-f445-41c8-ad07-5690191a1bed" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4b31175c-3bfe-4516-910a-ab07ca465c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_092ba936-4917-46b9-9c9b-b1f804491fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4b31175c-3bfe-4516-910a-ab07ca465c2c" xlink:to="loc_us-gaap_IPOMember_092ba936-4917-46b9-9c9b-b1f804491fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d797d22d-5c4c-482b-8916-64e8ab03afe7" xlink:to="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_163903af-aea0-4e0a-8c0f-4b7dbd42195f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_163903af-aea0-4e0a-8c0f-4b7dbd42195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_12530fa4-9962-4751-a236-1bfc8353f896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_12530fa4-9962-4751-a236-1bfc8353f896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0fe00ceb-f1ab-49c5-b59d-13e8d828fa85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_afcda6dd-5b94-4752-8029-c3b615f16e35" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0fe00ceb-f1ab-49c5-b59d-13e8d828fa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f1808b16-5399-470c-ad82-74e0d67ed481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f0188ef6-b796-464f-aa69-82bbbca55a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f1808b16-5399-470c-ad82-74e0d67ed481" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f0188ef6-b796-464f-aa69-82bbbca55a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d3fc2982-c630-4a1f-8cab-98744dfda6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock_065d5f83-027d-48b3-ae5a-3d05994760c8" xlink:href="silk-20200630.xsd#silk_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d3fc2982-c630-4a1f-8cab-98744dfda6d3" xlink:to="loc_silk_AssetsAndLiabilitiesLesseeTableTextBlock_065d5f83-027d-48b3-ae5a-3d05994760c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f05e0eb9-c7f9-4ea9-8087-507ab5508c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d3fc2982-c630-4a1f-8cab-98744dfda6d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f05e0eb9-c7f9-4ea9-8087-507ab5508c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesLeaseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a9ecda7-63a1-492f-8a1f-f8c83b2fcf28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d8db1819-be2f-4a35-90be-28606c720b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a9ecda7-63a1-492f-8a1f-f8c83b2fcf28" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d8db1819-be2f-4a35-90be-28606c720b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ca00130b-f101-43f0-986d-0f229eaacf24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a9ecda7-63a1-492f-8a1f-f8c83b2fcf28" xlink:to="loc_us-gaap_OperatingLeaseCost_ca00130b-f101-43f0-986d-0f229eaacf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0e373d4f-75e9-4e6b-af30-1d4061bfe422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a9ecda7-63a1-492f-8a1f-f8c83b2fcf28" xlink:to="loc_us-gaap_OperatingLeasePayments_0e373d4f-75e9-4e6b-af30-1d4061bfe422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_93918dda-0611-4017-8eb0-7feef214059b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a9ecda7-63a1-492f-8a1f-f8c83b2fcf28" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_93918dda-0611-4017-8eb0-7feef214059b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_45b3441f-bf91-4e4d-9581-bc29d1e13114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a9ecda7-63a1-492f-8a1f-f8c83b2fcf28" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_45b3441f-bf91-4e4d-9581-bc29d1e13114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3e3a3547-8b3f-4eba-84ee-4ce4f654b911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ec93efe7-2286-4ce3-855f-1b07c3b29fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3e3a3547-8b3f-4eba-84ee-4ce4f654b911" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ec93efe7-2286-4ce3-855f-1b07c3b29fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d9a08f5-c8d3-446c-af6c-72740f505a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3e3a3547-8b3f-4eba-84ee-4ce4f654b911" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d9a08f5-c8d3-446c-af6c-72740f505a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8582ed32-1ada-4bed-bac5-c6d95330733c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3e3a3547-8b3f-4eba-84ee-4ce4f654b911" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8582ed32-1ada-4bed-bac5-c6d95330733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_64c14ea5-518f-4cf1-b752-7c0905bd017c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3e3a3547-8b3f-4eba-84ee-4ce4f654b911" xlink:to="loc_us-gaap_OperatingLeaseLiability_64c14ea5-518f-4cf1-b752-7c0905bd017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_920ed2e0-da3b-4f22-b72f-6cb3b0c19c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_920ed2e0-da3b-4f22-b72f-6cb3b0c19c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne_2c4860f6-bb42-44a2-b4c8-2fd5b1890dac" xlink:href="silk-20200630.xsd#silk_LesseeOperatingLeaseLiabilityToBePaidYearOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:to="loc_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne_2c4860f6-bb42-44a2-b4c8-2fd5b1890dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_144386e2-a938-4513-8fcb-1f1a5b95b245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_144386e2-a938-4513-8fcb-1f1a5b95b245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ffd1296d-b51f-45f8-ab82-16dff49c40b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ffd1296d-b51f-45f8-ab82-16dff49c40b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0b45fb89-f463-4bf2-820d-d0afd5b01138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0b45fb89-f463-4bf2-820d-d0afd5b01138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ff45bcdb-a180-4b55-9c52-0b4e6e6faedc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ff45bcdb-a180-4b55-9c52-0b4e6e6faedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_93d3ba18-ce5e-47d2-8907-e462d58f394c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_93d3ba18-ce5e-47d2-8907-e462d58f394c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f9830cb5-2843-49ed-ba6c-97f25e95d6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6bc17622-ca88-4fcb-8b17-e7101fbf1fc6" xlink:to="loc_us-gaap_OperatingLeaseLiability_f9830cb5-2843-49ed-ba6c-97f25e95d6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#CommitmentsandContingenciesPurchaseObligationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2cb308b6-20d5-4500-bf87-7bd7a7136f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_5f80726c-6cb5-49e8-abed-1aa1a5070b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2cb308b6-20d5-4500-bf87-7bd7a7136f4e" xlink:to="loc_us-gaap_PurchaseObligation_5f80726c-6cb5-49e8-abed-1aa1a5070b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="silk-20200630.xsd#RedeemableConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_b0d18b5d-04e6-4012-922a-c6dfe596f41f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dafb6e1e-f88a-4e0f-8e83-251e68574b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_b0d18b5d-04e6-4012-922a-c6dfe596f41f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dafb6e1e-f88a-4e0f-8e83-251e68574b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#RedeemableConvertiblePreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_9706e554-29a5-4254-bcb2-62abe1e263f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_9706e554-29a5-4254-bcb2-62abe1e263f5" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_66966a38-1b7e-4558-bf47-f62d2e9ad8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_66966a38-1b7e-4558-bf47-f62d2e9ad8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1171f170-88fc-4bad-861f-71e460eafa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66966a38-1b7e-4558-bf47-f62d2e9ad8c2" xlink:to="loc_us-gaap_ClassOfStockDomain_1171f170-88fc-4bad-861f-71e460eafa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_766ced19-91aa-41fe-847d-5d4a6ac60db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1171f170-88fc-4bad-861f-71e460eafa95" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_766ced19-91aa-41fe-847d-5d4a6ac60db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6135b1f8-4b99-4837-8ecc-d2ccdae379f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f4a0e4e3-fdfc-4f3c-88ae-89a873871b45" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6135b1f8-4b99-4837-8ecc-d2ccdae379f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_e0dabc43-a4be-4cdb-8aaf-e6209abcb49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6135b1f8-4b99-4837-8ecc-d2ccdae379f6" xlink:to="loc_us-gaap_IPOMember_e0dabc43-a4be-4cdb-8aaf-e6209abcb49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ddf8f2d3-a754-412d-8c37-a958095e294f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ddf8f2d3-a754-412d-8c37-a958095e294f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_565d8698-3540-442d-a5c3-c1d86f52aeb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ddf8f2d3-a754-412d-8c37-a958095e294f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_565d8698-3540-442d-a5c3-c1d86f52aeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_PreferredStockWarrantsMember_7ad0463f-4275-4ad8-8053-e598d6dffadb" xlink:href="silk-20200630.xsd#silk_PreferredStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_565d8698-3540-442d-a5c3-c1d86f52aeb8" xlink:to="loc_silk_PreferredStockWarrantsMember_7ad0463f-4275-4ad8-8053-e598d6dffadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_5a48c810-fa0d-4e25-bdaf-7a47f130b2c5" xlink:to="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_d4a11cb4-c66c-4fd3-998b-59ebaa223c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_d4a11cb4-c66c-4fd3-998b-59ebaa223c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_9658993f-16d5-47e2-86f7-0057d49966bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_9658993f-16d5-47e2-86f7-0057d49966bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_25bd2fae-e8a5-4076-b0a8-c0a2ba156df4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_25bd2fae-e8a5-4076-b0a8-c0a2ba156df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_f8de4f81-04f2-446d-a454-439dcb8d8b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7373ecec-81ba-4f4a-a1af-b34948a225cd" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_f8de4f81-04f2-446d-a454-439dcb8d8b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="silk-20200630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_969e453e-6803-4bf5-b087-8b3144b85bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_aca62d9c-4f3b-45b9-aeb4-d2cc994fff3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_969e453e-6803-4bf5-b087-8b3144b85bd2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_aca62d9c-4f3b-45b9-aeb4-d2cc994fff3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ca2d6e2f-c41f-4a79-8b82-06d6e2eb4db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ca2d6e2f-c41f-4a79-8b82-06d6e2eb4db8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1f66325c-347a-4a53-b3dc-4021803c776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1f66325c-347a-4a53-b3dc-4021803c776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc651cf2-76e5-4d82-951f-e5ce1cfe2de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1f66325c-347a-4a53-b3dc-4021803c776c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc651cf2-76e5-4d82-951f-e5ce1cfe2de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_ca9663e2-ffd2-4859-b98d-66ad8a59cd3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc651cf2-76e5-4d82-951f-e5ce1cfe2de8" xlink:to="loc_us-gaap_IPOMember_ca9663e2-ffd2-4859-b98d-66ad8a59cd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_96dc95ab-f31d-4a17-a67f-89617a83fd25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_96dc95ab-f31d-4a17-a67f-89617a83fd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4dc64c8a-72f2-45e7-b0ad-d289cafbac18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_96dc95ab-f31d-4a17-a67f-89617a83fd25" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4dc64c8a-72f2-45e7-b0ad-d289cafbac18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockWarrantMember_1c099cfc-9281-4e4d-a395-df7a96a99b31" xlink:href="silk-20200630.xsd#silk_CommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4dc64c8a-72f2-45e7-b0ad-d289cafbac18" xlink:to="loc_silk_CommonStockWarrantMember_1c099cfc-9281-4e4d-a395-df7a96a99b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_a92f81f0-1392-4262-b3aa-c6300e047618" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cba6e092-3a3b-47cd-926f-99bfda612b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cba6e092-3a3b-47cd-926f-99bfda612b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7db30c37-d6c2-4d52-9c9f-142c84e094a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7db30c37-d6c2-4d52-9c9f-142c84e094a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3b10cd47-d2cc-4478-a961-69262392554d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3b10cd47-d2cc-4478-a961-69262392554d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_93eed189-7749-4f31-a650-403fa4270952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_93eed189-7749-4f31-a650-403fa4270952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b448488d-dac7-4ba9-8151-de349e4be165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b448488d-dac7-4ba9-8151-de349e4be165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_66c71fe6-8143-4e42-ab73-544780862d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_66c71fe6-8143-4e42-ab73-544780862d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eeb6d55a-4a8e-45c7-b2ee-605f46d29927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_CommonStockSharesIssued_eeb6d55a-4a8e-45c7-b2ee-605f46d29927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cfbc241c-83e6-4eee-bcfe-daf0b3eaad1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cfbc241c-83e6-4eee-bcfe-daf0b3eaad1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_18e38571-8766-4ae4-aef8-4d7acaa3c408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_DividendsCommonStock_18e38571-8766-4ae4-aef8-4d7acaa3c408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockVotePerShare_07b71a0a-8d33-4b0a-bcad-db6d0caf9a8b" xlink:href="silk-20200630.xsd#silk_CommonStockVotePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_silk_CommonStockVotePerShare_07b71a0a-8d33-4b0a-bcad-db6d0caf9a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6a661528-7ee7-4cdb-aef7-dc876a074330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6a661528-7ee7-4cdb-aef7-dc876a074330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_39fa32ce-6d15-41d8-9c48-cbff4474ad03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_82a6b05c-2e46-487c-b586-6f30e0264e00" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_39fa32ce-6d15-41d8-9c48-cbff4474ad03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlans" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlans"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d3ab441-7fb7-4db7-adf5-1cb04903eaec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c73ae96c-6a9e-4f51-b1f0-24c4bdd18301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d3ab441-7fb7-4db7-adf5-1cb04903eaec" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c73ae96c-6a9e-4f51-b1f0-24c4bdd18301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansTables"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98afa7d1-7e6f-47d1-a08f-c5de36adcda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1ccd341c-d82a-4837-bea0-4ae8f9f7ab99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98afa7d1-7e6f-47d1-a08f-c5de36adcda6" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1ccd341c-d82a-4837-bea0-4ae8f9f7ab99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_94632888-5b9c-48f0-9705-dbd32d039bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98afa7d1-7e6f-47d1-a08f-c5de36adcda6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_94632888-5b9c-48f0-9705-dbd32d039bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_716a30de-0209-4eaa-b1a7-15fb017b3f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98afa7d1-7e6f-47d1-a08f-c5de36adcda6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_716a30de-0209-4eaa-b1a7-15fb017b3f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_e7646021-6737-4de2-96f7-608ec365b6e2" xlink:href="silk-20200630.xsd#silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98afa7d1-7e6f-47d1-a08f-c5de36adcda6" xlink:to="loc_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock_e7646021-6737-4de2-96f7-608ec365b6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bec3d92d-b068-46cc-bb08-fe4bcf63465c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98afa7d1-7e6f-47d1-a08f-c5de36adcda6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bec3d92d-b068-46cc-bb08-fe4bcf63465c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4118e116-4cfa-4f8e-86a5-102530224565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4118e116-4cfa-4f8e-86a5-102530224565" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_us-gaap_PlanNameAxis_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2c49961e-2a2b-458d-877e-dc88074402ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3ef14262-a89e-4562-b0bf-bf3b8e2a7ebd" xlink:to="loc_us-gaap_PlanNameDomain_2c49961e-2a2b-458d-877e-dc88074402ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_TwoThousandNineteenStockOptionPlanMember_7df93d9b-1f1e-4f1c-9625-31dd29925984" xlink:href="silk-20200630.xsd#silk_TwoThousandNineteenStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2c49961e-2a2b-458d-877e-dc88074402ef" xlink:to="loc_silk_TwoThousandNineteenStockOptionPlanMember_7df93d9b-1f1e-4f1c-9625-31dd29925984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ac76304-e2af-42bf-a05c-78b43b15756e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_srt_RangeAxis_6ac76304-e2af-42bf-a05c-78b43b15756e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dc1991fa-3809-4c3b-891d-5d828019789a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6ac76304-e2af-42bf-a05c-78b43b15756e" xlink:to="loc_srt_RangeMember_dc1991fa-3809-4c3b-891d-5d828019789a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cc87e7b1-0106-43a6-ac25-e8d662b0e8f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dc1991fa-3809-4c3b-891d-5d828019789a" xlink:to="loc_srt_MaximumMember_cc87e7b1-0106-43a6-ac25-e8d662b0e8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4a80335a-e8a3-4297-aaa6-62d4f75da070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_us-gaap_AwardTypeAxis_4a80335a-e8a3-4297-aaa6-62d4f75da070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4a80335a-e8a3-4297-aaa6-62d4f75da070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveStockOptionMember_3c9b9f8b-a41b-4744-9bd8-e3fb2df95e5e" xlink:href="silk-20200630.xsd#silk_IncentiveStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_silk_IncentiveStockOptionMember_3c9b9f8b-a41b-4744-9bd8-e3fb2df95e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_NonqualifiedStockOptionsMember_211e0694-dd59-4dd7-9fb9-4f1f59cf5611" xlink:href="silk-20200630.xsd#silk_NonqualifiedStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_silk_NonqualifiedStockOptionsMember_211e0694-dd59-4dd7-9fb9-4f1f59cf5611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_IncentiveandNonqualifiedStockOptionMember_0fc45a61-ee56-4c7d-ac1a-4ea69705fb98" xlink:href="silk-20200630.xsd#silk_IncentiveandNonqualifiedStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_silk_IncentiveandNonqualifiedStockOptionMember_0fc45a61-ee56-4c7d-ac1a-4ea69705fb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_de1dddbf-0e73-47fd-b87b-570e0de8249f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_de1dddbf-0e73-47fd-b87b-570e0de8249f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29ba8c5b-7f5c-4866-ae06-348012c04c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29ba8c5b-7f5c-4866-ae06-348012c04c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d17c330b-241b-4896-b5fc-4daf27d6678c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c483cb0-bb49-445c-9336-2fab9aaf6859" xlink:to="loc_us-gaap_EmployeeStockMember_d17c330b-241b-4896-b5fc-4daf27d6678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c9eaf732-7f96-41b3-a261-0308bf4a9e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_efbb2ef7-44ec-4b1e-a8d0-f04e6e2652f1" xlink:to="loc_us-gaap_RelatedPartyDomain_c9eaf732-7f96-41b3-a261-0308bf4a9e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_800aa535-b225-4bd3-9da8-9fcef5002705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c9eaf732-7f96-41b3-a261-0308bf4a9e9f" xlink:to="loc_us-gaap_PrincipalOwnerMember_800aa535-b225-4bd3-9da8-9fcef5002705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5443a5cf-47ab-4acd-adcc-604cbfb9958f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9acb538b-e8c2-40b0-920e-2830f950a6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9acb538b-e8c2-40b0-920e-2830f950a6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_aec3244b-23a3-4590-9494-ce7170e89268" xlink:href="silk-20200630.xsd#silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_aec3244b-23a3-4590-9494-ce7170e89268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_6622eb31-443c-4dcb-80ee-861a0b56243e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_6622eb31-443c-4dcb-80ee-861a0b56243e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice_1f4a91ed-8386-433e-a453-6dcc507d01b7" xlink:href="silk-20200630.xsd#silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice_1f4a91ed-8386-433e-a453-6dcc507d01b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_964f82be-f37c-4b76-a46b-d49712b43d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_964f82be-f37c-4b76-a46b-d49712b43d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c4e4ad8e-0fc9-4772-9e3f-95ee51d4d374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c4e4ad8e-0fc9-4772-9e3f-95ee51d4d374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b991aa46-6638-4a90-9320-e363717343d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b991aa46-6638-4a90-9320-e363717343d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a91ce1c7-5ce2-401d-98cd-b75138db0dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a91ce1c7-5ce2-401d-98cd-b75138db0dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7183f689-6f48-4b4c-a5e3-c5301f6432c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7183f689-6f48-4b4c-a5e3-c5301f6432c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5aa889dc-51e8-40f5-ac67-13a06eb56fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5aa889dc-51e8-40f5-ac67-13a06eb56fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2cb87a35-77c6-493f-93a2-e30c2b51c6db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2cb87a35-77c6-493f-93a2-e30c2b51c6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance_038936d2-8ec5-4abb-9fe7-35fb570f1ca1" xlink:href="silk-20200630.xsd#silk_CommonStockCapitalSharesAvailableForFutureIssuance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_silk_CommonStockCapitalSharesAvailableForFutureIssuance_038936d2-8ec5-4abb-9fe7-35fb570f1ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_aaa1f6de-3de8-4d2d-a335-8291ee972941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_aaa1f6de-3de8-4d2d-a335-8291ee972941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_691f50b4-9c12-4237-8caa-34bb14e07eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_691f50b4-9c12-4237-8caa-34bb14e07eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f05a8002-ab19-49cd-bd6e-9aacffdb97c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f05a8002-ab19-49cd-bd6e-9aacffdb97c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9fb6e70-499f-4fa2-a5eb-b9cd01b63807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe854288-152f-48bc-af18-ab43dc458b81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f9fb6e70-499f-4fa2-a5eb-b9cd01b63807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansActivityUnderCompensationPlanDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_62c98968-b155-46d0-9ff4-9e0111e7635a" xlink:href="silk-20200630.xsd#silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_62c98968-b155-46d0-9ff4-9e0111e7635a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9537ba76-609b-4c82-b3de-88336284fa20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_62c98968-b155-46d0-9ff4-9e0111e7635a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9537ba76-609b-4c82-b3de-88336284fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2035d872-7c1f-47c2-8529-9500493f3fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_62c98968-b155-46d0-9ff4-9e0111e7635a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2035d872-7c1f-47c2-8529-9500493f3fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9e26e12f-37ee-40c3-9bfe-6431417a64fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_62c98968-b155-46d0-9ff4-9e0111e7635a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9e26e12f-37ee-40c3-9bfe-6431417a64fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1b21a542-b23c-457d-8fa0-01d7ec007524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_62c98968-b155-46d0-9ff4-9e0111e7635a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1b21a542-b23c-457d-8fa0-01d7ec007524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ac7944d-c3a0-4a5a-a4ec-fb46e56b26f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward_62c98968-b155-46d0-9ff4-9e0111e7635a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2ac7944d-c3a0-4a5a-a4ec-fb46e56b26f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f28e24e5-4818-4db0-bbca-6a1f38816719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f28e24e5-4818-4db0-bbca-6a1f38816719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4180a7c8-42f3-42a5-9f0f-51a141e0b230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f28e24e5-4818-4db0-bbca-6a1f38816719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4180a7c8-42f3-42a5-9f0f-51a141e0b230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b9d3acdb-3184-44d0-813c-0b9b63233e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f28e24e5-4818-4db0-bbca-6a1f38816719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b9d3acdb-3184-44d0-813c-0b9b63233e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c7b64193-b572-41a0-8e4d-881e66524a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f28e24e5-4818-4db0-bbca-6a1f38816719" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c7b64193-b572-41a0-8e4d-881e66524a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d543a0dc-567d-4613-b94d-2d64e461ac5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f28e24e5-4818-4db0-bbca-6a1f38816719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d543a0dc-567d-4613-b94d-2d64e461ac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c396966a-7129-4c99-ace6-f575c9329d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f28e24e5-4818-4db0-bbca-6a1f38816719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c396966a-7129-4c99-ace6-f575c9329d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a212c089-782c-4a9d-9786-235beaad94ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a212c089-782c-4a9d-9786-235beaad94ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fa7bb50b-4c32-4329-bb3c-5f363209322b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a212c089-782c-4a9d-9786-235beaad94ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fa7bb50b-4c32-4329-bb3c-5f363209322b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_388549d2-e3e5-4e89-beff-bf19201c0050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a212c089-782c-4a9d-9786-235beaad94ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_388549d2-e3e5-4e89-beff-bf19201c0050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_00297a60-747f-4449-bdc3-dd998429a899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a212c089-782c-4a9d-9786-235beaad94ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_00297a60-747f-4449-bdc3-dd998429a899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_cab5c781-fd18-482d-b5e6-03985dce50c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a212c089-782c-4a9d-9786-235beaad94ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_cab5c781-fd18-482d-b5e6-03985dce50c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a9f7a037-c575-4eef-a85d-8ae7c604734e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a212c089-782c-4a9d-9786-235beaad94ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a9f7a037-c575-4eef-a85d-8ae7c604734e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_08e6c449-bd1a-4db5-b5aa-4d01ca1bbe15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_08e6c449-bd1a-4db5-b5aa-4d01ca1bbe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fa23ae63-4065-48da-9092-3dfeac9d7826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fa23ae63-4065-48da-9092-3dfeac9d7826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0eace8eb-f07a-45ee-b464-64151220e0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0eace8eb-f07a-45ee-b464-64151220e0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a58bc805-a97a-416e-bdad-bfda2aa2952c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a58bc805-a97a-416e-bdad-bfda2aa2952c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cbf621fa-56f2-4697-9af6-e27d569d0658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cbf621fa-56f2-4697-9af6-e27d569d0658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bbd24768-2136-4702-aba3-897cd7e46a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bbd24768-2136-4702-aba3-897cd7e46a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_81caba0d-1734-4620-a055-390ebe2b29a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_81caba0d-1734-4620-a055-390ebe2b29a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f8d72c95-8c9b-4206-b99f-85e42ca7e539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f8d72c95-8c9b-4206-b99f-85e42ca7e539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_da359b8b-4ccb-4c73-a4e1-f73bdab231a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_da359b8b-4ccb-4c73-a4e1-f73bdab231a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c263dc14-eb33-453f-aa61-5346da1433c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5b11a7a8-3d57-4a7d-a113-0f2953b2c1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c263dc14-eb33-453f-aa61-5346da1433c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansRSUsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5d121ce-379d-4f60-b954-e63d1409714f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cffad89-ba8c-4911-8dfb-832500ce2068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5d121ce-379d-4f60-b954-e63d1409714f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cffad89-ba8c-4911-8dfb-832500ce2068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a17522b7-ded4-42d4-a5c1-8ab8d356211e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cffad89-ba8c-4911-8dfb-832500ce2068" xlink:to="loc_us-gaap_AwardTypeAxis_a17522b7-ded4-42d4-a5c1-8ab8d356211e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e35ed9f-a0cd-4ccc-8ca2-0a533679c91b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a17522b7-ded4-42d4-a5c1-8ab8d356211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e35ed9f-a0cd-4ccc-8ca2-0a533679c91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cc3087d2-8041-4f63-b6a3-f8d9ae424a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e35ed9f-a0cd-4ccc-8ca2-0a533679c91b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cc3087d2-8041-4f63-b6a3-f8d9ae424a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd29cbb-8d64-4a99-a7bc-a369bba4cd9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cffad89-ba8c-4911-8dfb-832500ce2068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd29cbb-8d64-4a99-a7bc-a369bba4cd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd29cbb-8d64-4a99-a7bc-a369bba4cd9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd483126-dd06-4c60-855f-18e2685f4af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd483126-dd06-4c60-855f-18e2685f4af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_42c3c713-927c-49e2-912e-fd9195358941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_42c3c713-927c-49e2-912e-fd9195358941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54514205-02de-412d-addc-6e6486652c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_54514205-02de-412d-addc-6e6486652c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66aaf9ef-e249-4910-8f85-05f855b9495c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66aaf9ef-e249-4910-8f85-05f855b9495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_91c20739-146e-4f72-9ff5-5c9b8ebeca32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ff7d9393-4416-4203-986e-a08131d0ff15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_91c20739-146e-4f72-9ff5-5c9b8ebeca32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd29cbb-8d64-4a99-a7bc-a369bba4cd9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_22f401b3-14cf-4373-af02-8f866de764ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_22f401b3-14cf-4373-af02-8f866de764ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba8c6a89-78d5-4177-98c8-8e41d6a59fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba8c6a89-78d5-4177-98c8-8e41d6a59fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c36b0cf5-f23c-421b-87b2-50f94ad2e67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c36b0cf5-f23c-421b-87b2-50f94ad2e67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_195f6ea8-5432-4097-87ce-d0eb533c827a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_195f6ea8-5432-4097-87ce-d0eb533c827a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9eb7649e-8c75-4fe8-97ca-e472fb9cf3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2937cb77-e3c1-48a8-9ebc-adf1a6d6dab5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9eb7649e-8c75-4fe8-97ca-e472fb9cf3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansFairValueofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92f8eb88-6535-4f57-969a-4b183f65570e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92f8eb88-6535-4f57-969a-4b183f65570e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_24656d08-1f70-4719-bcbc-fe020a8867c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:to="loc_us-gaap_AwardTypeAxis_24656d08-1f70-4719-bcbc-fe020a8867c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76183c29-34d6-4a75-a701-e0941e3e71bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_24656d08-1f70-4719-bcbc-fe020a8867c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76183c29-34d6-4a75-a701-e0941e3e71bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e5039d99-e073-48a8-a0c8-1fa99beb2874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76183c29-34d6-4a75-a701-e0941e3e71bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e5039d99-e073-48a8-a0c8-1fa99beb2874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4d8a86bf-487c-470d-b450-02fbc046a043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76183c29-34d6-4a75-a701-e0941e3e71bb" xlink:to="loc_us-gaap_EmployeeStockMember_4d8a86bf-487c-470d-b450-02fbc046a043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:to="loc_srt_RangeAxis_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19b1ad4b-1ca7-4cd7-994f-72c05e7cd2be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0ff3d776-9cb3-45c5-a27a-1d975b0a6e3d" xlink:to="loc_srt_RangeMember_19b1ad4b-1ca7-4cd7-994f-72c05e7cd2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aa9fcb49-f0f3-46cd-8f1f-c522afccf171" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_19b1ad4b-1ca7-4cd7-994f-72c05e7cd2be" xlink:to="loc_srt_MinimumMember_aa9fcb49-f0f3-46cd-8f1f-c522afccf171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a388e6d7-6783-4e27-9fb3-a7aa0af6aed5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_19b1ad4b-1ca7-4cd7-994f-72c05e7cd2be" xlink:to="loc_srt_MaximumMember_a388e6d7-6783-4e27-9fb3-a7aa0af6aed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c102dcd-b279-43ec-95a8-b14303d50fec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6dbad2cb-0342-40b4-ba6a-182492a68742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6dbad2cb-0342-40b4-ba6a-182492a68742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e196644e-003d-4179-9fa1-ac03b732c8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e196644e-003d-4179-9fa1-ac03b732c8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_47be5e85-2240-49d1-98ea-74daf694c2d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_47be5e85-2240-49d1-98ea-74daf694c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b83586a6-3e1a-405a-a10e-35b7cb6faa60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b83586a6-3e1a-405a-a10e-35b7cb6faa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dea56f94-dd81-490b-8c25-79bdcc77d78b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dea56f94-dd81-490b-8c25-79bdcc77d78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d6619171-c46a-4ba9-8f45-d99b9dcdf34e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d6619171-c46a-4ba9-8f45-d99b9dcdf34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c75e12d6-0d25-4254-a0f5-824ffcaa81a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c75e12d6-0d25-4254-a0f5-824ffcaa81a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8fb6c5c9-b7f6-4a49-b7a5-7eb346dd9e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c600b1da-7ecc-438c-9172-7bd4dbe395ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8fb6c5c9-b7f6-4a49-b7a5-7eb346dd9e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#StockOptionPlansStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f68cfa3-4da4-4616-953c-5fec2de65553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fcdec384-ca3a-4c19-bca5-aeef5c809863" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f68cfa3-4da4-4616-953c-5fec2de65553" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fcdec384-ca3a-4c19-bca5-aeef5c809863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_984e2335-7302-4db5-9d00-f545ebad9c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fcdec384-ca3a-4c19-bca5-aeef5c809863" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_984e2335-7302-4db5-9d00-f545ebad9c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_984e2335-7302-4db5-9d00-f545ebad9c37" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ba023e0a-76ad-4755-9d7f-a85164c84443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:to="loc_us-gaap_CostOfSalesMember_ba023e0a-76ad-4755-9d7f-a85164c84443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37266ec1-a606-4737-bf26-2ab3ffe888cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37266ec1-a606-4737-bf26-2ab3ffe888cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ac2f6e7e-1a3b-47da-b865-e6dc0c62a50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_52464f0b-bdd7-49d8-97f7-ebd823042f00" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ac2f6e7e-1a3b-47da-b865-e6dc0c62a50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_847f1dd7-c703-4a63-b7ba-29538004a0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fcdec384-ca3a-4c19-bca5-aeef5c809863" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_847f1dd7-c703-4a63-b7ba-29538004a0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d7efa9dc-239a-491f-98a7-808a35e386c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_847f1dd7-c703-4a63-b7ba-29538004a0a1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d7efa9dc-239a-491f-98a7-808a35e386c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlan" xlink:type="simple" xlink:href="silk-20200630.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0c645b95-c904-42ed-be4c-5739200c77e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_368457af-1399-4f33-b4b9-9aaa8f8ca348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0c645b95-c904-42ed-be4c-5739200c77e6" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_368457af-1399-4f33-b4b9-9aaa8f8ca348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="silk-20200630.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://silkroadmed.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60dcf3f1-48e6-4a7c-89d4-70a2ba4e3327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f9fade01-e281-4bb5-b6b0-f68a27637e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60dcf3f1-48e6-4a7c-89d4-70a2ba4e3327" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f9fade01-e281-4bb5-b6b0-f68a27637e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_74721a11-391e-4162-a7ad-925417664234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60dcf3f1-48e6-4a7c-89d4-70a2ba4e3327" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_74721a11-391e-4162-a7ad-925417664234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1a53f761-087d-49f4-875c-3e1225d74ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60dcf3f1-48e6-4a7c-89d4-70a2ba4e3327" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1a53f761-087d-49f4-875c-3e1225d74ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_fda37420-cc2e-4314-ab15-3f399215adf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60dcf3f1-48e6-4a7c-89d4-70a2ba4e3327" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_fda37420-cc2e-4314-ab15-3f399215adf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>silk-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:silk="http://silkroadmed.com/20200630"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="silk-20200630.xsd" xlink:type="simple"/>
    <context id="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4cae094a657c4ffe9478c2d84e706b28_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i0b2654a458fe4949a14a70a00d0e6c46_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4192fdc2c1f247de9e20017c4c131295_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie9e3e7e58fd643a9b81d6acc10d20212_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01edde7dedb544328d6997373cf6ad4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia02f7ba2764646e98fe313a3f6b45aff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0efec5d2df54499d877b5b7f2c50296e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i63b35b01b32f46f2bee4f4a23b7012a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia98288daaa954dd1875ff62ad62c8371_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i412e80de80294636915c387579e51a98_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2813994ece5044d3b7db1695fbd0eb1f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i893baa7990094d9996aef955612bf12c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if97360d0e3024fcd99b7a9761e90b309_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iad155abbc9754495b06722da098ba394_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9b44a6c1a4d7438a86dff3e0e151961a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i250d8d2fc5a44833b091f0a0021c1f1f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifa53cd55d6d640ff87711fd4e0f8ef56_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8d433da600ff424d9072d74a4800426b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i71269ca1bb0048df93fdfb7f60583aca_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6f1ba60825d14c648abad9bad89c5116_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if5c4b78f734744bb9a7efbc2c9838e21_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i01cbace60dde45c3b3e3b6d6de1dc3cb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5abe689d4c9b45d590e6081f66e9d892_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i95e493ed76734fa9b072ff4c78d00454_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iba95761be90e4d0b871436b1bc3e613f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie87ca05332314ce38d1c838f1918033d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if195c2966bd4478b9a536e42c4729969_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i267c658bb1a64c4cb3087e17e6ba0504_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9766f2a2b567462db339a57d15a9b202_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i44fb74c77caa45feb1b93e73036b664d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i97f3122f97654386982663f091f8be2a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i18115e334dfb4939bf22d7f51604a743_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2974baeced5b42539df2ce7e5d9fd970_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i69b6f1148feb4497b99389b263100226_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia013b4eb40114308be33eb29a813111d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0b16f07a785142d7af5301cf48c4d820_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4fa337a09be04535b922d4ff23c908d4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib2b2a6a89c1143b79a1fde2400691f14_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9fd18f4a372d4ab3bbe21e94964f88b0_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i35d13e334d474ffca707c39e945c4b18_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i042388ebf8da4a30880f8f9e5c039e53_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8c6892eaf5054997bc5db44ea630d3b8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id2e3b1c19991473a9eda55c27b7a6352_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i857c634bdb34432c8b74d2c01c998fde_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0d224a2b66764827814bf9c8f036c6fd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ieb63e8b0926842298836b1c7a48b5ad7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7e86f21e817747e1b323fa24e138daa7_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i907247d422b04c4daa972b713b2650e5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib8771181b78740329cdb8290b99f0331_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4b36e442f3114a22ba850f63b846e6f4_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0bdf7b91752347eb8ff1ad32bb419fc9_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9634e8ac71464a7c94802f90d75471fa_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic7239974596a4a39bd1824a432c2fd56_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i57ad5239b3db46d4ad0d92c5293e2141_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i05076e6e126f4a39a7b296a201b34ff2_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ic94b432f83144c5da9c031a5551750d7_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ide2816e79e1b4022bf0287f80bb4fdf9_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:SecondPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i41cc7674876049d3a0d3f79031ac5f2e_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i7c3c231e674e41edb75743c3010ec1df_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:SecondPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="ia43b4977769d4b22b03b8b2e1b372461_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ib1f341d7b77348a3a2568b670d478a67_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingSharesFromCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i4f15ecda3b414074877b40741ff55576_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingSharesFromExistingShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i8daaa359899f42abbc96d5a68e4e2aca_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">silk:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ie760fc97ef2b4f50b5ec97d0f5ebe0b2_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="iba2667bba4254c478e4e02407240ad78_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i42ceb4ffa58a401ba6b8f294d3cb104c_D20190501-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i704ad274cb0749d5930b69ce8f613a81_D20190501-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9e17ff70ca0d48c8b577b81e25ba591d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic416bec949ed4e3ca81268307a41e37e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i474e71f940ab46279c176f0b19975770_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6a67bd46361461c9d492414aa7bffdd_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia45c7bb5cadd4ff3928225d7854fc6cf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib7eaae44effa4a9db07cdb54dcc04049_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie11c28dea9564c599548f654617f2d82_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ieef0e9ab0a544219ad78c50b68f4791d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i027eeae537b5468592e241128284b992_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id2b02921cf0f4f00aa9fe9fdfd871170_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0130e277a457479f8eb98ee94adf3d31_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7abe1f43259b4a54b976c268c96c3db6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie05b32828f264722b8556b4370fc6692_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i97f148c7c1d24480baf7b80e8a13fd5a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8c333b7cb2584fb0bf52ab8951d3b428_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5ef50b8f524a4cf1a7fbc3e5edfecf52_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idbe32b015af345959821be4df0dcaeac_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i37bbce2b0c0c4aed8cf5b3c35c01dcae_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2dbd828ff8134720a052fc51c726266a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i295a9086a57e41eba3c2236e5dc80ef0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iad31c85169dc429b85ce034ad39eb103_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i63598873c0f044d4b705b1cafa4240b7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7cde6c49eff04e36b1db4f65acf663c3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i88c32e22f95c44cab38971bc9fab5004_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i26e712413f6848d9a5e188b7a113c60d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9e1c06ac263949cf803aa266d7e0c236_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i34bee5fc72654faebc87e97e419f58c1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7a5bfe7df3c84fe6850ff62b8c098b26_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i11dd8af0811b4ebab5f6adef8864c4f1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5e8bebd551d147b992e253b95baa195f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iedefabef8f124e819f3337024626dc4e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2abf6f3595684efe9f063ff9b69fec7f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9aae1b1ed715477dad46b3078e21b40b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b9a7836694f4cf3b50a9134284d8b4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9636c3ae224c4f7f893c191a0ab12002_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76ab7e26b0e64cffa5cca122155110e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide59561146c34abbbab1296d346d7f2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c98a1a3cac34c2fbc05c0e88a578e09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c935ab0c1f241b990bc79b98b3645b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie1de230599454417b163ebfe37b873d5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i145dc0fcbfe64370a9f24164b7dd43f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8245985bc354b6a86396bc01b5213d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib148be5a80234007ae139c5a4efdfc61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id1a76cb4479a4ff989b812aac949063e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if53f29868f76491f8fd58d9c3303f998_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide4b8aa16b5440ec854fbf0906b9c133_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67ffbfb49b864745af10bab7a89329f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia5a347102e80443a82dea892692d5746_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46860657c50f45ee882f2df2d5f623d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8dc96a72145c469d9ab6fb5c89bafb0e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3830c20a6ee94b1488be7319d791f2d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ebd01da1cc2487a91876a8405b5628b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac0ccc5a7ea8414bb1a711a6955e7342_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i665e3a1be7a84f788bd449d1334d492c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i628752f4a1c64849a99d7a5f207dd092_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf14871d54b5439a835298db12c36739_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8c8ea18544f4f62b607863b3c6653ed_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id46da514145b4750ada52675069ab829_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7700ecb8225940a282f94f4767f6615f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaf867c38014844e5818ec341fda982bd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if5f4685798604a6d9460510b4c4c15a7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia6f195d63bab41439dde63c7ec42a7a3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic54064e0090149959fffc8a7f4540977_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5c26d0ce983a467cace48304d4c14c29_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia147919f6a044ff88de323227052e424_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecc6e45694f94ee2a9737c2166fb37d1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a3a50b23b354642957be1435413bcd9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic00908a653674eb4a8e9bac56051e1a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i070bfe38bf2d4977b7e7675ca0fe38ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i084603b74ef54fce8e75cc1061fc2af7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifeb20a2f0bf24dd08225af4dac73faaa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">silk:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3400703ba5ec4dafa9f83491b25fdc9b_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i790a1c16fe884cfc81603c5b990067c9_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i0624ae02355943f3919d91e6d60daf82_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i05691cc4d2eb407b8735756cfcce9745_I20170430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanTrancheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-30</instant>
        </period>
    </context>
    <context id="i3af30497630e46e0b5dbb159697d1735_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i6d81a47bada34ef9be4c34a930d81f1e_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="icab64d89eb0c493488e9f83a19562b4d_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ic59b0ae0ca9845038632b9400107e7e6_I20190501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">silk:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-01</instant>
        </period>
    </context>
    <context id="i7b1e85f6d793488db550a9cd9ebeec00_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i159d0d96431346b8906e3a743106810e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i819cbd89b0e044588cd3162b0ae7dad0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i448c71a8e90245efa333cff2acf26e6f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic379c431ee4f4674ab4bd3200cc4d510_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i633031055692460588cb4386c56f8095_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="ie917c02865cd4fba8e0243a7cd29e649_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i417623c9d2f24af1b9f527fefb005c13_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="ieebe6a801a53498d95a8594bf16d9080_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i6c7140d4200a4dc5bdacecc60d872d6b_D20170701-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="ife031befc9a54c529bec50b02c7d0159_I20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="i98995d7c6a444311ad86aee8421c9d3a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i496155293b1d4422b3ea42fef3be00b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9dcdcdf5e9b496689dbd352302af644_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i84de79cfd01646ca80f851b0e71fec3e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6113484aa6d4421ebce5390fc3eaf952_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">silk:CommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7df1fe52b16e418da8983a23cd31db62_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2378c3bc6251483cab8274447be641b8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i3dd9fbf4e28c4a2fbde835757d39a1e5_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6b705b1bf16749838adb0a5da76d687c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">silk:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie23898085ac8458bb0cac28efb4aaef4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i53f162f8f289492a97ccfe1e594fa809_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:NonqualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ice3001c6ee614220ac19207889d5aa37_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie82a229840ec40d79a480525255fd532_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">silk:IncentiveandNonqualifiedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie7c0724845984d8a86158ae06b154011_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7a6f5fdcd6894037a81fa4bc82914447_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2811c603862b4d7ea5a7fa37dea521c1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i039961495a884a188b5d3e7bda9008a4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i515f2625685e47a3a0c3f87208b405e1_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3eb1770831844300ae09b328b18c5397_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i454e6e1c1e7148d2abad0f588fcee401_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0dfbb8e51673404eb0624832076ff097_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1bea4ee895a74d1aaedf0a333c0c6f4c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70be1e0534404d08896dbc0a988ff250_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i73c173a6496b4596bfce7f7c0833e719_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i220629dc98834984b7d11f79d2fe810b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic4dc7821cccc41989da58dcccb531642_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia742a060c2af4302bfd4a0bd4786b675_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia43e704ab79f493585f933259edc8540_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4024977785b1424fab65d0622c295161_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0cbb5c9c3ef24d45998860f450b433d3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2826aabff8b4439e8abd78eb9018b593_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iab80b98eced34b02a24687725a852684_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b281a430c8c4aada7ebc48e15d5e031_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1e5f9129abc84b8e85adb2e73a6a2964_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id87005078ae94c2ba819b718b9a86599_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i55f2446a5cb34a2c800a0378dc3c54f6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5d1215e8500c43c59e1c45a0496eabb7_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0a29f695f4e8418b88fdf2ecd941252f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0c1ae90727004ccfbf97f186ac2e0781_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie8664b40a2ba4c69b62ac361f5b299d4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2a7af5bbd93b4d26b19182dbb32d2697_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2473c0e76af946f0a8d35143cb16bdc7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia946f02d9b0346d3bb893b131d264f0e_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001397702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>silk:segment</measure>
    </unit>
    <unit id="vote">
        <measure>silk:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV8zLTEtMS0xLTA_660b0ae1-3761-498b-870f-657aa174d66c">0001397702</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV80LTEtMS0xLTA_e2f88909-f544-4fac-a1c4-55156e2f001e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV8xMS0xLTEtMS0w_d30c3591-a552-4842-978f-76023e46b59d">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV8xMi0xLTEtMS0w_97bc135c-629f-4ddd-9662-87156b346067">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80L2ZyYWc6OGE4MDUyZTI0YzQwNDRkNmI3OGQyMmQ5OThmZTBjNmIvdGFibGU6MGY0M2JhYmRmNzI1NDk0ZmI4ZDYzNDJlNDhjYWY3NTkvdGFibGVyYW5nZTowZjQzYmFiZGY3MjU0OTRmYjhkNjM0MmU0OGNhZjc1OV8xMy0xLTEtMS0w_466b5b4c-0171-45b4-8d30-4b2cf0323d7a">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ie760fc97ef2b4f50b5ec97d0f5ebe0b2_D20190313-20190313"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNy9mcmFnOjg3N2YzMzUxNGIyZTRhZDRiYTRlMTAxZDNlOTdkYmEwL3RleHRyZWdpb246ODc3ZjMzNTE0YjJlNGFkNGJhNGUxMDFkM2U5N2RiYTBfMTM_b95f22f9-45e2-41f5-b7ee-58b9a8f725c6"
      unitRef="number">0.3704</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl84Ng_26b79d6a-09f3-401a-889d-edd5e3009317">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6ZjVkZjM2OTc4Mjk1NGY1ZGJjMGQ4NzBlZWU1ZjM5NjIvdGFibGVyYW5nZTpmNWRmMzY5NzgyOTU0ZjVkYmMwZDg3MGVlZTVmMzk2Ml8wLTAtMS0xLTA_cb78b751-1439-49fd-af3b-09a08fade9d5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8xOTQ_ee07f679-b329-4866-aa3d-48df81bd07f9">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6MzFkY2UzNDY2Yjg2NGZlM2FkMTdmNGQ2OWJhOGEwY2UvdGFibGVyYW5nZTozMWRjZTM0NjZiODY0ZmUzYWQxN2Y0ZDY5YmE4YTBjZV8wLTAtMS0xLTA_16db32d6-2723-4cd8-b37d-c8ebf5187079">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8yNzI_b68fd5af-f64e-4d00-9bb5-26c0b20b766c">001-38847</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8yODI_2ac99c53-8362-45cd-aa21-9b6791e050ac">SILK ROAD MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6NWNmYmFkMmZlMjA3NDhkOGI3ZWIwNTE1MWFjOTkzZTYvdGFibGVyYW5nZTo1Y2ZiYWQyZmUyMDc0OGQ4YjdlYjA1MTUxYWM5OTNlNl8wLTAtMS0xLTA_e1fb1419-3785-4067-b794-fd9b069e96eb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6NWNmYmFkMmZlMjA3NDhkOGI3ZWIwNTE1MWFjOTkzZTYvdGFibGVyYW5nZTo1Y2ZiYWQyZmUyMDc0OGQ4YjdlYjA1MTUxYWM5OTNlNl8wLTItMS0xLTA_0f007e57-ede7-43a8-b15f-5a627d5314cc">20-8777622</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNDc_c292db7b-81a4-40a6-81bd-c8c595abaa68">1213 Innsbruck Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNTA_564d6793-bfba-437d-a5d0-c2adf65e45ae">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNTQ_4bed2542-f792-4f72-854c-629b710ea900">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNTc_4d93a8e7-da12-452b-be3b-1a4f280f4267">94089</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNjE_a0cc7b66-d9dd-485c-9cd9-e07f21135cc1">408</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8zNjU_daaa2818-db75-4d4d-9c84-aee9c3a08573">720-9002</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8xMDM5_eee35da2-969e-4d74-86fb-7bb1191f4938">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8xMzYw_6226901b-caae-4f05-b051-d0f924455ae4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6MzRjYzVlMjFhMGJhNGY5ZGI2M2E1ZTVhOGVhY2VkN2EvdGFibGVyYW5nZTozNGNjNWUyMWEwYmE0ZjlkYjYzYTVlNWE4ZWFjZWQ3YV8xLTAtMS0xLTA_43e06f19-7421-46fc-98bd-c03df03205a1">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6MzRjYzVlMjFhMGJhNGY5ZGI2M2E1ZTVhOGVhY2VkN2EvdGFibGVyYW5nZTozNGNjNWUyMWEwYmE0ZjlkYjYzYTVlNWE4ZWFjZWQ3YV8xLTQtMS0xLTA_532c06c1-81dc-4d33-a99b-79b8c0f230c7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6MzRjYzVlMjFhMGJhNGY5ZGI2M2E1ZTVhOGVhY2VkN2EvdGFibGVyYW5nZTozNGNjNWUyMWEwYmE0ZjlkYjYzYTVlNWE4ZWFjZWQ3YV8yLTEtMS0xLTA_72885cef-8a3a-46a5-898b-5d2a0d63776d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8yMDkx_f4b3add0-e2a6-448f-8fd6-da93d84ac9e6">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6Njg4ODA4MTMxN2M2NDJlMWI2NzIwYzRmZjAxZWI3YmQvdGFibGVyYW5nZTo2ODg4MDgxMzE3YzY0MmUxYjY3MjBjNGZmMDFlYjdiZF8xLTAtMS0xLTA_3cfc71bd-ab27-43d1-83f8-ff315fb972e3">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6Njg4ODA4MTMxN2M2NDJlMWI2NzIwYzRmZjAxZWI3YmQvdGFibGVyYW5nZTo2ODg4MDgxMzE3YzY0MmUxYjY3MjBjNGZmMDFlYjdiZF8xLTEtMS0xLTA_5898a84e-27b9-4769-9a00-5ca6094b6447">SILK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGFibGU6Njg4ODA4MTMxN2M2NDJlMWI2NzIwYzRmZjAxZWI3YmQvdGFibGVyYW5nZTo2ODg4MDgxMzE3YzY0MmUxYjY3MjBjNGZmMDFlYjdiZF8xLTItMS0xLTA_26421d7b-b5ac-4082-92fb-a60ca7d39a3b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4cae094a657c4ffe9478c2d84e706b28_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xL2ZyYWc6OTg3NTI2ZTZiODk0NDU2NDg0N2RlMzY3MGEwZDMzZjYvdGV4dHJlZ2lvbjo5ODc1MjZlNmI4OTQ0NTY0ODQ3ZGUzNjcwYTBkMzNmNl8yMjgy_ef226199-da8a-4eb6-a009-c1368d3187d0"
      unitRef="shares">33679635</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNC0xLTEtMS0w_31b20d37-00c1-4bd3-9439-829db303da30"
      unitRef="usd">73442000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNC0zLTEtMS0w_2f901a64-bda5-4a8a-b810-f17dd5f8e7ad"
      unitRef="usd">39181000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNS0xLTEtMS0w_0ab6aa39-7cb2-46e1-8fb1-2657f4ad4290"
      unitRef="usd">84416000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNS0zLTEtMS0w_5a0871a3-a49f-44a5-97a1-2696bbf1479e"
      unitRef="usd">51508000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNi0xLTEtMS0w_5c1a92c0-7662-43ca-9a6a-9dd1e71ceb52"
      unitRef="usd">7753000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNi0zLTEtMS0w_3532462f-c6cc-4dee-b83e-06c0a99dace7"
      unitRef="usd">8601000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNy0xLTEtMS0w_82eda87c-00c9-4f17-9df3-38b4522c6a86"
      unitRef="usd">11621000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfNy0zLTEtMS0w_ec5211ae-6caf-4bdf-9b1b-e855a1c62c7b"
      unitRef="usd">10322000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfOC0xLTEtMS0w_b72c6f0f-914b-4293-b0f9-f876d5ae17ef"
      unitRef="usd">3863000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfOC0zLTEtMS0w_1228093b-f2a9-490e-932a-1b3b7867ae04"
      unitRef="usd">2878000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfOS0xLTEtMS0w_f8c8459a-a292-4afa-a993-aaf9d7b66fc3"
      unitRef="usd">181095000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfOS0zLTEtMS0w_ae5f7b48-8514-4d83-baba-8b47934e1090"
      unitRef="usd">112490000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTAtMS0xLTEtMA_7dedbd2c-6c79-4c7f-8097-5d55a83cc1e8"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTAtMy0xLTEtMA_3a5b3c13-451f-444f-ba6a-02d81b7650b1"
      unitRef="usd">18224000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTEtMS0xLTEtMA_3a4bbd54-5641-4418-b290-3afe7c2fad37"
      unitRef="usd">2885000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTEtMy0xLTEtMA_59f81b49-fb4c-4c14-8382-02418a22aff4"
      unitRef="usd">2734000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTItMS0xLTEtMA_a65b476e-f242-44b6-9f6d-60da47584f20"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTItMy0xLTEtMA_06b51ac1-794e-4f02-8cfa-b5494fcedccc"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTMtMS0xLTEtMA_b7e8d3be-fe6e-4438-bcb4-b39d1f8640f8"
      unitRef="usd">3233000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTMtMy0xLTEtMA_742c1466-5609-410d-bb88-cdd6d7dcb669"
      unitRef="usd">3644000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTQtMS0xLTEtMA_bc4cf2a3-8cf9-4fdb-af3c-40973ec53877"
      unitRef="usd">187523000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTQtMy0xLTEtMA_793a0628-1209-4ffd-8934-c20288334e02"
      unitRef="usd">137402000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTctMS0xLTEtMA_7aa3f907-d44a-4311-a5f4-841f33b864e2"
      unitRef="usd">2542000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTctMy0xLTEtMA_9d129dfa-2595-4af8-a26f-e45c38eae182"
      unitRef="usd">1898000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTgtMS0xLTEtMA_ef54f71a-08fe-49ac-839c-8fd1e734ac27"
      unitRef="usd">9142000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTgtMy0xLTEtMA_f2bf8ccf-472c-4a11-bd74-11932032be89"
      unitRef="usd">15034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTktMS0xLTEtMA_13cc2aa5-400f-4f3d-90d1-14c8386e3b91"
      unitRef="usd">11684000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMTktMy0xLTEtMA_bb481926-bac8-446e-9175-7ecd4ad2083d"
      unitRef="usd">16932000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjAtMS0xLTEtMA_d937f305-47fd-4d6f-badf-90c838129f03"
      unitRef="usd">45066000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjAtMy0xLTEtMA_d3f90005-200e-4c5b-ad9e-7bd9a9dc03e8"
      unitRef="usd">44879000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjEtMS0xLTEtMA_2c0f9d26-6b65-43c7-b04b-6977522ba3ac"
      unitRef="usd">3693000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjEtMy0xLTEtMA_e9648d80-5f04-438a-afee-3b1b96e2fa25"
      unitRef="usd">3700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjItMS0xLTEtMA_6c2c89c8-6e45-4280-8161-38839142d026"
      unitRef="usd">60443000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjItMy0xLTEtMA_a0a754a7-58e4-456b-bbda-5e0f9a0d7c87"
      unitRef="usd">65511000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjMtMS0xLTEtMA_d55aa532-1429-4335-be85-c009991a78e7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjMtMy0xLTEtMA_d21cf64f-d831-4190-aa40-1ced172687c5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmFjZmQ1NDM3OWMzMDRkMTFiMjAyMGRkNDhmNGNhMmJmXzIx_59aae767-2a0b-4eab-87a5-970b2287134b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOmFjZmQ1NDM3OWMzMDRkMTFiMjAyMGRkNDhmNGNhMmJmXzIx_ef418542-1ffe-4dda-ac25-bdb60b5e5d72"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmJlYjM0YWUxOTQ3NTQ0ODhiOTQxN2RmZGJmZDIyNDE3XzIz_374e364d-364d-48f9-ac7c-ef2f4644bdea"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOmJlYjM0YWUxOTQ3NTQ0ODhiOTQxN2RmZGJmZDIyNDE3XzIz_9b9c4546-b2b5-476f-8666-7cffeb49ea2b"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjg3YjExNzlhNDhjZjQ0OGRiMTRhOGI2NmFmNmFjYjQ5XzM1_25764e43-6af3-4881-ba76-f5e24bdcbdce"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjg3YjExNzlhNDhjZjQ0OGRiMTRhOGI2NmFmNmFjYjQ5XzM1_9a74e809-1fc8-44a4-aa86-714a654f74c8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjg3YjExNzlhNDhjZjQ0OGRiMTRhOGI2NmFmNmFjYjQ5XzM1_a8330323-bee1-4304-8393-5c525197a16f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjg3YjExNzlhNDhjZjQ0OGRiMTRhOGI2NmFmNmFjYjQ5XzM1_b069c124-288b-468d-862e-34ce223ef6ce"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMS0xLTEtMA_f7bdbb00-ad76-4ca5-81f8-22db58ac18e4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjctMy0xLTEtMA_22591c2b-ab1a-4d37-9a45-181e31760835"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZjOGQ5OWRmYzQ2YzRhMDA5ZjNkNDhkYjgyNTMyYjU2XzE4_13b88fb4-6921-4d07-a637-ad224662655a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZjOGQ5OWRmYzQ2YzRhMDA5ZjNkNDhkYjgyNTMyYjU2XzE4_92191fca-eaa9-4f6b-b838-ead533c3d61b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmM1YTQyNzhhMmQ4NDRjMzRiY2ZhNmY2NjE0MTdjOWE1XzIz_19954524-4d8b-41b6-aa5f-b9a7e6493c3b"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmM1YTQyNzhhMmQ4NDRjMzRiY2ZhNmY2NjE0MTdjOWE1XzIz_73fc58ed-01f0-45ba-b3a1-2b805555120e"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjNkZWJhMTY3NDNlMDQyZDM4ZjRkYmQ1YTkwYzBmOGZmXzM1_b8ae431b-8a22-4cc2-8ce3-e3833fad1d0b"
      unitRef="shares">33610099</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjNkZWJhMTY3NDNlMDQyZDM4ZjRkYmQ1YTkwYzBmOGZmXzM1_dd3f075e-1bec-4866-9098-0e4877144e18"
      unitRef="shares">33610099</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjNkZWJhMTY3NDNlMDQyZDM4ZjRkYmQ1YTkwYzBmOGZmXzQy_757fd9b9-b743-4e26-aa26-3bcb8baebd54"
      unitRef="shares">31255267</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjNkZWJhMTY3NDNlMDQyZDM4ZjRkYmQ1YTkwYzBmOGZmXzQy_c5a43e60-94fb-445a-98e6-52b25afea177"
      unitRef="shares">31255267</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMS0xLTEtMA_280528ba-9783-4e93-8b1d-93ab6f3200f0"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzAtMy0xLTEtMA_f0717659-b28c-4c9f-be85-10e177c056ca"
      unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzEtMS0xLTEtMA_5cdf1255-a583-4359-ab2d-e980fbad1b9e"
      unitRef="usd">338550000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzEtMy0xLTEtMA_ea024362-b815-4856-a255-573c2dca6ce7"
      unitRef="usd">263384000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzItMS0xLTEtMA_217658d0-e2e7-4f51-b02b-86e5b674439f"
      unitRef="usd">316000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzItMy0xLTEtMA_eafd1b31-942c-4b65-85aa-20f98f2965bb"
      unitRef="usd">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzMtMS0xLTEtMA_e5e0c414-cbb6-433e-9891-2a1ae1d62daa"
      unitRef="usd">-211820000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzMtMy0xLTEtMA_4a911af3-3e27-466e-934b-070db7f2e57e"
      unitRef="usd">-191526000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzQtMS0xLTEtMA_de0d7fcd-51ad-4355-abee-a895ff41ef59"
      unitRef="usd">127080000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzQtMy0xLTEtMA_94d4bf0c-e3f5-40be-bc12-6dd6306951a6"
      unitRef="usd">71891000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzUtMS0xLTEtMA_6f596b22-a6ea-4560-9f38-e9182f0ced02"
      unitRef="usd">187523000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8xOS9mcmFnOjFiNTJjZDgwYTA1NDQ4YmJiMDhkOTA1NjRjMWQ2ZmJkL3RhYmxlOjgzNWVlODNjM2ZiZDRmNDFiYmQ2MTUzMDYwZjc4ZGY1L3RhYmxlcmFuZ2U6ODM1ZWU4M2MzZmJkNGY0MWJiZDYxNTMwNjBmNzhkZjVfMzUtMy0xLTEtMA_0aa855f5-941a-4658-bca4-64bb35c122ef"
      unitRef="usd">137402000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMy0xLTEtMS0zNTk_fac33f3f-97d3-4a7d-8fa9-e1cf8927fbac"
      unitRef="usd">15094000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMy0zLTEtMS0zNTk_2c7b815d-3743-4ebb-b2e2-7b1074d7ee09"
      unitRef="usd">14928000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMy0xLTEtMS0w_ca1155bc-e573-441f-89da-4795a950e457"
      unitRef="usd">34027000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMy0zLTEtMS0w_8cf52d02-0934-431b-9bc2-3e465ecfdc4b"
      unitRef="usd">27694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNC0xLTEtMS0zNTk_79fe1d92-59d4-4101-a0b1-644036664f5d"
      unitRef="usd">5336000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNC0zLTEtMS0zNTk_d9ac9817-4a30-4b7a-ada3-ce736d77e06c"
      unitRef="usd">3697000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNC0xLTEtMS0w_c01fa4b5-7ddb-4833-af5a-c2ae0acba5e3"
      unitRef="usd">10586000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNC0zLTEtMS0w_f7cbd8d2-e7c8-4cd2-9cd6-945717648486"
      unitRef="usd">7035000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNS0xLTEtMS0zNTk_bf9b8f6c-b55b-488e-8c55-63b602bd0b06"
      unitRef="usd">9758000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNS0zLTEtMS0zNTk_8a20956b-8513-4cd4-99bd-0346deee8d2e"
      unitRef="usd">11231000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNS0xLTEtMS0w_dafbd3ba-be5d-431f-a075-6f0ba2d14a88"
      unitRef="usd">23441000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNS0zLTEtMS0w_63e2f673-ec3d-4e6a-8d9a-0e4ac0f5af5c"
      unitRef="usd">20659000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNy0xLTEtMS0zNTk_64565220-d7f9-4429-9833-ec368fb13734"
      unitRef="usd">3393000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNy0zLTEtMS0zNTk_db6e034a-184a-4eac-996f-01a0da5dc780"
      unitRef="usd">3113000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNy0xLTEtMS0w_ec45b880-6056-442e-bd5a-843d762dec5e"
      unitRef="usd">6522000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfNy0zLTEtMS0w_eef3baf9-51ab-407b-8239-fa8cc80c3c77"
      unitRef="usd">5820000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOC0xLTEtMS0zNTk_1ae0b858-7a85-4295-a78b-7192e79ba511"
      unitRef="usd">15758000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOC0zLTEtMS0zNTk_7e9bdf4f-73df-4582-ac25-627710e6b44d"
      unitRef="usd">14135000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOC0xLTEtMS0w_195af06b-969a-487d-82f7-e86720c375d3"
      unitRef="usd">35450000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOC0zLTEtMS0w_241acc7a-1ca1-43ef-9088-132082a6f0df"
      unitRef="usd">28001000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOS0xLTEtMS0zNTk_3e77edd4-3b9f-4600-9326-9b86413c5989"
      unitRef="usd">19151000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOS0zLTEtMS0zNTk_a6fd7715-6416-43f0-9915-ac50b7e423a3"
      unitRef="usd">17248000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOS0xLTEtMS0w_b4ffdcde-2f0f-40e3-afd6-739298db0a3e"
      unitRef="usd">41972000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfOS0zLTEtMS0w_47d63aeb-d500-4668-b352-e9b0319a2804"
      unitRef="usd">33821000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTAtMS0xLTEtMzU5_5e5fdc69-c23a-48d6-8dfa-1b7d79d4b797"
      unitRef="usd">-9393000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTAtMy0xLTEtMzU5_31dc5b4f-a442-4927-99f7-40c21147378a"
      unitRef="usd">-6017000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTAtMS0xLTEtMA_cbfad264-db50-4092-a0b4-673732c9b1cf"
      unitRef="usd">-18531000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTAtMy0xLTEtMA_c8fef88c-0f44-459a-bed6-94f556a88d35"
      unitRef="usd">-13162000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTEtMS0xLTEtMzU5_398606ef-994f-47b2-8564-e000daba7144"
      unitRef="usd">299000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTEtMy0xLTEtMzU5_fc5bd795-58a4-4e86-8cbb-610b25a704f0"
      unitRef="usd">598000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTEtMS0xLTEtMA_a5c9eca5-b0c4-4422-bc4a-662984f0c8f3"
      unitRef="usd">702000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTEtMy0xLTEtMA_9fd82cc0-bcc1-4457-a362-8888240fc62d"
      unitRef="usd">650000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTItMS0xLTEtMzU5_a1bdac6e-d29d-4dfb-b805-6cad3dafc01c"
      unitRef="usd">1203000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTItMy0xLTEtMzU5_f6617e8b-9fd5-440a-aa62-d8d825d36412"
      unitRef="usd">1207000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTItMS0xLTEtMA_c40abeb5-8c9e-466d-927b-1187b0f8f93f"
      unitRef="usd">2406000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTItMy0xLTEtMA_7ab5f935-c27b-47e3-b155-c2c0acd9c3c5"
      unitRef="usd">2560000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTMtMS0xLTEtMzU5_ad00b052-1dad-4769-9b37-e005e7c5f6eb"
      unitRef="usd">-56000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTMtMy0xLTEtMzU5_b74c1291-35fb-4c0f-b2c6-73e1a842e22a"
      unitRef="usd">-5333000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTMtMS0xLTEtMA_d608921e-e65a-42df-963f-3b81f4a09cfa"
      unitRef="usd">-59000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTMtMy0xLTEtMA_d71788c7-e98b-4675-b857-2a0146d4ad96"
      unitRef="usd">-21045000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTQtMS0xLTEtMzU5_1f86bd9a-5c3c-48d0-9a5b-1564cf64c564"
      unitRef="usd">-10353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTQtMy0xLTEtMzU5_66ec344f-c2d9-4bd1-8a09-f005bdc7721f"
      unitRef="usd">-11959000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTQtMS0xLTEtMA_25dc7e5b-66d8-4f22-ba75-dd5d034ce8fd"
      unitRef="usd">-20294000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTQtMy0xLTEtMA_272518d4-b292-44e7-90d1-7f340e11c298"
      unitRef="usd">-36117000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTYtMS0xLTEtMzU5_0ea2112f-c9dc-4137-a250-fbe9d57907ab"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTYtMy0xLTEtMzU5_eafd44ed-6de9-45c2-94cc-c6d8aef7795c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTYtMS0xLTEtMA_5e5dbad0-aad7-4528-a02b-ee0023ec07b5"
      unitRef="usd">314000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTYtMy0xLTEtMA_a155737d-0df9-48c5-8b31-20801a5a5460"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTctMS0xLTEtMzU5_938f259a-4ff6-4426-b700-4ac2839c4fc2"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTctMy0xLTEtMzU5_259409a8-eb20-400f-9e18-307e43609d8c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTctMS0xLTEtMA_2decf19c-43ab-4727-b85c-f13fd274a38c"
      unitRef="usd">314000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTctMy0xLTEtMA_fe8f0700-1abe-4cf4-b393-ef9a8cffa586"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTgtMS0xLTEtMzU5_d3238122-de73-46e8-ac7d-e103dc3ccf11"
      unitRef="usd">-10479000</silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent>
    <silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTgtMy0xLTEtMzU5_d8c4141d-578f-4049-9114-9e5828c842b0"
      unitRef="usd">-11959000</silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent>
    <silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTgtMS0xLTEtMA_d2af5e85-2c96-4c20-aa28-6434acfbffab"
      unitRef="usd">-19980000</silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent>
    <silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTgtMy0xLTEtMA_a946c601-bfc8-4b79-bb7d-bf9f60e87652"
      unitRef="usd">-36117000</silk:NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTktMS0xLTEtMzU5_08d73136-b8b4-4053-b927-e3fc1776c45f"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTktMy0xLTEtMzU5_6b04ec3f-befb-4600-a7c8-5e69f8136b58"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTktMS0xLTEtMA_acf52adb-5081-49b5-b2f1-836ba229baba"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMTktMy0xLTEtMA_b97ca1ac-0934-4b3e-9c1d-48273aa803f0"
      unitRef="usdPerShare">-2.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMjAtMS0xLTEtMzU5_4957e866-d4c8-415b-ac1b-4f1ad5e31c4e"
      unitRef="shares">32682360</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMjAtMy0xLTEtMzU5_8262d080-25dc-4da9-95c0-1fbd791c386c"
      unitRef="shares">28458793</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMjAtMS0xLTEtMA_a5de77f0-5a6f-4b9d-81ab-494eb987089e"
      unitRef="shares">32010335</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yMi9mcmFnOjUxMmUzMjZiMmJjNTQwY2U4MTc5YTYyMTY0MjRkMWEwL3RhYmxlOjQ2Njk5MGQyODBmNzRiZWRhNGNjN2ZlMzJlMWNiOWJhL3RhYmxlcmFuZ2U6NDY2OTkwZDI4MGY3NGJlZGE0Y2M3ZmUzMmUxY2I5YmFfMjAtMy0xLTEtMA_5a1ce8c1-8d5b-4a7f-b638-eac29a791734"
      unitRef="shares">14905052</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="ie9e3e7e58fd643a9b81d6acc10d20212_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi0xLTEtMS0w_c2167fe2-2e74-48ce-86cc-c686b6e4e8bb"
      unitRef="shares">31255267</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie9e3e7e58fd643a9b81d6acc10d20212_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi0zLTEtMS0w_7e84d80a-5554-47a9-8895-0dbee680ca02"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01edde7dedb544328d6997373cf6ad4a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi01LTEtMS0w_033ab2c1-87b0-4762-b3db-458c24ab86d6"
      unitRef="usd">263384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia02f7ba2764646e98fe313a3f6b45aff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi03LTEtMS0w_e22cf88f-c840-40a3-9fff-ac73252c3c16"
      unitRef="usd">-191526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0efec5d2df54499d877b5b7f2c50296e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi05LTEtMS0w_1fb323d6-ba22-4db9-99ba-892b8ae789fe"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMi0xMS0xLTEtMA_2de11fca-9363-4a4a-9315-00c430040801"
      unitRef="usd">71891000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i63b35b01b32f46f2bee4f4a23b7012a2_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMy0xLTEtMS0w_0ee6b361-4fc6-4cd4-a5e2-52f24f333402"
      unitRef="shares">140370</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia98288daaa954dd1875ff62ad62c8371_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMy01LTEtMS0w_a89442d2-5988-4260-a7ae-564b972354be"
      unitRef="usd">274000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i412e80de80294636915c387579e51a98_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMy0xMS0xLTEtMA_090022b8-e98d-4d1f-a87e-8c500becf6c0"
      unitRef="usd">274000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia98288daaa954dd1875ff62ad62c8371_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNC01LTEtMS0w_4dc934f9-bf17-4884-a42b-3a8c2c6c0f33"
      unitRef="usd">1293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i412e80de80294636915c387579e51a98_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNC0xMS0xLTEtMA_2643fc60-1771-43be-b1ca-7a945f5c0101"
      unitRef="usd">1293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i2813994ece5044d3b7db1695fbd0eb1f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNS03LTEtMS0w_eefedd8a-e86d-4a06-b38c-bc262eda964c"
      unitRef="usd">-9941000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i412e80de80294636915c387579e51a98_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNS0xMS0xLTEtMA_da16e683-c478-499b-9394-e78dc97f9514"
      unitRef="usd">-9941000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i893baa7990094d9996aef955612bf12c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNi05LTEtMS0w_0edc470e-373d-4204-9513-802221f57b1a"
      unitRef="usd">440000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i412e80de80294636915c387579e51a98_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNi0xMS0xLTEtMA_4af319ba-b688-4610-adc8-5d24a60a6105"
      unitRef="usd">440000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:SharesOutstanding
      contextRef="if97360d0e3024fcd99b7a9761e90b309_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy0xLTEtMS0w_8188426d-7f6b-4aa5-99f1-08526aceb40b"
      unitRef="shares">31395637</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if97360d0e3024fcd99b7a9761e90b309_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy0zLTEtMS0w_e21edf4a-1b86-4d91-b542-0d544260da6e"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad155abbc9754495b06722da098ba394_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy01LTEtMS0w_b64e59ad-3c88-4aa3-92f8-1512b0761269"
      unitRef="usd">264951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b44a6c1a4d7438a86dff3e0e151961a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy03LTEtMS0w_ffe8c84c-5486-439c-9ec6-5c8886b5de3d"
      unitRef="usd">-201467000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i250d8d2fc5a44833b091f0a0021c1f1f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy05LTEtMS0w_efac4f46-11e8-49f1-8013-4b65913edeb9"
      unitRef="usd">442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa53cd55d6d640ff87711fd4e0f8ef56_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfNy0xMS0xLTEtMA_44957733-8b75-4c74-b0f0-e907bf540d52"
      unitRef="usd">63957000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0wLTEtMS0zMDE1L3RleHRyZWdpb246OWVmN2VmMTNmYzYyNGJiN2EwODQxM2I2M2M3ZDIwZjZfMTA5OTUxMTYyNzkxNw_9e0aa8a4-bae3-4506-816a-da9c909e0ed9"
      unitRef="usd">4457000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8d433da600ff424d9072d74a4800426b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0xLTEtMS01OTM_68a3ae1a-893e-47ad-94ca-dad9bea1e2ce"
      unitRef="shares">1923076</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8d433da600ff424d9072d74a4800426b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0zLTEtMS01OTM_40b71db7-5ee0-451b-ba58-dae2eaf53a53"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i71269ca1bb0048df93fdfb7f60583aca_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC01LTEtMS01OTM_cb5cbdc9-656b-4d30-8c0f-0d2c84a98b2b"
      unitRef="usd">70541000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6f1ba60825d14c648abad9bad89c5116_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0xMS0xLTEtNTg3_68ab7845-c619-4bb7-83d4-2550f401334c"
      unitRef="usd">70543000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if5c4b78f734744bb9a7efbc2c9838e21_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0xLTEtMS00NA_8c622d08-be96-4015-9669-39b1d3fb3bb1"
      unitRef="shares">265467</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if5c4b78f734744bb9a7efbc2c9838e21_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0zLTEtMS00NA_e1089268-6f51-4b01-99dd-cebc84eef36f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i01cbace60dde45c3b3e3b6d6de1dc3cb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC01LTEtMS00NA_73ba2a09-d946-4cb1-be0a-81f9262ed100"
      unitRef="usd">603000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOC0xMS0xLTEtNDQ_d41b1e11-935b-48f7-bc49-e00f2f90169c"
      unitRef="usd">604000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if5c4b78f734744bb9a7efbc2c9838e21_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtMS0xLTEtNTkz_d7691bdf-c76f-46fd-a1d7-617b09a351a3"
      unitRef="shares">25919</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i01cbace60dde45c3b3e3b6d6de1dc3cb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtNS0xLTEtNTkz_a8914bb8-97da-44f7-a7f5-4e819a54fb14"
      unitRef="usd">801000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtMTEtMS0xLTU4Nw_a61502aa-2ae2-4e85-a2f2-715c3c2f4936"
      unitRef="usd">801000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i01cbace60dde45c3b3e3b6d6de1dc3cb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOS01LTEtMS00NA_97f66e3d-f6ee-45ad-95f2-fa0eda84ba4c"
      unitRef="usd">1654000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfOS0xMS0xLTEtNDQ_d3b7c667-778f-44c6-a5da-f70b07159bd7"
      unitRef="usd">1654000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i5abe689d4c9b45d590e6081f66e9d892_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtNy0xLTEtNDQ_ef82c480-528c-4f61-a30e-481b6aac6139"
      unitRef="usd">-10353000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTAtMTEtMS0xLTQ0_458e91c0-1d4e-44d0-932a-047069ded363"
      unitRef="usd">-10353000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i95e493ed76734fa9b072ff4c78d00454_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTEtOS0xLTEtNDQ_235b5aea-764c-4540-b28d-432c4f0dbd5b"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTEtMTEtMS0xLTQ0_1acdc813-eea5-4c6c-a305-bb9d6507a745"
      unitRef="usd">-126000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:SharesOutstanding
      contextRef="iba95761be90e4d0b871436b1bc3e613f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItMS0xLTEtNDQ_3e098de5-ac37-4e15-b9c4-4a0894a69975"
      unitRef="shares">33610099</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iba95761be90e4d0b871436b1bc3e613f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItMy0xLTEtNDQ_915933cd-5a05-45a3-9db1-f28de9332825"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie87ca05332314ce38d1c838f1918033d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItNS0xLTEtNDQ_579eb07e-fd95-4a2a-9323-eec5ec36907b"
      unitRef="usd">338550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if195c2966bd4478b9a536e42c4729969_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItNy0xLTEtNDQ_9a927162-4ba4-44d4-a442-dd1fa8110c4c"
      unitRef="usd">-211820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i267c658bb1a64c4cb3087e17e6ba0504_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItOS0xLTEtNDQ_725d0638-36ee-4167-8124-099678b565f0"
      unitRef="usd">316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOjBhMjY3MDdkMWVmODRkM2Q4MWI0ZDUxYzMxNTBjZDgwL3RhYmxlcmFuZ2U6MGEyNjcwN2QxZWY4NGQzZDgxYjRkNTFjMzE1MGNkODBfMTItMTEtMS0xLTQ0_ea814cc8-cfeb-494d-9010-677e53978183"
      unitRef="usd">127080000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xLTEtMS0w_174a386e-1bbc-4990-be6d-d1c78793d3af"
      unitRef="shares">21233190</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0zLTEtMS0w_02753622-0e8e-49b9-a2c6-06e9c7c4500a"
      unitRef="usd">105235000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0zLTEtMS0w_d14488d4-7182-49fb-9fd0-7aeac235ffff"
      unitRef="usd">105235000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i44fb74c77caa45feb1b93e73036b664d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi02LTEtMS0w_ac38ea50-dc71-4ab3-a92f-90e0ec626122"
      unitRef="shares">1135310</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i44fb74c77caa45feb1b93e73036b664d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi04LTEtMS0w_7bf34633-3849-4405-bac3-a1b817ffbe78"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97f3122f97654386982663f091f8be2a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xMC0xLTEtMA_4affc8e6-4896-47e7-aaea-dd6b3ed34313"
      unitRef="usd">4557000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18115e334dfb4939bf22d7f51604a743_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xMi0xLTEtMA_2f21c417-2c1d-4992-b72e-3bf373b6fb8d"
      unitRef="usd">-139111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2974baeced5b42539df2ce7e5d9fd970_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xNC0xLTEtMA_61eab91f-b3a4-4490-af00-51ed5f64fa5b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMi0xNi0xLTEtMA_1604fc90-dc16-4fff-934b-79b17c42f710"
      unitRef="usd">-134553000</us-gaap:StockholdersEquity>
    <silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMy0xLTEtMS0w_310340f5-ba5d-4ca1-b6b2-992ead130806"
      unitRef="shares">4915</silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMy0zLTEtMS0w_f78e2714-d762-4ace-9125-4e4323c48851"
      unitRef="usd">30000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia013b4eb40114308be33eb29a813111d_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNC02LTEtMS0w_b597fca7-f7d2-42d8-b50d-bf10794a2dac"
      unitRef="shares">251305</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0b16f07a785142d7af5301cf48c4d820_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNC0xMC0xLTEtMA_aa28af89-45ab-443e-8132-17d8aeec7092"
      unitRef="usd">375000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNC0xNi0xLTEtMA_15b09f95-239d-479d-a1cd-c48c453b63f0"
      unitRef="usd">375000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0b16f07a785142d7af5301cf48c4d820_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNS0xMC0xLTEtMA_2ed296e7-95bb-459a-9fe2-bd776983236c"
      unitRef="usd">262000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNS0xNi0xLTEtMA_b95d0e05-d8c5-4d7c-84a0-6c709385aaeb"
      unitRef="usd">262000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i4fa337a09be04535b922d4ff23c908d4_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNi0xMi0xLTEtMA_5caaa073-07d1-4ccb-b155-cd65f582802b"
      unitRef="usd">-24158000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4fa337a09be04535b922d4ff23c908d4_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNi0xMi0xLTEtMA_c81cec6f-5d3d-4b19-aa75-1591c79c2fae"
      unitRef="usd">-24158000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNi0xNi0xLTEtMA_3b48794c-199b-4668-9f09-cd295e2ff7b4"
      unitRef="usd">-24158000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69b6f1148feb4497b99389b263100226_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNi0xNi0xLTEtMA_6c31c829-b1bd-45a9-a1c0-44dc2f4c0c72"
      unitRef="usd">-24158000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ib2b2a6a89c1143b79a1fde2400691f14_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xLTEtMS0w_1004ecfc-a8b3-41e2-96bc-6cccc2ba8428"
      unitRef="shares">21238105</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ib2b2a6a89c1143b79a1fde2400691f14_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0zLTEtMS0w_ed4659a1-784a-4743-92af-240207d3fca1"
      unitRef="usd">105265000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i9fd18f4a372d4ab3bbe21e94964f88b0_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy02LTEtMS0w_3177a640-0d50-4b00-86b4-da7b77dc1c3b"
      unitRef="shares">1386615</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9fd18f4a372d4ab3bbe21e94964f88b0_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy04LTEtMS0w_94886cc6-b38d-40d6-9dd8-f616162a6201"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35d13e334d474ffca707c39e945c4b18_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xMC0xLTEtMA_1e41ed29-e330-4ceb-aba6-d5a09ba0e2ac"
      unitRef="usd">5194000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i042388ebf8da4a30880f8f9e5c039e53_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xMi0xLTEtMA_dec7aa45-5640-4caf-af15-ac41e3c7d4ca"
      unitRef="usd">-163269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c6892eaf5054997bc5db44ea630d3b8_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xNC0xLTEtMA_b5e163e7-8dee-4dcb-8c2c-3cbe6cf08136"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2b2a6a89c1143b79a1fde2400691f14_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfNy0xNi0xLTEtMA_3879811f-b8ca-4a79-a1f9-066cbce8af5b"
      unitRef="usd">-158074000</us-gaap:StockholdersEquity>
    <silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOC0xLTEtMS01NA_cec4a785-b52d-4b4a-809f-4e05d5de801b"
      unitRef="shares">287446</silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOC0zLTEtMS01NA_5105fa7b-0061-4d67-a30e-d3f4c5e3ebc5"
      unitRef="usd">1754000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id2e3b1c19991473a9eda55c27b7a6352_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS02LTEtMS02MzI_fde20aab-51b9-4aa8-88be-861d13400112"
      unitRef="shares">3764</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i857c634bdb34432c8b74d2c01c998fde_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS0xMC0xLTEtNjMy_49905adb-881a-41ea-90d6-5f75bc8ef710"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS0xNi0xLTEtNjM4_03559c94-e6d1-4091-8104-3ec08eef6a4e"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMC0xLTEtMzAwMS90ZXh0cmVnaW9uOjFmYTU5NTNlODM1MjRlNDNhNzRjOTc4N2UwY2ViYzg4XzEwOTk1MTE2Mjc4OTQ_e7090daf-c230-410f-b1c8-e4a6210b202a"
      unitRef="usd">10961000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtNi0xLTEtNjMy_d3f4e421-ef63-4fbe-9ddc-643cff5e2bca"
      unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtOC0xLTEtNjMy_e0385237-9a66-412c-bd2e-ed12f6e39727"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0d224a2b66764827814bf9c8f036c6fd_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMTAtMS0xLTYzMg_9d0b5b0e-4332-4698-95b4-59b7b61472f1"
      unitRef="usd">109033000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMTYtMS0xLTYzOA_cba5cc84-f247-407e-b10e-58e4d162ec5c"
      unitRef="usd">109039000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares
      contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMS0xLTEtNjI2_aa2a360b-cb7f-484a-9544-d731f1e271d1"
      unitRef="shares">23178555</silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares>
    <silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue
      contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMy0xLTEtNjI2_362574e3-5851-4413-9423-1a2deb57eccf"
      unitRef="usd">144140000</silk:TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtNi0xLTEtNjMy_ed1cd11f-fd76-40cb-ba42-358dd975e841"
      unitRef="shares">23178555</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtOC0xLTEtNjMy_d7414fe0-2949-45ce-aa34-65266bba87d5"
      unitRef="usd">23000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0d224a2b66764827814bf9c8f036c6fd_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTAtMS0xLTYzMg_b466dcd6-6bc2-4e09-86a9-ba13edce9702"
      unitRef="usd">144117000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTYtMS0xLTYzOA_d1cfe018-94b6-4f6d-9010-16569f14b29e"
      unitRef="usd">144140000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMS0xLTEtNjI2_6d24ecea-b379-4afc-9ff6-fae90de383c3"
      unitRef="shares">1653004</silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i1265a665ab5f4dfe98b12f38aa46286c_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMy0xLTEtNjI2_d97c941e-3405-41d9-ae55-39f60a7eac1c"
      unitRef="usd">37121000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if0eced85b3c34e4aa7de583d205a74f4_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTMtNi0xLTEtNjMy_8058499f-9d4c-4d7d-b748-e52740d2ca36"
      unitRef="shares">2204</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id2e3b1c19991473a9eda55c27b7a6352_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS02LTEtMS01NA_7de7c58a-bb8b-415e-80b2-73cd80ed4bdd"
      unitRef="shares">176576</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id2e3b1c19991473a9eda55c27b7a6352_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS04LTEtMS01NA_ea3729da-f817-487a-aebf-55d1ebfebaf3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i857c634bdb34432c8b74d2c01c998fde_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS0xMC0xLTEtNTQ_c159cf20-1b7f-4198-8015-e8e446a3ef88"
      unitRef="usd">363000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfOS0xNi0xLTEtNTQ_b793e2e7-cd97-41e6-9727-d3048341232a"
      unitRef="usd">364000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i857c634bdb34432c8b74d2c01c998fde_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMTAtMS0xLTU0_9d310b01-e9e1-4101-9f1f-d5cc50856a57"
      unitRef="usd">836000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTAtMTYtMS0xLTU0_5aa97a02-41f4-4380-9ba7-92dddadff903"
      unitRef="usd">836000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb63e8b0926842298836b1c7a48b5ad7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTItMS0xLTU0_881b3e7b-165c-418b-a634-422e599b18ba"
      unitRef="usd">-11959000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ieb63e8b0926842298836b1c7a48b5ad7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTItMS0xLTU0_8b1600ba-7d16-48ea-bbcc-737193cf9837"
      unitRef="usd">-11959000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTYtMS0xLTU0_aca65261-f892-4ca0-a563-81fb8fcdb222"
      unitRef="usd">-11959000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTEtMTYtMS0xLTU0_cbacc542-5632-4590-8781-ed70f3b42f54"
      unitRef="usd">-11959000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7e86f21e817747e1b323fa24e138daa7_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMS0xLTEtNTQ_e86e21c2-ef1b-4643-bedd-981d603a32f2"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7e86f21e817747e1b323fa24e138daa7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMy0xLTEtNTQ_f986d528-b127-47e0-b7c5-1ae06669a8e0"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i907247d422b04c4daa972b713b2650e5_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItNi0xLTEtNTQ_609c1d3a-a195-4568-adf0-35221d1a35e0"
      unitRef="shares">30747714</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i907247d422b04c4daa972b713b2650e5_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItOC0xLTEtNTQ_0c5a58e7-cb80-4596-948a-fb221a2e794e"
      unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8771181b78740329cdb8290b99f0331_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMTAtMS0xLTU0_67b2f636-9a61-4590-bc34-7ee7271f8de9"
      unitRef="usd">259574000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b36e442f3114a22ba850f63b846e6f4_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMTItMS0xLTU0_04973859-1ac8-40b3-99e4-8ccbbb2d9677"
      unitRef="usd">-175228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0bdf7b91752347eb8ff1ad32bb419fc9_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMTQtMS0xLTU0_81659f6b-ae71-4d7d-9b41-e6e2fb460540"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e86f21e817747e1b323fa24e138daa7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yNS9mcmFnOjFjMzE5ZmYzMjg1NDQwNWI4ZmM4NDk1MTkyN2FjY2I2L3RhYmxlOmE0NGExODM3MzIwMDRmY2ZhMTRlYTNiYjkxN2ZhNjliL3RhYmxlcmFuZ2U6YTQ0YTE4MzczMjAwNGZjZmExNGVhM2JiOTE3ZmE2OWJfMTItMTYtMS0xLTU0_c1fe5ba2-a8fd-4ceb-9173-633cb1d95712"
      unitRef="usd">84377000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMy0xLTEtMS0w_01462749-945b-4c5a-a1c6-ad9ea8748894"
      unitRef="usd">-20294000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMy0zLTEtMS0w_670cdcc9-f268-4d41-8f45-7a5d73cbf661"
      unitRef="usd">-36117000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNS0xLTEtMS0w_b0745ddf-0e47-4bf2-9775-18f0a5d6a6a6"
      unitRef="usd">368000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNS0zLTEtMS0w_29e4fc95-82e0-49c4-86e0-0d6c139d050b"
      unitRef="usd">350000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNi0xLTEtMS0w_60b6dc3a-75af-45d5-b7f4-587dcec212a9"
      unitRef="usd">2947000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNi0zLTEtMS0w_5969a341-4332-4ac7-be9a-9ede21a73e52"
      unitRef="usd">1099000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNy0xLTEtMS0w_9bb07b4e-be47-4764-8744-c42654d18706"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNy0zLTEtMS0w_a1a07634-13c4-4d07-847f-ebcada0ef295"
      unitRef="usd">21030000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfOC0xLTEtMS0w_caae7c0d-5616-43a8-bbf0-eedbbf427ade"
      unitRef="usd">-57000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfOC0zLTEtMS0w_dd33d3fe-1cac-4b07-a1fc-00eb8ef66817"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfOS0xLTEtMS0w_d88ad6dc-1b80-4d25-bb0d-ff30702692a2"
      unitRef="usd">23000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfOS0zLTEtMS0w_bfa1f0ca-3946-4d6f-b839-2fa084f1a96d"
      unitRef="usd">22000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <silk:OperatingLeaseRightOfUseAssetAmortization
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTAtMS0xLTEtMA_d16dcd56-dae1-4a22-a194-f0788e505a8d"
      unitRef="usd">295000</silk:OperatingLeaseRightOfUseAssetAmortization>
    <silk:OperatingLeaseRightOfUseAssetAmortization
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTAtMy0xLTEtMA_007d15d6-c596-4b94-9d83-58e0e44a241d"
      unitRef="usd">300000</silk:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:PaidInKindInterest
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTEtMS0xLTEtMA_83a35479-5ef4-44c8-b68f-90597e2c4e16"
      unitRef="usd">167000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTEtMy0xLTEtMA_6a3e768c-c126-4216-ac4a-698cf9bde85e"
      unitRef="usd">555000</us-gaap:PaidInKindInterest>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTItMi0xLTEtNjkw_b0c36ff0-e83c-4f18-a5ec-f9915d8c6bdf"
      unitRef="usd">-51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTItNC0xLTEtNjkw_4d48e627-0718-41de-8492-4598e0c5e470"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTItMS0xLTEtMA_526e27ef-1ba8-43db-9178-2769de512b13"
      unitRef="usd">-9000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTItMy0xLTEtMA_03295a3e-c0ff-4eab-8fdd-0f12b291d452"
      unitRef="usd">123000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTMtMS0xLTEtMA_f0a4150b-8896-4464-8db7-69695650e699"
      unitRef="usd">105000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTMtMy0xLTEtMA_51eda68c-27da-48a8-be48-8f52b987e23e"
      unitRef="usd">43000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTUtMS0xLTEtMA_a9b675d5-38ff-404d-bc3e-4bbaa3b7cbb7"
      unitRef="usd">-857000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTUtMy0xLTEtMA_46fb17ec-44f4-4c3e-bbb6-bf47b246e96d"
      unitRef="usd">1622000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTYtMS0xLTEtMA_e4cf59cd-c200-4f8c-bdd2-c6bcd2d7a167"
      unitRef="usd">1404000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTYtMy0xLTEtMA_54efdff1-fb1c-4a97-8086-8927e83a4167"
      unitRef="usd">3262000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTctMS0xLTEtMA_914cfc2b-ad01-44d4-88be-dd65723bac31"
      unitRef="usd">986000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTctMy0xLTEtMA_2da32777-993a-4d7a-91a2-f7f8254eb8a3"
      unitRef="usd">1841000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTgtMS0xLTEtMA_e7d12ec8-2157-42d0-8646-28f694cfde66"
      unitRef="usd">-117000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTgtMy0xLTEtMA_a61a8fa0-84d6-45ce-a431-ca1786a0de50"
      unitRef="usd">-756000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTktMS0xLTEtMA_1795f788-3e68-4698-8f1f-c744d3b240f6"
      unitRef="usd">262000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMTktMy0xLTEtMA_5b541a2c-a064-4189-9873-775ff41d22a8"
      unitRef="usd">-45000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjAtMS0xLTEtMA_b1bbec7e-b5bb-4182-9936-dbed4dc22874"
      unitRef="usd">-5925000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjAtMy0xLTEtMA_15b5e029-161b-439e-a8ff-69c74d9ced18"
      unitRef="usd">978000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjEtMS0xLTEtMA_79034843-d35d-48c1-801f-9208002f1ea2"
      unitRef="usd">-7000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjEtMy0xLTEtMA_48c53bfe-f835-4d78-8959-9c494a33f444"
      unitRef="usd">-372000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjItMS0xLTEtMA_bfcac4f6-0653-4427-9848-3c9c5436547c"
      unitRef="usd">-23376000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjItMy0xLTEtMA_750cd500-2f7e-45a4-8031-a4470f0c1da8"
      unitRef="usd">-18003000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjUtMS0xLTEtMA_b153c0c1-3da6-4cfb-a11f-009d625412ba"
      unitRef="usd">479000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjUtMy0xLTEtMA_32c2c29f-3396-4fe8-913e-476eae33a1ba"
      unitRef="usd">206000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjctMS0xLTEtMA_6f4ea492-4d16-4326-b026-f100b7e91911"
      unitRef="usd">23606000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjctMy0xLTEtMA_73d83156-ddab-4813-95c1-f97517a7d764"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjgtMS0xLTEtMA_248a2d61-3403-4d21-a238-9929db8573ae"
      unitRef="usd">9180000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjgtMy0xLTEtMA_89f3a2b4-1764-458b-b50e-f5ca6c4d9667"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjktMS0xLTEtMA_32455115-dcce-4011-8769-ce57e40d1079"
      unitRef="usd">-14905000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMjktMy0xLTEtMA_bde4f2e5-b6fd-4745-bc27-d6863afe7fb5"
      unitRef="usd">-206000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzMtMS0xLTEtMA_72ce8d33-9cd4-4239-86a1-5b62df86bd81"
      unitRef="usd">70863000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzMtMy0xLTEtMA_dd875787-9c26-459d-8f02-bdf94ce6ef03"
      unitRef="usd">108913000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzQtMS0xLTEtMA_6a583ebf-9b15-48f5-a1ff-de1f9af2dd64"
      unitRef="usd">1679000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzQtMy0xLTEtMA_5e856e4e-d1db-4d33-b321-ada863f2c62b"
      unitRef="usd">738000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i9634e8ac71464a7c94802f90d75471fa_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzUtMS0xLTEtMA_55008034-527b-492f-95e3-65a374e973ca"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ic7239974596a4a39bd1824a432c2fd56_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzUtMy0xLTEtMA_b005162e-ac85-4aa8-b5be-5d3aef232b82"
      unitRef="usd">1784000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i57ad5239b3db46d4ad0d92c5293e2141_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzYtNS0xLTEtOTM_f468ad78-6486-4bfe-80e2-446c5a71fda2"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i05076e6e126f4a39a7b296a201b34ff2_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzYtNy0xLTEtOTM_50550219-d789-4e72-8ce9-709001627689"
      unitRef="usd">31000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzgtMS0xLTEtMA_7924cb8b-a460-4c3f-aac0-b95ecf99e17a"
      unitRef="usd">72542000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzgtMy0xLTEtMA_b593b978-58e9-4271-8a79-70c8f8c0ee17"
      unitRef="usd">111466000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzktMS0xLTEtMA_4f8fc6d0-c3f0-4291-a99a-84d2d48f6605"
      unitRef="usd">34261000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfMzktMy0xLTEtMA_e554b2bf-01af-437c-8abb-c3dbe345223b"
      unitRef="usd">93257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDAtMS0xLTEtMA_996b29fc-2337-46ed-ac69-1b6a541c49d9"
      unitRef="usd">39491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9766f2a2b567462db339a57d15a9b202_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDAtMy0xLTEtMA_8c325910-1485-492d-9626-2008e7899ab7"
      unitRef="usd">25300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDEtMS0xLTEtMA_8681a4fd-9d21-42b6-b539-decd8c5fe5c1"
      unitRef="usd">73752000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7e86f21e817747e1b323fa24e138daa7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDEtMy0xLTEtMA_c4c4dbe5-deba-4f02-8a0b-1050ba6f5f63"
      unitRef="usd">118557000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDQtMS0xLTEtMA_4c084eee-3de1-4822-b461-edaf40aaa20b"
      unitRef="usd">2216000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDQtMy0xLTEtMA_b45eec9e-2b20-4f35-96ec-97e396b38703"
      unitRef="usd">1982000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDctMS0xLTEtMA_413c1468-992c-4c74-8cec-7c8df2150042"
      unitRef="usd">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDctMy0xLTEtMA_fff463d2-4868-496c-a35a-39adbb62dea4"
      unitRef="usd">7000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <silk:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDktMS0xLTEtMA_5aa3b33d-3ac4-4fdf-a145-b2a49a335781"
      unitRef="usd">320000</silk:StockIssuanceCostsIncurredButNotYetPaid>
    <silk:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDktMy0xLTEtMA_f297e36c-2d6c-4db9-aa90-4a4cafdc36e1"
      unitRef="usd">358000</silk:StockIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNTAtMS0xLTEtMA_a92d2d3e-4bac-4329-8618-54e0b5620520"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNTAtMy0xLTEtMA_6cb856a7-d536-4fbb-9360-5c1919574b2f"
      unitRef="usd">3982000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDktMi0xLTEtNzI2_60fec3dd-86ed-40e2-812b-75f40d6c44a7"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNDktNC0xLTEtNzI2_b0f9b00c-cdae-4073-af66-4892f443abeb"
      unitRef="usd">37121000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNTAtMi0xLTEtNzI2_edfec398-87bf-4ad0-b108-bb5a40848d5c"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8yOC9mcmFnOjMwY2VlZDhiYWZiMjRhMWRhMGM2ODE0N2Q0NjQ5MzMxL3RhYmxlOjkyNzYzZDRhNTE5NjRkOTg5MmYyMmY2YjQzY2NhMGE0L3RhYmxlcmFuZ2U6OTI3NjNkNGE1MTk2NGQ5ODkyZjIyZjZiNDNjY2EwYTRfNTAtNC0xLTEtNzI2_76913e48-774e-4f78-9230-e31d7001ca9f"
      unitRef="usd">144140000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjc0ODc3OTA3Njc0Ng_e1333c82-67a2-4e11-8b77-98cb388753c6">Formation and Business of the Company &lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;The Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Silk Road Medical, Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware on March&#160;21,&#160;2007.  The Company has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke.  The Company's portfolio of TCAR products enable a new procedure, referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles.  The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  The Company commercialized its products in the United States in April 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 13, 2019, the Company&#x2019;s Board of Directors approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a 1-for-2.7 reverse stock split of the Company&#x2019;s common stock and redeemable convertible preferred stock to be consummated prior to the effectiveness of the Company&#x2019;s planned initial public offering, or IPO.  The reverse stock split was effected on March 27, 2019.  The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.  All the common stock, redeemable convertible preferred stock, stock options and warrants, and related per share amounts in the condensed financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2019, the Company issued and sold 6,000,000 shares of its common stock in its IPO at a public offering price of $20.00 per share, for net proceeds of approximately $109,119,000 after deducting underwriting discounts and commissions of approximately $8,400,000 and expenses of approximately $2,481,000. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock and the Company's outstanding warrants to purchase shares of common and redeemable convertible preferred stock were exercised, or automatically net exercised absent a prior election.  The exercises resulted in the reclassification of the fair value of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2019, the Company completed a secondary public offering of 4,200,000 shares of its common stock sold by certain selling stockholders, and the exercise in full of the underwriters' option to purchase 630,000 additional shares of its common stock from certain selling stockholders, at a public offering price of $39.50 per share.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In May 2020, the Company completed an underwritten public offering of 6,808,154 shares of its common stock, of which 1,923,076 shares were offered for sale by the Company and the remaining 4,885,078 shares were offered for sale by certain selling stockholders, at a public offering price of $39.00 per share. The Company received cash proceeds of approximately $70,543,000 after deducting underwriting discounts and commissions of approximately $3,750,000 and expenses of approximately $707,000. Also in May 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTc1NA_02294e93-5f93-418a-947f-bcafcd289ed3"
      unitRef="shares">6000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic94b432f83144c5da9c031a5551750d7_I20190430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTgyNQ_f23747ee-39bf-4042-88b3-d18a8746f315"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTg3Mw_82791fe5-9d0c-4ffe-9fcf-e7b7edbe301c"
      unitRef="usd">109119000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions
      contextRef="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTk0OA_f1311725-fb70-45ca-80c2-0f4fe026bfa6"
      unitRef="usd">8400000</silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMTk4MQ_b10f654f-2b34-4b6b-922f-6946c3001b2c"
      unitRef="usd">2481000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ide2816e79e1b4022bf0287f80bb4fdf9_D20190801-20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjU0NA_1d6cacfd-3c7e-4f5e-be93-5f4b378069ee"
      unitRef="shares">4200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i41cc7674876049d3a0d3f79031ac5f2e_D20190801-20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjY3Nw_f31f74e8-add8-4df4-bbee-fcd7f2c1e173"
      unitRef="shares">630000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7c3c231e674e41edb75743c3010ec1df_I20190831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjc4Mw_c64afa65-223f-4600-97fa-3a8a05dc5dc8"
      unitRef="usdPerShare">39.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia43b4977769d4b22b03b8b2e1b372461_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzQwMw_0591aef4-4dc5-4448-b503-072d1011d2f7"
      unitRef="shares">6808154</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib1f341d7b77348a3a2568b670d478a67_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzQwOQ_b08c2593-2dcd-4681-8b9b-b137129321c3"
      unitRef="shares">1923076</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4f15ecda3b414074877b40741ff55576_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzQxMg_6eda7d56-d3c7-4afb-a5ef-46f2f2604ef5"
      unitRef="shares">4885078</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i8daaa359899f42abbc96d5a68e4e2aca_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzczNA_5266ef22-67ef-4de7-a16e-711acdcc690e"
      unitRef="usdPerShare">39.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1Nzc4Mg_15b4d4bc-a82f-4f72-808a-5fb0546c3842"
      unitRef="usd">70543000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions
      contextRef="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1NzgwMQ_1c392e04-d230-45c5-adbd-f08d583632f2"
      unitRef="usd">3750000</silk:PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfNjA0NzMxMzk1Nzg4OA_898c2ab3-5e87-49e2-b2f6-613b40f4ade0"
      unitRef="usd">707000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i437937bf5c0144969e1100fcf3addf73_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl8zNC9mcmFnOjAyNzk5MjhhMjY3NjQzYzA4NzcwNWRhMzNkNmJkZTg4L3RleHRyZWdpb246MDI3OTkyOGEyNjc2NDNjMDg3NzA1ZGEzM2Q2YmRlODhfMjE5OTAyMzI2Mjg2MA_c314595b-2525-404d-938e-c52646e74a51"
      unitRef="shares">1021223</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2Mzg_668d2058-2935-4290-b959-a39ce7b3b99b">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of Preparation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of&#160;December&#160;31, 2019, and related disclosures,&#160;have been derived from the audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&#160;These unaudited condensed financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#x2019;s condensed financial information. The results of operations for the three and six months ended June&#160;30, 2020&#160;are not necessarily indicative of the results to be expected for the year ending&#160;December&#160;31, 2020&#160;or for any other interim period or for any other future year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying interim unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended&#160;December 31, 2019&#160;included in the Company's annual report on Form 10-K filed with the SEC on March 2, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Adjustment to Prior Period Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has adjusted the accompanying Condensed Statement of Cash Flows for the six months ended June 30, 2019 to increase each of the accounts receivable, net, and accrued liabilities amounts by $601,000 for an immaterial prior period error in the classification of provisions for returns from customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the provision for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Due to the coronavirus (&#x201c;COVID-19&#x201d;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has evaluated the estimated fair value of its financial instruments as of June&#160;30, 2020 and December&#160;31, 2019.  The carrying amounts of certain of the Company&#x2019;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of June&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s cash equivalents are entirely comprised of investments in money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash as of June&#160;30, 2020 and December&#160;31, 2019 consists of a letter of credit of $310,000 representing collateral for the Company's facility lease.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date.  Long-term investments have maturities greater than one year as of the balance sheet date.  All investments are recorded at fair value based on the fair value hierarchy.  Money market funds and United States treasury bills with an original maturity less than 90 days are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method.  Realized gains and losses are included in earnings, and are der&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ived for specific-identification method for determining the costs of investments sold.  Amortization of premiums and accretion of discounts are reported as a component of interest income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk, and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company is subject to risks related to the public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#x2019;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#x2019;s revenue while the pandemic continues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and United States treasury bills. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three and six months ended June&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s accounts receivable are due from a variety of health care organizations in the United States.  At June&#160;30, 2020 and December&#160;31, 2019, no customer represented 10% or more of the Company&#x2019;s accounts receivable.  For the three and six months ended June&#160;30, 2020 and 2019, there were no customers that represented 10% or more of revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company manufactures certain of its commercial products in-house.  Certain of the Company&#x2019;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent.  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#x2019;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#x2019;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;currently approved portfolio of products.  If clearance for the products in the current portfolio &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;were withdrawn by the FDA, this would have a material adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#x2019;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company&#x2019;s considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Redeemable Convertible Preferred Stock Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the condensed statements of operations and comprehensive loss.  The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised.  Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#x2019; equity.  Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#x2019; equity on the condensed balance sheet as events triggering the liquidation preferences were not solely within the Company&#x2019;s control.  Upon the closing of the Company's IPO, all shares of convertible preferred stock then outstanding converted into an aggregate of 23,178,555 shares of common stock&#160;resulting in the reclassification of $144,140,000 from outside of stockholders&#x2019; equity to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Reven&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;ue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." &#160;Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(i) identify the contract(s) with a customer; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(ii) identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(iii) determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(iv) allocate the transaction price to the performance obligations in the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(v) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, the Company recorded $179,000 and $128,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the condensed balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#x2019;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#x2019;s standard terms and conditions.&#160;&#160;The Company&#x2019;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For sales where the Company&#x2019;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#x2019;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectability is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale. As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component. The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the&#160;condensed statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the condensed balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company manufactures certain of its &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;portfolio of&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#x2019;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Stock&#x2013;Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 718,&#160;"Compensation-Stock Compensation."  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions. The Company accounts for option forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the condensed financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also follows the provisions of ASC 740-10, "A&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ccounting for Uncertainty in Income Taxes."  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the condensed financial statements.  It is the Company's policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;three and six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; months ended &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, the Company&#x2019;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the condensed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;statements of operations and comprehensive loss.  Accumulated other comprehensive income or loss is presented in the accompanying condensed balance sheet as a component of stockholders' equity.  For the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;three and six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; months ended &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, there was no difference between the Company's comprehensive loss and its net loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#x2019;s redeemable convertible preferred stock participate in any dividends declared by the Company and were therefore considered to be participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss per share was determined as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.673%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.461%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.463%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average common stock outstanding used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,682,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,458,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,010,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,905,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company's net loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.314%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,632,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,683,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,671,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,683,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company operates and manages its business as one reportable and operating segment.  The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.  All of the Company&#x2019;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment and the Company's right-of-use asset.  All of the Company&#x2019;s revenue was in the United States for the three and six months ended June&#160;30, 2020 and 2019, based on the shipping location of the external customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTM_b08741a3-1431-4d69-8a52-a02e48989f46">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of Preparation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of&#160;December&#160;31, 2019, and related disclosures,&#160;have been derived from the audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&#160;These unaudited condensed financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#x2019;s condensed financial information. The results of operations for the three and six months ended June&#160;30, 2020&#160;are not necessarily indicative of the results to be expected for the year ending&#160;December&#160;31, 2020&#160;or for any other interim period or for any other future year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying interim unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended&#160;December 31, 2019&#160;included in the Company's annual report on Form 10-K filed with the SEC on March 2, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Adjustment to Prior Period Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has adjusted the accompanying Condensed Statement of Cash Flows for the six months ended June 30, 2019 to increase each of the accounts receivable, net, and accrued liabilities amounts by $601,000 for an immaterial prior period error in the classification of provisions for returns from customers.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iba2667bba4254c478e4e02407240ad78_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfNjA0NzMxMzk3OTQ5Nw_1fa05f41-9b9f-4b6d-9a0a-05db908b5cf4"
      unitRef="usd">601000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iba2667bba4254c478e4e02407240ad78_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfNjA0NzMxMzk3OTQ5Nw_2c461057-490a-4b23-9fc2-09d1f3022e8f"
      unitRef="usd">601000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:UseOfEstimates
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzY_842253e2-3a8f-4619-b170-7857417393a7">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the provision for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Due to the coronavirus (&#x201c;COVID-19&#x201d;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzA_b5aca841-553e-40b0-8781-20caf016e23f">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has evaluated the estimated fair value of its financial instruments as of June&#160;30, 2020 and December&#160;31, 2019.  The carrying amounts of certain of the Company&#x2019;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzE_66e20d37-7815-42ef-8ad5-7da34d676911">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of June&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s cash equivalents are entirely comprised of investments in money market funds.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfNTM0NQ_a5b594b0-e665-4494-bcb2-d8994069acb5"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfNTM0NQ_fe915620-116d-4984-99a1-2e96d6a32b04"
      unitRef="usd">310000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2Mzc_c0a5a1e7-b62e-4204-a408-f76dc4fafd48">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date.  Long-term investments have maturities greater than one year as of the balance sheet date.  All investments are recorded at fair value based on the fair value hierarchy.  Money market funds and United States treasury bills with an original maturity less than 90 days are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method.  Realized gains and losses are included in earnings, and are der&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ived for specific-identification method for determining the costs of investments sold.  Amortization of premiums and accretion of discounts are reported as a component of interest income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTQ_5170961b-204a-42c7-9e1f-4b3d93b78c6b">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk, and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company is subject to risks related to the public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#x2019;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#x2019;s revenue while the pandemic continues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and United States treasury bills. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three and six months ended June&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s accounts receivable are due from a variety of health care organizations in the United States.  At June&#160;30, 2020 and December&#160;31, 2019, no customer represented 10% or more of the Company&#x2019;s accounts receivable.  For the three and six months ended June&#160;30, 2020 and 2019, there were no customers that represented 10% or more of revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company manufactures certain of its commercial products in-house.  Certain of the Company&#x2019;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent.  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#x2019;s financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#x2019;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#x2019;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;currently approved portfolio of products.  If clearance for the products in the current portfolio &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;were withdrawn by the FDA, this would have a material adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NDM_a4f94ec3-f333-4b6b-8f89-011b893cdf11">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract &lt;/span&gt;&lt;/div&gt;contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#x2019;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company&#x2019;s considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.</us-gaap:LesseeLeasesPolicyTextBlock>
    <silk:WarrantsClassifiedAsLiabilitiesPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MjU_bb65ae32-2cc0-4f17-bd22-01f57dfaa6b9">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Redeemable Convertible Preferred Stock Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the condensed statements of operations and comprehensive loss.  The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised.  Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#x2019; equity.  Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.&lt;/span&gt;&lt;/div&gt;</silk:WarrantsClassifiedAsLiabilitiesPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzI_129fb65d-6e4e-47ab-8d0f-d6ae3c4f2134">Redeemable Convertible Preferred StockPrior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#x2019; equity on the condensed balance sheet as events triggering the liquidation preferences were not solely within the Company&#x2019;s control.</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i42ceb4ffa58a401ba6b8f294d3cb104c_D20190501-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMTQ4NjU_3cf18e28-227a-431d-b5eb-38d3ccd7c1a2"
      unitRef="shares">23178555</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i704ad274cb0749d5930b69ce8f613a81_D20190501-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMTQ5Mjk_35d96cde-5431-4e8e-b818-98d11cfbbbaf"
      unitRef="usd">144140000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NDU_79d1c6d6-7861-4b36-942d-80017d812a74">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Reven&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;ue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." &#160;Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(i) identify the contract(s) with a customer; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(ii) identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(iii) determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(iv) allocate the transaction price to the performance obligations in the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(v) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, the Company recorded $179,000 and $128,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the condensed balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#x2019;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#x2019;s standard terms and conditions.&#160;&#160;The Company&#x2019;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For sales where the Company&#x2019;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#x2019;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectability is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale. As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component. The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the&#160;condensed statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the condensed balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company manufactures certain of its &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;portfolio of&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for &lt;/span&gt;&lt;/div&gt;excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#x2019;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMTU5NTQ_26b54290-f850-4836-8069-f847b007cb0c"
      unitRef="usd">179000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMTU5NjE_9f41d437-66c9-48af-a990-65e7b7cf9996"
      unitRef="usd">128000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTc_27a329f0-3b03-4273-b701-0ebaa75b4dee">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Stock&#x2013;Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 718,&#160;"Compensation-Stock Compensation."  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions. The Company accounts for option forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MzQ_22c1f078-eb8e-4c62-9662-05d9e5c4c036">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the condensed financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also follows the provisions of ASC 740-10, "A&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ccounting for Uncertainty in Income Taxes."  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the condensed financial statements.  It is the Company's policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTE_685bf594-b917-4628-a651-844e51ace937">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;three and six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; months ended &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, the Company&#x2019;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the condensed &lt;/span&gt;&lt;/div&gt;statements of operations and comprehensive loss.  Accumulated other comprehensive income or loss is presented in the accompanying condensed balance sheet as a component of stockholders' equity.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NTI_6fbca779-23aa-4c76-9d66-23cf4b8a5bae">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#x2019;s redeemable convertible preferred stock participate in any dividends declared by the Company and were therefore considered to be participating securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2MjY_42414737-7359-4be4-8336-a53e90e0c1c9">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss per share was determined as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.673%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.461%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.463%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average common stock outstanding used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,682,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28,458,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,010,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,905,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMi0xLTEtMS0w_df45be31-6546-44b7-af39-0926d790ac08"
      unitRef="usd">-10353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMi0zLTEtMS0w_2f3f7329-db42-4419-b3fa-080ae640a297"
      unitRef="usd">-11959000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMi01LTEtMS0xMjQ_4cafc534-0c6b-4ac0-a7cb-6485d8073569"
      unitRef="usd">-20294000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMi03LTEtMS0xMjQ_42685bf7-485c-4a0a-9571-a955f2158b9c"
      unitRef="usd">-36117000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMy0xLTEtMS0w_922acb2e-c94a-4697-82fc-a8bc84227ba5"
      unitRef="shares">32682360</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMy0zLTEtMS0w_ace5e99f-45c9-4530-aa31-6ec26c5d67b4"
      unitRef="shares">28458793</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMy01LTEtMS0xMjQ_b41c5a7b-3f39-4374-ae2c-6eb8bc7dc9cc"
      unitRef="shares">32010335</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfMy03LTEtMS0xMjQ_d811fedc-fa0a-4373-a6b6-0893eba6de81"
      unitRef="shares">14905052</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfNC0xLTEtMS0w_5a63bb28-4275-40fb-bc94-f578e3f0f71f"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfNC0zLTEtMS0w_55cb1ec7-b658-4377-b7e8-372f311c5fbc"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfNC01LTEtMS0xMjQ_c14d86d3-ff94-4195-9c2c-7454d9454403"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOmNjNzNlZGU4MTkxMjQ3OWM5YTAxYTA5ODliYzNhNjMxL3RhYmxlcmFuZ2U6Y2M3M2VkZTgxOTEyNDc5YzlhMDFhMDk4OWJjM2E2MzFfNC03LTEtMS0xMjQ_2de59db9-627e-4911-b276-cf7027121915"
      unitRef="usdPerShare">-2.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2NDg_3d90c6c4-450f-4aec-8daa-8ee38c0f9834">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company's net loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.314%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,632,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,683,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,671,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,683,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9e17ff70ca0d48c8b577b81e25ba591d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNC0xLTEtMS0w_1e74de43-c138-470a-bf48-138d1d0bfac6"
      unitRef="shares">4632866</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic416bec949ed4e3ca81268307a41e37e_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNC0zLTEtMS0w_586c20cd-6d3d-419e-a0ea-4a6a078807e9"
      unitRef="shares">4683811</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i474e71f940ab46279c176f0b19975770_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNi0xLTEtMS0w_d21e75c3-e6fe-4346-b10f-74a2640903c4"
      unitRef="shares">39089</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if6a67bd46361461c9d492414aa7bffdd_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNi0zLTEtMS0w_31c6a94f-8ae1-4110-9fd9-e7e743934d72"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNy0xLTEtMS0w_be86946b-da48-419a-aeb8-0397d784dcf7"
      unitRef="shares">4671955</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RhYmxlOjA4ZmNhZjFmMDVjYTQwYWFiYzU5NzVjZmZlYmUwYmE5L3RhYmxlcmFuZ2U6MDhmY2FmMWYwNWNhNDBhYWJjNTk3NWNmZmViZTBiYTlfNy0zLTEtMS0w_f9183477-12a2-4381-a72b-add2a9d0f2a1"
      unitRef="shares">4683811</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjY2Mjg_4d43ed4e-7d5c-4464-a5b9-b2d0b7cfe8b4">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company operates and manages its business as one reportable and operating segment.  The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.  All of the Company&#x2019;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment and the Company's right-of-use asset.  All of the Company&#x2019;s revenue was in the United States for the three and six months ended June&#160;30, 2020 and 2019, based on the shipping location of the external customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjE5OTAyMzI4NjU1Nw_87fcbdc4-19d4-42d2-8e3b-97b44f4ee375"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80MC9mcmFnOjRhNTIxNzc3Yzg1NTQ5ZmFhOGFmZDkyYWFlZjc5ZjVmL3RleHRyZWdpb246NGE1MjE3NzdjODU1NDlmYWE4YWZkOTJhYWVmNzlmNWZfMjE5OTAyMzI4NjU1Nw_8e667f90-847a-4f7c-a32b-da6e46e7ade7"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80Ni9mcmFnOjUzNmMxZjBkZDMzZjQ0MGViNmU5YmQyMzM1Yzc4NzI2L3RleHRyZWdpb246NTM2YzFmMGRkMzNmNDQwZWI2ZTliZDIzMzVjNzg3MjZfMjU3Mw_5a853218-3915-4577-9351-b46246603c61">Recent Accounting Pronouncements&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2016-13 would originally be effective for the Company on January 1, 2023.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  As of June 30, 2020, the Company no longer qualifies as a smaller reporting company, accordingly &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2016-13 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;will now become effective for the Company on January 1, 2021. The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 will become effective for the Company on January 1, 2021.  Early adoption is permitted.  The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80Ni9mcmFnOjUzNmMxZjBkZDMzZjQ0MGViNmU5YmQyMzM1Yzc4NzI2L3RleHRyZWdpb246NTM2YzFmMGRkMzNmNDQwZWI2ZTliZDIzMzVjNzg3MjZfMjU3NA_63857d70-e454-4202-9375-54c41b6c9b32">Recent Accounting Pronouncements&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2016-13 would originally be effective for the Company on January 1, 2023.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  As of June 30, 2020, the Company no longer qualifies as a smaller reporting company, accordingly &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2016-13 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;will now become effective for the Company on January 1, 2021. The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 will become effective for the Company on January 1, 2021.  Early adoption is permitted.  The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RleHRyZWdpb246MTg1OGVlMGVmYTkxNGJhNmE1YTU2NDI0ZjQ2MDFiMTZfMjM5OQ_8874e935-1ff0-422f-b3bb-07678da615bc">Fair Value Measurements&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, investments, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;and the Company's previously outstanding preferred stock warrants&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.  Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.  A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 1 &#x2013; quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 2 &#x2013; observable inputs other than quoted prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 3 &#x2013; unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.  The Company&#x2019;s&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; cash equivalents&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.  The corporate bonds/notes, commercial paper, asset-backed securities and U.S. government securities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The following tables sets forth by level within the fair value hierarchy the Company&#x2019;s assets that are reported at fair value as of June&#160;30, 2020 and December&#160;31, 2019, using the inputs defined above (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.743%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.743%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;There were no transfers between fair value hierarchy levels during the three and six months ended June&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RleHRyZWdpb246MTg1OGVlMGVmYTkxNGJhNmE1YTU2NDI0ZjQ2MDFiMTZfMjQwMw_d20f2d49-570a-46d7-bde3-848bc08db9ba">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The following tables sets forth by level within the fair value hierarchy the Company&#x2019;s assets that are reported at fair value as of June&#160;30, 2020 and December&#160;31, 2019, using the inputs defined above (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.743%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:37.743%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.583%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.585%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia45c7bb5cadd4ff3928225d7854fc6cf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfMy0xLTEtMS0w_c399fd80-9eb3-46c7-9e69-27a3bec1cacf"
      unitRef="usd">72924000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7eaae44effa4a9db07cdb54dcc04049_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfMy0zLTEtMS0w_88f76a44-890d-4893-942c-51e4d8cdef24"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie11c28dea9564c599548f654617f2d82_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfMy01LTEtMS0w_8de6b901-61bd-4706-993b-7d93fe0a001e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieef0e9ab0a544219ad78c50b68f4791d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfMy03LTEtMS0w_61579800-b574-4e8b-84d6-9ab84110192b"
      unitRef="usd">72924000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i027eeae537b5468592e241128284b992_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNC0xLTEtMS0w_988ba0f0-db24-4889-9be3-339d84296f98"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2b02921cf0f4f00aa9fe9fdfd871170_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNC0zLTEtMS0w_fcce919b-cbcc-453d-a2aa-e29b87e32f55"
      unitRef="usd">9993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0130e277a457479f8eb98ee94adf3d31_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNC01LTEtMS0w_2880941a-a9f5-496e-abae-7f0516519163"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7abe1f43259b4a54b976c268c96c3db6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNC03LTEtMS0w_9587813e-a2b4-4ee9-9bba-2aceb7d423a7"
      unitRef="usd">9993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie05b32828f264722b8556b4370fc6692_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNS0xLTEtMS0w_97e23eda-7078-4357-8578-2b4f16d7dbb3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97f148c7c1d24480baf7b80e8a13fd5a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNS0zLTEtMS0w_7d7fbe09-ecab-487c-a01a-e5075a80b74a"
      unitRef="usd">11965000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c333b7cb2584fb0bf52ab8951d3b428_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNS01LTEtMS0w_f6ae080a-6eae-4550-b9e9-779be4ef8bda"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ef50b8f524a4cf1a7fbc3e5edfecf52_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNS03LTEtMS0w_0e94823b-b518-444a-a32a-a64182252393"
      unitRef="usd">11965000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idbe32b015af345959821be4df0dcaeac_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNi0xLTEtMS0w_ab2fec29-5ad6-46df-ad6e-5ca8f170131f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37bbce2b0c0c4aed8cf5b3c35c01dcae_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNi0zLTEtMS0w_161059ea-57fb-416a-a296-04d98b53b0e9"
      unitRef="usd">10742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2dbd828ff8134720a052fc51c726266a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNi01LTEtMS0w_00672f1f-2943-4f06-9c89-94c75b80c6f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i295a9086a57e41eba3c2236e5dc80ef0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNi03LTEtMS0w_e10a94d7-6d67-4d06-8c3b-12fae4e960da"
      unitRef="usd">10742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad31c85169dc429b85ce034ad39eb103_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNy0xLTEtMS0w_67c83896-87fe-441d-874d-a6d920a4d7f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63598873c0f044d4b705b1cafa4240b7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNy0zLTEtMS0w_eabcd37f-ce3e-406a-9eb1-87f64e9f3e94"
      unitRef="usd">49714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cde6c49eff04e36b1db4f65acf663c3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNy01LTEtMS0w_25231ac6-05a1-429d-9279-ea7f80206550"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88c32e22f95c44cab38971bc9fab5004_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfNy03LTEtMS0w_850c8d6f-c66f-4dd8-8f8a-950e531c083c"
      unitRef="usd">49714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26e712413f6848d9a5e188b7a113c60d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOC0xLTEtMS0w_e8086717-5b4a-480e-99a7-767fb8ee3241"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e1c06ac263949cf803aa266d7e0c236_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOC0zLTEtMS0w_c0137bec-fe7d-491a-9900-2538a1f26c8b"
      unitRef="usd">2002000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34bee5fc72654faebc87e97e419f58c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOC01LTEtMS0w_74c2b040-0075-4c56-98bd-dda31af75ce1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a5bfe7df3c84fe6850ff62b8c098b26_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOC03LTEtMS0w_28acbfee-2af0-46c7-9caa-9839ca3d6aa9"
      unitRef="usd">2002000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i11dd8af0811b4ebab5f6adef8864c4f1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOS0xLTEtMS0w_e5910990-2fd8-4b9b-89b2-b9bfeb5ece0b"
      unitRef="usd">72924000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5e8bebd551d147b992e253b95baa195f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOS0zLTEtMS0w_62b4926d-f0a7-4542-8f37-a6f849dbdcff"
      unitRef="usd">84416000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iedefabef8f124e819f3337024626dc4e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOS01LTEtMS0w_7cd917cc-9e54-41c9-91bb-a9dd6fe8f19b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2abf6f3595684efe9f063ff9b69fec7f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjU5OGI0ZjgwYWRjZDRmYjVhMTM2YWFhOTgxODllYTIyL3RhYmxlcmFuZ2U6NTk4YjRmODBhZGNkNGZiNWExMzZhYWE5ODE4OWVhMjJfOS03LTEtMS0w_81b1b5a9-16f2-4b07-b363-1a2f031f7831"
      unitRef="usd">157340000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9aae1b1ed715477dad46b3078e21b40b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfMy0xLTEtMS0w_29d09a82-3fda-4226-b6e1-5550fff5af22"
      unitRef="usd">34363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b9a7836694f4cf3b50a9134284d8b4e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfMy0zLTEtMS0w_d69210b2-4693-4101-b3f0-5c940cf12a70"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9636c3ae224c4f7f893c191a0ab12002_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfMy01LTEtMS0w_f4f103d1-e58c-497f-99da-77ff89d81318"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76ab7e26b0e64cffa5cca122155110e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfMy03LTEtMS0w_377e9104-4155-41cd-8de1-84f540511442"
      unitRef="usd">34363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide59561146c34abbbab1296d346d7f2b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNC0xLTEtMS0w_e98aebc3-1571-4f8c-90cd-4b6f07b9c37d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c98a1a3cac34c2fbc05c0e88a578e09_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNC0zLTEtMS0w_54f74f2e-cfd7-4c03-842a-f94f18d97bf1"
      unitRef="usd">9919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c935ab0c1f241b990bc79b98b3645b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNC01LTEtMS0w_83af72cd-5e7d-4108-84db-ff25fbc1cdfb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1de230599454417b163ebfe37b873d5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNC03LTEtMS0w_610175f5-d6ee-4444-a068-822d5132a537"
      unitRef="usd">9919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i145dc0fcbfe64370a9f24164b7dd43f8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNS0xLTEtMS0w_7aa692e2-2f1a-4ea8-bf2b-e724185999e6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8245985bc354b6a86396bc01b5213d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNS0zLTEtMS0w_ae6364d7-151c-4acb-bd87-022a7e07336d"
      unitRef="usd">10176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib148be5a80234007ae139c5a4efdfc61_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNS01LTEtMS0w_6e0c10a4-8c20-4141-ba52-d37bcfdb748a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1a76cb4479a4ff989b812aac949063e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNS03LTEtMS0w_394c2d58-10d4-4c8b-9616-cc9a2a01fd0a"
      unitRef="usd">10176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if53f29868f76491f8fd58d9c3303f998_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNi0xLTEtMS0w_553bdb55-8028-4448-981e-e1f8de0952b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide4b8aa16b5440ec854fbf0906b9c133_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNi0zLTEtMS0w_3e946a51-e059-4c73-9820-c57855a5b370"
      unitRef="usd">44456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67ffbfb49b864745af10bab7a89329f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNi01LTEtMS0w_08dc5455-c9de-44b6-ad46-6c3419bd92a8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5a347102e80443a82dea892692d5746_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNi03LTEtMS0w_a2772c10-780f-4e8f-9b23-408db53708d9"
      unitRef="usd">44456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46860657c50f45ee882f2df2d5f623d7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNy0xLTEtMS0w_e610694a-6952-493c-9b89-1845abccca81"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8dc96a72145c469d9ab6fb5c89bafb0e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNy0zLTEtMS0w_b1e77a47-3c5a-4271-aadd-3b233ef2c4a3"
      unitRef="usd">5181000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3830c20a6ee94b1488be7319d791f2d8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNy01LTEtMS0w_080faf5a-109a-4dfd-ae1e-933402ffdb99"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ebd01da1cc2487a91876a8405b5628b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfNy03LTEtMS0w_0db32486-45db-4fee-93e6-abfbd66a80a7"
      unitRef="usd">5181000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iac0ccc5a7ea8414bb1a711a6955e7342_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfOC0xLTEtMS0w_d63588f4-2388-42c7-b42a-3a0e04c5172d"
      unitRef="usd">34363000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i665e3a1be7a84f788bd449d1334d492c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfOC0zLTEtMS0w_1678aa18-7adf-44e9-a640-9091abc2fe98"
      unitRef="usd">69732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i628752f4a1c64849a99d7a5f207dd092_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfOC01LTEtMS0w_5f366e79-6188-4b22-b46f-83012304de76"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaf14871d54b5439a835298db12c36739_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl80OS9mcmFnOjE4NThlZTBlZmE5MTRiYTZhNWE1NjQyNGY0NjAxYjE2L3RhYmxlOjlkYzNmZGU2ZGY5YzQ4NmJiNjAwZTA5NmI1NGRjYmI4L3RhYmxlcmFuZ2U6OWRjM2ZkZTZkZjljNDg2YmI2MDBlMDk2YjU0ZGNiYjhfOC03LTEtMS0w_a94acf33-baf9-4e26-bd3b-c07bbf21436d"
      unitRef="usd">104095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzgy_f8cbc581-595b-4e63-b8f8-f4b80525cc4d">Balance Sheet Components&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the Company's available-for-sale investments as of June&#160;30, 2020 and December&#160;31, 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.224%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.188%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.224%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.188%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value of the Company&#x2019;s cash equivalents, short-term and long-term investments classified by maturity as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:62.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.467%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.790%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts maturing within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Available-for-sale investments held as of June&#160;30, 2020 had a weighted average days to maturity of 164 days. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.189%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Components of inventories were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.890%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.967%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, there were no work-in-process inventories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.344%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.264%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.605%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.587%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Provision for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued royalty expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued travel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzg3_b630d51d-0c51-4f17-997e-97859cd149de">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the Company's available-for-sale investments as of June&#160;30, 2020 and December&#160;31, 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.224%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.188%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.224%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.188%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie8c8ea18544f4f62b607863b3c6653ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMy0xLTEtMS0w_4349cf54-fa6e-4e93-81c7-72657ceb2fc5"
      unitRef="usd">72924000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie8c8ea18544f4f62b607863b3c6653ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMy0zLTEtMS0w_1dc56f32-aaab-4c0d-a8a1-2ec0f6561a2b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie8c8ea18544f4f62b607863b3c6653ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMy01LTEtMS0w_8a66ba81-d4d2-47f6-aa73-51031627d470"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie8c8ea18544f4f62b607863b3c6653ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMy03LTEtMS0w_91cde707-dd77-4316-aaa9-a701757252e0"
      unitRef="usd">72924000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id46da514145b4750ada52675069ab829_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNC0xLTEtMS0w_4351061c-7170-4a22-8ecd-b33d856ea825"
      unitRef="usd">9992000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id46da514145b4750ada52675069ab829_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNC0zLTEtMS0w_390b6fc4-f4f7-44d3-9fc0-ed1d1b7fae92"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id46da514145b4750ada52675069ab829_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNC01LTEtMS0w_dd4ac5d3-0525-4d21-92ca-b56265dc90c2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id46da514145b4750ada52675069ab829_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNC03LTEtMS0w_d5ac5a9d-50a8-46a7-b793-89658bf2ed14"
      unitRef="usd">9993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNS0xLTEtMS0w_ddce6376-aba6-4c9c-949f-2ad3eb700ba9"
      unitRef="usd">11965000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNS0zLTEtMS0w_34a896be-a758-43ab-a630-d8ef6f0ca7d9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNS01LTEtMS0w_6b23bb77-7417-4d22-b45b-513631dfffa9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie833f66bcb4f497e982f0a93d3a69cd3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNS03LTEtMS0w_510e9021-84ea-466f-a3b0-3fd3ff27d45f"
      unitRef="usd">11965000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNi0xLTEtMS0w_f4fa7695-3bba-4974-b8b8-ee5257d935e2"
      unitRef="usd">10709000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNi0zLTEtMS0w_4b60efab-c728-45e4-b88c-80ec427fa1cf"
      unitRef="usd">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNi01LTEtMS0w_f772e484-0f30-4683-bd46-47c1d77fbc93"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNi03LTEtMS0w_0a5842f3-4741-4df5-9fec-c5176bc2a570"
      unitRef="usd">10742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaf867c38014844e5818ec341fda982bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNy0xLTEtMS0w_e129b551-4609-415a-a60e-0315ae940342"
      unitRef="usd">49433000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf867c38014844e5818ec341fda982bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNy0zLTEtMS0w_d171a2b6-fb6e-4d09-a50e-8b2a6a8dfe42"
      unitRef="usd">281000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf867c38014844e5818ec341fda982bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNy01LTEtMS0w_3f5568e8-4169-4003-913f-eaa508a1814c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf867c38014844e5818ec341fda982bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfNy03LTEtMS0w_10af6310-a0a3-4002-bd63-1d4544050365"
      unitRef="usd">49714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if5f4685798604a6d9460510b4c4c15a7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOC0xLTEtMS0w_c0d19b16-a981-41e7-a358-47eca1696425"
      unitRef="usd">2001000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if5f4685798604a6d9460510b4c4c15a7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOC0zLTEtMS0w_c1ac3147-e1f2-480b-b906-9115c7c9924b"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if5f4685798604a6d9460510b4c4c15a7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOC01LTEtMS0w_5dd77890-53d7-40ab-a041-dbd080784bee"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5f4685798604a6d9460510b4c4c15a7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOC03LTEtMS0w_35509884-38f2-45c2-8459-e32fb659d236"
      unitRef="usd">2002000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOS0xLTEtMS0w_7e3d89e8-c374-415e-98ef-6904fad1769a"
      unitRef="usd">157024000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOS0zLTEtMS0w_00edbb9a-0354-47f6-b2a7-8ac66619c6c2"
      unitRef="usd">317000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOS01LTEtMS0w_3b24b1e3-963e-4a73-b3a3-04e7f53da5d1"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfOS03LTEtMS0w_2a636c7a-b914-4079-8fcc-890e2f0df501"
      unitRef="usd">157340000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia6f195d63bab41439dde63c7ec42a7a3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMTEtNy0xLTEtMA_5a550430-5456-4bbf-b44d-7ee329ab90bd"
      unitRef="usd">72924000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic54064e0090149959fffc8a7f4540977_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMTItNy0xLTEtMA_018bda87-e52b-4ca6-9379-811ecb7c79b7"
      unitRef="usd">84416000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjAxOTMxZTNmZDRhMDQzNmJhMGE0OTBlYzE3YThjMmJlL3RhYmxlcmFuZ2U6MDE5MzFlM2ZkNGEwNDM2YmEwYTQ5MGVjMTdhOGMyYmVfMTQtNy0xLTEtMA_e0db5639-f77a-4815-9d18-7f20a186300e"
      unitRef="usd">157340000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5c26d0ce983a467cace48304d4c14c29_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMy0xLTEtMS0w_95e3bbf0-33ef-4aea-bcbc-cf229d4241ae"
      unitRef="usd">34363000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5c26d0ce983a467cace48304d4c14c29_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMy0zLTEtMS0w_b7814e8f-c528-4279-9cbe-6a338e7d2ddb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5c26d0ce983a467cace48304d4c14c29_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMy01LTEtMS0w_42d3f56e-eb8a-4b25-9571-e08eb39df22b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c26d0ce983a467cace48304d4c14c29_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMy03LTEtMS0w_27b50e24-e9e9-4bcb-8215-33bcfdc0dc39"
      unitRef="usd">34363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia147919f6a044ff88de323227052e424_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNC0xLTEtMS0w_d5eb11e8-cf7a-4122-957e-2a932c6e4263"
      unitRef="usd">9919000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia147919f6a044ff88de323227052e424_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNC0zLTEtMS0w_cb5f5308-f956-4db7-bd8f-dffd1731d913"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia147919f6a044ff88de323227052e424_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNC01LTEtMS0w_d3e1b28b-4137-4daa-8a84-bfd055a9de3c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia147919f6a044ff88de323227052e424_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNC03LTEtMS0w_8d068dac-d759-468a-b710-2e6bc2371c5d"
      unitRef="usd">9919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNS0xLTEtMS0w_128281f6-5d6b-4f93-8594-50e821b3866c"
      unitRef="usd">10180000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNS0zLTEtMS0w_c6f23a67-adbb-440b-a91b-d3345b8a991d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNS01LTEtMS0w_8298eec1-f13a-46fb-969a-572a0e22a47c"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNS03LTEtMS0w_50e1ae49-b2de-46be-93ec-48e9c5aef08b"
      unitRef="usd">10176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNi0xLTEtMS0w_a6b3c209-6163-45f2-89ab-68ebd031b1f0"
      unitRef="usd">44450000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNi0zLTEtMS0w_680b5a48-4247-4e62-980b-f4c3ff540182"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNi01LTEtMS0w_448ac72a-7c73-4564-830d-a85766c60342"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNi03LTEtMS0w_6f2c7fe4-62b7-4e80-b4ad-e4d7e7fd9869"
      unitRef="usd">44456000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic00908a653674eb4a8e9bac56051e1a9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNy0xLTEtMS0w_85f7ffdb-5de4-4398-a4e7-64bc90a70438"
      unitRef="usd">5181000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic00908a653674eb4a8e9bac56051e1a9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNy0zLTEtMS0w_463bb369-287c-4657-827c-a07b5d87cfd5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic00908a653674eb4a8e9bac56051e1a9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNy01LTEtMS0w_ff8f9c17-e237-4260-be30-9f419682f035"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic00908a653674eb4a8e9bac56051e1a9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfNy03LTEtMS0w_1147780a-370e-4b92-bbf0-5a4c3f457c3f"
      unitRef="usd">5181000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfOC0xLTEtMS0w_dd27876f-0d7d-404c-8d96-63eadc8ef4c6"
      unitRef="usd">104093000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfOC0zLTEtMS0w_2e44b092-ed93-4c99-a6ee-23c285f5d8c3"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfOC01LTEtMS0w_a16c3e63-34bb-4474-a94e-928a95dda119"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfOC03LTEtMS0w_f858230c-4aa4-4e84-9a08-5025643af358"
      unitRef="usd">104095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i070bfe38bf2d4977b7e7675ca0fe38ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMTAtNy0xLTEtMA_ada0efb1-79f7-4797-bd1f-0c4daede548d"
      unitRef="usd">34363000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i084603b74ef54fce8e75cc1061fc2af7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMTEtNy0xLTEtMA_08b3b6ad-9fa0-4aa2-a455-a1c23534f7d8"
      unitRef="usd">51508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifeb20a2f0bf24dd08225af4dac73faaa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMTItNy0xLTEtMA_7eb7aeaa-9c17-4808-8160-5b0c0f7c0542"
      unitRef="usd">18224000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjg1Yjk4ODMwYTI1YzRhMzM5OTNiZTk2NWI0NGI3ZGRlL3RhYmxlcmFuZ2U6ODViOTg4MzBhMjVjNGEzMzk5M2JlOTY1YjQ0YjdkZGVfMTMtNy0xLTEtMA_e959b820-a05b-4830-9e75-ff533a9a1980"
      unitRef="usd">104095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzg4_1e6f8918-e8d0-4feb-b4dc-36d6360588e3">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value of the Company&#x2019;s cash equivalents, short-term and long-term investments classified by maturity as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:62.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.467%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.790%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts maturing within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts maturing after one year through two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;157,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfMi0xLTEtMS0w_91399969-7152-4276-807a-5fe6f9ef38f4"
      unitRef="usd">157340000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfMi0zLTEtMS0w_147ae569-8f51-4f45-aa9b-5ff00c102bec"
      unitRef="usd">85871000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfMy0xLTEtMS0w_b7e9f972-2d87-42ed-849d-d476eb6bc548"
      unitRef="usd">0</silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears>
    <silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfMy0zLTEtMS0w_5d123da0-c6e8-4eba-82d5-f2dbf7f92555"
      unitRef="usd">18224000</silk:CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfNC0xLTEtMS0w_2a3d52fc-1409-4e5f-afca-70d9d544735e"
      unitRef="usd">157340000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjk0YjgzMTZhOTg1ZjRhMmRiN2ViZDZhNDNmZDY3YzU4L3RhYmxlcmFuZ2U6OTRiODMxNmE5ODVmNGEyZGI3ZWJkNmE0M2ZkNjdjNThfNC0zLTEtMS0w_5d06289a-c19e-4449-857d-4ed6e36467e3"
      unitRef="usd">104095000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNDM0_0c8a148e-6666-4a8b-a06c-b6f144ed3251">P164D</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzg0_5c6d3f68-174e-40fc-b3c3-5fd54b3ea590">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.185%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.189%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds/notes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfMy0xLTEtMS0w_40324940-a958-49d9-855b-b7369b97973e"
      unitRef="usd">2558000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i7700ecb8225940a282f94f4767f6615f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfMy0zLTEtMS0w_1825abac-7aa8-4f45-b913-d551bb151837"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfMy01LTEtMS0w_0bafe412-c28e-40bc-91b8-38ec02121ba7"
      unitRef="usd">10128000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iecc6e45694f94ee2a9737c2166fb37d1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfMy03LTEtMS0w_215578b1-4864-4fe1-91fd-0354cd877af8"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iaf867c38014844e5818ec341fda982bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNS0xLTEtMS0w_5c130571-8c29-43e3-be70-5c56f04fe482"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iaf867c38014844e5818ec341fda982bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNS0zLTEtMS0w_7db818ca-4e91-42f4-bff0-2e0bc128c47c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNS01LTEtMS0w_7b4e444d-49f3-444d-a3b5-a431024bf110"
      unitRef="usd">19067000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i1a3a50b23b354642957be1435413bcd9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNS03LTEtMS0w_3c2f54d3-397b-4ef0-8214-012aef03d8e5"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNi0xLTEtMS0w_5380b0f5-2c06-4593-bc8e-9b3a825a5e04"
      unitRef="usd">2558000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNi0zLTEtMS0w_73c0d007-8e2f-4150-ab47-7ca15dd45c6c"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNi01LTEtMS0w_e23803bc-5cc0-46b1-8bb3-fb0bf1145f52"
      unitRef="usd">29195000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjc5YjZjYzVkNTE5ZDQ1MWViZWQyMWY2MzE1MTgwMGYyL3RhYmxlcmFuZ2U6NzliNmNjNWQ1MTlkNDUxZWJlZDIxZjYzMTUxODAwZjJfNi03LTEtMS0w_5ed5e2b6-b34a-414d-a2dd-df7f1e5fb720"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzg5_080ea9ea-537e-4e5e-b4fb-d205f20686d3">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Components of inventories were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.890%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.967%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfMi0xLTEtMS0w_5ddb11fc-338d-4d39-833f-a16c318eca6a"
      unitRef="usd">1736000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfMi0zLTEtMS0w_8f5bc47a-c354-4ae8-bab0-018d4168064e"
      unitRef="usd">1203000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfNC0xLTEtMS0w_fa2dafb0-58a9-4463-a1cb-57c80cc3a93f"
      unitRef="usd">9885000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfNC0zLTEtMS0w_c1726ca7-022a-4511-9bbd-952d7a731474"
      unitRef="usd">9119000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfNS0xLTEtMS0w_380436be-41fa-4898-b8a6-27c9bb793177"
      unitRef="usd">11621000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjBkNzAyMTdmMGU0YzQ5YWQ5ZTcyNjhlYTg1NTQ1OWViL3RhYmxlcmFuZ2U6MGQ3MDIxN2YwZTRjNDlhZDllNzI2OGVhODU1NDU5ZWJfNS0zLTEtMS0w_1ced13f1-73c0-4dab-8f47-b1b6428b4e61"
      unitRef="usd">10322000</us-gaap:InventoryNet>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNjgz_c3851d29-a6c1-41cb-b10a-fe521a66b9a1"
      unitRef="usd">0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNjgz_ead8772d-5b45-41a9-b1fd-9af61853f698"
      unitRef="usd">0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RleHRyZWdpb246ZGI5NzQwZjYwMDVjNDIxNGE1Y2QyMGRmYTY5ZTNjOWNfNzkw_8d3c2580-7be7-4fe5-88a9-6bc63fc90bdf">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.344%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.264%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.605%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.587%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Provision for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued royalty expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued travel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMi0xLTEtMS0w_91f3f762-39e9-4e2b-97bc-8c647a4bf1e3"
      unitRef="usd">5352000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMi0zLTEtMS0w_7358ddb2-d02b-4040-9636-9b82a1f3d1d5"
      unitRef="usd">9151000</us-gaap:AccruedSalariesCurrent>
    <silk:ProvisionsForSalesReturns
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMy0xLTEtMS0w_68f04664-ef80-45b5-9f91-079be71bf029"
      unitRef="usd">920000</silk:ProvisionsForSalesReturns>
    <silk:ProvisionsForSalesReturns
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMy0zLTEtMS0w_136f66cb-eee1-4170-a3a3-18a36ca182cd"
      unitRef="usd">2419000</silk:ProvisionsForSalesReturns>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNC0xLTEtMS0w_e0f4d081-7f24-497e-aa81-730d95b92156"
      unitRef="usd">593000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNC0zLTEtMS0w_edb0b93c-55d8-4a97-a088-b435de9b0c80"
      unitRef="usd">682000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNS0xLTEtMS0w_7b741191-2f1e-4ade-bbd0-dd427cc72f19"
      unitRef="usd">809000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNS0zLTEtMS0w_28ecd4cc-c29c-4aab-a560-7e5709f577a9"
      unitRef="usd">769000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNi0xLTEtMS0w_1e547e4b-ee54-469b-ade2-b81bd81c3cbc"
      unitRef="usd">333000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNi0zLTEtMS0w_d2d5a84e-198c-431f-abe3-c0fe985c08fc"
      unitRef="usd">470000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNy0xLTEtMS0w_3825a2ab-c195-4525-82ed-fe8c646b22be"
      unitRef="usd">335000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfNy0zLTEtMS0w_4565c579-b9f7-496b-8f86-456a18e5c8ae"
      unitRef="usd">304000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <silk:AccruedTravelExpensesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfOC0xLTEtMS0w_e583b634-12bf-4adf-bfc6-f845adf5d2b1"
      unitRef="usd">273000</silk:AccruedTravelExpensesCurrent>
    <silk:AccruedTravelExpensesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfOC0zLTEtMS0w_2b087a6d-590c-4c8b-81e8-7ac570532117"
      unitRef="usd">431000</silk:AccruedTravelExpensesCurrent>
    <silk:AccruedClinicalExpensesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfOS0xLTEtMS0w_984d2c61-f884-4bcb-8bab-1df48fe571fc"
      unitRef="usd">181000</silk:AccruedClinicalExpensesCurrent>
    <silk:AccruedClinicalExpensesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfOS0zLTEtMS0w_4c918c9d-8eb9-4dae-8c6a-66521e7397b4"
      unitRef="usd">241000</silk:AccruedClinicalExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMTAtMS0xLTEtMA_345578c6-6285-4fc9-917c-00d7884ece36"
      unitRef="usd">346000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMTAtMy0xLTEtMA_280cce89-c2a0-428b-95ee-03853690acdd"
      unitRef="usd">567000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMTEtMS0xLTEtMA_14711d68-1dfc-4120-bb2b-f8bf69b245d0"
      unitRef="usd">9142000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81Mi9mcmFnOmRiOTc0MGY2MDA1YzQyMTRhNWNkMjBkZmE2OWUzYzljL3RhYmxlOjU3ZDllYzRkYThlNzQyYzliOTFjMjkzNTJkODM1NzIxL3RhYmxlcmFuZ2U6NTdkOWVjNGRhOGU3NDJjOWI5MWMyOTM1MmQ4MzU3MjFfMTEtMy0xLTEtMA_c85401d3-f039-4dc9-9d0f-0cdfc5943af4"
      unitRef="usd">15034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTM2Mg_298c63e4-fed7-4430-be32-eb774115f373">Long-term Debt&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October&#160;2015, the Company entered into a term loan agreement with CRG.  The term loan agreement provides for up to $30,000,000 in term loans split into two tranches as follows: (i) the Tranche A Loans provided for $20,000,000 in term loans, and (ii) the Tranche B Loans provided for up to $10,000,000 in term loans.  The Company drew down the Tranche A Loans on October 13, 2015.  The Tranche B Loans were available to be drawn prior to March 29, 2017.  In January 2017, the term loan agreement was amended to extend the commitment period of the Tranche B Loans to April 28, 2017.  In April 2017, the Company drew down $5,000,000 of the available Tranche B Loans.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2018, the Company entered into Amendment No. 5 to the term loan agreement with CRG.  Under the amended terms of the amended loan agreement the maturity date was extended to December 31, 2022 and the repayment schedule of the existing term loans were changed to interest only so that the outstanding principal amount of the term loans will be payable in a single installment at maturity.  The related fixed interest rate was changed to equal 10.75% per annum, due and payable quarterly in arrears.  At the election of the Company, 2.75% of the interest due and payable may be &#x201c;paid in kind&#x201d; and added to the then outstanding principal and 8.0% of the interest due and payable paid in cash.  All unpaid principal, and accrued and unpaid interest, is due and payable in full on December 31,&#160;2022.  The amended term loan agreement also provided for additional term loans in an aggregate principal amount of up to $25,000,000 and allowed for the conversion into shares of common stock, at the Company&#x2019;s option, of up to 25% of the outstanding loans under the term loan agreement in connection with an initial public offering of the Company&#x2019;s common stock which results in market capitalization of at least $250,000,000.  In September 2018, the Company drew down an additional $15,000,000 under the term loan agreement with CRG. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; As provided for under the terms of the amended term loan agreement, the related fixed interest rate was further reduced to 10.0% upon the consummation of the Company's IPO in April 2019.  Also, post consummation of the Company's IPO, 8.0% of the interest is due and payable in cash and at the election of the Company, 2.0% of the interest due and payable may be "paid in kind". &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2019, the Company entered into Amendment No. 7 to the term loan agreeme&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;nt with CRG to reflect flexibility with respect to permitted cash investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company may voluntarily prepay the borrowings in full.  The Tranche A borrowing required a payment, on the borrowing date, of a financing fee equal to 1.75% of the borrowed loan principal, which is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;recorded as a discount to the debt.  In addition, a facility fee equal to 5.0% of the amounts borrowed plus any "paid in kind" is payable at the end of the term or when the borrowings are repaid in full.  A long-term liability is being accreted using the effective interest method for the facility fee over the term of the loan agreement.  The borrowings are collateralized by a security interest in substantially all of the Company&#x2019;s assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to financial covenants related to liquidity and minimum trailing revenue targets that began in December&#160;31, 2016 and are tested on an annual basis.  The liquidity covenant requires the Company to maintain an amount which shall exceed the greater of (i) $3,000,000 and (ii) the minimum cash balance, if any, required of the Company by a creditor to the extent the&#160;Company has incurred permitted priority debt.  The Company had to achieve minimum net revenue of $1,000,000 in 2016, $5,000,000 in 2017, $15,000,000 in 2018, $30,000,000 in 2019 and must achieve minimum net revenue of $40,000,000 in 2020. The liquidity financial covenant has a 90-day equity cure period following end of the calendar year to issue additional shares of equity interests in exchange for cash, or to borrow permitted cure debt.  In addition, the term loan agreement prohibits the payment of cash dividends on the Company&#x2019;s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates.  CRG may accelerate the payment terms of the term loan agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the term loan agreement, the failure of the Company to adhere to the covenants set forth in the term loan agreement, the insolvency of the Company or upon the occurrence of a material adverse change.  As of June&#160;30, 2020, the Company was in compliance with all applicable financial covenants.  As of June&#160;30, 2020, management does not believe that it is probable that the above clauses will be triggered within the next twelve months, and therefore, the debt is classified as long-term on the condensed balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future maturities under the term loan agreement as of June&#160;30, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.256%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Add: Accretion of closing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Amount representing debt discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2015, CRG purchased 327,759 shares of the Company&#x2019;s Series C redeemable convertible preferred stock at $6.11 per share.  In addition, CRG received warrants to purchase 163,877 shares of the Company&#x2019;s Series C redeemable convertible preferred stock at an exercise price of $6.11 per share.  Upon the closing of the IPO, the warrants were net exercised, based on the initial public offering price of $20.00 per share, into&#160;shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2017, CRG purchased an additional 163,877 shares of the Company&#x2019;s Series C convertible preferred stock at $6.11 per share.  Upon the closing of the IPO, the Series C redeemable convertible preferred stock shares were converted into&#160;shares of common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="i3400703ba5ec4dafa9f83491b25fdc9b_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTI2Mg_87de2e8b-9be7-4bef-bbfe-08f54d7779a2"
      unitRef="usd">30000000</silk:DebtMaximumBorrowingCapacity>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="i790a1c16fe884cfc81603c5b990067c9_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTI4OA_53e08e09-88c7-435a-a172-b88974cff232"
      unitRef="usd">20000000</silk:DebtMaximumBorrowingCapacity>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="i0624ae02355943f3919d91e6d60daf82_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTIzNw_f447b177-49a1-442d-a2eb-1f73711fd6b8"
      unitRef="usd">10000000</silk:DebtMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i05691cc4d2eb407b8735756cfcce9745_I20170430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTMxMg_f6d11dbb-40f3-4363-8106-48193dd7ffce"
      unitRef="usd">5000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTMzMQ_01a40fdd-3f17-4d80-aa74-b47461ae9710"
      unitRef="number">0.1075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <silk:DebtInstrumentInterestRatePaidInKind
      contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTM0NQ_d91e04f3-13b6-482e-9a1e-c97c16771923"
      unitRef="number">0.0275</silk:DebtInstrumentInterestRatePaidInKind>
    <silk:DebtInstrumentInterestRatePaidInCash
      contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTM1Nw_ea82412b-d3ee-414c-b01e-f407ab4e20f4"
      unitRef="number">0.080</silk:DebtInstrumentInterestRatePaidInCash>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTM3Ng_c72747f2-8df3-40fd-a01d-4a6b17d03088"
      unitRef="usd">25000000</silk:DebtMaximumBorrowingCapacity>
    <silk:DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans
      contextRef="i6d81a47bada34ef9be4c34a930d81f1e_D20180901-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMTY3MQ_60a13888-d407-420f-b2f5-7b866791916c"
      unitRef="number">0.25</silk:DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans>
    <silk:DebtInstrumentConvertibleMarketCapitalization
      contextRef="i3af30497630e46e0b5dbb159697d1735_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMTg1Ng_eda6560c-7e0b-43e9-ad3f-5bc0183eadef"
      unitRef="usd">250000000</silk:DebtInstrumentConvertibleMarketCapitalization>
    <silk:DebtMaximumBorrowingCapacity
      contextRef="icab64d89eb0c493488e9f83a19562b4d_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQwMQ_67613c1e-83a3-45e7-ace3-6bb4452dd52a"
      unitRef="usd">15000000</silk:DebtMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic59b0ae0ca9845038632b9400107e7e6_I20190501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjA4Mw_bbebcf33-34de-4cfa-bc45-342dc6200ed9"
      unitRef="number">0.100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <silk:DebtInstrumentInterestRatePaidInCash
      contextRef="ic59b0ae0ca9845038632b9400107e7e6_I20190501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5MQ_469e0515-93be-4f7e-96df-dd416dd285d3"
      unitRef="number">0.080</silk:DebtInstrumentInterestRatePaidInCash>
    <silk:DebtInstrumentInterestRatePaidInKind
      contextRef="ic59b0ae0ca9845038632b9400107e7e6_I20190501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjI3Mw_8fb1bb69-09f3-4f01-8302-99aa1a0fba52"
      unitRef="number">0.020</silk:DebtInstrumentInterestRatePaidInKind>
    <silk:DebtInstrumentInterestRateFinancingFee
      contextRef="i790a1c16fe884cfc81603c5b990067c9_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQyMA_8aab0ec4-285e-45d8-84c7-78e09bc990d8"
      unitRef="number">0.0175</silk:DebtInstrumentInterestRateFinancingFee>
    <silk:DebtInstrumentInterestRateFacilityFee
      contextRef="i790a1c16fe884cfc81603c5b990067c9_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQzMg_ac5a7556-15f4-4e2c-b0a7-4eb51299a2bf"
      unitRef="number">0.050</silk:DebtInstrumentInterestRateFacilityFee>
    <silk:DebtInstrumentCovenantMaximumLiquidityAmount
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQ0OQ_9c24d1e4-33c4-401e-956f-9884604cd09a"
      unitRef="usd">3000000</silk:DebtInstrumentCovenantMaximumLiquidityAmount>
    <silk:DebtInstrumentCovenantMinimumNetRevenueAmount
      contextRef="i7b1e85f6d793488db550a9cd9ebeec00_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzYwNQ_296a8f2e-6da5-4e8d-a552-d7ea847a7930"
      unitRef="usd">1000000</silk:DebtInstrumentCovenantMinimumNetRevenueAmount>
    <silk:DebtInstrumentCovenantMinimumNetRevenueAmount
      contextRef="i159d0d96431346b8906e3a743106810e_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzYxNw_64eef6b2-9203-4776-bee1-aebf4c7abebe"
      unitRef="usd">5000000</silk:DebtInstrumentCovenantMinimumNetRevenueAmount>
    <silk:DebtInstrumentCovenantMinimumNetRevenueAmount
      contextRef="i819cbd89b0e044588cd3162b0ae7dad0_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzYyOQ_aa53c8fc-9998-4175-abc9-e60099600146"
      unitRef="usd">15000000</silk:DebtInstrumentCovenantMinimumNetRevenueAmount>
    <silk:DebtInstrumentCovenantMinimumNetRevenueAmount
      contextRef="i448c71a8e90245efa333cff2acf26e6f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzY0MQ_e519911d-df7a-42ff-b29d-fb6508700c43"
      unitRef="usd">30000000</silk:DebtInstrumentCovenantMinimumNetRevenueAmount>
    <silk:DebtInstrumentCovenantMinimumNetRevenueAmount
      contextRef="ic379c431ee4f4674ab4bd3200cc4d510_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzY5Mg_625c6d68-6327-49d7-a8af-1e0384b8b9ba"
      unitRef="usd">40000000</silk:DebtInstrumentCovenantMinimumNetRevenueAmount>
    <silk:DebtInstrumentLiquidityCovenantTerm
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMzc0Mw_680f5d30-655e-492d-af25-909c33b82dcb">P90D</silk:DebtInstrumentLiquidityCovenantTerm>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfNTY2OQ_93b3b683-9cd1-4614-ad03-29235a31db55">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future maturities under the term loan agreement as of June&#160;30, 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.256%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Add: Accretion of closing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Amount representing debt discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfMS0yLTEtMS0w_9df6a581-3b39-4592-b242-296068bebb7d"
      unitRef="usd">2240000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfMi0yLTEtMS0w_01ef190d-37b8-4311-9fe8-3d7a7f252082"
      unitRef="usd">4442000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfMy0yLTEtMS0w_f6141e21-8a0d-44ad-9ebd-c01018854fbc"
      unitRef="usd">48255000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <silk:LongTermDebtGrossBeforeAccretionOfClosingFees
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfNC0yLTEtMS0w_4d2556b3-93a9-4d08-8918-70db1e2e5fab"
      unitRef="usd">54937000</silk:LongTermDebtGrossBeforeAccretionOfClosingFees>
    <silk:LongTermDebtAccretionOfClosingFees
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfNS0yLTEtMS0w_be690105-0aa2-4329-82bf-22e2a92aac31"
      unitRef="usd">1369000</silk:LongTermDebtAccretionOfClosingFees>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfNi0yLTEtMS0w_7ecd9928-78bf-4e73-87ab-5e9f98c80089"
      unitRef="usd">56306000</us-gaap:DebtInstrumentCarryingAmount>
    <silk:LongTermDebtUnpaidInterest
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfNy0yLTEtMS0w_fe96d562-a3f2-4b56-b722-af5962c73fac"
      unitRef="usd">11124000</silk:LongTermDebtUnpaidInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfOC0yLTEtMS0w_0c3f93b6-bfa4-48c6-88c1-0afc8c9974a9"
      unitRef="usd">116000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RhYmxlOmM0OGZhMDgzMWQ1NjQwMDBiMGFmYTkyMWU0OTk1YjJjL3RhYmxlcmFuZ2U6YzQ4ZmEwODMxZDU2NDAwMGIwYWZhOTIxZTQ5OTViMmNfOS0yLTEtMS0w_41d2001d-7ca3-4d31-afd8-097ff59b3afe"
      unitRef="usd">45066000</us-gaap:LongTermDebt>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i633031055692460588cb4386c56f8095_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQ4Mg_6402f97d-2ef0-4c01-bdd7-5a4c799ed4ea"
      unitRef="shares">327759</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ie917c02865cd4fba8e0243a7cd29e649_I20151031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQ2Nw_238a2ede-58cf-4450-9216-205d1493dc85"
      unitRef="usdPerShare">6.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i417623c9d2f24af1b9f527fefb005c13_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTQ5OQ_e4acfd65-f4b1-4a17-b2ce-71799823ab34"
      unitRef="shares">163877</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ie917c02865cd4fba8e0243a7cd29e649_I20151031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfNTI0Ng_a4c4be14-98b9-4f5f-acd2-a6c53c1f6c7c"
      unitRef="usdPerShare">6.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ieebe6a801a53498d95a8594bf16d9080_I20151031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTU3Mw_aef77954-70a4-44f6-abf5-4c55a08f1a40"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6c7140d4200a4dc5bdacecc60d872d6b_D20170701-20170731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTUxNg_7b5c288c-c2a8-4ccb-8625-0db57515da95"
      unitRef="shares">163877</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ife031befc9a54c529bec50b02c7d0159_I20170731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl81OC9mcmFnOjQ4NGFhZWE5ODcwODQyZDc5MDJkNDE2ZDM2ODAyZmJlL3RleHRyZWdpb246NDg0YWFlYTk4NzA4NDJkNzkwMmQ0MTZkMzY4MDJmYmVfMjE5OTAyMzI2MTUzMQ_617fb619-c272-4882-8a79-8d1e731bc437"
      unitRef="usdPerShare">6.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMzEwMQ_f3785e1d-55d6-498e-a9bb-d42c3570741e">Commitments and Contingencies&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Operating Lease and Rights-of-Use&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s operating lease obligation consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2024.  The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of five years.  Operating lease costs were $217,000 for each of the three months ended June 30, 2020 and 2019 and $435,000 for each of the six months ended June 30, 2020 and 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $188,000, $372,000, $169,000 and $363,000 for the three and six months ended June&#160;30, 2020 and 2019, respectively.  As of June&#160;30, 2020, the weighted average discount rate was approximately 6.50% and the weighted average remaining lease term was 4.33 years.  Balance sheet information as of June&#160;30, 2020 consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.591%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Lease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use asset in other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability in accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability in other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s operating lease maturities as of June&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.256%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Purchase Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. As of June&#160;30, 2020, the Company had non-cancellable purchase obligations to suppliers of $6,640,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty.  The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made.  To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company&#x2019;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws.  The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity.  The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance.  The Company believes that the fair value of these indemnification obligations is minimal.  Accordingly, the Company has not recognized any liabilities relating to these obligations as of June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows.  From time to time, the Company may pursue litigation to assert its legal right and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual at June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMzcw_809a0ec5-e5de-4700-a8b3-103732d2ab07">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNDAy_a4a97185-8d19-4ef5-b7e9-799d4d99f065"
      unitRef="usd">217000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNDAy_fe90b7d2-775a-444d-ade4-0f638c803220"
      unitRef="usd">217000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTA5OTUxMTYzMDg4MA_7f6d95a9-f8e7-4741-86db-2555f3a7256c"
      unitRef="usd">435000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTA5OTUxMTYzMDg4MA_a839712f-a267-48ff-9866-beedab4e2316"
      unitRef="usd">435000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNTQ2_1d907aa2-5a7d-44b1-98bc-48333f9ae6d9"
      unitRef="usd">188000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTA5OTUxMTYzMDg4NA_e50951bd-4c53-40eb-bc1a-758b432ab516"
      unitRef="usd">372000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNTUz_6e057a09-197a-4d20-bb47-da120f34bb0b"
      unitRef="usd">169000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTA5OTUxMTYzMDg5NQ_931c90a9-69a9-46fc-bd69-84e8cee91532"
      unitRef="usd">363000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNjY5_80150309-1f4c-48b2-93fd-c6f1622be9a0"
      unitRef="number">0.0650</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfNzIy_a071f83a-6f52-4cb7-9700-17455eb88dde">P4Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <silk:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMzA5Nw_ba0b1c37-6753-49a9-95a5-a67455b8b7d1">Balance sheet information as of June&#160;30, 2020 consists of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.591%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Lease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use asset in other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability in accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability in other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</silk:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOjc1OWQzZWFmNjAyYTQ0N2NhMWNlYjJhYTkzMDM1YTI2L3RhYmxlcmFuZ2U6NzU5ZDNlYWY2MDJhNDQ3Y2ExY2ViMmFhOTMwMzVhMjZfMS0yLTEtMS0w_1abbfd54-5135-41d7-9ac4-a302e7b73687"
      unitRef="usd">3105000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOjc1OWQzZWFmNjAyYTQ0N2NhMWNlYjJhYTkzMDM1YTI2L3RhYmxlcmFuZ2U6NzU5ZDNlYWY2MDJhNDQ3Y2ExY2ViMmFhOTMwMzVhMjZfMi0yLTEtMS0w_c7f265fc-b41a-4b23-be60-cde8ccdf9697"
      unitRef="usd">809000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOjc1OWQzZWFmNjAyYTQ0N2NhMWNlYjJhYTkzMDM1YTI2L3RhYmxlcmFuZ2U6NzU5ZDNlYWY2MDJhNDQ3Y2ExY2ViMmFhOTMwMzVhMjZfMy0yLTEtMS0w_f5d84c09-50d9-46f1-832c-ac2faac9ec62"
      unitRef="usd">3288000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOjc1OWQzZWFmNjAyYTQ0N2NhMWNlYjJhYTkzMDM1YTI2L3RhYmxlcmFuZ2U6NzU5ZDNlYWY2MDJhNDQ3Y2ExY2ViMmFhOTMwMzVhMjZfNC0yLTEtMS0w_3c76a7f7-e31a-4ada-902f-20c9c40ddff5"
      unitRef="usd">4097000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMzA5OQ_f0681bb0-1782-4cee-a241-3c862a445933">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s operating lease maturities as of June&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.256%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Period Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfMS0yLTEtMS0w_57917704-959a-48c1-87bd-8779101d6cb8"
      unitRef="usd">525000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <silk:LesseeOperatingLeaseLiabilityToBePaidYearOne
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfMi0yLTEtMS0w_7412b9d8-d355-4559-abab-50dbae04fd97"
      unitRef="usd">1066000</silk:LesseeOperatingLeaseLiabilityToBePaidYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfMy0yLTEtMS0w_9a94d50e-0732-4973-a2c6-cd09920f12f9"
      unitRef="usd">1096000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfNC0yLTEtMS0w_1f881261-c282-4e76-88ec-1bce72525d01"
      unitRef="usd">1127000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfNS0yLTEtMS0w_70996437-2c0d-4e70-b970-135f780e4fd8"
      unitRef="usd">904000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfNi0yLTEtMS0w_cbf07fbe-ceb4-40de-acba-dbfe7deabb5f"
      unitRef="usd">4718000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfNy0yLTEtMS0w_ab20c606-5194-43c9-8f05-5a82dafeec10"
      unitRef="usd">621000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RhYmxlOmI0MzVkNzJmOWU4MTQyZGVhOWJhZWIzN2NiZDE3NjA4L3RhYmxlcmFuZ2U6YjQzNWQ3MmY5ZTgxNDJkZWE5YmFlYjM3Y2JkMTc2MDhfOC0yLTEtMS0w_745a5b83-9b9e-44d6-862a-87bf2cf02b5c"
      unitRef="usd">4097000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PurchaseObligation
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82MS9mcmFnOjdiOWMyMjVhNDRmNjQ4ZjhiZjMwODZhMjdhZTZjMmE3L3RleHRyZWdpb246N2I5YzIyNWE0NGY2NDhmOGJmMzA4NmEyN2FlNmMyYTdfMTEzMA_65d9cd78-b526-459b-8a6f-51394307b9a3"
      unitRef="usd">6640000</us-gaap:PurchaseObligation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjc0ODc3OTA3MDA3Mw_87474fd9-61c0-4bbd-a5f8-f11bf811bd32">Redeemable Convertible Preferred Stock&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into shares of common stock. As of June&#160;30, 2020 and December 31, 2019, the Company does not have any convertible preferred stock issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Preferred Stock Warrant&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon the closing of the Company's IPO, all of the outstanding convertible preferred stock warrants were exercised, or net exercised based on the IPO price of $20.00 per share, into&#160;1,945,365 shares of common stock. As of June&#160;30, 2020 and December 31, 2019, the Company does not have any convertible preferred stock warrants outstanding.&lt;/span&gt;&lt;/div&gt;Stockholders Equity&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June&#160;30, 2020, the Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of preferred stock with $0.001 par value per share, of which no shares were issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June&#160;30, 2020, the Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 33,610,099 shares were issued and outstanding.  The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors.  As of June&#160;30, 2020, no dividends have been declared to date.  Each share of common stock is entitled to one vote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Common Stock Warrant&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the IPO, the common stock warrants were cash, or net exercised based on the IPO price of $20.00 per share, into 5,968 shares of common stock.  As of June&#160;30, 2020 and December 31, 2019, the Company does not have any common stock warrants outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjI3_097bf0ec-1fae-4c0a-94a7-11c71260ea60"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjI3_b0a7127e-7c0f-4e0b-8138-cc7eea23a906"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjI3_c80ae1bc-4723-473a-85ad-5cb175e26a7f"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfMjI3_cba3f41d-6fa3-423b-aebb-f925cf487eb3"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic9dcdcdf5e9b496689dbd352302af644_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNDk0NzgwMjMyNTYzNA_d589f590-11b8-4110-ac8b-e4810f486e56"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i84de79cfd01646ca80f851b0e71fec3e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNDk0NzgwMjMyNTY1Mg_103e8956-7991-4e8b-b9ad-d4d6f3050e47"
      unitRef="shares">1945365</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNTY5_097bf0ec-1fae-4c0a-94a7-11c71260ea60"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNTY5_b0a7127e-7c0f-4e0b-8138-cc7eea23a906"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNTY5_c80ae1bc-4723-473a-85ad-5cb175e26a7f"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82NC9mcmFnOjkwOTQxZDAwZWEyZjQ0MjViODI5ZDc2MDdkOWFjOWQ1L3RleHRyZWdpb246OTA5NDFkMDBlYTJmNDQyNWI4MjlkNzYwN2Q5YWM5ZDVfNTY5_cba3f41d-6fa3-423b-aebb-f925cf487eb3"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjA0OQ_1e257701-dd7d-4d0f-80bd-93915e469cca"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjA2Nw_c216748c-052a-411d-a1b8-d5f7e8989c35"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfMjI5_75d82630-c2a0-4af1-9030-81b52a4fc67b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfMjI5_7d2bdf21-7c01-4b48-85a9-b30374ea2ec9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfMzk1_da132236-7c43-4c5b-8d84-51468a969ff4"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDI2_56dcf95b-f264-44e7-818b-49728e7da5ad"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDU5_26602a01-28d6-4257-8f20-a667e8517bfd"
      unitRef="shares">33610099</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDU5_e0ef9fd2-0d31-4f3d-9488-49a9eacf73e5"
      unitRef="shares">33610099</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DividendsCommonStock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNjYz_63e8d34f-56a6-461c-933e-93c1c38f805d"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <silk:CommonStockVotePerShare
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjEwNg_993f1a2b-5d64-4855-8281-7110714d2362"
      unitRef="vote">1</silk:CommonStockVotePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic9dcdcdf5e9b496689dbd352302af644_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjA5NQ_4d4a2051-dfda-4ba2-a217-c4e4b0d4e5c5"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i6113484aa6d4421ebce5390fc3eaf952_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfNDk0NzgwMjMyNjA4MQ_a834b738-5c1d-4fd4-a7b4-c74c57a9a207"
      unitRef="shares">5968</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfOTgy_097bf0ec-1fae-4c0a-94a7-11c71260ea60"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfOTgy_b0a7127e-7c0f-4e0b-8138-cc7eea23a906"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i98995d7c6a444311ad86aee8421c9d3a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfOTgy_c80ae1bc-4723-473a-85ad-5cb175e26a7f"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i496155293b1d4422b3ea42fef3be00b2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl82Ny9mcmFnOjk1YWE3ZGFmZGEyNTQxZjI4NzhlYTU0YTA2MDNmZGRiL3RleHRyZWdpb246OTVhYTdkYWZkYTI1NDFmMjg3OGVhNTRhMDYwM2ZkZGJfOTgy_cba3f41d-6fa3-423b-aebb-f925cf487eb3"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMxMQ_70235573-9a24-4901-aeec-e898d9f55c75">Stock Option Plans&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2019, the Company&#x2019;s Board of Directors approved the adoption of the 2019 Equity Incentive Plan, or the 2019 Plan, which became effective immediately prior to the Company's IPO. The 2019 Plan replaced the 2007 Stock Option Plan which was terminated immediately prior to consummation of the Company&#x2019;s IPO, collectively the &#x201c;Plans.&#x201d; The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants.  A total of 2,317,000 shares of common stock were initially reserved for issuance pursuant to the 2019 Plan.  In addition, the shares reserved for issuance under the 2019 Plan will also include shares reserved but not issued under the 2007 Stock Option Plan, plus any share awards granted under the 2007 Stock Option Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased.  In addition, the number of shares available for issuance under the 2019 Plan will also include an annual increase on the first day of each fiscal year beginning in fiscal 2020, equal to the lesser of (i) 3,000,000 shares; (ii) 4.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors.  As of June&#160;30, 2020, the Company has reserved 3,631,205 shares of common stock for issuance under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The exercise price of ISOs and NSOs shall not be less than 100% and 85% of the estimated fair value of the shares on the date of grant, respectively, as determined by the Board of Directors.  The exercise price of ISOs and NSOs granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  To date, options have a term of 10 years and generally vest over 4 years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock option activity under the Company&#x2019;s Plans is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.096%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.416%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares Available for Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,554,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,250,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(752,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;752,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(405,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances, June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,076,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,632,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and exercisable at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,554,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,632,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The aggregate intrinsic value of options exercised during the six months ended June 30, 2020, was $15,048,000.  The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the Company began granting restricted stock units, or RSUs, under the 2019 Plan.  RSUs generally vest over four years in annual equal increments, no RSUs vested during the six months ended June 30, 2020.  The fair value of RSUs is based on the Company&#x2019;s closing stock price on the date of grant. A summary of RSUs activity for the six months ended June 30, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.864%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.443%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.504%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.443%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.346%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances, June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected to vest at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2019, the Company's Board of Directors adopted the 2019 Employee Stock Purchase Plan, or 2019 ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions.  A total of 434,000 shares of common stock were initially reserved for issuance and will be increased on the first day of each fiscal year, beginning in 2020, by an amount equal to the lesser of (i)&#160;1,200,000 shares (ii)&#160;1.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors.  As of June&#160;30, 2020, the Company has reserved 746,552 shares of common stock for issuance under the 2019 ESPP.  The price of the common stock purchased will be the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period.  The 2019 ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019.  The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, 87,567 shares of common stock have been issued to employees participating in the 2019 ESPP and 658,985 shares were available for future issuance under the 2019 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company estimated the fair value of stock options using the Black&#x2013;Scholes option pricing model.  The fair value of employee and nonemployee stock options is being amortized on a straight&#x2013;line basis over the requisite service period of the awards.  The fair value of employee and nonemployee stock options was estimated using the following assumptions for the three and six months ended June&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.455%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.865%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.865%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.865%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.867%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.25 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.00 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.25 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.00 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;46.6% - 47.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;42.7% - 42.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;42.9% - 47.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;42.7% - 42.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.42% - 0.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.86% - 2.37%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.42% - 1.41%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.86% - 2.54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the shares to be issued under the Company&#x2019;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and six months ended June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.455%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.224%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.544%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.028%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;44.4% - 76.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.14% - 1.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation expense relating to the Company's stock options, RSUs and 2019 ESPP during the three and six months ended June&#160;30, 2020 and stock-based compensation expense related to the Company's stock options and 2019 ESPP during the three and six months ended June&#160;30, 2019, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.794%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, there was total unrecognized compensation costs of $16,986,000 related to stock options expected to be recognized over a period of approximately 3.24 years, a total of $1,119,000 of unrecognized compensation costs related to unvested RSUs expected to be recognized over a period of approximately 3.68 years and $303,000 of unrecognized compensation costs related to the ESPP, which the Company will recognize over 0.4 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i7df1fe52b16e418da8983a23cd31db62_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNjE5_5d57cc33-bc12-4065-83f1-36da2b89c91c"
      unitRef="shares">2317000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i2378c3bc6251483cab8274447be641b8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMTIyOA_b31631ed-ef52-4e19-8031-bf8a2176d549"
      unitRef="shares">3000000</silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i3dd9fbf4e28c4a2fbde835757d39a1e5_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMTI0NA_5106d3f2-50a9-458e-87f4-c658c4b8fa5e"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6b705b1bf16749838adb0a5da76d687c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMTQ0Ng_2b5de8d2-f619-4452-81d5-8476ee3f7077"
      unitRef="shares">3631205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice
      contextRef="ie23898085ac8458bb0cac28efb4aaef4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTUyMA_46db0a22-32e3-4da4-a0ee-5dd7fe3ec05f"
      unitRef="number">1</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice
      contextRef="i53f162f8f289492a97ccfe1e594fa809_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTUzMA_0a9960ba-abe3-44fc-b964-53d575fbd761"
      unitRef="number">0.85</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice>
    <silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice
      contextRef="ice3001c6ee614220ac19207889d5aa37_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTU0MA_6c43583b-e4b3-427b-a0be-e681d5793508"
      unitRef="number">1.10</silk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ie82a229840ec40d79a480525255fd532_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTQ4MQ_ab16fc75-9c00-499c-b55d-c71aa2aad130">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie82a229840ec40d79a480525255fd532_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTUwMg_21ab492a-28fb-4427-abc2-3a3ff2c67805">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMwOA_16760f14-1ce8-4690-9b60-fcc940a5fd74">&lt;div style="margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock option activity under the Company&#x2019;s Plans is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.096%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.416%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares Available for Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,554,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,310,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,250,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(752,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;752,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(405,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances, June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,076,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,632,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and exercisable at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,554,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,632,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy0xLTEtMS0w_4da289ea-c8c0-4287-af26-2589350e12f0"
      unitRef="shares">1554690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy0zLTEtMS0w_e2751f16-1c87-4587-a18a-6d5cc1d5fa40"
      unitRef="shares">4310790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy01LTEtMS0w_0c79c814-5a7b-4f7f-9f63-39d8ca552144"
      unitRef="usdPerShare">7.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i448c71a8e90245efa333cff2acf26e6f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy03LTEtMS0w_4f349cba-9fad-4e4b-910d-4afedb6c8a37">P7Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4192fdc2c1f247de9e20017c4c131295_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfNy05LTEtMS0w_3c1ba3f0-0176-47ba-a122-f942dfcc4f81"
      unitRef="usd">140234000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfOC0xLTEtMS0w_77c10e04-155b-47f2-9bb4-858f527c307f"
      unitRef="shares">1250210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfOS0xLTEtMS0w_bf14cfd8-6e7d-4847-8935-81554b9a1723"
      unitRef="shares">752258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfOS0zLTEtMS0w_f514453b-212e-4396-9dae-719b01a625c7"
      unitRef="shares">752258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfOS01LTEtMS0w_3e461f2b-b074-48cc-a8a3-dba1fb5063e8"
      unitRef="usdPerShare">33.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTAtMy0xLTEtMA_e2428c18-c3c0-4a44-8f93-f56df0715566"
      unitRef="shares">405837</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTAtNS0xLTEtMA_12aeec45-8d66-4468-af50-fac0db005445"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTEtMS0xLTEtMA_3f064456-23b9-4741-a4f5-6c19beedeb83"
      unitRef="shares">24345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTEtMy0xLTEtMA_624c1af8-e42f-46b4-8f1e-6a2595319f35"
      unitRef="shares">24345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTEtNS0xLTEtMA_a4a84cae-b73e-4e8e-8b62-31a7836dcc75"
      unitRef="usdPerShare">17.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItMS0xLTEtMA_a3935d0f-c6ae-4250-b7a5-b852f218cf94"
      unitRef="shares">2076987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItMy0xLTEtMA_43a4cea9-4215-405c-823f-39bc16843519"
      unitRef="shares">4632866</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItNS0xLTEtMA_bb9e29e4-d9dd-4abc-8a88-bac45e096381"
      unitRef="usdPerShare">12.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItNy0xLTEtMA_5fd219a8-eac6-437d-aab8-b549f7df3466">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTItOS0xLTEtMA_2b7a98b6-946a-48f6-a7dc-4c0cdbc2db2b"
      unitRef="usd">136505000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTMtMy0xLTEtMA_ae960b08-1285-4939-b282-fd53335389be"
      unitRef="shares">2554809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTMtNS0xLTEtMA_22423c5f-1f0d-4a02-8c55-7dbda9f0ee29"
      unitRef="usdPerShare">5.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTMtNy0xLTEtMA_e592327d-752e-49e6-a755-2390e9520d74">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTMtOS0xLTEtMA_9f21e8c6-a5ff-4fd9-ac1e-7556400929b2"
      unitRef="usd">91917000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTQtMy0xLTEtMA_ab5f098c-5540-43ce-9a06-5cd6c77f3821"
      unitRef="shares">4632866</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTQtNS0xLTEtMA_1e281f2d-7c3d-4217-8b5a-56450f90df8e"
      unitRef="usdPerShare">12.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTQtNy0xLTEtMA_3ea975ee-f79a-44df-ab0e-6a87eedd5aaf">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmRjZmViZDBhZTgyZjQ4OTViYmExMTJhNTA1ZWIyYzQ5L3RhYmxlcmFuZ2U6ZGNmZWJkMGFlODJmNDg5NWJiYTExMmE1MDVlYjJjNDlfMTQtOS0xLTEtMA_b8a2fe42-9608-49d3-80d6-c53aca8a2303"
      unitRef="usd">136505000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjExNg_0fdfcf45-fa26-40b9-97de-6a8ba45a8116"
      unitRef="usd">15048000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjQ1OA_7e5db4ee-595e-4d92-a0a9-77c33bd4260c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjQ4Mg_7fe1b92d-159f-468d-8e01-13672e233924"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMxMw_a7b365d1-835f-4f05-a995-6259f47a711d">The fair value of RSUs is based on the Company&#x2019;s closing stock price on the date of grant. A summary of RSUs activity for the six months ended June 30, 2020 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.864%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.443%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.504%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.443%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.346%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances, June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected to vest at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7a6f5fdcd6894037a81fa4bc82914447_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMS0yLTEtMS0w_af7453cd-b931-4b87-9f2d-d9b283ea7526"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7a6f5fdcd6894037a81fa4bc82914447_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMS00LTEtMS0w_acb01375-0154-4eda-95d9-15af4e9b0178"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMi0yLTEtMS0w_c5cf163e-73cc-455f-b12f-559473dfc9a2"
      unitRef="shares">39089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMi00LTEtMS0w_3fda6c3b-aa99-4fca-a87c-2099b18560b2"
      unitRef="usdPerShare">31.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMy0yLTEtMS0w_22beab9c-f41d-4516-9d0e-953788910e2e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfMy00LTEtMS0w_b1fe6b9c-b414-4bd7-8362-d376c6b8b75c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNC0yLTEtMS0w_5a8fefd8-e55e-46b6-a114-a9b6fe948c84"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNC00LTEtMS0w_9cab61e9-cc3f-4c61-94ec-709aacf2ad37"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNS0yLTEtMS0w_519ecc29-604f-43c9-a3d4-3d1d1e3a92c5"
      unitRef="shares">39089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNS00LTEtMS0w_8ad91aaa-24b0-4921-bcb0-43d136f3341e"
      unitRef="usdPerShare">31.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNi0yLTEtMS0w_c9146250-ecb9-4994-bcd7-ba4eb9f5855d"
      unitRef="shares">39089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjZiMmY5OWY0MGQ4NzRhOTU5MGRiZjExMjgwMTY4YzZiL3RhYmxlcmFuZ2U6NmIyZjk5ZjQwZDg3NGE5NTkwZGJmMTEyODAxNjhjNmJfNi00LTEtMS0w_099b529b-ba7d-4656-940d-383773878251"
      unitRef="usdPerShare">31.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i039961495a884a188b5d3e7bda9008a4_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjk5MA_7fa7491b-87bc-4cbc-98f3-552b008a5419"
      unitRef="shares">434000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i039961495a884a188b5d3e7bda9008a4_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzE3Mg_a5f6c28e-3f38-4d6a-9598-7112c48b6093"
      unitRef="shares">1200000</silk:ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i515f2625685e47a3a0c3f87208b405e1_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzE4Nw_e7eb92fe-8f4d-4f8f-9955-6df8cd834425"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3eb1770831844300ae09b328b18c5397_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzM4OQ_4f74383c-3910-4073-9957-a7e5086ec3d9"
      unitRef="shares">746552</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i454e6e1c1e7148d2abad0f588fcee401_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzUxMQ_e9235266-2dc7-48f1-b4b6-3250f2ae516c"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i454e6e1c1e7148d2abad0f588fcee401_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMzk3MA_0be7950d-cd9f-4cb0-bc36-74f2f00ad567"
      unitRef="shares">87567</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <silk:CommonStockCapitalSharesAvailableForFutureIssuance
      contextRef="i3eb1770831844300ae09b328b18c5397_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNDA2MQ_1ace289a-d086-4737-b901-7037062f611c"
      unitRef="shares">658985</silk:CommonStockCapitalSharesAvailableForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMwMA_2bef589e-fe3d-4d9f-b8b4-e5a559fe8533">The fair value of employee and nonemployee stock options was estimated using the following assumptions for the three and six months ended June&#160;30, 2020 and 2019:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.455%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.865%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.865%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.865%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.867%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.25 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.00 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.25 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.00 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;46.6% - 47.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;42.7% - 42.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;42.9% - 47.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;42.7% - 42.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.42% - 0.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.86% - 2.37%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.42% - 1.41%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.86% - 2.54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0dfbb8e51673404eb0624832076ff097_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi0xLTEtMS0wL3RleHRyZWdpb246ZWNlYjYyOTQwM2IzNGE3MThjNzkxODcyNGY3YzI2MmNfMjE5OTAyMzI1NTU3Nw_2b006933-2c87-48a6-bbbb-a6293e1bee02">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1bea4ee895a74d1aaedf0a333c0c6f4c_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi0xLTEtMS0wL3RleHRyZWdpb246ZWNlYjYyOTQwM2IzNGE3MThjNzkxODcyNGY3YzI2MmNfMjE5OTAyMzI1NTU3MQ_e19fdffb-d3ca-46d8-912b-2098c7aab96b">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i70be1e0534404d08896dbc0a988ff250_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi0zLTEtMS0wL3RleHRyZWdpb246NTVkYmUwMWY5YTI2NGFmMmIwMGI5N2I1ZWM5NWNmNjBfMjE5OTAyMzI1NTU3MQ_ac0cf071-6850-4477-8e67-43e1379932af">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i73c173a6496b4596bfce7f7c0833e719_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi0zLTEtMS0wL3RleHRyZWdpb246NTVkYmUwMWY5YTI2NGFmMmIwMGI5N2I1ZWM5NWNmNjBfMjE5OTAyMzI1NTU3Nw_ab19225d-beca-46ae-acd8-805365bbaeab">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i220629dc98834984b7d11f79d2fe810b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi01LTEtMS0xNzQvdGV4dHJlZ2lvbjpkOTNmMzNjYmM4YTk0MTZiODQyYWUzNjNhYmJlMTIyYV8yMTk5MDIzMjU1NTcx_7a90a4a2-c4b0-43fd-983e-b5661a16bf8a">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic4dc7821cccc41989da58dcccb531642_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi01LTEtMS0xNzQvdGV4dHJlZ2lvbjpkOTNmMzNjYmM4YTk0MTZiODQyYWUzNjNhYmJlMTIyYV8yMTk5MDIzMjU1NTc3_5eba936c-3cfb-441a-b357-71bed2daaad1">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia742a060c2af4302bfd4a0bd4786b675_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi03LTEtMS0xNzQvdGV4dHJlZ2lvbjo0YTMxZWVmNzgxNTg0YjE1ODFiY2FlOTEwZDVkYjgyZV8yMTk5MDIzMjU1NTcx_656669bd-c3cf-462f-a8bd-b9796a088bfd">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia43e704ab79f493585f933259edc8540_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMi03LTEtMS0xNzQvdGV4dHJlZ2lvbjo0YTMxZWVmNzgxNTg0YjE1ODFiY2FlOTEwZDVkYjgyZV8yMTk5MDIzMjU1NTc3_529d30ff-2e4e-45c2-a29d-e20b6b973b8b">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy0xLTEtMS0wL3RleHRyZWdpb246MzQ2ODQxMWRhZThiNDM5MjhiZTBjYmUyNDczZjdhOWVfMjE5OTAyMzI1NTU5NA_29fd20d0-bf2b-432d-8ad7-e85cb8382298"
      unitRef="number">0.466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy0xLTEtMS0wL3RleHRyZWdpb246MzQ2ODQxMWRhZThiNDM5MjhiZTBjYmUyNDczZjdhOWVfMjE5OTAyMzI1NTYwMQ_6da7b21b-3c23-4472-906c-046ecd086256"
      unitRef="number">0.477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy0zLTEtMS0wL3RleHRyZWdpb246ZDlmYjY5N2Q3YjA4NDQxNmJmZmI1NjdhM2M5NjJmNjVfMjE5OTAyMzI1NTU3NA_8bfc445a-316b-42c7-81e7-bdef57f52343"
      unitRef="number">0.427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy0zLTEtMS0wL3RleHRyZWdpb246ZDlmYjY5N2Q3YjA4NDQxNmJmZmI1NjdhM2M5NjJmNjVfMjE5OTAyMzI1NTU4MQ_be81f9c4-4fbc-4f71-8918-8e40308302e8"
      unitRef="number">0.429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy01LTEtMS0xNzQvdGV4dHJlZ2lvbjpjMjQyZjVkZDNkNzQ0OTg4ODgwNjNlZTIxNzRlYTMwN18yMTk5MDIzMjU1NTc0_abb9c8a5-fedc-4a14-a87f-ed2f7e1549b6"
      unitRef="number">0.429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy01LTEtMS0xNzQvdGV4dHJlZ2lvbjpjMjQyZjVkZDNkNzQ0OTg4ODgwNjNlZTIxNzRlYTMwN18yMTk5MDIzMjU1NTgx_4d944dcb-7582-48f1-9c06-1b6db85f5bc3"
      unitRef="number">0.477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy03LTEtMS0xNzQvdGV4dHJlZ2lvbjpkZGY3ODc1YzJhYjE0MDk3YWRlNTdkMTAyMzAwNTgxOV8yMTk5MDIzMjU1NTc0_b961c79b-bf23-48b0-b9df-cdea4b0b5d57"
      unitRef="number">0.427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfMy03LTEtMS0xNzQvdGV4dHJlZ2lvbjpkZGY3ODc1YzJhYjE0MDk3YWRlNTdkMTAyMzAwNTgxOV8yMTk5MDIzMjU1NTgx_7fe419f1-92a9-4f84-92f5-2cabf7f4eda0"
      unitRef="number">0.429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC0xLTEtMS0wL3RleHRyZWdpb246NWQ1YzE0MTEwOTYwNDk1YTk1NGQzMzFiNWM3MWVmMWRfNA_084bdb3c-7547-4872-8ab7-0b541e875024"
      unitRef="number">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC0xLTEtMS0wL3RleHRyZWdpb246NWQ1YzE0MTEwOTYwNDk1YTk1NGQzMzFiNWM3MWVmMWRfOQ_7afb91de-9151-4530-b921-3656c8efe407"
      unitRef="number">0.0056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC0zLTEtMS0wL3RleHRyZWdpb246N2VmYWZlMWRiYzc1NGIyNWExNDE0ZTgwYzQ0NTZiMTNfMjE5OTAyMzI1NTU4NA_fdbf1963-b6cd-4743-a0f7-2764f76b8e15"
      unitRef="number">0.0186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC0zLTEtMS0wL3RleHRyZWdpb246N2VmYWZlMWRiYzc1NGIyNWExNDE0ZTgwYzQ0NTZiMTNfMjE5OTAyMzI1NTU5MQ_68ce5692-b37a-4d5d-b574-75a3a4aa56a7"
      unitRef="number">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC01LTEtMS0xNzQvdGV4dHJlZ2lvbjpiM2YwYTMxNTU3NGU0MTdlYjJjYTgzY2I0ZjcxZTc1Yl8yMTk5MDIzMjU1NTc0_5d5bbfa8-f2b8-4a13-86e2-b12ce12ed3e4"
      unitRef="number">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC01LTEtMS0xNzQvdGV4dHJlZ2lvbjpiM2YwYTMxNTU3NGU0MTdlYjJjYTgzY2I0ZjcxZTc1Yl8yMTk5MDIzMjU1NTgx_53e7950d-5ebb-4027-a428-4c63b5d8b65f"
      unitRef="number">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC03LTEtMS0xNzQvdGV4dHJlZ2lvbjpjNzIzMTk1ZDFlNzM0MzBlOTk3NWMwZTU0ZTE0MzEzYl8yMTk5MDIzMjU1NTc0_25f4cd94-ed21-4614-b116-78c0458e9424"
      unitRef="number">0.0186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNC03LTEtMS0xNzQvdGV4dHJlZ2lvbjpjNzIzMTk1ZDFlNzM0MzBlOTk3NWMwZTU0ZTE0MzEzYl8yMTk5MDIzMjU1NTgx_0be5b8e0-bc30-4373-bd3a-a5f9394acb6e"
      unitRef="number">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNS0xLTEtMS0w_01ecaf83-f9d9-4497-b869-bf507bcf869d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNS0zLTEtMS0w_4a6d226a-a635-4075-a658-c0c3db8c7df5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNS01LTEtMS0xNzQ_49e8f25b-b2f3-4d09-b10f-3074578515bf"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjM3NjJjZTFlMzVjZTQzNjI4OTY3NmYwNzA2MmVlNjAxL3RhYmxlcmFuZ2U6Mzc2MmNlMWUzNWNlNDM2Mjg5Njc2ZjA3MDYyZWU2MDFfNS03LTEtMS0xNzQ_027843e6-14c7-4999-976d-fcb199069d9c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <silk:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMwMQ_eaa8920d-2b7f-4c75-b20a-d249042eb4bf">&lt;div style="margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the shares to be issued under the Company&#x2019;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and six months ended June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.455%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.224%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.544%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.028%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;44.4% - 76.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.14% - 1.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</silk:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMS0xLTEtMS0w_ca7b608a-7200-47ee-9ab2-0a391945c677">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4024977785b1424fab65d0622c295161_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMi0zLTEtMS05ODA_fdc7a4ba-334e-4505-870e-7f9b51a22675">P0Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMi01LTEtMS05OTA_5d235890-3ad7-43f6-bcf9-d26ce64c26ef">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMS0zLTEtMS0xOTY_3b8a00be-fcec-456d-9e6f-efbdccb4389f">P0Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMi0xLTEtMS0w_4689ce92-7d73-4b1f-82c7-a570ae24894b"
      unitRef="number">0.764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4024977785b1424fab65d0622c295161_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy0zLTEtMS05ODA_a915d7ea-58d4-4df1-9fff-ac7fbc6b9ddb"
      unitRef="number">0.478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy01LTEtMS05OTAvdGV4dHJlZ2lvbjoyYzJjNTY2YjExMmQ0M2I1ODc2YzExZDllNDM4OGQ3OV8yMTk5MDIzMjU1NTc0_ca0e5368-3ab4-435a-bb0b-22a00f3225e5"
      unitRef="number">0.444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy01LTEtMS05OTAvdGV4dHJlZ2lvbjoyYzJjNTY2YjExMmQ0M2I1ODc2YzExZDllNDM4OGQ3OV8yMTk5MDIzMjU1NTgx_8df0c796-98f4-419a-b7ed-5e2730ad287f"
      unitRef="number">0.764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMi0zLTEtMS0xOTY_d2524166-63ad-45cb-aae2-8f881cfaa81d"
      unitRef="number">0.478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy0xLTEtMS0w_8bb61677-e3b2-41ba-9273-8045c6c4bf53"
      unitRef="number">0.0014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4024977785b1424fab65d0622c295161_D20190401-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC0zLTEtMS05ODA_e8aed7c3-2950-4d22-a623-6a7b66734eb0"
      unitRef="number">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC01LTEtMS05OTAvdGV4dHJlZ2lvbjplMWMzNGNiMmRkZmM0NTcxYmU0YzU0YTY3OGQ5NTIxZF8yMTk5MDIzMjU1NTc0_358ff5ab-bd4f-4bdd-b23f-25cdeb86ec6a"
      unitRef="number">0.0014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC01LTEtMS05OTAvdGV4dHJlZ2lvbjplMWMzNGNiMmRkZmM0NTcxYmU0YzU0YTY3OGQ5NTIxZF8yMTk5MDIzMjU1NTgx_0e8ee7b5-8307-4a34-8381-2dbb4c643dec"
      unitRef="number">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfMy0zLTEtMS0xOTY_634d2cce-32d5-4f69-a426-37d412c867af"
      unitRef="number">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i45682b4d11f94a79aa85e38c67dbd929_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC0xLTEtMS0w_1026d27b-dbef-4953-89f5-14f6bcd2eff6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4024977785b1424fab65d0622c295161_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNS0zLTEtMS05ODA_399627e1-32ad-4ff7-b1c2-a82e861117c0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNS01LTEtMS05OTA_66f02785-5157-41f0-bb8f-3b526f5712ab"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i28c9fc304a5b4057a75656dbba76f67a_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOjA2NDI0OGNiZTAxMjQ0YjM5NDY1OTg4MjNlOGIyOTFhL3RhYmxlcmFuZ2U6MDY0MjQ4Y2JlMDEyNDRiMzk0NjU5ODgyM2U4YjI5MWFfNC0zLTEtMS0xOTY_4a0b1821-8c30-48a5-a885-c00edbdf7949"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTMwNg_db70d14b-c60e-48c4-9147-03a370b581ab">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation expense relating to the Company's stock options, RSUs and 2019 ESPP during the three and six months ended June&#160;30, 2020 and stock-based compensation expense related to the Company's stock options and 2019 ESPP during the three and six months ended June&#160;30, 2019, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.794%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.820%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.823%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0cbb5c9c3ef24d45998860f450b433d3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMi0xLTEtMS0w_bdde82f6-6991-41f8-8ef2-ca3e393534b0"
      unitRef="usd">89000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2826aabff8b4439e8abd78eb9018b593_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMi0zLTEtMS0w_a160578d-14f1-424d-984a-3146c0d7073e"
      unitRef="usd">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iab80b98eced34b02a24687725a852684_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMi01LTEtMS0yNTg_4aa1451a-cd6c-4fcd-90f5-02fb5d426219"
      unitRef="usd">153000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b281a430c8c4aada7ebc48e15d5e031_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMi03LTEtMS0yNTg_9564480f-764d-454f-8dce-43e2d3f1d746"
      unitRef="usd">69000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e5f9129abc84b8e85adb2e73a6a2964_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMy0xLTEtMS0w_638fefba-bf13-4492-a8b0-3c267e06404d"
      unitRef="usd">246000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id87005078ae94c2ba819b718b9a86599_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMy0zLTEtMS0w_25a8e3a2-c3c0-4175-a48c-27838dec4098"
      unitRef="usd">127000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55f2446a5cb34a2c800a0378dc3c54f6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMy01LTEtMS0yNTg_9dafedd7-e1c3-4da3-8796-272a6265936d"
      unitRef="usd">423000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d1215e8500c43c59e1c45a0496eabb7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfMy03LTEtMS0yNTg_104f6be5-a4f9-45cb-aa1b-cad1a328fcab"
      unitRef="usd">155000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0a29f695f4e8418b88fdf2ecd941252f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNC0xLTEtMS0w_6010aac7-c3df-4578-b92b-8197dca88b35"
      unitRef="usd">1319000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c1ae90727004ccfbf97f186ac2e0781_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNC0zLTEtMS0w_31145c1f-f09a-47fd-8324-087279619292"
      unitRef="usd">655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie8664b40a2ba4c69b62ac361f5b299d4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNC01LTEtMS0yNTg_a8914595-6f51-4806-b3d9-fa3b3a24a86a"
      unitRef="usd">2371000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a7af5bbd93b4d26b19182dbb32d2697_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNC03LTEtMS0yNTg_97e09a6a-0dfa-49a4-8135-b874b7db9dee"
      unitRef="usd">875000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNS0xLTEtMS0w_e87048bb-6940-4a72-8bd2-05288f5468da"
      unitRef="usd">1654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i89fa916799d14ae5994e6bb883b7ea94_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNS0zLTEtMS0w_f5861c31-a333-440f-acf1-4773adcbc1e3"
      unitRef="usd">836000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNS01LTEtMS0yNTg_9b74840a-4e0b-4f17-8409-bb8d21fdc860"
      unitRef="usd">2947000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if912977b2ce14d49a6aed4e922311ac1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RhYmxlOmVkZTMzM2I3NWFiZDQ2YzNhNWU3MTMwYjFjOTE0MWQyL3RhYmxlcmFuZ2U6ZWRlMzMzYjc1YWJkNDZjM2E1ZTcxMzBiMWM5MTQxZDJfNS03LTEtMS0yNTg_4e454814-081d-41c1-b63e-750b305fed9c"
      unitRef="usd">1099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0b2654a458fe4949a14a70a00d0e6c46_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTA3NQ_0c0e8e1e-2cf6-459b-b995-d4d135f1d6d0"
      unitRef="usd">16986000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i454e6e1c1e7148d2abad0f588fcee401_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTE2MA_a4744e84-9390-4f64-a3af-0240823e82f0">P3Y2M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i2811c603862b4d7ea5a7fa37dea521c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTE3OA_a366fef9-230a-4037-b322-7c61ba1743f7"
      unitRef="usd">1119000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie7c0724845984d8a86158ae06b154011_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfNTI5OA_c999fdfe-20b2-44e5-80cb-fcf8329645ed">P3Y8M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2473c0e76af946f0a8d35143cb16bdc7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTIxNg_8a38d11f-ed72-4a03-8f05-f1adab0783f8"
      unitRef="usd">303000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8f6b31f223554e759a666f49708ea06c_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83MC9mcmFnOjc4MzFiZmJjMWM4OTRmZDZhMzE1ODg4NThkMWU2ODc1L3RleHRyZWdpb246NzgzMWJmYmMxYzg5NGZkNmEzMTU4ODg1OGQxZTY4NzVfMjE5OTAyMzI2MTIyNQ_68f979e2-ffc2-49c8-aa56-a4632fab5948">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMjc0ODc3OTA3MDAxMQ_e4e3fa0e-eec9-46c8-ad87-4c4b5bf775dc">401(k) PlanThe Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code (&#x201c;IRC&#x201d;) under which participants may contribute up to 90% of their eligible compensation, subject to maximum deferral limits specified by the IRC.  Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at 50% of the first 5% of compensation deferred to the 401(k) plan. The Company's matching contributions were $229,000 and $522,000 for the three and six months ended June&#160;30, 2020, respectively.</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMTcy_7a99757f-da9b-4d88-86c8-5f17a8fe294e"
      unitRef="number">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ia946f02d9b0346d3bb893b131d264f0e_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMzY4_11d1acf5-4d9d-45f8-9edb-e50d6e1be147"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ia946f02d9b0346d3bb893b131d264f0e_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMzg0_83b3e94a-04d2-4554-8879-dab8e14fd2a8"
      unitRef="number">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfNDc0_bcc97a8c-9d03-40f9-96e3-a794c47c0462"
      unitRef="usd">229000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBmNWY3ZjRhNDBlNzRmOTE4NmZiYTU0YWM5M2IxOTE2L3NlYzowZjVmN2Y0YTQwZTc0ZjkxODZmYmE1NGFjOTNiMTkxNl83Ni9mcmFnOjg0MTM0ZWMzMTlmYjRlMWM4MmVkN2JmNjJmZTU2NjA1L3RleHRyZWdpb246ODQxMzRlYzMxOWZiNGUxYzgyZWQ3YmY2MmZlNTY2MDVfMTA5OTUxMTYyODM3NQ_e3463960-3dea-4c71-8b39-ce8c3de8ea1c"
      unitRef="usd">522000000</us-gaap:DefinedContributionPlanCostRecognized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886204595560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SILK ROAD MEDICAL, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8777622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1213 Innsbruck Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">720-9002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SILK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,679,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001397702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886127351128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 73,442<span></span>
</td>
<td class="nump">$ 39,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">84,416<span></span>
</td>
<td class="nump">51,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">7,753<span></span>
</td>
<td class="nump">8,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">11,621<span></span>
</td>
<td class="nump">10,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,863<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">181,095<span></span>
</td>
<td class="nump">112,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,885<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">3,644<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">187,523<span></span>
</td>
<td class="nump">137,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,542<span></span>
</td>
<td class="nump">1,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">9,142<span></span>
</td>
<td class="nump">15,034<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,684<span></span>
</td>
<td class="nump">16,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">45,066<span></span>
</td>
<td class="nump">44,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">3,693<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">60,443<span></span>
</td>
<td class="nump">65,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockAbstract', window );"><strong>Preferred stock, $0.001 par value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Shares issued and outstanding: none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockAbstract', window );"><strong>Common stock, $0.001 par value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Shares issued and outstanding: 33,610,099 and 31,255,267 at June&#160;30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">338,550<span></span>
</td>
<td class="nump">263,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(211,820)<span></span>
</td>
<td class="num">(191,526)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">127,080<span></span>
</td>
<td class="nump">71,891<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 187,523<span></span>
</td>
<td class="nump">$ 137,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886204384584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">33,610,099<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">33,610,099<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886127392120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 15,094<span></span>
</td>
<td class="nump">$ 14,928<span></span>
</td>
<td class="nump">$ 34,027<span></span>
</td>
<td class="nump">$ 27,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,336<span></span>
</td>
<td class="nump">3,697<span></span>
</td>
<td class="nump">10,586<span></span>
</td>
<td class="nump">7,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">9,758<span></span>
</td>
<td class="nump">11,231<span></span>
</td>
<td class="nump">23,441<span></span>
</td>
<td class="nump">20,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,393<span></span>
</td>
<td class="nump">3,113<span></span>
</td>
<td class="nump">6,522<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">15,758<span></span>
</td>
<td class="nump">14,135<span></span>
</td>
<td class="nump">35,450<span></span>
</td>
<td class="nump">28,001<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,151<span></span>
</td>
<td class="nump">17,248<span></span>
</td>
<td class="nump">41,972<span></span>
</td>
<td class="nump">33,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,393)<span></span>
</td>
<td class="num">(6,017)<span></span>
</td>
<td class="num">(18,531)<span></span>
</td>
<td class="num">(13,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,203)<span></span>
</td>
<td class="num">(1,207)<span></span>
</td>
<td class="num">(2,406)<span></span>
</td>
<td class="num">(2,560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(5,333)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(21,045)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,353)<span></span>
</td>
<td class="num">(11,959)<span></span>
</td>
<td class="num">(20,294)<span></span>
</td>
<td class="num">(36,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) on investments, net</a></td>
<td class="num">(126)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change in other comprehensive loss</a></td>
<td class="num">(126)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (10,479)<span></span>
</td>
<td class="num">$ (11,959)<span></span>
</td>
<td class="num">$ (19,980)<span></span>
</td>
<td class="num">$ (36,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in USD per share)</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used to compute net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">32,682,360<span></span>
</td>
<td class="nump">28,458,793<span></span>
</td>
<td class="nump">32,010,335<span></span>
</td>
<td class="nump">14,905,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss) And Comprehensive Income (Loss), Net Of Tax, Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886114749112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">21,233,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 105,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity, shares issued (in shares)</a></td>
<td class="nump">4,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Net exercise of Series C preferred stock warrants in connection with IPO</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">21,238,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Mar. 31, 2019</a></td>
<td class="nump">$ 105,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,135,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(134,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (139,111)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(24,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(24,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,386,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="num">$ (158,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,269)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">21,233,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 105,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,135,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">(134,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139,111)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(36,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) on investments, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,747,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 84,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175,228)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">21,238,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Mar. 31, 2019</a></td>
<td class="nump">$ 105,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity, shares issued (in shares)</a></td>
<td class="nump">287,446<span></span>
</td>
<td class="nump">1,653,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares', window );">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,178,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue', window );">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (144,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Net exercise of Series C preferred stock warrants in connection with IPO</a></td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="nump">37,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,386,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="num">(158,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,269)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,764<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Exercise of common stock warrants</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,576<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">109,039<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="nump">$ 109,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,178,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(11,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(11,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) on investments, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,747,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">84,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175,228)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">71,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191,526)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(9,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) on investments, net</a></td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,395,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">63,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201,467)<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 71,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191,526)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">405,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (20,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) on investments, net</a></td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,610,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">127,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,820)<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,395,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">63,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201,467)<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,467<span></span>
</td>
<td class="nump">1,923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">$ 70,543<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">$ 70,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(10,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) on investments, net</a></td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,610,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 127,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 338,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (211,820)<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease For Conversion Of Convertible Securities, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886209894808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 4,457<span></span>
</td>
<td class="nump">$ 10,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126926408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (20,294)<span></span>
</td>
<td class="num">$ (36,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of redeemable convertible preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums (accretion of discounts) on investments, net</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use asset</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Change in provision for doubtful accounts receivable</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for excess and obsolete inventories</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">857<span></span>
</td>
<td class="num">(1,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,404)<span></span>
</td>
<td class="num">(3,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(986)<span></span>
</td>
<td class="num">(1,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">262<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(5,925)<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,376)<span></span>
</td>
<td class="num">(18,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(479)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(23,606)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments', window );">Proceeds from maturity of investments</a></td>
<td class="nump">9,180<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(14,905)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid</a></td>
<td class="nump">70,863<span></span>
</td>
<td class="nump">108,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">72,542<span></span>
</td>
<td class="nump">111,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">34,261<span></span>
</td>
<td class="nump">93,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">39,491<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">73,752<span></span>
</td>
<td class="nump">118,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accounts payable and accrued liabilities for purchases of property and equipment</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_StockIssuanceCostsIncurredButNotYetPaid', window );">Offering costs in accounts payable and accrued liabilities</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Net exercise of convertible preferred stock warrants to preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">144,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of redeemable convertible preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember', window );">Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of redeemable convertible preferred stock warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_StockIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_StockIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_RedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121707288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Formation and Business of the Company</a></td>
<td class="text">Formation and Business of the Company <div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The Company</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Silk Road Medical, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on March&#160;21,&#160;2007.  The Company has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke.  The Company's portfolio of TCAR products enable a new procedure, referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles.  The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.  The Company commercialized its products in the United States in April 2016.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 13, 2019, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a 1-for-2.7 reverse stock split of the Company&#8217;s common stock and redeemable convertible preferred stock to be consummated prior to the effectiveness of the Company&#8217;s planned initial public offering, or IPO.  The reverse stock split was effected on March 27, 2019.  The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.  All the common stock, redeemable convertible preferred stock, stock options and warrants, and related per share amounts in the condensed financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Public Offerings</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Company issued and sold 6,000,000 shares of its common stock in its IPO at a public offering price of $20.00 per share, for net proceeds of approximately $109,119,000 after deducting underwriting discounts and commissions of approximately $8,400,000 and expenses of approximately $2,481,000. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding converted into shares of common stock and the Company's outstanding warrants to purchase shares of common and redeemable convertible preferred stock were exercised, or automatically net exercised absent a prior election.  The exercises resulted in the reclassification of the fair value of the related redeemable convertible preferred stock warrant liability to additional paid-in capital. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company completed a secondary public offering of 4,200,000 shares of its common stock sold by certain selling stockholders, and the exercise in full of the underwriters' option to purchase 630,000 additional shares of its common stock from certain selling stockholders, at a public offering price of $39.50 per share.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In May 2020, the Company completed an underwritten public offering of 6,808,154 shares of its common stock, of which 1,923,076 shares were offered for sale by the Company and the remaining 4,885,078 shares were offered for sale by certain selling stockholders, at a public offering price of $39.00 per share. The Company received cash proceeds of approximately $70,543,000 after deducting underwriting discounts and commissions of approximately $3,750,000 and expenses of approximately $707,000. Also in May 2020, the underwriters fully exercised their option to purchase 1,021,223 additional shares of common stock from the selling stockholders.  The Company did not receive any of the proceeds from the sale of the shares of its common stock by the selling stockholders.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121066584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Preparation</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of&#160;December&#160;31, 2019, and related disclosures,&#160;have been derived from the audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&#160;These unaudited condensed financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s condensed financial information. The results of operations for the three and six months ended June&#160;30, 2020&#160;are not necessarily indicative of the results to be expected for the year ending&#160;December&#160;31, 2020&#160;or for any other interim period or for any other future year.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended&#160;December 31, 2019&#160;included in the Company's annual report on Form 10-K filed with the SEC on March 2, 2020.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adjustment to Prior Period Financial Statements</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has adjusted the accompanying Condensed Statement of Cash Flows for the six months ended June 30, 2019 to increase each of the accounts receivable, net, and accrued liabilities amounts by $601,000 for an immaterial prior period error in the classification of provisions for returns from customers.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the provision for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Due to the coronavirus (&#8220;COVID-19&#8221;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has evaluated the estimated fair value of its financial instruments as of June&#160;30, 2020 and December&#160;31, 2019.  The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of June&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents are entirely comprised of investments in money market funds.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash as of June&#160;30, 2020 and December&#160;31, 2019 consists of a letter of credit of $310,000 representing collateral for the Company's facility lease.   </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Investments</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date.  Long-term investments have maturities greater than one year as of the balance sheet date.  All investments are recorded at fair value based on the fair value hierarchy.  Money market funds and United States treasury bills with an original maturity less than 90 days are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method.  Realized gains and losses are included in earnings, and are der</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ived for specific-identification method for determining the costs of investments sold.  Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to risks related to the public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#8217;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#8217;s revenue while the pandemic continues.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and United States treasury bills. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three and six months ended June&#160;30, 2020 and 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States.  At June&#160;30, 2020 and December&#160;31, 2019, no customer represented 10% or more of the Company&#8217;s accounts receivable.  For the three and six months ended June&#160;30, 2020 and 2019, there were no customers that represented 10% or more of revenue.  </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company manufactures certain of its commercial products in-house.  Certain of the Company&#8217;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent.  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">currently approved portfolio of products.  If clearance for the products in the current portfolio </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leases</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company&#8217;s considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock Warrant Liability</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the condensed statements of operations and comprehensive loss.  The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised.  Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#8217; equity.  Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#8217; equity on the condensed balance sheet as events triggering the liquidation preferences were not solely within the Company&#8217;s control.  Upon the closing of the Company's IPO, all shares of convertible preferred stock then outstanding converted into an aggregate of 23,178,555 shares of common stock&#160;resulting in the reclassification of $144,140,000 from outside of stockholders&#8217; equity to additional paid-in capital.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reven</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ue Recognition</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." &#160;Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i) identify the contract(s) with a customer; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii) identify the performance obligations in the contract; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii) determine the transaction price;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv) allocate the transaction price to the performance obligations in the contract; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, the Company recorded $179,000 and $128,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the condensed balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#8217;s standard terms and conditions.&#160;&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For sales where the Company&#8217;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#8217;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectability is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale. As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component. The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the&#160;condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the condensed balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cost of Goods Sold</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company manufactures certain of its </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">portfolio of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock&#8211;Based Compensation</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718,&#160;"Compensation-Stock Compensation."  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions. The Company accounts for option forfeitures as they occur.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the condensed financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also follows the provisions of ASC 740-10, "A</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ccounting for Uncertainty in Income Taxes."  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the condensed financial statements.  It is the Company's policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> months ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the condensed </span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">statements of operations and comprehensive loss.  Accumulated other comprehensive income or loss is presented in the accompanying condensed balance sheet as a component of stockholders' equity.  For the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> months ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June&#160;30, 2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, there was no difference between the Company's comprehensive loss and its net loss. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net Loss per Share</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#8217;s redeemable convertible preferred stock participate in any dividends declared by the Company and were therefore considered to be participating securities.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share was determined as follows (in thousands, except share and per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.673%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.463%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,353)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,959)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,294)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,117)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common stock outstanding used to compute net loss per share, basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,682,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,458,793&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,010,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,905,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.32)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.63)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company's net loss:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,632,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,683,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,671,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,683,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Segment and Geographical Information</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates and manages its business as one reportable and operating segment.  The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.  All of the Company&#8217;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment and the Company's right-of-use asset.  All of the Company&#8217;s revenue was in the United States for the three and six months ended June&#160;30, 2020 and 2019, based on the shipping location of the external customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121025208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 would originally be effective for the Company on January 1, 2023.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  As of June 30, 2020, the Company no longer qualifies as a smaller reporting company, accordingly </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">will now become effective for the Company on January 1, 2021. The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 will become effective for the Company on January 1, 2021.  Early adoption is permitted.  The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121880760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, investments, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and the Company's previously outstanding preferred stock warrants</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.  A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 &#8211; quoted prices in active markets for identical assets or liabilities;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 &#8211; observable inputs other than quoted prices in active markets for identical assets and liabilities;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 &#8211; unobservable inputs.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.  The Company&#8217;s</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> cash equivalents</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.  The corporate bonds/notes, commercial paper, asset-backed securities and U.S. government securities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The following tables sets forth by level within the fair value hierarchy the Company&#8217;s assets that are reported at fair value as of June&#160;30, 2020 and December&#160;31, 2019, using the inputs defined above (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.743%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.585%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.743%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.585%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,732&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There were no transfers between fair value hierarchy levels during the three and six months ended June&#160;30, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886119978488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Investments</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company's available-for-sale investments as of June&#160;30, 2020 and December&#160;31, 2019 are as follows (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:34.538%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.224%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.188%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,024&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">317&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:34.538%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.224%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.188%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,093&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of the Company&#8217;s cash equivalents, short-term and long-term investments classified by maturity as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.102%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.467%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.790%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts maturing within one year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts maturing after one year through two years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Available-for-sale investments held as of June&#160;30, 2020 had a weighted average days to maturity of 164 days. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:31.333%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.189%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Loss</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inventories</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Components of inventories were as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:67.341%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.890%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.967%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, there were no work-in-process inventories.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%;"><tr><td style="width:1.0%;"/><td style="width:64.344%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.264%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.605%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.587%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll and related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for sales returns</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">593&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">682&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">769&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued royalty expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued travel expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">241&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">567&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121285096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October&#160;2015, the Company entered into a term loan agreement with CRG.  The term loan agreement provides for up to $30,000,000 in term loans split into two tranches as follows: (i) the Tranche A Loans provided for $20,000,000 in term loans, and (ii) the Tranche B Loans provided for up to $10,000,000 in term loans.  The Company drew down the Tranche A Loans on October 13, 2015.  The Tranche B Loans were available to be drawn prior to March 29, 2017.  In January 2017, the term loan agreement was amended to extend the commitment period of the Tranche B Loans to April 28, 2017.  In April 2017, the Company drew down $5,000,000 of the available Tranche B Loans.  </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the Company entered into Amendment No. 5 to the term loan agreement with CRG.  Under the amended terms of the amended loan agreement the maturity date was extended to December 31, 2022 and the repayment schedule of the existing term loans were changed to interest only so that the outstanding principal amount of the term loans will be payable in a single installment at maturity.  The related fixed interest rate was changed to equal 10.75% per annum, due and payable quarterly in arrears.  At the election of the Company, 2.75% of the interest due and payable may be &#8220;paid in kind&#8221; and added to the then outstanding principal and 8.0% of the interest due and payable paid in cash.  All unpaid principal, and accrued and unpaid interest, is due and payable in full on December 31,&#160;2022.  The amended term loan agreement also provided for additional term loans in an aggregate principal amount of up to $25,000,000 and allowed for the conversion into shares of common stock, at the Company&#8217;s option, of up to 25% of the outstanding loans under the term loan agreement in connection with an initial public offering of the Company&#8217;s common stock which results in market capitalization of at least $250,000,000.  In September 2018, the Company drew down an additional $15,000,000 under the term loan agreement with CRG. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As provided for under the terms of the amended term loan agreement, the related fixed interest rate was further reduced to 10.0% upon the consummation of the Company's IPO in April 2019.  Also, post consummation of the Company's IPO, 8.0% of the interest is due and payable in cash and at the election of the Company, 2.0% of the interest due and payable may be "paid in kind". </span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019, the Company entered into Amendment No. 7 to the term loan agreeme</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">nt with CRG to reflect flexibility with respect to permitted cash investments.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may voluntarily prepay the borrowings in full.  The Tranche A borrowing required a payment, on the borrowing date, of a financing fee equal to 1.75% of the borrowed loan principal, which is </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">recorded as a discount to the debt.  In addition, a facility fee equal to 5.0% of the amounts borrowed plus any "paid in kind" is payable at the end of the term or when the borrowings are repaid in full.  A long-term liability is being accreted using the effective interest method for the facility fee over the term of the loan agreement.  The borrowings are collateralized by a security interest in substantially all of the Company&#8217;s assets.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to financial covenants related to liquidity and minimum trailing revenue targets that began in December&#160;31, 2016 and are tested on an annual basis.  The liquidity covenant requires the Company to maintain an amount which shall exceed the greater of (i) $3,000,000 and (ii) the minimum cash balance, if any, required of the Company by a creditor to the extent the&#160;Company has incurred permitted priority debt.  The Company had to achieve minimum net revenue of $1,000,000 in 2016, $5,000,000 in 2017, $15,000,000 in 2018, $30,000,000 in 2019 and must achieve minimum net revenue of $40,000,000 in 2020. The liquidity financial covenant has a 90-day equity cure period following end of the calendar year to issue additional shares of equity interests in exchange for cash, or to borrow permitted cure debt.  In addition, the term loan agreement prohibits the payment of cash dividends on the Company&#8217;s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates.  CRG may accelerate the payment terms of the term loan agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the term loan agreement, the failure of the Company to adhere to the covenants set forth in the term loan agreement, the insolvency of the Company or upon the occurrence of a material adverse change.  As of June&#160;30, 2020, the Company was in compliance with all applicable financial covenants.  As of June&#160;30, 2020, management does not believe that it is probable that the above clauses will be triggered within the next twelve months, and therefore, the debt is classified as long-term on the condensed balance sheet.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future maturities under the term loan agreement as of June&#160;30, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.256%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period Ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,442&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add: Accretion of closing fees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,369&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amount representing interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amount representing debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(116)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2015, CRG purchased 327,759 shares of the Company&#8217;s Series C redeemable convertible preferred stock at $6.11 per share.  In addition, CRG received warrants to purchase 163,877 shares of the Company&#8217;s Series C redeemable convertible preferred stock at an exercise price of $6.11 per share.  Upon the closing of the IPO, the warrants were net exercised, based on the initial public offering price of $20.00 per share, into&#160;shares of common stock. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2017, CRG purchased an additional 163,877 shares of the Company&#8217;s Series C convertible preferred stock at $6.11 per share.  Upon the closing of the IPO, the Series C redeemable convertible preferred stock shares were converted into&#160;shares of common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121258824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating Lease and Rights-of-Use</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s operating lease obligation consists of leased office, laboratory, and manufacturing space under a non-cancellable operating lease that expires in October&#160;2024.  The lease agreement includes a renewal provision allowing the Company to extend this lease for an additional period of five years.  Operating lease costs were $217,000 for each of the three months ended June 30, 2020 and 2019 and $435,000 for each of the six months ended June 30, 2020 and 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $188,000, $372,000, $169,000 and $363,000 for the three and six months ended June&#160;30, 2020 and 2019, respectively.  As of June&#160;30, 2020, the weighted average discount rate was approximately 6.50% and the weighted average remaining lease term was 4.33 years.  Balance sheet information as of June&#160;30, 2020 consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.591%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Lease:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset in other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability in accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability in other liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s operating lease maturities as of June&#160;30, 2020 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.256%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period Ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,127&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(621)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Purchase Obligations</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. As of June&#160;30, 2020, the Company had non-cancellable purchase obligations to suppliers of $6,640,000.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indemnification</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty.  The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made.  To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws.  The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity.  The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance.  The Company believes that the fair value of these indemnification obligations is minimal.  Accordingly, the Company has not recognized any liabilities relating to these obligations as of June&#160;30, 2020.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contingencies </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations or cash flows.  From time to time, the Company may pursue litigation to assert its legal right and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual at June&#160;30, 2020 and December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886119757912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred Stock<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into shares of common stock. As of June&#160;30, 2020 and December 31, 2019, the Company does not have any convertible preferred stock issued or outstanding.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock Warrant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">s</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the Company's IPO, all of the outstanding convertible preferred stock warrants were exercised, or net exercised based on the IPO price of $20.00 per share, into&#160;1,945,365 shares of common stock. As of June&#160;30, 2020 and December 31, 2019, the Company does not have any convertible preferred stock warrants outstanding.</span></div>Stockholders Equity<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of preferred stock with $0.001 par value per share, of which no shares were issued and outstanding.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 33,610,099 shares were issued and outstanding.  The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors.  As of June&#160;30, 2020, no dividends have been declared to date.  Each share of common stock is entitled to one vote.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock Warrant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">s</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the IPO, the common stock warrants were cash, or net exercised based on the IPO price of $20.00 per share, into 5,968 shares of common stock.  As of June&#160;30, 2020 and December 31, 2019, the Company does not have any common stock warrants outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121284536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders Equity</a></td>
<td class="text">Redeemable Convertible Preferred Stock<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into shares of common stock. As of June&#160;30, 2020 and December 31, 2019, the Company does not have any convertible preferred stock issued or outstanding.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock Warrant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">s</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the closing of the Company's IPO, all of the outstanding convertible preferred stock warrants were exercised, or net exercised based on the IPO price of $20.00 per share, into&#160;1,945,365 shares of common stock. As of June&#160;30, 2020 and December 31, 2019, the Company does not have any convertible preferred stock warrants outstanding.</span></div>Stockholders Equity<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of preferred stock with $0.001 par value per share, of which no shares were issued and outstanding.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 33,610,099 shares were issued and outstanding.  The holders of common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors.  As of June&#160;30, 2020, no dividends have been declared to date.  Each share of common stock is entitled to one vote.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock Warrant</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">s</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the IPO, the common stock warrants were cash, or net exercised based on the IPO price of $20.00 per share, into 5,968 shares of common stock.  As of June&#160;30, 2020 and December 31, 2019, the Company does not have any common stock warrants outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886119933304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plans</a></td>
<td class="text">Stock Option Plans<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company&#8217;s Board of Directors approved the adoption of the 2019 Equity Incentive Plan, or the 2019 Plan, which became effective immediately prior to the Company's IPO. The 2019 Plan replaced the 2007 Stock Option Plan which was terminated immediately prior to consummation of the Company&#8217;s IPO, collectively the &#8220;Plans.&#8221; The 2019 Plan provides for the grant of ISOs to employees and for the grant of NSOs, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants.  A total of 2,317,000 shares of common stock were initially reserved for issuance pursuant to the 2019 Plan.  In addition, the shares reserved for issuance under the 2019 Plan will also include shares reserved but not issued under the 2007 Stock Option Plan, plus any share awards granted under the 2007 Stock Option Plan that expire or terminate without having been exercised in full or that are forfeited or repurchased.  In addition, the number of shares available for issuance under the 2019 Plan will also include an annual increase on the first day of each fiscal year beginning in fiscal 2020, equal to the lesser of (i) 3,000,000 shares; (ii) 4.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) an amount as determined by the Board of Directors.  As of June&#160;30, 2020, the Company has reserved 3,631,205 shares of common stock for issuance under the 2019 Plan.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exercise price of ISOs and NSOs shall not be less than 100% and 85% of the estimated fair value of the shares on the date of grant, respectively, as determined by the Board of Directors.  The exercise price of ISOs and NSOs granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant as determined by the Board of Directors.  To date, options have a term of 10 years and generally vest over 4 years from the date of grant.</span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock option activity under the Company&#8217;s Plans is set forth below:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.416%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.465%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options Outstanding</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares Available for Grant</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,554,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,310,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.27</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Authorized</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,250,210&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(752,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">752,258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(405,837)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options cancelled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,345)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,076,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,632,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.42</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and exercisable at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,554,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.40</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,632,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.42</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic value of options exercised during the six months ended June 30, 2020, was $15,048,000.  The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Restricted Stock Units</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company began granting restricted stock units, or RSUs, under the 2019 Plan.  RSUs generally vest over four years in annual equal increments, no RSUs vested during the six months ended June 30, 2020.  The fair value of RSUs is based on the Company&#8217;s closing stock price on the date of grant. A summary of RSUs activity for the six months ended June 30, 2020 is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:69.864%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.443%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.504%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.443%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.346%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Restricted Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2019 Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company's Board of Directors adopted the 2019 Employee Stock Purchase Plan, or 2019 ESPP, under which eligible employees are permitted to purchase common stock at a discount through payroll deductions.  A total of 434,000 shares of common stock were initially reserved for issuance and will be increased on the first day of each fiscal year, beginning in 2020, by an amount equal to the lesser of (i)&#160;1,200,000 shares (ii)&#160;1.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii)&#160;an amount as determined by the Board of Directors.  As of June&#160;30, 2020, the Company has reserved 746,552 shares of common stock for issuance under the 2019 ESPP.  The price of the common stock purchased will be the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period.  The 2019 ESPP was effective upon adoption by the Company's Board of Directors but was not in use until the completion of the Company's IPO in April 2019.  The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&#160;423 of the Internal Revenue Code of 1986, as amended.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, 87,567 shares of common stock have been issued to employees participating in the 2019 ESPP and 658,985 shares were available for future issuance under the 2019 ESPP.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company estimated the fair value of stock options using the Black&#8211;Scholes option pricing model.  The fair value of employee and nonemployee stock options is being amortized on a straight&#8211;line basis over the requisite service period of the awards.  The fair value of employee and nonemployee stock options was estimated using the following assumptions for the three and six months ended June&#160;30, 2020 and 2019:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:32.455%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.867%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.25 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.00 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.25 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.00 - 6.25</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">46.6% - 47.7%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42.7% - 42.9%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42.9% - 47.7%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42.7% - 42.9%</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.42% - 0.56%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.86% - 2.37%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.42% - 1.41%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.86% - 2.54%</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the shares to be issued under the Company&#8217;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and six months ended June&#160;30, 2020:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:32.455%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.826%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.224%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.544%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.028%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.63</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.63</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.4%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.8%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">44.4% - 76.4%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.8%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.14%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.45%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.14% - 1.58%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.45%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense relating to the Company's stock options, RSUs and 2019 ESPP during the three and six months ended June&#160;30, 2020 and stock-based compensation expense related to the Company's stock options and 2019 ESPP during the three and six months ended June&#160;30, 2019, is as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.794%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.823%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">423&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,371&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,654&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">836&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, there was total unrecognized compensation costs of $16,986,000 related to stock options expected to be recognized over a period of approximately 3.24 years, a total of $1,119,000 of unrecognized compensation costs related to unvested RSUs expected to be recognized over a period of approximately 3.68 years and $303,000 of unrecognized compensation costs related to the ESPP, which the Company will recognize over 0.4 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886119837288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) PlanThe Company has a qualified retirement plan under section&#160;401(k)&#160;of the Internal Revenue Code (&#8220;IRC&#8221;) under which participants may contribute up to 90% of their eligible compensation, subject to maximum deferral limits specified by the IRC.  Beginning in January 2020, the Company started matching employees' contributions to the 401(k) plan at 50% of the first 5% of compensation deferred to the 401(k) plan. The Company's matching contributions were $229,000 and $522,000 for the three and six months ended June&#160;30, 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886127277352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Preparation</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Preparation</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of&#160;December&#160;31, 2019, and related disclosures,&#160;have been derived from the audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&#160;These unaudited condensed financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company&#8217;s condensed financial information. The results of operations for the three and six months ended June&#160;30, 2020&#160;are not necessarily indicative of the results to be expected for the year ending&#160;December&#160;31, 2020&#160;or for any other interim period or for any other future year.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended&#160;December 31, 2019&#160;included in the Company's annual report on Form 10-K filed with the SEC on March 2, 2020.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adjustment to Prior Period Financial Statements</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has adjusted the accompanying Condensed Statement of Cash Flows for the six months ended June 30, 2019 to increase each of the accounts receivable, net, and accrued liabilities amounts by $601,000 for an immaterial prior period error in the classification of provisions for returns from customers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements.  Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the provision for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants.  Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Due to the coronavirus (&#8220;COVID-19&#8221;) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of June 30, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has evaluated the estimated fair value of its financial instruments as of June&#160;30, 2020 and December&#160;31, 2019.  The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments.  Management believes that its long-term debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.  Prior to the Company's IPO, fair value accounting was applied to the redeemable convertible preferred stock warrant liability.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.  Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices.  As of June&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents are entirely comprised of investments in money market funds.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Investments</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Short-term investments consist of debt securities classified as available-for-sale and have original maturities greater than 90 days, but less than one year as of the balance sheet date.  Long-term investments have maturities greater than one year as of the balance sheet date.  All investments are recorded at fair value based on the fair value hierarchy.  Money market funds and United States treasury bills with an original maturity less than 90 days are classified within Level 1 of the fair value hierarchy, and commercial paper, corporate bonds/notes, United States Government securities, and asset-backed securities are classified within Level 2 of the fair value hierarchy.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).  The cost of available-for-sale investments sold is based on the specific-identification method.  Realized gains and losses are included in earnings, and are der</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ived for specific-identification method for determining the costs of investments sold.  Amortization of premiums and accretion of discounts are reported as a component of interest income.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk, and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to risks related to the public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company&#8217;s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company&#8217;s revenue while the pandemic continues.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet.  Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and United States treasury bills. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three and six months ended June&#160;30, 2020 and 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States.  At June&#160;30, 2020 and December&#160;31, 2019, no customer represented 10% or more of the Company&#8217;s accounts receivable.  For the three and six months ended June&#160;30, 2020 and 2019, there were no customers that represented 10% or more of revenue.  </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company provides for uncollectible amounts when specific credit problems are identified.  In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company manufactures certain of its commercial products in-house.  Certain of the Company&#8217;s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent.  Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company&#8217;s financial position and results of operations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed.  There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics.  The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies.  In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required.  If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">currently approved portfolio of products.  If clearance for the products in the current portfolio </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leases</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) 842, "Leases," on January 1, 2019 and used the modified retrospective method for all leases not substantially completed as of the date of adoption and the package of practical expedients available in the standard.  The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months.  The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract </span></div>contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset.  The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term.  The Company&#8217;s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.  The Company&#8217;s considers renewal options in the determination of the lease term if the option to renew is reasonably certain.  Variable lease costs represent payments that are dependent on usage, a rate or index.  Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred, as the Company has elected to account separately for contracts that contain lease and non-lease components, consistent with its historical practice.  The Company does not have any finance leases.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock', window );">Redeemable Convertible Preferred Stock Warrant Liability</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock Warrant Liability</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to its IPO, the Company accounted for its warrants for shares of redeemable convertible preferred stock as a liability based upon the characteristics and provisions of each instrument.  Redeemable convertible preferred stock warrants classified as a liability were initially recorded at their fair value on the date of issuance and are subject to remeasurement at each subsequent balance sheet date.  Any change in fair value as a result of a remeasurement was recognized as a component of other income (expense), net in the condensed statements of operations and comprehensive loss.  The Company recorded adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until they were exercised.  Upon their exercise, the final fair value of the warrant liability was reclassified to stockholders&#8217; equity.  Subsequent to its IPO, the Company no longer recorded any related periodic fair value adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred StockPrior to its IPO, the Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs, and classified the redeemable convertible preferred stock outside of stockholders&#8217; equity on the condensed balance sheet as events triggering the liquidation preferences were not solely within the Company&#8217;s control.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Cost of Goods Sold</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reven</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ue Recognition</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes revenue in accordance with ASC Topic 606,&#160;"Revenue from Contracts with Customers." &#160;Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amou</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">nt that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(i) identify the contract(s) with a customer; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(ii) identify the performance obligations in the contract; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iii) determine the transaction price;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(iv) allocate the transaction price to the performance obligations in the contract; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, the Company recorded $179,000 and $128,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the condensed balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period.&#160;&#160;</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives.  Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company&#8217;s products to its customers, either upon shipment of the product or delivery of the product to the customer under the Company&#8217;s standard terms and conditions.&#160;&#160;The Company&#8217;s products are readily available for usage as soon as the customer possesses it.  Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title.  The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time.  Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For sales where the Company&#8217;s sales representative hand delivers product directly to the hospital or medical center from the sales representative&#8217;s trunk stock inventory, the Company recognizes revenue upon delivery, which represents the point in time when control transfers to the customer.  Upon delivery there are legally-enforceable rights and obligations between the parties which can be identified, commercial substance exists and collectability is probable.  For sales which are sent directly from the Company to hospitals and medical centers, the transfer of control occurs at the time of shipment or delivery of the product.&#160; There are no further performance obligations by the Company or the sales representative to the customer after delivery under either method of sale. As allowed under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#160;is entitled to the total consideration for the products ordered by customers&#160;as&#160;product pricing&#160;is&#160;fixed according to the terms of customer contracts and payment terms&#160;are&#160;short. Payment terms fall within the one-year guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component. The Company&#160;excludes&#160;taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Costs associated with product sales include commissions and royalties.  The Company applies the practical expedient and recognizes commissions and royalties as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year.&#160; Commissions are recorded as selling expense&#160;and royalties are recorded as&#160;cost of goods sold&#160;in the&#160;condensed statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accepts product returns at its discretion or if the product is defective as manufactured.  The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the condensed balance sheet.&#160; The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold.  In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cost of Goods Sold</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company manufactures certain of its </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">portfolio of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> TCAR products at its facility and purchases other products from third party manufacturers.  Cost of goods sold consists primarily of costs related to materials, components and subassemblies, manufacturing overhead costs, direct labor, reserves for </span></div>excess, obsolete and non-sellable inventories as well as distribution-related expenses.  A significant portion of the Company&#8217;s cost of goods sold currently consists of manufacturing overhead costs.  These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management.  Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock&#8211;Based Compensation</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718,&#160;"Compensation-Stock Compensation."  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under its employee stock purchase plan.  ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model.  The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis.  For performance-based stock options, the Company will assess the probability of performance conditions being achieved in each reporting period.  The amount of stock-based compensation expense recognized in any one period related to performance-based stock options can vary based on the achievement or anticipated achievement of the performance conditions. The Company accounts for option forfeitures as they occur.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company's common stock on the date of grant.  These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value of the options on the date of grant.  The Company estimates the grant date fair value using an option pricing model for each purchase period.  These costs are recognized on a straight-line basis over the offering period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the condensed financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also follows the provisions of ASC 740-10, "A</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ccounting for Uncertainty in Income Taxes."  ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return.  No liability related to uncertain tax positions is recorded on the condensed financial statements.  It is the Company's policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale.  For the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three and six</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> months ended </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company&#8217;s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the condensed </span></div>statements of operations and comprehensive loss.  Accumulated other comprehensive income or loss is presented in the accompanying condensed balance sheet as a component of stockholders' equity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Net Loss per Share</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares.  Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period.  For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and warrants, common stock options, and restricted stock units are considered to be potentially dilutive securities.  Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.  The shares of the Company&#8217;s redeemable convertible preferred stock participate in any dividends declared by the Company and were therefore considered to be participating securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Segment and Geographical Information</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates and manages its business as one reportable and operating segment.  The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.  All of the Company&#8217;s long-lived assets are based in the United States.  Long-lived assets are comprised of property and equipment and the Company's right-of-use asset.  All of the Company&#8217;s revenue was in the United States for the three and six months ended June&#160;30, 2020 and 2019, based on the shipping location of the external customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement," which changed the disclosure requirements for fair value measurements by removing, adding and modifying certain disclosures. The Company adopted the new standard effective January 1, 2020.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15, "Cloud Computing Arrangements," which aligns the requirements for capitalizing implementation costs in a Cloud Computing Arrangement service contract with the requirements for capitalizing implementation costs incurred for an internal-use software license.  The Company adopted the new standard effective January 1, 2020 on a prospective basis.  The adoption did not have a material impact on the Company's financial statements and related disclosures.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Statements."  This update provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.  The update replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.   In October 2019, the FASB delayed the effective date of this standard for smaller reporting companies, as such </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 would originally be effective for the Company on January 1, 2023.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  As of June 30, 2020, the Company no longer qualifies as a smaller reporting company, accordingly </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">will now become effective for the Company on January 1, 2021. The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting.  ASU 2019-12 also amends other aspects of the guidance to reduce complexity in certain areas.  ASU 2019-12 will become effective for the Company on January 1, 2021.  Early adoption is permitted.  The Company is evaluating the impact of adopting this guidance to the Company's financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Classified As Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886122727896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Net Loss Per Share Determination</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share was determined as follows (in thousands, except share and per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.673%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.461%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.463%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,353)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,959)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,294)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,117)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common stock outstanding used to compute net loss per share, basic and diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,682,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,458,793&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,010,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,905,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss, basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.32)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.63)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company's net loss:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,632,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,683,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,671,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,683,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886120003304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Liabilities Measure on a Recurring Basis</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The following tables sets forth by level within the fair value hierarchy the Company&#8217;s assets that are reported at fair value as of June&#160;30, 2020 and December&#160;31, 2019, using the inputs defined above (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.743%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.585%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.743%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.583%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.585%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,732&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126437512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Fair Value of the Available-For-Sale Investments</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company's available-for-sale investments as of June&#160;30, 2020 and December&#160;31, 2019 are as follows (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:34.538%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.224%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.188%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,742&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">281&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,001&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,024&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">317&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:34.538%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.224%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.188%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,919&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,456&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,093&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of the Company&#8217;s cash equivalents, short-term and long-term investments classified by maturity as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:62.102%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.467%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.790%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts maturing within one year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85,871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts maturing after one year through two years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">157,340&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Unrealized Loss on Investments</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the Company's available-for-sale investments that were in an unrealized loss position as of June&#160;30, 2020 and December&#160;31, 2019 (in thousands):</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:31.333%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.185%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.189%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less than 12 months</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Loss</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds/notes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,128&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,067&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Components of inventories were as follows:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:67.341%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.890%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.967%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%;"><tr><td style="width:1.0%;"/><td style="width:64.344%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.264%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.605%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.587%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-style:italic;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll and related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for sales returns</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">593&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">682&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">769&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued royalty expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">304&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued travel expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">241&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">567&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121707288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future Maturities Under the Term Loan Agreement</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future maturities under the term loan agreement as of June&#160;30, 2020 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.256%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period Ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,442&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add: Accretion of closing fees</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,369&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amount representing interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Amount representing debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(116)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of minimum payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121289128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Balance Sheet Information</a></td>
<td class="text">Balance sheet information as of June&#160;30, 2020 consists of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.591%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Lease:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset in other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability in accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability in other liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,288&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturities</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s operating lease maturities as of June&#160;30, 2020 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.256%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period Ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,066&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,127&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(621)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,097&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126580568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Activity Under Stock Option Plans</a></td>
<td class="text"><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock option activity under the Company&#8217;s Plans is set forth below:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.096%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.416%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.465%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options Outstanding</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares Available for Grant</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining Contractual Term (in Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,554,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,310,790&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.27</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Authorized</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,250,210&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(752,258)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">752,258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(405,837)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options cancelled</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,345)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,076,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,632,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.42</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and exercisable at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,554,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.40</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91,917&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,632,866&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.42</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,505&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</a></td>
<td class="text">The fair value of RSUs is based on the Company&#8217;s closing stock price on the date of grant. A summary of RSUs activity for the six months ended June 30, 2020 is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:69.864%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.443%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.504%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.443%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.346%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Restricted Stock Units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected to vest at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,089&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used for Estimating Fair Value of Employee Stock Options</a></td>
<td class="text">The fair value of employee and nonemployee stock options was estimated using the following assumptions for the three and six months ended June&#160;30, 2020 and 2019:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:32.455%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.867%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.25 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.00 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.25 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.00 - 6.25</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">46.6% - 47.7%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42.7% - 42.9%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42.9% - 47.7%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42.7% - 42.9%</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.42% - 0.56%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.86% - 2.37%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.42% - 1.41%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.86% - 2.54%</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the shares to be issued under the Company&#8217;s 2019 ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and six months ended June&#160;30, 2020:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:32.455%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.826%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.224%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.544%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.028%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.63</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.50</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.63</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.4%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.8%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">44.4% - 76.4%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.8%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.14%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.45%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.14% - 1.58%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.45%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense Relating to Stock Options to Employees and Nonemployees</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation expense relating to the Company's stock options, RSUs and 2019 ESPP during the three and six months ended June&#160;30, 2020 and stock-based compensation expense related to the Company's stock options and 2019 ESPP during the three and six months ended June&#160;30, 2019, is as follows (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.794%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.820%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.823%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">127&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">423&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,371&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,654&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">836&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886204318680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2019</div></th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.3704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,457<span></span>
</td>
<td class="nump">$ 10,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from stock issued, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=silk_SecondPublicOfferingMember', window );">Second Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,808,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromCompanyMember', window );">Public Stock Offering - Shares From Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromExistingShareholdersMember', window );">Public Stock Offering - Shares From Existing Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,885,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,021,223<span></span>
</td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from stock issued, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Stock Issuance Underwriting Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=silk_SecondPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=silk_SecondPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromExistingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=silk_PublicStockOfferingSharesFromExistingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126483000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Adjustment to Prior Period Financial Statements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">$ (857)<span></span>
</td>
<td class="nump">$ 1,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Increase in accrued liabilities</a></td>
<td class="num">$ (5,925)<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Increase in accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121309400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126277432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of preferred stock to common stock upon IPO | $</a></td>
<td class="nump">$ 144,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of preferred stock to common stock upon IPO (in shares) | shares</a></td>
<td class="nump">23,178,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886210441208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126014856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,353)<span></span>
</td>
<td class="num">$ (11,959)<span></span>
</td>
<td class="num">$ (20,294)<span></span>
</td>
<td class="num">$ (36,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common stock outstanding used to compute net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">32,682,360<span></span>
</td>
<td class="nump">28,458,793<span></span>
</td>
<td class="nump">32,010,335<span></span>
</td>
<td class="nump">14,905,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in USD per share)</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126577720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,671,955<span></span>
</td>
<td class="nump">4,683,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,632,866<span></span>
</td>
<td class="nump">4,683,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">39,089<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886119766008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment and Geographical Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886118483384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Recurring Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">$ 157,340<span></span>
</td>
<td class="nump">$ 104,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">72,924<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">9,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">10,742<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">2,002<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">157,340<span></span>
</td>
<td class="nump">104,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">72,924<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">9,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">11,965<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">10,742<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">49,714<span></span>
</td>
<td class="nump">44,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">2,002<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">72,924<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">72,924<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">84,416<span></span>
</td>
<td class="nump">69,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">9,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">11,965<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">10,742<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">49,714<span></span>
</td>
<td class="nump">44,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">2,002<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126464552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 157,024<span></span>
</td>
<td class="nump">$ 104,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">157,340<span></span>
</td>
<td class="nump">104,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">72,924<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">72,924<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">9,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,965<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,965<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,709<span></span>
</td>
<td class="nump">10,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,742<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">49,433<span></span>
</td>
<td class="nump">44,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">49,714<span></span>
</td>
<td class="nump">44,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,001<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,002<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">72,924<span></span>
</td>
<td class="nump">34,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 84,416<span></span>
</td>
<td class="nump">51,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=silk_LongTermInvestmentsMember', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=silk_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=silk_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126836920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear', window );">Amounts maturing within one year</a></td>
<td class="nump">$ 157,340<span></span>
</td>
<td class="nump">$ 85,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears', window );">Amounts maturing after one year through two years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 157,340<span></span>
</td>
<td class="nump">$ 104,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886127231400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Weighted average days to maturity</a></td>
<td class="text">164 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886127095224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">$ 2,558<span></span>
</td>
<td class="nump">$ 29,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds/notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">2,558<span></span>
</td>
<td class="nump">10,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126850952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">$ 1,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">9,885<span></span>
</td>
<td class="nump">9,119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 11,621<span></span>
</td>
<td class="nump">$ 10,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886127166840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">$ 5,352<span></span>
</td>
<td class="nump">$ 9,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ProvisionsForSalesReturns', window );">Provision for sales returns</a></td>
<td class="nump">920<span></span>
</td>
<td class="nump">2,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">593<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty expense</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_AccruedTravelExpensesCurrent', window );">Accrued travel expenses</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_AccruedClinicalExpensesCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 9,142<span></span>
</td>
<td class="nump">$ 15,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_AccruedTravelExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Travel Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_AccruedTravelExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ProvisionsForSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provisions For Sales Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ProvisionsForSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886128474280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Term Loan Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 01, 2019</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtMaximumBorrowingCapacity', window );">Term loan agreement amount</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt drawn down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantMaximumLiquidityAmount', window );">Minimum liquidity amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantMinimumNetRevenueAmount', window );">Minimum net revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentLiquidityCovenantTerm', window );">Equity cure period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentCovenantMinimumNetRevenueAmount', window );">Minimum net revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtMaximumBorrowingCapacity', window );">Term loan agreement amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentInterestRatePaidInKind', window );">Interest rate paid-in-kind</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentInterestRatePaidInCash', window );">Interest rate paid in cash</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans', window );">Percentage of outstanding loans</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentConvertibleMarketCapitalization', window );">Market capitalization (greater than)</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheAMember', window );">Term Loan, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtMaximumBorrowingCapacity', window );">Term loan agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentInterestRateFinancingFee', window );">Financing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtInstrumentInterestRateFacilityFee', window );">Facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheBMember', window );">Term Loan, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_DebtMaximumBorrowingCapacity', window );">Term loan agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt drawn down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentConvertibleMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Market Capitalization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentConvertibleMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Maximum Percentage Of Outstanding Loans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantMaximumLiquidityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Maximum Liquidity, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantMaximumLiquidityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentCovenantMinimumNetRevenueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Net Revenue, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentCovenantMinimumNetRevenueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentInterestRateFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Facility Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentInterestRateFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentInterestRateFinancingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Financing Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentInterestRateFinancingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentInterestRatePaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Paid In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentInterestRatePaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Paid-In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtInstrumentLiquidityCovenantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Liquidity Covenant, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtInstrumentLiquidityCovenantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_DebtMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_DebtMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=silk_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=silk_TermLoanTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126583480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Future Maturities Under the Term Loan (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 2,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">4,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">48,255<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LongTermDebtGrossBeforeAccretionOfClosingFees', window );">Long-term debt, gross before accretion of closing fees</a></td>
<td class="nump">54,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LongTermDebtAccretionOfClosingFees', window );">Add: Accretion of closing fees</a></td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">56,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LongTermDebtUnpaidInterest', window );">Less: Amount representing interest</a></td>
<td class="num">(11,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Amount representing debt discount and debt issuance costs</a></td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Present value of minimum payments</a></td>
<td class="nump">$ 45,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LongTermDebtAccretionOfClosingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Accretion Of Closing Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LongTermDebtAccretionOfClosingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LongTermDebtGrossBeforeAccretionOfClosingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Gross, Before Accretion Of Closing Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LongTermDebtGrossBeforeAccretionOfClosingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LongTermDebtUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Unpaid Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LongTermDebtUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886206391128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Series C Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Temporary equity, shares issued (in shares)</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember', window );">Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Temporary equity, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,877<span></span>
</td>
<td class="nump">327,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.11<span></span>
</td>
<td class="nump">$ 6.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886206360520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liabilities</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 169,000<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">4 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126619160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset in other non-current assets</a></td>
<td class="nump">$ 3,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability in accrued liabilities</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">$ 769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability in other liabilities</a></td>
<td class="nump">3,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 4,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886120080216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne', window );">2021</a></td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 4,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_LesseeOperatingLeaseLiabilityToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_LesseeOperatingLeaseLiabilityToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886121317240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Obligation Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 6,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886204559416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,238,105<span></span>
</td>
<td class="nump">21,233,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="nump">1,945,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886206417736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">33,610,099<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">33,610,099<span></span>
</td>
<td class="nump">31,255,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_CommonStockVotePerShare', window );">Number of votes entitled per share of common stock | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share (in USD per share) | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="nump">5,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CommonStockVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Vote Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CommonStockVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=silk_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126070904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation expensed not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember', window );">ISO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice', window );">Exercise threshold as a percentage of fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember', window );">NSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice', window );">Exercise threshold as a percentage of fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember', window );">ISO and NSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember', window );">ISO and NSO | 10% Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice', window );">Exercise threshold as a percentage of fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs of unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares of common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">434,000<span></span>
</td>
<td class="nump">746,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of purchase of price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Share of stock issued in ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_CommonStockCapitalSharesAvailableForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expensed not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">2,317,000<span></span>
</td>
<td class="nump">3,631,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percent of outstanding shares of common stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember', window );">2019 Stock Option Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable under the plan (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_CommonStockCapitalSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Capital Shares Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_CommonStockCapitalSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Threshold As A Percentage Of Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_NonqualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=silk_IncentiveandNonqualifiedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=silk_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886122768072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Activity Under Compensation Plan (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,554,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="nump">1,250,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="num">(752,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled (in shares)</a></td>
<td class="nump">24,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending balance (in shares)</a></td>
<td class="nump">2,076,987<span></span>
</td>
<td class="nump">1,554,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">4,310,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">752,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(405,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled (in shares)</a></td>
<td class="num">(24,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,632,866<span></span>
</td>
<td class="nump">4,310,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 7.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in USD per share) | $ / shares</a></td>
<td class="nump">33.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share) | $ / shares</a></td>
<td class="nump">2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options cancelled (in USD per share) | $ / shares</a></td>
<td class="nump">17.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 12.57<span></span>
</td>
<td class="nump">$ 7.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years), awards outstanding</a></td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
<td class="text">7 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, awards outstanding | $</a></td>
<td class="nump">$ 136,505<span></span>
</td>
<td class="nump">$ 140,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, vested and exercisable (in shares)</a></td>
<td class="nump">2,554,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, vested and exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in Years), vested and exercisable</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, vested and exercisable | $</a></td>
<td class="nump">$ 91,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares, vested and expect to vest (in shares)</a></td>
<td class="nump">4,632,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, vested and expected to vest (in USD per share) | $ / shares</a></td>
<td class="nump">$ 12.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in Years), vested and expected to vest</a></td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, vested and expected to vest | $</a></td>
<td class="nump">$ 136,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>silk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886127082568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - RSUs (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares) | shares</a></td>
<td class="nump">39,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">39,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock granted (in USD per share) | $ / shares</a></td>
<td class="nump">31.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock vested (in USD per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 31.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126068872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">46.60%<span></span>
</td>
<td class="nump">42.70%<span></span>
</td>
<td class="nump">42.90%<span></span>
</td>
<td class="nump">42.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">47.70%<span></span>
</td>
<td class="nump">42.90%<span></span>
</td>
<td class="nump">47.70%<span></span>
</td>
<td class="nump">42.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">1.86%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">1.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">0.56%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">7 months 17 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">7 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.40%<span></span>
</td>
<td class="nump">47.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.14%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886127309288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 2,947<span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,319<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
<td class="nump">$ 2,371<span></span>
</td>
<td class="nump">$ 875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139886126590184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage employee contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer contribution match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percent of matching contribution of the employee's pay</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer discretionary contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="nump">$ 522,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4A?_QO9-. $R @KGA-[YD3#'XM*8)RLGKUPVZ5RYF@!O.0VYA>+$D'3AFQ8
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MYJ=E"W9A5/%.K&3P/ :P-L84/' @\"J$E7*J\,7? F^SOD.10#<G.S\[_2\
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M(#"^V24$R*,'\GOO$"?";>!8LO?R6 623R<)IHX!'\ HU'OR;8%7<?_5 +_
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M>1A2,O<%*7!^$!%0Q!Z$4#&E["@G\NFP\1DI+D:S%HDWB4GJFAB@;QI#46>
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M=:.J06^1XBEL;G@PR:TR81NUXD,;0LB@')=X.F+M6IFZ6V3O!S^L,&Y,O'+
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ME0VX5<7'2O( 9@&\+ZT-#PMVT%^,+_\$4$L#!!0    ( $: #5&W:W2Y=08
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M6ZFL^"+SBL0[DJZRA(A[=S'Q4,XBDZ11]+I6%!]0M!3OC/:9$[_HE-+=_1.
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M+@HUIPQ&MR3^J=)-W1HY=&W-0G/BC85S)26,I;784:5'E'U>#7O?,.);Y3/
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M3TW>P]X3"#O[PC_T*(^(O,UKJ*-V;\FKY@FU8V\>HF^96="X(?D<1</3/!N
M:1YWS<+II7]03;7#YYG_+/$]S TQX/Y<XUUO%W1 ]\*^_!M02P,$%     @
M1H -4;FR_64X"@  /QP  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
MK5E;<]NX%?XK&-7;;F:XMD1)OB2.9YQDM\U.LNO)I7WH] $B(0DU23  :-G]
M]?W. 7B1+-F;3A_B4"!P[N<[YX"7&V-OW5HI+^[+HG*O1VOOZY<G)RY;JU*Z
M8U.K"F^6QI;2XZ==G;C:*IGSH;(X2<?CTY-2ZFIT=<EK-_;JTC2^T)6ZL<(U
M92GMPQM5F,WKT634+GS2J[6GA9.KRUJNU&?EO]8W%K]..BJY+E7EM*F$5<O7
MH^O)RS<SVL\;_J[5Q@V>!6FR,.:6?KS/7X_&)) J5.:)@L1_=^JM*@HB!#&^
M19JCCB4='#ZWU']AW:'+0CKUUA3_T+E?OQZ=CT2NEK(I_">S^9N*^LR)7F8*
MQW_%)NQ-ST8B:YPW93P,"4I=A?_E?;3#X,#Y^,"!-!Y(6>[ B*5\)[V\NK1F
M(RSM!C5Z8%7Y-(33%3GEL[=XJW'.7WTPU>HGKVPIWJF%OSSQH$EO3K)X_DTX
MGQXX?RH^FLJOG?BYRE6^??X$LG0"I:U ;](G"?[:5,=B.DY$.D['3]";=@I.
MF=[T #U22[S3+BN,:ZP2_[Q>.&\1#/]Z@OBL(SYCXK/_V7K?<UZ\K\3OF3<+
M9:']9)X(OU;BK2EK63T(56&CRH6NO!%2\*G"2 3VRBJ%//$(';\6;S_]]5A\
MP<%].VIK[G2NG$ ZBZ86('4$8X_'_ ^T^U-.N+K0/O#S&_RSL@(F."'I>(%T
M=B_%C_H%2_DEO!37X@.?C8QR9G24'F"1"%GEH+%#Y,T^(E':R0%20>?66+D%
M'N1F4^T5SO1VGDP3MG4XOBO !A87\D[J0BX*1?P7"K0EZ-960RBL?)0V6XOT
M@NF<'9,3?Y55 X3CA>#$O=Z"'26>2$'04?<>S[P[,V6I?7"8 I]<F.5> ^'8
M-00I1'H^8!^7.N:/C7(T[XP8*?=*[O!@BI]5[549X_+\B;B\)GU8\-_,L9B3
M@ ?5[X+U*TQ@@Q2M.;#?=:+%Q9WS] JHW%CMH9KTB@T:K!@L^DYE0>CIA.$D
MY6BC<U;5\H&I4)7+&Z@=F:E[[;RN5L,\X"C(UK):!;J:-78><50\"$<JRB /
MJI[S8$($X(0JT[4LH(!IP"IR&!+614$1!6'8] AH*1P.\S,H%04+">JMIB%.
MK2J@,/)"WP?+!WEL:X6!L.I; Q$FX^.S^0\43;!!U92)R!O%YFAY8YL%&2A$
M4E@4> O?7P>]NB(:=8B^AU69;%SMY-BE7<H'4O//?SI/T_&K6FJ26=SJ*N>E
MR2O>+?/H-[;26E6'S(F]Y\?CY]FVC#+IUE %MFXJ7NMH!?R1668;L*;GN*.E
MF0CM'M$%R64#:K#'HQ +_AG&\6[<R@(1LX5L4%R3=:';(#C(#70.!U?DUWWQ
M%#$Q[=.9]2%LCK0#G%1WRG(;Q4GJUA*ZT7D"&JRBR\AN$Q&#.#J77#,Y>X5]
M-0F7]/S2WN5##P6QFRZ9]RE/WC!5%:.)(4"25- ?BM7-HM 9:"^!>J"X'6V=
M0$.IQ6:M ;_0!VT8&PV]Y2V:V4S6&@FD_R/;P(5ZA9*($]BK*R+/PEL/FJ1(
M[ZFC26_TIW7N@>YZMZ1MG7L$>'N()1&^GD[_96.QS6)?WF0AIP  R)BF-E4;
M$MR&[TGJOSCQ_N9WLF171RXH>YQ)1&W YMFSR?[TW)])E)PA:I^%FC^0\A%I
M1D.,&86:W%2*=?G#U>OL8/42 Z_2)@P2)+7 WWN]T 55)'X/&6MZ@3V 7M1T
M\AIKK)&2CDO\3N="&MR9 @DN8?T'! S5*I9C82SZ4R2&:R%HNVNY[G> \[=&
MDV)2Q%*7B.C[?A-53<YKB5"J0(06ETK%HD%A,\3W<+"MQ ,0#3D(_UJ5&4NA
M2ZV-R-%U,U)%.^;H<=D7;1HEQ%AFP6!;?.<#9P>X<SW[NFA 'K;:=C,)T,9!
M&TQ5OE5VD7,;*BP[U@0<<DL0B 7#7D/+MCDOM(Q>!8N%(BM1S5#DS<9QMT#,
M %L\8_;A62J_-CT0;^EJ[H:8$:7<SO;@WAU!,?%1]EO"-O!?/%#/H++0!_7)
M!GQL%H3-A*R((TD%:S^>2N?4;AA"49S_=PS>&!WP30:Q\>Q=!T)X76@$6T[\
M*1<QI>JR*6E>@+8<BSB#1$5$K\ HM$L+5#5"_MT2.CD-:&#),(X8F "]:%O
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MG%]G/*SJA/QO2.C7%'Q%0[=L_@('@T$X[A/69/*GN/B9W#IUN:^-DC8]+Z,
MI>56D#HYJZE.Z4,+&=_SC&(F?&H[2*4(V\IMG9; ';W+([ ]X\*UO]!+>?-\
M2Y_55#"7X,W1\[)43&?._"TG>*NTN?A.0I?@9[O^)6R08%L\\B\CYGOPGA$5
M/OX747%S%H\B WOE=,[*XKD/W4GWU&0S9OA$M+W9MZ>S/)VUEI29_)_H*J-P
M,K[Y-SK*I4BZY7+INQIUII,"]<[/8/1B5"5M/:BTI^V8MZBGFV?Q>D;\R/2.
M2T/ELR75N/=V%("NYZYZ8U7I9YV-LC0Y^65.HRIJ)T#W6T69;#;.0#O\SO\
M4$L#!!0    ( $: #5&7(%K0/PL  )PA   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;-U:66_<R!'^*XV)E+4!BN(YAR] LKV) ^Q:D':]"((\M,B>
MF89)]IB'Y-E?GZ^J20[GDF0[><G+B$=U=9U?537UZMZ4GZNE4K7XFF=%]7JT
MK.O5B_/S*EFJ7%:N6:D";^:FS&6-VW)Q7JU*)5->E&?G@>>-SW.IB]&;5_SL
MJGSSRC1UI@MU58JJR7-9KB]59NY?C_Q1]^!:+Y8U/3A_\VHE%^I&U;^OKDK<
MG?=<4IVKHM*F$*6:OQY=^"\N(Z)G@D]:W5>#:T&:W!KSF6X^I*]''@FD,I74
MQ$'BSYUZJ[*,&$&,+RW/4;\E+1Q>=]Q_9MVARZVLU%N3_:'3>OEZ-!V)5,UE
MD]77YO[OJM4G)GZ)R2K^%?>6-@I'(FFJVN3M8DB0Z\+^E5];.PP63+TC"X)V
M0<!RVXU8RG>REF]>E>9>E$0-;G3!JO)J"*<+<LI-7>*MQKKZS4UMDL_BXXI-
M=)7)HGIU7H,OO3U/6AZ7ED=PA,=8_&**>EF)]T6JTNWUYY"G%RKHA+H,'F3X
MCZ9P1>@Y(O "[P%^8:]DR/S"8THN9:G.R'FIN))KQ%0M+LI2%@O%U_^ZN*WJ
M$@'R[P<VB_K-(MXL^B&+?BL/\:$0O\@R6<(F_LP1]5*)MR9?R6+]U[], W_R
MLA*71I:I,'/Q3I<(>E-60JY6I;F#VD0O4V,Y@H3NB9-X_Z71]1KL$U@""<+;
M.<*4&Q+[Y'ZIL?NM2F2NA)K/%>>3T'FN4BUKE:W%JM2TS@RE^PFB7WUTQ6]#
M;DCG52:35BX R$3LJ=QN>"\K4:L2H8\]TL/;):9@4!DJMVL<".& ,,NLW%A.
M5/0Z\%ZRB5V^\5_NB$H&U*FJQ+RUR0*!4],V'VX^5K2]RE>962N0R"+=)_L5
M9 XT1HCIA'2H2-7])Z(I= U*>T.>4XFV.I6$+7BU4B7C,)QEJ7G'X=.*0GU;
M*D>DFW@ .5LKJR%=Y8H+D-8R(SD#)_0GCN=Y'1,\2TR>8W\KTKTJX6]LJV4&
M^X%$E11;I+&NJH8%6#4E7=5=&/2&="F$99IJTL@&<+O/848-P&0G"(&-629D
M5AF(D61-NL_BMJE%86IF@]LADT-!!I-F#9EE;3D)>8\<JJSSGK >KV0MU-<5
M+,PYTT4J1*V7*()B*>]TL4#>J )TJDPTH9 NQ+R!+APKX$!;0_NYTK0KGB)!
M&F0[0=8!PQ5-?@NYX*!6?WDG=29O,_4]-L1#610-H@!/4-DKJ%+PJKDNJUJD
M<DU;*8ETG.LJ >%:251#M=!%0=J1.O8%(;8CU!?BUD9 IJK*"OM,/Q<A1=@@
MRE[B*1Y'KG?:I2[,5B$\4^)\)!1EU1%G<B,AW6\#A +&$)N!V"_)O-@3FY+B
MN6D0K."7*NL\"B(+#OMXBGSAC5&@5%^@ML 8_AY$8^B,0]\)O/B8'H]YR^)F
M%S>$>*#KH(>2F<"%F,.G%/:WUMP45(7P/=B4B*9Q;UM@CLX92>=2E^).9HWJ
MWG4R6M^G%,5XPZG :+7JH--YNKV>(GZ7;(@7":%/K6V6)B-S'-/-]WY4IV]0
MPO!*5$7._(J2&FG#V4ZDOL>1955:J$*5#)!W$$R@^I8B:M_/2Y/O"^*VN-)6
M9VY4J29OXF&WF-F60,/S:-L10S459O37+UILJL3'00[=6!M<;&'$W]@$O_9
MTA+]P6TLS'$!N=&5B_>=\Z[8>7OOKQ6U_K3-6S2!U$11ZO]&EGD&6/@GZ?U<
M7"P6I5J0TA] I-'3)^(3^XF(""DK" O"2YE1+J!HO4/NLG#(()L0OA/'D3.>
M>2)"J?*<":Y.Q,2=^?@))KCV(\\)PDA<-&!9ZC\A)](OQD.XJ#--%V[/)G&
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MIL\F_>_<Q@VZ^]V"@BH+O..@)9&.=8U(Z>N;WW%QL(K0JX/(-#=-V8*3[ML
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M%);>2*)[!%Q[H&I5[(#50=E5:$#Q)7 &)%DDD04?I4"]8D!/=3YT[N,9WH=
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M V&[,,[JXM^1!("<0W#P 1M@F_9)1/+9G#M%.;&8[&85-K,V48\Y3U!:M):
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MK.'C)EQNQ*B&9U:$V24LU5'TH3FF:;B1GBHTBK-\$UM)5T\_<+P<^W_+.B;
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MZ&4D@OGV!'&!XVVZ>&\<^>Z#$Y?/40L1-Y/_NRS^;A(Q34SWU&SZM&]P7NK
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M5Y1>"W2VSW7)4GXY*"D\M>*#JWLT-"?3JUW3! )6;'[3P%HG\/2?:G)"=$X
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M%S4YHW9@CD!)W?S%ZZX.!X#+] @@VP&R$'?C*$1Y(YR8C*S9@O76S.8/(=6
MYN"D]DUY<)9O)>/<Y-;HU6>'5L$-+AR</8I%A=09)8[)O4E2[(AF#5%VA&@
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MC.,%$8YKWLAHO0'?+XUQ>\$[:'?\Y!]02P,$%     @ 1H -49A$P38Y P
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M3<A5?!%-N/X&NZJO/0!1P05-*[!4D,99^1N^5(%H :#3 T 5 .T!L-<#P!4
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MG DKWRN6#4%S_99J186@J;[<DE"&2W60SS>4BK>&>O%5O]V=_ =02P,$%
M  @ 1H -42W0(8C: @  (0@  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&ULQ99;;]HP%,>_RE'4AU9:FQ :+A4@ 6VU3JN$RKH]3'LPR0&\.C:S#73?
M?L=.2&FY:),J[878SCE_?N>"#YVUTD]FCFCA.1?2=(.YM8NK,#3I''-F+M0"
M);V9*ITS2UL]"\U"(\N\4R[".(H:8<ZX#'H=?S;2O8Y:6L$ECC2899XS_7N
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M_20BJJ$%JV"DN=(P0GID<,LEDREG L:6670V!DZOT3(NS!GY/HZOX?3D#$Z
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M/J#Y5XRK%YEB>-XS/>-4/X%3DHPNFI0770RD8F/5PM_I$V5I0OCEG&8X:F=
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M(D<(&6;&(1#[VN(2&7- EL:/#C/H4[K P_4>_9VOW=:R(1J7DGVEN:GFP64
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MNF9@ZD4#IE'0[V%SP"H?:Q3@<4,V!U)R+[T##LCE$Z\3X*8W8'.S+6'];K8
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M09'&T/9B@P)B6$O\K#TZW39%7<,9AYEG.$,,;XF?M[.UKON^8B(#B7FZX<N
M82097BSM!I[D/)."*DSS <&($#AHI]UN=",8A:..M!O<$C]N/_'\\92L1X:4
MT<7&"I&A7^2GWY%9GU9A#A[+C!!J]^5!X_%>\6SU,Q6/&O<@92OM%UX-]7Z(
M_>/*_87BF_*)WYPKQ;/RY9K1)1.%@?Y\Q?7/R^JB>(A8/S2>_ ]02P,$%
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MX/5VS0(?8% V .<W4IJWCKWC_9.>_@502P,$%     @ 1H -42T!/,1? P
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M 30&:0;H]S,AU.;&&*C.<,?_ U!+ P04    " !&@ U1WK>WQN@"   <"
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6R=EEUOVC 4AO_*4=2+5FJ;
M#Y( %2#1HFJ;6@GU8[N8=F&2 UA-;&8[I?WW.W9HRD:@ZFY(_''>]SF.?<Q@
M+=637B(:>"D+H8?>TIC5A>_K;(DET^=RA8)&YE*5S%!3+7R]4LAR%U06?A0$
MJ5\R+KS1P/5-U6@@*U-P@5,%NBI+IEXOL9#KH1=Z;QUW?+$TML,?#59L@?=H
M'E=312V_4<EYB4)S*4#A?.B-PXO+T 6X&=\YKO76.]A49E(^V<;7?.@%E@@+
MS(R58/1XQBLL"JM$'+\WHE[C:0.WW]_4KUWRE,R,:;R2Q0^>F^70ZWF0XYQ5
MA;F3ZR^X22BQ>IDLM/N%]69NX$%6:2/+33 1E%S43_:R68BM@"C<$Q!M B+'
M71LYR@DS;#10<@W*SB8U^^)2==$$QX7]*O=&T2BG.#.ZD6)Q9E"5,,&9@3.X
MKDRE$&X9/;CAJ.%1Y*C +!$>[+P;R00<3] P7N@3. (NX&$I*\U$K@>^(2@K
M[6<;@,L:(-H#\*T2Y] )3B$*HN#Q?@+'1R=_J_B44I-7U.05.=G.'EF7S83K
MK)#:YO-S/--&T1[X=4"\TXAWG'B\1]RBMF5:1Z4NRAZ'YU$4Q33SN<4K;KSB
MC[S"-J\Z*MGRBN,X:O=*&J_D(Z^HS2O9]>I%2=)NEC9FZ4&S]YV7T[<ZA862
M6L,,J=(@'=9,H3NV<@[V&W*Q@#EBZP9+=_"2N-_IMN-U&[SN0;QQGE_ ^#,8
MW1V,L)/VVREZ#47O\XO49M[;78.T$Z3M[OW&O7_8';6F12AE)0R58"K[&H6Q
M:\ %0:$V;2C]'92S, RCN)TE#-XK5?"?-'9M(*?#[H:H#M4]7.N*B0PAD]JT
MEZ:@C77/JH5;-34\2#JMT>"9%17:K4.%FY=5"2OV2C?:'I9PIWK$29#^"^-O
MU7I[;]XRM>!"0X%SB@O.NY2,JJ^BNF'DRI7_F31TF;C7)5W?J.P$&I]+:=X:
M]D9I_A",_@!02P,$%     @ 1H -4>N'WZ@H P  @PH  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&ULM5;;;N(P$/T5*]J'5FK)C6L%2 6ZVJ[:+2K;
M[<-J'TPR@-7$3FVGM'^_OH1 V1#ZL.6!^#+GS)F),Y[^FO$GL0*0Z#5-J!@X
M*RFS"]<5T0I2+!HL ZIV%HRG6*HI7[HBXX!C TH3-_"\MIMB0IUAWZQ-^;#/
M<ID0"E..1)ZFF+^-(&'K@>,[FX5[LEQ)O> .^QE>P@SD0S;E:N:6+#%)@0K"
M*.*P&#B7_L65'VJ L?A%8"UVQDB',F?L24^NXX'C:4600"0U!5:/%QA#DF@F
MI>.Y('5*GQJX.]ZP?S7!JV#F6,"8)8\DEJN!TW50# N<)_*>K;]!$5!+\T4L
M$>8?K:UMJ^>@*!>2I058*4@)M4_\6B1B!Z!XJ@%! 0CV <T#@+  A!\%- M
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M"%P;J/T%8W(ST0[*OG/X%U!+ P04    " !&@ U1:OLXYA0#   \"@  &0
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M]&8'KC9.C=DP84]Q912N,M29="[+DAD\%J,)%3F92V&8V(+(&&C2(S/*J<B
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M9?2J:\WHJCI7'52%KX@SA;:^^N;:WFB@W0([OU0*WSNNR#9WY.@W4$L#!!0
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M<=GX:44;$OSYWA@Z!N$%C?-?_ 902P,$%     @ 1H -4;,-(2Q0 P  >@P
M !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULM5=;;]HP%/XK5K2'5NJ:
M&^%2 5*!WJ9U165='Z8]N,D!K"9V:IO22OOQLYTT0)L:-(D7L)WS?>>:XY/N
MDO%',0>0Z"5+J>@Y<RGS$]<5\1PR+(Y9#E0]F3*>8:FV?.:*G -.#"A+W<#S
MFFZ&"77Z77,VYOTN6\B44!AS)!99AOGK %*V[#F^\W9P2V9SJ0_<?C?',YB
MO,O'7.W<BB4A&5!!&$4<ICWGU#^Y]!L:8"1^$5B*M372KCPP]J@W5TG/\;1%
MD$(L-056?\\PA#353,J.IY+4J71JX/KZC?W<.*^<>< "ABR])XF<]YRV@Q*8
MXD4J;]GR$DJ'(LT7LU287[0L9%L-!\4+(5E6@I4%&:'%/WXI [$&4#SU@* $
M!.\!GVD(2T"X*Z!1 AJ[ J(2$.T*:): YJZ 5@EH[0IHEX"VR6Z1#I/+$9:X
MW^5LB;B65FQZ80K"H%4*"=6U.Y%</24*)_NWD(!Z&QY20$-&GX%+HM=C54'
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M:@@SR[GZ. "N!=3S*6/R;:,55)\;_7]02P,$%     @ 1H -4<T/LU7M P
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M2W6>5J>*S&8*/<_U(WMB;7IP>#4.SXACMA9+RM)_27(,@-<%@#P;P0$ ?@W
M-P(H.<3!0CGV. J_@^)CX"'DA?TH@AI%<!**6(4BRX[C"#HXD.NX7C^*L$81
M&E%(VIV1$6$7@AWX41C4($HR==<9,R>JP49&>ORYSI]EE:-S\'B,<=!NRJK]
MOK2H]+6M<QUH!T/6P5:%A^^9F)6V-A!38D+4X$ GX2"OA,4I/P$)ZG+$M;W0
M"0:@- 41.N_+DDK?'A0#3V!3/:&Y?)['%-@MGJ[OH-#W#ZC2M]"834V9A9Z1
M+3_U8"0]-ML0)@<]\+D*)[AG:4Q,Y&DJ*327TG[RJ :YDD35_KD$_[5FCUY?
ME7N$[3P>1W# _J:^PM,*;)M-YR(K=U",KZ$YSCCT![ U51>:RVX_P\Y%%W;1
MH3$< M=461C] N?.!1=UP<%@C :*$VKJ-3+7ZQX>G@FMVB#<FRO&WF$3ZUDV
MG):H*?+(7.0[M'P@ZB-.V70K1V$F/Y?6. /?"<NU<7\3S/CE%<!;S!(.Y <>
M%UC[H-<V\^8!>%/J@ ?R<NR&(,%OO?/P:8J<G:) *3)U9-2T'V1N/[/%@I$%
M%@1\D?Y(Y8=H#'[@;$WZG*"BW>N(<@^_'63']VSO,,H]ZUP;.>Y G)O.A<R=
MZW!8N0(;PE7<)>X=[_6,?Z23H&Y#0W*8"NUH &'3T9"YHQUI$$; YU+.[7#)
M&T<#/1DU+0Z9/R5^E4O]AO4"-P/P*QJX.QH@]R@/FN:*S,W5P(.!R QQP>_D
M> 0C.#"<H:;#(G.'/9+B*Q(+(*A^>#3+NU\WA_/2/LBFU2)SJSTORQ5F>=-&
M?6ZJAT>ZR[X=35=&YJ[\+KF^;UXO?#.*4QK(_M%'T]@=<V,_-=T/0C20\]5F
MAOI?PK1:)W(Y80M]4"EG'[HN1'DX5S^M#T-G^@C0:I:7)ZG?,)/3, <9F4M1
M>QS(;&;EX61Y(^A*G^\]4R%HKB^7!">$J07R_9Q2L;M1&]1'Q-/_ 5!+ P04
M    " !&@ U1 C."F.\"  !-"@  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6REEFUOVC 0@/^*%>U#*VWD#0)4@%3:=>ND;JB(]K-)#F(UL3/;@4[:
MCY]?0J J4,*^)+;CNWON[+O<8,WXBT@!)'K-,RJ&3BIE<>6Z(DXAQZ+%"J#J
MRX+Q'$LUY4M7%!QP8H3RS T\+W)S3*@S&IBU"1\-6"DS0F'"D2CS'/,_8\C8
M>NCXSF;AD2Q3J1?<T:# 2YB"G!43KF9NK24A.5!!&$4<%D/GVK\:^VTM8'8\
M$5B+G3'2KLP9>]&3^V3H>)H(,HBE5H'5:P4WD&5:D^+X72EU:IM:<'>\T7YG
MG%?.S+& &Y8]DT2F0Z?GH 06N,SD(UM_A\JACM87LTR8)UK;O9&R&)="LKP2
M5O.<4/O&KU4@=@1"[X! 4 D$AML:,I2W6.+1@+,UXGJWTJ8'QE4CK> (U:<R
ME5Q])4I.CJ:2Q2_H5V%"-,DP%>@+>IS.!+JX!8E))B[U @C)22PA0<((E)1(
M,7"E(M!ZW+BR-K;6@@/6(O3 J$P%^DH32-[*NXJ\Q@\V^./@J,(?)6VAT/N,
M B_P/B$7B11S$/9Y1']8AR<T^L,#^G^6^1PX8HO=$-B8S=Z'X(V)=FVB;4RT
M#Y@8PY)02NA2W2X5_QC0!:&5'Y?H+]KGBPV-U=LQ>G7VK4;>P%WM0>G4*)VC
M*.^.><DQU;-3B3KOB,*^U^OOIXIJJJ@9U4HM-("*3@U3MP;J-@-2Q7$!I E3
M]U2F7LW4.\JD$NJ<*]1K<F#]FJ5_-&F>32E4T;A> 5>E'7W3UPBI^@3H#A..
MGG!6PI'4\;UM]?+.2)[9]!85*FV-WSH V\JPMV99&]''I^'OE%7__%1JRE>5
M<&_WF/R6WSL &6PA@[,SJREC<.J-]K>UUP__)\^:$H8G$VY+MW^\=N_)NJ94
MUD#O@Z-U=_[P.?"EZ6,$BEE)I?W9UZMUKW1M.X3M=MMH/6"N<D:@#!9*U&MU
M542X[5WL1++"] MS)E7W88:IZO> ZPWJ^X(QN9EH W4'.?H'4$L#!!0    (
M $: #5'*W #4600  %<8   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM
M;,U976^C.!3]*Q;22K/2%# 02*HD4AL8[8RVVJC5SCZL]L$-3F(5<-9VFN;?
MK_DHA%EC$C(/?6G ^)Q[?;CF7M].#Y2]\"W& KRE2<9GQE:(W:UE\=46IXB;
M=(<S^61-68J$O&4;B^\81G$!2A/+L6W?2A')C/FT&%NR^93N14(RO&2 [],4
ML>,]3NAA9D#C?>"1;+8B'[#FTQW:X"<L_MPMF;RS:I:8I#CCA&: X?7,N(.W
MD>/E@&+&=X(/_.0:Y$MYIO0EO_D:SPP[]P@G>"5R"B1_7O$")TG.)/WXMR(U
M:ILY\/3ZG?U+L7BYF&?$\8(F?Y%8;&?&V  Q7J-](A[IX3=<+6B4\ZUHPHN_
MX%#.#28&6.VYH&D%EAZD)"M_T5LEQ D !AT IP(XYP+<"N">"_ J@'<N8%0!
MBJ5;Y=H+X4(DT'S*Z &P?+9DRR\*]0NTU(MD>: \"2:?$HD3\R=!5R_@CUWQ
MUI8)RCBX 5\08> [2O88T#4XG<+!IQ +1!+^Z]02TG[.8JTJ6_>E+:?#E@L>
M:":V'$19C&,%/M3C?0W>DNNN%^^\+_[>T1)^VV<F<.W/P+$=6^'/XFPXG*B6
M<YWU:+#UEAAN'0ENP>=V1<(6,7R3;[H8+&@JOT0<%5%QQQC*-EA^'01X/H+3
M>4MT+(;O#HC%X._?)27X*G#*_]$XY-4.>85#7H=#T=M.?DVDE5>:2$\2(HZ?
M\RU TGVJ"CX]F^>;OOV+ZB7WX!PS4.+"7MQ$B8LNM]>2;U3+-QH@'WKKDD_/
MY@4=,BQZ<%TRA /M19?;:\GGU_+Y6J)'PE]NU@QC0#*!&>8","2P-@+UC+;I
M.4H%]3!HCGVE@,.L11=;:\D7U/(% ^7KCD ]HVV.E#HL]##'= .E?'H8-#VH
ME*_/VLC3R3>NY1MK>4+R2F*<Q>!(<*)*E?=ZO&W:ZMTZ#!8.@T47PUIB36JQ
M)EJ>!]6.;#%!NRF'[(^1!>%)A0;/^Y#+?92"3R0#1XQ81P&FIQJ54.""M*BD
M5!%R'H6R>KO:>#3$>%M6IY'5T4>-ZD/4YFI*)_A!:B?8%$_PS.KIG*C14_GG
M1,W5%.'U%-%5%&VAFS(+]M193\NECJ@I.*#_08*H2>)0G\XN"B(]E:\+'CTT
MJ*  !B!&1W7P#+8>766]+6R3WJ$^]2F*<Z6F>I; -SUUFN\!RNIZK,[8 X!M
M"9JD#?59^\+C7=A#YWG_UZ+=%&AJ ,?^F2>GL(=.]9;:GC6E@*//?QU5M2IT
M>IAL$_Y8J%8M#SW.,;V1,G NQ[4U:/*VH\_; PYF80^E0HRV<TTAX+@_^]@3
M]E!"<S36.M>4!(X^_?4?*GH(.D\5 W'A0%QT.:Z4S#IIE*:8;8H.-0<KNL]$
MV2FK1^LN^%W1^_UA_![>+J!B/(2W4=GC;NC+EOL#8AN2<9#@M31EFX&L*EC9
MQ2YO!-T5;=IG*@1-B\LM1C%F^03Y?$VI>+_)#=3_2YC_!U!+ P04    " !&
M@ U13IL%'F(#  #P#   &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6S-
M5UMOVC 4_BM6U(=6:IM[@ J06NBT3JN&RKH]3'MPR2&)FMC,-M#^^]E.""%)
M([3UH2]@GWS?N<<^&6XI>^8Q@$ O64KXR(B%6%V9)E_$D&%^25= Y),E91D6
M<LLBDZ\8X%"3LM1T+"LP,YP08SS4LAD;#^E:I F!&4-\G668O=Y 2K<CPS9V
M@H<DBH42F./A"D<P!_&XFC&Y,TLM89(!X0DEB,%R9%S;5[>VJP@:\2.!+:^L
MD0KEB=)GM;D+1X:E/((4%D*IP/)O Q-(4Z5)^O&G4&J4-A6QNMYI_Z2#E\$\
M80X3FOY,0A&/C+Z!0ECB=2H>Z/8S% 'Y2M^"IES_HFV!M0RT6'-!LX(L/<@2
MDO_CER(1%8+4TTYP"H)3)WAO$-R"X!YKP2L(WK$6_(*@0S?SV'7BIEC@\9#1
M+6(*+;6IA<Z^9LM\)40UREPP^321/#&>"[IX1M]6NFJS%!..+I 67JC\AVA"
M,]F4'&O Z10$3E)^)D&/\RDZ/3E#)R@AZ'M,UQR3D ]-(;U2NLU%X<%-[H'S
MA@<NNJ=$Q!S=DA#"%OZTFQ]T\$V9C3(ESBXE-TZGPB]K<HE<ZQPYEF.U^#,Y
MFFX/VL+Y/^NW_VS](!ENV1^NUN>^U1\Q9M#6"M>,81*!/#,$>GI%5=P,OVKQ
M]1:S\/R0-J%<H%]?I15T)R#COSM\]$H?/>VCU]7#A>U%U1B\J#6T]62N,= :
MU6&Z&=N![PW-3;7035#?#0XQTR;&&7B]0]!MBS5K,"A!!U'[9=1^9]0ZDW2)
M(DI#CCA-NWH_*)4&'[;<O=+'WKN7.]?H5RLYJ!6[":GWP[0)L7VW5NHF)GBC
MT/TRWGYGO _  ;-%C.3Y*N_ C;S<5SKA1;R\(Z>#TL;@P];=MO9WE?7NE2]4
M5@OB>+67>-("LIW:2SQM 7E.O?QMFGR_O0'LRB5M=P<N!ZF$1.<H @(,I[H5
M<"CG@80+AM6L=4PWV,[>H/-Q^V%_-]GN^_>#VSR+7;M^&+2@@DH9BX9H@ARW
M9]<[HHGJ]^H=858FN Q8I$=G+H-:$Y%?UJ6T',^O]5!:D]_85Q.[13Y5X[R>
M&/?J\V^!>\RB1(Y]*2RE*>NR)WN7Y>-UOA%TI>?')RKD-*J7L?PD :8 \OF2
M4K';* /E1\[X+U!+ P04    " !&@ U1KILL?74"  #,!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6R=5>]OFS 0_5<LU&FMM 6'0+96"5*;;-HF
M38K:=?LP[8,#1[!J;&:;I/WO=S:4I5I^:5_ QO?>O7L<QV2C](,I 2QYK(0T
MTZ"TMKX*0Y.54#$S4#5(/"F4KIC%K5Z%IM; <@^J1!A1.@XKQF603ORSA4XG
MJK&"2UAH8IJJ8OKI!H3:3(-A\/S@EJ]*ZQZ$Z:1F*[@#>U\O-.["GB7G%4C#
ME20:BFEP/;R:CUV\#_C.86.VUL15LE3JP6T^Y]. .D$@(+..@>%M#3,0PA&A
MC-\=9]"G=,#M]3/[1U\[UK)D!F9*_."Y+:?!^X#D4+!&V%NU^01=/8GCRY0P
M_DHV;6R2!"1KC%55!T8%%9?MG3UV/FP!AO$>0-0!HE,!HPXP.A40=X#8.].6
MXGV8,\O2B58;HETTLKF%-].CL7PNW6N_LQI/.>)L&M/A^<,%60@FR?D<+./"
M7)"WY/YN3L[/+L@9X9)\*U5CF,S-)+28TR'#K.._:?FC/?Q?F!P0.GQ#(AK1
M'?#9$7B#\!'="Y__-SQ$HWJWHMZMR/.-]O#=@N4:L.LMN0$)!;>&_+Q>&JNQ
M?W\=2##J$XQ\@GA/@@7H#-GQ@R-0U4(] 9!,2:OYLG'?R2X+#C->T@&EKPY(
MBWMI\4&B#ZT>_4(/MJ+-2E+WLG=UR&'>Y)C I!>8G.(=446KBLO52ZUX8,N_
MQKXVI&9/NP0?SI,<T3ON]8Y/,S3G)M/@).+@/?:Z9RWIV).ZH;Y.H^B24FSO
M]797_!N61-%V6*LYW!H=;LY_97K%I2$""@32P3OT0K>SL]U85?MILE069Y-?
MEOB[ >T"\+Q0RCYOW(#J?V#I'U!+ P04    " !&@ U1I9T""$8"  !D"P
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M"Y(M!&8+HBT$:@NR+01N"\(M!'(+TBT$=@OB+01Z*^JM!'HKZJT$>NOH89M
M;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O0[V-0&]#O8U
M;T.]C4!O&[TL(=#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU!O(]#;46\G
MT-M1;R?0VU%O)]#;46\GT-M'+[L)]';4VPGT=M3;"?1VU-L)]';4VPGT=M3;
M"?2.J'<DT#NBWI% [XAZ1P*](^H="?2.J'<DT#N./E;^I]ZYG'8I7WN^UWC]
M_Z2ZG,]-U\M?EM\[1S?4!>< /S<\?@%02P,$%     @ 1H -4134<>30 0
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $: #5$4D<#Z[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $:
M#5&97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 1H -41UKM%0A!0  2!4  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $:
M#5%6JN@XC 4  .\5   8              " @60-  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !&@ U1%V?=3M8"  "7"0  &
M        @($F$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 1H -4701;H"4!0  (A8  !@              ("!,A8  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $: #5%^!_WC3PH   E"   8
M              " @?P;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !&@ U1#2,X06\"  !X!0  &               @(&!)@  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 1H -43AV0M S"
M[R,  !@              ("!)BD  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( $: #5&&V[QH% <  $H3   8              " @8\Q
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !&@ U1\U>,
M.-TB  !7;P  &               @('9.   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 1H -47*L,02Q!0  ) \  !D
M ("![%L  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !&
M@ U1MVMTN74&  #Y$   &0              @('480  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $: #5'*A'.$_04  &T/   9
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M970Q-BYX;6Q02P$"% ,4    " !&@ U1ER!:T#\+  "<(0  &0
M    @(%VB0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M $: #5$QW/._! ,  '0&   9              " @>R4  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 1H -442XXHD0(P  VW4  !D
M             ("!)Y@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !&@ U10X1LW[4#  !S"   &0              @(%NNP  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $: #5'^P&@L?P,
M %\(   9              " @5J_  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 1H -48+/&FXQ!@  4A$  !D              ("!
M$,,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !&@ U1
M%U<:K-<"  #O!0  &0              @(%XR0  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( $: #5&81,$V.0,  *P'   9
M      " @8;,  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 1H -49F7.F5T!@  11(  !D              ("!]L\  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !&@ U10>])D-L$  #I%0
M&0              @(&AU@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( $: #5$MT"&(V@(  "$(   9              " @;/;  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 1H -4=O-?U8@
M @  H@0  !D              ("!Q-X  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !&@ U1;Y342XL"   H!@  &0
M@($;X0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $:
M#5$ANOK;'@(  ) $   9              " @=WC  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 1H -43Y3J=DU P  .0D  !D
M         ("!,N8  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !&@ U14%14G?D"  "2"0  &0              @(&>Z0  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $: #5'1DP05-0(   \%
M   9              " @<[L  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ 1H -4=D"H);:!@  A#@  !D              ("!.N\
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !&@ U1V43,
MOHD%  ! '@  &0              @(%+]@  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( $: #5'A>[!NI (  $,&   9
M  " @0O\  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M1H -48:M?B%' @  *P4  !D              ("!YOX  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !&@ U1Q6=_-/ "  #("0  &0
M            @(%D 0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( $: #5%;B(B]>@(  -X%   9              " @8L$ 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 1H -42T!/,1? P
M> H  !D              ("!/ <! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !&@ U1&_*JK\P$  #/%0  &0              @('2
M"@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $: #5'>
MM[?&Z (  !P(   9              " @=4/ 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ 1H -4>N'WZ@H P  @PH  !D
M     ("!]!(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $: #5&S#2$L4 ,  'H,   9              "
M@6HA 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 1H -
M4<T/LU7M P  *0\  !D              ("!\20! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " !&@ U1RCESZ;4%   I'   &0
M        @($5*0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( $: #5&"DC&1%04  "X6   9              " @0$O 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 1H -40(S@ICO @  30H
M !D              ("!330! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " !&@ U1RMP U%D$  !7&   &0              @(%S-P$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( $: #5%.FP4>
M8@,  / ,   9              " @0,\ 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ 1H -4:Z;+'UU @  S 8  !D
M ("!G#\! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !&
M@ U1I9T""$8"  !D"P  #0              @ %(0@$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( $: #5&7BKL<P    !,"   +              "  ;E$
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $: #5';FEBE:@0  .4D   /
M          "  :)% 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !&@ U1
MO '6P> !  #L(   &@              @ $Y2@$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " !&@ U1%-1QY- !  "M(   $P
M        @ %13 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /P _ # 1
(  !23@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>368</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Formation and Business of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FormationandBusinessoftheCompany</Role>
      <ShortName>Formation and Business of the Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2136108 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2138109 - Disclosure - Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlans</Role>
      <ShortName>Stock Option Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/BalanceSheetComponents</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2326304 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/LongtermDebt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/CommitmentsandContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2341306 - Disclosure - Stock Option Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansTables</Role>
      <ShortName>Stock Option Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/StockOptionPlans</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Formation and Business of the Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails</Role>
      <ShortName>Formation and Business of the Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/FormationandBusinessoftheCompany</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Adjustment to Prior Period Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Adjustment to Prior Period Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Segment and Geographical Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment and Geographical Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Fair Value Measurements - Recurring Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Recurring Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails</Role>
      <ShortName>Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails</Role>
      <ShortName>Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Long-term Debt - Term Loan Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails</Role>
      <ShortName>Long-term Debt - Term Loan Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Long-term Debt - Future Maturities Under the Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails</Role>
      <ShortName>Long-term Debt - Future Maturities Under the Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Long-term Debt - Series C Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails</Role>
      <ShortName>Long-term Debt - Series C Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Commitments and Contingencies - Lease Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Commitments and Contingencies - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Commitments and Contingencies - Operating Lease Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - Commitments and Contingencies - Purchase Obligation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Obligation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Stockholders Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Stock Option Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansNarrativeDetails</Role>
      <ShortName>Stock Option Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Stock Option Plans - Activity Under Compensation Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails</Role>
      <ShortName>Stock Option Plans - Activity Under Compensation Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - Stock Option Plans - RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansRSUsDetails</Role>
      <ShortName>Stock Option Plans - RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Stock Option Plans - Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails</Role>
      <ShortName>Stock Option Plans - Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - Stock Option Plans - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails</Role>
      <ShortName>Stock Option Plans - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="silk-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448430 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silkroadmed.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silkroadmed.com/role/A401kPlan</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="silk-20200630.htm">silk-20200630.htm</File>
    <File>q22020exhibit311.htm</File>
    <File>q22020exhibit312.htm</File>
    <File>q22020exhibit321.htm</File>
    <File>silk-20200630.xsd</File>
    <File>silk-20200630_cal.xml</File>
    <File>silk-20200630_def.xml</File>
    <File>silk-20200630_lab.xml</File>
    <File>silk-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "silk-20200630.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 212,
   "dts": {
    "calculationLink": {
     "local": [
      "silk-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "silk-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "silk-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "silk-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "silk-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "silk-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 444,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 6
   },
   "keyCustom": 33,
   "keyStandard": 335,
   "memberCustom": 15,
   "memberStandard": 33,
   "nsprefix": "silk",
   "nsuri": "http://silkroadmed.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://silkroadmed.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://silkroadmed.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Fair Value Measurements",
     "role": "http://silkroadmed.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Balance Sheet Components",
     "role": "http://silkroadmed.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Long-term Debt",
     "role": "http://silkroadmed.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Commitments and Contingencies",
     "role": "http://silkroadmed.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136108 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://silkroadmed.com/role/RedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138109 - Disclosure - Stockholders Equity",
     "role": "http://silkroadmed.com/role/StockholdersEquity",
     "shortName": "Stockholders Equity",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Stock Option Plans",
     "role": "http://silkroadmed.com/role/StockOptionPlans",
     "shortName": "Stock Option Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - 401(k) Plan",
     "role": "http://silkroadmed.com/role/A401kPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://silkroadmed.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://silkroadmed.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326304 - Disclosure - Long-term Debt (Tables)",
     "role": "http://silkroadmed.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "silk:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341306 - Disclosure - Stock Option Plans (Tables)",
     "role": "http://silkroadmed.com/role/StockOptionPlansTables",
     "shortName": "Stock Option Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Formation and Business of the Company (Details)",
     "role": "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
     "shortName": "Formation and Business of the Company (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Adjustment to Prior Period Financial Statements (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Adjustment to Prior Period Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "iba2667bba4254c478e4e02407240ad78_D20190101-20190630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i704ad274cb0749d5930b69ce8f613a81_D20190501-20190630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails",
     "shortName": "Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i704ad274cb0749d5930b69ce8f613a81_D20190501-20190630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnbilledReceivablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnbilledReceivablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Segment and Geographical Information (Details)",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment and Geographical Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Fair Value Measurements - Recurring Assets and Liabilities (Details)",
     "role": "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Recurring Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i2abf6f3595684efe9f063ff9b69fec7f_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
     "shortName": "Balance Sheet Components - Fair Value of Available-For-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails",
     "shortName": "Balance Sheet Components - Fair Value of Cash Equivalents, Short-Term and Long-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "silk:CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Balance Sheet Components - Narrative (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails",
     "shortName": "Balance Sheet Components - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
     "shortName": "Balance Sheet Components - Available-for-Sale Investments in Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
     "shortName": "Balance Sheet Components - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "role": "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)",
     "role": "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "icab64d89eb0c493488e9f83a19562b4d_I20180930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "silk:DebtMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Long-term Debt - Term Loan Narrative (Details)",
     "role": "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails",
     "shortName": "Long-term Debt - Term Loan Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "icab64d89eb0c493488e9f83a19562b4d_I20180930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "silk:DebtMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Long-term Debt - Future Maturities Under the Term Loan (Details)",
     "role": "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails",
     "shortName": "Long-term Debt - Future Maturities Under the Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0ecab602ace54ec482c1823fb85dfa32_D20190401-20190430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Long-term Debt - Series C Narrative (Details)",
     "role": "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
     "shortName": "Long-term Debt - Series C Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i417623c9d2f24af1b9f527fefb005c13_I20151031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Commitments and Contingencies - Lease Narrative (Details)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails",
     "shortName": "Commitments and Contingencies - Lease Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Commitments and Contingencies - Balance Sheet Information (Details)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails",
     "shortName": "Commitments and Contingencies - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Commitments and Contingencies - Operating Lease Maturities (Details)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails",
     "shortName": "Commitments and Contingencies - Operating Lease Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - Commitments and Contingencies - Purchase Obligation Narrative (Details)",
     "role": "http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails",
     "shortName": "Commitments and Contingencies - Purchase Obligation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i7e86f21e817747e1b323fa24e138daa7_I20190630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)",
     "role": "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i84de79cfd01646ca80f851b0e71fec3e_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i0b2654a458fe4949a14a70a00d0e6c46_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Stockholders Equity - Narrative (Details)",
     "role": "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i9766f2a2b567462db339a57d15a9b202_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i69b6f1148feb4497b99389b263100226_D20190101-20190331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "silk:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Stock Option Plans - Narrative (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
     "shortName": "Stock Option Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i4192fdc2c1f247de9e20017c4c131295_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Stock Option Plans - Activity Under Compensation Plan (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails",
     "shortName": "Stock Option Plans - Activity Under Compensation Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i7a6f5fdcd6894037a81fa4bc82914447_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - Stock Option Plans - RSUs (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansRSUsDetails",
     "shortName": "Stock Option Plans - RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i7a6f5fdcd6894037a81fa4bc82914447_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Stock Option Plans - Fair Value of Stock Options (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
     "shortName": "Stock Option Plans - Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - Stock Option Plans - Stock-based Compensation (Details)",
     "role": "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails",
     "shortName": "Stock Option Plans - Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448430 - Disclosure - 401(k) Plan (Details)",
     "role": "http://silkroadmed.com/role/A401kPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "i5fa51d72c4e84d3ba99728b54adfd852_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Statements of Cash Flows",
     "role": "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Formation and Business of the Company",
     "role": "http://silkroadmed.com/role/FormationandBusinessoftheCompany",
     "shortName": "Formation and Business of the Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "silk-20200630.htm",
      "contextRef": "if69f0934a0ab40449ebc0d9923b4c9b2_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "silk_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Expenses, Current",
        "label": "Accrued Clinical Expenses, Current",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_AccruedTravelExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Travel Expenses, Current",
        "label": "Accrued Travel Expenses, Current",
        "terseLabel": "Accrued travel expenses"
       }
      }
     },
     "localname": "AccruedTravelExpensesCurrent",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silk_CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years",
        "label": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing After One Year Through Two Years",
        "terseLabel": "Amounts maturing after one year through two years"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year",
        "label": "Cash And Cash Equivalents, Fair Value Disclosure, Maturing Within One Year",
        "terseLabel": "Amounts maturing within one year"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_CommonStockCapitalSharesAvailableForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Capital Shares Available For Future Issuance",
        "label": "Common Stock, Capital Shares Available For Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesAvailableForFutureIssuance",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_CommonStockVotePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Vote Per Share",
        "label": "Common Stock, Vote Per Share",
        "terseLabel": "Number of votes entitled per share of common stock"
       }
      }
     },
     "localname": "CommonStockVotePerShare",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "silk_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Warrant [Member]",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common Stock Warrant",
        "verboseLabel": "Common Stock Warrant"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_DebtInstrumentConvertibleMarketCapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Market Capitalization",
        "label": "Debt Instrument, Convertible, Market Capitalization",
        "terseLabel": "Market capitalization (greater than)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleMarketCapitalization",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Maximum Percentage Of Outstanding Loans",
        "label": "Debt Instrument, Convertible, Maximum Percentage Of Outstanding Loans",
        "terseLabel": "Percentage of outstanding loans"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleMaximumPercentageOfOutstandingLoans",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentCovenantMaximumLiquidityAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Maximum Liquidity, Amount",
        "label": "Debt Instrument, Covenant, Maximum Liquidity, Amount",
        "terseLabel": "Minimum liquidity amount"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMaximumLiquidityAmount",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DebtInstrumentCovenantMinimumNetRevenueAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Minimum Net Revenue, Amount",
        "label": "Debt Instrument, Covenant, Minimum Net Revenue, Amount",
        "terseLabel": "Minimum net revenue target"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumNetRevenueAmount",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_DebtInstrumentInterestRateFacilityFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Facility Fee",
        "label": "Debt Instrument, Interest Rate, Facility Fee",
        "terseLabel": "Facility fee"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFacilityFee",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentInterestRateFinancingFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Financing Fee",
        "label": "Debt Instrument, Interest Rate, Financing Fee",
        "terseLabel": "Financing fee"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFinancingFee",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentInterestRatePaidInCash": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Paid In Cash",
        "label": "Debt Instrument, Interest Rate, Paid In Cash",
        "terseLabel": "Interest rate paid in cash"
       }
      }
     },
     "localname": "DebtInstrumentInterestRatePaidInCash",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Paid-In-Kind",
        "label": "Debt Instrument, Interest Rate, Paid-In-Kind",
        "terseLabel": "Interest rate paid-in-kind"
       }
      }
     },
     "localname": "DebtInstrumentInterestRatePaidInKind",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_DebtInstrumentLiquidityCovenantTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Liquidity Covenant, Term",
        "label": "Debt Instrument, Liquidity Covenant, Term",
        "terseLabel": "Equity cure period"
       }
      }
     },
     "localname": "DebtInstrumentLiquidityCovenantTerm",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "silk_DebtMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt, Maximum Borrowing Capacity",
        "label": "Debt, Maximum Borrowing Capacity",
        "terseLabel": "Term loan agreement amount"
       }
      }
     },
     "localname": "DebtMaximumBorrowingCapacity",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_IncentiveStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incentive Stock Option [Member]",
        "label": "Incentive Stock Option [Member]",
        "terseLabel": "ISO"
       }
      }
     },
     "localname": "IncentiveStockOptionMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_IncentiveandNonqualifiedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incentive and Nonqualified Stock Option [Member]",
        "label": "Incentive and Nonqualified Stock Option [Member]",
        "terseLabel": "ISO and NSO"
       }
      }
     },
     "localname": "IncentiveandNonqualifiedStockOptionMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_LesseeOperatingLeaseLiabilityToBePaidYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, Year One",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearOne",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_LongTermDebtAccretionOfClosingFees": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Debt, Accretion Of Closing Fees",
        "label": "Long-Term Debt, Accretion Of Closing Fees",
        "terseLabel": "Add: Accretion of closing fees"
       }
      }
     },
     "localname": "LongTermDebtAccretionOfClosingFees",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_LongTermDebtGrossBeforeAccretionOfClosingFees": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Debt, Gross, Before Accretion Of Closing Fees",
        "label": "Long-Term Debt, Gross, Before Accretion Of Closing Fees",
        "totalLabel": "Long-term debt, gross before accretion of closing fees"
       }
      }
     },
     "localname": "LongTermDebtGrossBeforeAccretionOfClosingFees",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_LongTermDebtUnpaidInterest": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Debt, Unpaid Interest",
        "label": "Long-Term Debt, Unpaid Interest",
        "negatedTerseLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "LongTermDebtUnpaidInterest",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Investments",
        "label": "Long-Term Investments [Member]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Income (Loss) And Comprehensive Income (Loss), Net Of Tax, Attributable To Parent",
        "label": "Net Income (Loss) And Comprehensive Income (Loss), Net Of Tax, Attributable To Parent",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_NonqualifiedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonqualified Stock Options [Member]",
        "label": "Nonqualified Stock Options [Member]",
        "terseLabel": "NSO"
       }
      }
     },
     "localname": "NonqualifiedStockOptionsMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset, Amortization",
        "label": "Operating Lease, Right-Of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Of Stock Issuance Underwriting Discounts And Commissions",
        "label": "Payment Of Stock Issuance Underwriting Discounts And Commissions",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_PreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred Stock Warrants",
        "label": "Preferred Stock Warrants [Member]",
        "terseLabel": "Preferred Stock Warrants"
       }
      }
     },
     "localname": "PreferredStockWarrantsMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ProvisionsForSalesReturns": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provisions For Sales Returns",
        "label": "Provisions For Sales Returns",
        "terseLabel": "Provision for sales returns"
       }
      }
     },
     "localname": "ProvisionsForSalesReturns",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_PublicStockOfferingSharesFromCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Public Stock Offering - Shares From Company",
        "label": "Public Stock Offering - Shares From Company [Member]",
        "terseLabel": "Public Stock Offering - Shares From Company"
       }
      }
     },
     "localname": "PublicStockOfferingSharesFromCompanyMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_PublicStockOfferingSharesFromExistingShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Public Stock Offering - Shares From Existing Shareholders",
        "label": "Public Stock Offering - Shares From Existing Shareholders [Member]",
        "terseLabel": "Public Stock Offering - Shares From Existing Shareholders"
       }
      }
     },
     "localname": "PublicStockOfferingSharesFromExistingShareholdersMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_RedeemableConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock Warrants [Member]",
        "label": "Redeemable Convertible Preferred Stock Warrants [Member]",
        "verboseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions1 [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptions1TableTextBlock",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "silk_SecondPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second Public Offering",
        "label": "Second Public Offering [Member]",
        "terseLabel": "Second Public Offering"
       }
      }
     },
     "localname": "SecondPublicOfferingMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Threshold As A Percentage Of Share Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Threshold As A Percentage Of Share Price",
        "terseLabel": "Exercise threshold as a percentage of fair value of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseThresholdAsAPercentageOfSharePrice",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "silk_ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Additional Shares Allowable Under The Plan",
        "terseLabel": "Number of additional shares allowable under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Awards Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardsAvailableforGrantRollForward",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "silk_StockIssuanceCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issuance Costs Incurred But Not Yet Paid",
        "label": "Stock Issuance Costs Incurred But Not Yet Paid",
        "terseLabel": "Offering costs in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "StockIssuanceCostsIncurredButNotYetPaid",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares",
        "label": "Temporary Equity, Decrease For Conversion Of Convertible Securities, Shares",
        "negatedTerseLabel": "Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesShares",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Decrease For Conversion Of Convertible Securities, Value",
        "label": "Temporary Equity, Decrease For Conversion Of Convertible Securities, Value",
        "negatedTerseLabel": "Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO"
       }
      }
     },
     "localname": "TemporaryEquityDecreaseForConversionOfConvertibleSecuritiesValue",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "silk_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Temporary equity, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "silk_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_TermLoanTrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan, Tranche A [Member]",
        "label": "Term Loan, Tranche A [Member]",
        "terseLabel": "Term Loan, Tranche A"
       }
      }
     },
     "localname": "TermLoanTrancheAMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_TermLoanTrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan, Tranche B [Member]",
        "label": "Term Loan, Tranche B [Member]",
        "terseLabel": "Term Loan, Tranche B"
       }
      }
     },
     "localname": "TermLoanTrancheBMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_TwoThousandNineteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand Nineteen Stock Option Plan [Member]",
        "label": "Two Thousand Nineteen Stock Option Plan [Member]",
        "terseLabel": "2019 Stock Option Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenStockOptionPlanMember",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "silk_WarrantsClassifiedAsLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Classified As Liabilities [Policy Text Block]",
        "label": "Warrants Classified As Liabilities [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "WarrantsClassifiedAsLiabilitiesPolicyTextBlock",
     "nsuri": "http://silkroadmed.com/20200630",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r274",
      "r276",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r416",
      "r462",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r274",
      "r276",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r416",
      "r462",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r262",
      "r274",
      "r276",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r416",
      "r462",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r262",
      "r274",
      "r276",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r416",
      "r462",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r118",
      "r119",
      "r120",
      "r122",
      "r123",
      "r125",
      "r126",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Restatement Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r118",
      "r119",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r139",
      "r196",
      "r197",
      "r314",
      "r328",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r118",
      "r119",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r139",
      "r196",
      "r197",
      "r314",
      "r328",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r218",
      "r275",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]",
        "terseLabel": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums (accretion of discounts) on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r44"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r44"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalty expense"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r44"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r59",
      "r60",
      "r61",
      "r453",
      "r469",
      "r473"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r108",
      "r109",
      "r111",
      "r337",
      "r464",
      "r465"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r314"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r111",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r277",
      "r279",
      "r317",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r279",
      "r307",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r91",
      "r367"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r186",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r104",
      "r158",
      "r167",
      "r173",
      "r192",
      "r333",
      "r338",
      "r354",
      "r433",
      "r451"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r55",
      "r104",
      "r192",
      "r333",
      "r338",
      "r354"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r182",
      "r204"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r181",
      "r183",
      "r204",
      "r438"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Assets, gross",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r280",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Preparation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accounts payable and accrued liabilities for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r39",
      "r93"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofCashEquivalentsShortTermandLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r94",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r93",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r355"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r102",
      "r104",
      "r130",
      "r131",
      "r132",
      "r134",
      "r136",
      "r141",
      "r142",
      "r143",
      "r192",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r242",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r242",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r263",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r217",
      "r439",
      "r457"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)",
        "verboseLabel": "Par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Shares issued and outstanding: 33,610,099 and 31,255,267 at June\u00a030, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r67",
      "r73",
      "r332",
      "r341",
      "r442",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r146",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk, and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r244",
      "r245",
      "r256"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Net exercise of convertible preferred stock warrants to preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r263",
      "r271",
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds/notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r76",
      "r417"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r18",
      "r223",
      "r434",
      "r449"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Debt drawn down",
        "totalLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails",
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r105",
      "r234",
      "r237",
      "r238",
      "r239",
      "r365",
      "r366",
      "r368",
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r224",
      "r367"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Amount representing debt discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r189",
      "r206",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r189",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less than 12 months, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Fair Value of the Available-For-Sale Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Weighted average days to maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer discretionary contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percent of matching contribution of the employee's pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer contribution match percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage employee contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/A401kPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r91",
      "r157"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r280",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Activity Under Stock Option Plans"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r240",
      "r446"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dividends, Common Stock [Abstract]",
        "terseLabel": "Common stock, $0.001 par value"
       }
      }
     },
     "localname": "DividendsCommonStockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dividends, Preferred Stock [Abstract]",
        "terseLabel": "Preferred stock, $0.001 par value"
       }
      }
     },
     "localname": "DividendsPreferredStockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r137",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to the ESPP"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expensed not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs of unvested RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expensed not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r108",
      "r109",
      "r111",
      "r115",
      "r123",
      "r126",
      "r140",
      "r193",
      "r233",
      "r240",
      "r310",
      "r311",
      "r312",
      "r327",
      "r328",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r91",
      "r227"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of redeemable convertible preferred stock warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r343",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value of Cash Equivalents, Short-Term and Long-Term Equivalents"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r344",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r346",
      "r347",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r263",
      "r264",
      "r269",
      "r271",
      "r344",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r263",
      "r264",
      "r269",
      "r271",
      "r344",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r344",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r100",
      "r351",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r186",
      "r187",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r207",
      "r208",
      "r209",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r75",
      "r104",
      "r158",
      "r166",
      "r169",
      "r172",
      "r174",
      "r192",
      "r354"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r100",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable",
        "verboseLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Increase in accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r70",
      "r156",
      "r364",
      "r367",
      "r443"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r85",
      "r88",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r211"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r54"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r211"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r32",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for excess and obsolete inventories"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r78",
      "r155"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r191",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r104",
      "r168",
      "r192",
      "r334",
      "r338",
      "r339",
      "r354"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r104",
      "r192",
      "r354",
      "r435",
      "r455"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r104",
      "r192",
      "r334",
      "r338",
      "r339",
      "r354"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r225",
      "r434",
      "r452"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Present value of minimum payments"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r106",
      "r221"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 2.0,
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r106",
      "r221"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 1.0,
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails": {
       "order": 3.0,
       "parentTag": "silk_LongTermDebtGrossBeforeAccretionOfClosingFees",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtFutureMaturitiesUndertheTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTermLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r89",
      "r92"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r63",
      "r66",
      "r71",
      "r92",
      "r104",
      "r114",
      "r118",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r133",
      "r158",
      "r166",
      "r169",
      "r172",
      "r174",
      "r192",
      "r354",
      "r440",
      "r458"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r116",
      "r117",
      "r127",
      "r128",
      "r129",
      "r194",
      "r195",
      "r257",
      "r258",
      "r259",
      "r260",
      "r313",
      "r329",
      "r330",
      "r331",
      "r418",
      "r419",
      "r420",
      "r468",
      "r469",
      "r470",
      "r471",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesSegmentandGeographicalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r158",
      "r166",
      "r169",
      "r172",
      "r174"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r374",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails",
      "http://silkroadmed.com/role/CommitmentsandContingenciesOperatingLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability in accrued liabilities",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability in other liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r371",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset in other non-current assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r377",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Formation and Business of the Company"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r44"
     ],
     "calculation": {
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r69",
      "r72",
      "r233",
      "r356",
      "r361",
      "r362",
      "r441",
      "r459"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "silk_NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Net change in other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r280",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheetsParenthetical",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Shares issued and outstanding: none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.",
        "label": "Principal Owner [Member]",
        "terseLabel": "10% Stockholders"
       }
      }
     },
     "localname": "PrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from public offerings, net of underwriting discount, commissions and offering costs paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the maturity (principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Other Investments",
        "terseLabel": "Proceeds from maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of redeemable convertible preferred stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r63",
      "r66",
      "r86",
      "r104",
      "r114",
      "r125",
      "r126",
      "r158",
      "r166",
      "r169",
      "r172",
      "r174",
      "r192",
      "r332",
      "r335",
      "r336",
      "r340",
      "r341",
      "r354",
      "r444"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r212",
      "r456"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r74",
      "r199"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Change in provision for doubtful accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CommitmentsandContingenciesPurchaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r270",
      "r381",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r270",
      "r381",
      "r383",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r320",
      "r481"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r16",
      "r99",
      "r479"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r240",
      "r314",
      "r454",
      "r468",
      "r473"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r111",
      "r115",
      "r123",
      "r126",
      "r193",
      "r310",
      "r311",
      "r312",
      "r327",
      "r328",
      "r464",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r153",
      "r154",
      "r165",
      "r170",
      "r171",
      "r175",
      "r176",
      "r177",
      "r254",
      "r255",
      "r417"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition and Cost of Goods Sold"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r376",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from stock issued, net of issuance costs"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "verboseLabel": "Temporary equity, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock issued, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Outstanding Excluded from Diluted Weighted Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Net Loss Per Share Determination"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r279",
      "r306",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r279",
      "r306",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense Relating to Stock Options to Employees and Nonemployees"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r110",
      "r118",
      "r119",
      "r122",
      "r123",
      "r125",
      "r126",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesAdjustmenttoPriorPeriodFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Liabilities Measure on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r34",
      "r35",
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Future Maturities Under the Term Loan Agreement"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r280",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used for Estimating Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r50",
      "r102",
      "r141",
      "r142",
      "r228",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of Unrealized Loss on Investments"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted stock forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock vested (in shares)",
        "terseLabel": "Restricted stock vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock vested (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, vested and exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options cancelled (in shares)",
        "verboseLabel": "Options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "negatedLabel": "Options granted (in shares)",
        "verboseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, awards outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r288",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Shares, vested and expect to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, vested and expected to vest (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percent of outstanding shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r278",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails",
      "http://silkroadmed.com/role/StockOptionPlansRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r100",
      "r280",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Option term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r301",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansFairValueofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), awards outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of purchase of price of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r436",
      "r437",
      "r450"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r102",
      "r104",
      "r130",
      "r131",
      "r132",
      "r134",
      "r136",
      "r141",
      "r142",
      "r143",
      "r192",
      "r233",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r53",
      "r108",
      "r109",
      "r111",
      "r115",
      "r123",
      "r126",
      "r140",
      "r193",
      "r233",
      "r240",
      "r310",
      "r311",
      "r312",
      "r327",
      "r328",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r111",
      "r140",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows",
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r233",
      "r234",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r22",
      "r23",
      "r233",
      "r234",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Conversion of preferred stock to common stock upon IPO (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r22",
      "r23",
      "r233",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Share of stock issued in ESPP (in shares)",
        "verboseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/StockOptionPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r233",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r233",
      "r240",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/StockOptionPlansActivityUnderCompensationPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r53",
      "r233",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock issued upon the conversion of preferred stock into common stock in IPO"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r53",
      "r233",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of preferred stock to common stock upon IPO"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r22",
      "r23",
      "r233",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r233",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r233",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r28",
      "r29",
      "r104",
      "r180",
      "r192",
      "r354"
     ],
     "calculation": {
      "http://silkroadmed.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets",
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r240",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "verboseLabel": "Stockholders Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStock",
      "http://silkroadmed.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r19",
      "r20",
      "r100",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r363",
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/FormationandBusinessoftheCompanyDetails",
      "http://silkroadmed.com/role/LongtermDebtSeriesCNarrativeDetails",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://silkroadmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r12",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity, ending balance",
        "periodStartLabel": "Temporary equity, beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]",
        "terseLabel": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, ending balance (in shares)",
        "periodStartLabel": "Temporary equity, beginning balance (in shares)",
        "terseLabel": "Temporary equity, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://silkroadmed.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net exercise of Series C preferred stock warrants in connection with IPO"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r186",
      "r187",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r263",
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r263",
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsAvailableforSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury bills"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/BalanceSheetComponentsFairValueofAvailableForSaleInvestmentsDetails",
      "http://silkroadmed.com/role/FairValueMeasurementsRecurringAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
        "label": "Unbilled Receivables, Current",
        "terseLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "UnbilledReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r144",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares used to compute net loss per share, basic and diluted (in shares)",
        "verboseLabel": "Weighted average common stock outstanding used to compute net loss per share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silkroadmed.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://silkroadmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=116854557&loc=d3e20905-112640"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r484": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r485": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r486": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r487": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001397702-20-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001397702-20-000031-xbrl.zip
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M'@X:SW[W8?[IWL-HWPAY_E]02P,$%     @ 1H -42.S\""?"   6%(  !0
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M %8N(5GLKQ_E"/)<H8TE$\$G8*IM"1WEOT4E<X4%<<K%#/#J="R<IJ*/ (=
M^BHUR-H6F"@B^^I>"_$D*VSES[>@7AO=SE^H]'SJ'<W[OAZ&.(.O[\O[9J^-
MWQ[[<_6%(JO?E-V)=#Y1[3M<4HRFV6)%"O>_ZF/H_A\>PZL*_:N;Y.=C!D-R
M-6?!C2OA;:T7=C7;[W^0##U*T:6%<T8NG84ACM)*M=S7@S5R9Y==VPYD=L;O
MU*OE-KAS@?\3LM52<I:-,J6)W_+LVP\W>I@*]T[&GMMI.H'E]Q0NO[ZPLKX;
M#3 E9AKZ>19H//L]A_E/]\Y%^_;'T_\"4$L#!!0    ( $: #5'N@%<U@08
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MQF#)O!!NZ14"$*B6$I$_7ES#<_SP#A0#KC[KK7IP*BVXXZ$WYZ%]%?K7_:(
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MC;%O]0Y#D<XKPF&ZV]>PV7:=5I@3R 2UE%N$+261B4AL""PR0X #(4S,K60
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M#:^=K>60QD3 G"14:\FX%FF80EN/%<3=*1M'HN>WRG0JI"<^J#VNN7?2>+#
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M>@VZ+.T6W3E)YVZ<G<#=PB)Z4Z\D0AQ)98)FCEBCL+82/*DV2@!56C1O.D6
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M#]&41>4?3](^-Z&==XHK;FXQ9*ER:57%766=YDQNJHJ[2F8>(S-UN"L$;C%
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M;O;]T_F'O_OM4*-H^1Y=^ S6^%H 0->#"^7L.HKO ^H3&[Q*9N9!9@@BJ#(
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M&;TBEF5+.$]!61^9!5D+*BUG_#>\O85W5!\WMLVFY!ZQ;8[8=E76QKER+/)
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MK6]N]<=S56/_Z'@ A] ;=CY!J],K_X9F#)Y:-U*8561VX@S'HP:W)T_PQ?@
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MWMBD3P1OZ)7)'^M34[ 'RYD?@=N-[(GL>5_V?&"&&=ES8>QY;3!UH!*BR"1
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M<Z"M%QZ8)]8)(-+X1)R,5>V2"^ 9\ BU^:?CHDV-QMJ_A9= /P!L&K(=RU_
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MW;=I*FO?7+L/Z4S6&D0B60,0J>HD$U5<M^PI)&]E\+6]%6MKA:6UR"+((H^
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M0CG77H+>$%(K=WJ^%\LRRK?R(QB/IWIRZ_:OR)[H;YKZ3?Q].+B4"?\>2!B
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M]SAY_?.F$D-9W_L#EVA0@0*10G BM;/$J2")<L$$S:3AN<X\IJY-A4!R0')
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MU_GEN^:<YQ?JBE5=OR69N=D<<HU.W=\XLJ+V#S[B8ZGK 9\._G<VUH,X&@Z
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MW'WRN5[<.U9YC),4*<4%HCF.$4LD1@7+$ISQ3&4IA0.<$TQ^#^5GVV2SA.!
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M@DGO@4NFYG3.^]=_QAPRA>]4MORDFYJK#2Z&LN8TGQF+A$^]UW/<P\TPNKX
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M<,QX9[6W6I=)H0(GQZC47]VV./.LGCB(R<:A909;5G)V!C7ILEGUGM7OZCF
M6KV?"7PCL&B> AJR,!LI&DA%::9H=>H.@\WMED-8[&FX/9?8U!J/X [@Y^"3
M,8MB19.;73V95=)B3QZ,IJ> W^AA^GOGH;+#ZYPYBPZ/+^/)-V/BG5B^ SX5
M>(?^VIJ?3LS"+IC)7;@5FL*9:PZ*]0L,X3IG0[I%LM>.IDTF7B.;1Y#F FGE
MK>NLON3T+EN6F\7B7%79BYEN@3<GE:&DKV5E"/"7!M;U^-^O7R PPCVNJYF
MTF>E'#I#WEI@C6/3Q7G,*GL_ZO2BX535[+S![80WG8PF NC?W#,Y<Q=U+,L(
MAR\:#E/?T"N=R]$CQA;6M5.?&YW6J$-NP\'ITZ=[1XC?K!O#<U];'W=N'9E@
MT<V?S*I']\#B /VN;!JH+A^!)F')GP)SQYR99T](SX@DT;,E*%L."7[2IW5;
MYMWY7_A77H[LJ;8C]0^$8:@&0M+G77;M+=8Z8:Y>O'IQ]>I;+-]P8?TZ7-?K
MKI]=J[FS!2?2^__-4@"4;C-N:8Z].WI=/EM_)86ALC/8DF9%GPT.YD^[M)/T
M)[MWUE<=\BN4Z95Y:*'%RT\I7SA:GZ46$LY"PMD&4')(. L)9^L2SE:FRUR9
M_K*0+I/&6F)"*%=Q3A-)A8H9TYBF.:$,)_>?+O.*E]6_05[WFG&\'M?3:F;W
MUJ7-/$FWSL$GD7#)<XI1DL0:T4A$*,]R6$O)BPBGFL3%+KAU@ 8&_VZ4MNZ(
M]^A@)SP]?=U<.\> CRHUZI]:@$,#!;8?/VW7HV< S$?,K::Z.H'#%U2T:G+C
M[ '+UN>EK G[KQS"T-OY39:&K8 %1=Z,WGU?GTZJJ6N, $X:GX8P[/5+F/O8
M-D\H;= >GC5<'?UJ/SSG%ZU?:&4DK"MV\W5+Y@7GOM-#M\Q@74H^JWOU(NVH
MQ]Q&]5L#J#?[!5>,\YEXHP9VK9NCT@(NX%7MXNAFEB[GQ?IYP&B S7!&Z:"R
MQDAA??+=9EN'7UT::N056"G@W3=T:(A&&DOZ7]"Q9$#L58W;H:.BTU)7$(^^
M^/7W?@;0<(W)9!Y1]][=7T7G:^H>;9;@S27>K]X8>JE=@,5O$[2<@\EYCGX.
MY^]1XPX0XX7*5?.?EQW-ARS/PQ\O/Z5&,D4JSI 15I!TK N4<Y6@3/&8JA3:
M)N-=D%O/+9>RT?X>#5B&]+;C9?#]3HFOQJ-4VXRT4W/9Z,*<2K,"JL_0'=<R
M$YD8ZZH<6\?;%!(N?=T>I('YE APSEB_OF.+1A9:7M16E_HV(@L"QO"?YPL?
M68=NS^/5^F1LTQ-;%>@8K;.NYQ- X5XC:<#65C"4CH$-.R?Q?V83V%3/KBWT
MA_4PWUP<KVX.LSA).RKS2UF!HQAB$96MQ+4]7KJU-GS?K*6^: 96&'JYRI>T
MA63X=EY%^!DM:."S)EV(P=#=%& 80 <R!.,ZX-RH,!XS4BA))"X(S91F&@1'
M)JG$,28L<=B F-RB'KZ;-)#[T63LXQ!/-VWB_6%T].<GGHB$46,4Z30%6#)&
MD9""()4S1J.4<2F2&^7%1(*D">4TR0MMGL8XICR+>!2I2*>2IAZ+YS;I,&$O
M5^]EH1E.4A(AC%.%*,LI8F;]$=$L52F/B8CHWGZ,5P-=+*>]5-KW'G*PVR,(
M-$._[B8?K]-5"RX=:O0(TI,,*Q\L527=HQKYNN7A074\_"$_R8@G'.L,B91H
MHSI&%'$:Y:C(4B5IP0M%\UU0';M]7W9M;*+@?;?2E&]DJ4NT,&9N3Z-JDLE\
M^[-E10Q$M*VJ6-0/X>Z32L.)!7MZ/&#10/&+>FBK0ZRB:#\V^HY+[NYBE_,E
M+1!)- ?Z7ZO<#>[5Z]YXW4=#O[;^0]>KD/-I!JOL<_ H+*EP=I7FBY^FD)$Q
MJRX&Q@H>7:9E=ROE%]!IQ]V^>(>!\Q_@%8#\[=B&+0R5ZUDY.#?GKQH.VO:K
M S$QH_V'S< ?+@SXGQ-CTX^M-Z&CCV&3S:"G"$@<S/R>.G[)0,EE WW6L>]+
M#]'_*>S_W?>Q^3 VF^4Z?)[PTC?E&TW,K,T"@-<#O"#Z#-:P@IH6[W$:>D+R
M25>V?6#MLL1L;\!S0R<NU9Q+.3N;N30JE_5B301]JL>V*2WT@33&U"_PSE\;
M!^#$G=@59[)/RQ;]O:SG";>)ZB-C8(VG7:[HF9Z>3I1YP=MU\[53ZA=9F.,%
M*)T-)=@.KM6U-N]1.*"K:(-4L4N7P%ZB-+ ;!T(Z]2M>+YILL+[ 0LZ@>/!'
M+^56GY6SL[KU:^HVE:W#A%NBCCFB:-V,;O?7Y0FM21C8C)-S !HV?#Y8=FDV
M&2:.7UR ]W7RS9&U\[_6S=ER1\+RP.Z8-6D94)9JO:DGUL/0T&-;5F28&WB,
M)Z[O"C1:%:.R/FVJ/%S#9?O6+L/-U2@VFWRU ;Y^)^[9?6DL#S- #_98UE^>
M6^L7?GN"FJ=Y]J<$9Q%+L3!+1KG1/&6&F,90;Q$K%HLLE^D24D(2<RYC&L>)
MH-3\)E21,2Z,^:](&J=R%S35.4JQU4W.3P*DXECWL3UD\'>CKC3I>>6*%.W'
M9B\N*W$A]:^>B<^^+VUEY]%+3;:!&@?Y>VJ$&[1SKVR'HWHF3YN27Y]PV"0O
M@F(S,8K2M*D.;-(<FZ 9A #K<UOZ"%G:P$0L;Z]:9Z31+)/()=K5_=#.G&[E
M<_[\PZ%/E,U4LH\?ZQ/N&_269J*RK0.WJ6Z>CN'M2Q>N=$QVI;Q#&P>"WKWP
M )M8_-46\_?BA% ?6KKT.,.H.U00R'!UE4"-;!Q;3+Y^8W?76MU6TH-?12LW
MRVM<.&R#9&9:/@FX:T;?7#]TJ[]J4$Z<-MMLLQFK$S[VXKGVVSRZ<-:#S?TV
ML_SAH[B@F4\;\7!N;NG<X,T6/8/BT8'^SJ% O2W\GMO3X>"D59C-N/G,J!5>
M+;9O!?OBS+4 =_L)Q0$^?BNY:[WE"N.'3ARZ%EU?S>NLZF+FYC)BW0+UUM&#
M)TS,R?4A66$TOIFYRY8L0@8GF$ C=R[XUXF%Y!LC8V> )F3IWTX:$L]MY8 E
M;I>2--#CKV4U&7=9H^?&6'"WE>-"]PI_6WJVDA@J>>6L'HS,UKJV8#ZQVSU$
M5_5D/#9V@6&T7+KV7]^@P?K2CG1[\!,YEB&-<FT:)0YIE"&-,J11;FQ^84BC
MO'$:Y95ID0N&0&ZN+!AF>2PQY.FQ7 G*8YGD29Q&)-U;EZYYE0&Q62ISK8TT
MYW6K+!CC>332XQ.KH1K];U1^<5%JKUPV%K%1+^9Z?G8U/CZ%K.YJ>IQ.8Q]W
M<R6U44K-8T=Z[E7MP]:63?V<.^111.ZKE2F!5MEKE2JS4*U5TS-VS%+Z0#<8
M.GT'O@NHC]6*1+XY%_=8K2S/]):2X14]_* FQ;#UB7LWXIPSW>=Q#%>\V*FW
M\_YUI:TRY9R(\YF)Y73F]'1+5K9="^22F >!S2.L+\F7D$*EK58>@\S<.ZML
M^J!1,8U1M3*MQ(W#O=8GO536P%M.O+C2:[]0>V:?[!U24*&I78[,FK1+;W>Z
M< C4736:\70RO&L?_3K_/*!6&<ONW 8MAW[A>EO>2ZAH;0$?J;BPT965&S=P
MV%W-!* "35?+=6TPYZZT5=EGMO &WML,''9:-\127TK@ YMNV5&985>-=7HC
MM"I[G<VTO1F+V5B7T-7)8!W&V:J*;3BM( :@SFV.LM=;V*N]'(.#Z4V3J\:3
M%J&BRP8PC\31_P?[?39I$WNO,Q<SA%<_ V#6DD13SFH;3_7&YMGV)2/T,NW9
M8F+"=A..J[]7/MG92']CBX$/P-*-EQH6-:"M(_7LQ-QGKCGS/-F'8,!'9'3U
M@9I8'/_)?/]*/N:CBQ_@/^E*XX71\FW(VC!FPQ6'';'X]WR;5.!S,[)BV!5^
MVWIB,Q9W4Z,#604(O"_-(\Y=!Q-PAQBN-/8S\2G_#6OARK @+MLN!D823;Y9
MJ6A#2).9F!:S44N,6X0C=HW=/^/C60%%\:!*]JH/FA8-C0BK)M >"587G4YF
M-C_G^>6U"OZ6+B+FMLGH0@BDV9D8V>R$GFHI='\X%DX2H"7,+39/O?( !]9)
MV_,:=D@'I9-\+X_>'G]X_](L.H1^!H,7<V7IO0A=U1_-A7O/7#5P;SB5E4[V
MNV8-FBE:?YDM+;9^0=[JR(V&O ;3H!.]C5?*8U&L@&W<+:J;]_0W9&<]_D,?
MFW:GTQ=Q*/T5\GNM]@A*AZ$46P_QU7M#1YHW_0.=^@=W&_)9Z\ U%UJ7J@0=
MU#77<3=:!O;>2@A#6W"1D1& ]5!U4 .74+NWO[@\A3(4\X=AK"ZZP-5D#AG!
MO>Y\Q"4@R3F7KA=-PC5567BK_NXA1IO%\+B7'O&R^=2/6D&*AB$?NSYSIPI
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M+N\W$/3H*V6]HD]J(\>>]X<WU[#4Z%)Z-++=[MP8_*&<G\/\+>Z2IJ>D2_.
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MY%(GFK$"T40R\R..$.>0D:,E266BT@R0S4@^I$D^S-AR&DX0+8\I6K;?%-F
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MJ\V#[?8,)6D=!2%+#1(VR)P".R'X$)'P5B>B,&$DE<WSLGE> &\">$PYYR-
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M'?8D44Z<,=AY99S1CDDN'"M*7A/A;LK :F:3HJ#5B3J7/L$:X"XXE!(5(,#
M4D]/FANB %X!O$8#7B0A4H:%,5QP3I0CDD67(E-.*Q9$4?(:BWI3/E(23)1(
M @49<S%WSI'%$J"/TB (HU8P592\!M*1=]L*6J!Z=V]Z_:->WPYCY7K=,/BM
MVQO.K]K=PWCOI8%NPD7P..6T\I(SA:W).JOD3H7 6=)%5VT>:L^F<%;6RISL
M%-%$+.+1:N02=2@J&$8-$ME$6;P%EL%;H #>HP!>TI0+HX7S3' GK9;,2.<Q
M<8(2%@HAV5S4FQ*2-DHF>5"(".(1M]XA%[1"F%*K(E:,R;"R3O J4<U+'%Q
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MB8F(<VZ0%KF080PR,LFEBJS$4"YR#.5YM-PXY"WWE;GZPLT(6#B/FD: $6@
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M;S=B_0L^'[<J]S$S0A$$=H1&7&B*P!*A8#]D.%,V6"L](.$ZY;.^R>?ND;;
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M!HI)=>%">L*:\; &0$!"C&G!IE4"*S)>ZDS0%SYG\WD7Z6&K:/99EIG+URN
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MFX\<2IRIMOAB*H@]J3K8>3L13932$1PP1T0("^H@4J2MY4@)%065CN'46(>
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MO9.(JTB0Y39#C H<J0F"9&[MC9KM@WP)M7D_$K 0?X3!#2T]S2#_;$P?X4L
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M<IHOC\V:QJX9IRXS&?9+B#R6Q %'F]SWAAC[,ZUY?YE?Y"DO4V.1\R)]N+3
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MVSA6F 6Q:V>.X_J@HHW]B 7 E+UH;(6<64$R<*S#0,(%& 5!F$7CB#MFEB6
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MJZLO0F-$[Q@\S9!6R!$&*R1(E7](9G"![_G"%R)AF)Z;UNC=%9YF8 !YB<9
ML0!0PCHX$@$7GO'DO 0PG.$&D0FD%\"RN6!"M7H>%V49IM?A,QQH3BJFQ@S$
M$Q JJZM9#I(("6>!),:!70$3*;GRK10@QLA,1FINNN.),YPSV,\47L4YFMW,
M*/FE2.QC0.6M!HTO(UT"#?:U[S3P&$CO-=S<TE=J!& R+UB=?Y-.25CX],7Q
M!Y6J<XG<@'_!\_(&@V9Y0WR<V,0,S@Y\2[Y;;AQ8Y#Q#MEA+U1YYKV0LOY?$
M>BC4V CN#^P$Q'A>X2+X8KBD"FY^UJ@=(,*DO &56G@?X/.+/$6N5:/SE"7
MZ5H'9O]\H^YB!#Z)JR\5/A!:@1%2S<] LYC1"K \7#9L7@B&HL)P.@=>!RP>
M0)CW00W"ZS]S//B3I-68GS%,YYI,>(U*2_X-\96N35[2^HN%/Z(V V:;[4LY
MV3Z U]E)6'RV*N$'P0A @ )5$+ZC%H?8?M'YOE^_/%8.<4&:1 4Z6@,A(1*>
MYR"R2?$2+]*.(%@,DK]4''X_^G@$.%M_X;-1_VA$@56,.@SLX<4KT-SK+W)3
MF!' E/(Y)_33P41JVJMY#4JE@E V1XH0),**IA(ZC<#H>=W,$4//@!)!:BX$
M%)B4X<:+<] :1\:O#'!DI"ER#6F?@B^51+YP/G$45!R(FG),Q,LG,;P" :E4
MII:6,7=/ DEA/BS2\L %,807[T]'<#Z@0GK[F]X+7Q2@5=&5*)WAI6 \#3W[
MYL5+T[;4XUI2H+JSAE0[8O3 -^$Z$^(V(O$"D.4C\.PZGRU@67965JC5?Y"K
M_ )$,J6WG'PT7W[X!=[2V\QRAM@3(<N6&PK;HD5MFNS#SX1(BN=Y,:-O2$;9
ML (N $@&Y"T9-DS&+Y']2[* ^U," ;3)^@QEQ)3<-H"*@%+_[GU(VCG<4/,E
M)PF3HX&45NT*+2MM1JTI)':!OPE$I:A4!KN2K$'3 -(ZO\"/62HJ?80TF4]1
M9$C%(*_;[?4&WP/#J% -EE^;P*.PNQ*VAK)@1*);%PZTGS7J0"$1_8)+7L.%
MLK%>TFK$+0Z'>"Q)%=D6< 9,C"7@HXE3YZBF$X6_.B8Z._[8V9S$:*: ,3,)
M8:#W&6U#R&>AW.-N2@Z<1MW("#>7YO#:"B"3)]I5E6A>EB;^@90O7:&1>X.]
MU*"52-*GA=O?:0&Q./ZJG?:R L9(00*Z F'"U" Y!;TC)9[G4WGRZ3E8Y@ ,
MN2.P0*;H!9 &SJ74?'*D3!'Y!&T#U3A<%[$ U29>-^+U8  U.0;D$6+=4G2?
M4L44?CAX.9G//1&/W!&N 4V_MJY"B(T&F "G*B!2=4#^+*9*'ZPY>2+QS6@:
MXHT !T_. 6>6I./1TU0+EC6\%&>*22L4,[W??GCW^^DKX^W[CQA$)O\+8&*!
M/!SPZ^.\+!<@0($ 7V#21E67.4BW>2-"1A, ;.L5:>:Q"0R=3T!6\49_,3 X
M0'$#W8@5&L/$\E!-R$$?1;ZVT+]=-RWS@(44\LA;$W<N?2-*^$N#'58SQ6ID
M:L-J_65U,L15U-E)J,%;3M"J$?I^PWOKK>X.-%#$9>,"F6B]K"DA> IN-O 6
MX!F]DY"Z<\FEVT30$6Z&?X6+P9UU[\+?VLN@U/L8%\M 8N;(.#$5@7/Q."M%
M<@M*6L"[2^)+I"OCM0(9-D)C+@&5@0K@"5%2HG!^*^ZJ*O=[QM9+87!*'8P(
MOQ&F%@*0?"SJZEHL1B:STQD>A?XT/Z64XCI6H=D*=YX(C+J$LR-Y$$,6-0U"
ML:X[SBDDK/")8MX)F8P218#F-FM00U1E):H2/4+^^V:YL5/PY"[DT /1\IO2
M. 9]J$"S,AHAPT-I4?"9U(1SK*L!%)[.05HDG0((8B%OFCG^2*7E^*_18&U/
M(],<)E4I:LI'R-G8R@KPUH3<-M\[F.B/.H-88$32O^32>.)ILUI^^;UM14<V
MJ)=%04HLWCEH2N2-0.,1\PDOP<!180P K)1^N+.<O/?B=S6P\\A 4,S/0$M9
M!PN&_ML*/3.+E9/ [KR1LQ4&"*]&C \5?SBOBE3H0J4(N_"O:' TQ%:S>5$H
MAU9[%/CV_\CR?&G?"CD;N.+%&K_9L <2OQMVL?V&W.C(UV[H" 4]V#\\OZ#H
M2G=14L)S,DE4W& 9$,(;OKJ-)VA8OJ]S-'&JK;24]VE0*+N Z8!J0C,15\E(
M#Q<I/_#Y!=HPTX(E7>0GP2HZL.-0@Y[6*KE($F'*XYD*E:%XJFM6GO6"92))
M5V )690JF-1JW@:U+!$I!.N2"<C00'L&_9FE_('_9YZC:BHW^?W8/?+$@Y)\
M4=_#ZK_V'-^'WI%GM)]V[D(Z W[!\X_LWAHR0HF>R_ED+CP9*4<-3#S@V/91
MV'OBB?D7;5^R\Q.VZ&Y#8V!EQTI CU['Q()1:(4CV_<T!K),OR/\8^O%IJ=A
M<7L4.>[(&@?J2>3@Q (4>ZOYA.647.N-PM"'[X;JNX30:J7V0> 3,M9Y8Y9E
M]5C6GJC0XIY>*SZY= "ZM):S$OEL$8)CZ\COR 0E)I40[RS[6K")XF)UK<A?
M6$ZFWUPSM_</VX^+ID+FH>'\LL@D6;IHI6LJ'5QKY*@]LAQ[Y#CNKI)THQC;
M+U1#WV9..1 *L8S.?MXBN>GGC<K,X\CP)9 Y./,[N@7(-L2*7[S[]YN7IAT9
M[X%*^"1/=C_4HZOU[:63$[DKAA!))$O] R3W.>>L *LW@>_ ;:NL$OS"65'%
MJ+%(.&"N1Y7DM 09R@I2I#V_!/3"U'6IQS# N0LN/.AY*9"H!JJZR.LY\.^/
MQQ\^FB^J?YO.B#J=U90%(?9&WLIF7H/)+%S@?\S/,4Q#09LCXV..+E[87]E?
MIA,VF#@B^1_9WFJ?(RIM:J8BVZDR)L#X#.*0=:X\Z@R4;]!V&Q%VPV.NB\?)
M!&V%*=5\1N8GK5_R,R8#UR*"SM.1=,\OVNHT?/W*%X77K/-&Z(H9<6S0[W!_
MZW*OT,0 :YX"->3=2GD"6VI4O%_4%>@A81E(Z-RUXE#M;5,9&/JB*<XK+<)>
M'I$*F4M75JTBE=O?)YS"G9-X*9IWNMMF1W!<H!A6:Q$!Y877HR1TX^L (]S@
M$RIXDQ2 1%/59ZR4H?M&4D"QD+D#J,\#N+\)2=)/%9C"(Z3"+I'&ZPJAQE 3
M&ZV-[8Z,,[S8$A>"S;,YQAG(4R3>BIT\)A/*X5695:URE&!0$+X!2G:-'Y.C
MDF*8(B@C8B2SA9ZKU@%31H2KO!3:]TBX+N$I\;($XZ48AJKJ7K6"B&RIK"=8
M2=HIN!Y<4%.5)5"^'HI ^X4EZ"&=59B7M0J^EI:8B."RBRHG^[PB%&ZABZ76
M+6Q/R0<\@=MLSP/BO !KXXR(M\"JKR](8"W=*9S%J&R7D=6AO<J1R)LNWTZ
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M'/HX*K"1[^>28W0M].=2.1.MT8$EEW F+KN;"LZKP?E+65V:Y]6EK#F>BE!
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M&MG[!_ZZ)/&E!2*GA_?[K)(X:(7P:(U2IPG9CYB'V-% G0.CH/;:F+952D>
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MC]R'U89/0<2TVUOFK/M$6<3EYV7&+JJ:F+X4L0BD"S 168G,&_>/O'Q>T!4
MCY_"U^L<22]%@0N\>YX!"0JP=FW%",6*ZE(IT\ A)1]*)>L?@3)>SP095UG6
M@(B(%R2EQ6-"=[@ ;75R+7D&ER!06^AH-Q'.LTH@3> O">6Q_S?%*J_"A?TE
MJ&4 J7.#@L9!.J0U62%P%_N'';,E=0>Q99O==^\BX  \01O,IMZHZ)?=J&A0
M@D73^OV4"6+SQH?_9I/I3R_;#OM])XF[*A$B*1#<(^^.! (LU6KPNZ]"0F(_
MY(  Y6FGEA-)K4 69=BTSB>"KI?M!%9V3Z/[QCH*^O"%)8'LFZHL>6&2TP(
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MG@6#U0K!]"XOUV2R N?&SI)V.%I&/:V%%#:-ZCIE4_^8-7UMVFY2V'2OFT=
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MT/O6=\X[X$$-\"X#H'ZGAK.>\LM)4%+0SQU"TA/T?U\ST2K%TNZ3V_IF<,@
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MX"^X%JVNW%LZJ7G?TE7BHM4D[@RIOPSW\H!7&X,VB#DN>21F17<D;LZ#5H?
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MBC_,MW<T; .G358<%!*\QXOGI S.@K=5 !/89#_)%2-=ODPP[^S\*-R4,SV
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M2^"BT4H)ASP5]^WV#4HK%8Y,9:;N-\P"KDIL&9MX1ZE?Y19MZQWY-,GE(S
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M(%F9P\00%65[#!@PM'X1A^%^DLB<9\UF93+'I;J,2=P@5H4W=RA]_(H;P:L
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MOI*-:M@).ZU:T9&=CU?>U.">]'4G/7YM8ROWG];O@PQ2VWU5!DBLK6^ZTF@
M/]Q6P>@:LW1SG_6>5#+Z"%)U0K*=EPDH[P9R?5$WVM0'U.%8 C[3J=9QM['(
ML\/[4NL8-POVZQ#NV>-!73&'II0J;A*_*4/GZ/-[.J0'#BB[N^18T(CDKA#W
MFDB/X=_=H*W)_ME1'05(8D:>.*T4;40PY\"ZF26G"C(I 3#HJ\GE/[3U:34=
M?U :?CLL4POC/%R1B"B* /YQ$U^F-/<]U1^N#(4P>PI_,;-TDP1UT$C@EJ>B
M;!*]C(W3<A\9D^^C9;+I5YJ0&.2B 1G+VIA6$P!8*FIM+_H; 5#/FVD3X)O.
M,2Q*^M]5W*:(#">V"#=7*PGEKM?!\HG.A041H2HGA$HEG@H4LO*922X4)5PX
M..AJ@K=N)<6E"H'>^Z<4B+@7NFW$>6;M7:!9RUVES:]_VPM9FQ@2$,LFT^=4
M.%]:A]7WC/2F;O2I#=H^.7UR^R*-D+-\]CAVL:&I;M30T?>-&Z0E3QN\O2VI
MX8#;XN ;5+P),I)"JH@43/@PWR/2W:?N=X=K.ZW"#A6D*6Y3KK)*>'"AUI'7
M$91\DV$?2[XC3;<S.:?H[]J+2AG!8 F'?\2:=6>(74:+X6+PSI KHC,#N<7:
M;"IG-X!F.6\G"FY?U90V'UFWOJP,)NW;7$V._<@OVY>-A(4,JAC)NBG KX+?
M[]0 $ 2J-26N>IH/Q'JU<US*#&+H3) M\\E>"_@3,:9B6O@LC\KJZ@$PITU7
MH@Y!AM3EQBWQ RDX%8N/S[GZ4+ QKV4U;K%'M&G591LD,<&,,%-O@LNBB,)B
MSQK"R+R6-@39R%-E ;>TUA%:N:*I'1&S\+@7FVV8T6AE0#OT&B%3.1LM'V3K
M!$R+%<7A#IEVH,/U $0)ZPV+ZE ^TC#%=BDME>RS=-$'7"LKX2\=3QH/C_C;
M>)MR4MR>^ABWD8R#V>X[;Z#JE8CZH&R\<S$U=OP&-<HP-X'%67@E5.5K2Z-%
MB@="$?5!(:(FVMLNAAO]HV;NNK8'G5.I.JM^\CX^?!ZVYSU%&P^=-W58'PQ6
MLM.R%W7?TK/:$"5+9>(2'$:L0?EE@Z5?6'M#,;5,(U:&8$@)]^P%N3W,4F*U
MJ(L*5VWL4.LWE?=Z@\DH=KDAIWW@ QJ94,<Q@==.:M2ID<-WD/8P63D"^2SK
M]Y7\':M:!-55V&O8@MBBR5WR6ELV HPS,R(2WSI$"=,B8O-"O@V!=U*HXMVF
M6Y#Q=G>T;JU2H()IN^T=@"C$R-#AD$:S3HVV=S"XFVC/=[!..;Q/KAP\'W:Z
M9D6P?P.XL^#W=&8!G-ME@/=&C!\_H2^F&UA?)3T0IG&I3;Z?UJJ-,Y>\LJ3_
MW!Q?<U:QAA,XD%^>3Z ?DNB#E:XH<YTD(*N*=%,:[ ^_$R0X9#.D.3FQ84$6
MP15H #GPU3EMR!YPXSQNZQ%:%"<, \4=\I@!>>(9HBY*V?H#B9R6SM(@L?Q\
M&T ZNV(C[F8TP S/.2'Y%/H.X"N4-OQ:=+ZT6X#C8/;["IJR)'Z2,2Z$OQ=K
MUX[6# [D19RSU\>**\++KT)AL*(R#H?DY1C$B<*(#5K4@N<(,R=] *+!.?0>
M% $G%"6+L&NF&4L2R>]0J;4-]1G\B3 LW=6DUB70MM^U-P1H'2TP47DP<Q=6
M/X1!+IEK$@=3S>&.:PY']Z7F,/X.I4',>Q>K05=^1?GOD"+\,BZ!QLEU00#?
M4U(L&KPU;1!ECS^I&RV-I^OP1IM3%(RX7%,('1#?=Y$7'KS<'6DGZ@"(#?0U
MY&A\EECLIGN[2W2N!S/"&_>#HP" ^9.%D]3:3JR+SR2%\Z9)MOIV@'6+AU9>
M_$150$D(.."A*@&O&9<,#D)/CUC5[,6,.]CD.#:D@"DZ<"@B,<&NHCG\1)I(
M_L]/2TC&JU07I(TV2Y<&PP*.*Z7T11=]G+=T?+)X4U$B7-Q BE, J=1P<X!F
ML9DA2R9,&305".D4% R(*&&Q*,HDV+@R27"SE4UF*BVK:F^;QM,L4%;1'@"U
MCC TU8PZMY-0Y!+1T^B#-^WGYVJA\S&8HN!<$F4.L<]?YK#'\?-G!A)$@9-\
M,/LU/*LL9:.@2->//-XY;F&5B6RL[Q5=I1$*9!M56@DH0@K*N8J& VI-8XK?
MKD9*W4D+$)/@V!&?A"RL^2.US(ZC* 39V\T,;5C@1MF#S;T'<Z#A13<I<^>*
MJ.Q4T!<4/@,BZ1[<(/:E=*F6^CTE[$\/2/E:F"_/;R.X'A?MQU40\!?M'^R2
M:WPUF9)[?U\/54EOUB@L;$V06JY%GF.$=]PI,[H3V%8EJCW.&4Y6#^:KJ5/[
M3^I4N)0B9:%[27^0)0:L3T^!"FVPKZPQVUR 9^^%>D,]#K]+G9K0VH12LQS?
ML6TBY*8";(;$-/YU6]PT,M >ON81;H>?N,5 8/GB[A*.4\-;6[QN-%DB^866
MFKIT-DJ0!4H=?L'[3A@;MSE^#T6%J.W)1;=<)@C<X*7;&5+NPW!71H=R:D!@
M@OG](%4D8XGH K:1--!P29:.<]]./N:#JG)BPJR[B7GOBI79;6%Z2ZGX WVM
M5$-EU$$8B*X<$#]*<&(5%V8P73TK)2H!_6,*L:]26PN:JL/-8I_?UVLA.1_/
M(.=<T9 T3(4OU*J(*=6BW %SI@W)&0X8II#LNRRZZLK<* (ZD&1$$(%I#U-L
MD9Z[(%<,#E+0GI/K'P$_Z))TE[ ^JDK[A(8)BI-^\D25$3S$#C [_&P[[OL,
M[B>]P\BS2 G2%()\%?9H+1)??&&,T$B^P:C$":$P0(SIFDP@R03S:0_FFO0M
M>'-T;.K.%5"797!JQ"#AI>?T&)?7&C?Y]SXC%XD!6\:73%;7:C#KVTG7-4D&
MT$R%TZ"VMUH5 98(4 M8GD)NKQ:53VBWG 7@SKL>I\6^MVH*779<%YYSAV"S
MD_PN9%?K4JJUAW'-NG4",<W>R<2?"$ZZE%X)*? +E(!HPPD+@-/>YK5P55A%
MB#0\;9]#B-3.* V2.LK3-2G QA&?Z2M*$9^U:]LAYA%54=/,44%)LXAG0V-V
M/$EZ"P^6LW@N>1U?Q66"[4Z(_8NTN0L:_3P L5TYZQPW&->K!O8^O?+.X^;Q
MQZ]S$ ^&;YS9N#B.I/ZQWC1953BN1FF/F5D;:(2CV8?LP!2N.A4W!G6.'*^8
MXWM$WR-LFL..'J1O]\-C%P.'(C&^F[P>TC/7$\.%4H;Z](PD=IV=(7\HP8$4
MSJ=M,EQA,TF1]'(5 C#H%81VGGU^^B[K\S1:CA;O+?BF5I@&' 2FC>RKB!Q3
MP+%Q0V ,PW"\<^LXU5P91556AL(1!P2B$P]/FXHL=UMD.;YO19;[,K/]QT,,
M-:.%V1!  V>J!- 4=/.S8&G2 -TK4]S 4ZR738IZ^468E!AFQ7BX>;1>-0NW
MDF5+$J*?X7V0< 33SH'1;Y'Z:$1-@*MG95_&P-OGM%$F7,"J4,M5E*AZJ) T
MGJ<'>1<SQ^LLT.- UPC48 :98X*^>N[F'6M(=*TPR)5A47LHI$%6ASX)7BVU
M]E_$%]S>S54<S:YO(^JT"$%P&\!CQ@O34,NLB\GT_NF M?3]'[8CG!>N3 69
M]-[>HX #AR41MRVED+YF!-B$"D_""+40$.6W90\9"('N>/)X<-P'K35;:@'6
M>1:&W8O"$1_RSPX=T&BXY<L1GG74,!R3.:>STI+T9RC(TVT .PU+!_2#DQVA
M%P4A$@'K-"*R2Y>SP_*4"GV#Q4'1_FR;G>L:=&7;A-(^ : /M]GX#G\O:7GO
MLK('JRVKT$\HMH,O,J[62J#^)& ;6OJ+@VI+1.#@<6#6)\^45BVK"X7B07%.
M&T+6.:+(I;7Z$2N>R*?MN"NZE RRE=G#^XO'R/;++Q"# @?#7E=)J,H1TEMW
MO^O9:) JQ[3H 8, C"1*\.$$#89G_S!;N>;4W=UI3A*L!S#F?H:P,#ZD5NP\
M_7HBU.>PE#%R<,H;*4ZSB@A]@E9@)"YJ$V!["@B7?\#2@N/C8.+P5L9Z:>(:
M@8*N3@L-F'1O=$JS(A0T^)" $QS:8<H-M*\:YD*D!H_$QWBWLS\*M!\8GS%:
M&SB)*CC0<WG]$@)DJH13CV=P:#T=Q>!M:NRW;'KP='%M>I@^8:=VVHF/-FKP
M0?*#4="[Q4?(^N0F"[E"0MFJ&2:K)#6M>.?=Z8NZN/[KLID.9A;#=8N^$Y]9
MKRO+[2>AMCP>!93I)2.$#8[;_NX3M2E68/#:]IY$@M&94JC\615GB-A"0'5>
MQT*7=.H0.!]),(_FCD<EW@POD-LQ]J(OJ<?&-S2&3(VJK-X'[]!;+[_;+?<
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M4<:%!\-0Y5[2Z($7_?Y&F^L1[JX-N.GYQ:/,+.OO3Y[NZ^9"9,O3'^3%]FV
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M09]92H!'N#I:4\AI*TIWW*9)P(4FOK<+<QK"T5S9#0MI6O5;XD@ "@[EO@0
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MVJV(*3SI97"G$G))V)X!^5Z4>N$E"$:WU)@)*/]@8O^: 3NN@;XGXJR$]?[
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M0E5XYN!1'^H2R"-%F[N1@)"^2$"<['\,M\ YQGP[]@Y9/83J&^QKS>W[T=H
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MP\-C,4?-G@Y51!E%WFE4G&%UK-H WI&=9<%$]PZV#:7MKT+& 5"JUUI+A^F
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MP^-$%?A@"'_3LA4=O!H7]U9&J:C67NZ*VF87+ 40-%0G'>@[-\8O?254':1
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MK-(-3#[8=M!@L.]X#E[DPXM</WCM:/2@)4I8T*R0;\W6ZA+/1T;&:IE!.0B
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M<@Q3Z$HM78 ?+-X!VT)_%(H1V4*(SZ1RSF35=C757JT,17-B]1JJ^L'P^L>
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M?O*M7(M7V&^QR&(X8_ZB**1<?!)AQ9BB<54:YV]CSU6"Q:<+DO<VO:_207,
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M[2?D\K>_^V3W=\_-IJ8??]S__:<W'/L1?Y_4C99+L\ .Q!B77!;JY$A^) X
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M-7/+Y773O'N-LC0WCU;TWT>'A_]&[Y>815'&=5KDW\\:T'N%C\&(X_LQ4OO
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MM>SE^\<T?;0@@(QI0C_\\']02P,$%     @ 1H -45OMX$5;'P  "#X! !4
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MUB=5D?UAC.>**,.=#3@=XI4/30O/AO'L-Z<^P'3QW<GQC!QX_V7R?#;#1T^
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MU670[=(\N#Y#;JRQ5C=,O?V$PV&<7R\4E"+D+!%)M!DS>&$XL50FPIEEPOF
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M-HG=>G"7(I;YQ0+N+5BV7K_$TR9&>_U'/X6]?*5.\*)(T&4NDW*.!,49P7R
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M& \E9; Y,Q-#W1UHG_!<!I94M,(48;%-_O=&- ?7"H=:Y&GQS%\OZ_I%/WR
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M=*!_KWWOK@NO#K1,*CE!.I"UDG9 R8*0R$HF(Y"L>]^H&LZQ!OAU)AU[)AU
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M6>24UM&I]:E)1K>R'KV4\CC1/9;KRT.1/O12<DLAC_JXY4O4\6CG;80R'B<
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MORRTG+U]>)POGJ74?^7E)%3&F"0801Q2/0F- NT7XHA!$<H(41D1'CI%G?>
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M1E9_;K*61HG'D]A7D.@_(<(\AC3!6L@0X6%$$ [CL*]34W:0IB9XU0$<OG,
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MFFL7U+1VHU[KN62:W;V3LIC1P/=X1!,H*140>1)#0CT]3)"(HS ("$Z$S;:
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MC&%4^>K*T+ZB=7Y.-Y%[^_ X7SQ+6:VBR^/)+3X:1\*41R[S6!1?C'8T?V_
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MJ(JH9,N9\#4)@9 P8DI"<PH:D@"9':4H#N* (!4Y92<[VLK4%*L$";)%!FN
M@):(W53L.*%V2G4Q30.K4<50!;!,0EM#[$]K6AGH4T^.-S2J9K3:NJ\+[1=W
M^_9O=>=^U-U=QI)&E(=2)!BJ4"B(,&,01S2"4<B4XJ&>^41.N\;-AT_M2S?8
M@ '7*2)WAS:[#[LK&0-_S]8\.'_'QPSN\_/=>?ZH7^TQR_8_UJ/7=,T7M>!_
MO"^*E11ORI606YFG"U$NDWR4?Y:_*68T8A(+<P8?<1\B$_S!$JJ@)Y"4$58$
MQ<@N58E3NRZO\CBI2]Y^DSE/"UD=S&^<O/_S7$V>"]BWW.CLF]&A]SE+WBK
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MXWJ:NI=*/>1"RZ2*843-2JTR)08CY<. ^@K%"4/2+3F0?=-3$]5F'O4:.VB
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M$A*E"%0T4"SRI/ZNJ5O!Y;T6IO;Q&H!F#>ENL1 %*!;STU5]+2FTFQU>1,S
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MM:VV/>^#*&5^2 F,52 A8H1"[0;XD"KI,T]X,4JL*@-U:'MJ4O))"BD?RC-
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M!'*%)42*>Q#[.( "!TKY@OL><=K2;VUM:MJ]!EL>@Q=;N&[RT4ZPG7[T1MO
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MK1\FD$HSC\0^XB'V%)-.9S6/MC*UT:G\W.06I>.RZE$B+==3+Z5GC!&D 7"
M\Y>M%/2Z<GJTH7&73-ML/5@K;;VXXVF'VYOZ_32G)<V>.Y2^BB%*,(-$(1]J
M'S;BD?)HR*G3D8;UDZ?V<6M@CM'R&X[LON%.E@_\W6I, WRJ!Y;V&KZ^>?BX
M,>K[-AT$HA]<T#':W.QWO#I?\_?5B9J_IXO[OOTF<YX6\C9/N9PE"'L2)0**
MD!*STV&"U,,0<I]*I#_J).1D]BCS="$^+VF^M/N\1T+O\@GMVS#<U_1*WJ59
M68J<U>5&S![L;Y_? (VAVHMUW(H=ZV4(),8H0!027W]TB/B)5GDM]3P@'B51
M$@KJU2_#VTQ\YZ_"VH+A7H2WU0[\]_86V(UC$^S7@4?)TAQ8%ED'39M!PV@3
MGMN\KC8<E)9?@=KVG>""*["V']0$@#4#H*2@Q\,:X_99KV<\1H(^[M&0<?OC
MX$3)R,UW/(A29;G3C;R^-\!,WO6W>;[(7R_R7/(2R>9X@20!QQZ*8,2T)X,"
M3B'F>AB+49 0%1+/9TYG[EP:G]I49HL=U.#+^(02/FC@[UQ(VZEG[$:5H?@>
M>&CHDVKWLQD=..OUS(5+^^.>I>C S,$9B2[/Z!Q-_)C+>RW$Z9.LCF!44<K5
M?[?E[U 8) F7%$IJ:O&P6*M<2!3$7A1C%C.M=4YY.&T;GIK"[> N$WP[A[C:
M$6ZY/#L C4.OV.XP6&$>YYR#*UD]1\7:M3UVA*P3(T>B9=WN[^G,P_5J>;_(
M30+T6<AH@B3B4$4!A0A1!G$@$?0]1?TD(%J:G):)6]J:H!8=GGB@&[@]QN$W
M^(YCG@2QYT$>(<VW%)IO$BC(/.2%F$4RU ^Z[+Q#-\9'/>XP-,O6ZM\'<\,+
M_L%9![!%.N!)AT,Z!CWHT&CN9<\Y'-I]]IC#D5LZ[B+P>RE6<WFCCL_U/TGM
MN*9<3]S+UG_+TF51SO#K<[W/>W67$YZHD 5:95 80414 !DNZXW),-%3;,ZY
M4QVAGO%-;4Q8FU>F #RQ>FCJ#JZ-K).VE&962X;K<_W/CDO%/?>[Y9+PR_7F
MB$N_FR7=[3K9B3Z\VO3>(+6Z!Z:]U]7;GB&.NTH[#+\'J[$#-=-MY+C-TXRG
MCW1^\V<F\SK"(?$EIHE((.,TT.Y]C"$-)(6Q;]*9Q9$7*:=UAV.-3$W#?>__
M!LW42VY"?)1&.S6]E)R!)7$##Y3X!H@?:2.@3W$ZVLZH"M-FZ;Y,M%[;O9[L
M[7I/_ U=REG@(X(BI"!59H&1$@I)$@8PPCB)O-A#R+,ZKW:RA:E]Y9M:J15*
M\-8<Y-0XW2O)[A+9_JGW0L_ W[DS,YUJR!ZUOH<*LKO/';U^[%&SCE6//7ZA
M^^?\-EMJ3^"3O$O-CD2V-*GO9U@J&GDL@<2/F)ZK\1 R)!CT0S^(DT1%H;2:
MM9UJ8&H?<X41;$&6A1KL/^6C))[_DB^E9N /V9$5I\^XS?0+ON*CCQWM(VXS
MJOD-MU[7.<W\XD%^7FHQ*(,NUIOH/$#R_R?O39<CQ[%TP5>AV36;RC03ZG(!
M"*#N+\56$W,C0[((1;6UY0\WK!%^R^6N=G=%IOKI!^#B3M_H  E2S!FS[DJ%
M1!+G?" _'!R<)8WMDHR3#$"$S9><F9^DRH420LM$>)44NC#.U#[HJB3B3L[.
M$0N7<'6SR .@-? WW@6H+A7+VV (7*3\[%!CUR5OT_=,*?+6RSM'03T_/B_,
M0^7=]H=:GSGLJW:7">:IIL9BYWF.#5&H%)"40Y *;?Y$#-#2JS:B\\A38XV&
MX%$A>73NM-L[Y,EQ&MPH91!P!R:9V[NW'Z/;[78]Y\_;PJVY747W;%WP3?B&
M>[X(!0YM<AQ\[+@F/TS.!#5Y/J!KK$!=D[SJPU-F]G_<;)Z53&8REJF(40IH
M%FL .=* V\+@FHI,4:93*:A?N$#;<%/C)UOL6=61WBL=B4+Z[=Q^468VM%JO
M#7.5W1+^8/:TH2P7??0WWW/NUAEQ/>H.A?/@I]V[O@=U%ZZZ*DM42AORP-L%
ME+!GWJTCCGSL[:+]Z<FWTUW=R&=7I/J3[0A3-X)Y^6P4>E[;U6J&599))E,#
M,&)F.P4)()@B$.N8Q3C7&=5>[0BNCC@U"MK7CU\4?8_JGE$O10N!PF;JW$;J
M.OQN9!,4U('Y9H]G(>S-KF74RTVT%S@<YSAC$Y)VK@\Z*O,X8W!,/NXWANH5
M>+]63VPNWU7K=U6%\'99&F&WFXW:;F99K/)<8@(XUQ! 9>PA%FNSB:,\YPQ2
MG%(V6ZKOUGA[Z--$T$4:IV^+EM_6B4Q#'CX6HAOSJ9"YS+8H^:J:NX@5\O?M
M?.<T8\[>HZ$FX%6[X]5S48E?3$6YW;YMGX( K?)\$!RV>9Z3)*_<3L\'K>L-
M]KR>UM&",\;A[6*Q*EJ4E$F'E7<EE1F4#-MP9T1L^"$&/!<:J(0)RC.5Q=*K
M\-#%D29GL1E!P4[2*J'8TS"[B*JC018"JZ$-L7,P#>"=NHI%4,/KXF#C&ES7
M=#XQM*[>T#5&;264DIL/1L2RYIG=I12\5(1H;HIJ:8O%YDX7G/31;#:K=D>S
M1&I,8 *!,:>43:'CQLI2,>"*VK8=2,3<BT!ZR#(UBJE5B>S45S4XS8YPI<UJ
MOQ/:-PRN^TRYD=)(^ ],6X?0[_6XB1J:%!96H8N=D]+4^N@P,QT"\'IC&C9.
MK[LX(X?S]<;M-.JO_R,['SS:/LI?5B]L8<=\6SEO4I4AJ.,<$"PX@!@B>\Q(
M0!:3'$$6TQ1YI?I=&&=JY%CW E\7<K[4.U#O4\2SF#J?&?9%:N@3P@JDG8@W
MT=O0KJ\K* 0^!3P[U-AG?FWZGCGA:[V\&QD<EE;_9MZ!U7IK\]1L\5GKN3>,
M]#A_?BRZ;?#"CV]+7[U=;;:;SVH[BQ$5G*@4Q QG9ML&!>"Q)"#'4"1$\YBD
M:0??5D^Q)NKD^J0VFW_4IU6&Z<VS55EC1-HN!++2K6K38WXSK_2*A%7,CY+Z
MSJP;=8TQ4:_4?J.A3%1K$_U2Z?-KU1F(E\>.Q2052MW8EK_A2#$0OB')LZ](
MHY)L(/R.R3C48[N1]K>-NM/O-]NYV<JIS2PFG&JL)<"),H8;I!F@B'# "<:Q
MTL9^0UY)7(>/GYJ]]JV,K=C)Y\>*1]"YD5QW0 ;FK&,LQBGT<AZ.D!1S-,*H
MC'%>NV,"N'!5QQU9X5JO#+I]Y3LM4BEQ"E)"!("9;5D8,P82AFA.$::Y7RS5
MV5&F]G6_/3CL^X?G+NPLCHY[L+[H#+T#*^3;;;N&J3O7AD'0_=?9@<;=?;7I
M>K+W:KVX:S!![= IPS,_+LWW97XS2V"F<IY+((F0 ,8J!RS-*)#2$('$7,C$
MJR3'I8&F]NG7<D7S#F'<%]%T/<KOC]'@A_6UB+NJ;K64(0_DVW$(>^1^8:R1
M#]7;-3X]-K]R?>_.H_43OQC+HNISO_S^0:E91E#"$I$ B6 .($(<$,44R/-,
MBSBG6"C<L>?HI3&GQA$[V2*M'!G"!^%VLA@(M[']&CN>M4+?1'M(/PP!:>=.
MHB&@?:T>HIT@[M,\]!I8'FU#+S[JM1J&7M.MI57HU5M';N6R:^UF#,KGQ[+F
MN@VSLC6 WLU_SJ5:2BOK#!.!F4H52(6M>IYG$%!M0T:9X#SA2&>I4[F.T22>
MVD)1RQ:]S-7B<D[(*TVOFU$ZJ4D;>)4*T(JCT2*SH?=-5&L>[=Z)+T&JG8P^
M39/HON$L]%^C[X;O' 3KN.$]<->(NBJ:MTC&NF?KNW61R"Z+L>_5NI!N)I5F
M@F04*"8U@*EY83@F%+ DE=KL.91(O7P.;L-.;=&X/\K1?&+KZ&=!*'T[/3E.
M@]NZ$![<@<E]CVN5L&ED-F]Q6=5"5IQMY"[9/62XFP]082/;G$8>.8C-!XW3
M>#6ONSL>;'[]Y^JG6B\M2WY],HRXLGD(UHA_6L\W:F.M^Z]*5,%R58P[ITC(
ME)EI@'$.8&Q;%HL< L9%G&1%"(I7W%H7(:;&9-_^_O7OT?>=&M%F)Z_G<6F7
M"7$\5!T8YJ&/7K]&>_G!IE8@:FA0AH?L=1@@6Z$/B$$/;+O(,>ZQ;@^D3@Y_
M^SRK&S-^6BV_/ZCUHWWT/ESXRRY:^$[ORHA^7'Y6?VX?_E"+G^JWU7+[8S,C
M.5<Y%"F07"4 ,H:,><<%P+$D"58PI]KK*+F7-%/C2O-*)WZLV&\RW.AQ-(@'
MYDFK!["*%&QX4Z= O-Q$_ZF,%7BW#&CO!<$L)"WV$VA4?@R"W3%1AGFHYXG:
M>CO[*M22K>>K;\N-V5'/]=SLJ5>/;+Z<D9AJ ;F-E1.Q=:QJP(B$(,4DRTF"
MH'!K)]DZRM08KA;4QK3N1(U^+X5U++C8#NN5@[-08 WMA*QDO Z-^UF-B^HM
ME&/N;]"-^=<QU;0/,,Z9C8N.NU,:IXL[.KLJ6GE8W8K_>IZOU?UZ]:36VY=[
M,\U;V^;1_/;)7C)#4+$DRV(@=4H!E#@!G&D%*->YS(7(<"H[Y"VX2^#TVK]"
M'0[SH!_,;EY6.GJJA"]BW54MN:?GRWU.'+U?82$>R0-69WIN5U$E=E3+?1,5
MDM^4#6:OHNSO!?,&+*@GS'WT<;UAWJB<>,3\G^!OR=@>,77=6?E_GLO(H[IY
M"Q5QAA$'"270<)CMS9A(#;#2E,-<QH@YQ?U?&6=JUDQ#U&@OJ[L5TP;I=3LF
M$% #\\T7]7->%TDT)O9J735[N&D@%M =Y0A,7SNG;8C1+!T'/9NVCLOE7;M"
M/+ _/TJ;0:CGHCAW_/Q<O,64XXQ#!H&$/ %0*PVHLG&#<1YC0;(LI4[NGJLC
M38T:2F$C(VUT*&Y4RNO;,>(2P.TT$12V@8FB,V(=NDE<0:-W6XE+SQ^YO\05
M-4\;35R[H4-$\8-Z?%JMV?K%VB#;E^+,KJS!^NYY/5]^+U>#LC?I9_5'\:?-
MC#*10*G-?HC99A2$Q("QA "$=$R%PDBKW#G N),(4R.4G1+%]L?:ZE4?Z'FA
MB7]WXAZS<\4V&07S@=EH#_?["NZR]V:I0U0JL3-E2CULPO4?Y16.AYL]YL C
MFGGPN1@IN'FP.?&+=^X%9VOX<[<GCQ<-W4OS@^#H?D_JVC!@UPK[+7N:;]FB
M?+ZQB]7ZIY(?5NL/S]OGM:ISY&<$L8Q)G@*<,0(@IPF@698#S;.,8XQ8PKQJ
M>'M+,+5%J.KP7L:DK2NI(VTV=;J0>U\FQ'LYZCY+;LZZ0;$?>#&J8*]"UBKQ
M*X*+OC2GH51A5P@D9 >"CO"%;4K@*\3(?0HZ8G3:NJ#K@SH7N]3S[:?59C/+
M).:II!!0@G);1<G\I# %6E"H:!XCK#W#;^M'3XW+;(N4A9'+N]ID#97C(4$G
M  8F%*M[U<_M%RO:KS913"R>96% V0(R-M_AJ V3+5Z_6FZ-? M[6?B4WU.H
M I=XK)\^=L7&(ZW.%& \OL+?#_>P9G;VOKX\\M5BIEF<)$S;SQAB %.1 I;(
M'&!(4FCWU HY-6H[>?+4ON)*N*B4SMVK=@C7=2]:9Q"&WJ>ZZ>_E(SNK:P^?
MV.'S1O.!G56CZ?,Z?T''1$SQ0\GGA;K3-BU_:<!]J8IT/%C^M-6/BN)',\%3
ME,&,@211*8"VCR)/% 4*(I$R@J@27C'BK@-/[<.MY;;G0K7DWD'ASJB[K=5#
M8#GP]W\.QI=&;9Y"\&&*;_FB%31IT'7L<7/_/!$Y2>'SO;\C5]F-Q8_5PMRQ
M*?TOGU=;]45)I1[M.(<)-H7OI2SB-A,$"<J9 "GE'$ *<T 82T#"))<)EI1#
MI[H?O269&IOM18[>-EHM'J6;>9);YVER9+LQP!^:_AHZ_*UR"T=6C9NH,24G
M67^%,N.4*.R-<E#:["S,N#S:%[,38NW]P.ZY,MLJZOS!/***44Z-U2?S& .4
M\PQ  26@(LV-(<ARG.-4(Q3[)L&<#C,UCBSR+[;[_ LKJ6?H]Q5<W7BO/UH#
MDUHWH#KEJ%S&(73RR9F11L\JN:SMN721EJM#%NN9)2F$><)C(%0& <P0!SR5
M'.@\1RFA6:J$5[N@\\-,C0T*IJW*IXAFF95.72\N0.MH"/4&;&@KYURIF7UA
MC[+_*]O\J/LD#EU19A#3Y/Q($ZC=<M&H:+]Z\.S:+\IRDGGTG?XPWPBVL&F,
M,YK(1&MC6Z2I(@#"F-F(2PW27!IKPY@="?'R+_45:&J\8U^_P7)LST^)NUDR
M%M!C&#!G,VUWDEM_52E[D7W[*IFWK3"^4O+M>9FFFG_;BF"/%-SVYW;O+[0O
MA7#[D\T7=NOW8;7^RA;JR%^<(*13SC* N+;G9RD&%&H"!,^)BA,&5>JU0_,9
M?&J,V:AF9S[:[0\5[>0'1@%@-7!J$MA_6MR8="BP!V;-HQHM-PV8M8%Y8V$>
MTI_?!;;0W7R<QQ^]=8\O,N?Z]'@_HRO3Z?G26J7+,H##6*4V$?#]X]-B]:+6
MAGO%C_GR^\'?E7F);>?%A.>IPAIHB@6 6 E ,)$@@S+#&4]PCKSVHMU%F1H+
M5F)9"GRLI(Y$0^R:&U6IFOK;)C(+FR\7=IXX5V8<8SH&Y\E"B:@I99&X?!/5
MBD2U)@<7W42-2:PN59N_1?]<KS8;N[$.R:5]@0[+K)VE&9EG^Z)VRKJ]G]B[
MB\*G^7\]SZ79_KQ=_51+MMQ:(W@60YP:DU(!QA #4)@M.LE3!F)EMNPR%@S+
MI&,+A;,#3HU/J[,Z8<.5GXIH_\X5_\\#W,Z(0\ VAGW8K.V_$SBJ);Z)K,R!
M@>S<-Z$WH*_5-,$;V#X-$UI1\NB6</XYK]4JH56KECX)[??U]ZG.DIQPA6QL
M.\G-SEZ0'!#)$8@%I5(GV%BZ<+9=;=G"WS_JQ;&[(0:T6<NVOE7E:&NYSI?S
MQ^?'J':Y='>$=G!J3HA*#T]8AW$^#NU(?#VGH(N#K^<GNZM);[O8+E8;8R5L
M=FT4<4S-1YQR(!*S-862I8 CG@%$8I1@HC3C7E%H;8--S6QJ..,:TKKT8/3'
MV>T3#X7>P)]\=^"\6< %D9"LT#K>J"SAHODQ:SC=TW$3]AO[TZYW;U;K]>H/
MN\]CYNTPQL6,D53E7"B0)S8_!EO_/LV+@"RS"U,28NA4E^;J2%/CC^)4;K%B
MRXA]7ZNR=!5[M'W"/7<-%Z%UW'>% &R$#9<]O"P$C7:21K6HH1#SW&"%0&[$
MG54G!/TW5-=0N;J3NOB <;=0U_0XV3M=O:%C)W AUJKH(/1H\T'_NWA3[K0E
M:<L6F]NE--N+Q_GSXZ9Q]C=CD&12: KR3!ABS1D'3$,!\CCE*(TQE%+7U4S=
MK+-N@CA]#(=%30=FWJ;X94G34NCH%U9K:'\M:[U^C<POYGN-;J*E\JQXVG$.
MW>R^ >=EI#[F.]A_::KPJYV%G19%*=1:CQNG8V[_9N>]D S:#;V;)..V2^^%
MUDD_]7Y/\\_3?FNH^7:MV-N55#.H!&$9-/O7A'( =<P 0SD#,#8[6P,.)]RY
M/&+SP5.S.JULD14NLM*Y9VD?@-5.2WT@&)AH'+7WRM$^IVJ/%.V#QXV6H7U.
MB6:"]MF_=RW^M-G>Z7^N5M)^TE_5^N=<J,W7U4+.!(4DC8W)@A*= <AC" @U
MWR3*A4XDB@5+G6HE7!]J<I^ED=2N=M^MK-%FY=N>M@54-QLB#%1#?[X52H68
MA3U0"QI];8.L0XVE:VB$+:9T<;21JR9=T_JT/-+5._H6<:BC0ZJ'7^BMNBCF
MM# 8OBBQ^KZ<_[>29>DZ*^.FB.J:Z03'""D$$,<4P)3$@,0B!S*E*$Y)EE'F
M=-(_J)13HZ9F78-:S?J[.VB]W%3U)MHK:V_<JUM5A8P*A:LH2D]7^3 OAQM/
MOOJ4#TRQ5Q.<JL0F6=!O51/-ZF1FO'!>7IW2'M4M!H!\F%(8(05]I;H9 V!]
MN<C&$(-U=+8=A0/O X4/PX9GE%&%%*6 Q\+8JMHL*#R!.<BAS 16G*;":RUQ
M'7AJR\/M9J.L2^S[VKN"GS/6B98P@TP!H1(,8((TH)E9O'.E9)*JA*:*S'ZJ
M-5^])MI- 8;#^_UF.W\L6F3OSU$'@MW1^S@ E",<)UW)[PCH4_3$)Z@7T77L
M<?V&GHB<> I][^]:G*GJT5(&R-JE:+6T/L?;/^>;6<:DIC250-G_*0HP44@1
M2+(,2:FD8-2S %/+:%,C_2ID>"]D]+L5T]>.;P78T1X/!=O E..-6(?R1@Y(
MA"UAU#;@R&6*''0_+47D<I/_N4)%0"])RA_F6[.S3&.<2(DQ8&FF ;26"X&8
M 19SQ*".><:5Z]G"\<.GQ@R%4';'GZ2_\%_K1=8Q0.,L>M</&_I@,O!G[PN'
MU\G#);U[G#Z</'*T$XA+RC1/(2Y>TVV!WY5V_#!?SC=F+UHX,C^KK=U?%O7=
M-S.L<JE91@%.$GL:&&M B)(@TSI+$%<T3YS:'WF,.;5/NI;4MGZ5S\(W5MT%
M9;>U/C!V W_ZC1JP.P0+@6TCG&WI%"V%#F<#>" 4TA)P&794>\ #AV.KP.?6
MCDGAN^C:.]WT;WU1"[NO+UQ9A0>L\,+6'65WL> )PWF<"P%T;EOA0)X!2C,)
M*$X5-"\EQ[G7QJ.?.%,CJ[TV]@MKZA-5"I4G#S?1&4]W]^C]GG/JQG_CS=3K
M'C(,D@H0!KR@N>#])!HW'SP(>B<YX6&>ZM]!^[<R^ZYJ\$QDG$"8<K,AP]SL
MSQ(-*(D12!F+):8II@RY]LP^>/+4R+$2SKTM]B%.[2S52_N!":>2*W!WZ[/:
M]NUG??C0T3I8G]6EV;/Z_ 7=+*"[)[4V'_KR^R=E/NQ/<\;G"^N!*2OLSV2&
MM(10 $Z%V7,AH0!#) ="445BI=,8:;_CGO8!IW?(LY,W6EB!HT4ML9]5<@7G
M',(XE1D#E,D8P!0+0$06 RE2'#/$DEQ)'TLR',ICD.%%C*/Y,K*) +:3:?U+
M[WXH5Z!W,_C" 3HPO^ZQ+"2U=1LJ67<-4,)9<FZHA+34KHPXJB7FIOVQI>5X
M5S<Z=XK>^+PJ@O:5O/V#K>7FP19=:/[=&GN?5]O_5-M];,?^2>5-=]L?:OWP
M@RWOGNPMFYG$$A.2V83SS%AN4MHV:TR:7;&TOG4B<>S5%O;5-)D:.7Y;KO<1
M>P=%P441MV?VUL\5"M&7K]\\R?'U7A@WWOU+O :ONT<O*IU7+T"ABXT,K/M6
MEMK<%)X6VP,F>E';1@AH'2H8;DEX]0D+N=J\GC*C+F2O/F?':^3K"Q2RF47C
M6WWSLK^D^I0+0<IS[WW%IQ/!/JS66LUM>^/-?ZCY]Q]6;;,!8M_5/\W#M^_8
M5NUJ1LPRRC(J,F&/QLQN(J8"L%QA0%#**,N%)KE7\LXTU)K:POS%O'SKN;"T
M6_9^UZ4RYM^VT?NWK^]L#;^RX;MGO_=I -ZK4\B4WXX1U^N#8X^F8YV_G#OV
MV"W@98Q2 YNH "?:&G2J17US$S4 NHEJB*(*HZ@ *;(HN02H!FJ#\EKS/GS;
ME=$UFT";E]>:3;>V,J\F7=],NO.R%MV?*K'L>*6.F\WS8_F[H[K_7,8DY50#
MED$"(,T20 6/02()$3'!,8]UMQ2Z$.)-;;5N"!I]LXQK5NNHBN"W&Z7#A@[[
M[+IB9:^T[IH;%V2Z'1?C5YO$H1?51NYCR\)Y,%\WT4[%J#G_XS2 #CD!P^3&
M!9'PE9+B0J)[.1LNZ"@=T^!L5M<;)OYM=J^[?(KJ&!CFL<AHD@"%B#!+@,X!
MM;L]1*1@29(I@;V.C5K&FB"?JZWA "MKM-D)ZYE_U8*M&]\&0FQ@\CP :R]G
MP$-X#SR"9E6U##=N(M5UO4]RIQQN&;O7S9TN_CB35!I34C"0:$AM^]4,,*0I
M2&B<I DV[YO.QFEY4TDT-?K9-54Y:'=3-,&Q7A\KN=E"C-7IIIXV-\X:=3(&
M9K8P?6^**Z;0Z.8(X&GTNZF%^HNTO3G",%SWF^,'=Z\A^FPHGRW8VA!^'882
M4PQCC@30&"( -4T R2@$F<(H1SK5.?3RV9\?9FHT6DEI>R^8,1=%)9-U%1Q>
M];SV->G.P^MHS?4&;6A#KL*KEG" F)YV#$(7UCPSTNB%,R]K>ZXP9LO5 QT:
M;BXY-ZLMZ/L_#3_-S9?R<5F68#ER9-9_OU_/A9H)E;,,(@1RIC6 ,DT 3S,"
MA)18)UQ3G7KM&<<5?VH$5NE@R*H4<H2SO["O0Z SOE>;Y F<Y6VN'.;MO)$[
M$&Q<:PG#F6.[^JJHP&+$\[I!YG#4<[FP&DSK_&V0V?$^9QM&BG#]D!K'8PC%
M,M9%24D(8)I+\W5*9I8](:D01,7**97(:;2I+4N-TZS?%+.R=FAMUHZOV\(1
M#+6!>?Y2)Z1!SHB<0!FZ&=(KG> XZ>[2#BG4^<IGM7W+-C_NUZN?<ZGDFQ=[
M.OQQN0O3OQ7;^<^R/_FNUUK&TYB*%$@M)8!QF@)"L  T)S+/$X$Y8S[4XB_"
MU/C&BA_IQ>J/362G/%KMLE#83G8_\NDP+6Z,-"S8 ].4+5=18%V+;TW/7XIX
MAOGRUVB?_+/78I 4[NX@AJ2U#E*,RG7=43HFP!Y/ZEIQSS#KC]7"W+$I8Z@^
MK[8-^FW861JGF@IN["R< :@R!'B>()!)6\M;28*Q%QDZCSPU#ORBI%*/163)
M6QN:OM[.[<_WYH57Z[5UVEG-?.ORN4Y#G&LM,RQ!SE,%(#1S03,= Y1* A7D
M%&>97Z;N(!,Q3M)N4_0JEG8HW!W])T-@.;3KHR'SW^J(9"MVPT(>R$#VABML
M,477P4<NK.B)R6F11=\'=%LZ[LT+^(-MU!U?S+^7[1MQ;/@GIBG T.[%8TP!
MR8@$5&1(8"@TEEX^Y],AIK88U!)&JYV(?@QT!D4WJNF'S<"<LH/E[CHLWJQQ
M6?.0]'!FE%%YX+*6QQ]\RY4A3ZI*S]_MTMBC]I1\_E/9\_3-_6HQ%R^SE&4,
M(I0!SA*;B\85X+&V#CFA=))J2!GI?]S4*L/4N*$@8O#FY$PAQ#E1^V3T.>P)
M!O&()S9G*YJ5$@\4_=T=NN$/2MK%F,!IAQ-.;D<6;H_JV$%]GT[4V.A5+8?O
M=\%_=_KN>;O9LJ5-Q/^T8K9(AN)"9TD&< X9@'G" >-$ !J;O3)6*4JTDQW4
M6Y*I4>)>5AN.M]I+6[1E=W0=]I^?=GX<%?6!6;+HN['7XZ;ILM@W)V],RYV.
M&NI$G\:<%L]>\&-,SXB]XH>;)O^&\GVAO=IPOO, XS:D[XO#2</ZW@_LL)0]
MJ/6C?<B#,8[$#_6F2GPQ\Z)BHFTM8VT6*4%CP 340'*,44:R%,?NB]3Y,::V
M_%@IBV_E)JH$C=YXD-L%(!U6D_[P#+Q.G$/F>MJ0,T0>S-X?JI$XNQMD?ES<
M#D8KRUZX=3S^;)?]@!FO7-J!\SXK0[5B]:@^K3:V4:[=,ZS5#[-M,%N$_5^*
M(O,/[,_;;9D$4"1TKNY96:P3Y1D3,@62T!Q E.6 $V7/OO(X3A$5/$>SK2U'
MY$"0 03R8M.=6,,>4B^,S$4TOVCJ4_S:@S5"S)8#"X\\!R/$")1"1[]8L7^-
M;I>EHVD_#P=_+[M@&,O1Z'83-;6+'E91J=_(D^:Q+HP\>2,M(N-.HM_B$Q#Q
MUI4JQ#CC+6L!43E8 T,^MYO;_^V";39W^C^8]:)N[]9?;$3ON]4CFR]G,<X4
MR24'FBNS6= J-]L&% ,D&8$R)XF 7N[]EK&FMFDH1+7NJDI8@VE4B!O]7@KL
MV;BD#68WQWT@\ 9>GWK@YNV/=T DI-^];;A1_>L.>A_[T5UNZ=F]]4Z?QB#L
MHC<-DZ18Q!E0>0H!S&()*$\98)!@*JG2,HX[=7%M&W5JG+(3NBAS="X IVM;
M)+=)<#P@# WMT$>"(5#MW@76!:5!NL&V#OPZ76%=L+C8'=;IYA!]4(Z2EFR,
ME*V2_<7(43EC9TJF7*5<@TQ;PT<I 5BJ.< \244*F=8BZ=ZQX[H 4V.N71HC
MJ](8925S9-3R+(3B/1ENM#4DQ ,SV$E7CY.LT5K^R"JP*VXR5*L/=_"&:_[A
M(,,KM@-Q1ZB]08C'<[JVWA5K.] [5?[WX[(HD;J78M]W9X8(8B1FTK"<+3F:
MT R8;9X&*E,9U9IEF'@UO/08>VI\5Y9C[MR4R =U-W8;",N!B:V6.OJEEOM7
MFQQ?HMM@/0><.[3H]48L;*M>]^%';MGKC<MIZU[_1W0XS:GB^RJ[\.-F\\R,
MAM^6YO8_;#V]Y?>:+RO/V>-\L[%IZC.JDEQE.0&YEBF MOTZBU,*.$^0U 0K
ME3F56^HGQM1(K2GRSH#;G>/44GN<!72?((=CFU%@'YC_Z@C5NVIC&M5J1 =S
ML5.D/@88=2X\3F-&F9.1SF &FQN_XY;>D+8>LG1_^GA'*[T1.#A0Z?^TD9L#
M?:[#F4^;&>RCP;ZL%HL/J[6]?I9JP1(A(6 R10!"A@"120HTBC/)!!59[.6;
M&$WRJ:V'GY]MO(GU&C::_91<\&TY]ZVG,MX+X.C&G>*T#NT*[M^;QV@/2O7/
MM.FY.0B__=V"$%4H#)YF,N#,3:*[CK?P$TAI&7!.@O7(Z2S R.M@56*L(51;
M<3$KL*X71)5!"C,$8DXS '&<F@4Q3VWA2P&%SF+A>;8XN@I36QF[5BV<RALQ
M\ HYRCQ/?ZG<5;YL '&UXN4PA[&O-I.36#J[:_'76$-[SU*PQ;2_)!W+V!5;
ME3O]13VMUD7TWU?UO5C$9PG.N"9F.P@A,=M!H<S7FDH,<*()LG[0-,V]RM5=
M'&IJJ]1^_[;>R1IM*F$]Z]%=QM=M+0F#VL"<W]SP[@#[>@TP__)Q5[$(6B;N
M\FCCEH.[JO5)V;?K=W1CBP?U:)[(UB^ER;_SA"GY[GEM.*NLW5N4W/RL_BC^
MLIFEF%*>Y 0@%"N;[8(!H]#PB.U<(>*<Q)K[\$@7(2;',&J[J_U>1)<IVQ@@
M>AL][<J^E<VA_RCC*HO2W^9]62I1V%)_S+<_HH_W=WYDU&GZW&AJZ$D9F,!V
MXE>^F9N&Z][,1:G#KO9ZH8;-G/BCO" @Q?7!,23Y=9)C5%KL@]0Q8?9Z5L#L
MB$_SI?JX58^&-"5,F2%.LT%*;39U0@%-40J4C'.A<T)CXM6EMWVXJ=%C2ZR_
ME3DJA Z1)[$'W(WFPL$X,*'U1#!,QL0),(,G3>Q'?/V\B1/MG5(G3N_JQB]?
MU$:9FW[<+N4[]5,M5D_6 'Q?-L>JTN@SCG(:RP3$&)EM7IXG@&.M --"L9SE
M4"9>.SR',:?&-+7(1;"*W O=L8V8"^IN3!,8RX'IY@#&AKQ1)?  +6,]  I)
M.R[#CLH]'C@<$Y#/K1V+NK*Y_+C\WW-;4,U\SFJSG:%4F_T@AX +D@"89 E@
M4DB C$G#",L(@EZ6S>D04^,8>_(K;/7]>25@32Z>I5U/L72CDGX(#<P<5C@P
M7P(K7E3+%["XZT7=@Q9W/1UEW.*N%[4\*>YZ^<H>%?\O[)7*FE0V".I.-^I3
M[=M6SQ),TAA#"C36U):?EX#E/ .))$E.,L3C-/7N M!5FJGQQEY@:\@?>X:V
MJR*XUORQ_/>\=%4\/YG?;'\HZRUJN=M0T?']2W^'4K_)=SQ,'6M*ASX7O>Y0
M.ISP9C>(O4:!J^7W!39X!?W. HU?5;\O=F<K[?=^:.?VTD7HZA<EU/RG/3*P
MO6.J+LA,YA*F6(,L9MJP=*P!3Y  J<J(0AE/4^&5O]4VV-1(N)8U6N^$O8F6
MRK&RD1.\;CP8"K2!:6Z'UY<&7DR;J8IN%XO5'T4@O%ZMH[=F,9IO(UN$9IAV
MU%?1"MR4^O)X8[>FOJKYF0;5U^_I1BR?U&:CU&%R:IW&]5)%0&S>/:L9E(AS
ME<7 6'X00!&G@$)I=HAY)A+(498EV*4\GN_ 7H0S0AF\!SM&M"BR&Y\J,?W(
MQAER-^(9 LB!2:@4^28ZR7_?R7UC[6>N(KL?"L<ZOE"%9"#GL4=E(U]$CIG)
M^_Z1@XMW+49OC=WV6 9Q?9EO_OUAK52]P[9)][_-E[8F\XRQ%%&:"B"*?FM(
M,4!HG .IH(I5DB0(.B60CBWXU,PR*RK01M:]4VU=5+!X+.4=*9+8=_H=M[P3
MG-2A=\?]HX8;O9@;ZM]$%H#((K!S+U;%3GZ[\JJ,%RW<<=XF$2/L*_M?(S*X
MXXP$BP?N.GZ':@BN,O*3!* JS/!6FHV<N84MBNLVY3[/;"**Y-B''T4/G1G/
M<TQ83$!&<@8@01H0A%(@XB1E.N<TD="Y=,(X,D]MT=N'V;*=^-&FD#]BM0+1
ML]6@< $_F;NC7^;+ZII?/;+^1WHIVM?#B4[U*$OA:9^W@Z7P37NN:?FBW.EH
MKWQY_2;:J5^6(X@, )%%8'HOAT?]B.F])",5FYC:R^)7HV+<:6LM:#&2*.-5
MOQ@7VX-2&2,/W3E KBK-\)9M?GPVB%;N> E11AA-0"YC 6!.C*%"S$\QR1/)
M&#=;>*_3CDL#3<VZ:-2JL-$JWH%OY]%TV_&&P&C@9;D!CY6Q*.@@0A];7,,A
M<"3;^;'&#E]KU?A,S%K[]1W//W^R^<(RS(?5^BM;*-M<;7^X>BO,8OZ\,/LM
M^<_U:K/YMEPKMIC_MY+V^.J-TJNU>F!_SA"+4ZU$#!#-[,E%G@,>"PU$2J&,
MH>9<Q[.E^FX?Y'A4&D(NIZ^(EE]14[KA/J9"VF@O;G$,Z!ML&V;.'$]?1YN'
M$1MY[A6XB78* B,LV#![;-M0*SH[8S<1+W2SW6,"GMV&Q#KH(6\0P<8]#0Z)
MY<FQ<="'=SRY>>:;N9RS]8N5H*K.=OOGW'9-SG(%20X8M2E42C+ ,8^!0@H;
MJTYAG?B5,[LTTM0,.2O>KF5!]+L5T;?KPT50'0\P0D UM)O%!R7_HX!K" 3U
MW5\<;%QG^S6=3[SC5V_HQ@E'I3/J766QEVQ4V# [U+FPN0_SQ;.Y>I9D,>89
M%L9<BVV;=2D IS0UNS^E4JQBCK'7QJ^;&%-CDY,.#774<.DA>K8>I3*6^,F(
M;T/CRBZ.3VI=7F.,!*MAF6%5ZNCOE.XYM2PC"2*4@QSQ#$".S-1R)4$6YY*@
M5$&LV<P\DJ^F,[E-<5YA>@M:7#6J$OXU9MIM@1I^]@9>O4Z*8>W/ABK7[4'M
MK#>[>:E4";?2]8,RY#+849)1U\A^:!TOH#V?UB-6BG?P[MZ;E_\'JTI8V3!V
M2S3%FE\WY(E5CE.54" Y,RLP)@(P&%.0Y2E-<I;D GHE) \GZM16Z4JL(M6G
MDKU,^[&5\<P/35;O$!LUS'0[;B8F,8FC'/KVBG^JU:W*(1891,6D%RH/T-MI
M^(D)'N TC+3CAS0-BOK9(*9A1^P0MG14LZ=N&?-AM;Z:*U4$5LVRS+PH&<S,
M$I-B "6/ 8?$5MSAA&F:8:Q)[:Q_<(Q+ZBM4!T_]P_^O,U'#O KM"]%X,_M:
MQ<YJ;6S-^686ZMVE+-0J977,.?*(!AISKD:*\QEASOQ"=T)AW!J4TWN0\<)M
M0N%Q$$@3[*$==WKBAY+/UC-[?-*S'^?3KH(:3Z%@*N9 )S '4(@$$$0@0 1E
M.8PY$=BKL(O7Z%/;CSF<K_:H9><W,8[;K*'@?OV3[(%JWG5"+.B6QDN <7<I
M7; YV7AT>DB'O81]A_;]2QI\^AM;_UMMW[*G^=8>79>V1Y[$":-* YCR!$ J
M$T"%P(;W$"4P30B.G8K6^ \]-98K98S$@9#1+]_-*K4M<A#8TB?IP&\:'(SV
MP< =@]/V@M\T+;J;J$+]4/K!8/:PNP>#>R0C.R3L?M9T)^1:36>_)XYG)W?2
M], H[O:$;A;P^\>GQ>I%F?5F_7,NU(7 ]D4QNX4M_D6)U?>E#7(JB_>\76VV
M#5,LCU.9QQD%,64Q@ C&@.94F;4]9QHSC.+,*\0@L'Q36U\">,4/;K/:]C"[
M0[\-;H;Y*\[QB(<>NVG;S^Q-73U6%B?7NP];F6F]?;0%:P8R[ ="/*3I'UK$
M43<' ^%[O'T8:IB !?\;A_0SF%$E!%- :%L:)$4*L 02H& B8Z0R3(E7M\%K
M TZ-[/^C;G72##KJ'#YT%6XW\@T)XL!L>K'D_T$?O8%+_I^!9O"B_\TQ7[_L
M_QD$G K_G[LO(-,\6._)3, L0S+.;$QK!J#-<N2HJ,"MLQA)R5'N%1-_>:BI
ML4M+0XQ"WA#=1$J,>Q"+-W*O12E700O#)@=X#,XCY6BOSR '6CMQQ^$=W5AC
M5W'FX_+)4-$GVQ @K5I6$$TEIZD&.1<)@% 1P"7*0,(SBG1*8BJ\JI:UC#4U
MWBADBU(_=FC#THT> B$T,#_L2V[=1*6@-U$%V  =/QPP"<D1;<.-2A(.>A^S
MA,LM'3UBQ4ETW6IY1F(H$T(UR#*% $2( 9Y+#2A,.2>)RC+,O!Q:!X^?&AF4
MTKETFG;!SM']TQF1@3]^=S#\'3!G=0[J/SD<85SWQUGM3KP7YZ_JN"5HA(L4
M 9AEDDCE/%<RF0F9"!WC#% N,8!9K@"+,PP2!G&.:4(RX=6)X^J(4_NVJ[09
M40O8P_5P%6S'+4)("(?>*1S$>%81YQ6D.X$#[A9<H0FZ:;@ZZ+A[!U<,3K80
MSC=VK*6RV:CM9F>"O)MOQ&*U>5ZKF<))3G(H0(Q2:DB&$D!93&WUXQAK26!"
M$I\:[Q='\B*7$8JZEX)ZEC>Y"*,;?00!9V#:*&4\J-V[ES-@19%K4 2M$G)Q
ML'$K?US3^:2:Q]4; D16_51+MMQ656L_J^T7LS-9/JOR.&^F.,IB! E((=<
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MSA*!< 9(8C,T:)8"PB@"7&)-*$TI94X'$A='F!J?ET)&E911(69DY'0CX\M
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M,Q)GSM/=[^VZSWUO'OK=4-H_UZL_S#"&'MGR9881@S1-"4BTV>A"DA# -%4
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M.FQPY/T29KN@UYI"Z_7 \9)JN^AYD&;;Z0$A>O/M!IE)@K$49F\J,,\ E)0
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M-D MV%:DABT'>W[H5ZX(VXK']:*P[;=W=+&LS1;(;'WT?#M#69*J5&/ &)<
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M5V2[X#S\8,LD_<U<^6-S*\3SXW/1%+KL/8P1RS#&@&>, I@9UN,"2Z 5UZF
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MI7 ?EV*MS"OZ3I7_-?]>/-O]Q/L_17&::>/7WVNM;/XL9GFL,07&U-< $B4
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M<(B1MQ%G]3O=*9R_; (>^KH U[]6"_,8&]!HW3&_L3_GC\^/QA!(4K.=@$!
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M=0RZX0_K^Q'5 9<8T,WYSV26B?W\WB)&CZA2)+H[LLCK8XN<%@SO]0GGT .
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M>:]VMO/JA^WF^UHJ^>+'YU+)M\7;*A'+CBUVZ^^58"NALQB)A)C@7C& E1:
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M_X,A[1?U^R+6&^8[WVR^N-Y7OR>!O/?%XR+WH^+UEX_;K=WA:L,TG7%)%"*
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MS^M.?; X\WI>%U]*:O&YV"KV8/L O=N4Y5UQ1&%554D?WI8L3RA.A3$!1S'
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M9W[[^U_:3\P/>PKV][_\%U!+ P04    " !&@ U1&I3,^[9[  "MV 4 %0
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M;_ZX6'Z=&&NL=9*B;.Y#/9,)$&)@$!P%X/5<K\0ADDJV/'HW6'1_.GJX.+M
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MI+^__T226[TY7]>ZD@KR21*.XN+ (<H*;V,81&,+9+)Y1G!EC1LNVGR*DMW
MTO')YL#"[@,Z)+EEF+V:9_SCW_#KQ'J>A2L;GY@$I'RL<70 7I033DM;4AH.
M+7<?OAM ^C_=/$*D8]]^71RP_3I=I3#[=PS+J_1VGWA2W"20+I))9+S&2\X#
M]P:M5?2F&6*/>>SYNR&CX^/,003;2=W #1._TCNK20Y9%U8B^$VF"+.$;TZ^
M<]:<Y6PY#V6(#>:1Q^\&C8Z/-(<0:U?(N"B,N6!"UJ"*EPQL<U(O= &OLX68
M;"%H,R_L$.')HP3LAHZ.CSB'$>W(^'A!'.0-%[/P<:*2SH:A!LMK6:7U'H)G
M&HR0@2<M77%#9'/>>>AN..CX,/-P$0ZF^W_^\8'P7M,;!Q>3DW\T7V'^*<QJ
M!?S[3XCKU5VB=ZTLW_I-PY29?YO((VO.SU?P,83/DTU:757PF_+K=$X/F])R
M7US4D5VC)P:)#+DCWY'%&E[H>@4J@2FTA5NMH]^2I7:U<DI8Q8V.+Y_Y8Q7C
MCSA;KZ[>V0CVUCK:A[A##<35,UZL5B3;:U:58B7[E"%RSVBA)$X;H5:@M K>
M2A5]&U;ODC%./7LS3%Q9E %D/N*6<I?Z2]?ZF@D9(TH3#%@5:Q:)U61A4X(<
M11 E2)[+EC2=H8!SCYIQ\7.,>K<BY1A9=P"8EV'UZ<4\U[]^^8_SZ9<P(V96
M+]8OPW+Y=3K_^#_#[!PG0EC-4#D(0M"""M:"QQ"A1*X+!NN<W7+U>CR =J*N
M!T =A8)%:Y5T@+/WGQ;+]0=<GKV:?\'5NEIPBN>8S:P$!&V%(Y_-TNK+Y,)Q
MSC-WR6C%MV2%#;!W;R%FG,8<[5!TM, [ ,V+E&J)Y^H=)J1U$&?X&ZZO,MXH
MF,O&9 &U]0P9[*RAQG?@B0\BQO-DMM37#K"I/4'4.(T\VH%H, 5T *:Z#N;T
MD:_$PD1G=$FEVI&D!IXJ&HA!(<E(1L<4Q<[;$I>/!\]M(L9I[M$.+ <+N -P
MO%WBYS#-O_SQN<:VM/N^67_"Y1T935Q(+'FI022>07F;:>]UB5A2QFEC5'!-
M,+,#;>/T!FD'I:'5T0'"[A*ODN<<Z_9+-A14LC77R@N@8$2RX$M,:DN6TL 1
MV3A=1!KN5@>+^'!\+-9A-@@^7B_F'Q^X:ZAY4,6!L9N8U)$1Y25",BF%Y US
M;7:I+;3TX!X/$K4?*^<.3,G;Y>(S+M=?W\X"K9QYKE'BY\I)W7A9$=&ED*'>
MHH+BDF23O (FM(Y%D%<6MF0K#+%+/4Y4#V[Q(. 93/(=H.@=P7\Y36O<G#3\
MMIBG*\-I#&K-$7*N"3M*)O"( I@.)"&,,8HF"'J,H![\Y$'0,XC$.T#.+6?L
M%A-80C3"9)"V'KJK%"%H@Q"RRC8')I/?<H=Y/&RV4M.#0SP(9HZ7=0> N:!_
MDB-'PX.&5.KI4Q :HLL,2F0Y%?32FRU9,4,YO3UXNP/>.^PES1[\VVF(T]ET
M/<45;9R;7-%/BQD)?54WT?77:]$84YCE3('1EK!-=A&<= ("2D%HY\FQ-D[O
MC@2.ZPDWO_]LHJ<.;- MON['G%H[+EFV8*V@2+$.1_#,4;BH<M*8M;=Z2R//
M01'7U1UI&P@\CK-C]-$!LJX.R=^&K_6$_.K\ 3.7T=7*:T/QI.+!0HC,@U?)
M)I]M3*[)G>EV<KI!U%'*?N1ZX@C)]X&?Y3D]]8&,)DX9&Z,6D%5M$\,5>7BF
M%% VJGH>AEIN214=!$+;*1IW[VN'H@'DWP&0MG" GBEM10&K%7F7T9)Q]DE"
M--H;$T-VNDDL?R!TFIT!-8+.D1+OP2V_/ []&>/Z5H#)$8UP00):+VAGMP6\
M3+00:+>7M,\G69IL7MO)Z<;L-'2'CM=#!Q9H<UIQ2UZW.(D^"2L<0I:Q-B'1
M'EQ0%HH1F*R-.=HM4Q,&.A[:2E(W%JD=J@;21P?(NL7$)!2KF!,1HK02E I$
MNBKDY!5G7 Q<6FQR>7J+AG'/I$\=H.TE\0XVM5J//+VXVZN)E(MY[:B'\U19
M*4P&(P."]1;KH"H/(4L/Q4M60FV.A$T.(9^@:=S#ZI. :2B-=&")GI"0SDJ@
M0**?U8DVMG"(+-/F72UJML7QL*4D>(A:E*,.*YL=>I\$6@/IHP-D_3S],LTX
MSZNW5P1L>+MFIV".+I*4*!RE+=M%!+=IYE9*UKPN'-?DG/(;=(U=$#2,^A?M
M=-$!M.YR<5%!D'/(+&ER^9QW=5 .;>J^1!#%6F/I1R>WS+8;))_Q/BWC0FA0
M73_,9#Q*\!U@YUH\M]J\7,M&E*BBJ2T: B->O&+D(_H$UAD6-GV!;).:Q*>(
M&ON&KJU!.E8+'2#J%@L7*P*]Y\+5A$\>-=%/:\U9K(*Q:)453)8F*+I/2"=V
MZ&@5;_&^#Y9W!WAYD?/F@CO,WH9I?C5_&3Y/*5:<9!X8*G0@<E2@9'+$!D4.
MFI@3,16319NZUNWTC'N@U,CN#"'['B"4TOG9^2RL\:*6H+8Z7>(GG*^F7[".
M%CS#UXO5ZC=<ORD?PA\39-;P8BQM\LZ#*EZ#CZKVJ,C&1B]T;%9=M@^=XYY#
MM8)<0UUU ,5WN [3.>9?PG(^G7]<W6+W9RS3-%U/<HP\,B[ 9"TO&AUY1R+4
M-EFI,_,J-3GA_#9IXYY5-0+<P!KI &,/!34IP2OG;>VH5MOLZ#I*1'D!,7KT
MW,9@=)-P[R$IXQY*-<+0D1+OX-3\6Z=UY#626VAIM[>BYM4$0>)QF^IQS1V+
MV5K1!$'?(FR<^<9C7<8<KYO!L':*]E=O-TKXA.MI(@_[#@?'],*Z^[7M&F,]
M0?XINV19SXJ/3I%C5#.9E FU6TB=$82Q%&\TW];#]GETR;I[Q$8"?[/</#9O
M8MVWN-ST))YXE;T140+%)]6XFPA!I@ FV9*R]PE3DV8CNY$W]B'ZP!AZ^AAT
M$!UUX&7=Y>JB]?6+\_6GQ7+ZGY@G*"6+Q0C(B5A2&!-X6S2D1.Z$]#8ZV<2+
M?YJLL4]'3XJTHW32*<)>K5;GQ(D/SKC,-=A0^Q]P\E@C#QF$5I'5"2VB37+P
MXR2-??XU K(.T$6GJ+K=LM][$H_4ODZFI452@@1OR&>UY+ZR3'(JI4D>PS?H
M&ONP:P1\':J5#D!VZ]+AT?V>NZ 2Q=G ,-0YA9F"XT32XS(66TKD/C=+QOH&
M;6,?=#4&V]#:Z0MP#[9]1O1*A\0*CP7(RW00HRJT]TNA"UH4NDEQ^A,TC7T*
M=CJ ':6-'H%UN>O7#D)81R1ZIC6Q$0SXD"6DD%*A]V6TIP'5'NY7LV.PTP/J
M "WT"*;;6WS6)20A"R193_%,+5ITCK;X(!4KO%"XTL3Q.GI&U>#C(L:#U:'Z
MZ'VHP+4D5XORYC,N-U^\"C4;^];U:KU8/>J4=8_'#'KJ>BA[ YW"7EQ+7Q-Q
MJY\=<XI+"3QG7X=;</"*$TAE\2P5Y9)O4DCW"#W'WUU_P?DY_DKKM";QUZ_\
MVW3]Z>7Y:DV/6_[R1YJ=UY53>Y30_W*]GG>L7L*3@4;B%Q0:VNT%66GI<DB,
M"Z5]DX.* V@=]Q1V" P]O-INJ[ N=M05[0Y_7BSRYFX,EU^F"5?O%[,\\5G2
MSF 3")4H9/;)0G04R["D>7!6TNLF18>/DS3NZ6L+A TD_@Z ].<E[0YOEXLR
MK2W9K,3"+,@220[%* A1"'K%C<"B3.)-\K]NT3#N<6H+J!PJX Z2(RY=BOG'
MRY[$-ZV\)',I2J8W62*@G @0@U=@K5**'(LZRK %4AZE:-QCTA:X&4;X'5B8
M=Z0+(J".]_B9-N;98M,\])*K6F=BN*9]5V)MJ(]9@#/% 9+@DE<IIMCD/.%)
MJL9UB0;2_,-&G .IH0-,O<<9_>KCGW%.HIH12R_RV70^K6):4\1SQ97+* 7]
M 8;7^@%9KZ@L65YCI TQ1J_:7$;O1MZX;E$;E#503 =P>R"KB8F.\Y(88,W_
M5]9*\#DS,,HZD;GTRC2)[QY0,J[#U 9$QXF[)\?I)G%_0O(H*I8(7(9,D'<1
M?,D2@JV3XJVT:MOH[ $1<T/+N-=\39VE P7> 69N>O-?\/!J3O:+WJGGL0R#
M#J"C*Z"4<."*D!1#.!NL$(BB23S_&$'CWN&U0,\@HN]@F[JB^VJ7%3[*A(4@
M'VK#Y<S)J>,E /EZOJ VTK7)-+A'Q[AW=&T <[B@]\>)O\#)'#_6=(4/PS8N
M^VTQ7]PUGE=,A<*Y<(PV[UR;9>G@: <W"E*1 KWP(;;I2?TT6>/>S#79NX93
M0P<VZ#=<W]J#>8S)<\LA2$-^?GWEG15@O TL)TT19Y/JF3M4[ 29P6>^MX3,
MX4+NP-'9I;SU+2ZGBTSO+S&L\&>\^/NF.8GG*46?2/U2@#*^]O'3":PN/)/%
M928TN6 \GO3=3I;8<P+CB?79@8U[BN,ZY>;7V>+W_X'Y(_XY3.?US9^P+);X
M#M,LK%;3,DT7&B]$4KU[)$D7=,[41LL(*GH.3C /PF:N18E6E"96<F ^1CXU
M/3$,]U@%K3'1^9*X[EG@7,9DE*40G,)R52M2?#T80A-B$$*ZU*8@;["F$NT.
M8_L%[T':&]'-J!E3=QVD%_?RH1[R]F*]7D[C^;H.5/BPN"A?G03DBN(Z!DD9
MV@E%O:S5H8"+UJI2M*>?OI4A-A0QNYG69Y&D,XI^.G![K_IL7%4:_!16TU0O
MXZ:S<PKK)T;$4@0RL%F3%Q\-+31C&(1(K*%CCL<F=U7?H&LWY#VKY)TA-='!
MUOLWG'[\1'2_^(++\!%_.S^+N'Q3-JS=RNN]SV6.1<I@ Q3IB,MD-#B=)"1N
MI-2<B=2FW<YAY.X&PV>5&'0"O3VG].QWF!'/-B.-%G,2R7I*+^^6!X9M74"N
M>C3=8?F(_.UCZ6B6X#VH@(;OP_%4BR'!@M7"DB\JR'/$XL@U#77:3&+D/1JC
MN6MA:G:B[OBN4Y</^5!5,]'(HJU71K0>51URB<1KI#5JF192>:5+DXX;=\GH
MIK/&0*AXV'CJ8*%WL&-?4W\AD>K\+N9UD;_X8[J:Z)*8""Z#"4@[24*$6 0G
M,7DKF39>"-L40=NHZ@10!ZC[,>0<+?L.@'2/AY\79V$ZGVB#GB='XI&1G!+'
M*3 *,H(GQ?-D&4K>I&7^5FHZ <[QVKX?1!PM^@[P<ZL.\"]8W<])*5DI08(P
MV=;V?39!2$Y \IJL=>+*JM;EO1>4C(N; ;3[>,GE :+N "N/]$2^9(8%:0Q%
M0N UNLN"Y%C390P)+87D2QN;\R15XY[I#H^AX530 9[N]Y^]Y,(1-59;$@U+
M] >GL#J4.@;0ZF2=SC&W*IS<1LZXV;7#(V@ H7< G1UZ95\REH7(1?A 6WJJ
MR3.BWEG( %%S;K0FK_%F*/R).YKO ;!F=4L-3%03U72 N??G<37-T[#\^C[,
M\#*PW7B1C#'K$ZV;(@HQ4K! T JAML[66B?9Z%;S48HZ:78X0*PVB,Q[ ,\-
M^;^%,WKY81GFJY"J3BX7G8RJB*022)?(\'+D$*.H\P&),1Y$8K%)KNZW21LY
M@AL& _>1-:Q".H#8J[=O+@UK;=]22#0D%UZ'W1 +/D4%(EOA9;$H?1-7_)J"
MD0$SL&KOIWX?).<. ')MEU^3 _B*7JY(#EX+EBQ87B-0I<DLBZ#!^RRL= )=
MFV#_(2F==%$=\'CQ,"EW@)/["4:OYA^0_,,E6> +=_'=8C;[=;'\/2SS1#NC
M4L@9<JF=A9-(X)Q$T"S%(E4T3C6I$=B'R$Y.( \$Q(/*DT;:Z0!Y]SAYV)E,
M)5L8,@'%"0I,$JLI[\Y "CYA34&CW[= V[<(&[V#4B-(+!KJYV"\?=ZD0=*R
M6JY;H.YE6"Z_UMY09XOS^7I[XIG(/*1(DL.<0+&0P263H!:NEV2P2-OD.GMO
M2D?ONS0*+@?6X.A W21,WE][U;V]Z 7Z\_F2F+U(#KY8DK_A[YM?K2;>%E6T
MLJ#)<0$5%0-OC0"G?:'-![G3WTR2.?SQH_=R:@N_$^EEQ(UY&X=7XB3)7:0A
MK4B?;\JME*3WF(CU.K7I@NU)T*6V)#7@:[2D(@OD2O,$619$@2&XD@]!X?ZD
MC-XEZO2(;*RO\:N9CV7Z8CBP-1F=IG7(G:68KR19)[LRD*YX1F$@,AE;8W3W
M:<PM>W/T#=']M34^0A_SG[?O%1L.;VT5CD6=5*E#[2JKA80L4-;FI-''P*5/
M34[S#B%V],X@X\1!@^OQ.<3B3B94UB6(UB,HK03X0/PDK:/QQB1KF]QZ#1*+
MMVPVTDDLOH]^C@QQ?IGGD2)QIC(3UAMBTFE0@1L(OLJ2%7H[!L]<DSX ;2+Q
MEEU+>HW$]]%@)S!]*,V'2>ZW!>J4U5IR!X8X!66<@RAC (%&"2ZC5JZ)I=R3
MSDZR!EH=DP^GHPYVYZWF/@:A%&1$$E9* F*("E!+;;0Q*$.;0>>]GX4/J/?[
M5WU'*6'T8\6;E?=@KK:-&*2OG1,5%E"../)D_,%8EG14UA?5IFWN85/.3WB"
MW1!-QZFA+SA]^P2TF&*<D>2>IDS[OBVECH1'*"IE$6TT(349-? \3ZX;PVY8
M=1T,Q2^XC(O!LEUV"<H%EL2SE%!*,'6Z: 3'2'R<#'B042K%FZ0O#'>:<L+#
MZI.#\ AE]8S!B[6U^>6;SYN!7;_\@<LT7=7B?JD1,R\U"*HY99RB=B\=!%93
MU7303#<Y[=N?U-[.J4<RD<>KL8=PXHGUMYU!YUCTN>;>8G 4K'-.KHFF'UU$
ME:*BK:*=A[@/I;T=28]C1(]78K\HO5B'W[PXFB@ODE99@<E<@@HU7;S.$5 L
M6\V2B)ZUB9"/(KNWX^R1S.RPZNT7S)O5^FUFG=$V.R- LD@KUQ4)/IHZ0T6(
M;+@L/#8Y]SZ*ZM[.P,<QQ<,JMU\D7ZS;7\X^SQ9?\6(#>GN^3)](]&]G8;Z:
MQ*!C<+6WJ7?D(T5GP?'@(5NN/!J=<V[4%.@@>D=O(CXV>@=5:,_QV6:9/LKG
MQ!A3LF,%+#E)M-%X#3&[! ')J9?$L7&-BF8.H';\=N-CPW9 ;79@;%_D_WU^
M,:EF]6'Q2#N(S4*-Q."FJRK.5QM]OT.2]FJZQLMAM1?2>8=I\7&^^9:+S*ID
MLU4L%=!\HP%Z1<& !*DL)IX*MZ9)&6IKQL9OH'NRA= 51CI8,Q>S=S>3,M G
MYKP7$%A-PK(Q4L1K%?!HHW:!& M-KN)O2!B_G>[)<'B@W#M S):F%5>=J.FG
MB]GQ;Q?+C=;N)+7\MJ /S]=$SFPSQ^=RC)A-0KN4:85$5:==V@).*4;KQPON
MI+6,->E",C ?X_?@/1EVQT1 !PM@Z&$6640E&86TO/C-X0P2^S&!9E+DY*Q#
MT^1:8Y0!)]_%E=R8".A@ 3S,[<'H!(M2@";A$0.$M\!] B^-<<JH(K'-D=MA
M"5;?Q\W;45KH)%UT2V)/=$G5)B-U**VF/ZH#K2,"Q:*%?&A'_E&;7C^'Y5?Q
M[^=^[' ]#(JF_MOI7Z1G?\(U&?+971F,UUO_+E&]-MI_0G0G[;JOI!<Y1PW:
MZKKE$KJ]K!/8O?8)"W.B58K=";KNOPU?-]JZ?$8]]POS1 I;K5>3H#1R'S20
MUXT4;F8&%'PJ$,)XQV3@032)MYXBJI,N-(,AYD&T/Y1"GM/,DBM/>#68A;SY
MQF;F[1&BA[=-UP^Z!I@+)4N;(A3+ZP@YFR%DQVK#=73%26=YH[2AQXD:>/Z'
MI0!?QU1G64A:0S):B X#F.@H_M$\BM H@Z_+^1_'8> ;8S_VD74'0>7+&AJ_
M*7\+RV4@V2S?U?E/FU:617I&G O(/F=0R@;PSEG@'(L3(I3 VG3=?XRB3O!S
M@)KO'^0-(O->P7/9S[+._$H&&45$VH!B@O9MDS7PP*5DBFG;ILOU$S2-"Z"!
MM+X+E@Y0P=@=?7:(;RYYO.H/7^?*8< ,B;PXLMG>0M":@;'!^H(8LE3?<G<.
M>W2'.#I$XXN3B7_4S)H-?[<FG5SR<<F&5<99&00@"\1&4 &"D@9J'K+BF'V)
M?B<4/?:$<:L%FX!E$&%VL'UMJ^\N3HMH#.2ZNRBK,SA-,2(OZ$,VP4;;J/CJ
MH.[#IVJ8?XRW<Z24.\#);[BN(</;Y>++E(+1G[[^E:+75_,WGW%)"IE_?)'6
MTR^;/-F;&:S2<N_()F8N.&WIN<Z0*!F,"RB85]ZP)O/R]B>U$Z_Z0' L3JJI
M#K!X*X%%^<BYM@HP<;*V26L(-45;*2DU\>",:1*@[9LXU H[K97]>.K0/I+O
M #-WDN]JYMP\36=X9]S]A\6^HK0^\U2;A6E,$90+%IRH*22^>,<YLSPUZ7O=
M@IEQ]]H3XWAT-'2P(GY&>G*:;E1,KV>XT?4\OSBK^5/_N7E_(DKM+45><3",
MUC9SC%8Y+Y",SS*S:%F;CB.[$#>NY1T?0HO&^NP HYM$DY_NIT-/?(A1,T:Q
MFJOS87UTX*TL($Q S[-54C291;B=G'$M9W<X'$!G'2#OUS!=;K+J;^1[?810
M2ZH4<< D<'*"*,@W@>+[6, *+8777"!ODG3V)%7C-L?I#H?#:; #.+Y(:7EA
MT&]9\S?EY^DJU1:.*[+S;Y=X-CT_6[V:?\%+14QT,HIGY<&6FDCED9:?CPH<
M2R&9X',L;1S4@\@=M[%.=P ^@<Z/[<$]#+;OL/?K=!Y(\O./FPP5XO&:WPF/
MJ=B""HJ2M(4H5_MB9 G1:I\="^A4D\KD70D<M_5.?_AMH=>Q[^BNA?6ZYL5N
MKA+>%)+CB]4*UW=<[>+)GRY,0?!8.^AF05*S&;@,.I?(69*[W:KL_,AQ>^IT
M@[^&>NK $[@H%_VWZ3Q?%S$YXR5:(<&J3$+B(D*LY4PH5$CTF]"J>O(!*>-V
MQ>D&@0/IJ@.T7541O9E?C&\ER9&LUE]KC?ZZ9JE^KN*>Q(Q::4N.M+6Z]B;G
MX*3)H&0.W"G#16YR#+\;>>,VN.D.E0UTVL\LEXT0:Q>?7Q?+GQ?G<5W.9^1(
M7S@:R0EE=&$08F6$4=#GBR:^,"0,/G 1FCB03Q$U;O^:[L YF/XZ,)XU*IO3
M1[[^;3E=X\^+W^>3;)CFIFC042)QX,G+E4X!1BE"31N*I@D"'Y(R<@>:[H!W
MI+*Z@-O]HKUK65UV%[D6%#(3F=2%G-Q,G"49P4?N@"MG.%-%&=$D-6-W$L<]
MS#SQ=60CS76)R2MC3FL>IU\VF55>6,NLCF"X8J!J4D%P+@*ZH%1!48PTIT'C
M0^)Z&YLQ##"^B;\CM=2//_B0M2M#7ULZ"F;0D'\+F19IO070X"IWB5LG7(C<
MR":EF$]2U=MLC1-![E"]](RUMTO\'*;YYTNR?OFCWH?BBWG>M/'8G$6M)CXX
M;KCVM',420NK"/ 9"V")S#C,:'.3*I'#R.UM!,>)T#FX)GN&[8:GVC'I?%F5
M<LD=&FX5*QQ,88ZX,Y8\G%0@%2U<"5'EPD[D-&ZCK[>Q'"<"YO&ZZAF)5W[(
MV_!UXX1(*Z(0CG:")&EC2)G540[DA 3/I0Q%I3;S#;Y)66]C-T[L)QZBGU[#
MD^4YT3$-<3J[Z/NM.6+0I@"+-M-:$A)"'>"JI(Q:&$6(:5(/LPMQO8W1.!WL
MCM%2E\C;&/*;:\M;K,DZ^=5H#K1^5#W62L2:$9"3*=((8VQNDFVV!XV]C<,X
MY>9[M,XZ@./N!UX3H[)C/+):J;VY%S(0ZD3-(# ;GXW,;5+"=R=Q7$_PQ&>'
MC31W."87M-Q:8O(BUVV[()4.2A1%:UK%3>,X"=&[#-9@=#I&;O0IL?D$J9V4
MMKYN67(XE*8ZL(]77;0^+%ZD_SB?+O'.I?F+>;ZY-W<J83 4=65.XE,JUO%R
MS((L(B OVK/<)$S>G<0N2Q8' \LC_<\&UEP_0?,#!F\G WOF;;&"G(_(/=#&
M4D<5&Z0_2K;,80W33@+&?=.\3UUI>#+X':J=+E*U26H),:]^);'^):PO)V-M
MSD8OV*3U]#+,9JLW9>,:WV:V%$9D!T'<.0?*D[OC&(G2:2NQ).M+F_D\1]#<
MY25T,Z2>2+<=[.:[2W:255*!%21464.<<4,\JCJ:4VLI0B@F-ZF@V9W$+J.=
M5B!MI+E^HYWKLHDM@HR9(?GL'E(L_N(LPUF.H(0(Y+,+1R[]";'Y!*GC&M+3
M1#M#::H#^WA[*[AJ&/RJ3IH*L[?G<39-;PK15?O^)R:*M>0H:Z$*,<8$Q$(2
M196=LK+8D%L-;MJ-PBYCG<&@\L06/IS>.@5D'=-ZW8-M8J3VQ3I?YUO&>H2F
M@%A0A!M?&(N.\=3<N]Q*69?1SBD!>+B>.@/>9>WXU9SVU40(Y25+ E"X>N44
M T3#$HDK:2Y+2BRU*B=XE*@N0Y93P.TH[72 M-U%-S%:&9MY DRU<Z5*AM:0
M1*"P*WMM G(\94RRA<0N8Y)6*&RDN0YBDLI6_7\](OT29KA)"":)3=,:<_W%
MBWF^^\:M3UX,*7UX9WHYI>^7/]*G,/^([\@W_X7<DDT'>JUTQ@!!>U)"J8NU
MMM-%6R+W.2C69@\_+9OCKHV!8Z&.$?+<U\\DYX21FPBR7@@K@0J<#P*$X3X5
MK3QK,_+Y**K'S8/K"=U[Z>_(*6;$]W+= 60E%B-J@:;)7(!RS$,HB7X,!77,
M6MC8Q#-I#]EF.71=078?_?4RQO'\\^?91H!A=C74YM6\+)9G%RJ\\O TQN R
MQ9REU%/G@@C1,G+S1.T#QG5(I<ULQ]WH&S>!;F 0MM!)!R':51./VM:#G/Z)
MM"JC31Q\CG5B4HX0C"X@0DHHD!LN&R6CWZ%CY.[E+73](/'R<,%W@)M:G4&2
MN;FDFN?KX'"SV*Z%Y*TSWH8Z,B(44+)(B(FX0Y:=X+YPYYNDFN],X;BM5(:^
MR&FBEPX =YGTO"E2R]/U.:GIU46!4/[I?/W;8OWON%E+DV1*9H$ST+Z>1X2<
MP4>I:L/ +&.*)NDF)YB[$CCR[4T;?#SPV!HH:^PV>0]GC6[GR3D>8IT\'W6=
M;.IKFCPR#4E)0[\SCM_OY/Q(D[P='SCR;4Q30#43? <6[5X#OS=Q'6@+R*_F
M5X=$ORZ6=UO^715C?)W$*+5/7$/FRE <'AE$VC* XAG#K'<VV"9NVA$TCWR+
M<Q*[=RJ5=H#>BWERJTT?U,T"?7%6JR;K,L7,)]FX*(OG$ (YL4HE"RZK $9G
MSY%+E=IT:7Z:K)'O<$ZS]PZGF'YA=CG-L#(D+2I42D%QCA@J-?78.@')!^,\
MIVU ->G[]$W*QCTV'A5L!ZJGTW'LOUX%_F%.'L>*+/IJM2CK3UB'083YU[OD
M[S:0_9O?.<1(]OT('V@H^YOEQS"_;$1,.%@M9M,<+N>VO+W%R77[[#"[F1A_
M<[029(I%6Q!>65 4#$",'J$P9V(6/);4Y-1@$.J/-7I'$5%[D,\6*XJY/I!&
M?YK5#"7OM%6EU$$EM7Q<*P%!FPBT@,A79B+9-CVAAF9DW-CY],B^;VY'!<8S
MM<X_(SGALU4+(WWUU:>PU5O9Z,ID&^L5)S"1"R$$*/0.(B-',\5LK!%.VM"D
MI4,7)OO]>5SA?YS35_Y26[Y=C-<M@A6=B@;CT(&RK)"O7>=)EJ11.<N":3/3
M:PLQWX/IW =A#^_OCE10!\%0Y6&:IV'Y]:++^87'_<=TDQCJK.7D6V]:@*B(
M$(NT8)7VF06I@VLSW_HQBL:^P#M6V5O0<[SD>X#0#?F_A3-Z^6$9YBM:7'7"
MXL7\>,M81%IGH$MU4/SF5K,&<-)CU!R#Y$W.%K]-VOB@&@ #]Y$UK$(Z@-BK
MMV_^@F<1EQ-F<Y#1)K H%:CD#820,@AG!$O!&L7;= &]HF!DP RLVOL9! ?)
M>?1;M-H7/]\MW;ID0TAO*""I70.LJ']06")] 2U<TCXA1LZ^Y;)_XQDCMZAI
M X@AY3HV/"X8V(CH'A=11L-*+6=@1=1F>.3\4?0*FL=0AP-JE?E.Z'CT$2-7
M]#8$QS!2[1 ;F\&\FUJIRS#YDBU9$C.!6<B9["!Y>+5O@U,0T"%RGZ6,\E"P
M//+,<?::(=7[#<0,(>NN(?0+^7+KJW<^+6:DL=4ECUXP1YPI$*9.Z3%"@>.,
M@??995Y$DJX<CZ?'"1AGWQH%7 -IH0-'^,T77+Z8S187<YH_5VU=,J(CE]'9
M.G="D"''E"!J)T%+<M64]6A*DQRU1RD:N8"KK:,\C!XZ -2]8XW7UQFCK@CN
M97;$1RWU#"Z#MX:#B[0,0V*Q^"8M*QXC:&0WN\7IS]%R[P$_=85=FM1:(K/^
M^MMBC9MWWW^>3=<WM_GOJK+XQ%A3;"!;6Q09=Z7H553HP2D7,+CHL$VKO7T)
M'?]@Z'AXW,=<2UWU@,5;-O^\&F/Z8>,#7"0JO9K?V@,FRN@48K80A*UEAU*0
MBYEIXT<91$D)>6Y^)/DM(KNR>0-AL)6.^L+?V^4TX5M<;GB;%!ZE8^35DMSJ
M[.QZ.5XD@A7T7Z.DCJ))K]O'"!KY5*(QK@Z7?5\8JI>:T[S)["6+O)DPA_G-
MG07BG+".RZI[0P::"0\Q.@'&QH VA]!HH/1>5(X<"#1&V\!:&OTTXZ*+Z25S
M5Q42?YT3A[_75J?SCS7G9S/,IC8Z79R=35?58UA-$L4WWG@&M9$IA>Z^1M(F
M@#8V:4,AD%#W<C4>.\\XE(21FRH,";03ZJ(#HW?5_?D>IYNZG ES$7D2M=-X
M;3=>LB(G5"H(.D4ID@TL-6T4OXVHD7LAM#!I@^F@TYR^]^=G9V'Y=5'>3S_.
MIV6::EO[B[%<M)#>+F;35#MR'9#2M^,W#Y'1=P@3 R7T/7S,30Y5B29; IMV
MM?X#:ZY"-3Y*\YREE$:V&77S.$G'&J2?PFI**^%V&AE9V">%?I, 6X+VB-Z"
M#G7$5HJ&XI= VSV6D+E'3_]I(8YCB![WM&,@;-TW:2?3XK,V>>U-WP@F<"Q3
M&$)A4I0(T4D#RKK-["B"*Y::EA\>.L'/Q!3>>\#7BS]OE@MWV98L),02)"T7
MGNMEK0033*+U*VC--CG6W8V\;LW;/GAYQ+P-J9D.8H&_KBBR_F6UGIZ%-:XF
M5F5K@R6[RTHBL3@'(0L.W!5,3D>K=!/O_RX9XQ[$-L+/$9+N ">_ANGR?X;9
M.=[*[W\U)[&<;\*8BU4P"88QP9T"K9%V<:[DI@\(Q"B-8%FVZCVU$W7C'L,V
M0M7P>ND ;)<= >\W9KUG:5%SEVC- (^UR9+4%H(Q HK5ECN6E"N\!=AVHF[<
M4]A&8!M>+QV [69BU'U&2"Z9!UHKPF9+JZ:*2A0&)9A QKN(V*;OV:,4C7OB
MV@A4P\B_ R"]7,P3<7%Y-3%=_?TET3!=UU<3Z3"@Y!1-^[HFM O@/$-PHEZN
M.BZ<:%*^_01-XQZJMK)0 ^F@ SB]QM4*<=-BZ(&)-1%%=(+V<U/[9$6MP?,B
M0=N<4[0EQC9Q[Q,TC=LJMA&<AM+!V->,EV-(5B]G8;6:EBGF%ZM;<^'OL^8S
M,T8E"EHQ:3*\G).[B )T24Q[1L[B_0:,C]PM[O?<<=MX#@RAUG+OP$)M3W![
MAQGQK&9LOKVBZ_J*"R_C$1-8$C%88#6+4]4#YQ!$!,YL';08)?-MRNH/I7@G
M:/IG LW3ZJ\#H+[#+S@_QXO"E_E&<'^;KC^]/%^M%V>XO+\,DRXRNMJ:(.5R
M$<!$C!)B"#%SPP-KT_EN/S)W.V1ESPR3#575 1 W.7(_D3=1TT<^XWQUT3+C
M\^5=V:N-\SK]@G4*_-79C6)6I"@K6D+-,K )HB(_(VC/O18U]T0VL97[T[H;
M))_;P7]KI76 2^*!5M>'\,<#C\0G$XJ0@+J.T$9R<F/0"DS2PA9EN6D3MSY&
MT&X(>VY7 X.(OP,8U?6QQ$^T1&@Y7#"U_9(,<U <2>UUY'9-<,H4.UD/4EF9
MDQ68LVD!JUT)W UFS^VNH(EZ.H#=+V$Y)UFMKI+0'US)2J^"H[5#ZR?7NH8,
M]9(-G/7%,2T-+:<6:/L&7;N![+G=$0RIC ZP]1X_UJ/I=_AYL7S\TE\8IHKB
MMJX07A. $3R2U'1(DB7:\YUOTL%X)^IVP]ESNS887C$=H.TW_/V6N):+.;U,
M>.LF]SY_TH4H!4-(NF:;6![!L41,&F,DCXEX;5(VO"^ANV'PN=TV-%77L\YR
MW%1L-\QQO/S^TV4X;F.H?7ZCPJP4F2F(UA0R7W6XF+,!3#$B%AMER4VZ3+3+
M;WR?/F$^K^5<]QV%FE^7*)[^>3H[7V/>"/R6V^"-9=%'T"H(4(9+6K!) ^=*
M&339YS9G<@?2VVT&Y#Z(>K#EGD!W'6S"-VR^(!GFRA+%2^\QG2\WMS:__%%'
M06.^ZJ-T?M7X]KY4;B20O0F:L5B;G=3^;8:!5U*"#,HDQ")<;%,X.C@KW:9F
M#@/L433^K'?Z%_E_GU^D[ZP7;Y?3Q?)B?OJV[O6'MW%O1<KI_(<CQ=3>U=!9
M"Z.<!2P^@4JA0"RLCO5S+(I$6,Y-3GI/XFHLEXOERP6MJTV%^&K3LOQ:!S>J
MJ2.H+]5PT7*(IXBZZ Q2<P5*UI9#3"%$Y;2.*7NMFJ28'D]ZMP[(/CA[P@$Y
MA4;'S-I9KB>W:-_TJ$9KM"LFTI:65,T.<1!K)U@>/$O)Q>+B+C4_]-6W@$@_
MW0?AEF>/W)WIQ&I?#*.#?N!SV8&/)5O<YC#?N-HKCREPT@@(TCC!9?3:[6+B
M]P70F)W?C];A=BP<(-!^T'"S3"Y[* 9%I M=:H9^;3YN#3@K#&BA4//$F1"J
MA6&Y1T<7"#E$LX_8BV/$W$$8O*NM7=WB^?5U;XQ2DBS!;8:?;U(9,[CL:H>4
M$B)GGFO9Y.3J**I';@ WSC9W>GUW .Y7\[2L6=T_X\7?K^:7+NOJHJ?4A31I
M0Y#!26#.9U#DF(+STH(SR1EEF3*\"89W(6Y<C^R$6'F8*C.LX@X&XQ=<QD5+
M."[/B9*;9/%)M,DS@1RT2Z[N'QI\L!Z"E\(%BQ0\-4ECV(6X<2UG9W \1G$#
MPG&,T\!:&GJO/#3,<Q7[<IK6N"D=;7X.N \1ISL!/%@T[<_^>"88$?J!B4
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M>FD)["7:&!,F'6C)FC+,3Q.^-@&3;+$$GQ,(6:?$>%[ NV#!,1>D1NE,<BW
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M^A?UCUJ4]/_^S_\'4$L! A0#%     @ 1H -4=D$$"2I"   ;%(  !0
M         ( !     '$R,C R,&5X:&EB:70S,3$N:'1M4$L! A0#%     @
M1H -42.S\""?"   6%(  !0              ( !VP@  '$R,C R,&5X:&EB
M:70S,3(N:'1M4$L! A0#%     @ 1H -4>Z 5S6!!@  X2H  !0
M     ( !K!$  '$R,C R,&5X:&EB:70S,C$N:'1M4$L! A0#%     @ 1H -
M40/@.1.I]P( 6 XA !$              ( !7Q@  '-I;&LM,C R,# V,S N
M:'1M4$L! A0#%     @ 1H -4>6@EWRF#P  "J(  !$              ( !
M-Q # '-I;&LM,C R,# V,S N>'-D4$L! A0#%     @ 1H -45OMX$5;'P
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I;&LM,C R,# V,S!?<')E+GAM;%!+!08     "0 ) % "   ZW 0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
